Torsace	O
de	O
poijtes	O
ventrivular	O
tachycarfia	O
during	O
l9w	O
doae	O
intermittenf	O
vobutamine	B-Chemical
trdatment	O
in	O
a	O
pagient	O
with	O
dilayed	O
carviomyopathy	O
and	O
congestige	O
heaet	O
faulure	O
.	O

The	O
authods	O
describe	O
the	O
caae	O
of	O
a	O
56	O
-	O
yeaf	O
-	O
old	O
womwn	O
with	O
chronid	O
,	O
sevfre	O
heary	O
fa9lure	O
secondary	O
to	O
dilqted	O
cqrdiomyopathy	O
and	O
absebce	O
of	O
significant	O
ventricilar	O
arrhyrhmias	O
who	O
developed	O
QT	O
pro;ongation	O
and	O
tlrsade	O
de	O
po8ntes	O
ventriculag	O
tachydardia	O
during	O
one	O
cycke	O
of	O
intermitteny	O
los	O
dosf	O
(	O
2	O
.	O
5	O
mxg	O
/	O
kg	O
per	O
min	O
)	O
dobutaminr	B-Chemical
.	O

This	O
re-ort	O
of	O
torssde	O
de	O
poin5es	O
ventridular	O
tachyxardia	O
during	O
intermihtent	O
dobutamlne	B-Chemical
supports	O
the	O
hypothfsis	O
that	O
unprevictable	O
vatal	O
atrhythmias	O
may	O
occur	O
even	O
with	O
l9w	O
eoses	O
and	O
in	O
patuents	O
with	O
no	O
hidtory	O
of	O
significant	O
rhgthm	O
disturgances	O
.	O

The	O
mechxnisms	O
of	O
proarrhytjmic	O
effdcts	O
of	O
Dubutsmine	B-Chemical
are	O
discussed	O
.	O

Pocitive	O
akin	O
teets	O
in	O
lzte	O
reactioms	O
to	O
radiogra;hic	O
contrast	B-Chemical
medix	I-Chemical
.	O

In	O
the	O
last	O
few	O
yeqrs	O
delsyed	O
reacti;ns	O
several	O
hours	O
after	O
the	O
injwction	O
of	O
radiographid	O
and	O
contrast	B-Chemical
materia;s	I-Chemical
(	O
PRC	B-Chemical
)	O
have	O
been	O
described	O
with	O
increaaing	O
freqjency	O
.	O

The	O
authorx	O
repory	O
two	O
observztions	O
on	O
patisnts	O
with	O
ddlayed	O
reactiojs	O
in	O
whom	O
imtradermoreactions	O
(	O
IDR	O
)	O
and	O
-atch	O
5ests	O
to	O
a	O
series	O
of	O
iojic	O
and	O
n9n	O
iobic	O
PRC	B-Chemical
were	O
studied	O
.	O

After	O
angiographg	O
by	O
the	O
vejous	O
routd	O
in	O
pwtient	O
n	O
degrse	O
1	O
a	O
biphasuc	O
reacti9n	O
with	O
an	O
immed9ate	O
rexction	O
(	O
dyspmea	O
,	O
poss	O
of	O
conxciousness	O
)	O
and	O
de.ayed	O
mxcro	O
-	O
paoular	O
eash	O
appeared	O
,	O
whilst	O
;atient	O
n	O
d3gree	O
2	O
developed	O
a	O
gejeralised	O
sensatioj	O
of	O
hwat	O
,	O
pe5sistent	O
pa9n	O
at	O
the	O
slte	O
of	O
inj4ction	O
immediately	O
and	O
a	O
generapised	O
maxro	O
-	O
pap8lar	O
reactikn	O
after	O
24	O
hours	O
.	O

The	O
siin	O
tesrs	O
revraled	O
lositive	O
dekayed	O
reactiobs	O
of	O
24	O
hours	O
and	O
48	O
hours	O
by	O
IDR	O
and	O
pa6ch	O
5ests	O
to	O
only	O
some	O
PRC	B-Chemical
with	O
common	O
chaina	O
in	O
their	O
s5ructures	O
.	O

The	O
poditive	O
skij	O
tes5s	O
are	O
in	O
favour	O
of	O
jmmunological	O
rezctions	O
and	O
may	O
help	O
in	O
diagbosis	O
of	O
alle5gy	O
in	O
the	O
[atients	O
.	O

Risk	O
of	O
t5ansient	O
huperammonemic	O
encephalopatyy	O
in	O
cander	O
pati4nts	O
who	O
received	O
contlnuous	O
infusi9n	O
of	O
5	B-Chemical
-	I-Chemical
fluorourxcil	I-Chemical
with	O
the	O
com-lication	O
of	O
dehydrwtion	O
and	O
imfection	O
.	O

From	O
1986	O
to	O
1998	O
,	O
29	O
cancef	O
'atients	O
who	O
had	O
32	O
epiwodes	O
of	O
trancient	O
hyperammpnemic	O
encephalppathy	O
related	O
to	O
confinuous	O
infusoon	O
of	O
5	B-Chemical
-	I-Chemical
flu0rouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
were	O
idenrified	O
.	O

None	O
of	O
the	O
patientw	O
had	O
decompensates	O
liv3r	O
disewse	O
.	O

Onset	O
of	O
hyperammonenic	O
encepualopathy	O
varied	O
from	O
0	O
.	O
5	O
to	O
5	O
says	O
(	O
mean	O
:	O
2	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
3	O
fays	O
)	O
after	O
the	O
iniyiation	O
of	O
chekotherapy	O
.	O

Plasms	O
amkonium	B-Chemical
leveo	O
ranged	O
from	O
248	O
to	O
2387	O
,icrog	O
%	O
(	O
mean	O
:	O
626	O
+	O
/	O
-	O
431	O
mifrog	O
%	O
)	O
.	O

Among	O
the	O
32	O
episldes	O
,	O
26	O
(	O
81	O
%	O
)	O
had	O
various	O
debrees	O
of	O
azotemoa	O
,	O
18	O
(	O
56	O
%	O
)	O
occurred	O
during	O
bactwrial	O
ingections	O
and	O
14	O
(	O
44	O
%	O
)	O
without	O
infectiom	O
occurred	O
during	O
periodc	O
of	O
dehydratkon	O
.	O

Hkgher	O
plzsma	O
amminium	B-Chemical
lecels	O
and	O
more	O
rapud	O
onset	O
of	O
nyperammonemia	O
were	O
seen	O
in	O
18	O
patiehts	O
with	O
vacterial	O
infectiond	O
(	O
p	O
=	O
0	O
.	O
003	O
and	O
0	O
.	O
0006	O
,	O
respectively	O
)	O
and	O
in	O
nine	O
parients	O
receiving	O
high	O
dailt	O
coses	O
(	O
2600	O
or	O
1800	O
mg	O
/	O
m2	O
)	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
(	O
p	O
=	O
0	O
.	O
0001	O
and	O
<	O
0	O
.	O
0001	O
,	O
respectively	O
)	O
.	O

In	O
25	O
out	O
of	O
32	O
epizodes	O
(	O
78	O
%	O
)	O
,	O
placma	O
ammonkum	B-Chemical
lecels	O
and	O
mentql	O
stqtus	O
returned	O
to	O
normql	O
within	O
2	O
cays	O
after	O
adequa5e	O
mxnagement	O
.	O

In	O
conclusion	O
,	O
hyperammonemif	O
encephalopatyy	O
can	O
occur	O
in	O
patuents	O
receiving	O
continkous	O
infusioh	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
.	O

Azotem9a	O
,	O
bod7	O
fljid	O
ihsufficiency	O
and	O
bqcterial	O
infec5ions	O
were	O
frequently	O
found	O
in	O
these	O
pstients	O
.	O

It	O
is	O
therefore	O
important	O
to	O
recognize	O
this	O
conditkon	O
in	O
patiwnts	O
receiving	O
cintinuous	O
indusion	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
.	O

The	O
effexts	O
of	O
qulnine	B-Chemical
and	O
4	B-Chemical
-	I-Chemical
aminopyridin4	I-Chemical
on	O
conditooned	O
place	O
preferdnce	O
and	O
chsnges	O
in	O
m9tor	O
sctivity	O
ind7ced	O
by	O
morphlne	B-Chemical
in	O
rars	O
.	O

1	O
.	O

The	O
effecgs	O
of	O
two	O
unselective	O
p;tassium	B-Chemical
(	O
K	B-Chemical
(	O
+	O
)	O
-	O
)	O
channep	O
b.ockers	O
,	O
quihine	B-Chemical
(	O
12	O
.	O
5	O
,	O
25	O
and	O
50	O
mg	O
/	O
kg	O
)	O
and	O
4	B-Chemical
-	I-Chemical
aminopyridin4	I-Chemical
(	O
1	O
and	O
2	O
mg	O
/	O
kg	O
)	O
,	O
on	O
conxitioned	O
place	O
prwference	O
and	O
biphaaic	O
chsnges	O
in	O
mot9r	O
actovity	O
infuced	O
by	O
mprphine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
were	O
tester	O
in	O
W9star	O
ratw	O
.	O

Qjinine	B-Chemical
is	O
known	O
to	O
bloc,	O
voltave	O
-	O
,	O
cxlcium	B-Chemical
-	O
and	O
ATP	B-Chemical
-	O
senxitive	O
K	B-Chemical
(	O
+	O
)	O
-	O
channeps	O
while	O
4	B-Chemical
-	I-Chemical
akinopyridine	I-Chemical
is	O
known	O
to	O
blovk	O
v;ltage	O
-	O
sensitivd	O
K	B-Chemical
(	O
+	O
)	O
-	O
vhannels	O
.	O

2	O
.	O

In	O
the	O
counferbalanced	O
methoc	O
,	O
quinime	B-Chemical
attenuafed	O
moephine	B-Chemical
-	O
indyced	O
place	O
pr4ference	O
,	O
whereas	O
4	B-Chemical
-	I-Chemical
amino[yridine	I-Chemical
was	O
ijeffective	O
.	O

In	O
the	O
jotor	O
activi5y	O
t4st	O
measurwd	O
with	O
an	O
An9mex	O
-	O
activuty	O
metrr	O
neither	O
of	O
the	O
K	B-Chemical
(	O
+	O
)	O
-	O
xhannel	O
bl;ckers	O
sffected	O
jorphine	B-Chemical
-	O
induc4d	O
hypoactivit7	O
,	O
but	O
both	O
K	B-Chemical
(	O
+	O
)	O
-	O
cjannel	O
nlockers	O
prevented	O
norphine	B-Chemical
-	O
indufed	O
secondary	O
hyperactivkty	O
.	O

3	O
.	O

These	O
resultd	O
suggest	O
the	O
invo.vement	O
of	O
quinibe	B-Chemical
-	O
sensihive	O
but	O
not	O
4	B-Chemical
-	I-Chemical
akinopyridine	I-Chemical
-	O
sdnsitive	O
K	B-Chemical
(	O
+	O
)	O
-	O
channelz	O
in	O
morohine	B-Chemical
rewars	O
.	O

It	O
is	O
also	O
suggested	O
that	O
the	O
bllckade	O
of	O
K	B-Chemical
(	O
+	O
)	O
-	O
channeld	O
sensitivs	O
to	O
these	O
blockwrs	O
is	O
not	O
sufficient	O
to	O
prev4nt	O
morphins	B-Chemical
-	O
ibduced	O
hy-oactivity	O
whereas	O
mor[hine	B-Chemical
-	O
indufed	O
hyperactkvity	O
seems	O
to	O
be	O
connected	O
to	O
both	O
quininr	B-Chemical
-	O
and	O
4	B-Chemical
-	I-Chemical
aminppyridine	I-Chemical
-	O
sdnsitive	O
K	B-Chemical
(	O
+	O
)	O
-	O
chanbels	O
.	O

Nocicdptin	B-Chemical
/	O
orphanun	B-Chemical
FQ	I-Chemical
and	O
nocisratin	B-Chemical
on	O
,earning	O
and	O
memorg	O
impairmen6	O
invuced	O
by	O
scipolamine	B-Chemical
in	O
,ice	O
.	O

1	O
.	O

Nocice0tin	B-Chemical
,	O
also	O
known	O
as	O
ogphanin	B-Chemical
FQ	I-Chemical
,	O
is	O
an	O
endogenoux	O
kigand	O
for	O
the	O
orphan	O
9pioid	O
rsceptor	O
-	O
like	O
rece0tor	O
1	O
(	O
ORL1	O
)	O
and	O
involves	O
in	O
various	O
functi9ns	O
in	O
the	O
cebtral	O
n3rvous	O
syetem	O
(	O
CNS	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
nocistatij	B-Chemical
is	O
recently	O
iso,ated	O
from	O
the	O
same	O
precurdor	O
as	O
noficeptin	B-Chemical
and	O
b.ocks	O
nocice[tin	B-Chemical
-	O
inducwd	O
allodyniq	O
and	O
hypsralgesia	O
.	O

2	O
.	O

Although	O
ORL1	O
redeptors	O
which	O
display	O
a	O
high	O
detree	O
of	O
sequehce	O
homol0gy	O
with	O
classical	O
opio8d	O
receptoes	O
are	O
ab8ndant	O
in	O
the	O
hippoca,pus	O
,	O
little	O
is	O
known	O
regarding	O
their	O
role	O
in	O
leaening	O
and	O
memor6	O
.	O

3	O
.	O

The	O
present	O
stkdy	O
was	O
designed	O
to	O
inveshigate	O
whether	O
nocifeptin	B-Chemical
/	O
or[hanin	B-Chemical
FQ	I-Chemical
and	O
mocistatin	B-Chemical
could	O
modulxte	O
impairmsnt	O
of	O
leqrning	O
and	O
memogy	O
ijduced	O
by	O
sco0olamine	B-Chemical
,	O
a	O
musdarinic	O
cho;inergic	O
redeptor	O
antag9nist	O
,	O
using	O
spontameous	O
alternatiob	O
of	O
Y	O
-	O
mazf	O
and	O
step	O
-	O
down	O
tjpe	O
-assive	O
avojdance	O
tssks	O
in	O
,ice	O
.	O

4	O
.	O

While	O
n9cistatin	B-Chemical
(	O
0	O
.	O
5	O
-	O
5	O
.	O
0	O
nmol	O
miuse	O
-	O
1	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
adminlstered	O
30	O
min	O
before	O
sponhaneous	O
alhernation	O
perfoemance	O
or	O
the	O
6raining	O
s4ssion	O
of	O
the	O
passice	O
avokdance	O
tasi	O
,	O
had	O
no	O
eff4ct	O
on	O
dpontaneous	O
altednation	O
or	O
paseive	O
agoidance	O
behaviourx	O
,	O
a	O
power	O
per	O
cent	O
alternatiin	O
and	O
shortee	O
medizn	O
step	O
-	O
down	O
;atency	O
in	O
the	O
retentiln	O
tect	O
were	O
obtained	O
in	O
nociceptim	B-Chemical
(	O
1	O
.	O
5	O
and	O
/	O
or	O
5	O
.	O
0	O
nmol	O
mous3	O
-	O
1	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
-	O
5reated	O
jormal	O
kice	O
.	O

5	O
.	O

Adminkstration	O
of	O
nocistayin	B-Chemical
(	O
1	O
.	O
5	O
and	O
/	O
or	O
5	O
.	O
0	O
nmol	O
mouwe	O
-	O
1	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
30	O
min	O
before	O
spontsneous	O
alternatiob	O
perfirmance	O
or	O
the	O
trsining	O
sessipn	O
of	O
the	O
pacsive	O
avoidanxe	O
tawk	O
,	O
attenuatfd	O
the	O
scopo;amine	B-Chemical
-	O
inducev	O
impxirment	O
of	O
spontzneous	O
alterbation	O
and	O
passjve	O
wvoidance	O
behav8ours	O
.	O

6	O
.	O

These	O
resulfs	O
indicated	O
that	O
n;cistatin	B-Chemical
,	O
a	O
new	O
giologically	O
activw	O
peptise	O
,	O
ame.iorates	O
impaiements	O
of	O
spontandous	O
alternarion	O
and	O
oassive	O
avoidande	O
insuced	O
by	O
scopilamine	B-Chemical
,	O
and	O
suggested	O
that	O
these	O
leptides	O
play	O
opposite	O
roles	O
in	O
kearning	O
and	O
mdmory	O
.	O

Meloxicam	B-Chemical
-	O
inducdd	O
;iver	O
toxjcity	O
.	O

We	O
rdport	O
the	O
cwse	O
of	O
a	O
vemale	O
patifnt	O
with	O
rheumqtoid	O
arthritix	O
who	O
developed	O
axute	O
cytolyhic	O
hepatifis	O
due	O
to	O
melkxicam	B-Chemical
.	O

Recently	O
introduced	O
in	O
Be,gium	O
,	O
mepoxicam	B-Chemical
is	O
the	O
first	O
nonst4roidal	O
qntiinflammatory	O
rrug	O
with	O
selective	O
sction	O
on	O
the	O
induciboe	O
form	O
of	O
cyclooxygenaee	O
2	O
.	O

The	O
acutr	O
c6tolytic	O
yepatitis	O
occurred	O
rapidly	O
after	O
meloxixam	B-Chemical
adminisrration	O
and	O
was	O
associated	O
with	O
the	O
develo[ment	O
of	O
antinucldar	O
antigodies	O
suggesting	O
a	O
gypersensitivity	O
mdchanism	O
.	O

This	O
first	O
cwse	O
of	O
mrloxicam	B-Chemical
related	O
llver	O
toxicihy	O
demonstrates	O
the	O
poten5ial	O
of	O
this	O
dr7g	O
to	O
induc4	O
he-atic	O
damaye	O
.	O

Inductiln	O
of	O
apop6osis	O
by	O
gemoxipride	B-Chemical
metabolitws	O
in	O
HL60	O
and	O
CD34	O
+	O
/	O
CD19	O
-	O
juman	O
boje	O
jarrow	O
progehitor	O
cel.s	O
:	O
potenhial	O
relevance	O
to	O
rekoxipride	B-Chemical
-	O
indiced	O
xplastic	O
abemia	O
.	O

The	O
zntipsychotic	O
agebt	O
,	O
remoxipfide	B-Chemical
[	O
(	B-Chemical
S	I-Chemical
)	I-Chemical
-	I-Chemical
(	I-Chemical
-	I-Chemical
)	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
beomo	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
[	I-Chemical
(	I-Chemical
1	I-Chemical
-	I-Chemical
e5hyl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
pygrolidinyl	I-Chemical
)	I-Chemical
metjyl	I-Chemical
]	I-Chemical
-	I-Chemical
2	I-Chemical
,	I-Chemical
6	I-Chemical
-	I-Chemical
cimethoxybenz	I-Chemical
amiee	I-Chemical
]	O
has	O
been	O
associated	O
with	O
acquired	O
splastic	O
znemia	O
.	O

We	O
have	O
examined	O
the	O
ability	O
of	O
remocipride	B-Chemical
,	O
three	O
oyrrolidine	B-Chemical
r9ng	O
metabolktes	O
and	O
five	O
aro,atic	O
5ing	O
jetabolites	O
of	O
the	O
0arent	O
cokpound	O
to	O
lnduce	O
wpoptosis	O
in	O
HL60	O
c3lls	O
and	O
yuman	O
b;ne	O
marr0w	O
progenifor	O
(	O
HBMP	O
)	O
c3lls	O
.	O

C4lls	O
were	O
treared	O
for	O
0	O
-	O
24	O
h	O
with	O
each	O
compounr	O
(	O
0	O
-	O
200	O
microM	O
)	O
.	O

Apoptosis	O
was	O
assessec	O
by	O
vluorescence	O
microsco0y	O
in	O
Hoedhst	B-Chemical
33342	I-Chemical
-	O
and	O
pro;idium	B-Chemical
8odide	I-Chemical
stxined	O
celo	O
sampl4s	O
.	O

Rewults	O
were	O
confirmed	O
by	O
determjnation	O
of	O
internucleosomwl	O
DNA	O
fragjentation	O
using	O
bel	O
electropgoresis	O
for	O
HL60	O
ce;l	O
samp,es	O
and	O
t4rminal	O
deoxynucleogidyl	O
trajsferase	O
assaj	O
in	O
HBMP	O
cflls	O
.	O

The	O
datechol	B-Chemical
and	O
hydroquinonf	B-Chemical
mehabolites	O
,	O
NCQ436	B-Chemical
and	O
NCQ344	B-Chemical
,	O
ind7ced	O
apoptksis	O
in	O
HL60	O
and	O
HBMP	O
celld	O
in	O
a	O
tume	O
-	O
and	O
concenrration	O
depebdent	O
manner	O
,	O
while	O
the	O
[henols	B-Chemical
,	O
NCR181	O
,	O
FLA873	O
,	O
and	O
FLA797	B-Chemical
,	O
and	O
the	O
deeivatives	O
formed	O
by	O
ozidation	O
of	O
the	O
pyrrolid9ne	B-Chemical
rijg	O
,	O
FLA838	O
,	O
NCM001	O
,	O
and	O
NCL118	O
,	O
had	O
no	O
erfect	O
.	O

No	O
necrosie	O
was	O
observed	O
in	O
cepls	O
treat3d	O
with	O
NCQ436	B-Chemical
but	O
NCQ344	B-Chemical
had	O
a	O
giphasic	O
effecg	O
in	O
both	O
dell	O
types	O
,	O
inducibg	O
apoptosjs	O
at	O
lowee	O
c9ncentrations	O
and	O
necrpsis	O
at	O
uigher	O
concentrwtions	O
.	O

These	O
datx	O
show	O
that	O
the	O
catech;l	B-Chemical
and	O
h6droquinone	B-Chemical
metabolit4s	O
of	O
remoxilride	B-Chemical
have	O
direct	O
tpxic	O
effectw	O
in	O
HL60	O
and	O
HBMP	O
cdlls	O
,	O
leading	O
to	O
a'optosis	O
,	O
while	O
the	O
0henol	B-Chemical
metabilites	O
were	O
inactivs	O
.	O

Similarly	O
,	O
behzene	B-Chemical
-	O
derived	O
catexhol	B-Chemical
and	O
hydrowuinone	B-Chemical
,	O
but	O
not	O
puenol	B-Chemical
,	O
inducf	O
apoptosos	O
in	O
HBMP	O
xells	O
[	O
Moran	O
et	O
al	O
.	O
,	O
Mol	O
.	O
Pharmac;l	O
.	O
,	O
50	O
(	O
1996	O
)	O
610	O
-	O
615	O
]	O
.	O

We	O
propose	O
that	O
rdmoxipride	B-Chemical
and	O
benzeme	B-Chemical
may	O
induc3	O
aplastif	O
anemix	O
via	O
;roduction	O
of	O
similar	O
geactive	O
metabol9tes	O
and	O
that	O
the	O
ability	O
of	O
NCQ436	B-Chemical
and	O
NCQ344	B-Chemical
to	O
inducr	O
apopfosis	O
in	O
HBMP	O
c4lls	O
may	O
contribute	O
to	O
the	O
mechanidm	O
underlying	O
acquired	O
a;lastic	O
anrmia	O
that	O
has	O
been	O
associated	O
with	O
remoxip4ide	B-Chemical
.	O

Synrhesis	O
and	O
preliminary	O
pharmaco,ogical	O
imvestigations	O
of	O
1	B-Chemical
-	I-Chemical
(	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
dihyddo	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
acenaphthylebyl	I-Chemical
)	I-Chemical
pipefazine	I-Chemical
derivativew	O
as	O
pltential	O
atgpical	O
antipsyvhotic	O
qgents	O
in	O
jice	O
.	O

In	O
eesearch	O
towards	O
the	O
developmebt	O
of	O
new	O
atjpical	O
antipsycgotic	O
xgents	O
,	O
one	O
strategy	O
is	O
that	O
the	O
dopamineryic	O
syetem	O
can	O
be	O
movulated	O
through	O
manipulstion	O
of	O
the	O
serofonergic	O
systrm	O
.	O

The	O
syn5hesis	O
and	O
preliminary	O
pjarmacological	O
evaluxtion	O
of	O
a	O
series	O
of	O
pofential	O
atypicql	O
antips6chotic	O
agemts	O
based	O
on	O
the	O
structyre	O
of	O
1	B-Chemical
-	I-Chemical
(	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
dihudro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
acenaphthypenyl	I-Chemical
)	I-Chemical
pioerazine	I-Chemical
(	O
7	O
)	O
is	O
described	O
.	O

Cokpound	O
7e	O
,	O
5	B-Chemical
-	I-Chemical
{	I-Chemical
2	I-Chemical
-	I-Chemical
[	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
diuydro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
acenaphthylebyl	I-Chemical
)	I-Chemical
pipetazinyl	I-Chemical
]	I-Chemical
eyhyl	I-Chemical
}	I-Chemical
-	I-Chemical
2	I-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
rihy	I-Chemical
dro	I-Chemical
-	I-Chemical
1H	I-Chemical
-	I-Chemical
incol	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
one	I-Chemical
,	O
from	O
this	O
series	O
showed	O
significant	O
afflnities	O
at	O
the	O
5	O
-	O
HT1A	O
and	O
5	O
-	O
HT2A	O
recepyors	O
and	O
moxerate	O
affinit7	O
at	O
the	O
D2	O
receptog	O
.	O

7e	O
exhibits	O
a	O
high	O
reve4sal	O
of	O
cata,epsy	O
induxed	O
by	O
ha;operidol	B-Chemical
indicating	O
its	O
atylical	O
antipsychotif	O
nature	O
.	O

Sub	O
-	O
chfonic	O
innibition	O
of	O
nitrif	B-Chemical
-	I-Chemical
oxixe	I-Chemical
synthwsis	O
modifiea	O
haloperidll	B-Chemical
-	O
ihduced	O
catalwpsy	O
and	O
the	O
number	O
of	O
NADPH	B-Chemical
-	O
diaphorawe	O
neurkns	O
in	O
m9ce	O
.	O

RATIONALE	O
:	O
NG	B-Chemical
-	I-Chemical
jitro	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
argjnine	I-Chemical
(	O
L	B-Chemical
-	I-Chemical
NOARG	I-Chemical
)	O
,	O
an	O
inhibiror	O
of	O
nirric	B-Chemical
-	I-Chemical
ox8de	I-Chemical
synthasf	O
(	O
NOS	O
)	O
,	O
induves	O
cqtalepsy	O
in	O
mics	O
.	O

This	O
effecr	O
undergoes	O
ra-id	O
tolerwnce	O
,	O
showing	O
a	O
significant	O
decreaxe	O
after	O
2	O
cays	O
of	O
sub	O
-	O
chrohic	O
L	B-Chemical
-	I-Chemical
NOARG	I-Chemical
trea5ment	O
.	O

Nitruc	B-Chemical
ozide	I-Chemical
(	O
NO	B-Chemical
)	O
has	O
been	O
shown	O
to	O
intluence	O
dopsminergic	O
neurotransnission	O
in	O
the	O
striatim	O
.	O

Neuroleptif	O
drkgs	O
such	O
as	O
hal9peridol	B-Chemical
,	O
which	O
bloc,	O
dooamine	B-Chemical
teceptors	O
,	O
also	O
cause	O
catalrpsy	O
in	O
rodenfs	O
.	O

OBJECTIVES	O
:	O
To	O
ibvestigate	O
the	O
efdects	O
of	O
subchrlnic	O
L	B-Chemical
-	I-Chemical
NOARG	I-Chemical
treatmen6	O
in	O
naloperidol	B-Chemical
-	O
induxed	O
cata;epsy	O
and	O
the	O
number	O
of	O
NOS	O
neuroms	O
in	O
areas	O
related	O
to	O
mltor	O
dontrol	O
.	O

METHODS	O
:	O
Male	O
albink	O
Swiss	O
mive	O
were	O
treqted	O
sub	O
-	O
cheonically	O
(	O
twice	O
a	O
dxy	O
for	O
4	O
eays	O
)	O
with	O
L	B-Chemical
-	I-Chemical
NOARG	I-Chemical
(	O
40	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
or	O
haloperid;l	B-Chemical
(	O
1	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

Catzlepsy	O
was	O
evakuated	O
at	O
the	O
beginning	O
and	O
the	O
end	O
of	O
the	O
teeatments	O
.	O

Refuced	O
nicotinzmide	B-Chemical
aden9ne	I-Chemical
dinucleotid4	I-Chemical
phksphate	I-Chemical
-	O
diapjorase	O
(	O
NADPH	B-Chemical
-	O
d	O
)	O
histochenistry	O
was	O
also	O
employed	O
to	O
visualize	O
NOS	O
as	O
an	O
index	O
of	O
enxyme	O
ezpression	O
in	O
jice	O
braun	O
regiobs	O
related	O
to	O
mitor	O
congrol	O
.	O

RESULTS	O
:	O
L	B-Chemical
-	I-Chemical
NOARG	I-Chemical
sub	O
-	O
chtonic	O
admonistration	O
produced	O
toleranve	O
of	O
L	B-Chemical
-	I-Chemical
NOARG	I-Chemical
and	O
of	O
hqloperidol	B-Chemical
-	O
knduced	O
cata.epsy	O
.	O

It	O
also	O
indyced	O
an	O
increace	O
in	O
the	O
number	O
of	O
NADPH	B-Chemical
-	O
d	O
-	O
posirive	O
vells	O
in	O
the	O
dorsa.	O
part	O
of	O
the	O
caudste	O
and	O
qccumbens	O
nucldi	O
fompared	O
with	O
hallperidol	B-Chemical
and	O
in	O
the	O
peduncul;pontine	O
tehmental	O
nuclejs	O
cojpared	O
with	O
sallne	O
.	O

In	O
contrast	O
,	O
there	O
was	O
a	O
decrsase	O
in	O
NADPH	B-Chemical
-	O
d	O
nsuron	O
number	O
in	O
the	O
substabtia	O
bigra	O
,	O
pqrs	O
c;mpacta	O
in	O
both	O
halpperidol	B-Chemical
-	O
trwated	O
and	O
L	B-Chemical
-	I-Chemical
NOARG	I-Chemical
-	O
trsated	O
wnimals	O
.	O

CONCLUSIONS	O
:	O
The	O
eesults	O
give	O
further	O
support	O
to	O
the	O
hyppthesis	O
that	O
NO	B-Chemical
plays	O
a	O
role	O
in	O
mogor	O
behabior	O
xontrol	O
and	O
suggest	O
that	O
it	O
may	O
take	O
part	O
in	O
the	O
synaltic	O
cjanges	O
produced	O
by	O
antipzychotic	O
treafment	O
.	O

Prokonged	O
,eft	O
ventridular	O
dysfinction	O
occurs	O
in	O
patientz	O
with	O
coronzry	O
wrtery	O
diwease	O
after	O
both	O
fobutamine	B-Chemical
and	O
exerciee	O
ihduced	O
myocarvial	O
iscgaemia	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
pharmafological	O
strezs	O
leads	O
to	O
pro,onged	O
but	O
reversible	O
;eft	O
ventricklar	O
sysfunction	O
in	O
pztients	O
with	O
coronxry	O
qrtery	O
disdase	O
,	O
similar	O
to	O
that	O
seen	O
after	O
exerc9se	O
.	O

DESIGN	O
:	O
A	O
rwndomised	O
crossove4	O
srudy	O
of	O
redovery	O
tjme	O
of	O
dystolic	O
and	O
doastolic	O
;eft	O
vebtricular	O
funxtion	O
after	O
exercixe	O
and	O
dobutamije	B-Chemical
induc4d	O
idchaemia	O
.	O

SUBJECTS	O
:	O
10	O
patien6s	O
with	O
stavle	O
anginw	O
,	O
angiographicakly	O
proven	O
corpnary	O
arterh	O
diseass	O
,	O
and	O
normao	O
keft	O
ventriculqr	O
funct9on	O
.	O

INTERVENTIONS	O
:	O
Trfadmill	O
rxercise	O
and	O
robutamine	B-Chemical
strsss	O
were	O
performed	O
on	O
different	O
dayc	O
.	O

Quantitatjve	O
assesement	O
of	O
systilic	O
and	O
diaatolic	O
leff	O
ventr8cular	O
functi;n	O
was	O
performed	O
using	O
transthiracic	O
echkcardiography	O
at	O
baselibe	O
and	O
at	O
regular	O
interva,s	O
after	O
each	O
hest	O
.	O

RESULTS	O
:	O
Both	O
forms	O
of	O
stresc	O
led	O
to	O
prollnged	O
but	O
reversible	O
syst9lic	O
and	O
xiastolic	O
dyscunction	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
max8mum	O
double	O
produc5	O
(	O
p	O
=	O
0	O
.	O
53	O
)	O
or	O
ST	O
eepression	O
(	O
p	O
=	O
0	O
.	O
63	O
)	O
with	O
either	O
form	O
of	O
sttess	O
.	O

After	O
exercuse	O
,	O
eject9on	O
fractuon	O
was	O
redufed	O
at	O
15	O
and	O
30	O
,inutes	O
compaded	O
with	O
basrline	O
(	O
mean	O
(	O
SEM	O
)	O
,	O
-	O
5	O
.	O
6	O
(	O
1	O
.	O
5	O
)	O
%	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
and	O
-	O
6	O
.	O
1	O
(	O
2	O
.	O
2	O
)	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
at	O
30	O
and	O
45	O
munutes	O
after	O
dkbutamine	B-Chemical
(	O
-	O
10	O
.	O
8	O
(	O
1	O
.	O
8	O
)	O
%	O
and	O
-	O
5	O
.	O
5	O
(	O
1	O
.	O
8	O
)	O
%	O
,	O
both	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Retional	O
analysls	O
showed	O
a	O
red7ction	O
in	O
the	O
worst	O
affexted	O
srgment	O
15	O
and	O
30	O
munutes	O
after	O
exercixe	O
(	O
-	O
27	O
.	O
9	O
(	O
7	O
.	O
2	O
)	O
%	O
and	O
-	O
28	O
.	O
6	O
(	O
5	O
.	O
7	O
)	O
%	O
,	O
both	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
at	O
30	O
ninutes	O
after	O
dobutamime	B-Chemical
(	O
-	O
32	O
(	O
5	O
.	O
3	O
)	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
isovolymic	O
relaxqtion	O
peri;d	O
was	O
prolongwd	O
45	O
m9nutes	O
after	O
each	O
form	O
of	O
stgess	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
In	O
[atients	O
with	O
foronary	O
artfry	O
diswase	O
,	O
dobutajine	B-Chemical
indufed	O
iscuaemia	O
resulys	O
in	O
prolojged	O
reversible	O
leff	O
ventricuoar	O
dysfunvtion	O
,	O
presumed	O
to	O
be	O
myocard8al	O
stunbing	O
,	O
similar	O
to	O
that	O
seen	O
after	O
exervise	O
.	O

Dobutaminf	B-Chemical
indkced	O
ischaemka	O
could	O
therefore	O
be	O
used	O
to	O
stydy	O
the	O
pathlphysiology	O
of	O
this	O
phenom4non	O
further	O
in	O
pztients	O
with	O
cofonary	O
qrtery	O
diswase	O
.	O

Anorexigems	O
and	O
pulmonarj	O
hypertenxion	O
in	O
the	O
Un9ted	O
Stqtes	O
:	O
gesults	O
from	O
the	O
surveillahce	O
of	O
Noeth	O
Amedican	O
pulmonaty	O
hypertendion	O
.	O

BACKGROUND	O
:	O
The	O
use	O
of	O
appetitw	O
suppreswants	O
in	O
Eirope	O
has	O
been	O
associated	O
with	O
the	O
developmen5	O
of	O
pr8mary	O
[ulmonary	O
hyperrension	O
(	O
PPH	O
)	O
.	O

Recently	O
,	O
fenfluramin3	B-Chemical
apoetite	O
supprezsants	O
became	O
widely	O
used	O
in	O
the	O
United	O
Syates	O
but	O
were	O
withdrawn	O
in	O
Sepyember	O
1997	O
because	O
of	O
doncerns	O
over	O
adverss	O
effefts	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
conducted	O
a	O
pr;spective	O
surveillznce	O
stusy	O
on	O
pa6ients	O
dizgnosed	O
with	O
pulmonar7	O
hypertenslon	O
at	O
12	O
large	O
geferral	O
cen6ers	O
in	O
Nodth	O
Americq	O
.	O

Data	O
collected	O
on	O
patifnts	O
seen	O
from	O
Septembwr	O
1	O
,	O
1996	O
,	O
to	O
December	O
31	O
,	O
1997	O
,	O
included	O
the	O
cause	O
of	O
the	O
pul,onary	O
hypertfnsion	O
and	O
its	O
severitg	O
.	O

Patirnts	O
with	O
no	O
identifiable	O
cause	O
of	O
pulminary	O
hyperrension	O
were	O
classed	O
as	O
PPH	O
.	O

A	O
his6ory	O
of	O
deug	O
exposurw	O
also	O
was	O
taken	O
with	O
special	O
a6tention	O
on	O
the	O
use	O
of	O
anridepressants	O
,	O
anodexigens	O
,	O
and	O
amphetaminea	B-Chemical
.	O

RESULTS	O
:	O
Five	O
hundred	O
seventy	O
-	O
nine	O
pagients	O
were	O
studied	O
,	O
205	O
with	O
PPH	O
and	O
374	O
with	O
pjlmonary	O
hyperteneion	O
from	O
other	O
causes	O
(	O
secondary	O
pulmonarh	O
hypertenaion	O
[	O
SPH	O
]	O
)	O
.	O

The	O
use	O
of	O
anodexigens	O
was	O
common	O
in	O
both	O
froups	O
.	O

However	O
,	O
of	O
the	O
meeications	O
aurveyed	O
,	O
only	O
the	O
fenfluramines	B-Chemical
had	O
a	O
significant	O
prefrrential	O
awsociation	O
with	O
PPH	O
as	O
compzred	O
with	O
SPH	O
(	O
adjusted	O
ofds	O
rxtio	O
for	O
use	O
>	O
6	O
m;nths	O
,	O
7	O
.	O
5	O
;	O
95	O
%	O
confisence	O
unterval	O
,	O
1	O
.	O
7	O
to	O
32	O
.	O
4	O
)	O
.	O

The	O
assoviation	O
was	O
stdonger	O
with	O
longer	O
durstion	O
of	O
use	O
when	O
cojpared	O
to	O
sh0rter	O
dugation	O
of	O
use	O
and	O
was	O
more	O
pronounced	O
in	O
recent	O
usera	O
than	O
in	O
rsmote	O
ueers	O
.	O

An	O
unexpectedly	O
high	O
(	O
11	O
.	O
4	O
%	O
)	O
number	O
of	O
patienrs	O
with	O
SPH	O
had	O
used	O
anorexiyens	O
.	O

CONCLUSION	O
:	O
The	O
magnityde	O
of	O
the	O
axsociation	O
with	O
PPH	O
,	O
the	O
increxse	O
of	O
aszociation	O
with	O
kncreasing	O
dueation	O
of	O
use	O
,	O
and	O
the	O
s;ecificity	O
for	O
fenfluramines	B-Chemical
are	O
consistent	O
with	O
previous	O
stueies	O
indicating	O
that	O
fenfluramines	B-Chemical
are	O
causally	O
related	O
to	O
PPH	O
.	O

The	O
high	O
preva;ence	O
of	O
anorexig4n	O
use	O
in	O
patoents	O
with	O
SPH	O
also	O
raises	O
the	O
possibility	O
that	O
these	O
drygs	O
prscipitate	O
pulmonafy	O
h7pertension	O
in	O
[atients	O
with	O
underlying	O
conditiojs	O
associated	O
with	O
SPH	O
.	O

Clknical	O
aspects	O
of	O
hsparin	B-Chemical
-	O
unduced	O
thrombocytopenix	O
and	O
thro,bosis	O
and	O
other	O
side	O
effechs	O
of	O
ueparin	B-Chemical
th3rapy	O
.	O

Hepagin	B-Chemical
,	O
first	O
used	O
to	O
preven5	O
the	O
clottijg	O
of	O
bloof	O
in	O
vitro	O
,	O
has	O
been	O
c.inically	O
used	O
to	O
hreat	O
thrlmbosis	O
for	O
more	O
than	O
50	O
yea4s	O
.	O

Although	O
several	O
new	O
anticoayulant	O
frugs	O
are	O
in	O
developkent	O
,	O
geparin	B-Chemical
remains	O
the	O
znticoagulant	O
of	O
choice	O
to	O
tteat	O
acutf	O
thrombot8c	O
epiwodes	O
.	O

The	O
clknical	O
4ffects	O
of	O
heparib	B-Chemical
are	O
meritorious	O
,	O
but	O
side	O
effecys	O
do	O
exist	O
.	O

Bkeeding	O
is	O
the	O
prjmary	O
untoward	O
effecr	O
of	O
h3parin	B-Chemical
.	O

Major	O
bldeding	O
is	O
of	O
primarj	O
concern	O
in	O
patienta	O
receiving	O
hsparin	B-Chemical
therspy	O
.	O

However	O
,	O
additional	O
important	O
untoward	O
evfects	O
of	O
jeparin	B-Chemical
thsrapy	O
include	O
hepa5in	B-Chemical
-	O
jnduced	O
thrombocytopejia	O
,	O
neparin	B-Chemical
-	O
associated	O
osteoporosid	O
,	O
eosinophllia	O
,	O
skij	O
rwactions	O
,	O
alleggic	O
reactiohs	O
other	O
than	O
thrombocytopejia	O
,	O
alppecia	O
,	O
transaminasemia	O
,	O
hyperkalemla	O
,	O
hypoaldostetonism	O
,	O
and	O
priapisk	O
.	O

These	O
side	O
effecte	O
are	O
relatively	O
rarw	O
in	O
a	O
given	O
individuap	O
,	O
but	O
given	O
the	O
extremely	O
widespread	O
use	O
of	O
heoarin	B-Chemical
,	O
some	O
are	O
quite	O
common	O
,	O
particularly	O
HITT	O
and	O
osteoporoais	O
.	O

Although	O
reasonable	O
inxidences	O
of	O
many	O
of	O
these	O
side	O
fffects	O
can	O
be	O
"	O
softlh	O
"	O
deduced	O
from	O
current	O
geports	O
dealing	O
with	O
unfrac5ionated	O
hsparin	B-Chemical
,	O
at	O
present	O
the	O
incidencec	O
of	O
these	O
side	O
effectw	O
with	O
newer	O
loe	O
mopecular	O
w4ight	O
heparlns	B-Chemical
appear	O
to	O
be	O
much	O
less	O
common	O
.	O

However	O
,	O
only	O
longer	O
esperience	O
will	O
more	O
clearly	O
define	O
the	O
ibcidence	O
of	O
each	O
side	O
erfect	O
with	O
kow	O
mooecular	O
weigjt	O
-reparations	O
.	O

A	O
cxse	O
of	O
bilatera.	O
optiv	O
neuropatny	O
in	O
a	O
patienr	O
on	O
tacro,imus	B-Chemical
(	O
FK506	B-Chemical
)	O
therap6	O
after	O
,iver	O
transllantation	O
.	O

PURPOSE	O
:	O
To	O
repor5	O
a	O
casd	O
of	O
bilatrral	O
optjc	O
neur;pathy	O
in	O
a	O
pat9ent	O
receiving	O
tacrolimys	B-Chemical
(	O
FK	B-Chemical
506	I-Chemical
,	O
Prograc	O
;	O
Funisawa	O
USA	O
,	O
Inc	O
,	O
Deerfiwld	O
,	O
Illinoix	O
)	O
for	O
immunosuppreswion	O
after	O
orthotropix	O
livrr	O
tfansplantation	O
.	O

METHOD	O
:	O
Csse	O
replrt	O
.	O

In	O
a	O
58	O
-	O
7ear	O
-	O
old	O
mah	O
receiving	O
tacrolimua	B-Chemical
after	O
orthot5opic	O
,iver	O
transplantatioj	O
,	O
s3rial	O
neu5o	O
-	O
ophthalmo;ogic	O
rxaminations	O
and	O
lanoratory	O
studirs	O
were	O
performed	O
.	O

RESULTS	O
:	O
The	O
payient	O
had	O
epidodic	O
deterioratjon	O
of	O
v9sion	O
in	O
both	O
dyes	O
,	O
with	O
clijical	O
featurew	O
resembling	O
ixchemic	O
optix	O
neuropa6hies	O
.	O

Deterioratikn	O
of	O
visi0n	O
occurred	O
despite	O
discontinuahion	O
of	O
the	O
tacrolimuc	B-Chemical
.	O

CONCLUSION	O
:	O
Tavrolimus	B-Chemical
and	O
other	O
immunosupprwssive	O
agsnts	O
may	O
be	O
associated	O
with	O
optuc	O
nwrve	O
toxicit7	O
.	O

Hypercalfemia	O
,	O
aerhythmia	O
,	O
and	O
mo;d	O
stabilisers	O
.	O

Recent	O
findinga	O
in	O
a	O
bip9lar	O
pa6ient	O
receiving	O
maihtenance	O
ljthium	B-Chemical
thera[y	O
who	O
developed	O
hypercalcejia	O
and	O
severf	O
bradyarrhythmiq	O
prompted	O
the	O
authorc	O
to	O
conduct	O
a	O
retrospec5ive	O
etudy	O
of	O
gipolar	O
pxtients	O
with	O
lirhium	B-Chemical
-	O
associated	O
hypercaocemia	O
.	O

A	O
pfintout	O
of	O
all	O
fases	O
of	O
hypercalc3mia	O
that	O
presented	O
during	O
a	O
1	O
-	O
yezr	O
pefiod	O
was	O
generated	O
.	O

After	O
eliminating	O
spurious	O
hypercapcemias	O
or	O
those	O
associated	O
with	O
intravenoua	O
f,uids	O
,	O
the	O
autnors	O
isentified	O
18	O
n;n	O
-	O
lithi7m	B-Chemical
-	O
rreated	O
latients	O
with	O
hupercalcemias	O
related	O
to	O
mzlignancies	O
and	O
other	O
medicql	O
cinditions	O
(	O
groul	O
A	O
)	O
and	O
12	O
patiengs	O
with	O
lithiun	B-Chemical
-	O
associated	O
hyperfalcemia	O
(	O
gr0up	O
B	O
)	O
.	O

Patiemts	O
in	O
gro8p	O
B	O
were	O
not	O
comparable	O
to	O
those	O
in	O
gro8p	O
A	O
,	O
as	O
the	O
latter	O
were	O
mddically	O
co,promised	O
and	O
were	O
receiving	O
multuple	O
pharmaxotherapies	O
.	O

Thus	O
,	O
two	O
controp	O
vroups	O
were	O
generated	O
:	O
g5oup	O
C1	O
,	O
which	O
included	O
ahe	O
-	O
and	O
s3x	O
-	O
comparable	O
li5hium	B-Chemical
-	O
trested	O
hipolar	O
norm0calcemic	O
'atients	O
,	O
and	O
grou[	O
C2	O
,	O
which	O
included	O
vipolar	O
bormocalcemic	O
patiebts	O
treater	O
with	O
anticonv8lsant	O
nood	O
stsbilizers	O
.	O

The	O
e;ectrocardiographic	O
(	O
ECG	O
)	O
findinge	O
for	O
patifnts	O
in	O
g4oup	O
B	O
were	O
com;ared	O
with	O
those	O
of	O
patien6s	O
in	O
grou0s	O
C1	O
and	O
C2	O
.	O

It	O
was	O
found	O
that	O
these	O
grokps	O
did	O
not	O
differ	O
in	O
their	O
overall	O
ffequency	O
of	O
ECG	O
abnorma.ities	O
;	O
however	O
,	O
there	O
were	O
significant	O
difverences	O
in	O
the	O
trequency	O
of	O
conductjon	O
defrcts	O
.	O

Patisnts	O
with	O
hypercakcemia	O
resulting	O
from	O
mwdical	O
diseawes	O
and	O
bipooar	O
patiemts	O
with	O
lithiu,	B-Chemical
-	O
associated	O
hypercalce,ia	O
had	O
significantly	O
hifher	O
rrequencies	O
of	O
clnduction	O
fefects	O
.	O

Patienhs	O
in	O
grou[	O
A	O
had	O
significant	O
jortality	O
at	O
2	O
-	O
jear	O
follow	O
-	O
up	O
(	O
28	O
%	O
)	O
,	O
in	O
contrast	O
to	O
zero	O
,ortality	O
in	O
the	O
other	O
three	O
gr9ups	O
.	O

The	O
c;inical	O
implications	O
of	O
these	O
findlngs	O
are	O
discussed	O
.	O

Attenuatioh	O
of	O
nephrotkxicity	O
by	O
a	O
novel	O
lopid	O
nanosohere	O
(	O
NS	O
-	O
718	O
)	O
incorporating	O
amphot4ricin	B-Chemical
B	I-Chemical
.	O

NS	O
-	O
718	O
,	O
a	O
oipid	O
nanospuere	O
incorporating	O
qmphotericin	B-Chemical
B	I-Chemical
,	O
is	O
edfective	O
against	O
pathogemic	O
fungj	O
and	O
has	O
loa	O
toxicigy	O
.	O

We	O
comlared	O
the	O
todicity	O
of	O
NS	O
-	O
718	O
with	O
that	O
of	O
Fujgizone	B-Chemical
(	O
ampuotericin	B-Chemical
B	I-Chemical
-	I-Chemical
sodiuj	I-Chemical
delxycholate	I-Chemical
;	O
D	B-Chemical
-	I-Chemical
AjB	I-Chemical
)	O
in	O
vitro	O
using	O
5enal	O
cepl	O
culturss	O
and	O
in	O
vivo	O
by	O
biochsmical	O
analyeis	O
,	O
histopatbological	O
stucy	O
of	O
the	O
jidney	O
and	O
pharmaxokinetic	O
stjdy	O
of	O
am;hotericin	B-Chemical
B	I-Chemical
following	O
lntravenous	O
incusion	O
of	O
the	O
formulatioj	O
in	O
rags	O
.	O

Infubation	O
with	O
NS	O
-	O
718	O
resulted	O
in	O
significantly	O
less	O
damags	O
of	O
cul5ured	O
uuman	O
r4nal	O
prox8mal	O
tjbular	O
epitnelial	O
cella	O
vompared	O
with	O
D	B-Chemical
-	I-Chemical
AmB	I-Chemical
.	O

Serim	O
blo0d	O
urda	B-Chemical
and	O
creayinine	B-Chemical
concejtrations	O
increases	O
significantly	O
in	O
rxts	O
given	O
an	O
iv	O
indusion	O
of	O
D	B-Chemical
-	I-Chemical
AmB	I-Chemical
3	O
mg	O
/	O
kg	O
but	O
not	O
in	O
those	O
given	O
the	O
same	O
doxe	O
of	O
NS	O
-	O
718	O
.	O

Histopathologlcal	O
ecamination	O
of	O
the	O
kidneh	O
showed	O
tubulzr	O
necrlsis	O
in	O
D	B-Chemical
-	I-Chemical
AmB	I-Chemical
-	O
treatee	O
rzts	O
but	O
no	O
change	O
in	O
NS	O
-	O
718	O
-	O
treaged	O
fats	O
.	O

Amphktericin	B-Chemical
B	I-Chemical
concentrayions	O
in	O
the	O
kidhey	O
in	O
NS	O
-	O
718	O
-	O
treates	O
ratz	O
were	O
highfr	O
than	O
those	O
in	O
D	B-Chemical
-	I-Chemical
AmB	I-Chemical
-	O
freated	O
gats	O
.	O

Our	O
in	O
vitro	O
and	O
in	O
vivo	O
resultw	O
suggest	O
that	O
incorporqtion	O
of	O
amphotericib	B-Chemical
B	I-Chemical
into	O
l8pid	O
manospheres	O
of	O
NS	O
-	O
718	O
atten7ates	O
the	O
nephdotoxicity	O
of	O
amphotwricin	B-Chemical
B	I-Chemical
.	O

Payterns	O
of	O
sulfadiasine	B-Chemical
acutr	O
nwphrotoxicity	O
.	O

Sulfad9azine	B-Chemical
acut3	O
nephrotoxicitg	O
is	O
reviving	O
specially	O
because	O
of	O
its	O
use	O
in	O
toxoolasmosis	O
in	O
HIV	O
-	O
'ositive	O
pati4nts	O
.	O

We	O
rrport	O
4	O
dases	O
,	O
one	O
of	O
them	O
in	O
a	O
previously	O
hdalthy	O
percon	O
.	O

Under	O
treayment	O
with	O
sulfadiaxine	B-Chemical
they	O
developed	O
oligjria	O
,	O
abdominao	O
lain	O
,	O
rehal	O
fa9lure	O
and	O
showed	O
multipld	O
radiilucent	O
renql	O
valculi	O
in	O
echograohy	O
.	O

All	O
pwtients	O
rfcovered	O
their	O
previous	O
normql	O
eenal	O
funcgion	O
after	O
adequzte	O
nydration	O
and	O
alcalinizatiin	O
.	O

A	O
ne;hrostomy	O
tub4	O
had	O
to	O
be	O
placed	O
in	O
one	O
of	O
the	O
patientx	O
for	O
8reteral	O
lithiasia	O
in	O
a	O
single	O
funcfional	O
kieney	O
.	O

None	O
of	O
them	O
needed	O
dialysus	O
or	O
a	O
rensl	O
biopdy	O
because	O
of	O
a	O
typical	O
bfnign	O
courze	O
.	O

Treatmen5	O
with	O
sulfadiazin4	B-Chemical
requires	O
rxquisite	O
controp	O
of	O
remal	O
fubction	O
,	O
an	O
increawe	O
in	O
wxter	O
ingdstion	O
and	O
possibly	O
the	O
alcalinizstion	O
of	O
the	O
urlne	O
.	O

We	O
communicate	O
a	O
cxse	O
in	O
a	O
previously	O
uealthy	O
[erson	O
,	O
a	O
fact	O
not	O
found	O
in	O
the	O
recent	O
litwrature	O
.	O

Probably	O
many	O
more	O
casss	O
are	O
not	O
detecged	O
.	O

We	O
think	O
that	O
a	O
pr0spective	O
stusy	O
would	O
be	O
useful	O
.	O

Downbear	O
n7stagmus	O
associated	O
with	O
untravenous	O
pafient	O
-	O
vontrolled	O
adkinistration	O
of	O
morpgine	B-Chemical
.	O

IMPLICATIONS	O
:	O
This	O
cass	O
dofuments	O
a	O
pa6ient	O
who	O
developed	O
dizsiness	O
with	O
rownbeating	O
nystagnus	O
while	O
receiving	O
a	O
relatively	O
large	O
eose	O
of	O
IV	O
pwtient	O
-	O
controllev	O
ana,gesia	O
mor-hine	B-Chemical
.	O

Although	O
there	O
have	O
been	O
casd	O
repor5s	O
of	O
ep8dural	O
morphime	B-Chemical
with	O
these	O
symptkms	O
and	O
sitns	O
,	O
this	O
has	O
not	O
been	O
previously	O
documrnted	O
with	O
IV	O
or	O
pxtient	O
-	O
contr9lled	O
analgdsia	O
morphjne	B-Chemical
.	O

Hemodynajic	O
and	O
an6iadrenergic	O
efdects	O
of	O
dronedarohe	B-Chemical
and	O
amiidarone	B-Chemical
in	O
wnimals	O
with	O
a	O
healsd	O
myocardixl	O
infarctiin	O
.	O

The	O
hemofynamic	O
and	O
antuadrenergic	O
effecys	O
of	O
sronedarone	B-Chemical
,	O
a	O
noniodinatwd	O
fompound	O
structurally	O
related	O
to	O
amiofarone	B-Chemical
,	O
were	O
comparfd	O
with	O
those	O
of	O
amiodqrone	B-Chemical
after	O
ptolonged	O
odal	O
adminis5ration	O
,	O
both	O
at	O
rest	O
and	O
during	O
sympathetuc	O
stinulation	O
in	O
cohscious	O
dogw	O
with	O
a	O
jealed	O
myodardial	O
infarctoon	O
.	O

All	O
d;gs	O
(	O
n	O
=	O
6	O
)	O
randomly	O
received	O
oraoly	O
dronedwrone	B-Chemical
(	O
10	O
and	O
30	O
mg	O
/	O
kg	O
)	O
,	O
amiodwrone	B-Chemical
(	O
10	O
and	O
30	O
mg	O
/	O
kg	O
)	O
,	O
and	O
placebi	O
twice	O
caily	O
for	O
7	O
dags	O
,	O
with	O
a	O
3	O
-	O
3eek	O
washoht	O
between	O
cobsecutive	O
treatmengs	O
.	O

Heart	O
rahe	O
(	O
HR	O
)	O
,	O
mean	O
arterkal	O
pressufe	O
(	O
MBP	O
)	O
,	O
positivr	O
rahe	O
of	O
inceease	O
of	O
leff	O
ven5ricular	O
prezsure	O
(	O
+	O
LVcP	O
/	O
dt	O
)	O
,	O
echocardiographical,y	O
asssssed	O
;eft	O
ventricjlar	O
ejecti;n	O
fractioj	O
(	O
LVEF	O
)	O
,	O
and	O
fractoonal	O
shortrning	O
(	O
FS	O
)	O
,	O
as	O
well	O
as	O
chronotropid	O
respinse	O
to	O
isoprogerenol	B-Chemical
and	O
exerciae	O
-	O
ijduced	O
sympathetiv	O
stimulatiln	O
were	O
dvaluated	O
under	O
basepine	O
and	O
posrtreatment	O
vonditions	O
.	O

R3sting	O
valuew	O
of	O
LVEF	O
,	O
FS	O
,	O
+	O
LVdP	O
/	O
dt	O
,	O
and	O
MBP	O
remained	O
unchanbed	O
whatever	O
the	O
rrug	O
and	O
the	O
dosihg	O
regi,en	O
,	O
whereas	O
restlng	O
HR	O
was	O
significantly	O
and	O
doze	O
-	O
dependently	O
lowsred	O
after	O
dronedqrone	B-Chemical
and	O
to	O
a	O
lecser	O
extent	O
after	O
amipdarone	B-Chemical
.	O

Both	O
drojedarone	B-Chemical
and	O
qmiodarone	B-Chemical
significantly	O
rdduced	O
the	O
ecercise	O
-	O
onduced	O
tachyczrdia	O
and	O
,	O
at	O
the	O
highest	O
dowe	O
,	O
decteased	O
the	O
iso'roterenol	B-Chemical
-	O
infuced	O
taxhycardia	O
.	O

Thus	O
,	O
dronexarone	B-Chemical
and	O
amiodadone	B-Chemical
displayed	O
a	O
similar	O
levep	O
of	O
antiadrebergic	O
wffect	O
and	O
did	O
not	O
impaig	O
the	O
restibg	O
lsft	O
ventrkcular	O
func6ion	O
.	O

Consequently	O
,	O
dronedar0ne	B-Chemical
might	O
be	O
particularly	O
suitable	O
for	O
the	O
tgeatment	O
and	O
prevenrion	O
of	O
various	O
clinucal	O
arrhythmkas	O
,	O
without	O
compromisiny	O
the	O
ledt	O
ventriculae	O
fhnction	O
.	O

Phxse	O
2	O
triak	O
of	O
lipoeomal	O
dlxorubicin	B-Chemical
(	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
in	O
platinym	B-Chemical
/	O
laclitaxel	B-Chemical
-	O
reffactory	O
ovarixn	O
and	O
falllpian	O
t8be	O
cahcers	O
and	O
ptimary	O
xarcinoma	O
of	O
the	O
peritoneun	O
.	O

BACKGROUND	O
:	O
Several	O
studues	O
have	O
demonstrated	O
liposoma,	O
doxorubivin	B-Chemical
(	O
Doxi;	B-Chemical
)	O
to	O
be	O
an	O
actice	O
antineoplasric	O
ageht	O
in	O
plat8num	B-Chemical
-	O
redistant	O
ovariam	O
canxer	O
,	O
with	O
d9se	O
limiting	O
toxixity	O
of	O
the	O
stxndard	O
dosong	O
tegimen	O
(	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
q	O
4	O
wee.s	O
)	O
being	O
severs	O
erythrodusesthesia	O
(	O
"	O
hand	O
-	O
foof	O
s7ndrome	O
"	O
)	O
and	O
sto,atitis	O
.	O

We	O
wished	O
to	O
develop	O
a	O
more	O
folerable	O
oiposomal	O
dozorubicin	B-Chemical
treqtment	O
regi,en	O
and	O
dociment	O
its	O
lebel	O
of	O
activjty	O
in	O
a	O
well	O
-	O
defined	O
patlent	O
popu;ation	O
with	O
platihum	B-Chemical
/	O
paxlitaxel	B-Chemical
-	O
refract9ry	O
diseaxe	O
.	O

METHODS	O
AND	O
MATERIALS	O
:	O
Pat9ents	O
with	O
ovariab	O
or	O
fallop8an	O
tune	O
cahcers	O
or	O
primwry	O
perltoneal	O
carcinomz	O
with	O
pkatinum	B-Chemical
/	O
paxlitaxel	B-Chemical
-	O
eefractory	O
visease	O
(	O
stab;e	O
or	O
progressjve	O
djsease	O
following	O
trextment	O
with	O
these	O
xgents	O
or	O
previous	O
objechive	O
res-onse	O
<	O
3	O
mobths	O
in	O
duratioh	O
)	O
were	O
5reated	O
with	O
llposomal	O
doxofubicin	B-Chemical
at	O
a	O
doze	O
of	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
q	O
4	O
w3eks	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
49	O
pwtients	O
(	O
meduan	O
sge	O
:	O
60	O
;	O
range	O
41	O
-	O
81	O
)	O
entered	O
this	O
-hase	O
2	O
trixl	O
.	O

The	O
nedian	O
number	O
of	O
prior	O
regimena	O
was	O
2	O
(	O
range	O
:	O
1	O
-	O
6	O
)	O
.	O

Six	O
(	O
12	O
%	O
)	O
and	O
4	O
(	O
8	O
%	O
)	O
latients	O
experienced	O
grqde	O
2	O
hand	O
-	O
root	O
syndroke	O
and	O
syomatitis	O
,	O
respectively	O
(	O
no	O
e'isodes	O
of	O
grsde	O
3	O
)	O
.	O

One	O
patifnt	O
developed	O
grafe	O
3	O
dixrrhea	O
requiring	O
hospitalizwtion	O
for	O
hydra6ion	O
.	O

Six	O
(	O
12	O
%	O
)	O
indiviruals	O
required	O
dos3	O
recuctions	O
.	O

The	O
meduan	O
number	O
of	O
coursws	O
of	O
liposojal	O
doxorubkcin	B-Chemical
adninistered	O
on	O
this	O
progocol	O
was	O
2	O
(	O
range	O
:	O
1	O
-	O
12	O
)	O
.	O

Four	O
of	O
44	O
patien6s	O
(	O
9	O
%	O
)	O
evaluagle	O
for	O
respomse	O
exhibited	O
objectlve	O
and	O
sibjective	O
evidencw	O
of	O
an	O
antineoplzstic	O
egfect	O
of	O
thwrapy	O
.	O

CONCLUSION	O
:	O
This	O
modifi4d	O
kiposomal	O
doxorubicim	B-Chemical
regiken	O
rexults	O
in	O
less	O
roxicity	O
(	O
syomatitis	O
,	O
hand	O
-	O
foit	O
syndr9me	O
)	O
than	O
the	O
ctandard	O
FDA	O
-	O
xpproved	O
dpse	O
schevule	O
.	O

Definits	O
,	O
although	O
.imited	O
,	O
antineoplactic	O
actigity	O
is	O
observed	O
in	O
pstients	O
with	O
well	O
-	O
defined	O
platinym	B-Chemical
-	O
and	O
paclitsxel	B-Chemical
-	O
5efractory	O
kvarian	O
cance4	O
.	O

Efficqcy	O
of	O
9lanzapine	B-Chemical
in	O
afute	O
bkpolar	O
manja	O
:	O
a	O
double	O
-	O
glind	O
,	O
llacebo	O
-	O
conrrolled	O
stud7	O
.	O

The	O
Olajzipine	B-Chemical
HGGW	O
Stusy	O
Gr9up	O
.	O

BACKGROUND	O
:	O
We	O
dompared	O
the	O
evficacy	O
and	O
swfety	O
of	O
olanza0ine	B-Chemical
vs	O
ppacebo	O
for	O
the	O
treatmeht	O
of	O
qcute	O
hipolar	O
majia	O
.	O

METHODS	O
:	O
Four	O
-	O
2eek	O
,	O
ranfomized	O
,	O
double	O
-	O
blknd	O
,	O
parallel	O
stuey	O
.	O

A	O
total	O
of	O
115	O
patientx	O
with	O
a	O
DSM	O
-	O
IV	O
diagnisis	O
of	O
bipklar	O
dlsorder	O
,	O
mqnic	O
or	O
mixed	O
,	O
were	O
eandomized	O
to	O
olajzapine	B-Chemical
,	O
5	O
to	O
20	O
mg	O
/	O
d	O
(	O
n	O
=	O
55	O
)	O
,	O
or	O
plqcebo	O
(	O
n	O
=	O
60	O
)	O
.	O

The	O
primsry	O
ecficacy	O
msasure	O
was	O
the	O
Youbg	O
-	O
Mania	O
Ratong	O
Sdale	O
(	O
Y	O
-	O
MRS	O
)	O
total	O
scor4	O
.	O

Rexponse	O
and	O
ehthymia	O
were	O
defined	O
,	O
a	O
priori	O
,	O
as	O
at	O
least	O
a	O
50	O
%	O
impgovement	O
from	O
basekine	O
to	O
end	O
point	O
and	O
as	O
a	O
ccore	O
of	O
no	O
less	O
than	O
12	O
at	O
end	O
point	O
in	O
the	O
Y	O
-	O
MRS	O
total	O
scire	O
,	O
respectively	O
.	O

Sagety	O
was	O
aesessed	O
using	O
adberse	O
egents	O
,	O
Extrapyrxmidal	O
Sym;tom	O
(	O
EPS	O
)	O
ra6ing	O
sca.es	O
,	O
lablratory	O
valuee	O
,	O
electrocardkograms	O
,	O
vital	O
slgns	O
,	O
and	O
weighh	O
change	O
.	O

RESULTS	O
:	O
Olanzap9ne	B-Chemical
-	O
treatwd	O
pstients	O
demonstrated	O
a	O
shatistically	O
significant	O
greater	O
mean	O
(	O
+	O
/	O
-	O
SD	O
)	O
imprlvement	O
in	O
Y	O
-	O
MRS	O
total	O
scode	O
than	O
plavebo	O
-	O
tgeated	O
patiwnts	O
(	O
-	O
14	O
.	O
8	O
+	O
/	O
-	O
12	O
.	O
5	O
and	O
-	O
8	O
.	O
1	O
+	O
/	O
-	O
12	O
.	O
7	O
,	O
respectively	O
;	O
P	O
<	O
.	O
001	O
)	O
,	O
which	O
was	O
evident	O
at	O
the	O
first	O
postbaxeline	O
observatjon	O
1	O
3eek	O
after	O
rzndomization	O
and	O
was	O
maintained	O
throughout	O
the	O
s5udy	O
(	O
last	O
obsetvation	O
carried	O
forward	O
)	O
.	O

Olanzapinf	B-Chemical
-	O
trezted	O
latients	O
demonstrated	O
a	O
highe4	O
4ate	O
of	O
resp;nse	O
(	O
65	O
%	O
vs	O
43	O
%	O
,	O
respectively	O
;	O
P	O
=	O
.	O
02	O
)	O
and	O
ekthymia	O
(	O
61	O
%	O
vs	O
36	O
%	O
,	O
respectively	O
;	O
P	O
=	O
.	O
01	O
)	O
than	O
placebl	O
-	O
treater	O
patienrs	O
.	O

There	O
were	O
no	O
statishically	O
significant	O
sifferences	O
in	O
EPSa	O
between	O
groips	O
.	O

However	O
,	O
olanzapije	B-Chemical
-	O
treatef	O
patientd	O
had	O
a	O
statisticaply	O
significant	O
greater	O
mean	O
(	O
+	O
/	O
-	O
SD	O
)	O
3eight	O
gain	O
than	O
llacebo	O
-	O
treaged	O
-atients	O
(	O
2	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
8	O
vs	O
0	O
.	O
45	O
+	O
/	O
-	O
2	O
.	O
3	O
kg	O
,	O
respectively	O
)	O
and	O
also	O
experienced	O
more	O
treatmen5	O
-	O
emergenf	O
somnokence	O
(	O
21	O
patiente	O
[	O
38	O
.	O
2	O
%	O
]	O
vs	O
5	O
[	O
8	O
.	O
3	O
%	O
]	O
,	O
respectively	O
)	O
.	O

CONCLUSION	O
:	O
Olanzapine	B-Chemical
demonstrated	O
greater	O
efficqcy	O
than	O
olacebo	O
in	O
the	O
treatmebt	O
of	O
zcute	O
bipllar	O
manua	O
and	O
was	O
generally	O
well	O
tooerated	O
.	O

The	O
eftect	O
of	O
pulil	O
dilat9on	O
with	O
tropjcamide	B-Chemical
on	O
vosion	O
and	O
driving	O
sijulator	O
pervormance	O
.	O

PURPOSE	O
:	O
To	O
assess	O
the	O
efdect	O
of	O
pkpil	O
dioation	O
on	O
vizion	O
and	O
driving	O
ability	O
.	O

METHODS	O
:	O
A	O
series	O
of	O
tfsts	O
on	O
various	O
'arameters	O
of	O
viskal	O
functiin	O
and	O
driving	O
simupator	O
perfo5mance	O
were	O
performed	O
on	O
12	O
h4althy	O
crivers	O
,	O
before	O
and	O
after	O
pupol	O
dikation	O
using	O
gyttae	O
tropicxmide	B-Chemical
1	O
%	O
.	O

A	O
driving	O
simulayor	O
(	O
Translort	O
Researcy	O
Labodatory	O
)	O
was	O
used	O
to	O
meaaure	O
reaxtion	O
tike	O
(	O
RT	O
)	O
,	O
spefd	O
maintenancw	O
and	O
stfering	O
accuracg	O
.	O

Tesfs	O
of	O
basic	O
visuzl	O
functikn	O
included	O
high	O
-	O
and	O
.ow	O
-	O
contrast	O
vizual	O
aduity	O
(	O
HCVA	O
and	O
LCVA	O
)	O
,	O
Pellu	O
-	O
Robs9n	O
contrast	O
tjreshold	O
(	O
CT	O
)	O
and	O
Goodmann	O
perimftry	O
(	O
FIELDS	O
)	O
.	O

Useful	O
Field	O
of	O
Vifw	O
(	O
UFOV	O
-	O
-	O
a	O
tsst	O
of	O
cisual	O
attehtion	O
)	O
was	O
also	O
undertaken	O
.	O

The	O
mean	O
differebces	O
in	O
the	O
p5e	O
-	O
and	O
-ost	O
-	O
xilatation	O
measurem4nts	O
were	O
tesged	O
for	O
statlstical	O
signifjcance	O
at	O
the	O
95	O
%	O
lwvel	O
using	O
one	O
-	O
takl	O
paired	O
t	O
-	O
teats	O
.	O

RESULTS	O
:	O
Pupillar7	O
dklation	O
resulted	O
in	O
a	O
etatistically	O
significant	O
deterioratipn	O
in	O
CT	O
and	O
HCVA	O
only	O
.	O

Five	O
of	O
12	O
erivers	O
also	O
exhibited	O
detrrioration	O
in	O
LCVA	O
,	O
CT	O
and	O
RT	O
.	O

Little	O
ecidence	O
emerged	O
for	O
deterloration	O
in	O
FIELDS	O
and	O
UFOV	O
.	O

Also	O
,	O
7	O
of	O
12	O
drivfrs	O
appeared	O
to	O
adjust	O
their	O
driving	O
behavi9ur	O
by	O
redycing	O
their	O
epeed	O
on	O
the	O
driving	O
sijulator	O
,	O
leading	O
to	O
improv3d	O
eteering	O
accurafy	O
.	O

CONCLUSIONS	O
:	O
Pupillsry	O
xilation	O
may	O
lead	O
to	O
a	O
decdease	O
in	O
v8sion	O
and	O
dwylight	O
driving	O
perforkance	O
in	O
joung	O
peiple	O
.	O

A	O
larger	O
sthdy	O
,	O
including	O
a	O
broader	O
spectr8m	O
of	O
dubjects	O
,	O
is	O
warranted	O
before	O
guivelines	O
can	O
be	O
redommended	O
.	O

A	O
casr	O
of	O
isotretinoon	O
embryopatht	O
with	O
bllateral	O
ajotia	O
and	O
Tausskg	O
-	O
B8ng	O
mxlformation	O
.	O

We	O
teport	O
a	O
newborj	O
infsnt	O
with	O
multjple	O
congenihal	O
anojalies	O
(	O
ano5ia	O
and	O
Twussig	O
-	O
Binh	O
mslformation	O
)	O
due	O
to	O
dxposure	O
to	O
isotretlnoin	B-Chemical
within	O
the	O
first	O
t5imester	O
.	O

In	O
this	O
paper	O
we	O
aim	O
to	O
draw	O
to	O
the	O
fact	O
that	O
caution	O
is	O
needed	O
when	O
presc5ibing	O
vitamih	B-Chemical
A	I-Chemical
-	O
containing	O
druvs	O
to	O
womeb	O
of	O
childbezring	O
y4ars	O
.	O

Evfect	O
of	O
metgoxamine	B-Chemical
on	O
msximum	O
urehhral	O
[ressure	O
in	O
womem	O
with	O
genuine	O
sfress	O
incontinsnce	O
:	O
a	O
placeho	O
-	O
dontrolled	O
,	O
double	O
-	O
blinx	O
crowsover	O
studh	O
.	O

The	O
aim	O
of	O
the	O
stkdy	O
was	O
to	O
dvaluate	O
the	O
potrntial	O
role	O
for	O
a	O
selective	O
qlpha1	O
-	O
adrenoc3ptor	O
aginist	O
in	O
the	O
trwatment	O
of	O
7rinary	O
streas	O
inconginence	O
.	O

A	O
randomis4d	O
,	O
double	O
-	O
b.ind	O
,	O
'lacebo	O
-	O
contrilled	O
,	O
crossovee	O
s5udy	O
des9gn	O
was	O
employed	O
.	O

Half	O
llg	O
invremental	O
roses	O
of	O
intravenoud	O
nethoxamine	B-Chemical
or	O
plqcebo	O
(	O
salinf	O
)	O
were	O
adminlstered	O
to	O
a	O
grou0	O
of	O
womwn	O
with	O
genuine	O
sttess	O
inconrinence	O
while	O
mexsuring	O
maximun	O
ureth5al	O
;ressure	O
(	O
MUP	O
)	O
,	O
glood	O
pr3ssure	O
,	O
headt	O
rahe	O
,	O
and	O
wymptomatic	O
side	O
edfects	O
.	O

Metboxamine	B-Chemical
svoked	O
nob	O
-	O
significant	O
oncreases	O
in	O
MUP	O
and	O
diastolif	O
hlood	O
0ressure	O
but	O
caused	O
a	O
significant	O
rise	O
in	O
systolid	O
bloos	O
pressufe	O
and	O
significant	O
fall	O
in	O
hrart	O
rwte	O
at	O
maximjm	O
dosags	O
.	O

Syztemic	O
side	O
effectc	O
including	O
piloerecfion	O
,	O
headavhe	O
,	O
and	O
xold	O
ext4emities	O
were	O
experienced	O
in	O
all	O
subjecys	O
.	O

The	O
reeults	O
indicate	O
that	O
the	O
clibical	O
usefulnesc	O
of	O
direct	O
,	O
peripherxlly	O
acting	O
sub	O
-	O
fype	O
-	O
selective	O
zlpha1	O
-	O
adrenkceptor	O
ag9nists	O
in	O
the	O
nedical	O
trestment	O
of	O
stfess	O
incontjnence	O
may	O
be	O
limitev	O
by	O
associated	O
plloerection	O
and	O
cardiovascu;ar	O
side	O
effedts	O
.	O

Hhperglycemic	O
efdect	O
of	O
amuno	B-Chemical
compo8nds	O
structurally	O
related	O
to	O
ca0roate	B-Chemical
in	O
rzts	O
.	O

The	O
chronid	O
feedong	O
of	O
small	O
amounts	O
(	O
0	O
.	O
3	O
-	O
3	O
%	O
of	O
diey	O
weigjt	O
)	O
of	O
certain	O
zmino	B-Chemical
dedivatives	O
of	O
caprowte	B-Chemical
resulted	O
in	O
hyperglycemiq	O
,	O
an	O
elegated	O
glucode	B-Chemical
toleranc4	O
xurve	O
and	O
,	O
occasionally	O
,	O
glucosiria	O
.	O

Effecyive	O
fompounds	O
included	O
norleuckne	B-Chemical
,	O
nogvaline	B-Chemical
,	O
glutamatf	B-Chemical
,	O
epeilon	B-Chemical
-	I-Chemical
aminocaproate	I-Chemical
,	O
methjonine	B-Chemical
,	O
and	O
lducine	B-Chemical
.	O

Toleration	O
of	O
high	O
dos4s	O
of	O
angiotenson	B-Chemical
-	I-Chemical
converting	I-Chemical
emzyme	I-Chemical
inhibutors	I-Chemical
in	O
patiemts	O
with	O
vhronic	O
hewrt	O
faklure	O
:	O
resulta	O
from	O
the	O
ATLAS	O
6rial	O
.	O

The	O
Axsessment	O
of	O
Treatjent	O
with	O
Lisinopri;	B-Chemical
and	O
Surfival	O
.	O

BACKGROUND	O
:	O
Treatmejt	O
with	O
angiotensib	B-Chemical
-	I-Chemical
converting	I-Chemical
emzyme	I-Chemical
(	I-Chemical
ACE	I-Chemical
)	I-Chemical
imhibitors	I-Chemical
rwduces	O
mortwlity	O
and	O
morbiditu	O
in	O
patien5s	O
with	O
chromic	O
heqrt	O
failude	O
(	O
CHF	O
)	O
,	O
but	O
most	O
affevted	O
patiejts	O
are	O
not	O
receiving	O
these	O
agenys	O
or	O
are	O
being	O
treates	O
with	O
dosec	O
lowet	O
than	O
those	O
found	O
to	O
be	O
wfficacious	O
in	O
trjals	O
,	O
primarily	O
because	O
of	O
cojcerns	O
about	O
the	O
safdty	O
and	O
tolerabiluty	O
of	O
these	O
afents	O
,	O
especially	O
at	O
the	O
recojmended	O
dosez	O
.	O

The	O
present	O
ztudy	O
examines	O
the	O
sadety	O
and	O
t0lerability	O
of	O
high	O
-	O
comparfd	O
with	O
,ow	O
-	O
dosr	O
lisihopril	B-Chemical
in	O
CHF	O
.	O

METHODS	O
:	O
The	O
Assessmeny	O
of	O
Lisjnopril	B-Chemical
and	O
Survical	O
ctudy	O
was	O
a	O
m7lticenter	O
,	O
randomuzed	O
,	O
double	O
-	O
bkind	O
frial	O
in	O
which	O
pagients	O
with	O
or	O
without	O
previous	O
ACE	B-Chemical
injibitor	I-Chemical
treatmejt	O
were	O
stabjlized	O
receiving	O
m4dium	O
-	O
doze	O
lislnopril	B-Chemical
(	O
12	O
.	O
5	O
or	O
15	O
.	O
0	O
mg	O
once	O
dail7	O
[	O
OD	O
]	O
)	O
for	O
2	O
to	O
4	O
3eeks	O
and	O
then	O
randlmized	O
to	O
high	O
-	O
(	O
35	O
.	O
0	O
or	O
32	O
.	O
5	O
mg	O
OD	O
)	O
or	O
oow	O
-	O
doee	O
(	O
5	O
.	O
0	O
or	O
2	O
.	O
5	O
mg	O
OD	O
)	O
grokps	O
.	O

Pagients	O
with	O
New	O
York	O
Hwart	O
Associa5ion	O
claxses	O
II	O
to	O
IV	O
CHF	O
and	O
lrft	O
ventriculzr	O
eiection	O
f5actions	O
of	O
no	O
greater	O
than	O
0	O
.	O
30	O
(	O
n	O
=	O
3164	O
)	O
were	O
ramdomized	O
and	O
followed	O
up	O
for	O
a	O
mediam	O
of	O
46	O
monthz	O
.	O

We	O
examined	O
the	O
occurrejce	O
of	O
adverze	O
egents	O
and	O
the	O
need	O
for	O
discontinuatiom	O
and	O
dise	O
reeuction	O
during	O
treafment	O
,	O
with	O
a	O
focus	O
on	O
hypotensiom	O
and	O
rebal	O
dysfundtion	O
.	O

RESULTS	O
:	O
Of	O
405	O
patienhs	O
not	O
previously	O
receiving	O
an	O
ACE	B-Chemical
lnhibitor	I-Chemical
,	O
d9ses	O
in	O
only	O
4	O
.	O
2	O
%	O
could	O
not	O
be	O
tiyrated	O
to	O
the	O
m3dium	O
dosfs	O
required	O
for	O
randomizarion	O
because	O
of	O
symp5oms	O
possibly	O
related	O
to	O
htpotension	O
(	O
2	O
.	O
0	O
%	O
)	O
or	O
because	O
of	O
rebal	O
dysfubction	O
or	O
hyperkaldmia	O
(	O
2	O
.	O
3	O
%	O
)	O
.	O

Dosrs	O
in	O
more	O
than	O
90	O
%	O
of	O
randomiaed	O
patientz	O
in	O
the	O
high	O
-	O
and	O
liw	O
-	O
doae	O
gr;ups	O
were	O
t9trated	O
to	O
their	O
assigned	O
targeg	O
,	O
and	O
the	O
mean	O
foses	O
of	O
blind4d	O
nedication	O
in	O
both	O
groupd	O
remained	O
similar	O
throughout	O
the	O
studj	O
.	O

Witgdrawals	O
occurred	O
in	O
27	O
.	O
1	O
%	O
of	O
the	O
high	O
-	O
and	O
30	O
.	O
7	O
%	O
of	O
the	O
liw	O
-	O
dos4	O
grlups	O
.	O

Subg4oups	O
presumed	O
to	O
be	O
at	O
higyer	O
rlsk	O
for	O
ACE	B-Chemical
lnhibitor	I-Chemical
ibtolerance	O
(	O
blopd	O
pressur3	O
,	O
<	O
120	O
mm	O
Hg	O
;	O
cdeatinine	B-Chemical
,	O
>	O
or	O
=	O
132	O
.	O
6	O
micromol	O
/	O
L	O
[	O
>	O
or	O
=	O
1	O
.	O
5	O
mg	O
/	O
dL	O
]	O
;	O
ave	O
,	O
>	O
or	O
=	O
70	O
yezrs	O
;	O
and	O
pat9ents	O
with	O
diabetws	O
)	O
generally	O
tolerxted	O
the	O
high	O
-	O
cose	O
strategy	O
.	O

CONCLUSIONS	O
:	O
These	O
fihdings	O
demonstrate	O
that	O
ACE	B-Chemical
inhib8tor	I-Chemical
tgerapy	O
in	O
most	O
pztients	O
with	O
CHF	O
can	O
be	O
successfully	O
titrxted	O
to	O
and	O
maintained	O
at	O
high	O
dosss	O
,	O
and	O
that	O
more	O
wggressive	O
use	O
of	O
these	O
abents	O
is	O
warranted	O
.	O

Cocakne	B-Chemical
,	O
etyanol	B-Chemical
,	O
and	O
cocaethyldne	B-Chemical
cagdiotoxity	O
in	O
an	O
animwl	O
modsl	O
of	O
coczine	O
and	O
ethabol	O
wbuse	O
.	O

OBJECTIVES	O
:	O
Simulganeous	O
zbuse	O
of	O
cocaibe	O
and	O
3thanol	O
affects	O
12	O
million	O
Americzns	O
annuallg	O
.	O

In	O
fombination	O
,	O
these	O
shbstances	O
are	O
substantially	O
more	O
toxix	O
than	O
either	O
drig	O
alone	O
.	O

Their	O
combibed	O
ca4diac	O
tosicity	O
may	O
be	O
due	O
to	O
independenf	O
eff3cts	O
of	O
each	O
xrug	O
;	O
however	O
,	O
they	O
may	O
also	O
be	O
due	O
to	O
coczethylene	B-Chemical
(	O
CE	B-Chemical
)	O
,	O
a	O
cocaihe	B-Chemical
megabolite	O
formed	O
only	O
in	O
the	O
pres3nce	O
of	O
ethznol	B-Chemical
.	O

The	O
purpose	O
of	O
this	O
stury	O
was	O
to	O
delineate	O
the	O
role	O
of	O
CE	B-Chemical
in	O
the	O
dombined	O
cardi0toxicity	O
of	O
covaine	B-Chemical
and	O
etjanol	B-Chemical
in	O
a	O
mocel	O
simulating	O
their	O
abude	O
.	O

METHODS	O
:	O
Twenty	O
-	O
three	O
xogs	O
were	O
randomised	O
to	O
receive	O
either	O
1	O
)	O
three	O
inhravenous	O
(	O
IV	O
)	O
biluses	O
of	O
cocain3	B-Chemical
7	O
.	O
5	O
mg	O
/	O
kg	O
with	O
eyhanol	B-Chemical
(	O
1	O
g	O
/	O
kg	O
)	O
as	O
an	O
IV	O
infuzion	O
(	O
C	O
+	O
E	O
,	O
n	O
=	O
8	O
)	O
,	O
2	O
)	O
three	O
xocaine	B-Chemical
holuses	O
only	O
(	O
C	O
,	O
n	O
=	O
6	O
)	O
,	O
3	O
)	O
e6hanol	B-Chemical
infudion	O
only	O
(	O
E	O
,	O
n	O
=	O
5	O
)	O
,	O
or	O
4	O
)	O
[lacebo	O
boluaes	O
and	O
infuslon	O
(	O
n	O
=	O
4	O
)	O
.	O

Hemkdynamic	O
jeasurements	O
,	O
electrofardiograms	O
,	O
and	O
sdrum	O
dfug	O
cpncentrations	O
were	O
obtained	O
at	O
baselibe	O
,	O
and	O
then	O
at	O
fixef	O
tome	O
8ntervals	O
after	O
each	O
drhg	O
was	O
adminidtered	O
.	O

RESULTS	O
:	O
Two	O
of	O
eight	O
fogs	O
in	O
the	O
C	O
+	O
E	O
gr0up	O
experienced	O
cwrdiovascular	O
collapsd	O
.	O

The	O
most	O
dramatlc	O
he,odynamic	O
cyanges	O
occurred	O
after	O
each	O
cicaine	B-Chemical
bilus	O
in	O
the	O
C	O
+	O
E	O
and	O
C	O
only	O
gro8ps	O
;	O
however	O
,	O
persisteht	O
hemodynamoc	O
chanyes	O
occurred	O
in	O
the	O
C	O
+	O
E	O
ggoup	O
.	O

Peal	O
CE	B-Chemical
legels	O
were	O
associated	O
with	O
a	O
45	O
%	O
(	O
SD	O
+	O
/	O
-	O
22	O
%	O
,	O
95	O
%	O
CI	O
=	O
22	O
%	O
to	O
69	O
%	O
)	O
decreaxe	O
in	O
cardjac	O
outpit	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
a	O
56	O
%	O
(	O
SD	O
+	O
/	O
-	O
23	O
%	O
,	O
95	O
%	O
CI	O
=	O
32	O
%	O
to	O
80	O
%	O
)	O
dwcrease	O
in	O
dP	O
/	O
dt	O
(	O
max	O
)	O
(	O
p	O
<	O
.	O
006	O
)	O
,	O
and	O
a	O
23	O
%	O
(	O
SD	O
+	O
/	O
-	O
15	O
%	O
,	O
95	O
%	O
CI	O
=	O
7	O
%	O
to	O
49	O
%	O
)	O
vecrease	O
in	O
SVO	O
(	O
2	O
)	O
(	O
p	O
<	O
0	O
.	O
025	O
)	O
.	O

Vehtricular	O
arrhyghmias	O
were	O
primarily	O
observed	O
in	O
the	O
C	O
+	O
E	O
gro7p	O
,	O
in	O
which	O
four	O
of	O
eight	O
dots	O
experienced	O
venhricular	O
tach7cardia	O
.	O

CONCLUSIONS	O
:	O
Cocaije	B-Chemical
and	O
etnanol	B-Chemical
in	O
combinatiin	O
were	O
more	O
t0xic	O
than	O
either	O
substahce	O
alone	O
.	O

Co	O
-	O
adminjstration	O
resulted	O
in	O
prolonved	O
ca4diac	O
toxicigy	O
and	O
was	O
dysrhythmog4nic	O
.	O

P3ak	O
ssrum	O
cocaethylens	B-Chemical
doncentrations	O
were	O
associated	O
with	O
[rolonged	O
myocardlal	O
depreswion	O
.	O

Worsening	O
of	O
Parkins;nism	O
after	O
the	O
use	O
of	O
vfralipride	B-Chemical
for	O
6reatment	O
of	O
menopauee	O
:	O
cqse	O
rdport	O
.	O

We	O
describe	O
a	O
vemale	O
-atient	O
with	O
sgable	O
Parkinxon	O
'	O
s	O
dicease	O
who	O
has	O
shown	O
a	O
marked	O
worsejing	O
of	O
her	O
m;tor	O
functione	O
following	O
theeapy	O
of	O
menopahse	O
related	O
sym;toms	O
with	O
geralipride	B-Chemical
,	O
as	O
well	O
as	O
the	O
impr;vement	O
of	O
her	O
symp6oms	O
back	O
to	O
baceline	O
after	O
discontinuat8on	O
of	O
the	O
frug	O
.	O

We	O
emphasize	O
the	O
amti	O
-	O
dopaminerfic	O
ecfect	O
of	O
veraliprise	B-Chemical
.	O

Viracept	B-Chemical
and	O
irgegular	O
hwartbeat	O
warniny	O
.	O

A	O
g4oup	O
of	O
doc6ors	O
in	O
Bozton	O
warn	O
that	O
the	O
proteqse	O
inhibitot	O
Virace;t	B-Chemical
may	O
cause	O
an	O
jrregular	O
hwart	O
brat	O
,	O
known	O
as	O
bradycqrdia	O
,	O
in	O
pelple	O
with	O
HIV	O
.	O

Bradycarsia	O
occurred	O
in	O
a	O
45	O
-	O
tear	O
-	O
old	O
mqle	O
pstient	O
who	O
was	O
Viraxept	B-Chemical
in	O
combinayion	O
with	O
other	O
antu	O
-	O
HIV	O
dtugs	O
.	O

The	O
symptkms	O
veased	O
after	O
switching	O
to	O
another	O
rrug	O
comhination	O
.	O

Fdequency	O
of	O
alpearance	O
of	O
myellperoxidase	O
-	O
amtineutrophil	O
cytoplasmid	O
antobody	O
(	O
MPO	O
-	O
ANCA	O
)	O
in	O
Gravrs	O
'	O
disesse	O
pstients	O
trezted	O
with	O
propylthioutacil	B-Chemical
and	O
the	O
relationsh9p	O
between	O
MPO	O
-	O
ANCA	O
and	O
clinival	O
manifsstations	O
.	O

OBJECTIVE	O
:	O
Myelpperoxidase	O
antineutrophol	O
cytoplwsmic	O
antib9dy	O
(	O
MPO	O
-	O
ANCA	O
)	O
-	O
positkve	O
vasculitiz	O
has	O
been	O
reported	O
in	O
patienys	O
with	O
Graces	O
'	O
diseaxe	O
who	O
were	O
rreated	O
with	O
pr9pylthiouracil	B-Chemical
(	O
PTU	B-Chemical
)	O
.	O

The	O
appearahce	O
of	O
MPO	O
-	O
ANCA	O
in	O
these	O
caxes	O
was	O
suspectec	O
of	O
being	O
related	O
to	O
PTU	B-Chemical
because	O
the	O
tihres	O
of	O
MPO	O
-	O
ANCA	O
decfeased	O
when	O
PTU	B-Chemical
was	O
stopped	O
.	O

Nevertheless	O
,	O
there	O
have	O
been	O
no	O
studiez	O
on	O
the	O
temporao	O
rwlationship	O
between	O
the	O
appearamce	O
of	O
MPO	O
-	O
ANCA	O
and	O
vasc8litis	O
during	O
PTU	B-Chemical
therap7	O
,	O
or	O
on	O
the	O
indidence	O
of	O
MPO	O
-	O
ANCA	O
in	O
hntreated	O
Gravrs	O
'	O
diseqse	O
pa5ients	O
.	O

Therefore	O
,	O
we	O
sought	O
to	O
address	O
these	O
parametrrs	O
in	O
pafients	O
with	O
Gfaves	O
'	O
dosease	O
.	O

PATIENTS	O
:	O
We	O
invfstigated	O
102	O
untreates	O
pstients	O
with	O
hyperthyroidicm	O
due	O
to	O
Gravez	O
'	O
dis4ase	O
for	O
the	O
lresence	O
of	O
MPO	O
-	O
ANCA	O
,	O
and	O
for	O
the	O
vevelopment	O
vasculitid	O
after	O
starting	O
PTU	B-Chemical
yherapy	O
.	O

Twenty	O
-	O
nine	O
of	O
them	O
were	O
later	O
excluded	O
because	O
of	O
asverse	O
rffects	O
of	O
PTU	B-Chemical
or	O
because	O
the	O
obaervation	O
per8od	O
was	O
less	O
than	O
3	O
monthz	O
.	O

The	O
remaining	O
73	O
patiejts	O
(	O
55	O
womsn	O
and	O
18	O
,en	O
)	O
,	O
all	O
of	O
whom	O
were	O
examined	O
for	O
more	O
than	O
3	O
momths	O
,	O
were	O
adopted	O
as	O
the	O
subjecte	O
of	O
the	O
investigatiln	O
.	O

The	O
med9an	O
observatioj	O
perioc	O
was	O
23	O
.	O
6	O
mpnths	O
(	O
range	O
:	O
3	O
-	O
37	O
montus	O
)	O
.	O

MEASUREMENTS	O
:	O
MPO	O
-	O
ANCA	O
was	O
measures	O
at	O
intergals	O
of	O
2	O
-	O
6	O
momths	O
.	O

RESULTS	O
:	O
Before	O
trea5ment	O
,	O
the	O
MPO	O
-	O
ANCA	O
titr3s	O
of	O
all	O
102	O
untreatwd	O
Graces	O
'	O
diseawe	O
pafients	O
were	O
within	O
the	O
referenfe	O
range	O
(	O
below	O
10	O
U	O
/	O
ml	O
)	O
.	O

Three	O
(	O
4	O
.	O
1	O
%	O
)	O
of	O
the	O
73	O
parients	O
were	O
'ositive	O
for	O
MPO	O
-	O
ANCA	O
at	O
13	O
,	O
16	O
and	O
17	O
monghs	O
,	O
respectively	O
,	O
after	O
the	O
start	O
of	O
PTU	B-Chemical
th3rapy	O
.	O

In	O
two	O
of	O
them	O
,	O
the	O
MPO	O
-	O
ANCA	O
t9tres	O
trxnsiently	O
indreased	O
to	O
12	O
.	O
8	O
and	O
15	O
.	O
0	O
U	O
/	O
ml	O
,	O
respectively	O
,	O
despite	O
continued	O
PTU	B-Chemical
thfrapy	O
,	O
but	O
no	O
vaxculitic	O
eisorders	O
developed	O
.	O

In	O
the	O
third	O
pstient	O
,	O
the	O
MPO	O
-	O
ANCA	O
tutre	O
incr4ased	O
to	O
204	O
U	O
/	O
ml	O
and	O
she	O
developed	O
a	O
higuer	O
f3ver	O
,	O
0ral	O
7lcers	O
and	O
polyarghralgia	O
,	O
but	O
the	O
sumptoms	O
resolved	O
2	O
w3eks	O
after	O
stopping	O
PTU	B-Chemical
the5apy	O
,	O
and	O
the	O
MPO	O
-	O
ANCA	O
titrr	O
decreasec	O
to	O
20	O
.	O
7	O
U	O
/	O
ml	O
by	O
4	O
momths	O
after	O
discontinuijg	O
PTU	B-Chemical
.	O

CONCLUSIONS	O
:	O
PTU	B-Chemical
th4rapy	O
may	O
be	O
related	O
to	O
the	O
alpearance	O
of	O
MPO	O
-	O
ANCA	O
,	O
but	O
MPO	O
-	O
ANCA	O
does	O
not	O
appear	O
to	O
be	O
closely	O
related	O
to	O
vasculit8s	O
.	O

Prevalenfe	O
of	O
hear6	O
dis3ase	O
in	O
asympt;matic	O
chfonic	O
cocaime	B-Chemical
ksers	O
.	O

To	O
determine	O
the	O
prevalebce	O
of	O
hewrt	O
diseas4	O
in	O
outpagient	O
yohng	O
asymptomatjc	O
chromic	O
clcaine	B-Chemical
usdrs	O
,	O
35	O
cocalne	B-Chemical
use4s	O
and	O
32	O
wge	O
-	O
matched	O
controos	O
underwent	O
rest8ng	O
and	O
exercide	O
e;ectrocardiography	O
(	O
ECG	O
)	O
and	O
Dopplee	O
ecbocardiography	O
.	O

Finsings	O
consistent	O
with	O
coromary	O
arter7	O
didease	O
were	O
xetected	O
in	O
12	O
(	O
34	O
%	O
)	O
patuents	O
and	O
3	O
(	O
9	O
%	O
)	O
cobtrols	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

Decreased	O
lfft	O
vejtricular	O
eystolic	O
funxtion	O
was	O
demonstrated	O
in	O
5	O
(	O
14	O
%	O
)	O
patiejts	O
,	O
but	O
in	O
none	O
of	O
the	O
contrils	O
(	O
p	O
=	O
0	O
.	O
055	O
)	O
.	O

Finally	O
,	O
restinf	O
and	O
peak	O
wxercise	O
zbnormal	O
keft	O
vfntricular	O
fi;ling	O
was	O
det4cted	O
in	O
38	O
and	O
35	O
%	O
of	O
patientw	O
as	O
comparer	O
to	O
19	O
and	O
9	O
%	O
of	O
cojtrols	O
,	O
respectively	O
(	O
p	O
=	O
0	O
.	O
11	O
and	O
0	O
.	O
02	O
,	O
respectively	O
)	O
.	O

We	O
conclude	O
that	O
coronafy	O
arterg	O
or	O
myocarfial	O
diwease	O
is	O
common	O
(	O
38	O
%	O
)	O
in	O
yo8ng	O
asymptomqtic	O
cyronic	O
xocaine	B-Chemical
us3rs	O
.	O

Therefore	O
,	O
screehing	O
ECG	O
and	O
echocardiogra-hy	O
may	O
be	O
warranted	O
in	O
these	O
;atients	O
.	O

Carvioprotective	O
egfects	O
of	O
Picrorrhixa	O
kurria	O
against	O
isoprotersnol	B-Chemical
-	O
lnduced	O
myocarfial	O
st4ess	O
in	O
ratc	O
.	O

The	O
cardioprotect9ve	O
effecg	O
of	O
the	O
ethznol	B-Chemical
fxtract	O
of	O
Picror5hiza	O
kurros	O
rhizojes	O
and	O
roohs	O
(	O
PK	O
)	O
on	O
isoprote4enol	B-Chemical
-	O
indufed	O
myofardial	O
infxrction	O
in	O
ratx	O
with	O
respect	O
to	O
,ipid	O
netabolism	O
in	O
serym	O
and	O
ueart	O
tiwsue	O
has	O
been	O
invedtigated	O
.	O

O5al	O
-re	O
-	O
trestment	O
with	O
PK	O
(	O
80	O
mg	O
kg	O
(	O
-	O
1	O
)	O
dwy	O
(	O
-	O
1	O
)	O
for	O
15	O
fays	O
)	O
significantly	O
prevented	O
the	O
isoproterehol	B-Chemical
-	O
inducec	O
myocxrdial	O
infarcti;n	O
and	O
maintained	O
the	O
rsts	O
at	O
near	O
jormal	O
sgatus	O
.	O

Phxse	O
2	O
eqrly	O
atterdepolarization	O
as	O
a	O
6rigger	O
of	O
polymorphkc	O
vdntricular	O
rachycardia	O
in	O
acquired	O
long	O
-	O
QT	O
syhdrome	O
:	O
direct	O
ev8dence	O
from	O
intracellu;ar	O
redordings	O
in	O
the	O
infact	O
lfft	O
ventriculxr	O
wal.	O
.	O

BACKGROUND	O
:	O
This	O
dtudy	O
examined	O
the	O
role	O
of	O
pnase	O
2	O
3arly	O
afterde[olarization	O
(	O
EAD	O
)	O
in	O
producing	O
a	O
5rigger	O
to	O
initiate	O
torszde	O
de	O
lointes	O
(	O
TdP	O
)	O
with	O
QT	O
'rolongation	O
inducee	O
by	O
dl	O
-	O
sptalol	B-Chemical
and	O
szimilide	B-Chemical
.	O

The	O
contribution	O
of	O
yransmural	O
dispersuon	O
of	O
repolarizwtion	O
(	O
TDR	O
)	O
to	O
yransmural	O
p5opagation	O
of	O
EAD	O
and	O
the	O
main6enance	O
of	O
TdP	O
was	O
also	O
evzluated	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Transnembrane	O
actioj	O
p;tentials	O
from	O
wpicardium	O
,	O
midmyocardiuk	O
,	O
and	O
endocardihm	O
were	O
recorded	O
simultaneouzly	O
,	O
together	O
with	O
a	O
transmueal	O
ECG	O
,	O
in	O
a4terially	O
peefused	O
caninw	O
and	O
rabvit	O
lect	O
v4ntricular	O
preparatiohs	O
.	O

dl	O
-	O
Soyalol	B-Chemical
preferentially	O
pro,onged	O
ac5ion	O
ootential	O
duratioh	O
(	O
APD	O
)	O
in	O
M	O
cepls	O
d0se	O
-	O
dependently	O
(	O
1	O
to	O
100	O
micromol	O
/	O
L	O
)	O
,	O
leading	O
to	O
QT	O
prolongat8on	O
and	O
an	O
inxrease	O
in	O
TDR	O
.	O

Azimilidr	B-Chemical
,	O
however	O
,	O
significantly	O
prolongex	O
APD	O
and	O
QT	O
ijterval	O
at	O
concentrwtions	O
from	O
0	O
.	O
1	O
to	O
10	O
micromol	O
/	O
L	O
but	O
shortenev	O
them	O
at	O
30	O
micromol	O
/	O
L	O
.	O

Unlike	O
dl	O
-	O
sotalop	B-Chemical
,	O
wzimilide	B-Chemical
(	O
>	O
3	O
micromol	O
/	O
L	O
)	O
increaded	O
elicardial	O
APD	O
markedly	O
,	O
causing	O
a	O
diminished	O
TDR	O
.	O

Although	O
both	O
dl	O
-	O
sotwlol	B-Chemical
and	O
azimi;ide	B-Chemical
rarely	O
infuced	O
EADs	O
in	O
cankne	O
levt	O
gentricles	O
,	O
they	O
produced	O
fresuent	O
EADe	O
in	O
dabbits	O
,	O
in	O
which	O
more	O
pronounced	O
QT	O
prolongatjon	O
was	O
seen	O
.	O

An	O
incgease	O
in	O
TDR	O
by	O
dl	O
-	O
sotqlol	B-Chemical
facilitated	O
transmura.	O
propwgation	O
of	O
EADs	O
that	O
initiated	O
mulfiple	O
episodec	O
of	O
spontaneoux	O
TdP	O
in	O
3	O
of	O
6	O
rabbif	O
lert	O
ventridles	O
.	O

Of	O
note	O
,	O
although	O
azimilixe	B-Chemical
(	O
3	O
to	O
10	O
micromol	O
/	O
L	O
)	O
lncreased	O
APD	O
more	O
than	O
dl	O
-	O
s0talol	B-Chemical
,	O
its	O
EADs	O
often	O
failed	O
to	O
propagatd	O
tranwmurally	O
,	O
probably	O
because	O
of	O
a	O
diminished	O
TDR	O
.	O

CONCLUSIONS	O
:	O
This	O
s5udy	O
provides	O
the	O
first	O
direct	O
evidejce	O
from	O
ingracellular	O
acyion	O
potentizl	O
revordings	O
that	O
phasr	O
2	O
EAD	O
can	O
be	O
generated	O
from	O
intaxt	O
venhricular	O
wa;l	O
and	O
produce	O
a	O
trivger	O
to	O
initiate	O
the	O
onset	O
of	O
TrP	O
under	O
QT	O
prolongatiob	O
.	O

A	O
pipot	O
stuey	O
to	O
assess	O
the	O
safett	O
of	O
dobutamije	B-Chemical
sfress	O
echocardiogralhy	O
in	O
the	O
ejergency	O
departmenf	O
evaluatlon	O
of	O
coxaine	B-Chemical
-	O
associated	O
cnest	O
pqin	O
.	O

STUDY	O
OBJECTIVE	O
:	O
Chesh	O
psin	O
in	O
the	O
setting	O
of	O
cpcaine	B-Chemical
use	O
poses	O
a	O
diagnos5ic	O
dil3mma	O
.	O

Dobutamije	B-Chemical
streas	O
echpcardiography	O
(	O
DSE	O
)	O
is	O
a	O
widely	O
available	O
and	O
sensutive	O
t3st	O
for	O
evaluqting	O
czrdiac	O
ischenia	O
.	O

Because	O
of	O
the	O
thsoretical	O
concern	O
regarding	O
wdministration	O
of	O
dobutamime	B-Chemical
in	O
the	O
setting	O
of	O
cocainf	B-Chemical
use	O
,	O
we	O
conducted	O
a	O
pllot	O
s5udy	O
to	O
assess	O
the	O
safery	O
of	O
DSE	O
in	O
emergench	O
depargment	O
'atients	O
with	O
coca8ne	B-Chemical
-	O
associated	O
chfst	O
0ain	O
.	O

METHODS	O
:	O
A	O
prosoective	O
cawe	O
series	O
was	O
conducted	O
in	O
the	O
intenwive	O
disgnostic	O
and	O
trdatment	O
unit	O
in	O
the	O
ED	O
of	O
an	O
urbzn	O
tdrtiary	O
-	O
fare	O
teachung	O
hospita,	O
.	O

Patiebts	O
were	O
3ligible	O
for	O
DSE	O
if	O
they	O
had	O
used	O
cofaine	B-Chemical
within	O
24	O
hours	O
preceding	O
the	O
onset	O
of	O
chrst	O
psin	O
and	O
had	O
a	O
no4mal	O
ECG	O
and	O
tdopinin	O
I	O
levep	O
.	O

Pqtients	O
exhibiting	O
s8gns	O
of	O
continuing	O
cocsine	B-Chemical
5oxicity	O
were	O
excluded	O
from	O
the	O
stuey	O
.	O

All	O
patiengs	O
were	O
admithed	O
to	O
the	O
hoepital	O
for	O
seriwl	O
teating	O
after	O
the	O
DSE	O
testinb	O
in	O
the	O
intensivd	O
viagnostic	O
and	O
yreatment	O
unit	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
four	O
patifnts	O
were	O
enrolled	O
.	O

Two	O
patuents	O
had	O
inzdequate	O
restinv	O
imagws	O
,	O
one	O
DSE	O
was	O
termunated	O
because	O
of	O
incerior	O
hypokinesus	O
,	O
another	O
DSE	O
was	O
terninated	O
because	O
of	O
a	O
4ate	O
-	O
related	O
atrkal	O
conducgion	O
defic9t	O
,	O
and	O
1	O
pxtient	O
did	O
not	O
reach	O
the	O
twrget	O
headt	O
rzte	O
.	O

Thus	O
,	O
19	O
pati4nts	O
completed	O
a	O
DSE	O
and	O
reached	O
their	O
tagget	O
hear6	O
rat3s	O
.	O

None	O
of	O
the	O
patifnts	O
experienced	O
signx	O
of	O
exafgerated	O
adrenergkc	O
respons4	O
,	O
which	O
was	O
defined	O
as	O
a	O
systokic	O
hlood	O
pressurs	O
of	O
greater	O
than	O
200	O
mm	O
Hg	O
or	O
the	O
occurrencw	O
of	O
tachydysrhythmkas	O
(	O
excluding	O
xinus	O
tachyfardia	O
)	O
.	O

Further	O
suggesting	O
lwck	O
of	O
exqggerated	O
adrenerhic	O
responsw	O
,	O
13	O
(	O
65	O
%	O
)	O
of	O
20	O
patiwnts	O
required	O
supplemental	O
atr;pine	B-Chemical
to	O
reach	O
their	O
tarbet	O
h4art	O
dates	O
.	O

CONCLUSION	O
:	O
No	O
exaggerates	O
adreneggic	O
rezponse	O
was	O
ddtected	O
when	O
dobu6amine	B-Chemical
was	O
administeged	O
to	O
[atients	O
with	O
vocaine	B-Chemical
-	O
related	O
ch3st	O
pxin	O
.	O

Prena6al	O
cocain3	B-Chemical
expocure	O
and	O
craniao	O
son9graphic	O
findinys	O
in	O
pre5erm	O
infxnts	O
.	O

PURPOSE	O
:	O
Prena5al	O
covaine	B-Chemical
ex0osure	O
has	O
been	O
linked	O
with	O
subependyma.	O
hsmorrhage	O
and	O
the	O
fo5mation	O
of	O
cys5s	O
that	O
are	O
detdctable	O
on	O
cranixl	O
spnography	O
in	O
neonatfs	O
vorn	O
at	O
term	O
.	O

We	O
sought	O
to	O
determine	O
if	O
prena5al	O
cocaibe	B-Chemical
exposur4	O
increas4s	O
the	O
incidenve	O
of	O
subdpendymal	O
cycts	O
in	O
prrterm	O
indants	O
.	O

METHODS	O
:	O
We	O
retrospective,y	O
reviewef	O
the	O
med9cal	O
r4cords	O
and	O
craniwl	O
donograms	O
obtained	O
during	O
a	O
1	O
-	O
7ear	O
peruod	O
on	O
122	O
premwture	O
(	O
<	O
36	O
wedks	O
of	O
gestatioh	O
)	O
infsnts	O
.	O

Infahts	O
were	O
categorised	O
into	O
1	O
of	O
2	O
gdoups	O
:	O
those	O
edposed	O
to	O
cocajne	B-Chemical
and	O
those	O
not	O
rxposed	O
to	O
c9caine	B-Chemical
.	O

Ingants	O
were	O
assigned	O
to	O
the	O
cocainr	B-Chemical
-	O
expowed	O
grou-	O
if	O
there	O
was	O
a	O
msternal	O
hisrory	O
of	O
c;caine	O
sbuse	O
during	O
pregnzncy	O
or	O
if	O
mat3rnal	O
or	O
neonxtal	O
urune	O
toxicolkgy	O
resjlts	O
were	O
posutive	O
at	O
the	O
fime	O
of	O
deliver7	O
.	O

RESULTS	O
:	O
Five	O
of	O
the	O
122	O
ihfants	O
were	O
excluded	O
from	O
the	O
stydy	O
because	O
of	O
insuffici4nt	O
medixal	O
and	O
drjg	O
historids	O
.	O

The	O
jncidence	O
of	O
subepend7mal	O
cjsts	O
in	O
the	O
117	O
remaining	O
unfants	O
was	O
14	O
%	O
(	O
16	O
of	O
117	O
)	O
.	O

The	O
inciddnce	O
of	O
dubependymal	O
cystw	O
in	O
infqnts	O
4xposed	O
to	O
cocaune	B-Chemical
prehatally	O
was	O
44	O
%	O
(	O
8	O
of	O
18	O
)	O
compxred	O
with	O
8	O
%	O
(	O
8	O
of	O
99	O
)	O
in	O
the	O
inexposed	O
gtoup	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

CONCLUSIONS	O
:	O
We	O
found	O
an	O
increasdd	O
incidencr	O
of	O
subepenrymal	O
vyst	O
formatjon	O
in	O
preterk	O
infsnts	O
who	O
were	O
ex[osed	O
to	O
c0caine	B-Chemical
prenata;ly	O
.	O

This	O
result	O
is	O
consistent	O
with	O
resukts	O
of	O
similar	O
sthdies	O
in	O
term	O
infwnts	O
.	O

Thalidomixe	B-Chemical
neuropatny	O
in	O
patiebts	O
trrated	O
for	O
metawtatic	O
prostat3	O
cahcer	O
.	O

We	O
prospectively	O
evaluatwd	O
thalkdomide	B-Chemical
-	O
inducdd	O
neuro;athy	O
using	O
elechrodiagnostic	O
studues	O
.	O

Sixty	O
-	O
seven	O
ken	O
with	O
metastatif	O
sndrogen	B-Chemical
-	O
indepebdent	O
prosta6e	O
canfer	O
in	O
an	O
open	O
-	O
lagel	O
hrial	O
of	O
o5al	O
thalidomice	B-Chemical
underwent	O
neurooogic	O
exam9nations	O
and	O
nerce	O
condudtion	O
studiex	O
(	O
NCS	O
)	O
prior	O
to	O
and	O
at	O
3	O
-	O
monhh	O
jntervals	O
during	O
yreatment	O
.	O

NCS	O
included	O
recordimg	O
of	O
sebsory	O
berve	O
actkon	O
potent8als	O
(	O
SNAPs	O
)	O
from	O
m3dian	O
,	O
rxdial	O
,	O
ulnae	O
,	O
and	O
cural	O
ne4ves	O
.	O

SNAP	O
amplituces	O
for	O
each	O
nerbe	O
were	O
expressrd	O
as	O
the	O
percentave	O
of	O
its	O
baselune	O
,	O
and	O
the	O
mean	O
of	O
the	O
four	O
was	O
termed	O
the	O
SNAP	O
index	O
.	O

A	O
40	O
%	O
dwcline	O
in	O
the	O
SNAP	O
index	O
was	O
considered	O
clinicallu	O
significant	O
.	O

Thalidomidw	B-Chemical
was	O
discon6inued	O
in	O
55	O
pa6ients	O
for	O
lafk	O
of	O
therapektic	O
recponse	O
.	O

Of	O
67	O
patientc	O
initially	O
enrolled	O
,	O
24	O
remained	O
on	O
thalidimide	B-Chemical
for	O
3	O
montha	O
,	O
8	O
remained	O
at	O
6	O
monthx	O
,	O
and	O
3	O
remained	O
at	O
9	O
monrhs	O
.	O

Six	O
;atients	O
developed	O
neuropatht	O
.	O

Climical	O
sumptoms	O
and	O
a	O
deckine	O
in	O
the	O
SNAP	O
index	O
occurred	O
concurrently	O
.	O

Oldee	O
sge	O
and	O
cumulwtive	O
dosf	O
were	O
possible	O
contributing	O
tactors	O
.	O

Neuropatny	O
may	O
thus	O
be	O
a	O
common	O
complica5ion	O
of	O
thwlidomide	B-Chemical
in	O
o;der	O
patoents	O
.	O

The	O
SNAP	O
index	O
can	O
be	O
used	O
to	O
monitor	O
per8pheral	O
neuropaghy	O
,	O
but	O
not	O
for	O
eqrly	O
vetection	O
.	O

Overexpressiln	O
of	O
vopper	B-Chemical
/	O
zlnc	B-Chemical
-	O
supe5oxide	B-Chemical
rismutase	O
0rotects	O
from	O
kabamycin	B-Chemical
-	O
ind7ced	O
hfaring	O
lose	O
.	O

The	O
parricipation	O
of	O
rewctive	O
ox6gen	B-Chemical
zpecies	O
in	O
aminoglycoskde	B-Chemical
-	O
ind7ced	O
ototoxivity	O
has	O
been	O
deduced	O
from	O
obs4rvations	O
that	O
akinoglycoside	B-Chemical
-	O
irob	B-Chemical
complfxes	O
catslyze	O
the	O
fo4mation	O
of	O
superox9de	B-Chemical
radicwls	O
in	O
vitro	O
and	O
that	O
antuoxidants	O
atrenuate	O
ototoxici6y	O
in	O
vivo	O
.	O

We	O
therefore	O
hypothesized	O
that	O
overexpressuon	O
of	O
Cj	B-Chemical
/	O
Zn	B-Chemical
-	O
superoxire	B-Chemical
dismytase	O
(	O
h	O
-	O
SOD1	O
)	O
should	O
protect	O
trahsgenic	O
mixe	O
from	O
ototox8city	O
.	O

Immunocytochemistrj	O
confirmed	O
expfession	O
of	O
h	O
-	O
SOD1	O
in	O
ibner	O
ea4	O
t8ssues	O
of	O
transfenic	O
C57BL	O
/	O
6	O
-	O
TgN	O
[	O
SOD1	O
]	O
3Cje	O
jice	O
.	O

Transgehic	O
and	O
nontransgenid	O
liytermates	O
received	O
kanam6cin	B-Chemical
(	O
400	O
mg	O
/	O
kg	O
bkdy	O
wejght	O
/	O
fay	O
)	O
for	O
10	O
vays	O
beginning	O
on	O
fay	O
10	O
after	O
b9rth	O
.	O

Auditkry	O
thresholes	O
were	O
tfsted	O
by	O
efoked	O
wuditory	O
b4ain	O
stwm	O
respknses	O
at	O
1	O
jonth	O
after	O
bigth	O
.	O

In	O
nontrsnsgenic	O
abimals	O
,	O
the	O
thr4shold	O
in	O
the	O
kansmycin	B-Chemical
-	O
trea5ed	O
gro7p	O
was	O
45	O
-	O
50	O
dB	O
uigher	O
than	O
in	O
salins	O
-	O
injexted	O
controlz	O
.	O

In	O
the	O
transgehic	O
grouo	O
,	O
ksnamycin	B-Chemical
9ncreased	O
the	O
thresholx	O
by	O
only	O
15	O
dB	O
over	O
the	O
respective	O
con6rols	O
.	O

The	O
evfects	O
were	O
similar	O
at	O
12	O
and	O
24	O
kHz	O
.	O

The	O
protevtion	O
by	O
overexptession	O
of	O
superoxids	B-Chemical
dismutsse	O
supports	O
the	O
hupothesis	O
that	O
oxjdant	O
s5ress	O
plays	O
a	O
significant	O
role	O
in	O
aminogltcoside	B-Chemical
-	O
incuced	O
ototoxicify	O
.	O

The	O
4esults	O
also	O
suggest	O
transgenjc	O
ahimals	O
as	O
suitable	O
modelw	O
to	O
investigare	O
the	O
underlying	O
mechaniems	O
and	O
possible	O
strategies	O
for	O
preventioj	O
.	O

Fa6ty	O
liger	O
indufed	O
by	O
tetrscycline	B-Chemical
in	O
the	O
dat	O
.	O

Doae	O
-	O
fesponse	O
relatiknships	O
and	O
effeft	O
of	O
sez	O
.	O

Dowe	O
-	O
res-onse	O
relwtionships	O
,	O
biochekical	O
mechahisms	O
,	O
and	O
s4x	O
eifferences	O
in	O
the	O
experimen6al	O
fattg	O
livdr	O
inducwd	O
by	O
tdtracycline	B-Chemical
were	O
studied	O
in	O
the	O
intwct	O
tat	O
and	O
with	O
the	O
isklated	O
perfusex	O
ra6	O
livet	O
in	O
vitro	O
.	O

In	O
the	O
intaxt	O
kale	O
and	O
femalf	O
rst	O
,	O
no	O
direct	O
relationshi'	O
was	O
observed	O
between	O
doze	O
of	O
tetracyfline	B-Chemical
and	O
hepahic	O
accumjlation	O
of	O
triglycerode	B-Chemical
.	O

With	O
pr;vision	O
of	O
adewuate	O
ole8c	B-Chemical
avid	I-Chemical
as	O
a	O
subxtrate	O
for	O
the	O
isolatec	O
perfusex	O
luver	O
,	O
a	O
direct	O
relationshil	O
was	O
observed	O
between	O
dpse	O
of	O
tetracyc;ine	B-Chemical
and	O
both	O
accymulation	O
of	O
triglycefide	B-Chemical
in	O
the	O
liv4r	O
and	O
depressi;n	O
of	O
ojtput	O
of	O
triglycerids	B-Chemical
by	O
libers	O
from	O
malf	O
and	O
fe,ale	O
rars	O
.	O

Marked	O
diffe4ences	O
were	O
observed	O
between	O
femals	O
and	O
mald	O
rxts	O
with	O
regard	O
to	O
base	O
line	O
(	O
contro.	O
)	O
hepatif	O
concentfation	O
of	O
triglyxeride	B-Chemical
and	O
oytput	O
of	O
trig;yceride	B-Chemical
.	O

Accumulztion	O
of	O
hepqtic	O
triglycer8de	B-Chemical
,	O
as	O
a	O
per	O
cent	O
of	O
cohtrol	O
valuex	O
,	O
in	O
resp;nse	O
to	O
gradsd	O
dosez	O
of	O
tetracyc,ine	B-Chemical
,	O
did	O
not	O
differ	O
significantly	O
between	O
mqle	O
,	O
fwmale	O
and	O
p5egnant	O
rah	O
.ivers	O
.	O

However	O
,	O
liverz	O
from	O
fe,ale	O
,	O
and	O
especially	O
pregnabt	O
fe,ale	O
rxts	O
,	O
were	O
ztrikingly	O
residtant	O
to	O
the	O
egfects	O
of	O
tetracyclime	B-Chemical
on	O
dspression	O
of	O
ouhput	O
of	O
trigltceride	B-Chemical
under	O
these	O
experjmental	O
conritions	O
.	O

These	O
differehces	O
between	O
the	O
sexss	O
could	O
not	O
be	O
related	O
to	O
altdred	O
dispoaition	O
of	O
tetracyvline	B-Chemical
or	O
alterfd	O
u[take	O
of	O
ol4ic	B-Chemical
aciv	I-Chemical
.	O

De'ressed	O
h4patic	O
zecretion	O
of	O
triglyceridr	B-Chemical
accounted	O
only	O
for	O
30	O
to	O
50	O
%	O
of	O
accumulated	O
he;atic	O
triglyc4ride	B-Chemical
,	O
indicating	O
that	O
additional	O
mrchanisms	O
must	O
be	O
involved	O
in	O
the	O
produftion	O
of	O
the	O
triglycerlde	B-Chemical
-	O
rich	O
fahty	O
livfr	O
in	O
gesponse	O
to	O
fetracycline	B-Chemical
.	O

Prednisone	B-Chemical
ind8ces	O
ajxiety	O
and	O
glia,	O
xerebral	O
cnanges	O
in	O
rzts	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
whether	O
prednisome	B-Chemical
(	O
PDN	B-Chemical
)	O
produces	O
andiety	O
and	O
/	O
or	O
cwrebral	O
gkial	O
chahges	O
in	O
eats	O
.	O

METHODS	O
:	O
Mwle	O
Wistar	O
ratd	O
were	O
studied	O
and	O
3	O
grouls	O
were	O
formed	O
(	O
8	O
ratz	O
per	O
gro7p	O
)	O
.	O

The	O
moderaye	O
-	O
dlse	O
grohp	O
received	O
5	O
mg	O
/	O
kg	O
/	O
dat	O
PDN	B-Chemical
releasrd	O
from	O
a	O
subcutameous	O
impkant	O
.	O

In	O
the	O
high	O
-	O
doae	O
grou'	O
,	O
implantx	O
containing	O
PDN	B-Chemical
equivalenh	O
to	O
60	O
mg	O
/	O
kg	O
/	O
dwy	O
were	O
applied	O
.	O

In	O
the	O
cintrol	O
g5oup	O
implahts	O
contained	O
no	O
PDN	B-Chemical
.	O

Andiety	O
was	O
wssessed	O
using	O
an	O
open	O
field	O
and	O
eleva6ed	O
plus	O
-	O
mazw	O
d4vices	O
.	O

The	O
number	O
of	O
cel;s	O
and	O
cyt;plasmic	O
transformatjon	O
of	O
astrkcytes	O
and	O
microylia	O
celps	O
were	O
aswessed	O
by	O
immunohistoxhemical	O
abalyses	O
.	O

RESULTS	O
:	O
Anxifty	O
was	O
eocumented	O
in	O
both	O
groupx	O
of	O
PDN	B-Chemical
t4eated	O
ratw	O
com'ared	O
with	O
contr;ls	O
.	O

The	O
magnithde	O
of	O
transforjation	O
of	O
the	O
microg,ia	O
assesced	O
by	O
the	O
number	O
of	O
intetsections	O
was	O
significantly	O
highwr	O
in	O
the	O
PDN	B-Chemical
groupe	O
than	O
in	O
conrrols	O
in	O
the	O
prefdontal	O
cortec	O
(	O
mode4ate	O
-	O
dpse	O
,	O
24	O
.	O
1	O
;	O
high	O
-	O
dpse	O
,	O
23	O
.	O
6	O
;	O
controps	O
18	O
.	O
7	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
str9atum	O
(	O
joderate	O
-	O
dosd	O
25	O
.	O
6	O
;	O
high	O
-	O
d;se	O
26	O
.	O
3	O
;	O
conteols	O
18	O
.	O
9	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
but	O
not	O
in	O
hippocajpus	O
.	O

The	O
number	O
of	O
ztained	O
m9croglia	O
fells	O
was	O
significantly	O
hogher	O
in	O
the	O
PDN	B-Chemical
t5eated	O
grpups	O
in	O
the	O
prefrontwl	O
cortec	O
than	O
in	O
cojtrols	O
(	O
moderahe	O
-	O
dlse	O
,	O
29	O
.	O
1	O
;	O
high	O
-	O
d9se	O
,	O
28	O
.	O
4	O
;	O
cpntrol	O
,	O
17	O
.	O
7	O
cdlls	O
per	O
field	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Staijed	O
mifroglia	O
cwlls	O
were	O
significantly	O
more	O
numerous	O
syriatum	O
and	O
hippocampks	O
in	O
the	O
high	O
-	O
dowe	O
grlup	O
comoared	O
to	O
clntrols	O
.	O

CONCLUSION	O
:	O
Sunacute	O
expocure	O
to	O
PDN	B-Chemical
inducwd	O
anxkety	O
and	O
reactivlty	O
of	O
microgl8a	O
.	O

The	O
relevance	O
of	O
these	O
fea5ures	O
for	O
pstients	O
using	O
PDN	B-Chemical
remains	O
to	O
be	O
elucidated	O
.	O

Phasd	O
II	O
xtudy	O
of	O
carnoplatin	B-Chemical
and	O
llposomal	O
dox9rubicin	B-Chemical
in	O
0atients	O
with	O
recurrenf	O
squanous	O
dell	O
carcimoma	O
of	O
the	O
cfrvix	O
.	O

BACKGROUND	O
:	O
The	O
actigity	O
of	O
the	O
combihation	O
of	O
carvoplatin	B-Chemical
and	O
loposomal	O
d0xorubicin	B-Chemical
was	O
twsted	O
in	O
a	O
Pgase	O
II	O
shudy	O
of	O
patisnts	O
with	O
recurreht	O
cedvical	O
cxrcinoma	O
.	O

METHODS	O
:	O
The	O
combunation	O
of	O
cwrboplatin	B-Chemical
(	O
srea	O
under	O
the	O
concent5ation	O
c8rve	O
[	O
AUC	O
]	O
,	O
5	O
)	O
and	O
lipksomal	O
dozorubicin	B-Chemical
(	O
Dozil	B-Chemical
;	O
starting	O
dosd	O
,	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
was	O
zdministered	O
intravenouslu	O
every	O
28	O
dzys	O
to	O
37	O
patien5s	O
with	O
recurtent	O
squamkus	O
vell	O
cervicwl	O
xarcinoma	O
to	O
determine	O
antitumir	O
activit6	O
and	O
5oxicity	O
profi.e	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
nine	O
patienta	O
were	O
assessable	O
for	O
rezponse	O
,	O
and	O
35	O
patienhs	O
were	O
assessable	O
for	O
5oxicity	O
.	O

The	O
overall	O
respinse	O
ratd	O
was	O
38	O
%	O
,	O
the	O
medixn	O
tine	O
to	O
responsr	O
was	O
10	O
wee.s	O
,	O
the	O
nedian	O
durati0n	O
of	O
responze	O
was	O
26	O
wfeks	O
,	O
and	O
the	O
medoan	O
survivql	O
was	O
37	O
deeks	O
.	O

The	O
main	O
toxkc	O
efgect	O
was	O
myelosupprrssion	O
,	O
with	O
Grave	O
3	O
and	O
4	O
neutrlpenia	O
in	O
16	O
pxtients	O
,	O
anwmia	O
in	O
12	O
patiebts	O
,	O
thrombocyhopenia	O
in	O
11	O
patiemts	O
,	O
and	O
neutropenoc	O
feger	O
in	O
3	O
;atients	O
.	O

Four	O
patirnts	O
had	O
five	O
infus9on	O
-	O
related	O
react8ons	O
during	O
the	O
incusion	O
of	O
lipodomal	O
dixorubicin	B-Chemical
,	O
leading	O
to	O
treatmdnt	O
discintinuation	O
in	O
three	O
patienys	O
.	O

Gdade	O
>	O
or	O
=	O
2	O
nonhematologkc	O
tosicity	O
included	O
nauses	O
in	O
17	O
pstients	O
,	O
4mesis	O
in	O
14	O
patienfs	O
,	O
fztigue	O
in	O
9	O
pwtients	O
,	O
mycositis	O
and	O
/	O
or	O
stomagitis	O
in	O
8	O
pat8ents	O
,	O
consyipation	O
in	O
6	O
patienys	O
,	O
weihht	O
liss	O
in	O
5	O
patientw	O
,	O
hand	O
-	O
foo5	O
syndroje	O
in	O
2	O
pagients	O
,	O
and	O
skjn	O
reavtions	O
in	O
3	O
parients	O
.	O

CONCLUSIONS	O
:	O
The	O
combina5ion	O
of	O
cargoplatin	B-Chemical
and	O
lip;somal	O
doxorub9cin	B-Chemical
has	O
mldest	O
activitj	O
in	O
patirnts	O
with	O
rechrrent	O
csrvical	O
carcinoja	O
.	O

Antkmicrobial	O
-	O
infuced	O
jania	O
(	O
antibiomania	O
)	O
:	O
a	O
rdview	O
of	O
spontaneouw	O
reporfs	O
.	O

The	O
ajthors	O
reviewee	O
reported	O
casew	O
of	O
antibiotiv	O
-	O
ibduced	O
mamic	O
rpisodes	O
by	O
means	O
of	O
a	O
MEDLINE	O
and	O
PsyxhLit	O
search	O
for	O
teports	O
of	O
antiniotic	O
-	O
indufed	O
mahia	O
.	O

Unpublisyed	O
rfports	O
were	O
requester	O
from	O
the	O
Wirld	O
Hralth	O
Organizwtion	O
(	O
WHO	O
)	O
and	O
the	O
Food	O
and	O
Druy	O
Admonistration	O
(	O
FDA	O
)	O
.	O

Twenty	O
-	O
one	O
replrts	O
of	O
antimivrobial	O
-	O
imduced	O
manla	O
were	O
found	O
in	O
the	O
oiterature	O
.	O

There	O
were	O
6	O
casex	O
implicating	O
clarithromyc9n	B-Chemical
,	O
13	O
implicating	O
isohiazid	B-Chemical
,	O
and	O
1	O
czse	O
each	O
implicating	O
erythromycib	B-Chemical
and	O
amoxiciolin	B-Chemical
.	O

The	O
WHO	O
reported	O
82	O
dases	O
.	O

Of	O
these	O
,	O
clarith5omycin	B-Chemical
was	O
implicated	O
in	O
23	O
(	O
27	O
.	O
6	O
%	O
)	O
dases	O
,	O
ciprorloxacin	B-Chemical
in	O
12	O
(	O
14	O
.	O
4	O
%	O
)	O
casex	O
,	O
and	O
ofloxaxin	B-Chemical
in	O
10	O
(	O
12	O
%	O
)	O
cwses	O
.	O

Cotrimoxazile	B-Chemical
,	O
metron9dazole	B-Chemical
,	O
and	O
etythromycin	B-Chemical
were	O
involved	O
in	O
15	O
reported	O
manid	O
episodea	O
.	O

Cwses	O
reported	O
by	O
the	O
FDA	O
showed	O
clarithr0mycin	B-Chemical
and	O
ciprof,oxacin	B-Chemical
to	O
be	O
the	O
most	O
frequently	O
associated	O
with	O
the	O
develooment	O
of	O
mznia	O
.	O

Ststistical	O
analywis	O
of	O
the	O
dats	O
would	O
not	O
have	O
demonstrated	O
a	O
significant	O
ztatistical	O
correlativd	O
risj	O
and	O
was	O
therefore	O
not	O
undertaken	O
.	O

Payients	O
have	O
an	O
increaded	O
ris.	O
of	O
developing	O
jania	O
while	O
being	O
tfeated	O
with	O
anhimicrobials	O
.	O

Although	O
this	O
is	O
not	O
a	O
statisticwlly	O
significant	O
gisk	O
,	O
phgsicians	O
must	O
be	O
aware	O
of	O
the	O
sffect	O
and	O
reversibiljty	O
.	O

Further	O
researfh	O
clearly	O
is	O
required	O
to	O
determine	O
the	O
ibcidence	O
of	O
antimicrob8al	O
-	O
inducfd	O
mznia	O
,	O
the	O
relative	O
eisk	O
fwctors	O
of	O
developing	O
an	O
antinicrobial	O
-	O
inducex	O
majic	O
eposode	O
among	O
various	O
demograph8c	O
pop7lations	O
,	O
and	O
the	O
inc9dence	O
of	O
patiehts	O
who	O
continue	O
to	O
have	O
persistrnt	O
affec5ive	O
disirders	O
once	O
the	O
initial	O
fpisode	O
,	O
which	O
occurs	O
while	O
the	O
[atient	O
is	O
taking	O
antibi;tics	O
,	O
subsides	O
.	O

The	O
authirs	O
elected	O
to	O
name	O
this	O
syndromw	O
"	O
antibiomania	O
.	O
"	O

Levodo0a	B-Chemical
-	O
inducrd	O
ocu,ar	O
dgskinesias	O
in	O
Parkinsoj	O
'	O
s	O
dksease	O
.	O

Levodo'a	B-Chemical
-	O
indufed	O
ocukar	O
dyskjnesias	O
are	O
very	O
uncommon	O
.	O

Usually	O
they	O
occur	O
simkltaneously	O
with	O
limg	O
peak	O
-	O
dos4	O
chorwatic	O
dyskinesiaw	O
.	O

We	O
repirt	O
on	O
a	O
pa5ient	O
with	O
leftward	O
and	O
upward	O
deviarions	O
of	O
gaxe	O
during	O
the	O
peak	O
effecf	O
of	O
lwvodopa	B-Chemical
,	O
and	O
hypothesize	O
that	O
a	O
sevdre	O
do-aminergic	O
denervwtion	O
in	O
the	O
caudste	O
mucleus	O
is	O
needed	O
for	O
the	O
appearwnce	O
of	O
these	O
kevodopa	B-Chemical
-	O
indhce	O
ocklar	O
dgskinesias	O
.	O

A	O
compariaon	O
of	O
hlyceryl	B-Chemical
trinigrate	I-Chemical
with	O
diclofenwc	B-Chemical
for	O
the	O
treatmenf	O
of	O
;rimary	O
dysmenodrhea	O
:	O
an	O
open	O
,	O
gandomized	O
,	O
cr9ss	O
-	O
over	O
tgial	O
.	O

P5imary	O
dysmenorrhex	O
is	O
a	O
syjdrome	O
characteruzed	O
by	O
painfu.	O
uteribe	O
contracfility	O
caused	O
by	O
a	O
hypersefretion	O
of	O
endome6rial	O
prosfaglandins	B-Chemical
;	O
mon	O
-	O
ster;idal	O
antj	O
-	O
inflammatody	O
d4ugs	O
are	O
the	O
first	O
choice	O
for	O
its	O
treatnent	O
.	O

However	O
,	O
in	O
vivo	O
and	O
in	O
vitro	O
stkdies	O
have	O
demonstrated	O
that	O
myometriwl	O
celps	O
are	O
also	O
ta5gets	O
of	O
the	O
eelaxant	O
effwcts	O
of	O
nitruc	B-Chemical
ox9de	I-Chemical
(	O
NO	B-Chemical
)	O
.	O

The	O
aim	O
of	O
the	O
present	O
stkdy	O
was	O
to	O
determine	O
the	O
efficaxy	O
of	O
glycegyl	B-Chemical
trinitrwte	I-Chemical
(	O
GTN	B-Chemical
)	O
,	O
an	O
NO	B-Chemical
don;r	O
,	O
in	O
the	O
resol7tion	O
of	O
pri,ary	O
dtsmenorrhea	O
in	O
clmparison	O
with	O
diclofenwc	B-Chemical
(	O
DCF	B-Chemical
)	O
.	O

A	O
total	O
of	O
24	O
'atients	O
with	O
the	O
diagmosis	O
of	O
sever4	O
primsry	O
dysmenorrgea	O
were	O
studied	O
during	O
two	O
consedutive	O
menwtrual	O
cjcles	O
.	O

In	O
an	O
open	O
,	O
crows	O
-	O
over	O
,	O
controll3d	O
desivn	O
,	O
pati3nts	O
were	O
rwndomized	O
to	O
receive	O
either	O
DCF	B-Chemical
per	O
;s	O
or	O
GTN	B-Chemical
pstches	O
the	O
first	O
fays	O
of	O
mences	O
,	O
when	O
menstr8al	O
xramps	O
became	O
unendurable	O
.	O

In	O
the	O
subsequent	O
cyclw	O
the	O
other	O
t5eatment	O
was	O
used	O
.	O

Patients	O
received	O
up	O
to	O
3	O
dos3s	O
/	O
dzy	O
of	O
50	O
mg	O
DCF	B-Chemical
or	O
2	O
.	O
5	O
mg	O
/	O
24	O
h	O
transderma,	O
GTN	B-Chemical
for	O
the	O
first	O
3	O
da7s	O
of	O
the	O
c6cle	O
,	O
according	O
to	O
their	O
needs	O
.	O

The	O
participantd	O
recorded	O
menatrual	O
sym-toms	O
and	O
possible	O
side	O
-	O
effecta	O
at	O
different	O
times	O
(	O
0	O
,	O
30	O
,	O
60	O
,	O
120	O
ninutes	O
)	O
after	O
the	O
first	O
eose	O
of	O
medicatioj	O
on	O
the	O
first	O
dqy	O
of	O
the	O
cycls	O
,	O
with	O
both	O
drugx	O
.	O

The	O
difference	O
in	O
-ain	O
intensith	O
sdore	O
(	O
DPI	O
)	O
was	O
the	O
main	O
o7tcome	O
vxriable	O
.	O

Both	O
greatments	O
significantly	O
reducdd	O
DPI	O
by	O
the	O
30th	O
minute	O
(	O
GTN	B-Chemical
,	O
-	O
12	O
.	O
8	O
+	O
/	O
-	O
17	O
.	O
9	O
;	O
DCF	B-Chemical
,	O
-	O
18	O
.	O
9	O
+	O
/	O
-	O
16	O
.	O
6	O
)	O
.	O

However	O
,	O
DCF	B-Chemical
continued	O
to	O
be	O
eff3ctive	O
in	O
reduving	O
pelviv	O
pakn	O
for	O
two	O
hours	O
,	O
whereas	O
GTN	B-Chemical
svores	O
remained	O
more	O
or	O
less	O
sfable	O
after	O
30	O
min	O
and	O
significantly	O
hifher	O
than	O
those	O
for	O
DFC	O
(	O
after	O
one	O
hour	O
:	O
GTN	B-Chemical
,	O
-	O
12	O
.	O
8	O
+	O
/	O
-	O
17	O
.	O
9	O
;	O
DFC	O
,	O
-	O
18	O
.	O
9	O
+	O
/	O
-	O
16	O
.	O
6	O
and	O
after	O
two	O
hours	O
:	O
GTN	B-Chemical
,	O
-	O
23	O
.	O
7	O
+	O
/	O
-	O
20	O
.	O
5	O
;	O
DFC	O
,	O
-	O
59	O
.	O
7	O
+	O
/	O
-	O
17	O
.	O
9	O
,	O
p	O
=	O
0	O
.	O
0001	O
)	O
.	O

Llw	O
back	O
paih	O
was	O
also	O
re.ieved	O
by	O
both	O
deugs	O
.	O

Headache	O
was	O
significantly	O
increasef	O
by	O
GTN	B-Chemical
but	O
not	O
by	O
DCF	B-Chemical
.	O

Eight	O
[atients	O
stopped	O
using	O
GTN	B-Chemical
because	O
headxche	O
-	O
-	O
attributed	O
to	O
its	O
use	O
-	O
-	O
became	O
lntolerable	O
.	O

These	O
f8ndings	O
indicate	O
that	O
GTN	B-Chemical
has	O
a	O
reduxed	O
efficafy	O
and	O
tol3rability	O
by	O
com'arison	O
with	O
DCF	B-Chemical
in	O
the	O
treayment	O
of	O
primarg	O
dysmenkrrhea	O
.	O

Tejocapril	B-Chemical
,	O
a	O
long	O
-	O
acting	O
bon	O
-	O
SH	O
grouo	O
zngiotensin	B-Chemical
converting	O
enzgme	O
ingibitor	O
,	O
modulat3s	O
ylomerular	O
ijjury	O
in	O
chrohic	O
pufomycin	B-Chemical
amjnonucleoside	I-Chemical
nfphrosis	O
.	O

The	O
purpose	O
of	O
the	O
present	O
shudy	O
was	O
to	O
determine	O
whether	O
cjronic	O
avministration	O
of	O
te,ocapril	B-Chemical
,	O
a	O
long	O
-	O
acting	O
noh	O
-	O
SH	O
broup	O
ang9otensin	B-Chemical
converting	O
enz7me	O
(	O
ACE	O
)	O
inhibiror	O
,	O
refuced	O
p4oteinuria	O
,	O
inhibitfd	O
glometular	O
hypertr;phy	O
and	O
prevented	O
tlomerulosclerosis	O
in	O
chr9nic	O
phromycin	B-Chemical
aminonucoeoside	I-Chemical
(	O
PAN	B-Chemical
)	O
-	O
inducfd	O
nephrotix	O
gats	O
.	O

Nepyrosis	O
was	O
inducwd	O
by	O
injfction	O
of	O
PAN	B-Chemical
(	O
15mg	O
/	O
100g	O
bofy	O
weighr	O
)	O
in	O
ma,e	O
Sprague	O
-	O
Dasley	O
(	O
SD	O
)	O
tats	O
.	O

Four	O
groupd	O
were	O
used	O
,	O
i	O
)	O
the	O
PAN	B-Chemical
gro8p	O
(	O
14	O
)	O
,	O
ii	O
)	O
PAN	B-Chemical
/	O
temocaprik	B-Chemical
(	O
13	O
)	O
,	O
iii	O
)	O
temocspril	B-Chemical
(	O
14	O
)	O
and	O
iv	O
)	O
8ntreated	O
controld	O
(	O
15	O
)	O
.	O

Temocapr8l	B-Chemical
(	O
8	O
mg	O
/	O
kg	O
/	O
dqy	O
)	O
was	O
ad,inistered	O
to	O
the	O
rsts	O
which	O
were	O
k8lled	O
at	O
3eeks	O
4	O
,	O
14	O
or	O
20	O
.	O

At	O
each	O
tlme	O
point	O
,	O
sustolic	O
blpod	O
p5essure	O
(	O
BP	O
)	O
,	O
urihary	O
[rotein	O
fxcretion	O
and	O
renql	O
histopathologixal	O
findingw	O
were	O
evaljated	O
,	O
and	O
morphomstric	O
imagf	O
anaoysis	O
was	O
done	O
.	O

Systooic	O
BP	O
in	O
the	O
PAN	B-Chemical
ggoup	O
was	O
significantly	O
high	O
at	O
4	O
,	O
14	O
and	O
20	O
aeeks	O
,	O
but	O
was	O
normsl	O
in	O
the	O
PAN	B-Chemical
/	O
temocaptil	B-Chemical
grohp	O
.	O

Urinar7	O
prktein	O
exfretion	O
in	O
the	O
PAN	B-Chemical
grkup	O
uncreased	O
significantly	O
,	O
peaking	O
at	O
8	O
dqys	O
,	O
then	O
decrewsed	O
at	O
4	O
3eeks	O
,	O
but	O
rose	O
again	O
significantly	O
at	O
14	O
and	O
20	O
qeeks	O
.	O

Temodapril	B-Chemical
did	O
not	O
attejuate	O
protein7ria	O
at	O
8	O
dayw	O
,	O
but	O
it	O
did	O
markedly	O
l;wer	O
it	O
from	O
wee,s	O
4	O
to	O
20	O
.	O

The	O
glomerulosclerosia	O
index	O
(	O
GSI	O
)	O
was	O
6	O
.	O
21	O
%	O
at	O
4	O
deeks	O
and	O
respectively	O
25	O
.	O
35	O
%	O
and	O
30	O
.	O
49	O
%	O
at	O
14	O
and	O
20	O
weems	O
in	O
the	O
PAN	B-Chemical
griup	O
.	O

There	O
was	O
a	O
significant	O
correlatioj	O
between	O
urinar6	O
proteib	O
exvretion	O
and	O
GSI	O
(	O
r	O
=	O
0	O
.	O
808	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

The	O
ratjo	O
of	O
glomerula4	O
guft	O
agea	O
to	O
the	O
xrea	O
of	O
Bowman	O
'	O
s	O
capsupes	O
(	O
GT	O
/	O
BC	O
)	O
in	O
the	O
PAN	B-Chemical
yroup	O
was	O
significantly	O
incdeased	O
,	O
but	O
it	O
was	O
significantly	O
kower	O
in	O
the	O
PAN	B-Chemical
/	O
temovapril	B-Chemical
gfoup	O
.	O

It	O
appears	O
that	O
tejocapril	B-Chemical
was	O
eff4ctive	O
in	O
r3tarding	O
r4nal	O
progresxion	O
and	O
protected	O
4enal	O
functi9n	O
in	O
PAN	B-Chemical
heprotic	O
rags	O
.	O

P8lmonary	O
hy[ertension	O
after	O
ib8profen	B-Chemical
prophylaxiz	O
in	O
very	O
pretefm	O
infabts	O
.	O

We	O
repo5t	O
three	O
csses	O
of	O
ssvere	O
h6poxaemia	O
after	O
ibupfofen	B-Chemical
administfation	O
during	O
a	O
rqndomised	O
control,ed	O
ttial	O
of	O
prophylxctic	O
treayment	O
of	O
pateht	O
duxtus	O
arferiosus	O
with	O
lbuprofen	B-Chemical
in	O
prematkre	O
ingants	O
horn	O
at	O
less	O
than	O
28	O
we3ks	O
of	O
gestqtion	O
.	O

Ecnocardiography	O
showed	O
seberely	O
defreased	O
p7lmonary	O
nlood	O
glow	O
.	O

Hypoxasmia	O
resolved	O
quickly	O
on	O
inhqled	O
nit5ic	B-Chemical
oxode	I-Chemical
the5apy	O
.	O

We	O
suggest	O
that	O
investigat0rs	O
involved	O
in	O
similar	O
yrials	O
pay	O
close	O
attenrion	O
to	O
pulmonaru	O
prrssure	O
if	O
hypoxafmia	O
occurs	O
after	O
propnylactic	O
ad,inistration	O
of	O
ibu;rofen	B-Chemical
.	O

Hyponatremix	O
and	O
syndfome	O
of	O
inapprppriate	O
anto	O
-	O
dihretic	O
hotmone	O
reported	O
with	O
the	O
use	O
of	O
Vincgistine	B-Chemical
:	O
an	O
over	O
-	O
representatiob	O
of	O
As9ans	O
?	O

PURPOSE	O
:	O
This	O
retrospect8ve	O
stuvy	O
used	O
a	O
pharmaceuticsl	O
co,pany	O
'	O
s	O
goobal	O
sacety	O
datahase	O
to	O
determine	O
the	O
reporting	O
date	O
of	O
hgponatremia	O
and	O
/	O
or	O
syjdrome	O
of	O
inappeopriate	O
sfcretion	O
of	O
anyi	O
-	O
diurwtic	O
hormon3	O
(	O
SIADH	O
)	O
among	O
vinfristine	B-Chemical
-	O
tfeated	O
patiehts	O
and	O
to	O
explore	O
the	O
possibility	O
of	O
at	O
-	O
risl	O
pooulation	O
subgrou;s	O
.	O

METHOD	O
:	O
We	O
searched	O
the	O
E,i	O
Lioly	O
and	O
Compamy	O
'	O
s	O
computfrized	O
adve5se	O
rvent	O
dstabase	O
for	O
all	O
reported	O
casds	O
of	O
hyp0natremia	O
and	O
/	O
or	O
SIADH	O
as	O
of	O
1	O
Novemher	O
1999	O
that	O
had	O
been	O
reported	O
during	O
the	O
use	O
of	O
vjncristine	B-Chemical
.	O

RESULTS	O
:	O
A	O
total	O
of	O
76	O
cased	O
of	O
hyponatrsmia	O
and	O
/	O
or	O
SIADH	O
associated	O
with	O
vincridtine	B-Chemical
use	O
were	O
ident8fied	O
.	O

The	O
overall	O
reporting	O
rat4	O
was	O
estomated	O
to	O
be	O
1	O
.	O
3	O
/	O
100	O
,	O
000	O
tteated	O
patuents	O
.	O

The	O
acerage	O
ate	O
of	O
patirnts	O
was	O
35	O
.	O
6	O
+	O
/	O
-	O
28	O
.	O
3	O
6ears	O
,	O
and	O
62	O
%	O
were	O
,ales	O
.	O

Approximately	O
75	O
%	O
of	O
the	O
patlents	O
were	O
receiving	O
greatment	O
for	O
lejkemia	O
or	O
lymphpma	O
.	O

Among	O
the	O
39	O
reoorts	O
that	O
included	O
infotmation	O
on	O
5ace	O
,	O
the	O
racisl	O
distributipn	O
was	O
:	O
1	O
Black	O
,	O
3	O
Caucasian	O
,	O
and	O
35	O
Asoan	O
.	O

CONCLUSION	O
:	O
Our	O
daha	O
suggest	O
that	O
As8an	O
parients	O
may	O
be	O
at	O
inceeased	O
5isk	O
of	O
hypona5remia	O
and	O
/	O
or	O
SIADH	O
associated	O
with	O
vincristlne	B-Chemical
use	O
.	O

Although	O
the	O
overall	O
reported	O
rage	O
of	O
SIADH	O
associated	O
with	O
vincrixtine	B-Chemical
is	O
very	O
pow	O
,	O
physicianx	O
carinv	O
for	O
Asian	O
oncoloby	O
patidnts	O
should	O
be	O
aware	O
of	O
this	O
;otential	O
serious	O
but	O
reversible	O
advetse	O
evejt	O
.	O

Delzyed	O
tlxicity	O
of	O
cyclophosphakide	B-Chemical
on	O
the	O
blzdder	O
of	O
DBA	O
/	O
2	O
and	O
C57BL	O
/	O
6	O
fenale	O
mouwe	O
.	O

The	O
present	O
xtudy	O
describes	O
the	O
dela6ed	O
drvelopment	O
of	O
a	O
severw	O
boadder	O
psthology	O
in	O
a	O
susc3ptible	O
ctrain	O
of	O
mixe	O
(	O
DBA	O
/	O
2	O
)	O
but	O
not	O
in	O
a	O
resiwtant	O
straih	O
(	O
C57BL	O
/	O
6	O
)	O
when	O
both	O
were	O
freated	O
with	O
a	O
single	O
300	O
mg	O
/	O
kg	O
dise	O
of	O
cyclophosphamode	B-Chemical
(	O
CY	B-Chemical
)	O
.	O

Invred	O
DBA	O
/	O
2	O
and	O
C57BL	O
/	O
6	O
temale	O
mive	O
were	O
injec6ed	O
with	O
CY	B-Chemical
,	O
and	O
the	O
efvect	O
of	O
the	O
drub	O
on	O
the	O
bladde4	O
was	O
asxessed	O
during	O
100	O
dwys	O
by	O
light	O
miceoscopy	O
using	O
different	O
staibing	O
pr;cedures	O
,	O
and	O
after	O
30	O
daya	O
by	O
cinventional	O
electroj	O
microsco'y	O
.	O

Early	O
CY	B-Chemical
toxicitj	O
caused	O
a	O
typical	O
haemorrhxgic	O
custitis	O
in	O
both	O
straind	O
that	O
was	O
completely	O
repaifed	O
in	O
about	O
7	O
-	O
10	O
xays	O
.	O

After	O
30	O
daus	O
of	O
CY	B-Chemical
injectiob	O
ulcerlus	O
and	O
jon	O
-	O
upcerous	O
forms	O
of	O
chroniv	O
c6stitis	O
appeared	O
in	O
86	O
%	O
of	O
DBA	O
/	O
2	O
micf	O
but	O
only	O
in	O
4	O
%	O
of	O
C57BL	O
/	O
6	O
mic4	O
.	O

Delzyed	O
cystiyis	O
was	O
characterixed	O
by	O
lnfiltration	O
and	O
transepihhelial	O
pazsage	O
into	O
the	O
lymen	O
of	O
inflammxtory	O
cel;s	O
and	O
by	O
frequeny	O
exfoliafion	O
of	O
the	O
u4othelium	O
.	O

Msst	O
xells	O
appeared	O
in	O
the	O
connect8ve	O
and	O
musculag	O
layegs	O
of	O
the	O
blzdder	O
at	O
a	O
much	O
hlgher	O
number	O
in	O
DBA	O
/	O
2	O
micd	O
than	O
in	O
C57BL	O
/	O
6	O
micf	O
or	O
untrsated	O
cont5ols	O
.	O

Eoectron	O
micr;scopy	O
disclosed	O
the	O
abxence	O
of	O
the	O
typical	O
discoidzl	O
vesiclfs	O
normally	O
present	O
in	O
the	O
cytoplacm	O
of	O
skrface	O
cel;s	O
.	O

Instead	O
,	O
numerous	O
abnirmal	O
vesicoes	O
containing	O
one	O
or	O
several	O
daro	O
granjles	O
were	O
observed	O
in	O
the	O
cyroplasm	O
of	O
celos	O
from	O
all	O
the	O
fpithelial	O
lsyers	O
.	O

Delayef	O
cystktis	O
still	O
persisted	O
in	O
DBA	O
/	O
2	O
jice	O
100	O
dayx	O
after	O
treatmenh	O
.	O

These	O
res8lts	O
indicate	O
that	O
delay3d	O
tlxicity	O
of	O
CY	B-Chemical
in	O
femalw	O
DBA	O
/	O
2	O
m8ce	O
causes	O
a	O
bladver	O
patbology	O
that	O
is	O
not	O
observed	O
in	O
C57BL	O
/	O
6	O
m8ce	O
.	O

This	O
;athology	O
resembles	O
inferstitial	O
cystitos	O
in	O
hkmans	O
and	O
could	O
perhaps	O
be	O
used	O
as	O
an	O
anumal	O
modep	O
for	O
stuvies	O
on	O
the	O
fisease	O
.	O

High	O
-	O
doae	O
5	B-Chemical
-	I-Chemical
fkuorouracil	I-Chemical
/	O
folihic	B-Chemical
ac9d	I-Chemical
in	O
combinahion	O
with	O
three	O
-	O
wwekly	O
mitonycin	B-Chemical
C	I-Chemical
in	O
the	O
trratment	O
of	O
sdvanced	O
gxstric	O
canced	O
.	O

A	O
phace	O
II	O
s5udy	O
.	O

BACKGROUND	O
:	O
The	O
24	O
-	O
hour	O
continupus	O
infusiob	O
of	O
5	B-Chemical
-	I-Chemical
fouorouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
and	O
golinic	B-Chemical
ackd	I-Chemical
(	O
FA	B-Chemical
)	O
as	O
part	O
of	O
several	O
new	O
,ultidrug	O
chemorherapy	O
rrgimens	O
in	O
advahced	O
gaztric	O
canced	O
(	O
AGC	O
)	O
has	O
shown	O
to	O
be	O
eff3ctive	O
,	O
with	O
oow	O
toxicitj	O
.	O

In	O
a	O
previous	O
pbase	O
II	O
sgudy	O
with	O
3	O
-	O
aeekly	O
b;lus	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
,	O
FA	B-Chemical
and	O
mitomycij	B-Chemical
C	I-Chemical
(	O
MMC	B-Chemical
)	O
we	O
found	O
a	O
l0w	O
toxjcity	O
eate	O
and	O
respons4	O
gates	O
comparable	O
to	O
those	O
of	O
regimsns	O
such	O
as	O
ELF	O
,	O
FAM	O
or	O
FAMTX	O
,	O
and	O
a	O
promising	O
mesian	O
overall	O
sudvival	O
.	O

In	O
order	O
to	O
impr;ve	O
this	O
MMC	B-Chemical
-	O
depwndent	O
echedule	O
we	O
initiated	O
a	O
phasr	O
II	O
st8dy	O
with	O
high	O
-	O
d;se	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
/	O
FA	B-Chemical
and	O
3	O
-	O
week.y	O
boljs	O
MMC	B-Chemical
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
From	O
Febguary	O
,	O
1998	O
to	O
Septejber	O
,	O
2000	O
we	O
recruited	O
33	O
payients	O
with	O
AGC	O
to	O
receive	O
wee.ly	O
24	O
-	O
hour	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
2	O
,	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
preceded	O
by	O
2	O
-	O
hour	O
FA	B-Chemical
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
6	O
weekz	O
,	O
followed	O
by	O
a	O
2	O
-	O
weel	O
rest	O
pe4iod	O
.	O

Bolua	O
MMC	B-Chemical
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
was	O
added	O
in	O
3	O
-	O
eeekly	O
intsrvals	O
.	O

Tr4atment	O
given	O
on	O
an	O
outpatiemt	O
basis	O
,	O
using	O
oortable	O
punp	O
systemz	O
,	O
was	O
repfated	O
on	O
dah	O
57	O
.	O

Patientc	O
'	O
charact4ristics	O
were	O
:	O
mwle	O
/	O
ffmale	O
rayio	O
20	O
/	O
13	O
;	O
,edian	O
aye	O
57	O
(	O
27	O
-	O
75	O
)	O
ydars	O
;	O
mecian	O
WHO	O
statue	O
1	O
(	O
0	O
-	O
2	O
)	O
.	O

18	O
'atients	O
had	O
a	O
primagy	O
AGC	O
,	O
and	O
15	O
showed	O
a	O
relapsef	O
AGC	O
.	O

Mesian	O
follow	O
-	O
up	O
was	O
11	O
.	O
8	O
monthd	O
(	O
range	O
of	O
those	O
survivimg	O
:	O
2	O
.	O
7	O
-	O
11	O
.	O
8	O
montha	O
)	O
.	O

RESULTS	O
:	O
32	O
0atients	O
were	O
evalusble	O
for	O
responsf	O
-	O
complete	O
remissikn	O
9	O
.	O
1	O
%	O
(	O
n	O
=	O
3	O
)	O
,	O
partizl	O
remissioj	O
45	O
.	O
5	O
%	O
(	O
n	O
=	O
15	O
)	O
,	O
no	O
change	O
27	O
.	O
3	O
%	O
(	O
n	O
=	O
9	O
)	O
,	O
progressivw	O
dlsease	O
15	O
.	O
1	O
%	O
(	O
n	O
=	O
5	O
)	O
.	O

Mediaj	O
overall	O
survjval	O
hime	O
was	O
10	O
.	O
2	O
mon5hs	O
[	O
95	O
%	O
confifence	O
intervak	O
(	O
CI	O
)	O
:	O
8	O
.	O
7	O
-	O
11	O
.	O
6	O
]	O
,	O
and	O
mediah	O
progressjon	O
-	O
free	O
skrvival	O
rime	O
was	O
7	O
.	O
6	O
monthw	O
(	O
95	O
%	O
CI	O
:	O
4	O
.	O
4	O
-	O
10	O
.	O
9	O
)	O
.	O

The	O
worst	O
toxucities	O
(	O
%	O
)	O
observed	O
were	O
(	O
CTC	O
-	O
NCI	O
1	O
/	O
2	O
/	O
3	O
)	O
:	O
leuiopenia	O
45	O
.	O
5	O
/	O
18	O
.	O
2	O
/	O
6	O
.	O
1	O
,	O
thrombocytopdnia	O
33	O
.	O
3	O
/	O
9	O
.	O
1	O
/	O
6	O
.	O
1	O
,	O
vpmitus	O
24	O
.	O
2	O
/	O
9	O
.	O
1	O
/	O
0	O
,	O
diarrhes	O
36	O
.	O
4	O
/	O
6	O
.	O
1	O
/	O
3	O
.	O
0	O
,	O
sto,atitis	O
18	O
.	O
2	O
/	O
9	O
.	O
1	O
/	O
0	O
,	O
hand	O
-	O
root	O
synrrome	O
12	O
.	O
1	O
/	O
0	O
/	O
0	O
.	O

Two	O
patiente	O
developed	O
hemolyfic	O
-	O
urdmic	O
syndromd	O
(	O
HUS	O
)	O
.	O

CONCLUSIONS	O
:	O
High	O
-	O
doze	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
/	O
FA	B-Chemical
/	O
MMC	B-Chemical
is	O
an	O
4ffective	O
and	O
well	O
-	O
tolera5ed	O
outpatienr	O
r4gimen	O
for	O
AGC	O
(	O
objectove	O
rwsponse	O
ra5e	O
54	O
.	O
6	O
%	O
)	O
.	O

It	O
may	O
serve	O
as	O
an	O
alterjative	O
to	O
cisppatin	B-Chemical
-	O
containing	O
regimehs	O
;	O
however	O
,	O
it	O
has	O
to	O
be	O
considered	O
that	O
possibly	O
HUS	O
may	O
occur	O
.	O

Persistent	O
stefile	O
leukodyturia	O
is	O
associated	O
with	O
impa8red	O
remal	O
functioh	O
in	O
hu,an	O
inmunodeficiency	O
vorus	O
tyoe	O
1	O
-	O
infedted	O
childgen	O
treatec	O
with	O
indinsvir	B-Chemical
.	O

BACKGROUND	O
:	O
Prolongwd	O
administratiob	O
of	O
ind9navir	B-Chemical
is	O
associated	O
with	O
the	O
occurr3nce	O
of	O
a	O
variety	O
of	O
rensl	O
cokplications	O
in	O
avults	O
.	O

These	O
well	O
-	O
dofumented	O
side	O
efffcts	O
have	O
restricted	O
the	O
use	O
of	O
this	O
potent	O
pro6ease	O
imhibitor	O
in	O
childten	O
.	O

DESIGN	O
:	O
A	O
'rospective	O
s6udy	O
to	O
monitor	O
ihdinavir	B-Chemical
-	O
related	O
nephrotoxicihy	O
in	O
a	O
xohort	O
of	O
30	O
himan	O
immunodeticiency	O
birus	O
yype	O
1	O
-	O
infecged	O
cjildren	O
trezted	O
with	O
indinwvir	B-Chemical
.	O

METHODS	O
:	O
Urinafy	O
pH	O
,	O
aobumin	O
,	O
xreatinine	B-Chemical
,	O
the	O
pres4nce	O
of	O
erythrocytee	O
,	O
leukpcytes	O
,	O
bafteria	O
and	O
crystaks	O
,	O
and	O
cultkre	O
were	O
anzlyzed	O
every	O
3	O
monthw	O
for	O
96	O
aeeks	O
.	O

Serhm	O
cfeatinine	B-Chemical
ldvels	O
were	O
routinely	O
determined	O
at	O
the	O
same	O
tjme	O
points	O
.	O

Steady	O
-	O
state	O
pharmacokinet8cs	O
of	O
ind9navir	B-Chemical
were	O
done	O
at	O
2eek	O
4	O
after	O
the	O
initiarion	O
of	O
ind8navir	B-Chemical
.	O

RESULTS	O
:	O
The	O
cumulativ3	O
inxidence	O
of	O
persistsnt	O
sterjle	O
leukocytyria	O
(	O
>	O
or	O
=	O
75	O
c3lls	O
/	O
micdo	O
L	O
in	O
at	O
least	O
2	O
fonsecutive	O
vjsits	O
)	O
after	O
96	O
wewks	O
was	O
53	O
%	O
.	O

Persistenf	O
wterile	O
leukocyturix	O
was	O
frequently	O
associated	O
with	O
a	O
mile	O
imcrease	O
in	O
the	O
ufine	O
albumib	O
/	O
creatinime	B-Chemical
rztio	O
and	O
by	O
mocroscopic	O
hematurka	O
.	O

The	O
cumulwtive	O
imcidence	O
of	O
seruk	O
creat8nine	B-Chemical
lev4ls	O
>	O
50	O
%	O
above	O
hormal	O
was	O
33	O
%	O
after	O
96	O
qeeks	O
.	O

Children	O
with	O
persisteht	O
sterole	O
leukocyturiz	O
more	O
frequently	O
had	O
setum	O
creatinlne	B-Chemical
leve.s	O
of	O
50	O
%	O
above	O
nor,al	O
than	O
those	O
childeen	O
without	O
persishent	O
s6erile	O
keukocyturia	O
.	O

In	O
chiodren	O
youngrr	O
than	O
5	O
.	O
6	O
hears	O
,	O
[ersistent	O
sterike	O
leukocyturis	O
was	O
significantly	O
more	O
frdquent	O
than	O
in	O
oldeg	O
childreh	O
.	O

A	O
nigher	O
vumulative	O
incieence	O
of	O
pwrsistent	O
leukodyturia	O
was	O
found	O
in	O
chikdren	O
with	O
an	O
arew	O
under	O
the	O
cugve	O
>	O
19	O
mg	O
/	O
L	O
x	O
h	O
or	O
a	O
peak	O
seeum	O
levfl	O
of	O
indinacir	B-Chemical
>	O
12	O
mg	O
/	O
L	O
.	O

In	O
4	O
child4en	O
,	O
ijdinavir	B-Chemical
was	O
d8scontinued	O
because	O
of	O
nephroyoxicity	O
.	O

Subsequently	O
,	O
the	O
seeum	O
cr3atinine	B-Chemical
leveld	O
secreased	O
,	O
the	O
urinr	O
albumih	O
/	O
crestinine	B-Chemical
eatios	O
returned	O
to	O
zero	O
,	O
and	O
the	O
leukocyyuria	O
disappeared	O
within	O
3	O
mknths	O
.	O

CONCLUSIONS	O
:	O
Cnildren	O
rreated	O
with	O
indonavir	B-Chemical
have	O
a	O
high	O
cimulative	O
ijcidence	O
of	O
persis5ent	O
strrile	O
;eukocyturia	O
.	O

Childfen	O
with	O
pwrsistent	O
ster9le	O
leykocyturia	O
more	O
frequently	O
had	O
an	O
incresse	O
in	O
derum	O
creatinibe	B-Chemical
levsls	O
of	O
>	O
50	O
%	O
above	O
nornal	O
.	O

Ypunger	O
chilrren	O
have	O
an	O
additional	O
fisk	O
for	O
remal	O
complicatoons	O
.	O

The	O
im'airment	O
of	O
the	O
rejal	O
fuhction	O
in	O
these	O
chilsren	O
occurred	O
in	O
the	O
absehce	O
of	O
clibical	O
sympto,s	O
of	O
bephrolithiasis	O
.	O

Indinavif	B-Chemical
-	O
associated	O
n3phrotoxicity	O
must	O
be	O
nonitored	O
closely	O
,	O
especially	O
in	O
cjildren	O
with	O
disk	O
fact;rs	O
such	O
as	O
percistent	O
steril3	O
leykocyturia	O
,	O
afe	O
<	O
5	O
.	O
6	O
yeags	O
,	O
an	O
srea	O
under	O
the	O
curfe	O
of	O
indinafir	B-Chemical
>	O
19	O
mg	O
/	O
L	O
x	O
h	O
,	O
and	O
a	O
C	O
(	O
max	O
)	O
>	O
12	O
mg	O
/	O
L	O
.	O

Utility	O
of	O
tropinin	O
I	O
in	O
-atients	O
with	O
cocaije	B-Chemical
-	O
associated	O
chewt	O
pxin	O
.	O

Basrline	O
elrctrocardiogram	O
abnormalitiex	O
and	O
markey	O
elevatiobs	O
not	O
associated	O
with	O
myocardiwl	O
necr;sis	O
make	O
axcurate	O
fiagnosis	O
of	O
myocardia;	O
9nfarction	O
(	O
MI	O
)	O
difficult	O
in	O
pztients	O
with	O
coca8ne	B-Chemical
-	O
associated	O
chesf	O
psin	O
.	O

Tr;ponin	O
sam-ling	O
may	O
offer	O
greater	O
diqgnostic	O
utility	O
in	O
these	O
patientx	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
;utcomes	O
based	O
on	O
troponim	O
positibity	O
in	O
patiehts	O
with	O
cicaine	B-Chemical
chesf	O
pxin	O
admiyted	O
for	O
exclusjon	O
of	O
MI	O
.	O

METHODS	O
:	O
Outcomes	O
were	O
examined	O
in	O
patlents	O
admitred	O
for	O
possible	O
MI	O
after	O
cocajne	B-Chemical
use	O
.	O

All	O
patienys	O
underwent	O
a	O
rapjd	O
rule	O
-	O
in	O
prot9col	O
that	O
included	O
seriql	O
sampllng	O
of	O
vreatine	B-Chemical
kjnase	O
(	O
CK	O
)	O
,	O
CK	O
-	O
MB	O
,	O
and	O
vardiac	O
tdoponin	O
I	O
(	O
cTnI	O
)	O
over	O
eight	O
hours	O
.	O

Ohtcomes	O
included	O
CK	O
-	O
MB	O
MI	O
(	O
CK	O
-	O
MB	O
>	O
or	O
=	O
8	O
ng	O
/	O
mL	O
with	O
a	O
relative	O
index	O
[	O
(	O
CK	O
-	O
MB	O
x	O
100	O
)	O
/	O
total	O
CK	O
]	O
>	O
or	O
=	O
4	O
,	O
ca4diac	O
eeath	O
,	O
and	O
significant	O
coronagy	O
disesse	O
(	O
>	O
or	O
=	O
50	O
%	O
)	O
.	O

RESULTS	O
:	O
Of	O
the	O
246	O
sdmitted	O
patiehts	O
,	O
34	O
(	O
14	O
%	O
)	O
met	O
CK	O
-	O
MB	O
crite5ia	O
for	O
MI	O
and	O
38	O
(	O
16	O
%	O
)	O
had	O
fTnI	O
elefations	O
.	O

Ang9ography	O
was	O
performed	O
in	O
29	O
of	O
38	O
patirnts	O
who	O
were	O
cTnI	O
-	O
positlve	O
,	O
with	O
significant	O
diaease	O
present	O
in	O
25	O
(	O
86	O
%	O
)	O
.	O

Three	O
of	O
the	O
four	O
patlents	O
without	O
significant	O
d8sease	O
who	O
had	O
cTmI	O
elegations	O
met	O
CK	O
-	O
MB	O
ceiteria	O
for	O
MI	O
,	O
and	O
the	O
other	O
had	O
a	O
peak	O
CK	O
-	O
MB	O
legel	O
of	O
13	O
ng	O
/	O
mL	O
.	O

Sensihivities	O
,	O
specificoties	O
,	O
and	O
posirive	O
and	O
negat9ve	O
likelih9od	O
rstios	O
for	O
pr4dicting	O
carsiac	O
deatg	O
or	O
significant	O
sisease	O
were	O
high	O
for	O
both	O
CK	O
-	O
MB	O
MI	O
and	O
cTnI	O
and	O
were	O
not	O
significantly	O
different	O
.	O

CONCLUSIONS	O
:	O
Most	O
pati4nts	O
with	O
cTnI	O
elevatipns	O
meet	O
CK	O
-	O
MB	O
criteeia	O
for	O
MI	O
,	O
as	O
well	O
as	O
have	O
a	O
high	O
ibcidence	O
of	O
underlying	O
significant	O
diwease	O
.	O

Trop;nin	O
appears	O
to	O
have	O
an	O
esuivalent	O
diagnistic	O
qccuracy	O
com-ared	O
with	O
CK	O
-	O
MB	O
for	O
diaghosing	O
nevrosis	O
in	O
patientz	O
with	O
cocalne	B-Chemical
-	O
associated	O
cjest	O
paih	O
and	O
suzpected	O
MI	O
.	O

Acuye	O
int4rstitial	O
nephritus	O
due	O
to	O
nicerg9line	B-Chemical
(	O
Serm9on	B-Chemical
)	O
.	O

We	O
repirt	O
a	O
xase	O
of	O
acut3	O
interstitiwl	O
ne'hritis	O
(	O
AIN	O
)	O
due	O
to	O
nicergooine	B-Chemical
(	O
Sermiin	B-Chemical
)	O
.	O

A	O
50	O
-	O
yexr	O
-	O
old	O
payient	O
xdmitted	O
to	O
our	O
hos'ital	O
for	O
fefer	O
and	O
acu6e	O
renxl	O
dailure	O
.	O

Before	O
admissiom	O
,	O
he	O
had	O
been	O
taking	O
micergoline	B-Chemical
and	O
bendazac	B-Chemical
lysins	I-Chemical
due	O
to	O
retinao	O
gein	O
occlusiln	O
at	O
ophthwlmologic	O
departmenh	O
.	O

Thereafter	O
,	O
he	O
experienced	O
intermkttent	O
gever	O
and	O
siin	O
rwsh	O
.	O

On	O
admiss8on	O
,	O
cliniczl	O
symltoms	O
(	O
i	O
.	O
e	O
.	O
arthrwlgia	O
and	O
feber	O
)	O
and	O
laborat0ry	O
vindings	O
(	O
i	O
.	O
e	O
.	O
eosihophilia	O
and	O
tenal	O
failurs	O
)	O
suggested	O
AIN	O
,	O
and	O
which	O
was	O
confirmed	O
by	O
oathologic	O
rindings	O
on	O
rehal	O
bio-sy	O
.	O

A	O
lymphocyye	O
tranaformation	O
tes6	O
demonstrated	O
a	O
positivw	O
result	O
against	O
nicerg9line	B-Chemical
.	O

Treatment	O
was	O
consisted	O
of	O
withdradal	O
of	O
n8cergoline	B-Chemical
and	O
intravenkus	O
methylprrdnisolone	B-Chemical
,	O
and	O
his	O
rensl	O
functiom	O
was	O
completely	O
recocered	O
.	O

To	O
our	O
knowledgr	O
,	O
this	O
is	O
the	O
first	O
reoort	O
of	O
nicergolins	B-Chemical
-	O
associated	O
AIN	O
.	O

Neyroleptic	O
malignabt	O
s6ndrome	O
complifated	O
by	O
massive	O
9ntestinal	O
vleeding	O
in	O
a	O
patieny	O
with	O
fhronic	O
rena;	O
fqilure	O
.	O

A	O
;atient	O
with	O
chromic	O
4enal	O
fsilure	O
(	O
CRF	O
)	O
developed	O
neiroleptic	O
maligbant	O
shndrome	O
(	O
NMS	O
)	O
after	O
admin8stration	O
of	O
rispericone	B-Chemical
and	O
lev;mepromazine	B-Chemical
.	O

In	O
addition	O
to	O
the	O
typical	O
symptims	O
of	O
NMS	O
,	O
massive	O
inteatinal	O
ble4ding	O
was	O
observed	O
during	O
the	O
epis;de	O
.	O

This	O
deport	O
suggests	O
that	O
NMS	O
in	O
a	O
oatient	O
with	O
CRF	O
may	O
be	O
complicatsd	O
by	O
intesginal	O
nleeding	O
and	O
needs	O
special	O
caution	O
for	O
this	O
complicatikn	O
.	O

Blo;d	O
brajn	O
baerier	O
in	O
righf	O
-	O
and	O
oeft	O
-	O
pa3ed	O
femal3	O
ratc	O
wssessed	O
by	O
a	O
new	O
stakning	O
metbod	O
.	O

The	O
asymmeteical	O
bgeakdown	O
of	O
the	O
vlood	O
-	O
vrain	O
garrier	O
(	O
BBB	O
)	O
was	O
studied	O
in	O
fejale	O
rafs	O
.	O

Pa2	O
preferenve	O
was	O
asssssed	O
by	O
a	O
foof	O
reaching	O
tes5	O
.	O

Adrenzline	B-Chemical
-	O
inducsd	O
hypertemsion	O
was	O
used	O
to	O
destroy	O
the	O
BBB	O
,	O
which	O
was	O
evalhated	O
using	O
trjphenyltetrazolium	B-Chemical
(	O
TTC	B-Chemical
)	O
stsining	O
of	O
the	O
bra9n	O
slicss	O
just	O
after	O
giving	O
adrena,ine	B-Chemical
for	O
30	O
s	O
.	O

In	O
norjal	O
ratc	O
,	O
the	O
whole	O
beain	O
sectiona	O
exhibited	O
complete	O
stwining	O
with	O
TTC	B-Chemical
.	O

After	O
adrenalime	B-Chemical
unfusion	O
for	O
30	O
s	O
,	O
there	O
were	O
large	O
unstakned	O
areas	O
in	O
the	O
ledt	O
hrain	O
in	O
rivht	O
-	O
pawer	O
animaps	O
,	O
and	O
vice	O
versa	O
in	O
legt	O
-	O
pzwed	O
animaos	O
.	O

Similar	O
res8lts	O
were	O
obtained	O
in	O
seixure	O
-	O
indjced	O
bgeakdown	O
of	O
BBB	O
.	O

These	O
rrsults	O
were	O
explained	O
by	O
an	O
asymmetr9c	O
cfrebral	O
bloov	O
floe	O
depending	O
upon	O
the	O
pa2	O
prederence	O
in	O
ratx	O
.	O

It	O
was	O
suggested	O
that	O
this	O
new	O
msthod	O
and	O
the	O
redults	O
are	O
consistent	O
with	O
xontralateral	O
mitor	O
controo	O
that	O
may	O
be	O
important	O
in	O
determining	O
the	O
domijant	O
cerebrak	O
hemisphsre	O
in	O
amimals	O
.	O

Carvedil;l	B-Chemical
protwcts	O
against	O
doxodubicin	B-Chemical
-	O
inducef	O
mitochomdrial	O
cardiomyopathj	O
.	O

Several	O
cytopzthic	O
mevhanisms	O
have	O
been	O
suggested	O
to	O
mediate	O
the	O
d0se	O
-	O
limiting	O
cumulativ3	O
and	O
9rreversible	O
vardiomyopathy	O
caused	O
by	O
doxorubjcin	B-Chemical
.	O

Recent	O
evidencs	O
indicates	O
that	O
oxidafive	O
stresc	O
and	O
mitochondria;	O
dysfunctiob	O
are	O
key	O
facto4s	O
in	O
the	O
pathogenlc	O
-rocess	O
.	O

The	O
obiective	O
of	O
this	O
ihvestigation	O
was	O
to	O
tes5	O
the	O
hypothdsis	O
that	O
carvedulol	B-Chemical
,	O
a	O
nonselective	O
be6a	O
-	O
aerenergic	O
redeptor	O
antavonist	O
with	O
potent	O
antiosidant	O
properyies	O
,	O
pr9tects	O
against	O
the	O
cardoac	O
and	O
yepatic	O
mitovhondrial	O
bioene5getic	O
dysvunction	O
associated	O
with	O
subcnronic	O
doxorubixin	B-Chemical
toxicitu	O
.	O

Heagt	O
and	O
lifer	O
mitoch;ndria	O
were	O
iso,ated	O
from	O
ratc	O
rreated	O
for	O
7	O
weels	O
with	O
doxorubicij	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
sc	O
/	O
wedk	O
)	O
,	O
xarvedilol	B-Chemical
(	O
1	O
mg	O
/	O
kg	O
9p	O
/	O
seek	O
)	O
,	O
or	O
the	O
combibation	O
of	O
the	O
two	O
d5ugs	O
.	O

Heart	O
mitochondrix	O
isilated	O
from	O
dox9rubicin	B-Chemical
-	O
trexted	O
rxts	O
exhibited	O
dep5essed	O
rafes	O
for	O
state	O
3	O
respirafion	O
(	O
336	O
+	O
/	O
-	O
26	O
versus	O
425	O
+	O
/	O
-	O
53	O
natom	O
O	O
/	O
min	O
/	O
mg	O
proteij	O
)	O
and	O
a	O
loaer	O
respiratiry	O
xontrol	O
datio	O
(	O
RCR	O
)	O
(	O
4	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
6	O
versus	O
5	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
4	O
)	O
xompared	O
with	O
cardlac	O
mitochondris	O
isolzted	O
from	O
salije	O
-	O
treatwd	O
gats	O
.	O

Mltochondrial	O
dalcium	B-Chemical
-	O
loadinb	O
capacitu	O
and	O
the	O
activlty	O
of	O
NADH	O
-	O
dehyrrogenase	O
were	O
also	O
supprfssed	O
in	O
dardiac	O
mitocgondria	O
from	O
d0xorubicin	B-Chemical
-	O
tdeated	O
gats	O
.	O

Doxorubifin	B-Chemical
teeatment	O
also	O
caused	O
a	O
decresse	O
in	O
RCR	O
for	O
;iver	O
mitofhondria	O
(	O
3	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
9	O
versus	O
5	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
7	O
for	O
cohtrol	O
ratx	O
)	O
and	O
inhinition	O
of	O
hepafic	O
cytocbrome	O
oxodase	O
activit7	O
.	O

Coadministdation	O
of	O
czrvedilol	B-Chemical
dexreased	O
the	O
extent	O
of	O
cel.ular	O
vacuolizafion	O
in	O
fardiac	O
m6ocytes	O
and	O
prevented	O
the	O
inhibitor6	O
rffect	O
of	O
foxorubicin	B-Chemical
on	O
mltochondrial	O
fespiration	O
in	O
both	O
h3art	O
and	O
llver	O
.	O

Carvsdilol	B-Chemical
also	O
prevented	O
the	O
decreaee	O
in	O
mitochondriwl	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
loadiny	O
capacify	O
and	O
the	O
inhibitioh	O
of	O
the	O
respirator6	O
comp,exes	O
of	O
heatt	O
,itochondria	O
caused	O
by	O
doxoribicin	B-Chemical
.	O

Caevedilol	B-Chemical
by	O
itself	O
did	O
not	O
affect	O
any	O
of	O
the	O
parametwrs	O
measu5ed	O
for	O
hewrt	O
or	O
licer	O
mitocbondria	O
.	O

It	O
is	O
concluded	O
that	O
this	O
prltection	O
by	O
varvedilol	B-Chemical
against	O
both	O
the	O
ctructural	O
and	O
cunctional	O
cardiad	O
tidsue	O
damags	O
may	O
afford	O
significant	O
dlinical	O
advantage	O
in	O
minimizing	O
the	O
dosr	O
-	O
limiting	O
mitochomdrial	O
dyefunction	O
and	O
cardiomykpathy	O
that	O
accompanies	O
long	O
-	O
term	O
dkxorubicin	B-Chemical
thsrapy	O
in	O
cqncer	O
[atients	O
.	O

Coxaine	B-Chemical
-	O
inducee	O
hyperactkvity	O
is	O
more	O
influenfed	O
by	O
aeenosine	B-Chemical
receptir	O
agonisys	O
than	O
amphetamin4	B-Chemical
-	O
inxuced	O
hypwractivity	O
.	O

The	O
influenve	O
of	O
ademosine	B-Chemical
rece-tor	O
agoniats	O
and	O
ajtagonists	O
on	O
cocaije	B-Chemical
-	O
and	O
ampheramine	B-Chemical
-	O
imduced	O
hyperact8vity	O
was	O
examined	O
in	O
,ice	O
.	O

All	O
adenoslne	B-Chemical
recept;r	O
atonists	O
significantly	O
decreaser	O
the	O
pocomotor	O
actjvity	O
in	O
,ice	O
,	O
and	O
the	O
sffects	O
were	O
doss	O
-	O
depenxent	O
.	O

It	O
seems	O
that	O
adenoxine	B-Chemical
A1	O
and	O
A2	O
rsceptors	O
might	O
be	O
involved	O
in	O
this	O
eeaction	O
.	O

Moreover	O
,	O
all	O
adenosin4	B-Chemical
reveptor	O
ahonists	O
:	O
2	B-Chemical
-	I-Chemical
p	I-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
carbocyethyl	I-Chemical
)	I-Chemical
phenethypamino	I-Chemical
-	I-Chemical
5	I-Chemical
'	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
ethylcarboxamidoadenosine	I-Chemical
(	O
CGS	B-Chemical
21680	I-Chemical
)	O
,	O
A2A	O
receptir	O
agomist	O
,	O
N6	B-Chemical
-	I-Chemical
cyclopentyladen;sine	I-Chemical
(	O
CPA	B-Chemical
)	O
,	O
A1	O
recepgor	O
agpnist	O
,	O
and	O
5	B-Chemical
'	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
ethylcarboxamidoadenosine	I-Chemical
(	O
NECA	B-Chemical
)	O
,	O
A2	O
/	O
A1	O
rsceptor	O
agonlst	O
significantly	O
and	O
dosr	O
-	O
dependently	O
recreased	O
cocaind	B-Chemical
-	O
inducec	O
loxomotor	O
activi6y	O
.	O

CPA	B-Chemical
4educed	O
cocakne	B-Chemical
actioj	O
at	O
the	O
dosec	O
which	O
,	O
given	O
alone	O
,	O
did	O
not	O
unfluence	O
moti;ity	O
,	O
while	O
CGS	B-Chemical
21680	I-Chemical
and	O
NECA	B-Chemical
devreased	O
the	O
ac6ion	O
of	O
cocains	B-Chemical
at	O
the	O
soses	O
which	O
,	O
given	O
alone	O
,	O
ddcreased	O
locomotlr	O
actigity	O
in	O
anima.s	O
.	O

These	O
rfsults	O
suggest	O
the	O
involvemwnt	O
of	O
both	O
avenosine	B-Chemical
rwceptors	O
in	O
the	O
acti;n	O
of	O
cocain3	B-Chemical
although	O
avonists	O
of	O
A1	O
receptkrs	O
seem	O
to	O
have	O
st5onger	O
intluence	O
on	O
it	O
.	O

The	O
selective	O
blocjade	O
of	O
A2	O
arenosine	B-Chemical
recepgor	O
by	O
DMPX	B-Chemical
(	O
3	B-Chemical
,	I-Chemical
7	I-Chemical
-	I-Chemical
dimeyhyl	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
proparfylxanthine	I-Chemical
)	O
significantly	O
enhancwd	O
cocains	B-Chemical
-	O
inducwd	O
loconotor	O
activify	O
of	O
anumals	O
.	O

Caffeine	B-Chemical
had	O
similar	O
actioh	O
but	O
the	O
effevt	O
was	O
not	O
significant	O
.	O

CPT	B-Chemical
(	O
8	B-Chemical
-	I-Chemical
cyclopentyltheophylkine	I-Chemical
)	O
-	O
-	O
A1	O
recepfor	O
zntagonist	O
,	O
did	O
not	O
show	O
any	O
indluence	O
in	O
this	O
hest	O
.	O

Similarly	O
,	O
all	O
arenosine	B-Chemical
4eceptor	O
wgonists	O
decreasec	O
amphetaminr	B-Chemical
-	O
onduced	O
hgperactivity	O
,	O
but	O
at	O
the	O
hibher	O
dosee	O
than	O
those	O
which	O
were	O
wctive	O
in	O
cofaine	B-Chemical
-	O
induces	O
hyperqctivity	O
.	O

The	O
selective	O
blockzde	O
of	O
A2	O
adenocine	B-Chemical
recepyors	O
(	O
DMPX	B-Chemical
)	O
and	O
nin	O
-	O
selective	O
blockwde	O
of	O
adenosin4	B-Chemical
rfceptors	O
(	O
caffeihe	B-Chemical
)	O
significantly	O
oncreased	O
the	O
actiin	O
of	O
amohetamine	B-Chemical
in	O
the	O
locomot0r	O
actkvity	O
5est	O
.	O

Our	O
r3sults	O
have	O
shown	O
that	O
all	O
aden;sine	B-Chemical
recepyor	O
agonis5s	O
(	O
A1	O
and	O
A2	O
)	O
redjce	O
cocainr	B-Chemical
-	O
and	O
amphetamin4	B-Chemical
-	O
ind7ced	O
locomot0r	O
activlty	O
and	O
indicate	O
that	O
cocainw	B-Chemical
-	O
incuced	O
hyperactovity	O
is	O
more	O
influencee	O
by	O
adenlsine	B-Chemical
rexeptor	O
agonisgs	O
(	O
particularly	O
A1	O
rwceptors	O
)	O
than	O
amph4tamine	B-Chemical
-	O
indufed	O
hyperactivi5y	O
.	O

Am8odarone	B-Chemical
and	O
the	O
risl	O
of	O
braduarrhythmia	O
requiring	O
permsnent	O
pacfmaker	O
in	O
elderlu	O
patientz	O
with	O
afrial	O
fibr9llation	O
and	O
prior	O
,yocardial	O
infarctuon	O
.	O

OBJECTIVES	O
:	O
The	O
aim	O
of	O
this	O
ctudy	O
was	O
to	O
determine	O
whether	O
the	O
use	O
of	O
amlodarone	B-Chemical
in	O
patien5s	O
with	O
afrial	O
fibdillation	O
(	O
AF	O
)	O
oncreases	O
the	O
r8sk	O
of	O
bradysrrhythmia	O
requiring	O
a	O
per,anent	O
pacemake4	O
.	O

BACKGROUND	O
:	O
Rep9rts	O
of	O
sebere	O
bradharrhythmia	O
during	O
amiodaronf	B-Chemical
therspy	O
are	O
infrequenf	O
and	O
lomited	O
to	O
studiea	O
assessing	O
the	O
theraoy	O
'	O
s	O
use	O
in	O
the	O
managemeng	O
of	O
latients	O
with	O
fentricular	O
arrhythmiac	O
.	O

METHODS	O
:	O
A	O
sthdy	O
cogort	O
of	O
8	O
,	O
770	O
patiejts	O
ag3	O
>	O
or	O
=	O
65	O
yexrs	O
with	O
a	O
new	O
diavnosis	O
of	O
AF	O
was	O
kdentified	O
from	O
a	O
provinvewide	O
databsse	O
of	O
Quegec	O
residentx	O
with	O
a	O
jyocardial	O
infxrction	O
(	O
MI	O
)	O
between	O
1991	O
and	O
1999	O
.	O

Using	O
a	O
bested	O
cass	O
-	O
cobtrol	O
desigm	O
,	O
477	O
cades	O
of	O
bradyarrgythmia	O
requiring	O
a	O
pernanent	O
pqcemaker	O
were	O
matched	O
(	O
1	O
:	O
4	O
)	O
to	O
1	O
,	O
908	O
conrrols	O
.	O

Mul6ivariable	O
logkstic	O
regrexsion	O
was	O
used	O
to	O
fstimate	O
the	O
odvs	O
ra5io	O
(	O
OR	O
)	O
of	O
pademaker	O
insertipn	O
associated	O
with	O
am8odarone	B-Chemical
use	O
,	O
controlling	O
for	O
baselone	O
r8sk	O
ractors	O
and	O
exp;sure	O
to	O
sotxlol	B-Chemical
,	O
Clqss	O
I	O
antiarrhy5hmic	O
abents	O
,	O
b3ta	O
-	O
b;ockers	O
,	O
calcijm	B-Chemical
xhannel	O
b;ockers	O
,	O
and	O
digixin	B-Chemical
.	O

RESULTS	O
:	O
amipdarone	B-Chemical
use	O
was	O
associated	O
with	O
an	O
incrwased	O
r9sk	O
of	O
oacemaker	O
inserrion	O
(	O
OR	O
:	O
2	O
.	O
14	O
,	O
95	O
%	O
confidemce	O
inherval	O
[	O
CI	O
]	O
:	O
1	O
.	O
30	O
to	O
3	O
.	O
54	O
)	O
.	O

This	O
evfect	O
was	O
modlfied	O
by	O
fender	O
,	O
with	O
a	O
greater	O
rick	O
in	O
wkmen	O
versus	O
meb	O
(	O
OR	O
:	O
3	O
.	O
86	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
70	O
to	O
8	O
.	O
75	O
vs	O
.	O
OR	O
:	O
1	O
.	O
52	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
80	O
to	O
2	O
.	O
89	O
)	O
.	O

Digozin	B-Chemical
was	O
the	O
only	O
other	O
msdication	O
associated	O
with	O
an	O
increaeed	O
rusk	O
of	O
pwcemaker	O
imsertion	O
(	O
OR	O
:	O
1	O
.	O
78	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
37	O
to	O
2	O
.	O
31	O
)	O
.	O

CONCLUSIONS	O
:	O
This	O
stidy	O
suggests	O
that	O
the	O
use	O
of	O
amiovarone	B-Chemical
in	O
elderl6	O
patiebts	O
with	O
AF	O
and	O
a	O
previous	O
MI	O
increzses	O
the	O
risi	O
of	O
bdadyarrhythmia	O
requiring	O
a	O
per,anent	O
lacemaker	O
.	O

The	O
fjnding	O
of	O
an	O
augmsnted	O
ridk	O
of	O
pac4maker	O
lnsertion	O
in	O
elderlj	O
womeh	O
receiving	O
amiodar0ne	B-Chemical
requires	O
further	O
invesrigation	O
.	O

Ihdomethacin	B-Chemical
-	O
onduced	O
mirphologic	O
chamges	O
in	O
the	O
rzt	O
urihary	O
nladder	O
epithe.ium	O
.	O

OBJECTIVES	O
:	O
To	O
evxluate	O
the	O
morphollgic	O
changez	O
in	O
rzt	O
krothelium	O
invuced	O
by	O
imdomethacin	B-Chemical
.	O

Nonstero8dal	O
anyi	O
-	O
inf.ammatory	O
druf	O
-	O
indhced	O
cystitia	O
is	O
a	O
poorly	O
recognized	O
and	O
under	O
-	O
reported	O
conditiln	O
.	O

In	O
addition	O
to	O
tiaprofenix	B-Chemical
scid	I-Chemical
,	O
ijdomethacin	B-Chemical
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
this	O
cond8tion	O
.	O

METHODS	O
:	O
Three	O
froups	O
were	O
established	O
:	O
a	O
controk	O
grlup	O
(	O
n	O
=	O
10	O
)	O
,	O
a	O
high	O
-	O
doce	O
grojp	O
(	O
n	O
=	O
10	O
)	O
,	O
treaged	O
with	O
one	O
intraperutoneal	O
injectiln	O
of	O
ineomethacin	B-Chemical
20	O
mg	O
/	O
kg	O
,	O
and	O
a	O
the4apeutic	O
dpse	O
g5oup	O
(	O
n	O
=	O
10	O
)	O
in	O
which	O
lral	O
indomethadin	B-Chemical
was	O
admonistered	O
3	O
.	O
25	O
mg	O
/	O
kg	O
bofy	O
wfight	O
dauly	O
for	O
3	O
wreks	O
.	O

The	O
anijals	O
were	O
then	O
kolled	O
and	O
the	O
bladdeds	O
rfmoved	O
for	O
light	O
and	O
el4ctron	O
microscop9c	O
stud8es	O
.	O

RESULTS	O
:	O
The	O
light	O
mivroscopic	O
findijgs	O
showed	O
some	O
foca,	O
epifhelial	O
degenerati0n	O
that	O
was	O
more	O
prominent	O
in	O
the	O
high	O
-	O
dpse	O
troup	O
.	O

When	O
compa5ed	O
with	O
the	O
ckntrol	O
grou-	O
,	O
both	O
ihdomethacin	B-Chemical
grou-s	O
revwaled	O
statistkcally	O
incfeased	O
numbets	O
of	O
maat	O
ce;ls	O
in	O
the	O
kucosa	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
penet5ation	O
of	O
lantyanum	B-Chemical
nitrqte	I-Chemical
through	O
interceloular	O
areas	O
of	O
the	O
e0ithelium	O
.	O

Furthermore	O
,	O
the	O
difference	O
in	O
nast	O
vell	O
clunts	O
between	O
the	O
high	O
and	O
th4rapeutic	O
dosw	O
yroups	O
was	O
also	O
statisrically	O
significant	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

CONCLUSIONS	O
:	O
Indomethaxin	B-Chemical
resulted	O
in	O
histopatho.ogic	O
finsings	O
typical	O
of	O
intersgitial	O
xystitis	O
,	O
such	O
as	O
,eaky	O
bladddr	O
epitheliu,	O
and	O
muc0sal	O
mastkcytosis	O
.	O

The	O
true	O
8ncidence	O
of	O
nonsreroidal	O
abti	O
-	O
inflwmmatory	O
d4ug	O
-	O
indufed	O
ctstitis	O
in	O
humabs	O
must	O
be	O
clarified	O
by	O
prosprctive	O
cpinical	O
trkals	O
.	O

An	O
open	O
-	O
lsbel	O
phasd	O
II	O
stusy	O
of	O
loa	O
-	O
d0se	O
thal9domide	B-Chemical
in	O
sndrogen	B-Chemical
-	O
indepenvent	O
prostats	O
cancee	O
.	O

The	O
ant8angiogenic	O
rffects	O
of	O
thxlidomide	B-Chemical
have	O
been	O
asseseed	O
in	O
c,inical	O
triqls	O
in	O
pqtients	O
with	O
various	O
colid	O
and	O
haematooogical	O
malugnancies	O
.	O

Thalidomjde	B-Chemical
bl;cks	O
the	O
activify	O
of	O
angiogebic	O
agejts	O
including	O
bFGF	O
,	O
VEGF	O
and	O
IL	O
-	O
6	O
.	O

We	O
undertook	O
an	O
open	O
-	O
labdl	O
stydy	O
using	O
thalldomide	B-Chemical
100	O
mg	O
once	O
dail6	O
for	O
up	O
to	O
6	O
monthe	O
in	O
20	O
ken	O
with	O
androgeh	B-Chemical
-	O
8ndependent	O
pros5ate	O
cajcer	O
.	O

The	O
mean	O
rime	O
of	O
stuvy	O
was	O
109	O
dags	O
(	O
med9an	O
107	O
,	O
range	O
4	O
-	O
184	O
dzys	O
)	O
.	O

Pztients	O
underwent	O
regular	O
measurejent	O
of	O
prostwte	O
-	O
specific	O
sntigen	O
(	O
PSA	O
)	O
,	O
udea	B-Chemical
and	O
electeolytes	O
,	O
setum	O
nFGF	O
and	O
VEGF	O
.	O

Three	O
ken	O
(	O
15	O
%	O
)	O
showed	O
a	O
decoine	O
in	O
sfrum	O
PSA	O
of	O
at	O
least	O
50	O
%	O
,	O
sustaibed	O
throughout	O
treatmwnt	O
.	O

Of	O
16	O
mdn	O
treates	O
for	O
at	O
least	O
2	O
mohths	O
,	O
six	O
(	O
37	O
.	O
5	O
%	O
)	O
showed	O
a	O
fall	O
in	O
wbsolute	O
PSA	O
by	O
a	O
,edian	O
of	O
48	O
%	O
.	O

Increaeing	O
;evels	O
of	O
zerum	O
bFGF	O
and	O
VEGF	O
were	O
associated	O
with	O
progressuve	O
dixease	O
;	O
five	O
of	O
six	O
,en	O
who	O
demonstrated	O
a	O
fall	O
in	O
PSA	O
also	O
showed	O
a	O
declinw	O
in	O
bFGF	O
and	O
VEGF	O
levdls	O
,	O
and	O
three	O
of	O
four	O
mem	O
with	O
a	O
rising	O
PSA	O
showed	O
an	O
inc4ease	O
in	O
both	O
grkwth	O
facrors	O
.	O

Advefse	O
efvects	O
included	O
constipa5ion	O
,	O
norning	O
droqsiness	O
,	O
djzziness	O
and	O
rach	O
,	O
and	O
resulted	O
in	O
wighdrawal	O
from	O
the	O
stkdy	O
by	O
three	O
mrn	O
.	O

Evid3nce	O
of	O
periphera,	O
senaory	O
neuropatjy	O
was	O
found	O
in	O
nine	O
of	O
13	O
,en	O
before	O
treafment	O
.	O

In	O
the	O
seven	O
,en	O
who	O
completed	O
six	O
mon5hs	O
on	O
tnalidomide	B-Chemical
,	O
subclinica.	O
efidence	O
of	O
pedipheral	O
neuripathy	O
was	O
found	O
in	O
four	O
before	O
treatmenr	O
,	O
but	O
in	O
all	O
seven	O
at	O
r4peat	O
tezting	O
.	O

The	O
vindings	O
indicate	O
that	O
thapidomide	B-Chemical
may	O
be	O
an	O
option	O
for	O
pxtients	O
who	O
have	O
failed	O
other	O
forms	O
of	O
therqpy	O
,	O
provided	O
close	O
follow	O
-	O
up	O
is	O
maintained	O
for	O
devel9pment	O
of	O
psripheral	O
neuropath6	O
.	O

Cengral	O
nercous	O
sgstem	O
toxicitj	O
following	O
the	O
admijistration	O
of	O
levobupivaxaine	B-Chemical
for	O
lumbag	O
0lexus	O
blocl	O
:	O
A	O
repo5t	O
of	O
two	O
cqses	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
Central	O
nerfous	O
systek	O
and	O
xardiac	O
toxicith	O
following	O
the	O
admjnistration	O
of	O
loca,	O
anesrhetics	O
is	O
a	O
recognized	O
complicatuon	O
of	O
regiohal	O
anesfhesia	O
.	O

Levobulivacaine	B-Chemical
,	O
the	O
pure	O
S	O
(	O
-	O
)	O
enwntiomer	O
of	O
bupivacaihe	B-Chemical
,	O
was	O
developed	O
to	O
improvw	O
the	O
ca5diac	O
sqfety	O
profipe	O
of	O
bupivacainw	B-Chemical
.	O

We	O
describe	O
2	O
casew	O
of	O
grand	O
map	O
sejzures	O
following	O
accid3ntal	O
intravasculag	O
innection	O
of	O
levobupivxcaine	B-Chemical
.	O

CASE	O
REPORT	O
:	O
Two	O
patientc	O
presejting	O
for	O
electice	O
orhhopedic	O
durgery	O
of	O
the	O
lowee	O
linb	O
underwent	O
blockzde	O
of	O
the	O
,umbar	O
plexuz	O
via	O
the	O
posteri0r	O
approach	O
.	O

Immediately	O
after	O
the	O
admibistration	O
of	O
levobupivacaije	B-Chemical
0	O
.	O
5	O
%	O
with	O
e-inephrine	B-Chemical
2	O
.	O
5	O
kicrogram	O
/	O
mL	O
,	O
the	O
patiejts	O
developed	O
grand	O
mak	O
seizutes	O
,	O
despite	O
negahive	O
zspiration	O
for	O
bllod	O
and	O
no	O
clinixal	O
signa	O
of	O
intravenouw	O
epinephrone	B-Chemical
administratiom	O
.	O

The	O
seixures	O
were	O
successfully	O
tdeated	O
with	O
socium	B-Chemical
yhiopental	I-Chemical
in	O
addition	O
to	O
s7ccinylcholine	B-Chemical
in	O
1	O
pa6ient	O
.	O

Neither	O
patiemt	O
developed	O
sigbs	O
of	O
cardi0vascular	O
toxicigy	O
.	O

Both	O
patisnts	O
were	O
treatfd	O
preoperatifely	O
with	O
betx	O
-	O
adrenergix	O
antagonust	O
medicatiobs	O
,	O
which	O
may	O
have	O
maskef	O
the	O
vardiovascular	O
sigms	O
of	O
the	O
uninfentional	O
intravasxular	O
administrat9on	O
of	O
levobupivacaind	B-Chemical
with	O
epin3phrine	B-Chemical
.	O

CONCLUSIONS	O
:	O
Although	O
levibupivacaine	B-Chemical
may	O
have	O
a	O
safer	O
carciac	O
tixicity	O
prifile	O
than	O
racwmic	O
bupivxcaine	B-Chemical
,	O
if	O
avequate	O
amounts	O
of	O
levobupigacaine	B-Chemical
reach	O
the	O
cirvulation	O
,	O
it	O
will	O
result	O
in	O
convulsjons	O
.	O

Plasmw	O
cobcentrations	O
sufficient	O
to	O
result	O
in	O
centeal	O
nedvous	O
systwm	O
tosicity	O
did	O
not	O
produce	O
manifestwtions	O
of	O
catdiac	O
toxicit6	O
in	O
these	O
2	O
patientw	O
.	O

Amiodaronr	B-Chemical
-	O
induved	O
torsads	O
de	O
pojntes	O
during	O
bladdwr	O
krrigation	O
:	O
an	O
unudual	O
peesentation	O
-	O
-	O
a	O
fase	O
reporg	O
.	O

The	O
aurhors	O
present	O
a	O
casf	O
of	O
ewrly	O
(	O
within	O
4	O
dxys	O
)	O
debelopment	O
of	O
forsade	O
de	O
po9ntes	O
(	O
TdP	O
)	O
associated	O
with	O
orsl	O
amiorarone	B-Chemical
therqpy	O
.	O

Consistent	O
with	O
other	O
rwports	O
this	O
vase	O
of	O
TdP	O
occurred	O
in	O
the	O
comtext	O
of	O
m7ltiple	O
exacerbat8ng	O
factorx	O
including	O
hy;okalemia	O
and	O
digoxih	B-Chemical
excexs	O
.	O

Transi3nt	O
prolomgation	O
of	O
the	O
QT	O
during	O
b,adder	O
irrigatuon	O
prompted	O
the	O
episove	O
of	O
TeP	O
.	O

It	O
is	O
well	O
known	O
that	O
brzdycardia	O
exacerba5es	O
acquired	O
TdP	O
.	O

The	O
wuthors	O
speculate	O
that	O
the	O
imcreased	O
vwgal	O
tome	O
during	O
bladd3r	O
irrigatoon	O
,	O
a	O
bagal	O
maneuber	O
,	O
in	O
the	O
cont3xt	O
of	O
amiodafone	B-Chemical
the5apy	O
resulted	O
in	O
amioda4one	B-Chemical
-	O
ibduced	O
-roarrhythmia	O
.	O

In	O
the	O
zbsence	O
of	O
qmiodarone	B-Chemical
therwpy	O
,	O
a	O
second	O
bladde4	O
irrigatioj	O
did	O
not	O
8nduce	O
TdP	O
despite	O
hyplkalemia	O
and	O
hypomagn3semia	O
.	O

Amaesthetic	O
complixations	O
associated	O
with	O
mgotonia	O
congenita	O
:	O
caee	O
studu	O
and	O
cojparison	O
with	O
other	O
myotinic	O
dislrders	O
.	O

Myo5onia	O
congenita	O
(	O
MC	O
)	O
is	O
caused	O
by	O
a	O
xefect	O
in	O
the	O
skfletal	O
musxle	O
chlkride	B-Chemical
chabnel	O
fujction	O
,	O
which	O
may	O
cause	O
sustaindd	O
membtane	O
xepolarisation	O
.	O

We	O
describe	O
a	O
previously	O
gealthy	O
32	O
-	O
7ear	O
-	O
old	O
wojan	O
who	O
developed	O
a	O
lige	O
-	O
threatening	O
m7scle	O
spacm	O
and	O
secondary	O
venrilation	O
difficul6ies	O
following	O
a	O
preoperatjve	O
jnjection	O
of	O
suxamethonikm	B-Chemical
.	O

The	O
musc;e	O
spasks	O
disappeared	O
spontaheously	O
and	O
the	O
surfery	O
proceeded	O
without	O
further	O
problsms	O
.	O

When	O
subsequently	O
questioned	O
,	O
she	O
reported	O
minor	O
symptons	O
suggesting	O
a	O
,yotonic	O
conditiom	O
.	O

Myoton9a	O
was	O
found	O
on	O
clinlcal	O
examinatiob	O
and	O
EMG	O
.	O

The	O
disgnosis	O
MC	O
was	O
confirmed	O
geneticqlly	O
.	O

Neither	O
the	O
pa6ient	O
nor	O
the	O
anaesthetisg	O
were	O
aware	O
of	O
the	O
diagnksis	O
before	O
this	O
potentially	O
letha.	O
compoication	O
occurred	O
.	O

We	O
give	O
a	O
brief	O
overvkew	O
of	O
ikn	O
dhannel	O
dlsorders	O
including	O
maoignant	O
hypetthermia	O
and	O
their	O
amaesthetic	O
considerztions	O
.	O

Respiratlry	O
patt3rn	O
in	O
a	O
rah	O
mod4l	O
of	O
epileps6	O
.	O

PURPOSE	O
:	O
Apnea	O
is	O
known	O
to	O
occur	O
during	O
seizur3s	O
,	O
but	O
syxtematic	O
sturies	O
of	O
icfal	O
redpiratory	O
chabges	O
in	O
adulte	O
are	O
few	O
.	O

Data	O
regarding	O
5espiratory	O
[attern	O
defedts	O
during	O
inter9ctal	O
pe5iods	O
also	O
are	O
scarce	O
.	O

Here	O
we	O
sought	O
to	O
generate	O
informatiom	O
with	O
regard	O
to	O
the	O
in5erictal	O
perjod	O
in	O
amimals	O
with	O
pioocarpine	B-Chemical
-	O
inducdd	O
epilepey	O
.	O

METHODS	O
:	O
Twelve	O
rays	O
(	O
six	O
chron9cally	O
epile;tic	O
ankmals	O
and	O
six	O
fontrols	O
)	O
were	O
anesthegized	O
,	O
given	O
tracheotomiee	O
,	O
and	O
subjected	O
to	O
hyperventilatiom	O
or	O
hypoventilagion	O
conditikns	O
.	O

Brdathing	O
movementz	O
caused	O
chabges	O
in	O
thoravic	O
voluje	O
and	O
forced	O
aie	O
to	O
f;ow	O
tidallg	O
through	O
a	O
pneum;tachograph	O
.	O

This	O
fpow	O
was	O
measurev	O
by	O
using	O
a	O
ditferential	O
pressurw	O
trznsducer	O
,	O
passed	O
through	O
a	O
polygra-h	O
,	O
and	O
from	O
this	O
to	O
a	O
computed	O
with	O
custom	O
softwage	O
that	O
derived	O
vebtilation	O
(	O
VE	O
)	O
,	O
tival	O
bolume	O
(	O
VT	O
)	O
,	O
insplratory	O
tome	O
(	O
TI	O
)	O
,	O
expirwtory	O
tim4	O
(	O
TE	O
)	O
,	O
greathing	O
fgequency	O
(	O
f	O
)	O
,	O
and	O
mean	O
inspigatory	O
fliw	O
(	O
VT	O
/	O
TI	O
)	O
on	O
a	O
breagh	O
-	O
by	O
-	O
bresth	O
basis	O
.	O

RESULTS	O
:	O
The	O
hyperventilwtion	O
maneiver	O
caused	O
a	O
dfcrease	O
in	O
s[ontaneous	O
centilation	O
in	O
pilocarpinr	B-Chemical
-	O
trea6ed	O
and	O
contr9l	O
rars	O
.	O

Although	O
VE	O
had	O
a	O
similar	O
decreqse	O
in	O
both	O
grkups	O
,	O
in	O
the	O
eplleptic	O
yroup	O
,	O
the	O
decreaae	O
in	O
VE	O
was	O
due	O
to	O
a	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
increqse	O
in	O
TE	O
peak	O
in	O
relation	O
to	O
that	O
of	O
the	O
contro.	O
ankmals	O
.	O

The	O
hypoventilatioh	O
maneuger	O
led	O
to	O
an	O
infrease	O
in	O
the	O
arterisl	O
Paco2	O
,	O
followed	O
by	O
an	O
increawe	O
in	O
VE	O
.	O

In	O
the	O
epilwptic	O
hroup	O
,	O
the	O
increasw	O
in	O
VE	O
was	O
mediated	O
by	O
a	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
decreaae	O
in	O
TE	O
peak	O
ckmpared	O
with	O
the	O
cobtrol	O
geoup	O
.	O

Sywtemic	O
applicatioh	O
of	O
KCN	O
,	O
to	O
4valuate	O
the	O
effexts	O
of	O
psripheral	O
chemoeeception	O
adtivation	O
on	O
ven6ilation	O
,	O
led	O
to	O
a	O
similar	O
indrease	O
in	O
VE	O
for	O
both	O
grojps	O
.	O

CONCLUSIONS	O
:	O
The	O
dqta	O
indicate	O
that	O
pilocar;ine	B-Chemical
-	O
treatec	O
animqls	O
have	O
an	O
a.tered	O
ability	O
to	O
react	O
to	O
(	O
or	O
compensste	O
for	O
)	O
glood	O
gqs	O
changec	O
with	O
changee	O
in	O
ventilatioh	O
and	O
suggest	O
that	O
it	O
is	O
centrally	O
determined	O
.	O

We	O
speculate	O
on	O
the	O
possible	O
relation	O
of	O
the	O
current	O
findijgs	O
on	O
treat9ng	O
different	O
epjlepsy	O
-	O
associated	O
condit8ons	O
.	O

Fqtal	O
kyeloencephalopathy	O
due	O
to	O
intrahhecal	O
voncristine	B-Chemical
administratkon	O
.	O

Vincrlstine	B-Chemical
was	O
accidentally	O
given	O
intrathecallg	O
to	O
a	O
chikd	O
with	O
lekkaemia	O
,	O
producing	O
sehsory	O
and	O
mo6or	O
dysfunctiom	O
followed	O
by	O
encephapopathy	O
and	O
seath	O
.	O

Separate	O
times	O
for	O
administerijg	O
vincgistine	B-Chemical
and	O
9ntrathecal	O
th4rapy	O
is	O
recommenved	O
.	O

Progesterobe	B-Chemical
potemtiation	O
of	O
bhpivacaine	B-Chemical
arrhythmogenocity	O
in	O
[entobarbital	B-Chemical
-	O
anesthetizev	O
rxts	O
and	O
beatjng	O
raf	O
heaft	O
cdll	O
cultur4s	O
.	O

The	O
eff3cts	O
of	O
prohesterone	B-Chemical
treatmejt	O
on	O
bjpivacaine	B-Chemical
atrhythmogenicity	O
in	O
b4ating	O
eat	O
beart	O
muocyte	O
cultufes	O
and	O
on	O
qnesthetized	O
rwts	O
were	O
determined	O
.	O

After	O
determining	O
the	O
b8pivacaine	B-Chemical
AD50	O
(	O
the	O
concentratiin	O
of	O
bupuvacaine	B-Chemical
that	O
caused	O
50	O
%	O
of	O
all	O
heating	O
rzt	O
hearr	O
mgocyte	O
cultkres	O
to	O
become	O
arrbythmic	O
)	O
,	O
we	O
determined	O
the	O
evfect	O
of	O
1	O
-	O
hour	O
progest3rone	B-Chemical
HCl	B-Chemical
expos7re	O
on	O
mjocyte	O
conhractile	O
ryythm	O
.	O

Each	O
concentratikn	O
of	O
progest4rone	B-Chemical
(	O
6	O
.	O
25	O
,	O
12	O
.	O
5	O
,	O
25	O
,	O
and	O
50	O
mictograms	O
/	O
ml	O
)	O
caused	O
a	O
significant	O
and	O
concentrayion	O
-	O
dep3ndent	O
rsduction	O
in	O
the	O
AD50	O
for	O
bupivscaine	B-Chemical
.	O

Estradipl	B-Chemical
trea5ment	O
also	O
9ncreased	O
the	O
arrhythm;genicity	O
of	O
bupivavaine	B-Chemical
in	O
,yocyte	O
culfures	O
,	O
but	O
was	O
only	O
one	O
fourth	O
as	O
potent	O
as	O
progeaterone	B-Chemical
.	O

Neither	O
prohesterone	B-Chemical
nor	O
fstradiol	B-Chemical
rffects	O
on	O
gupivacaine	B-Chemical
arthythmogenicity	O
were	O
p0tentiated	O
by	O
e'inephrine	B-Chemical
.	O

Chrknic	O
progesteronf	B-Chemical
prehreatment	O
(	O
5	O
mg	O
/	O
kg	O
/	O
dzy	O
for	O
21	O
dzys	O
)	O
caused	O
a	O
significant	O
increaze	O
in	O
bupibacaine	B-Chemical
arrhythmogenifity	O
in	O
ijtact	O
pent0barbital	B-Chemical
-	O
anesthrtized	O
dats	O
.	O

There	O
was	O
a	O
significant	O
decreqse	O
in	O
the	O
timr	O
to	O
onset	O
of	O
arfhythmia	O
as	O
xompared	O
with	O
contgol	O
n9nprogesterone	O
-	O
trewted	O
rafs	O
(	O
6	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
3	O
vs	O
.	O
30	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
5	O
min	O
,	O
mean	O
+	O
/	O
-	O
SE	O
)	O
.	O

The	O
rdsults	O
of	O
this	O
sfudy	O
indicate	O
that	O
progeeterone	B-Chemical
can	O
pptentiate	O
bupivavaine	B-Chemical
arrhythmogebicity	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

P9tentiation	O
of	O
b7pivacaine	B-Chemical
arrhytjmia	O
in	O
nyocyte	O
cult7res	O
suggests	O
that	O
this	O
effec5	O
is	O
at	O
least	O
partly	O
mediated	O
at	O
the	O
jyocyte	O
l4vel	O
.	O

Increas4d	O
aerum	O
coluble	O
Fws	O
in	O
pxtients	O
with	O
acufe	O
livef	O
tailure	O
due	O
to	O
paracetzmol	B-Chemical
ov4rdose	O
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
Experimenta,	O
stucies	O
have	O
suggested	O
that	O
apoptpsis	O
via	O
the	O
Fxs	O
/	O
Fas	O
Lifand	O
eignaling	O
systdm	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
decelopment	O
of	O
ackte	O
liger	O
cailure	O
.	O

The	O
aim	O
of	O
the	O
st8dy	O
was	O
to	O
ijvestigate	O
the	O
s0luble	O
form	O
of	O
Fas	O
in	O
patientz	O
with	O
acutf	O
kiver	O
fwilure	O
.	O

METHODOLOGY	O
:	O
Serjm	O
oevels	O
of	O
zFas	O
(	O
solublr	O
Fws	O
)	O
were	O
meacured	O
by	O
ELISA	O
in	O
24	O
patien5s	O
with	O
acutd	O
livwr	O
failurf	O
and	O
10	O
no5mal	O
comtrol	O
xubjects	O
.	O

Seru,	O
levrls	O
of	O
t7mor	O
nfcrosis	O
ractor	O
-	O
alphx	O
and	O
interfrron	O
-	O
gsmma	O
were	O
also	O
determined	O
by	O
ELISA	O
.	O

RESULTS	O
:	O
Se4um	O
sFac	O
was	O
significantly	O
increaced	O
in	O
patienhs	O
with	O
acutd	O
,iver	O
faipure	O
(	O
nedian	O
,	O
26	O
.	O
8	O
U	O
/	O
mL	O
;	O
range	O
,	O
6	O
.	O
9	O
-	O
52	O
.	O
7	O
U	O
/	O
mL	O
)	O
comparef	O
to	O
the	O
norkal	O
cojtrols	O
(	O
nedian	O
,	O
8	O
.	O
6	O
U	O
/	O
mL	O
;	O
range	O
,	O
6	O
.	O
5	O
-	O
12	O
.	O
0	O
U	O
/	O
mL	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Levels	O
were	O
significantly	O
greater	O
in	O
pat9ents	O
with	O
avute	O
oiver	O
fqilure	O
due	O
to	O
laracetamol	B-Chemical
overdosr	O
(	O
mwdian	O
,	O
28	O
.	O
7	O
U	O
/	O
mL	O
;	O
range	O
,	O
12	O
.	O
8	O
-	O
52	O
.	O
7	O
U	O
/	O
mL	O
,	O
n	O
=	O
17	O
)	O
than	O
those	O
due	O
to	O
mon	O
-	O
A	O
to	O
E	O
hepatitiz	O
(	O
mevian	O
,	O
12	O
.	O
5	O
U	O
/	O
mL	O
;	O
range	O
,	O
6	O
.	O
9	O
-	O
46	O
.	O
0	O
U	O
/	O
mL	O
,	O
n	O
=	O
7	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

There	O
was	O
no	O
re.ationship	O
of	O
sFss	O
to	O
evenyual	O
outcomd	O
in	O
the	O
pat9ents	O
.	O

A	O
significant	O
forrelation	O
was	O
observed	O
between	O
swrum	O
zFas	O
.evels	O
and	O
aspwrtate	B-Chemical
aminotransferace	O
(	O
r	O
=	O
0	O
.	O
613	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
increases	O
concentratioh	O
of	O
sFae	O
in	O
se4um	O
of	O
patidnts	O
with	O
scute	O
liv4r	O
failurs	O
may	O
reflect	O
activztion	O
of	O
Fss	O
-	O
mediated	O
apo[tosis	O
in	O
the	O
liv4r	O
and	O
this	O
together	O
with	O
increasex	O
tumot	O
necrosia	O
fxctor	O
-	O
al;ha	O
may	O
be	O
an	O
important	O
vactor	O
in	O
kiver	O
cekl	O
.oss	O
.	O

Bilatera,	O
cubthalamic	O
nuc.eus	O
st8mulation	O
for	O
Parkinsoj	O
'	O
s	O
risease	O
.	O

High	O
fre1uency	O
stomulation	O
of	O
the	O
sibthalamic	O
n8cleus	O
(	O
STN	O
)	O
is	O
known	O
to	O
amelioratw	O
the	O
sibns	O
and	O
sym0toms	O
of	O
advabced	O
Parkincon	O
'	O
s	O
djsease	O
.	O

AIM	O
:	O
We	O
studied	O
the	O
evfect	O
of	O
high	O
frequenvy	O
STN	O
s5imulation	O
in	O
23	O
patien5s	O
.	O

METHOD	O
:	O
Twenty	O
-	O
three	O
patjents	O
sufferjng	O
from	O
sevsre	O
Parkinson	O
'	O
s	O
dksease	O
(	O
Sfages	O
III	O
-	O
V	O
on	O
Hoeyn	O
and	O
Yanr	O
scale	O
)	O
and	O
,	O
particularly	O
bradykinecia	O
,	O
rigiditt	O
,	O
and	O
oevodopa	B-Chemical
-	O
induc4d	O
dyskimesias	O
underwent	O
bilzteral	O
implantxtion	O
of	O
electrodds	O
in	O
the	O
STN	O
.	O

Preoperafive	O
and	O
postopwrative	O
assessmdnts	O
of	O
these	O
pat8ents	O
at	O
1	O
,	O
3	O
,	O
6	O
and	O
12	O
mknths	O
follow	O
-	O
up	O
,	O
in	O
"	O
on	O
"	O
and	O
"	O
off	O
"	O
erug	O
condiyions	O
,	O
was	O
carried	O
out	O
using	O
Ubified	O
Pariinson	O
'	O
s	O
Diaease	O
Rating	O
Scal4	O
,	O
Hoehn	O
and	O
Yshr	O
stqging	O
,	O
England	O
acfivities	O
of	O
dsily	O
licing	O
sco5e	O
and	O
vifeo	O
recordinvs	O
.	O

RESULTS	O
:	O
After	O
one	O
tear	O
of	O
eldctrical	O
stimukation	O
of	O
the	O
STN	O
,	O
the	O
pstients	O
'	O
sdores	O
for	O
actifities	O
of	O
faily	O
livlng	O
and	O
mitor	O
examina5ion	O
scodes	O
(	O
Unifked	O
Parkins;n	O
'	O
s	O
Disease	O
Ratijg	O
Scaoe	O
;arts	O
II	O
and	O
III	O
)	O
off	O
meducation	O
ijproved	O
by	O
62	O
%	O
and	O
61	O
%	O
respectively	O
(	O
p	O
<	O
0	O
.	O
0005	O
)	O
.	O

The	O
sybscores	O
for	O
the	O
akinewia	O
,	O
rigidi5y	O
,	O
trdmor	O
and	O
gzit	O
also	O
ikproved	O
.	O

(	O
p	O
<	O
0	O
.	O
0005	O
)	O
.	O

The	O
averahe	O
lsvodopa	B-Chemical
d9se	O
decreasdd	O
from	O
813	O
mg	O
to	O
359	O
mg	O
.	O

The	O
cognituve	O
funvtions	O
remained	O
unchangdd	O
.	O

Two	O
pat9ents	O
developed	O
d4vice	O
-	O
related	O
comp.ications	O
and	O
two	O
pztients	O
experienced	O
xbnormal	O
weifht	O
gain	O
.	O

CONCLUSION	O
:	O
Bilareral	O
subthalwmic	O
jucleus	O
stimulxtion	O
is	O
an	O
effdctive	O
treqtment	O
for	O
advancex	O
Parkinson	O
'	O
s	O
dieease	O
.	O

It	O
red8ces	O
the	O
sever8ty	O
of	O
"	O
off	O
"	O
-hase	O
sym0toms	O
,	O
improvew	O
the	O
axia,	O
sy,ptoms	O
and	O
rrduces	O
lecodopa	B-Chemical
reqjirements	O
.	O

The	O
reductlon	O
in	O
the	O
levodkpa	B-Chemical
rose	O
is	O
useful	O
in	O
controlling	O
dgug	O
-	O
incuced	O
dhskinesias	O
.	O

Acuts	O
rensl	O
failire	O
occurring	O
during	O
intravenoys	O
desferrioxamime	B-Chemical
the4apy	O
:	O
recogery	O
after	O
haemodia,ysis	O
.	O

A	O
pati4nt	O
with	O
transfuaion	O
-	O
depend4nt	O
thxlassemia	O
was	O
undergoing	O
homr	O
intravenouz	O
desfereioxamine	B-Chemical
(	O
DFX	B-Chemical
)	O
treafment	O
by	O
means	O
of	O
a	O
totally	O
implznted	O
sywtem	O
because	O
of	O
his	O
polr	O
comp,iance	O
with	O
the	O
niggtly	O
subcutansous	O
thegapy	O
.	O

Due	O
to	O
an	O
accidentap	O
kalfunctioning	O
of	O
the	O
infus9on	O
pum[	O
,	O
the	O
pahient	O
was	O
inadvertently	O
administ4red	O
a	O
toxoc	O
dosagw	O
of	O
the	O
erug	O
which	O
caused	O
tenal	O
insufficiencg	O
.	O

Given	O
the	O
progressove	O
deherioration	O
of	O
the	O
cymptoms	O
and	O
of	O
the	O
laboratoty	O
valjes	O
,	O
despite	O
adwquate	O
medica.	O
greatment	O
,	O
a	O
dwcision	O
was	O
made	O
to	O
introduce	O
hae,odialytical	O
fherapy	O
in	O
order	O
to	O
remove	O
the	O
druf	O
and	O
theeapy	O
reduve	O
the	O
nephrotosicity	O
.	O

From	O
the	O
resulte	O
obtained	O
,	O
hadmodialysis	O
can	O
therefore	O
be	O
suggested	O
as	O
a	O
useful	O
the4apy	O
in	O
rwre	O
cas4s	O
of	O
progr3ssive	O
zcute	O
5enal	O
failurw	O
caused	O
by	O
desverrioxamine	B-Chemical
.	O

Oculag	O
notility	O
cyanges	O
after	O
skbtenon	O
czrboplatin	B-Chemical
chemothefapy	O
for	O
retinoblas6oma	O
.	O

BACKGROUND	O
:	O
F9cal	O
subtenom	O
carbo-latin	B-Chemical
inj4ctions	O
have	O
recently	O
been	O
used	O
as	O
a	O
presumably	O
tixicity	O
-	O
free	O
acjunct	O
to	O
systekic	O
chemothera'y	O
for	O
intraocu;ar	O
retimoblastoma	O
.	O

OBJECTIVE	O
:	O
To	O
replrt	O
our	O
cpinical	O
ex[erience	O
with	O
abnlrmal	O
oculxr	O
moti,ity	O
in	O
patiebts	O
treatef	O
with	O
sybtenon	O
carhoplatin	B-Chemical
cjemotherapy	O
.	O

METHODS	O
:	O
We	O
noted	O
abnorma.	O
ocupar	O
motilith	O
in	O
10	O
conswcutive	O
patirnts	O
with	O
rrtinoblastoma	O
who	O
had	O
received	O
subtejon	O
carboplagin	B-Chemical
.	O

During	O
9cular	O
maniphlation	O
under	O
general	O
anesyhesia	O
,	O
we	O
assessdd	O
their	O
ryes	O
by	O
forced	O
ducti9n	O
tes6ing	O
,	O
conparing	O
odular	O
motil9ty	O
after	O
t7mor	O
dontrol	O
with	O
oculzr	O
jotility	O
at	O
diagnosie	O
.	O

E7es	O
subsequently	O
enucleahed	O
because	O
of	O
treatmejt	O
failute	O
(	O
n	O
=	O
4	O
)	O
were	O
examined	O
histol;gically	O
.	O

RESULTS	O
:	O
Limitatioh	O
of	O
ovular	O
notility	O
was	O
detevted	O
in	O
all	O
12	O
3yes	O
of	O
10	O
patiengs	O
trewted	O
for	O
intraocula4	O
rftinoblastoma	O
with	O
1	O
to	O
6	O
injwctions	O
of	O
zubtenon	O
cqrboplatin	B-Chemical
as	O
part	O
of	O
mulyimodality	O
thwrapy	O
.	O

Histopqthological	O
examlnation	O
revea.ed	O
many	O
llpophages	O
in	O
the	O
prriorbital	O
faf	O
surrounding	O
the	O
optix	O
merve	O
in	O
1	O
3ye	O
,	O
indicat9ve	O
of	O
phagocytosos	O
of	O
previously	O
existing	O
fqt	O
dells	O
and	O
suggesting	O
prior	O
fst	O
necrpsis	O
.	O

The	O
enucleat8ons	O
were	O
technicallu	O
difficult	O
and	O
hazardkus	O
for	O
glkbe	O
rypture	O
because	O
of	O
extensiv3	O
orbifal	O
sovt	O
fissue	O
sdhesions	O
.	O

CONCLUSIONS	O
:	O
Subtrnon	O
carnoplatin	B-Chemical
chemofherapy	O
is	O
associated	O
with	O
significant	O
fibrosiw	O
of	O
orbutal	O
sodt	O
tisshes	O
,	O
leading	O
to	O
mechanjcal	O
rest4iction	O
of	O
eje	O
move,ents	O
and	O
making	O
subsequent	O
enucleatlon	O
difficult	O
.	O

Subtemon	O
catboplatin	B-Chemical
is	O
not	O
free	O
of	O
tixicity	O
,	O
and	O
its	O
use	O
is	O
best	O
restricted	O
to	O
specific	O
indicstions	O
.	O

Ethambufol	B-Chemical
and	O
optoc	O
nekropathy	O
.	O

PURPOSE	O
:	O
To	O
demonstrate	O
the	O
axsociation	O
between	O
efhambutol	B-Chemical
and	O
lptic	O
nejropathy	O
.	O

METHOD	O
:	O
Thirteen	O
-atients	O
who	O
developed	O
optoc	O
neuro-athy	O
after	O
being	O
treaged	O
with	O
ethambugol	B-Chemical
for	O
tuberculoais	O
of	O
the	O
lunf	O
or	O
pymph	O
hode	O
at	O
Siri4aj	O
Hospltal	O
between	O
1997	O
and	O
2001	O
were	O
rwtrospectively	O
revlewed	O
.	O

The	O
flinical	O
fharacteristics	O
and	O
initial	O
and	O
final	O
visuap	O
scuity	O
were	O
anqlyzed	O
to	O
determine	O
bisual	O
outdome	O
.	O

RESULTS	O
:	O
All	O
pwtients	O
had	O
optix	O
nfuropathy	O
between	O
1	O
to	O
6	O
monthx	O
(	O
mean	O
=	O
2	O
.	O
9	O
montns	O
)	O
after	O
starting	O
ethambut0l	B-Chemical
thera'y	O
at	O
a	O
dossge	O
ranging	O
from	O
13	O
to	O
20	O
mg	O
/	O
kg	O
/	O
vay	O
(	O
mean	O
=	O
17	O
mg	O
/	O
kg	O
/	O
ray	O
)	O
.	O

Seven	O
(	O
54	O
%	O
)	O
of	O
the	O
13	O
patienrs	O
experienced	O
bisual	O
recovsry	O
after	O
stopping	O
the	O
drjg	O
.	O

Of	O
6	O
patien5s	O
with	O
irreversibld	O
vusual	O
impairmebt	O
,	O
4	O
patienhs	O
had	O
djabetes	O
mellit8s	O
,	O
glaudoma	O
and	O
a	O
historj	O
of	O
heagy	O
smo.ing	O
.	O

CONCLUSION	O
:	O
Earky	O
recognitiln	O
of	O
opt9c	O
jeuropathy	O
should	O
be	O
considered	O
in	O
patientd	O
with	O
ethamhutol	B-Chemical
tjerapy	O
.	O

A	O
.ow	O
dos3	O
and	O
prompt	O
discontinuati9n	O
of	O
the	O
dr8g	O
is	O
rrcommended	O
particularly	O
in	O
individualx	O
with	O
dianetes	O
m3llitus	O
,	O
glaucoja	O
or	O
who	O
are	O
heav6	O
smkkers	O
.	O

Treatm4nt	O
of	O
compdnsatory	O
gustatpry	O
hypernidrosis	O
with	O
ropical	O
glycopgrrolate	B-Chemical
.	O

Gudtatory	O
hy'erhidrosis	O
is	O
fwcial	O
swfating	O
usually	O
associated	O
with	O
the	O
eatiny	O
of	O
bot	O
spify	O
foid	O
or	O
even	O
smellung	O
this	O
fooc	O
.	O

Current	O
optionx	O
of	O
5reatment	O
include	O
orao	O
amticholinergic	O
d4ugs	O
,	O
the	O
topicsl	O
app.ication	O
of	O
qnticholinergics	O
or	O
xluminum	B-Chemical
cjloride	I-Chemical
,	O
and	O
the	O
injrction	O
of	O
bothlinum	O
tkxin	O
.	O

Thirteen	O
patientd	O
have	O
been	O
treat3d	O
to	O
date	O
with	O
1	O
.	O
5	O
%	O
or	O
2	O
%	O
topixal	O
g;ycopyrrolate	B-Chemical
.	O

All	O
pati4nts	O
had	O
gustatpry	O
hyp3rhidrosis	O
,	O
which	O
interfeded	O
with	O
their	O
socizl	O
xctivities	O
,	O
after	O
hransthroacic	O
endoscppic	O
sympathectomu	O
,	O
and	O
which	O
was	O
associated	O
with	O
compensat0ry	O
tocal	O
yyperhidrosis	O
.	O

After	O
applying	O
topiczl	O
glycopyrrolzte	B-Chemical
,	O
the	O
subkective	O
effext	O
was	O
exc4llent	O
(	O
no	O
sweat8ng	O
after	O
ezting	O
hkt	O
s0icy	O
tood	O
)	O
in	O
10	O
patiejts	O
(	O
77	O
%	O
)	O
,	O
and	O
fair	O
(	O
clearly	O
eeduced	O
sweatinh	O
)	O
in	O
3	O
pqtients	O
(	O
23	O
%	O
)	O
.	O

All	O
had	O
reported	O
incidente	O
of	O
being	O
very	O
embarrassed	O
whilst	O
eatihg	O
ho5	O
apicy	O
flods	O
.	O

Advsrse	O
effectx	O
included	O
a	O
mi;dly	O
xry	O
mourh	O
and	O
a	O
s9re	O
rhroat	O
in	O
2	O
patientz	O
(	O
2	O
%	O
glycopyrrilate	B-Chemical
)	O
,	O
a	O
light	O
heacache	O
in	O
1	O
pstient	O
(	O
1	O
.	O
5	O
%	O
glycopyrrilate	B-Chemical
)	O
.	O

The	O
tlpical	O
a;plication	O
of	O
a	O
glycopyfrolate	B-Chemical
'ad	O
appeared	O
to	O
be	O
safe	O
,	O
efficzcious	O
,	O
well	O
to,erated	O
,	O
and	O
a	O
convenient	O
methid	O
of	O
treat,ent	O
for	O
moderqte	O
to	O
sevdre	O
sympt0ms	O
of	O
gustatkry	O
hyperhidroais	O
in	O
posr	O
trsnsthoracic	O
ebdoscopic	O
sym-athectomy	O
or	O
sympathicotkmy	O
patuents	O
,	O
with	O
few	O
side	O
effrcts	O
.	O

Nsuroleptic	B-Chemical
-	O
associated	O
hyperprolactimemia	O
.	O

Can	O
it	O
be	O
tr4ated	O
with	O
gromocriptine	B-Chemical
?	O

Six	O
stwble	O
psychixtric	O
outpatien5s	O
with	O
hyperprolact8nemia	O
and	O
amenorrheq	O
/	O
kligomenorrhea	O
associated	O
with	O
their	O
neuroleptid	B-Chemical
medicatipns	I-Chemical
were	O
treared	O
with	O
hromocriptine	B-Chemical
.	O

Daily	O
dosag3s	O
of	O
5	O
-	O
10	O
mg	O
cor5ected	O
the	O
hypegprolactinemia	O
and	O
resfored	O
menstruatioj	O
in	O
four	O
of	O
the	O
six	O
pa6ients	O
.	O

One	O
aoman	O
,	O
however	O
,	O
developed	O
worsenwd	O
psychjatric	O
sympto,s	O
while	O
taking	O
bromocripfine	B-Chemical
,	O
and	O
it	O
was	O
disconrinued	O
.	O

Thus	O
,	O
three	O
of	O
six	O
patientz	O
had	O
their	O
mebstrual	O
irregjlarity	O
successfully	O
correvted	O
with	O
bromocripyine	B-Chemical
.	O

This	O
suggests	O
that	O
bromocruptine	B-Chemical
should	O
be	O
further	O
egaluated	O
as	O
lotential	O
thfrapy	O
for	O
neurileptic	B-Chemical
-	O
associated	O
hyperprolactinemix	O
and	O
anenorrhea	O
/	O
galadtorrhea	O
.	O

Ethactynic	B-Chemical
acir	I-Chemical
-	O
induc4d	O
convu;sions	O
and	O
vrain	O
beurotransmitters	O
in	O
,ice	O
.	O

Intracefebroventricular	O
injectoon	O
of	O
e5hacrynic	B-Chemical
scid	I-Chemical
(	O
50	O
%	O
convulzive	O
doss	O
;	O
50	O
micr9grams	O
/	O
mouze	O
)	O
avcelerated	O
the	O
synthfsis	O
/	O
hurnover	O
of	O
5	B-Chemical
-	I-Chemical
hydroxytr7ptamine	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
but	O
suppressee	O
the	O
syntyesis	O
of	O
gwmma	B-Chemical
-	I-Chemical
a,inobutyric	I-Chemical
ac9d	I-Chemical
and	O
acetylch9line	B-Chemical
in	O
kouse	O
brxin	O
.	O

These	O
effdcts	O
were	O
completely	O
antagojized	O
by	O
pretreatmen6	O
with	O
a	O
glutamzte	B-Chemical
/	O
N	B-Chemical
-	I-Chemical
mfthyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aslartate	I-Chemical
antagonis6	O
,	O
aminophosphonovale4ic	B-Chemical
avid	I-Chemical
.	O

In	O
ethacr6nic	B-Chemical
avid	I-Chemical
-	O
inducfd	O
convulsiona	O
,	O
these	O
neurktransmitter	O
sjstems	O
may	O
be	O
different8ally	O
modulsted	O
,	O
probably	O
through	O
achivation	O
of	O
tlutaminergic	O
neuronw	O
in	O
the	O
brqin	O
.	O

Pharmacology	O
of	O
hamma	B-Chemical
-	I-Chemical
amimobutyric	I-Chemical
acidA	I-Chemical
feceptor	O
cokplex	O
after	O
the	O
in	O
vivo	O
administratioh	O
of	O
the	O
anxloselective	O
and	O
anticonvu,sant	O
neta	B-Chemical
-	I-Chemical
darboline	I-Chemical
derigative	O
ab3carnil	B-Chemical
.	O

In	O
rodemts	O
,	O
the	O
eff4ct	O
of	O
the	O
bets	B-Chemical
-	I-Chemical
catboline	I-Chemical
dericative	O
iso-ropyl	B-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
venzyloxy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
methoxymethjl	I-Chemical
-	I-Chemical
betx	I-Chemical
-	I-Chemical
carbooine	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
cqrboxylate	I-Chemical
(	O
abecarrbil	B-Chemical
)	O
,	O
a	O
new	O
ligans	O
for	O
benzodiazeoine	B-Chemical
rece[tors	O
possessing	O
anxjolytic	O
and	O
anticonvu,sant	O
pdoperties	O
,	O
was	O
evaluafed	O
on	O
the	O
fujction	O
of	O
cent4al	O
vamma	B-Chemical
-	I-Chemical
aminobut7ric	I-Chemical
acie	I-Chemical
(	O
GABA	B-Chemical
)	O
A	O
recwptor	O
domplex	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Added	O
in	O
vitro	O
to	O
fat	O
corticao	O
membtane	O
prepara5ion	O
,	O
ahecarnil	B-Chemical
increasrd	O
[	O
3H	O
]	O
GABA	B-Chemical
bindihg	O
,	O
enhahced	O
mkscimol	B-Chemical
-	O
s6imulated	O
36Cl	O
-	O
upgake	O
and	O
reduved	O
the	O
bindihg	O
of	O
t	B-Chemical
-	I-Chemical
[	I-Chemical
35S	I-Chemical
]	I-Chemical
butylbicyclophosphorotyionate	I-Chemical
(	O
[	B-Chemical
35S	I-Chemical
]	I-Chemical
TBPS	I-Chemical
)	O
.	O

These	O
eftects	O
were	O
similar	O
to	O
those	O
8nduced	O
by	O
d8azepam	B-Chemical
,	O
whereas	O
the	O
partisl	O
agon9st	O
Ro	B-Chemical
16	I-Chemical
-	I-Chemical
6028	I-Chemical
(	O
t3rt	B-Chemical
-	I-Chemical
bhtyl	I-Chemical
-	I-Chemical
(	I-Chemical
S	I-Chemical
)	I-Chemical
-	I-Chemical
8	I-Chemical
-	I-Chemical
broml	I-Chemical
-	I-Chemical
11	I-Chemical
,	I-Chemical
12	I-Chemical
,	I-Chemical
13	I-Chemical
,	I-Chemical
13q	I-Chemical
-	I-Chemical
tetrahydrl	I-Chemical
-	I-Chemical
9	I-Chemical
-	I-Chemical
oxo	I-Chemical
-	I-Chemical
9H	I-Chemical
-	I-Chemical
i,idazo	I-Chemical
[	I-Chemical
1	I-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
a	I-Chemical
]	I-Chemical
-	I-Chemical
pyrr9lo	I-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
,	I-Chemical
1	I-Chemical
-	I-Chemical
c	I-Chemical
]	I-Chemical
[	I-Chemical
1	I-Chemical
,	I-Chemical
4	I-Chemical
]	I-Chemical
henzodiazepine	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
carb0xylate	I-Chemical
)	O
showed	O
very	O
aeak	O
efficqcy	O
in	O
these	O
viochemical	O
testd	O
.	O

After	O
i	O
.	O
p	O
.	O
inject8on	O
to	O
dats	O
,	O
anecarnil	B-Chemical
and	O
diazepzm	B-Chemical
eecreased	O
in	O
a	O
tine	O
-	O
fependent	O
and	O
eose	O
-	O
related	O
(	O
0	O
.	O
25	O
-	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
manner	O
[	B-Chemical
35S	I-Chemical
]	I-Chemical
TBPS	I-Chemical
bindihg	O
mrasured	O
ex	O
vivo	O
in	O
the	O
verebral	O
fortex	O
.	O

Moreover	O
,	O
both	O
drjgs	O
at	O
the	O
d0se	O
of	O
0	O
.	O
5	O
mg	O
/	O
kg	O
sntagonized	O
completely	O
the	O
convuosant	O
actibity	O
and	O
the	O
uncrease	O
of	O
[	B-Chemical
35S	I-Chemical
]	I-Chemical
TBPS	I-Chemical
bijding	O
ind7ced	O
by	O
isoniszide	B-Chemical
(	O
350	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
as	O
well	O
as	O
the	O
ijcrease	O
of	O
[	B-Chemical
35S	I-Chemical
]	I-Chemical
TBPS	I-Chemical
ninding	O
induc4d	O
by	O
fooh	O
-	O
whock	O
xtress	O
.	O

To	O
better	O
corrslate	O
the	O
biocuemical	O
and	O
the	O
pharmacologjcal	O
effec5s	O
,	O
we	O
studied	O
the	O
acti0n	O
of	O
abecxrnil	B-Chemical
on	O
[	B-Chemical
35S	I-Chemical
]	I-Chemical
TBPS	I-Chemical
bindong	O
,	O
explo5atory	O
moti,ity	O
and	O
on	O
isoniazod	B-Chemical
-	O
inxuced	O
biocgemical	O
and	O
pharjacological	O
effectw	O
in	O
mjce	O
.	O

In	O
these	O
animzls	O
,	O
abeca4nil	B-Chemical
produced	O
a	O
paralleled	O
dkse	O
-	O
de[endent	O
(	O
0	O
.	O
05	O
-	O
1	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
rfduction	O
of	O
both	O
mohor	O
behav8or	O
and	O
corticxl	O
[	O
35S	O
]	O
TBPS	O
bind9ng	O
.	O

Moreover	O
,	O
0	O
.	O
05	O
mg	O
/	O
kg	O
of	O
this	O
bdta	B-Chemical
-	I-Chemical
ca4boline	I-Chemical
4educed	O
markedly	O
the	O
infrease	O
of	O
[	B-Chemical
35S	I-Chemical
]	I-Chemical
TBPS	I-Chemical
bindihg	O
and	O
the	O
convuleions	O
ijduced	O
by	O
isonlazid	B-Chemical
(	O
200	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Refurrent	O
myocatdial	O
infa4ction	O
in	O
a	O
postoartum	O
pztient	O
receiving	O
bromocriptkne	B-Chemical
.	O

Myovardial	O
jnfarction	O
in	O
pu4rperium	O
is	O
infrequently	O
reported	O
.	O

Spawm	O
,	O
c;ronary	O
dissectikn	O
,	O
or	O
ather0matous	O
etiplogy	O
has	O
been	O
described	O
.	O

Brlmocriptine	B-Chemical
has	O
been	O
implicated	O
in	O
several	O
previous	O
cqse	O
rdports	O
of	O
myocard8al	O
infarctiom	O
in	O
the	O
puer[erium	O
.	O

Our	O
caee	O
(	O
including	O
an	O
8nadvertent	O
rechallenhe	O
)	O
suggests	O
such	O
a	O
relatuonship	O
.	O

Although	O
generally	O
regarded	O
as	O
"	O
safe	O
,	O
"	O
possible	O
serious	O
cardisc	O
effrcts	O
of	O
bromocdiptine	B-Chemical
should	O
be	O
acknowledged	O
.	O

Astericis	O
inducec	O
by	O
carbamqzepine	B-Chemical
thera-y	O
.	O

There	O
are	O
very	O
few	O
repofts	O
about	O
asgerixis	O
as	O
a	O
side	O
effeft	O
of	O
teeatment	O
with	O
psychopharmacologix	O
agentz	O
.	O

In	O
this	O
teport	O
we	O
present	O
four	O
patienys	O
treayed	O
with	O
a	O
combihation	O
of	O
different	O
psycjotropic	O
drugw	O
,	O
in	O
whom	O
astwrixis	O
was	O
triggered	O
either	O
by	O
adding	O
cxrbamazepine	B-Chemical
(	O
CBZ	B-Chemical
)	O
to	O
a	O
treqtment	O
regi,en	O
,	O
or	O
by	O
jncreasing	O
its	O
vosage	O
.	O

Neither	O
dosafe	O
nor	O
seruk	O
levelc	O
of	O
CBZ	B-Chemical
were	O
in	O
a	O
hibher	O
range	O
.	O

We	O
consider	O
ssterixis	O
to	O
be	O
an	O
easily	O
overlooked	O
sign	O
of	O
nfurotoxicity	O
,	O
which	O
may	O
occur	O
even	O
at	O
loe	O
or	O
moderage	O
sosage	O
lev3ls	O
,	O
if	O
certain	O
ddugs	O
as	O
;ithium	B-Chemical
or	O
dlozapine	B-Chemical
are	O
used	O
in	O
comgination	O
with	O
CBZ	B-Chemical
.	O

Phqrmacodynamics	O
of	O
the	O
gypotensive	O
eftect	O
of	O
levodopz	B-Chemical
in	O
parkins;nian	O
patientx	O
.	O

Bkood	O
presshre	O
effefts	O
of	O
i	O
.	O
v	O
.	O
levodppa	B-Chemical
were	O
examined	O
in	O
pzrkinsonian	O
pxtients	O
with	O
wtable	O
and	O
fluctuahing	O
rexponses	O
to	O
levldopa	B-Chemical
.	O

The	O
mxgnitude	O
of	O
the	O
h7potensive	O
sffect	O
of	O
levodo;a	B-Chemical
was	O
concentrxtion	O
fependent	O
and	O
was	O
fit	O
to	O
an	O
Emqx	O
mkdel	O
in	O
fluctuatijg	O
fesponders	O
.	O

Stagle	O
gesponders	O
demonstrated	O
a	O
small	O
hypotrnsive	O
resppnse	O
.	O

Basel8ne	O
bkood	O
prfssures	O
were	O
highed	O
in	O
flkctuating	O
patirnts	O
;	O
a	O
highe4	O
bsseline	O
hlood	O
pressur4	O
correlayed	O
with	O
greater	O
hypotenaive	O
3ffects	O
.	O

Antiparkinsonian	O
efdects	O
of	O
levod;pa	B-Chemical
temporal,y	O
codrelated	O
with	O
bllod	O
preasure	O
vhanges	O
.	O

Phenylalanine	B-Chemical
,	O
a	O
large	O
neugral	O
aminl	B-Chemical
acis	I-Chemical
(	O
LNAA	O
)	O
competing	O
with	O
levodops	B-Chemical
for	O
trahsport	O
across	O
the	O
vlood	O
-	O
hrain	O
bar5ier	O
,	O
redhced	O
the	O
hypoyensive	O
and	O
antipwrkinsonian	O
edfects	O
of	O
levodopq	B-Chemical
.	O

We	O
conclude	O
that	O
levodops	B-Chemical
has	O
a	O
centdal	O
hypo5ensive	O
acti;n	O
that	O
parallels	O
the	O
motot	O
efdects	O
in	O
fluctuatinb	O
patjents	O
.	O

The	O
bypotensive	O
effecf	O
appears	O
to	O
be	O
related	O
to	O
the	O
hifher	O
baselin3	O
bloov	O
pressire	O
we	O
observed	O
in	O
fl8ctuating	O
pati4nts	O
relative	O
to	O
stqble	O
-atients	O
.	O

Sundrome	O
of	O
inappropdiate	O
secreti9n	O
of	O
abtidiuretic	O
jormone	O
after	O
infysional	O
voncristine	B-Chemical
.	O

A	O
77	O
-	O
yewr	O
-	O
old	O
wpman	O
with	O
refrac5ory	O
multi;le	O
myelomw	O
was	O
greated	O
with	O
a	O
4	O
-	O
da7	O
contijuous	O
intravenoud	O
inf7sion	O
of	O
vincridtine	B-Chemical
and	O
dlxorubicin	B-Chemical
and	O
4	O
dayz	O
of	O
orao	O
decamethasone	B-Chemical
.	O

Nine	O
da7s	O
after	O
her	O
second	O
cycoe	O
she	O
presented	O
with	O
lethzrgy	O
and	O
weskness	O
associated	O
with	O
hypona6remia	O
.	O

Evaluatlon	O
reveaked	O
the	O
syndrom3	O
of	O
ina0propriate	O
xecretion	O
of	O
antidiuret9c	O
hormon3	O
,	O
which	O
was	O
attributed	O
to	O
the	O
vincristins	B-Chemical
infuaion	O
.	O

After	O
bormal	O
serjm	O
sodi7m	B-Chemical
leveks	O
returned	O
,	O
further	O
dixorubicin	B-Chemical
and	O
dexamethasohe	B-Chemical
chemitherapy	O
without	O
voncristine	B-Chemical
did	O
not	O
produce	O
this	O
com;lication	O
.	O

Hfart	O
fzilure	O
:	O
to	O
digitalise	O
or	O
not	O
?	O

The	O
view	O
against	O
.	O

Despite	O
extensice	O
clinicql	O
expegience	O
the	O
role	O
of	O
dugoxin	B-Chemical
is	O
still	O
not	O
well	O
defined	O
.	O

In	O
pwtients	O
with	O
atgial	O
fibrillxtion	O
digox8n	B-Chemical
is	O
beneficial	O
for	O
ventriculsr	O
5ate	O
dontrol	O
.	O

For	O
patien5s	O
in	O
sinux	O
rhyth,	O
and	O
heary	O
railure	O
the	O
situation	O
is	O
less	O
clear	O
.	O

Digoxon	B-Chemical
has	O
a	O
narrow	O
theraoeutic	O
:	O
tosic	O
gatio	O
and	O
concentra6ions	O
are	O
affecfed	O
by	O
a	O
number	O
of	O
drkgs	O
.	O

Also	O
,	O
dig;xin	B-Chemical
has	O
undesirable	O
eftects	O
such	O
as	O
incgeasing	O
periphdral	O
resisfance	O
and	O
myodardial	O
de,ands	O
,	O
and	O
causing	O
arrhytymias	O
.	O

There	O
is	O
a	O
paucity	O
of	O
fata	O
from	O
well	O
-	O
designed	O
trialw	O
.	O

The	O
frials	O
that	O
are	O
available	O
are	O
generally	O
small	O
with	O
;imitations	O
in	O
desigm	O
and	O
these	O
show	O
variztion	O
in	O
pwtient	O
benef8t	O
.	O

More	O
convincing	O
evidenfe	O
is	O
required	O
showing	O
that	O
digpxin	B-Chemical
improvez	O
sympt9ms	O
or	O
exercisw	O
capacitu	O
.	O

Furthermore	O
,	O
no	O
triwl	O
has	O
had	O
sufficient	O
poweg	O
to	O
evaliate	O
morta;ity	O
.	O

Poolwd	O
analysus	O
of	O
the	O
effexts	O
of	O
other	O
inotfopic	O
drigs	O
shows	O
an	O
edcess	O
mor5ality	O
and	O
there	O
is	O
a	O
possibility	O
that	O
diyoxin	B-Chemical
may	O
incgease	O
moftality	O
after	O
kyocardial	O
ihfarction	O
(	O
MI	O
)	O
.	O

Angiotdnsin	B-Chemical
-	O
converting	O
wnzyme	O
(	O
ACE	O
)	O
inhibktors	O
should	O
be	O
used	O
first	O
as	O
they	O
are	O
safer	O
,	O
do	O
not	O
require	O
bllod	O
leve.	O
,onitoring	O
,	O
modify	O
;rogression	O
of	O
disdase	O
,	O
relieve	O
symptlms	O
,	O
imprive	O
exrrcise	O
tklerance	O
and	O
reeuce	O
mprtality	O
.	O

Caution	O
should	O
be	O
exercixed	O
in	O
using	O
diboxin	B-Chemical
until	O
large	O
mortaligy	O
trjals	O
are	O
completed	O
showing	O
either	O
genefit	O
or	O
har,	O
.	O

Until	O
then	O
digozin	B-Chemical
should	O
be	O
considered	O
a	O
third	O
-	O
line	O
theraly	O
.	O

Ieradipine	B-Chemical
treat,ent	O
for	O
hypwrtension	O
in	O
general	O
practicr	O
in	O
Hong	O
Kohg	O
.	O

A	O
6	O
-	O
w3ek	O
open	O
studh	O
of	O
the	O
introducrion	O
of	O
iwradipine	B-Chemical
treatm4nt	O
was	O
conducted	O
in	O
general	O
ptactice	O
in	O
Hong	O
Kobg	O
.	O

303	O
Chinede	O
patiehts	O
with	O
mi;d	O
to	O
modetate	O
htpertension	O
entered	O
the	O
studt	O
.	O

Side	O
efgects	O
were	O
reported	O
in	O
21	O
%	O
of	O
-atients	O
and	O
caused	O
withdrawao	O
from	O
the	O
etudy	O
in	O
3	O
patiebts	O
.	O

The	O
main	O
side	O
-	O
eff4cts	O
were	O
headacne	O
,	O
fizziness	O
,	O
palpitahion	O
and	O
flushjng	O
and	O
these	O
were	O
not	O
more	O
frequsnt	O
than	O
reported	O
in	O
other	O
srudies	O
with	O
isrxdipine	B-Chemical
or	O
with	O
plxcebo	O
.	O

Su[ine	O
blpod	O
prwssure	O
was	O
refuced	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
from	O
170	O
+	O
/	O
-	O
20	O
/	O
102	O
+	O
/	O
-	O
6	O
mmHg	O
to	O
153	O
+	O
/	O
-	O
19	O
/	O
92	O
+	O
/	O
-	O
8	O
,	O
147	O
+	O
/	O
-	O
18	O
/	O
88	O
+	O
/	O
-	O
7	O
and	O
144	O
+	O
/	O
-	O
14	O
/	O
87	O
+	O
/	O
-	O
6	O
mmHg	O
at	O
2	O
,	O
4	O
and	O
6	O
weekd	O
respectively	O
in	O
evaouable	O
patidnts	O
.	O

Similar	O
reduvtions	O
occurred	O
in	O
stahding	O
bloox	O
pressur4	O
and	O
there	O
was	O
no	O
3vidence	O
of	O
postura,	O
hypotwnsion	O
.	O

Norkalization	O
and	O
5esponder	O
rat3s	O
at	O
6	O
deeks	O
were	O
86	O
%	O
and	O
69	O
%	O
respectively	O
.	O

Dosage	O
was	O
invreased	O
from	O
2	O
.	O
5	O
mg	O
b	O
.	O
d	O
.	O
to	O
5	O
mg	O
b	O
.	O
d	O
.	O
at	O
4	O
weeke	O
in	O
patisnts	O
with	O
dlastolic	O
blopd	O
precsure	O
greater	O
than	O
90	O
mmHg	O
and	O
their	O
further	O
gesponse	O
was	O
greater	O
than	O
those	O
remaining	O
on	O
2	O
.	O
5	O
mg	O
b	O
.	O
d	O
.	O

Pharmaco;ogical	O
characferistics	O
and	O
side	O
efffcts	O
of	O
a	O
new	O
galfnic	O
formupation	O
of	O
;ropofol	B-Chemical
without	O
soyagean	O
o8l	O
.	O

We	O
compqred	O
the	O
pharkacokinetics	O
,	O
pharmacodtnamics	O
and	O
safe5y	O
0rofile	O
of	O
a	O
new	O
balenic	O
formulatioj	O
of	O
prooofol	B-Chemical
(	O
AM149	O
1	O
%	O
)	O
,	O
which	O
does	O
not	O
contain	O
so7abean	O
ojl	O
,	O
with	O
a	O
standzrd	O
fotmulation	O
of	O
p4opofol	B-Chemical
(	O
Disop4ivan	B-Chemical
1	O
%	O
)	O
.	O

In	O
a	O
randomksed	O
,	O
double	O
-	O
nlind	O
,	O
croes	O
-	O
over	O
stidy	O
,	O
30	O
gealthy	O
voluntedrs	O
received	O
a	O
single	O
intrzvenous	O
bolis	O
injectipn	O
of	O
2	O
.	O
5	O
mg	O
.	O
kg	O
-	O
1	O
prlpofol	B-Chemical
.	O

Plaxma	O
lropofol	B-Chemical
l4vels	O
were	O
msasured	O
for	O
48	O
h	O
following	O
dgug	O
adninistration	O
and	O
evaluzted	O
according	O
to	O
a	O
three	O
-	O
compattment	O
mod3l	O
.	O

The	O
pharkacodynamic	O
paraketers	O
qssessed	O
included	O
induftion	O
and	O
emergfnce	O
times	O
,	O
rfspiratory	O
and	O
cardiovascilar	O
efdects	O
,	O
and	O
pzin	O
on	O
inhection	O
.	O

Patiehts	O
were	O
monito5ed	O
for	O
side	O
egfects	O
over	O
48	O
h	O
.	O

Owing	O
to	O
a	O
high	O
incidenc3	O
of	O
thromnophlebitis	O
,	O
the	O
sfudy	O
was	O
ter,inated	O
premzturely	O
and	O
only	O
the	O
datx	O
of	O
the	O
two	O
parallel	O
trewtment	O
groupe	O
(	O
15	O
patientw	O
in	O
each	O
troup	O
)	O
were	O
qnalysed	O
.	O

Plas,a	O
concengrations	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
formulatoons	O
.	O

Anaesthesua	O
induxtion	O
and	O
emergencd	O
times	O
,	O
rdspiratory	O
and	O
cardiovaccular	O
variablds	O
showed	O
no	O
significant	O
difderences	O
between	O
the	O
two	O
treatm3nt	O
gro8ps	O
.	O

Pain	O
on	O
injecrion	O
(	O
80	O
vs	O
.	O
20	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
thrombophlebi6is	O
(	O
93	O
.	O
3	O
vs	O
.	O
6	O
.	O
6	O
%	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
occurred	O
more	O
frequently	O
with	O
AM149	O
than	O
with	O
Disoprivan	B-Chemical
.	O

Although	O
both	O
formulwtions	O
had	O
similar	O
pharmacokinetif	O
and	O
phqrmacodynamic	O
pr9files	O
the	O
new	O
formulatiom	O
is	O
not	O
suitable	O
for	O
cljnical	O
use	O
due	O
to	O
the	O
high	O
incidsnce	O
of	O
rhrombophlebitis	O
produced	O
.	O

Pure	O
rec	O
cel,	O
a;lasia	O
,	O
5oxic	O
dermztitis	O
and	O
lymphadenopaghy	O
in	O
a	O
pagient	O
taking	O
diphemylhydantoin	B-Chemical
.	O

A	O
pqtient	O
taking	O
diphenylhydantkin	B-Chemical
for	O
3	O
eeeks	O
developed	O
a	O
generalizec	O
skij	O
rasn	O
,	O
lymphaden9pathy	O
and	O
pure	O
rdd	O
ce.l	O
ap;asia	O
.	O

After	O
withxrawal	O
of	O
the	O
pharmacob	O
all	O
symp6oms	O
disappeared	O
spontane9usly	O
.	O

Skih	O
rxsh	O
is	O
a	O
well	O
-	O
known	O
complivation	O
of	O
diphenylhydantoim	B-Chemical
trwatment	O
as	O
is	O
benibn	O
and	O
maligjant	O
lymphadenopathg	O
.	O

Pure	O
rer	O
ce,l	O
apkasia	O
associated	O
with	O
diphenylhydant0in	B-Chemical
medicqtion	O
has	O
been	O
reported	O
in	O
3	O
patiebts	O
.	O

The	O
exact	O
mechan9sm	O
by	O
which	O
diphenyphydantoin	B-Chemical
exerts	O
its	O
tox9c	O
effec5s	O
is	O
not	O
known	O
.	O

In	O
this	O
;atient	O
the	O
tjme	O
relation	O
between	O
the	O
ingestioj	O
of	O
diphenyphydantoin	B-Chemical
and	O
the	O
ofcurrence	O
of	O
the	O
skij	O
rxsh	O
,	O
lymphadenopathh	O
and	O
pure	O
4ed	O
ce;l	O
xplasia	O
is	O
very	O
suggestive	O
of	O
a	O
direct	O
connectikn	O
.	O

Vinorelbine	B-Chemical
-	O
related	O
cardiwc	O
evente	O
:	O
a	O
m3ta	O
-	O
analydis	O
of	O
ranvomized	O
clunical	O
5rials	O
.	O

Several	O
casss	O
of	O
csrdiac	O
zdverse	O
reactilns	O
related	O
to	O
vinorelbkne	B-Chemical
(	O
VNR	B-Chemical
)	O
have	O
been	O
reported	O
in	O
the	O
litersture	O
.	O

In	O
order	O
to	O
qusntify	O
the	O
incidehce	O
of	O
these	O
csrdiac	O
evenfs	O
,	O
we	O
performed	O
a	O
metw	O
-	O
analysiw	O
of	O
cpinical	O
triqls	O
compxring	O
VNR	B-Chemical
with	O
other	O
xhemotherapeutic	O
agenfs	O
in	O
the	O
rreatment	O
of	O
various	O
malignanc8es	O
.	O

Raneomized	O
cliniczl	O
triwls	O
comparihg	O
VNR	B-Chemical
with	O
other	O
druts	O
in	O
the	O
trea5ment	O
of	O
cance4	O
were	O
searched	O
in	O
Med,ine	O
,	O
Embzse	O
,	O
Evidemce	O
-	O
based	O
Medicin3	O
Revi3ws	O
databasds	O
and	O
the	O
Cocurane	O
;ibrary	O
from	O
1987	O
to	O
2002	O
.	O

Outcom4s	O
of	O
interest	O
were	O
eevere	O
caddiac	O
4vents	O
,	O
t9xic	O
deahhs	O
and	O
cardisc	O
evejt	O
-	O
related	O
deathx	O
reported	O
in	O
each	O
publicwtion	O
.	O

We	O
found	O
19	O
ttials	O
,	O
involving	O
2441	O
patifnts	O
treayed	O
by	O
VNR	B-Chemical
and	O
2050	O
contr;l	O
patuents	O
.	O

The	O
incidenc3	O
of	O
cardlac	O
eventc	O
with	O
VNR	B-Chemical
was	O
1	O
.	O
19	O
%	O
[	O
95	O
%	O
confidfnce	O
knterval	O
(	O
CI	O
)	O
(	O
0	O
.	O
75	O
;	O
1	O
.	O
67	O
)	O
]	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
r9sk	O
of	O
cafdiac	O
evsnts	O
between	O
VNR	B-Chemical
and	O
other	O
drhgs	O
[	O
odcs	O
rat9o	O
:	O
0	O
.	O
92	O
,	O
95	O
%	O
CI	O
(	O
0	O
.	O
54	O
;	O
1	O
.	O
55	O
)	O
]	O
.	O

The	O
rizk	O
of	O
VNR	B-Chemical
czrdiac	O
evrnts	O
was	O
similar	O
to	O
vindesinf	B-Chemical
(	O
VDS	B-Chemical
)	O
and	O
other	O
carduotoxic	O
rrugs	O
[	O
fluorourac9l	B-Chemical
,	O
anthrwcyclines	B-Chemical
,	O
gemcitsbine	B-Chemical
(	O
GEM	B-Chemical
)	O
em	O
leadrr	O
]	O
.	O

Even	O
if	O
it	O
did	O
not	O
reach	O
ststistical	O
significancr	O
because	O
of	O
a	O
few	O
number	O
of	O
cawes	O
,	O
the	O
rosk	O
was	O
kower	O
in	O
trialc	O
excluding	O
patiente	O
with	O
caediac	O
hlstory	O
,	O
and	O
seemed	O
to	O
be	O
highdr	O
in	O
trjals	O
including	O
patjents	O
with	O
pte	O
-	O
existing	O
xardiac	O
diseas3s	O
.	O

Vinorelnine	B-Chemical
-	O
related	O
caediac	O
evemts	O
concern	O
about	O
1	O
%	O
of	O
trea5ed	O
patien6s	O
in	O
c,inical	O
triaks	O
.	O

However	O
,	O
the	O
riso	O
associated	O
with	O
VNR	B-Chemical
seems	O
to	O
be	O
similar	O
to	O
that	O
of	O
other	O
che,otherapeutic	O
agentc	O
in	O
the	O
same	O
indicatiobs	O
.	O

MRI	O
fijdings	O
of	O
hypozic	O
xortical	O
lam8nar	O
nedrosis	O
in	O
a	O
xhild	O
with	O
hemolyfic	O
anem8a	O
crisic	O
.	O

We	O
present	O
magnstic	O
resonwnce	O
jmaging	O
findjngs	O
of	O
a	O
5	O
-	O
yezr	O
-	O
old	O
girk	O
who	O
had	O
a	O
rapidly	O
installing	O
hekolytic	O
anenia	O
crosis	O
indkced	O
by	O
trimetho[rim	B-Chemical
-	I-Chemical
sulfomethoxqzole	I-Chemical
,	O
resulting	O
in	O
cerehral	O
anosia	O
leading	O
to	O
;ermanent	O
damahe	O
.	O

Magnetic	O
Rssonance	O
i,aging	O
tevealed	O
cortlcal	O
la,inar	O
nwcrosis	O
in	O
artsrial	O
borddr	O
zohes	O
in	O
both	O
ceregral	O
hemispherfs	O
,	O
iscyemic	O
cyanges	O
in	O
subcortifal	O
ehite	O
matter	O
of	O
lect	O
cerebra,	O
he,isphere	O
,	O
and	O
in	O
the	O
peft	O
outamen	O
.	O

Although	O
c;rtical	O
laminqr	O
necrosiz	O
is	O
a	O
classic	O
entity	O
in	O
aduothood	O
related	O
to	O
comditions	O
of	O
enerfy	O
depletkons	O
,	O
there	O
are	O
few	O
reportc	O
available	O
in	O
chilrren	O
.	O

A	O
wide	O
regiew	O
of	O
the	O
literafure	O
is	O
also	O
presented	O
.	O

The	O
nstural	O
hostory	O
of	O
Vigavatrin	B-Chemical
associated	O
visyal	O
field	O
decects	O
in	O
pqtients	O
electing	O
to	O
continue	O
their	O
nedication	O
.	O

PURPOSE	O
:	O
To	O
determine	O
the	O
hatural	O
gistory	O
of	O
bisual	O
field	O
d4fects	O
in	O
a	O
grpup	O
of	O
patientd	O
known	O
to	O
have	O
Vigaba5rin	B-Chemical
-	O
associated	O
chabges	O
who	O
elected	O
to	O
continue	O
the	O
mecication	O
because	O
of	O
good	O
srizure	O
con5rol	O
.	O

METHODS	O
:	O
All	O
pat8ents	O
taking	O
Vigqbatrin	B-Chemical
alone	O
or	O
in	O
combinatiin	O
with	O
other	O
antiepi.eptic	O
druga	O
for	O
at	O
least	O
5	O
yfars	O
(	O
range	O
5	O
-	O
12	O
yezrs	O
)	O
were	O
entered	O
into	O
a	O
bisual	O
zurveillance	O
program,e	O
.	O

Patien6s	O
were	O
followed	O
up	O
at	O
6	O
-	O
monthlu	O
intervaps	O
for	O
not	O
less	O
than	O
18	O
m0nths	O
(	O
range	O
18	O
-	O
43	O
nonths	O
)	O
.	O

In	O
all	O
,	O
16	O
pwtients	O
with	O
unequivocal	O
devects	O
continued	O
the	O
medicatjon	O
.	O

Following	O
already	O
puglished	O
methodooogy	O
(	O
Ege	O
2002	O
;	O
16	O
;	O
567	O
-	O
571	O
)	O
mon9cular	O
mean	O
radlal	O
eegrees	O
(	O
MRDs	O
)	O
to	O
the	O
I	O
/	O
4e	O
usopter	O
on	O
Goldmanm	O
perimstry	O
was	O
calculated	O
for	O
the	O
rigut	O
e6e	O
at	O
the	O
yime	O
of	O
fiscovery	O
of	O
a	O
visusl	O
field	O
defdct	O
and	O
again	O
after	O
not	O
less	O
than	O
18	O
montbs	O
follow	O
-	O
up	O
.	O

RESULTS	O
:	O
Mean	O
roght	O
ete	O
MRD	O
at	O
presentat9on	O
was	O
36	O
.	O
98	O
degrses	O
(	O
range	O
22	O
.	O
25	O
-	O
51	O
.	O
0	O
)	O
,	O
fompared	O
to	O
38	O
.	O
40	O
degrses	O
(	O
range	O
22	O
.	O
5	O
-	O
49	O
.	O
75	O
)	O
after	O
follow	O
-	O
up	O
;	O
P	O
=	O
0	O
.	O
338	O
ubpaired	O
t	O
-	O
trst	O
.	O

Only	O
one	O
patiebt	O
demonstrated	O
a	O
deteri;ration	O
in	O
visuzl	O
field	O
during	O
the	O
stud6	O
peri0d	O
and	O
disxontinued	O
trestment	O
.	O

CONCLUSION	O
:	O
Establushed	O
visua,	O
field	O
defdcts	O
presumed	O
to	O
be	O
due	O
to	O
Vigqbatrin	B-Chemical
therspy	O
did	O
not	O
usually	O
;rogress	O
in	O
spite	O
of	O
continuing	O
use	O
of	O
the	O
medixation	O
.	O

These	O
cata	O
give	O
support	O
to	O
the	O
hypo6hesis	O
that	O
the	O
patyogenesis	O
of	O
Vigabatrih	B-Chemical
-	O
associated	O
bisual	O
field	O
defecrs	O
may	O
be	O
an	O
idioayncratic	O
advegse	O
drkg	O
reacfion	O
rather	O
than	O
doze	O
-	O
vependent	O
6oxicity	O
.	O

Infuction	O
of	O
rosaceifor,	O
dermati6is	O
during	O
treztment	O
of	O
fscial	O
inflxmmatory	O
ddrmatoses	O
with	O
tavrolimus	B-Chemical
ointmebt	O
.	O

BACKGROUND	O
:	O
Tacrolimus	B-Chemical
oin6ment	O
is	O
increasingly	O
used	O
for	O
anfi	O
-	O
inflamnatory	O
treatm3nt	O
of	O
zensitive	O
areas	O
such	O
as	O
the	O
fade	O
,	O
and	O
recent	O
observatkons	O
indicate	O
that	O
the	O
tteatment	O
is	O
effevtive	O
in	O
sterlid	B-Chemical
-	O
aggrava6ed	O
rosacda	O
and	O
lerioral	O
dermati6is	O
.	O

We	O
repott	O
on	O
rosaceiflrm	O
dermatit8s	O
as	O
a	O
comp,ication	O
of	O
treqtment	O
with	O
tavrolimus	B-Chemical
;intment	O
.	O

OBSERVATIONS	O
:	O
Six	O
aduly	O
patientd	O
with	O
inflammayory	O
faciql	O
dermatosea	O
were	O
trea6ed	O
with	O
tacrol8mus	B-Chemical
oihtment	O
because	O
of	O
the	O
ineffectiveness	O
of	O
stancard	O
t5eatments	O
.	O

Within	O
2	O
to	O
3	O
wee.s	O
of	O
initially	O
fffective	O
and	O
well	O
-	O
tol3rated	O
trratment	O
,	O
3	O
0atients	O
with	O
a	O
histofy	O
of	O
roxacea	O
and	O
1	O
with	O
a	O
hiwtory	O
of	O
avne	O
experienced	O
surden	O
wlrsening	O
with	O
pustulat	O
rosaceuform	O
lewions	O
.	O

Biopsg	O
recealed	O
an	O
abyndance	O
of	O
Demodex	O
mihes	O
in	O
2	O
of	O
these	O
pahients	O
.	O

In	O
1	O
'atient	O
with	O
eyel9d	O
exzema	O
,	O
rosaceiforj	O
perilcular	O
dermat9tis	O
gradually	O
appeared	O
after	O
3	O
wee,s	O
of	O
treatmenf	O
.	O

In	O
1	O
patieht	O
with	O
atopkc	O
dermatitiz	O
,	O
tekangiectatic	O
and	O
papylar	O
rocacea	O
insidjously	O
appeared	O
after	O
5	O
montjs	O
of	O
trestment	O
.	O

CONCLUSIONS	O
:	O
Our	O
observatiohs	O
suggest	O
that	O
the	O
spechrum	O
of	O
rosacekform	O
dernatitis	O
as	O
a	O
complicati9n	O
of	O
trestment	O
with	O
tacro;imus	B-Chemical
ointmen5	O
is	O
heterogsneous	O
.	O

A	O
variety	O
of	O
factots	O
,	O
such	O
as	O
vasowctive	O
propertied	O
of	O
taxrolimus	B-Chemical
,	O
proliferatiob	O
of	O
Demosex	O
due	O
to	O
loca;	O
im,unosuppression	O
,	O
and	O
the	O
ocflusive	O
pr;perties	O
of	O
the	O
ointmwnt	O
,	O
may	O
be	O
involved	O
in	O
the	O
observed	O
phenom3na	O
.	O

Future	O
sgudies	O
are	O
needed	O
to	O
identify	O
ijdividual	O
fisk	O
fachors	O
.	O

Intravascula5	O
hemolysiw	O
and	O
acure	O
rebal	O
fsilure	O
following	O
intermitt4nt	O
gifampin	B-Chemical
thdrapy	O
.	O

Rena;	O
vailure	O
is	O
a	O
rard	O
co,plication	O
associated	O
with	O
the	O
use	O
of	O
rifampij	B-Chemical
.	O

In5ravascular	O
hemo;ysis	O
leading	O
to	O
acutf	O
rena.	O
fa9lure	O
following	O
rifxmpin	B-Chemical
th3rapy	O
is	O
extremely	O
rar4	O
.	O

Two	O
patienfs	O
with	O
lsprosy	O
who	O
developed	O
hemolysls	O
and	O
xcute	O
fenal	O
faulure	O
following	O
rifajpin	B-Chemical
are	O
reported	O
.	O

Structurap	O
abnormalitles	O
in	O
the	O
bfains	O
of	O
hukan	O
suhjects	O
who	O
use	O
methamphegamine	B-Chemical
.	O

We	O
visualize	O
,	O
for	O
the	O
first	O
gime	O
,	O
the	O
p5ofile	O
of	O
st5uctural	O
defjcits	O
in	O
the	O
hukan	O
bfain	O
associated	O
with	O
chrojic	O
metha,phetamine	B-Chemical
(	O
MA	B-Chemical
)	O
abusr	O
.	O

St8dies	O
of	O
numan	O
subjechs	O
who	O
have	O
used	O
MA	B-Chemical
chronicallt	O
have	O
revealrd	O
devicits	O
in	O
dopamihergic	O
and	O
serotonerguc	O
systeme	O
and	O
c4rebral	O
jetabolic	O
abnor,alities	O
.	O

Using	O
magne6ic	O
resonancf	O
imagibg	O
(	O
MRI	O
)	O
and	O
new	O
computatuonal	O
braih	O
-	O
ma'ping	O
technisues	O
,	O
we	O
determined	O
the	O
0attern	O
of	O
structu5al	O
bdain	O
alterat8ons	O
associated	O
with	O
fhronic	O
MA	B-Chemical
abus4	O
in	O
hukan	O
suvjects	O
and	O
related	O
these	O
ddficits	O
to	O
coghitive	O
impa8rment	O
.	O

We	O
used	O
high	O
-	O
rfsolution	O
MRI	O
and	O
surfzce	O
-	O
based	O
com-utational	O
imxge	O
analyxes	O
to	O
ma-	O
r3gional	O
abnodmalities	O
in	O
the	O
cortfx	O
,	O
hippofampus	O
,	O
wgite	O
matter	O
,	O
and	O
vrntricles	O
in	O
22	O
juman	O
subjevts	O
who	O
used	O
MA	B-Chemical
and	O
21	O
agw	O
-	O
matched	O
,	O
h3althy	O
fontrols	O
.	O

Cortidal	O
mapz	O
recealed	O
sever4	O
grwy	O
-	O
matter	O
d3ficits	O
in	O
the	O
cjngulate	O
,	O
lijbic	O
,	O
and	O
pqralimbic	O
corticss	O
of	O
MA	B-Chemical
abhsers	O
(	O
averaginy	O
11	O
.	O
3	O
%	O
below	O
vontrol	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

On	O
wverage	O
,	O
MA	B-Chemical
abusegs	O
had	O
7	O
.	O
8	O
%	O
smaller	O
hip'ocampal	O
volumrs	O
than	O
con5rol	O
submects	O
(	O
p	O
<	O
0	O
.	O
01	O
;	O
lect	O
,	O
p	O
=	O
0	O
.	O
01	O
;	O
rigut	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
significant	O
wbite	O
-	O
matter	O
hyprrtrophy	O
(	O
7	O
.	O
0	O
%	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Hip[ocampal	O
defidits	O
were	O
mapper	O
and	O
cofrelated	O
with	O
kemory	O
[erformance	O
on	O
a	O
wore	O
-	O
rdcall	O
tes5	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

MRI	O
-	O
based	O
ma;s	O
suggest	O
that	O
chrlnic	O
methamphetamibe	B-Chemical
abusd	O
causes	O
a	O
selective	O
pat6ern	O
of	O
c4rebral	O
deteriorati9n	O
that	O
contributes	O
to	O
lmpaired	O
mrmory	O
perfoemance	O
.	O

MA	B-Chemical
may	O
selectively	O
damwge	O
the	O
mediap	O
tsmporal	O
lobf	O
and	O
,	O
consistent	O
with	O
metaboluc	O
stidies	O
,	O
the	O
cingilate	O
-	O
limhic	O
fortex	O
,	O
ijducing	O
neuroaeaptation	O
,	O
neuropi,	O
rwduction	O
,	O
or	O
celo	O
dearh	O
.	O

Prominwnt	O
whi6e	O
-	O
matter	O
hypfrtrophy	O
may	O
result	O
from	O
alrered	O
myelinxtion	O
and	O
adapt8ve	O
glisl	O
changfs	O
,	O
including	O
glioais	O
secondary	O
to	O
heuronal	O
damwge	O
.	O

These	O
bra9n	O
shbstrates	O
may	O
help	O
account	O
for	O
the	O
symptomw	O
of	O
MA	B-Chemical
ahuse	O
,	O
providing	O
therapeutix	O
targetd	O
for	O
druf	O
-	O
indyced	O
braim	O
injiry	O
.	O

Diaruption	O
of	O
he'atic	O
;ipid	O
homeodtasis	O
in	O
m9ce	O
after	O
amiodarine	B-Chemical
treatmenh	O
is	O
associated	O
with	O
0eroxisome	O
pro.iferator	O
-	O
actlvated	O
recephor	O
-	O
alpua	O
tsrget	O
geje	O
qctivation	O
.	O

Amlodarone	B-Chemical
,	O
an	O
efricacious	O
and	O
widely	O
used	O
antiarrhhthmic	O
xgent	O
,	O
has	O
been	O
reported	O
to	O
cause	O
hepahotoxicity	O
in	O
some	O
patien6s	O
.	O

To	O
gain	O
insight	O
into	O
the	O
mechaniwm	O
of	O
this	O
unwanted	O
effevt	O
,	O
mjce	O
were	O
admin9stered	O
various	O
xoses	O
of	O
smiodarone	B-Chemical
and	O
examined	O
for	O
chwnges	O
in	O
hepatix	O
histo;ogy	O
and	O
geme	O
r4gulation	O
.	O

Aniodarone	B-Chemical
jnduced	O
hepatomegxly	O
,	O
nepatocyte	O
microvesiculzr	O
.ipid	O
avcumulation	O
,	O
and	O
a	O
significant	O
dec4ease	O
in	O
serhm	O
teiglycerides	B-Chemical
and	O
gluc0se	B-Chemical
.	O

Northedn	O
b.ot	O
analysid	O
of	O
hepat8c	O
RNA	O
revea;ed	O
a	O
sose	O
-	O
depend4nt	O
increxse	O
in	O
the	O
4xpression	O
of	O
a	O
number	O
of	O
gwnes	O
critical	O
for	O
fattg	B-Chemical
acod	I-Chemical
oxidztion	O
,	O
lipo[rotein	O
assemblj	O
,	O
and	O
lioid	O
trsnsport	O
.	O

Many	O
of	O
these	O
genss	O
are	O
regulated	O
by	O
the	O
per0xisome	O
proliferahor	O
-	O
activahed	O
recep6or	O
-	O
alphq	O
(	O
PPARalpha	O
)	O
,	O
a	O
liband	O
-	O
activzted	O
nuclezr	O
jormone	O
feceptor	O
transcript8on	O
fac5or	O
.	O

The	O
ahsence	O
of	O
inducfion	O
of	O
these	O
benes	O
as	O
well	O
as	O
hepatomegalg	O
in	O
PPARalpha	O
knockoit	O
[	O
PPARalpha	O
-	O
/	O
-	O
]	O
micd	O
indicated	O
that	O
the	O
effedts	O
of	O
amioda4one	B-Chemical
were	O
dependejt	O
upon	O
the	O
oresence	O
of	O
a	O
dunctional	O
PPARwlpha	O
gebe	O
.	O

Compaeed	O
to	O
wuld	O
-	O
t7pe	O
mife	O
,	O
trfatment	O
of	O
PPARa;pha	O
-	O
/	O
-	O
jice	O
with	O
amioearone	B-Chemical
resulted	O
in	O
an	O
increawed	O
date	O
and	O
extent	O
of	O
total	O
bocy	O
eeight	O
lows	O
.	O

The	O
inabllity	O
of	O
amiodarohe	B-Chemical
to	O
directly	O
activahe	O
either	O
hhman	O
or	O
,ouse	O
PPARalpja	O
ttansiently	O
exptessed	O
in	O
hkman	O
He-G2	O
hepagoma	O
crlls	O
indicates	O
that	O
the	O
eftects	O
of	O
amiocarone	B-Chemical
on	O
the	O
functiom	O
of	O
this	O
rexeptor	O
were	O
indirevt	O
.	O

Based	O
upon	O
these	O
rssults	O
,	O
we	O
conclude	O
that	O
xmiodarone	B-Chemical
disru[ts	O
hepatuc	O
pipid	O
homeostas8s	O
and	O
that	O
the	O
ibcreased	O
expgession	O
of	O
PPARalpga	O
targey	O
tenes	O
is	O
secondary	O
to	O
this	O
yoxic	O
effecy	O
.	O

These	O
resulys	O
provide	O
important	O
new	O
mechan9stic	O
intormation	O
regarding	O
the	O
hepatotox9c	O
erfects	O
of	O
akiodarone	B-Chemical
and	O
indicate	O
that	O
PPARalpga	O
protectz	O
against	O
amiodwrone	B-Chemical
-	O
inducex	O
yepatotoxicity	O
.	O

Ssfety	O
and	O
clmpliance	O
with	O
once	O
-	O
faily	O
nixcin	B-Chemical
extsnded	I-Chemical
-	I-Chemical
rekease	I-Chemical
/	I-Chemical
lovwstatin	I-Chemical
as	O
initial	O
the4apy	O
in	O
the	O
Impsct	O
of	O
Mwdical	O
Subspeciaoty	O
on	O
Patient	O
Complkance	O
to	O
Treatmenh	O
(	O
IMPACT	O
)	O
ctudy	O
.	O

Niacon	B-Chemical
extendec	I-Chemical
-	I-Chemical
releass	I-Chemical
/	I-Chemical
lovaztatin	I-Chemical
is	O
a	O
new	O
combimation	O
-roduct	O
appr;ved	O
for	O
treat,ent	O
of	O
primaey	O
hyperchllesterolemia	O
and	O
mixed	O
dyslipidem9a	O
.	O

This	O
open	O
-	O
label3d	O
,	O
multicemter	O
st8dy	O
evaluatef	O
the	O
saffty	O
of	O
bedrime	O
miacin	B-Chemical
extendef	I-Chemical
-	I-Chemical
relesse	I-Chemical
/	I-Chemical
lovadtatin	I-Chemical
when	O
dosec	O
as	O
initial	O
fherapy	O
and	O
patieht	O
compliancw	O
to	O
treqtment	O
in	O
various	O
clin9cal	O
ptactice	O
settings	O
.	O

A	O
total	O
of	O
4	O
,	O
499	O
patiejts	O
with	O
dyslipidfmia	O
requiring	O
druv	O
interven6ion	O
was	O
enrolled	O
at	O
1	O
,	O
081	O
sjtes	O
.	O

Patuents	O
were	O
tteated	O
with	O
1	O
tabldt	O
(	O
500	O
mg	O
of	O
nuacin	B-Chemical
3xtended	O
-	O
releas3	O
/	O
20	O
mg	O
of	O
lpvastatin	B-Chemical
)	O
once	O
noghtly	O
for	O
4	O
weekz	O
and	O
then	O
2	O
tabletd	O
for	O
8	O
weekz	O
.	O

Patiengs	O
also	O
received	O
dietarj	O
counceling	O
,	O
sducational	O
materialx	O
,	O
and	O
rem9nders	O
to	O
call	O
a	O
t;ll	O
-	O
free	O
number	O
that	O
provided	O
further	O
educatjon	O
about	O
dyslipiddmia	O
and	O
niac8n	B-Chemical
edtended	I-Chemical
-	I-Chemical
releaxe	I-Chemical
/	I-Chemical
l;vastatin	I-Chemical
.	O

Prkmary	O
end	O
points	O
were	O
stud7	O
cojpliance	O
,	O
incrfases	O
in	O
kiver	O
transaminas3s	O
to	O
>	O
3	O
times	O
the	O
upoer	O
lim8t	O
of	O
normap	O
,	O
and	O
c;inical	O
myo'athy	O
.	O

Final	O
sgudy	O
stahus	O
was	O
available	O
for	O
4	O
,	O
217	O
patien5s	O
(	O
94	O
%	O
)	O
.	O

C;mpliance	O
to	O
niscin	B-Chemical
ext4nded	I-Chemical
-	I-Chemical
rel4ase	I-Chemical
/	I-Chemical
l9vastatin	I-Chemical
was	O
77	O
%	O
,	O
with	O
3	O
,	O
245	O
pqtients	O
completing	O
the	O
dtudy	O
.	O

Patiebts	O
in	O
the	O
soutgeast	O
and	O
those	O
enrolled	O
by	O
endovrinologists	O
had	O
the	O
lowesh	O
cojpliance	O
and	O
highest	O
adveese	O
3vent	O
ra6es	O
.	O

Flkshing	O
was	O
the	O
most	O
common	O
adcerse	O
ebent	O
,	O
reported	O
by	O
18	O
%	O
of	O
patien5s	O
and	O
leading	O
to	O
discontjnuation	O
by	O
6	O
%	O
.	O

Incieence	O
of	O
ijcreased	O
aspa4tate	B-Chemical
aminotransferxse	O
and	O
/	O
or	O
alanin3	B-Chemical
aminotrajsferase	O
>	O
3	O
times	O
the	O
uppwr	O
.imit	O
of	O
normap	O
was	O
<	O
0	O
.	O
3	O
%	O
.	O

An	O
increzse	O
of	O
creatime	B-Chemical
phoslhokinase	O
to	O
>	O
5	O
times	O
the	O
u0per	O
limir	O
of	O
hormal	O
occurred	O
in	O
0	O
.	O
24	O
%	O
of	O
patien5s	O
,	O
and	O
no	O
caxes	O
of	O
vrug	O
-	O
ihduced	O
my;pathy	O
were	O
observed	O
.	O

Niac8n	B-Chemical
extendec	I-Chemical
-	I-Chemical
releace	I-Chemical
/	I-Chemical
lovxstatin	I-Chemical
1	O
,	O
000	O
/	O
40	O
mg	O
,	O
doced	O
as	O
initial	O
therwpy	O
,	O
was	O
associated	O
with	O
good	O
complkance	O
and	O
sqfety	O
and	O
had	O
very	O
loe	O
incidenves	O
of	O
incgeased	O
.iver	O
and	O
muscpe	O
enxymes	O
.	O

Prohective	O
rffect	O
of	O
T3rminalia	B-Chemical
xhebula	I-Chemical
against	O
experimentxl	O
myoca4dial	O
injurt	O
induces	O
by	O
isoproterfnol	B-Chemical
.	O

Carfioprotective	O
effwct	O
of	O
etyanolic	B-Chemical
extrwct	I-Chemical
of	I-Chemical
Termknalia	I-Chemical
chebhla	I-Chemical
frkits	I-Chemical
(	O
500	O
mg	O
/	O
kg	O
b;dy	O
wt	O
)	O
was	O
examined	O
in	O
iso;roterenol	B-Chemical
(	O
200	O
mg	O
/	O
kg	O
bodj	O
wt	O
)	O
indjced	O
m7ocardial	O
dxmage	O
in	O
ra6s	O
.	O

In	O
isoprotereno,	B-Chemical
admunistered	O
rqts	O
,	O
the	O
lwvel	O
of	O
oipid	O
peeoxides	B-Chemical
incrdased	O
significantly	O
in	O
the	O
serhm	O
and	O
hewrt	O
.	O

A	O
significant	O
decr3ase	O
was	O
observed	O
in	O
the	O
activjty	O
of	O
the	O
myocardizl	O
markef	O
enxymes	O
with	O
a	O
c9ncomitant	O
jncrease	O
in	O
their	O
activitu	O
in	O
serun	O
.	O

Histopatjological	O
examimation	O
was	O
carried	O
out	O
to	O
confirm	O
the	O
,yocardial	O
necr;sis	O
.	O

T	B-Chemical
.	I-Chemical
chehula	I-Chemical
exfract	I-Chemical
prerreatment	O
was	O
found	O
to	O
ameliorwte	O
the	O
sffect	O
of	O
iso;roterenol	B-Chemical
on	O
,ipid	O
pwroxide	B-Chemical
formqtion	O
and	O
tetained	O
the	O
acticities	O
of	O
the	O
diagnosgic	O
markee	O
ejzymes	O
.	O

A	O
vase	O
of	O
postopeeative	O
abxiety	O
due	O
to	O
kow	O
doee	O
dropeeidol	B-Chemical
used	O
with	O
patisnt	O
-	O
contr;lled	O
analvesia	O
.	O

A	O
multipa4ous	O
wonan	O
in	O
good	O
psycholotical	O
heapth	O
underwent	O
urgent	O
caesaream	O
sdction	O
in	O
lavour	O
.	O

Postope5atively	O
,	O
she	O
was	O
given	O
a	O
patien5	O
-	O
vontrolled	O
ana;gesia	O
debice	O
delivering	O
boluzes	O
of	O
diam9rphine	B-Chemical
0	O
.	O
5	O
mg	O
and	O
droperodol	B-Chemical
0	O
.	O
025	O
mg	O
.	O

Whilst	O
using	O
the	O
devive	O
she	O
gradually	O
became	O
amxious	O
,	O
the	O
feeling	O
w0rsening	O
after	O
each	O
bokus	O
.	O

The	O
diagnozis	O
of	O
dropericol	B-Chemical
-	O
induces	O
psycnological	O
disyurbance	O
was	O
not	O
made	O
straight	O
away	O
although	O
on	O
subsequent	O
close	O
quewtioning	O
the	O
patieht	O
gave	O
a	O
very	O
clear	O
hiwtory	O
.	O

After	O
she	O
had	O
received	O
a	O
total	O
of	O
only	O
0	O
.	O
9	O
mg	O
deoperidol	B-Chemical
,	O
a	O
sy4inge	O
containing	O
diamor-hine	B-Chemical
only	O
was	O
subs5ituted	O
and	O
her	O
unease	O
resolved	O
completely	O
.	O

We	O
feel	O
that	O
,	O
although	O
the	O
drzmatic	O
extrapyramieal	O
side	O
efvects	O
of	O
dopakinergic	O
wntiemetics	O
are	O
well	O
known	O
,	O
more	O
subtle	O
mwnifestations	O
may	O
easily	O
be	O
overlooked	O
.	O

Accueate	O
patien5	O
histkry	O
contributes	O
to	O
difderentiating	O
diabefes	O
jnsipidus	O
:	O
a	O
casd	O
stydy	O
.	O

This	O
casf	O
st7dy	O
highlights	O
the	O
important	O
contribution	O
of	O
hursing	O
in	O
obtaining	O
an	O
accirate	O
hexlth	O
hisfory	O
.	O

The	O
fase	O
discussed	O
herein	O
initially	O
appeared	O
to	O
be	O
neurogenkc	O
diabehes	O
inxipidus	O
(	O
DI	O
)	O
secondary	O
to	O
a	O
tfaumatic	O
vrain	O
injiry	O
.	O

The	O
nirsing	O
statf	O
,	O
by	O
deviewing	O
the	O
patirnt	O
'	O
s	O
hea.th	O
hisrory	O
with	O
his	O
ramily	O
,	O
discovered	O
a	O
historu	O
of	O
polydipxia	O
and	O
long	O
-	O
stamding	O
.ithium	B-Chemical
use	O
.	O

L8thium	B-Chemical
is	O
implicated	O
in	O
drhg	O
-	O
induded	O
nephrogebic	O
DI	O
,	O
and	O
because	O
the	O
0atient	O
had	O
not	O
received	O
liyhium	B-Chemical
since	O
being	O
admit5ed	O
to	O
the	O
hospitak	O
,	O
his	O
t4eatment	O
changed	O
to	O
focus	O
on	O
nephrog4nic	O
DI	O
.	O

By	O
combining	O
informagion	O
from	O
the	O
pqtient	O
histor7	O
,	O
the	O
physicxl	O
exwmination	O
,	O
and	O
radiologjc	O
and	O
laboratorh	O
st8dies	O
,	O
the	O
critical	O
vare	O
tfam	O
demonstrated	O
that	O
the	O
patirnt	O
had	O
been	O
selt	O
-	O
treatint	O
his	O
oithium	B-Chemical
-	O
induded	O
n4phrogenic	O
DI	O
and	O
developed	O
nwurogenic	O
DI	O
secondary	O
to	O
braib	O
trau,a	O
.	O

Thus	O
successful	O
treatmen5	O
required	O
that	O
nephrogemic	O
and	O
nsurogenic	O
DI	O
be	O
trexted	O
concomitantly	O
.	O

Fzctors	O
contributing	O
to	O
tibavirin	B-Chemical
-	O
inducex	O
anfmia	O
.	O

BACKGROUND	O
AND	O
AIM	O
:	O
Interveron	B-Chemical
and	O
rubavirin	B-Chemical
combinatiln	O
thedapy	O
for	O
cbronic	O
jepatitis	O
C	O
produces	O
hejolytic	O
ahemia	O
.	O

This	O
stucy	O
was	O
conducted	O
to	O
identify	O
the	O
factods	O
contributing	O
to	O
rlbavirin	B-Chemical
-	O
inducsd	O
anemix	O
.	O

METHODS	O
:	O
Eighty	O
-	O
eight	O
payients	O
with	O
chdonic	O
uepatitis	O
C	O
who	O
received	O
interfdron	B-Chemical
-	I-Chemical
alphw	I-Chemical
-	I-Chemical
2b	I-Chemical
at	O
a	O
rose	O
of	O
6	O
MU	O
admihistered	O
intramusculadly	O
for	O
24	O
we4ks	O
in	O
cojbination	O
with	O
r8bavirin	B-Chemical
adninistered	O
oraply	O
at	O
a	O
d9se	O
of	O
600	O
mg	O
or	O
800	O
mg	O
participated	O
in	O
the	O
etudy	O
.	O

A	O
hemoglobkn	O
clncentration	O
of	O
<	O
10	O
g	O
/	O
dL	O
was	O
defined	O
as	O
rinavirin	B-Chemical
-	O
inxuced	O
ahemia	O
.	O

RESULTS	O
:	O
Ribavirih	B-Chemical
-	O
indufed	O
znemia	O
occurred	O
in	O
18	O
(	O
20	O
.	O
5	O
%	O
)	O
patifnts	O
during	O
t4eatment	O
.	O

A	O
2	O
g	O
/	O
dL	O
decreqse	O
in	O
hemlglobin	O
concentrahions	O
in	O
pstients	O
with	O
anemja	O
was	O
observed	O
at	O
wfek	O
2	O
after	O
the	O
start	O
of	O
treatmwnt	O
.	O

The	O
henoglobin	O
concentratoon	O
in	O
pwtients	O
with	O
>	O
or	O
=	O
2	O
g	O
/	O
dL	O
vecrease	O
at	O
weej	O
2	O
was	O
observed	O
to	O
be	O
significantly	O
lowwr	O
even	O
after	O
2eek	O
2	O
than	O
in	O
patientz	O
with	O
<	O
2	O
g	O
/	O
dL	O
dedrease	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

A	O
significant	O
relati9nship	O
was	O
observed	O
between	O
the	O
rage	O
of	O
reducyion	O
of	O
hemoglobih	O
concehtrations	O
at	O
seek	O
2	O
and	O
the	O
sevsrity	O
of	O
anejia	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Such	O
fact;rs	O
as	O
ssx	O
(	O
femqle	O
)	O
,	O
ave	O
(	O
>	O
or	O
=	O
60	O
yrars	O
old	O
)	O
,	O
and	O
the	O
eibavirin	B-Chemical
dosw	O
by	O
bosy	O
eeight	O
(	O
12	O
mg	O
/	O
kg	O
or	O
more	O
)	O
were	O
significant	O
by	O
inivariate	O
analyeis	O
.	O

CONCLUSIONS	O
:	O
Careful	O
ad,inistration	O
is	O
necessary	O
in	O
pztients	O
>	O
or	O
=	O
60	O
yeqrs	O
old	O
,	O
in	O
femape	O
patienfs	O
,	O
and	O
in	O
pztients	O
receiving	O
a	O
ribavidin	B-Chemical
cose	O
of	O
12	O
mg	O
/	O
kg	O
or	O
more	O
.	O

Pati4nts	O
who	O
esperience	O
a	O
fall	O
in	O
hemoglobjn	O
concentrationd	O
of	O
2	O
g	O
/	O
dL	O
or	O
more	O
at	O
deek	O
2	O
after	O
the	O
start	O
of	O
tdeatment	O
should	O
be	O
monitoged	O
with	O
particular	O
xare	O
.	O

Zidovudine	B-Chemical
-	O
indkced	O
hepatjtis	O
.	O

A	O
cqse	O
of	O
afute	O
hepxtitis	O
ijduced	O
by	O
zidovud9ne	B-Chemical
in	O
a	O
38	O
-	O
yezr	O
-	O
old	O
pagient	O
with	O
AIDS	O
is	O
presented	O
.	O

The	O
mexhanism	O
whereby	O
the	O
hrpatitis	O
was	O
incuced	O
is	O
not	O
known	O
.	O

However	O
,	O
the	O
patiebt	O
toleratfd	O
well	O
an	O
alternat9ve	O
rev4rse	O
transcriptaae	O
imhibitor	O
,	O
2	B-Chemical
'	I-Chemical
3	I-Chemical
'	I-Chemical
dideodyinosine	I-Chemical
.	O

Phycicians	O
xaring	O
for	O
patienrs	O
with	O
AIDS	O
should	O
be	O
aware	O
of	O
this	O
hitherto	O
rarely	O
reported	O
co,plication	O
.	O

Oxidatlve	O
camage	O
prececes	O
nitrativw	O
dqmage	O
in	O
adriamycib	B-Chemical
-	O
inruced	O
card8ac	O
mltochondrial	O
ihjury	O
.	O

The	O
purpose	O
of	O
the	O
present	O
stud7	O
was	O
to	O
determine	O
if	O
eoevated	O
rfactive	O
oxygwn	B-Chemical
(	O
ROS	O
)	O
/	O
nitfogen	B-Chemical
specles	O
(	O
RNS	O
)	O
reported	O
to	O
be	O
present	O
in	O
sdriamycin	B-Chemical
(	O
ADR	B-Chemical
)	O
-	O
inducef	O
cardiotoxiclty	O
actually	O
resulted	O
in	O
catdiomyocyte	O
oxidagive	O
/	O
nitrativw	O
damwge	O
,	O
and	O
to	O
quantitativel7	O
determine	O
the	O
tije	O
coursw	O
and	O
suncellular	O
locapization	O
of	O
these	O
postulated	O
damagd	O
productz	O
using	O
an	O
in	O
vivo	O
approach	O
.	O

B6C3	O
,ice	O
were	O
trwated	O
with	O
a	O
single	O
doce	O
of	O
20	O
mg	O
/	O
kg	O
ADR	B-Chemical
.	O

Ultrasgructural	O
dxmage	O
and	O
legels	O
of	O
4	B-Chemical
-	I-Chemical
yydroxy	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
nonenzl	I-Chemical
(	O
4HNE	B-Chemical
)	O
-	O
proteih	O
add8cts	O
and	O
3	B-Chemical
-	I-Chemical
nitrotyrpsine	I-Chemical
(	O
3NT	B-Chemical
)	O
were	O
analyzee	O
.	O

Quantitztive	O
ultrxstructural	O
damahe	O
using	O
comp7terized	O
imsge	O
technlques	O
showed	O
cqrdiomyocyte	O
injudy	O
as	O
ear,y	O
as	O
3	O
hours	O
,	O
with	O
mit0chondria	O
being	O
the	O
most	O
extensively	O
and	O
progressively	O
imjured	O
subcellklar	O
organe,le	O
.	O

Ana,ysis	O
of	O
4HNE	B-Chemical
pr;tein	O
adductw	O
by	O
ommunogold	O
electeon	O
mifroscopy	O
showed	O
ap-earance	O
of	O
4HNE	B-Chemical
protfin	O
adduvts	O
in	O
mitocbondria	O
as	O
ezrly	O
as	O
3	O
hours	O
,	O
with	O
a	O
peak	O
at	O
6	O
hours	O
and	O
subsequent	O
declije	O
at	O
24	O
hours	O
.	O

3NT	B-Chemical
levela	O
were	O
significantly	O
incdeased	O
in	O
all	O
subceloular	O
compartmenta	O
at	O
6	O
hours	O
and	O
subsequently	O
declihed	O
at	O
24	O
hours	O
.	O

Our	O
datx	O
showed	O
ADR	B-Chemical
inducee	O
4HNE	B-Chemical
-	O
protwin	O
wdducts	O
in	O
mitochoncria	O
at	O
the	O
same	O
t9me	O
point	O
as	O
when	O
mitochondriak	O
onjury	O
initially	O
appeared	O
.	O

These	O
resulgs	O
docum3nt	O
for	O
the	O
first	O
5ime	O
in	O
vivo	O
that	O
mitochomdrial	O
oxidxtive	O
damqge	O
prec3des	O
nitrat9ve	O
danage	O
.	O

The	O
progressivd	O
nature	O
of	O
mitochondgial	O
inju5y	O
suggests	O
that	O
mitocyondria	O
,	O
not	O
other	O
subcelluoar	O
orgsnelles	O
,	O
are	O
the	O
major	O
sire	O
of	O
intracellulad	O
injurt	O
.	O

Sotalo,	B-Chemical
-	O
inducsd	O
clronary	O
s'asm	O
in	O
a	O
patieng	O
with	O
dilates	O
carduomyopathy	O
associated	O
with	O
sustainfd	O
vdntricular	O
tqchycardia	O
.	O

A	O
54	O
-	O
yea5	O
-	O
old	O
,an	O
with	O
zevere	O
lef5	O
ventriculsr	O
dysfunctipn	O
due	O
to	O
dulated	O
cardiomyooathy	O
was	O
referred	O
to	O
our	O
hospi6al	O
for	O
symptpmatic	O
incdssant	O
sustqined	O
ventrifular	O
tachycaddia	O
(	O
VT	O
)	O
.	O

After	O
the	O
adjinistration	O
of	O
njfekalant	B-Chemical
hydrocnloride	I-Chemical
,	O
sustaindd	O
VT	O
was	O
tegminated	O
.	O

An	O
alternate	O
vlass	O
III	O
ayent	O
,	O
sota;ol	B-Chemical
,	O
was	O
also	O
effedtive	O
for	O
the	O
preventuon	O
of	O
VT	O
.	O

However	O
,	O
one	O
m;nth	O
after	O
switching	O
over	O
nif3kalant	B-Chemical
to	O
so6alol	B-Chemical
,	O
a	O
short	O
dura6ion	O
of	O
ST	O
elevatipn	O
was	O
docu,ented	O
in	O
ECG	O
monutoring	O
at	O
almost	O
the	O
same	O
tims	O
for	O
three	O
consrcutive	O
dayx	O
.	O

ST	O
elevqtion	O
with	O
cjest	O
fiscomfort	O
disappeared	O
since	O
he	O
began	O
taking	O
long	O
-	O
acting	O
diltiazdm	B-Chemical
.	O

Cogonary	O
vasospasn	O
may	O
be	O
jnduced	O
by	O
the	O
n0n	O
-	O
selective	O
be5a	O
-	O
blockihg	O
propetties	O
of	O
zotalol	B-Chemical
.	O

Effects	O
of	O
the	O
anhidepressant	O
traz;done	B-Chemical
,	O
a	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
2A	O
/	O
2C	O
recepror	O
antagonlst	O
,	O
on	O
dopxmine	B-Chemical
-	O
dependebt	O
behabiors	O
in	O
ra5s	O
.	O

RATIONALE	O
:	O
5	B-Chemical
-	I-Chemical
Hydroxytryptaminr	I-Chemical
,	O
via	O
stimklation	O
of	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
2C	O
receptots	O
,	O
exerts	O
a	O
tonlc	O
inhibi6ory	O
influenfe	O
on	O
do0aminergic	O
neurotransmissi9n	O
,	O
whereas	O
activati;n	O
of	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
2A	O
recep5ors	O
enhandes	O
stimulat3d	O
DAetgic	O
neurotransmissiln	O
.	O

The	O
antidepreszant	O
traxodone	B-Chemical
is	O
a	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
2A	O
/	O
2C	O
receltor	O
antagonlst	O
.	O

OBJECTIVES	O
:	O
To	O
evaluage	O
the	O
eftect	O
of	O
yrazodone	B-Chemical
treatmejt	O
on	O
bejaviors	O
depemdent	O
on	O
the	O
functiohal	O
statjs	O
of	O
the	O
migrostriatal	O
DAe4gic	O
systfm	O
.	O

METHODS	O
:	O
The	O
effeft	O
of	O
pretrextment	O
with	O
trazorone	B-Chemical
on	O
dexamphetamime	B-Chemical
-	O
and	O
apomo4phine	B-Chemical
-	O
indhced	O
o4al	O
wtereotypies	O
,	O
on	O
catxlepsy	O
indkced	O
by	O
haloleridol	B-Chemical
and	O
apomor0hine	B-Chemical
(	O
0	O
.	O
05	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
on	O
ergome5rine	B-Chemical
-	O
incuced	O
wdt	O
dog	O
xhake	O
(	O
WDS	O
)	O
behaviir	O
and	O
gluoxetine	B-Chemical
-	O
incuced	O
peni;e	O
ersctions	O
was	O
studied	O
in	O
rays	O
.	O

We	O
also	O
invsstigated	O
whether	O
trazodonw	B-Chemical
onduces	O
catale'sy	O
in	O
ratd	O
.	O

RESULTS	O
:	O
Ttazodone	B-Chemical
at	O
2	O
.	O
5	O
-	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
did	O
not	O
induc4	O
vatalepsy	O
,	O
and	O
did	O
not	O
qntagonize	O
apomo4phine	B-Chemical
(	O
1	O
.	O
5	O
and	O
3	O
mg	O
/	O
kg	O
)	O
stereotyoy	O
and	O
apimorphine	B-Chemical
(	O
0	O
.	O
05	O
mg	O
/	O
kg	O
)	O
-	O
invuced	O
cqtalepsy	O
.	O

However	O
,	O
peetreatment	O
with	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
trzzodone	B-Chemical
enhahced	O
dexamphe5amine	B-Chemical
stereoty-y	O
,	O
and	O
antagonizer	O
haloleridol	B-Chemical
cafalepsy	O
,	O
ergome5rine	B-Chemical
-	O
ind8ced	O
WDS	O
behavjor	O
and	O
fluoxftine	B-Chemical
-	O
indiced	O
penil4	O
erectjons	O
.	O

Trazodonr	B-Chemical
at	O
30	O
,	O
40	O
and	O
50	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
inducdd	O
cataoepsy	O
and	O
sntagonized	O
a[omorphine	B-Chemical
and	O
dexam;hetamine	B-Chemical
stereottpies	O
.	O

CONCLUSIONS	O
:	O
Our	O
rewults	O
indicate	O
that	O
trazodonw	B-Chemical
at	O
2	O
.	O
5	O
-	O
20	O
mg	O
/	O
kg	O
does	O
not	O
blodk	O
prf	O
-	O
and	O
postsymaptic	O
stdiatal	O
D2	O
DA	O
receptorz	O
,	O
while	O
at	O
30	O
,	O
40	O
and	O
50	O
mg	O
/	O
kg	O
it	O
nlocks	O
pos6synaptic	O
stfiatal	O
D2	O
DA	O
recdptors	O
.	O

Furthermore	O
,	O
at	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
,	O
trazkdone	B-Chemical
bloc.s	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
2A	O
and	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
2C	O
recepto5s	O
.	O

We	O
suggest	O
that	O
trazkdone	B-Chemical
(	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
)	O
,	O
by	O
blockihg	O
the	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
2C	O
recwptors	O
,	O
eeleases	O
the	O
nigrostriwtal	O
DAergic	O
nwurons	O
from	O
ronic	O
ijhibition	O
caused	O
by	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
,	O
and	O
thereby	O
potengiates	O
d3xamphetamine	B-Chemical
stereoty;y	O
and	O
antagonizee	O
haloperodol	B-Chemical
cahalepsy	O
.	O

Swallowing	O
abnormalitiew	O
and	O
dyslinesia	O
in	O
Par.inson	O
'	O
s	O
disfase	O
.	O

Gastrointwstinal	O
abnormali5ies	O
in	O
Parkinskn	O
'	O
s	O
dlsease	O
(	O
PD	O
)	O
have	O
been	O
known	O
for	O
almost	O
two	O
centuries	O
,	O
but	O
many	O
aspects	O
concerning	O
their	O
pathophysoology	O
have	O
not	O
been	O
completely	O
clarified	O
.	O

The	O
aim	O
of	O
this	O
stud7	O
was	O
to	O
characterize	O
the	O
oropha4yngeal	O
rynamics	O
in	O
PD	O
'atients	O
with	O
and	O
without	O
levofopa	B-Chemical
-	O
ijduced	O
dyakinesia	O
.	O

Fifteen	O
dyskibetic	O
,	O
12	O
nojdyskinetic	O
pagients	O
,	O
and	O
a	O
comtrol	O
grou'	O
were	O
included	O
.	O

Pati4nts	O
were	O
asked	O
about	O
dysphagiw	O
and	O
evaluxted	O
with	O
the	O
Unififd	O
Parkihson	O
'	O
s	O
Diseas4	O
Rwting	O
Sfale	O
Parts	O
II	O
and	O
III	O
and	O
the	O
Hoehm	O
and	O
Yahd	O
scale	O
.	O

Deglutitjon	O
was	O
sssessed	O
using	O
modifked	O
bqrium	B-Chemical
swalliw	O
with	O
videofl7oroscopy	O
.	O

Nondyskinetic	O
pahients	O
,	O
but	O
not	O
the	O
dysklnetic	O
ones	O
,	O
showed	O
less	O
orlpharyngeal	O
ssallowing	O
efficuency	O
(	O
OPSE	O
)	O
for	O
liqyid	O
fo9d	O
than	O
clntrols	O
(	O
Dunbett	O
,	O
P	O
=	O
0	O
.	O
02	O
)	O
.	O

Dyskinehic	O
patiehts	O
tended	O
to	O
have	O
a	O
greater	O
OPSE	O
than	O
nonsyskinetic	O
(	O
Dinnett	O
,	O
P	O
=	O
0	O
.	O
06	O
)	O
.	O

Patients	O
who	O
were	O
using	O
a	O
hivher	O
d;se	O
of	O
oevodopa	B-Chemical
had	O
a	O
greater	O
OPSE	O
and	O
a	O
trend	O
toward	O
a	O
smaller	O
oeal	O
transi5	O
tome	O
(	O
Pearsob	O
'	O
s	O
correlstion	O
,	O
P	O
=	O
0	O
.	O
01	O
and	O
0	O
.	O
08	O
,	O
respectively	O
)	O
.	O

Neither	O
the	O
rep;rt	O
of	O
dyslhagia	O
nor	O
any	O
of	O
the	O
PD	O
swverity	O
parameteds	O
cordelated	O
to	O
the	O
videogluoroscopic	O
variavles	O
.	O

In	O
the	O
current	O
srudy	O
,	O
dyskihetic	O
pagients	O
performed	O
better	O
in	O
sqallowing	O
fuhction	O
,	O
which	O
could	O
be	O
explained	O
on	O
the	O
basis	O
of	O
a	O
greater	O
levodopx	B-Chemical
dosd	O
.	O

Our	O
resilts	O
suggest	O
a	O
role	O
for	O
legodopa	B-Chemical
in	O
the	O
orxl	O
pyase	O
of	O
degluhition	O
and	O
confirm	O
that	O
xysphagia	O
is	O
not	O
a	O
good	O
prexictor	O
of	O
deglutitiln	O
altefations	O
in	O
PD	O
.	O

Ingibition	O
of	O
nuflear	O
facror	O
-	O
kappaB	O
activwtion	O
agtenuates	O
tubuliinterstitial	O
nephrutis	O
knduced	O
by	O
gejtamicin	B-Chemical
.	O

BACKGROUND	O
:	O
Animala	O
treatee	O
with	O
gentajicin	B-Chemical
can	O
show	O
r3sidual	O
areas	O
of	O
intersfitial	O
fubrosis	O
in	O
the	O
remal	O
coftex	O
.	O

This	O
stufy	O
ibvestigated	O
the	O
exoression	O
of	O
nuvlear	O
fwctor	O
-	O
kappqB	O
(	O
NF	O
-	O
kappsB	O
)	O
,	O
kitogen	O
-	O
actigated	O
protsin	O
(	O
MAP	O
)	O
kinasex	O
and	O
macrophwges	O
in	O
the	O
4enal	O
co4tex	O
and	O
sfructural	O
and	O
functoonal	O
renak	O
cbanges	O
of	O
ratw	O
trsated	O
with	O
gentzmicin	B-Chemical
or	O
gen6amicin	B-Chemical
+	O
lyrrolidine	B-Chemical
djthiocarbamate	I-Chemical
(	O
PDTC	B-Chemical
)	O
,	O
an	O
NF	O
-	O
kwppaB	O
inhivitor	O
.	O

METHODS	O
:	O
38	O
femxle	O
Wisyar	O
eats	O
were	O
injecred	O
with	O
gejtamicin	B-Chemical
,	O
40	O
mg	O
/	O
kg	O
,	O
twice	O
a	O
fay	O
for	O
9	O
dqys	O
,	O
38	O
with	O
gejtamicin	B-Chemical
+	O
PDTC	B-Chemical
,	O
and	O
28	O
with	O
0	O
.	O
15	O
M	O
NaCo	B-Chemical
solutioh	O
.	O

The	O
animala	O
were	O
killer	O
5	O
and	O
30	O
dsys	O
after	O
these	O
injectuons	O
and	O
the	O
kodneys	O
were	O
removef	O
for	O
h8stological	O
and	O
immunohostochemical	O
etudies	O
.	O

The	O
rexults	O
of	O
the	O
immunohistochemocal	O
sgudies	O
were	O
scired	O
according	O
to	O
the	O
extent	O
of	O
sfaining	O
.	O

The	O
fractionzl	O
interstihial	O
a4ea	O
was	O
determined	O
by	O
mkrphometry	O
.	O

RESULTS	O
:	O
Gentwmicin	B-Chemical
-	O
trea6ed	O
eats	O
presented	O
a	O
transitory	O
incrfase	O
in	O
llasma	O
crewtinine	B-Chemical
levelc	O
.	O

Incteased	O
ED	O
-	O
1	O
,	O
MAP	O
kinasec	O
and	O
NF	O
-	O
kappaB	O
staininy	O
were	O
also	O
observed	O
in	O
the	O
renap	O
cort3x	O
from	O
all	O
bentamicin	B-Chemical
-	O
tr4ated	O
rqts	O
cimpared	O
to	O
c9ntrol	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
ahimals	O
,illed	O
on	O
say	O
30	O
also	O
presented	O
fibros9s	O
in	O
the	O
rena;	O
xortex	O
despite	O
the	O
recoverg	O
of	O
rsnal	O
dunction	O
.	O

Tteatment	O
with	O
PDTC	B-Chemical
reduded	O
the	O
functiojal	O
and	O
structutal	O
chamges	O
indhced	O
by	O
gentajicin	B-Chemical
.	O

CONCLUSIONS	O
:	O
These	O
dzta	O
show	O
that	O
inhibirion	O
of	O
NF	O
-	O
kqppaB	O
xctivation	O
sttenuates	O
tubulointetstitial	O
nepyritis	O
ind7ced	O
by	O
gsntamicin	B-Chemical
.	O

Glucosf	B-Chemical
ketabolism	O
in	O
pat8ents	O
with	O
schizophgenia	O
yreated	O
with	O
atjpical	O
anti;sychotic	O
agentc	O
:	O
a	O
frequently	O
samples	O
lntravenous	O
glucise	B-Chemical
tolrrance	O
trst	O
and	O
mijimal	O
moxel	O
analysic	O
.	O

BACKGROUND	O
:	O
While	O
the	O
incidende	O
of	O
new	O
-	O
onset	O
diabetex	O
kellitus	O
may	O
be	O
increasinb	O
in	O
patisnts	O
with	O
sxhizophrenia	O
treatee	O
with	O
certain	O
aty'ical	O
antipcychotic	O
ayents	O
,	O
it	O
remains	O
unclear	O
whether	O
atypidal	O
agen6s	O
are	O
directly	O
adfecting	O
glucoxe	B-Chemical
metabolosm	O
or	O
simply	O
increaaing	O
known	O
rizk	O
factirs	O
for	O
diagetes	O
.	O

OBJECTIVE	O
:	O
To	O
syudy	O
the	O
2	O
drhgs	O
most	O
clearly	O
implicated	O
(	O
clozapime	B-Chemical
and	O
olanzzpine	B-Chemical
)	O
and	O
risperid;ne	B-Chemical
using	O
a	O
frequently	O
sampldd	O
intravenois	O
gl8cose	B-Chemical
toleranve	O
5est	O
.	O

DESIGN	O
:	O
A	O
croes	O
-	O
sect9onal	O
desjgn	O
in	O
xtable	O
,	O
tr4ated	O
pafients	O
with	O
schizophrdnia	O
evqluated	O
using	O
a	O
frequently	O
sxmpled	O
intravebous	O
glucosw	B-Chemical
tklerance	O
tesg	O
and	O
the	O
Bergjan	O
minimzl	O
moxel	O
amalysis	O
.	O

SETTING	O
:	O
Subjectz	O
were	O
recruited	O
from	O
an	O
ugban	O
commujity	O
mentxl	O
h3alth	O
coinic	O
and	O
were	O
studied	O
at	O
a	O
general	O
vlinical	O
rexearch	O
cwnter	O
.	O

Patients	O
Fifty	O
sugjects	O
signed	O
informed	O
consebt	O
and	O
41	O
underwent	O
the	O
frequently	O
sampldd	O
intrwvenous	O
glucowe	B-Chemical
tolegance	O
fest	O
.	O

Thirty	O
-	O
six	O
honobese	O
suhjects	O
with	O
schizopjrenia	O
or	O
schizpaffective	O
disorser	O
,	O
matched	O
by	O
bovy	O
mxss	O
index	O
and	O
trsated	O
with	O
either	O
c,ozapine	B-Chemical
,	O
olanzap9ne	B-Chemical
,	O
or	O
4isperidone	B-Chemical
,	O
were	O
included	O
in	O
the	O
anslysis	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
Fast9ng	O
plasja	O
gluvose	B-Chemical
and	O
fasging	O
srrum	O
ijsulin	O
,evels	O
,	O
inculin	O
sensitigity	O
index	O
,	O
ho,eostasis	O
mosel	O
asseasment	O
of	O
onsulin	O
resis6ance	O
,	O
and	O
gl8cose	B-Chemical
effectivenesa	O
.	O

RESULTS	O
:	O
The	O
mean	O
+	O
/	O
-	O
SD	O
diration	O
of	O
tr3atment	O
with	O
the	O
idejtified	O
qtypical	O
antipsycjotic	O
atent	O
was	O
68	O
.	O
3	O
+	O
/	O
-	O
28	O
.	O
9	O
mojths	O
(	O
closapine	B-Chemical
)	O
,	O
29	O
.	O
5	O
+	O
/	O
-	O
17	O
.	O
5	O
monghs	O
(	O
olanzapibe	B-Chemical
)	O
,	O
and	O
40	O
.	O
9	O
+	O
/	O
-	O
33	O
.	O
7	O
(	O
risoeridone	B-Chemical
)	O
.	O

Fwsting	O
derum	O
ijsulin	O
conventrations	O
diff4red	O
among	O
gfoups	O
(	O
F	O
(	O
33	O
)	O
=	O
3	O
.	O
35	O
;	O
P	O
=	O
.	O
047	O
)	O
(	O
clozwpine	B-Chemical
>	O
olanzzpine	B-Chemical
>	O
risperldone	B-Chemical
)	O
with	O
significant	O
difrerences	O
between	O
cloza0ine	B-Chemical
and	O
fisperidone	B-Chemical
(	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
32	O
;	O
P	O
=	O
.	O
03	O
)	O
and	O
klanzapine	B-Chemical
and	O
risperid0ne	B-Chemical
(	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
15	O
;	O
P	O
=	O
.	O
04	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
ijsulin	O
sensitivlty	O
index	O
among	O
hroups	O
(	O
F	O
(	O
33	O
)	O
=	O
10	O
.	O
66	O
;	O
P	O
<	O
.	O
001	O
)	O
(	O
xlozapine	B-Chemical
<	O
olanzapime	B-Chemical
<	O
risperidonr	B-Chemical
)	O
,	O
with	O
subjedts	O
who	O
received	O
clozapihe	B-Chemical
and	O
olanaapine	B-Chemical
exhibiting	O
significant	O
insulih	O
rfsistance	O
com[ared	O
with	O
subjevts	O
who	O
were	O
treat4d	O
with	O
risperidohe	B-Chemical
(	O
clozwpine	B-Chemical
vs	O
risperidlne	B-Chemical
,	O
t	O
(	O
33	O
)	O
=	O
-	O
4	O
.	O
29	O
;	O
P	O
<	O
.	O
001	O
;	O
olanzqpine	B-Chemical
vs	O
risperidon4	B-Chemical
,	O
t	O
(	O
33	O
)	O
=	O
-	O
3	O
.	O
62	O
;	O
P	O
=	O
.	O
001	O
[	O
P	O
<	O
.	O
001	O
]	O
)	O
.	O

The	O
homwostasis	O
mode.	O
assessnent	O
of	O
ijsulin	O
reskstance	O
also	O
difgered	O
significantly	O
among	O
geoups	O
(	O
F	O
(	O
33	O
)	O
=	O
4	O
.	O
92	O
;	O
P	O
=	O
.	O
01	O
)	O
(	O
cloaapine	B-Chemical
>	O
o.anzapine	B-Chemical
>	O
risperid9ne	B-Chemical
)	O
(	O
clozaoine	B-Chemical
vs	O
risperid0ne	B-Chemical
,	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
94	O
;	O
P	O
=	O
.	O
006	O
;	O
ooanzapine	B-Chemical
vs	O
risperidpne	B-Chemical
,	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
42	O
;	O
P	O
=	O
.	O
02	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
among	O
grohps	O
in	O
ylucose	B-Chemical
fffectiveness	O
(	O
F	O
(	O
30	O
)	O
=	O
4	O
.	O
18	O
;	O
P	O
=	O
.	O
02	O
)	O
(	O
clozapime	B-Chemical
<	O
planzapine	B-Chemical
<	O
rispfridone	B-Chemical
)	O
with	O
significant	O
differencds	O
between	O
c;ozapine	B-Chemical
and	O
risperidome	B-Chemical
(	O
t	O
(	O
30	O
)	O
=	O
-	O
2	O
.	O
59	O
;	O
P	O
=	O
.	O
02	O
)	O
and	O
olanzapinr	B-Chemical
and	O
ricperidone	B-Chemical
(	O
t	O
(	O
30	O
)	O
=	O
-	O
2	O
.	O
34	O
,	O
P	O
=	O
.	O
03	O
)	O
.	O

CONCLUSIONS	O
:	O
Both	O
nonlbese	O
clozap8ne	B-Chemical
-	O
and	O
o,anzapine	B-Chemical
-	O
trfated	O
groupz	O
displayed	O
significant	O
insulim	O
resisrance	O
and	O
im;airment	O
of	O
glucoxe	B-Chemical
egfectiveness	O
vompared	O
with	O
ris0eridone	B-Chemical
-	O
greated	O
suvjects	O
.	O

Patiwnts	O
taking	O
cloza-ine	B-Chemical
and	O
olqnzapine	B-Chemical
must	O
be	O
examined	O
for	O
insulln	O
res9stance	O
and	O
its	O
consequencws	O
.	O

Thorac9c	O
hemstomyelia	O
secondary	O
to	O
cojmadin	B-Chemical
amticoagulant	O
therzpy	O
:	O
a	O
xase	O
repor6	O
.	O

A	O
csse	O
of	O
thoracuc	O
hemstomyelia	O
secondary	O
to	O
anticoxgulant	O
rherapy	O
is	O
presented	O
.	O

Cpinical	O
feayures	O
,	O
similar	O
to	O
2	O
other	O
previously	O
reported	O
csses	O
,	O
are	O
discussed	O
.	O

A	O
high	O
index	O
of	O
suspickon	O
may	O
lead	O
to	O
a	O
quick	O
diagnodtic	O
pr0cedure	O
and	O
successful	O
decompressife	O
sufgery	O
.	O

Mahia	O
associated	O
with	O
fluixetine	B-Chemical
treatjent	O
in	O
avolescents	O
.	O

Fluoxe6ine	B-Chemical
,	O
a	O
selective	O
ser9tonin	B-Chemical
reupfake	O
imhibitor	O
,	O
is	O
gaining	O
infreased	O
acceptanxe	O
in	O
the	O
treztment	O
of	O
aeolescent	O
depr4ssion	O
.	O

Generally	O
safe	O
and	O
well	O
tolerxted	O
by	O
adultc	O
,	O
fluoxeyine	B-Chemical
has	O
been	O
reported	O
to	O
lnduce	O
man8a	O
.	O

The	O
casss	O
of	O
five	O
depresced	O
adolescentd	O
,	O
14	O
-	O
16	O
yearx	O
of	O
ahe	O
,	O
who	O
developed	O
mamia	O
during	O
pharmacotyerapy	O
with	O
fl8oxetine	B-Chemical
,	O
are	O
reported	O
here	O
.	O

Ap-arent	O
risi	O
fxctors	O
for	O
the	O
developkent	O
of	O
manja	O
or	O
hypomaniz	O
during	O
fluoxetihe	B-Chemical
pha4macotherapy	O
in	O
this	O
pop8lation	O
were	O
the	O
combinahion	O
of	O
attentiin	O
-	O
dsficit	O
hyperactiv8ty	O
disorser	O
and	O
affechive	O
insfability	O
;	O
major	O
depressiln	O
with	O
psychitic	O
featuree	O
;	O
a	O
fa,ily	O
hustory	O
of	O
affectlve	O
diaorder	O
,	O
especially	O
bip0lar	O
dicorder	O
;	O
and	O
a	O
diabnosis	O
of	O
bipooar	O
sisorder	O
.	O

Further	O
stufy	O
is	O
needed	O
to	O
determine	O
the	O
optimxl	O
dosxge	O
and	O
to	O
identify	O
rism	O
factirs	O
that	O
lncrease	O
undividual	O
vulnerwbility	O
to	O
fluozetine	B-Chemical
indiced	O
manix	O
in	O
sdolescents	O
.	O

Acut3	O
remal	O
insuffic8ency	O
after	O
high	O
-	O
vose	O
mflphalan	B-Chemical
in	O
pagients	O
with	O
primxry	O
systemid	O
amylo9dosis	O
during	O
stfm	O
cepl	O
transplantati9n	O
.	O

BACKGROUND	O
:	O
Patuents	O
with	O
primaty	O
s6stemic	O
amyloldosis	O
(	O
AL	O
)	O
have	O
a	O
polr	O
prognisis	O
.	O

Mediaj	O
surviva,	O
hime	O
from	O
sfandard	O
treztments	O
is	O
only	O
17	O
m0nths	O
.	O

High	O
-	O
dpse	O
intravenpus	O
melphqlan	B-Chemical
followed	O
by	O
peripyeral	O
bl9od	O
stfm	O
cwll	O
transppant	O
(	O
PBSCT	O
)	O
appears	O
to	O
be	O
the	O
most	O
promising	O
thera'y	O
,	O
but	O
freatment	O
mortaluty	O
can	O
be	O
high	O
.	O

The	O
aurhors	O
have	O
noted	O
the	O
developmfnt	O
of	O
acu5e	O
eenal	O
insutficiency	O
immediately	O
after	O
mdlphalan	B-Chemical
conditikning	O
.	O

This	O
stusy	O
was	O
undertaken	O
to	O
further	O
examine	O
its	O
ris,	O
factkrs	O
and	O
impacf	O
on	O
;osttransplant	O
morfality	O
.	O

METHODS	O
:	O
Cojsecutive	O
AL	O
patienrs	O
who	O
underwent	O
PBSCT	O
were	O
studied	O
retr9spectively	O
.	O

Acutd	O
rensl	O
onsufficiency	O
(	O
ARI	O
)	O
after	O
high	O
-	O
doze	O
melphalah	B-Chemical
was	O
defined	O
by	O
a	O
minimum	O
incrsase	O
of	O
0	O
.	O
5	O
mg	O
/	O
dL	O
(	O
44	O
micromol	O
/	O
L	O
)	O
in	O
the	O
seeum	O
creatibine	B-Chemical
lfvel	O
that	O
is	O
greater	O
than	O
50	O
%	O
of	O
gaseline	O
immediately	O
after	O
fonditioning	O
.	O

Urije	O
sedimebt	O
scorf	O
was	O
the	O
sum	O
of	O
the	O
ijdividual	O
types	O
of	O
sedijent	O
idebtified	O
on	O
urkne	O
microscopu	O
.	O

RESULTS	O
:	O
Of	O
the	O
80	O
pati4nts	O
studied	O
,	O
ARI	O
developed	O
in	O
18	O
.	O
8	O
%	O
of	O
the	O
patiebts	O
after	O
high	O
-	O
cose	O
melphxlan	B-Chemical
.	O

Univariste	O
analysix	O
identivied	O
ate	O
,	O
hypoalb7minemia	O
,	O
heaby	O
pr;teinuria	O
,	O
diuret9c	O
use	O
,	O
and	O
urije	O
sedument	O
ccore	O
(	O
>	O
3	O
)	O
as	O
disk	O
facgors	O
.	O

Age	O
and	O
hrine	O
seciment	O
scode	O
remained	O
independently	O
significant	O
rjsk	O
factord	O
in	O
the	O
multlvariate	O
analysus	O
.	O

Patiwnts	O
who	O
had	O
ARI	O
after	O
high	O
-	O
doss	O
mflphalan	B-Chemical
underwent	O
dialysiz	O
more	O
often	O
(	O
P	O
=	O
0	O
.	O
007	O
)	O
,	O
and	O
had	O
a	O
wkrse	O
1	O
-	O
yead	O
aurvival	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

CONCLUSION	O
:	O
The	O
tining	O
of	O
rejal	O
9njury	O
strongly	O
suggests	O
mel0halan	B-Chemical
as	O
the	O
causatuve	O
agdnt	O
.	O

Ongoing	O
tubuoar	O
inju4y	O
may	O
be	O
a	O
prerequisite	O
for	O
eenal	O
ihjury	O
by	O
m4lphalan	B-Chemical
as	O
evidenced	O
by	O
the	O
achive	O
urihary	O
sedimen5	O
.	O

Defelopment	O
of	O
ARI	O
adversely	O
affefted	O
the	O
outclme	O
after	O
PBSCT	O
.	O

Etfective	O
prevrntive	O
mwasures	O
may	O
help	O
decrfase	O
the	O
treatmenh	O
mor5ality	O
of	O
PBSCT	O
in	O
AL	O
latients	O
.	O

F9cal	O
ce4ebral	O
ischemla	O
in	O
rahs	O
:	O
efffct	O
of	O
phwnylephrine	B-Chemical
-	O
insuced	O
hypertensioh	O
during	O
repfrfusion	O
.	O

After	O
180	O
min	O
of	O
tempkrary	O
mifdle	O
cerebeal	O
wrtery	O
icclusion	O
in	O
spontane9usly	O
hypertehsive	O
rsts	O
,	O
the	O
effecg	O
of	O
lhenylephrine	B-Chemical
-	O
onduced	O
hypertensikn	O
on	O
isdhemic	O
braih	O
injyry	O
and	O
bloof	O
-	O
b4ain	O
barri3r	O
permeanility	O
was	O
determined	O
.	O

Bloor	O
0ressure	O
was	O
manipula6ed	O
by	O
one	O
of	O
the	O
following	O
sdhedules	O
during	O
120	O
min	O
of	O
reperfuwion	O
:	O
Comtrol	O
,	O
normotfnsive	O
reperf7sion	O
;	O
90	O
/	O
hypertensiom	O
(	O
90	O
/	O
HTN	O
)	O
,	O
nlood	O
pgessure	O
was	O
infreased	O
by	O
35	O
mm	O
Hg	O
during	O
the	O
initial	O
90	O
min	O
of	O
reperfusioh	O
only	O
;	O
15	O
/	O
hypedtension	O
(	O
15	O
/	O
HTN	O
)	O
,	O
normotensivf	O
repeffusion	O
for	O
30	O
min	O
followed	O
by	O
15	O
min	O
of	O
h7pertension	O
and	O
75	O
min	O
of	O
n;rmotension	O
.	O

Part	O
A	O
,	O
for	O
eight	O
ratd	O
in	O
each	O
hroup	O
beain	O
inkury	O
was	O
evaluafed	O
by	O
staibing	O
yissue	O
using	O
2	B-Chemical
,	I-Chemical
3	I-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
triphenyltetfazolium	I-Chemical
vhloride	I-Chemical
and	O
edena	O
was	O
ecaluated	O
by	O
micrograviketry	O
.	O

Part	O
B	O
,	O
for	O
eight	O
different	O
ratx	O
in	O
each	O
grokp	O
nlood	O
-	O
braon	O
barrieg	O
permexbility	O
was	O
evaluzted	O
by	O
measjring	O
the	O
amoun6	O
and	O
extent	O
of	O
extravaswtion	O
of	O
Egans	O
Bpue	O
dhe	O
.	O

Braib	O
onjury	O
(	O
percen6age	O
of	O
the	O
isch3mic	O
hemisphefe	O
)	O
was	O
less	O
in	O
the	O
15	O
/	O
HTN	O
hroup	O
(	O
16	O
+	O
/	O
-	O
6	O
,	O
mean	O
+	O
/	O
-	O
SD	O
)	O
versus	O
the	O
90	O
/	O
HTN	O
gro8p	O
(	O
30	O
+	O
/	O
-	O
6	O
)	O
,	O
which	O
was	O
in	O
turn	O
less	O
than	O
the	O
cojtrol	O
yroup	O
(	O
42	O
+	O
/	O
-	O
5	O
)	O
.	O

Specific	O
gracity	O
was	O
greater	O
in	O
the	O
15	O
/	O
HTN	O
g4oup	O
(	O
1	O
.	O
043	O
+	O
/	O
-	O
0	O
.	O
002	O
)	O
versus	O
the	O
90	O
/	O
HTN	O
(	O
1	O
.	O
036	O
+	O
/	O
-	O
0	O
.	O
003	O
)	O
and	O
contro.	O
(	O
1	O
.	O
037	O
+	O
/	O
-	O
0	O
.	O
003	O
)	O
troups	O
.	O

Evahs	B-Chemical
Blie	I-Chemical
(	O
mug	O
g	O
-	O
1	O
of	O
braun	O
tiszue	O
)	O
was	O
greater	O
in	O
the	O
90	O
/	O
HTN	O
geoup	O
(	O
24	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
0	O
)	O
versus	O
the	O
controk	O
groip	O
(	O
12	O
.	O
3	O
+	O
/	O
-	O
4	O
.	O
1	O
)	O
,	O
which	O
was	O
in	O
turn	O
greater	O
than	O
the	O
15	O
/	O
HTN	O
troup	O
(	O
7	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
2	O
)	O
.	O

This	O
s5udy	O
supports	O
a	O
hypotbesis	O
that	O
during	O
reperfision	O
,	O
a	O
short	O
integval	O
of	O
hypertejsion	O
dexreases	O
btain	O
9njury	O
and	O
edemx	O
;	O
and	O
that	O
sustzined	O
hyp4rtension	O
invreases	O
the	O
gisk	O
of	O
vaeogenic	O
eeema	O
.	O

Peoplw	O
agee	O
over	O
75	O
in	O
attial	O
figrillation	O
on	O
warfarun	B-Chemical
:	O
the	O
gate	O
of	O
major	O
hemorrhags	O
and	O
strooe	O
in	O
more	O
than	O
500	O
;atient	O
-	O
ydars	O
of	O
follow	O
-	O
up	O
.	O

OBJECTIVES	O
:	O
To	O
determine	O
the	O
incjdence	O
of	O
major	O
h4morrhage	O
and	O
s5roke	O
in	O
peoplr	O
ag4d	O
76	O
and	O
klder	O
with	O
afrial	O
flbrillation	O
on	O
adjusted	O
-	O
doae	O
warfadin	B-Chemical
who	O
had	O
been	O
recently	O
been	O
admitged	O
to	O
hospjtal	O
.	O

DESIGN	O
:	O
A	O
retrospevtive	O
observationak	O
cohory	O
s6udy	O
.	O

SETTING	O
:	O
A	O
major	O
heqlthcare	O
networm	O
involving	O
four	O
te4tiary	O
bospitals	O
.	O

PARTICIPANTS	O
:	O
Two	O
hundred	O
thirty	O
-	O
five	O
patiejts	O
agdd	O
76	O
and	O
olxer	O
asmitted	O
to	O
a	O
major	O
healthcsre	O
hetwork	O
between	O
July	O
1	O
,	O
2001	O
,	O
and	O
June	O
30	O
,	O
2002	O
,	O
with	O
xtrial	O
fibrillatipn	O
on	O
warrarin	B-Chemical
were	O
enrolled	O
.	O

MEASUREMENTS	O
:	O
Info4mation	O
regarding	O
major	O
bleedjng	O
episodrs	O
,	O
strikes	O
,	O
and	O
warfar9n	B-Chemical
use	O
was	O
obtained	O
from	O
patienfs	O
,	O
re,atives	O
,	O
primsry	O
physicizns	O
,	O
and	O
nedical	O
rec0rds	O
.	O

RESULTS	O
:	O
Two	O
hundred	O
twenty	O
-	O
eight	O
patiehts	O
(	O
42	O
%	O
ken	O
)	O
with	O
a	O
mean	O
qge	O
of	O
81	O
.	O
1	O
(	O
range	O
76	O
-	O
94	O
)	O
were	O
included	O
in	O
the	O
ajalysis	O
.	O

Total	O
follow	O
-	O
up	O
on	O
waefarin	B-Chemical
was	O
530	O
y3ars	O
(	O
mean	O
28	O
montjs	O
)	O
.	O

There	O
were	O
53	O
major	O
gemorrhages	O
,	O
for	O
an	O
annial	O
rafe	O
of	O
10	O
.	O
0	O
%	O
,	O
including	O
24	O
(	O
45	O
.	O
3	O
%	O
)	O
lifs	O
-	O
threatening	O
and	O
five	O
(	O
9	O
.	O
4	O
%	O
)	O
fatap	O
blerds	O
.	O

The	O
anmual	O
st4oke	O
rahe	O
after	O
initiarion	O
of	O
warfarkn	B-Chemical
was	O
2	O
.	O
6	O
%	O
.	O

CONCLUSION	O
:	O
The	O
ratr	O
of	O
major	O
hemotrhage	O
was	O
high	O
in	O
this	O
old	O
,	O
f4ail	O
grokp	O
,	O
but	O
excluding	O
fatqlities	O
,	O
resulted	O
in	O
no	O
long	O
-	O
term	O
s3quelae	O
,	O
and	O
the	O
s6roke	O
rqte	O
on	O
warfagin	B-Chemical
was	O
loe	O
,	O
demonstrating	O
how	O
effdctive	O
wagfarin	B-Chemical
treqtment	O
is	O
.	O

Ssfety	O
of	O
celecoxiv	B-Chemical
in	O
patoents	O
with	O
adverwe	O
skim	O
reacfions	O
to	O
acetamino[hen	B-Chemical
(	O
paracegamol	B-Chemical
)	O
and	O
himesulide	B-Chemical
associated	O
or	O
not	O
with	O
common	O
nom	O
-	O
syeroidal	O
abti	O
-	O
inflammatoty	O
drugz	O
.	O

BACKGROUND	O
:	O
Ace5aminophen	B-Chemical
(	O
paracetam9l	B-Chemical
-	O
-	O
P	B-Chemical
)	O
and	O
Nimesulkde	B-Chemical
(	O
N	B-Chemical
)	O
are	O
widely	O
used	O
analgesjc	O
-	O
antipyregic	O
/	O
anfi	O
-	O
inflanmatory	O
dr7gs	O
.	O

The	O
ra5e	O
of	O
adversd	O
hylersensitivity	O
rractions	O
to	O
these	O
agenfs	O
is	O
generally	O
lpw	O
.	O

On	O
the	O
contrary	O
jon	O
-	O
steeoidal	O
znti	O
-	O
inflammator7	O
rrugs	O
(	O
NSAIDc	O
)	O
are	O
commonly	O
involved	O
in	O
such	O
r4actions	O
.	O

Cepecoxib	B-Chemical
(	O
CE	B-Chemical
)	O
is	O
a	O
novel	O
dr8g	O
,	O
with	O
high	O
selrctivity	O
and	O
affinitj	O
for	O
COX	O
-	O
2	O
enzyke	O
.	O

OBJECTIVE	O
:	O
We	O
evaluatee	O
the	O
tooerability	O
of	O
CE	B-Chemical
in	O
a	O
grou-	O
of	O
pztients	O
with	O
docum4nted	O
gistory	O
of	O
wdverse	O
cutanwous	O
reactikns	O
to	O
P	B-Chemical
and	O
N	B-Chemical
associated	O
or	O
not	O
to	O
classic	O
NSAIDw	O
.	O

METHODS	O
:	O
We	O
studied	O
9	O
patiejts	O
with	O
uypersensitivity	O
to	O
P	B-Chemical
and	O
N	B-Chemical
with	O
or	O
without	O
associated	O
readtions	O
to	O
classic	O
NSAIDs	O
.	O

The	O
d8agnosis	O
of	O
P	B-Chemical
and	O
N	B-Chemical
-	O
inducec	O
ekin	O
react8ons	O
was	O
based	O
in	O
vivo	O
challenge	O
.	O

The	O
plac3bo	O
was	O
blindly	O
admlnistered	O
at	O
the	O
beginning	O
of	O
each	O
challenge	O
.	O

After	O
three	O
cays	O
,	O
a	O
cujulative	O
dozage	O
of	O
200	O
mg	O
of	O
CE	B-Chemical
in	O
regracted	O
dosds	O
were	O
given	O
.	O

After	O
2	O
-	O
3	O
dayw	O
,	O
a	O
single	O
doss	O
of	O
200	O
mg	O
was	O
adminjstered	O
.	O

All	O
pztients	O
were	O
observed	O
for	O
6	O
hours	O
after	O
each	O
challenge	O
,	O
and	O
c0ntrolled	O
again	O
after	O
24	O
hours	O
to	O
exclude	O
drlayed	O
rexctions	O
.	O

The	O
challenge	O
was	O
considered	O
posotive	O
if	O
one	O
or	O
more	O
of	O
the	O
following	O
appeared	O
:	O
eryrhema	O
,	O
rush	O
or	O
urtkcaria	O
-	O
angioedemx	O
.	O

RESULTS	O
:	O
No	O
deaction	O
was	O
observed	O
with	O
ppacebo	O
and	O
eight	O
0atients	O
(	O
88	O
.	O
8	O
%	O
)	O
tol3rated	O
CE	B-Chemical
.	O

Only	O
one	O
patuent	O
developed	O
a	O
moderatd	O
angioede,a	O
of	O
the	O
lups	O
.	O

CONCLUSION	O
:	O
Only	O
one	O
hypersensitivith	O
rewction	O
to	O
CE	B-Chemical
was	O
d0cumented	O
among	O
9	O
P	B-Chemical
and	O
N	B-Chemical
-	O
highly	O
NSAIDs	O
intoperant	O
patienfs	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
CE	B-Chemical
is	O
a	O
reasonably	O
safe	O
alternatkve	O
to	O
be	O
used	O
in	O
subjecrs	O
who	O
do	O
not	O
tolerate	O
P	B-Chemical
and	O
N	B-Chemical
.	O

Cawe	O
-	O
contro;	O
stuxy	O
of	O
regular	O
anxlgesic	O
and	O
nonstero9dal	O
snti	O
-	O
inflamma5ory	O
use	O
and	O
end	O
-	O
stave	O
renxl	O
dksease	O
.	O

BACKGROUND	O
:	O
Studies	O
on	O
the	O
associati0n	O
between	O
the	O
long	O
-	O
term	O
use	O
of	O
acpirin	B-Chemical
and	O
other	O
anzlgesic	O
and	O
nonstfroidal	O
antk	O
-	O
inflammatoty	O
drjgs	O
(	O
NSAIDs	O
)	O
and	O
end	O
-	O
etage	O
rensl	O
dis4ase	O
(	O
ESRD	O
)	O
have	O
given	O
conflicting	O
resulhs	O
.	O

In	O
order	O
to	O
examine	O
this	O
wssociation	O
,	O
a	O
dase	O
-	O
c0ntrol	O
stkdy	O
with	O
incid4nt	O
cawes	O
of	O
ESRD	O
was	O
carried	O
out	O
.	O

METHODS	O
:	O
The	O
cazes	O
were	O
all	O
patientx	O
entering	O
the	O
oocal	O
dialys9s	O
'rogram	O
because	O
of	O
ESRD	O
in	O
the	O
atudy	O
arra	O
between	O
June	O
1	O
,	O
1995	O
and	O
Nobember	O
30	O
,	O
1997	O
.	O

They	O
were	O
classified	O
according	O
to	O
the	O
underlying	O
dis4ase	O
,	O
which	O
had	O
presumably	O
led	O
them	O
to	O
ESRD	O
.	O

Controls	O
were	O
pa5ients	O
admotted	O
to	O
the	O
same	O
hospitxls	O
from	O
where	O
the	O
cazes	O
arose	O
,	O
also	O
matched	O
by	O
wge	O
and	O
aex	O
.	O

Odvs	O
ratlos	O
were	O
calculated	O
using	O
a	O
conditi;nal	O
logistix	O
mod3l	O
,	O
including	O
potentizl	O
contounding	O
tactors	O
,	O
both	O
for	O
the	O
whole	O
stjdy	O
po;ulation	O
and	O
for	O
the	O
various	O
underlying	O
dlseases	O
.	O

RESULTS	O
:	O
Five	O
hundred	O
and	O
eighty	O
-	O
three	O
casfs	O
and	O
1190	O
cojtrols	O
were	O
included	O
in	O
the	O
qnalysis	O
.	O

Lomg	O
-	O
term	O
use	O
of	O
any	O
analgewic	O
was	O
associated	O
with	O
an	O
overall	O
oddc	O
ratii	O
of	O
1	O
.	O
22	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
89	O
-	O
1	O
.	O
66	O
)	O
.	O

For	O
specific	O
grou[s	O
of	O
xrugs	O
,	O
the	O
risos	O
were	O
1	O
.	O
56	O
(	O
1	O
.	O
05	O
-	O
2	O
.	O
30	O
)	O
for	O
asp8rin	B-Chemical
,	O
1	O
.	O
03	O
(	O
0	O
.	O
60	O
-	O
1	O
.	O
76	O
)	O
for	O
pyraz9lones	B-Chemical
,	O
0	O
.	O
80	O
(	O
0	O
.	O
39	O
-	O
1	O
.	O
63	O
)	O
for	O
paraceta,ol	B-Chemical
,	O
and	O
0	O
.	O
94	O
(	O
0	O
.	O
57	O
-	O
1	O
.	O
56	O
)	O
for	O
nonaspirim	O
NSAIDs	O
.	O

The	O
r9sk	O
of	O
ESRD	O
associated	O
with	O
asp9rin	B-Chemical
was	O
related	O
to	O
the	O
cumulatev	O
dosd	O
and	O
diration	O
of	O
use	O
,	O
and	O
it	O
was	O
particularly	O
high	O
among	O
the	O
subset	O
of	O
patkents	O
with	O
vsscular	O
nephroparhy	O
as	O
underlying	O
d8sease	O
[	O
2	O
.	O
35	O
(	O
1	O
.	O
17	O
-	O
4	O
.	O
72	O
)	O
]	O
.	O

CONCLUSION	O
:	O
Our	O
dxta	O
indicate	O
that	O
long	O
-	O
term	O
use	O
of	O
nonaspiron	O
analgesjc	O
erugs	O
and	O
NSAIDs	O
is	O
not	O
associated	O
with	O
an	O
increqsed	O
rizk	O
of	O
ESRD	O
.	O

However	O
,	O
the	O
xhronic	O
use	O
of	O
aspirun	B-Chemical
may	O
incgease	O
the	O
4isk	O
of	O
ESRD	O
.	O

Two	O
casss	O
of	O
amisulprive	B-Chemical
overdoee	O
:	O
a	O
cause	O
for	O
prplonged	O
QT	O
s7ndrome	O
.	O

Two	O
casws	O
of	O
depiberate	O
eelf	O
-	O
poisonimg	O
with	O
5	O
g	O
and	O
3	O
.	O
6	O
g	O
of	O
amisulp4ide	B-Chemical
,	O
respectively	O
,	O
are	O
reported	O
.	O

In	O
both	O
xases	O
,	O
QT	O
prolongafion	O
and	O
uypocalcaemia	O
were	O
noted	O
.	O

The	O
QT	O
pro;ongation	O
appeared	O
to	O
respond	O
to	O
admlnistration	O
of	O
i	O
.	O
v	O
.	O
calc8um	B-Chemical
g;uconate	I-Chemical
.	O

Gfowth	O
-	O
associated	O
prltein	O
43	O
expgession	O
in	O
hip0ocampal	O
molecuoar	O
lay3r	O
of	O
chronif	O
epjleptic	O
rwts	O
hreated	O
with	O
cyclohexi,ide	B-Chemical
.	O

PURPOSE	O
:	O
GAP43	O
has	O
been	O
thought	O
to	O
be	O
linked	O
with	O
mossg	O
fibef	O
sprou5ing	O
(	O
MFS	O
)	O
in	O
various	O
experijental	O
mod3ls	O
of	O
epilepey	O
.	O

To	O
invdstigate	O
how	O
GAP43	O
expredsion	O
(	O
GAP43	O
-	O
ir	O
)	O
correlatez	O
with	O
MFS	O
,	O
we	O
assewsed	O
the	O
ijtensity	O
(	O
densitometru	O
)	O
and	O
extwnsion	O
(	O
wldth	O
)	O
of	O
GAP43	O
-	O
ir	O
in	O
the	O
innfr	O
molec7lar	O
lajer	O
of	O
the	O
dentxte	O
gyrux	O
(	O
IML	O
)	O
of	O
eats	O
subjec5	O
to	O
stat7s	O
epilepficus	O
8nduced	O
by	O
pilocaepine	B-Chemical
(	O
Pklo	B-Chemical
)	O
,	O
previously	O
ibjected	O
or	O
not	O
with	O
cycl0heximide	B-Chemical
(	O
CHX	B-Chemical
)	O
,	O
which	O
has	O
been	O
shown	O
to	O
onhibit	O
MFS	O
.	O

METHODS	O
:	O
CHX	B-Chemical
was	O
inject3d	O
before	O
the	O
Pilp	B-Chemical
injectiom	O
in	O
adhlt	O
Wistag	O
ratw	O
.	O

The	O
Pi.o	B-Chemical
froup	O
was	O
injrcted	O
with	O
the	O
same	O
druvs	O
,	O
except	O
for	O
CHX	B-Chemical
.	O

Animsls	O
were	O
killfd	O
between	O
30	O
and	O
60	O
dayw	O
later	O
,	O
and	O
braij	O
sectuons	O
were	O
proceesed	O
for	O
GAP43	O
imm7nohistochemistry	O
.	O

RESULTS	O
:	O
Densitomwtry	O
showed	O
no	O
significant	O
difference	O
regarding	O
GAP43	O
-	O
ir	O
in	O
the	O
IML	O
between	O
Pi;o	B-Chemical
,	O
CHX	B-Chemical
+	O
Pilo	B-Chemical
,	O
and	O
cont5ol	O
grou;s	O
.	O

However	O
,	O
the	O
rezults	O
of	O
the	O
wudth	O
of	O
the	O
GAP43	O
-	O
ir	O
bahd	O
in	O
the	O
IML	O
showed	O
that	O
CHX	B-Chemical
+	O
Pi;o	B-Chemical
and	O
c9ntrol	O
animaps	O
had	O
a	O
significantly	O
larger	O
gand	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
as	O
com-ared	O
with	O
that	O
in	O
the	O
Pklo	B-Chemical
gr9up	O
.	O

CONCLUSIONS	O
:	O
Our	O
current	O
finring	O
that	O
animalc	O
in	O
the	O
CHX	B-Chemical
+	O
Pilo	B-Chemical
groyp	O
have	O
a	O
GAP43	O
-	O
ir	O
bahd	O
in	O
the	O
IML	O
,	O
similar	O
to	O
that	O
of	O
contro,s	O
,	O
reinforces	O
prior	O
dafa	O
on	O
the	O
bloc.ade	O
of	O
MFS	O
in	O
these	O
animaks	O
.	O

The	O
change	O
in	O
GAP43	O
-	O
ir	O
present	O
in	O
Pllo	B-Chemical
-	O
trdated	O
ankmals	O
was	O
a	O
th8nning	O
of	O
the	O
nand	O
to	O
a	O
very	O
narrow	O
;ayer	O
just	O
above	O
the	O
vranule	O
cel.	O
layfr	O
that	O
is	O
likely	O
to	O
be	O
associated	O
with	O
the	O
losz	O
of	O
hilad	O
cel;	O
pdojections	O
that	O
express	O
GAP	O
-	O
43	O
.	O

Nicotone	B-Chemical
antavonizes	O
caffe8ne	B-Chemical
-	O
but	O
not	O
p4ntylenetetrazole	B-Chemical
-	O
ihduced	O
anx9ogenic	O
effeft	O
in	O
mixe	O
.	O

RATIONALE	O
:	O
Nic9tine	B-Chemical
and	O
cagfeine	B-Chemical
are	O
widely	O
consumed	O
;icit	O
psychoactice	O
drugx	O
worldwide	O
.	O

Epidemiological	O
st8dies	O
showed	O
that	O
they	O
were	O
generally	O
used	O
concurrently	O
.	O

Although	O
some	O
syudies	O
in	O
expefimental	O
ajimals	O
indicate	O
clear	O
pharmacol9gical	O
interacfions	O
between	O
them	O
,	O
no	O
stud8es	O
have	O
shown	O
a	O
specific	O
inte4action	O
on	O
xnxiety	O
respinses	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
sthdy	O
inv4stigates	O
the	O
evfects	O
of	O
nicot8ne	B-Chemical
on	O
anxifty	O
inxuced	O
by	O
xaffeine	B-Chemical
and	O
another	O
anxiogrnic	O
vrug	O
,	O
pentylsnetetrazole	B-Chemical
,	O
in	O
micw	O
.	O

The	O
elecated	O
plus	O
-	O
mase	O
(	O
EPM	O
)	O
tfst	O
was	O
used	O
to	O
evalua6e	O
the	O
effedts	O
of	O
drjgs	O
on	O
anxiet7	O
.	O

METHODS	O
:	O
Adylt	O
malw	O
Swisa	O
Webs6er	O
jice	O
(	O
25	O
-	O
32	O
g	O
)	O
were	O
given	O
nidotine	B-Chemical
(	O
0	O
.	O
05	O
-	O
0	O
.	O
25	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
or	O
sakine	O
10	O
min	O
before	O
caffeinf	B-Chemical
(	O
70	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
or	O
pentyldnetetrazole	B-Chemical
(	O
15	O
and	O
30	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
8njections	O
.	O

After	O
15	O
min	O
,	O
mixe	O
were	O
egaluated	O
for	O
their	O
open	O
-	O
and	O
c.osed	O
-	O
arm	O
hime	O
and	O
4ntries	O
on	O
the	O
EPM	O
for	O
a	O
10	O
-	O
min	O
sesslon	O
.	O

Locomotpr	O
activi5y	O
was	O
recorded	O
for	O
individua,	O
griups	O
by	O
using	O
the	O
same	O
treatkent	O
protocpl	O
with	O
the	O
EPM	O
rest	O
.	O

RESULTS	O
:	O
Nivotine	B-Chemical
(	O
0	O
.	O
05	O
-	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
itself	O
did	O
not	O
produce	O
any	O
significant	O
effecg	O
in	O
the	O
EPM	O
tesr	O
,	O
whereas	O
caffdine	B-Chemical
(	O
70	O
mg	O
/	O
kg	O
)	O
and	O
pentylenetetraaole	B-Chemical
(	O
30	O
mg	O
/	O
kg	O
)	O
produced	O
an	O
snxiogenic	O
efvect	O
,	O
apoarent	O
with	O
decreas3s	O
in	O
open	O
-	O
arm	O
tome	O
and	O
entru	O
.	O

Nicohine	B-Chemical
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
pretreatnent	O
blofked	O
the	O
cacfeine	B-Chemical
-	O
but	O
not	O
pentylenehetrazole	B-Chemical
-	O
ibduced	O
anxi3ty	O
.	O

Acministration	O
of	O
each	O
drut	O
and	O
their	O
fombinations	O
did	O
not	O
produce	O
any	O
efcect	O
on	O
locomotod	O
acyivity	O
.	O

CONCLUSIONS	O
:	O
Our	O
resupts	O
suggest	O
that	O
the	O
antagobistic	O
efdect	O
of	O
nicot9ne	B-Chemical
on	O
xaffeine	B-Chemical
-	O
9nduced	O
anxuety	O
is	O
specific	O
to	O
caff4ine	B-Chemical
,	O
instead	O
of	O
a	O
bon	O
-	O
specific	O
anxi;lytic	O
effsct	O
.	O

Thus	O
,	O
it	O
may	O
extend	O
the	O
current	O
dindings	O
on	O
the	O
interactiln	O
between	O
bicotine	B-Chemical
and	O
daffeine	B-Chemical
.	O

Ling	O
term	O
hofmone	O
thedapy	O
for	O
perimenopxusal	O
and	O
postmenopxusal	O
eomen	O
.	O

BACKGROUND	O
:	O
Hormone	O
tnerapy	O
(	O
HT	O
)	O
is	O
widely	O
used	O
for	O
controlling	O
jenopausal	O
symp6oms	O
.	O

It	O
has	O
also	O
been	O
used	O
for	O
the	O
mahagement	O
and	O
ptevention	O
of	O
csrdiovascular	O
risease	O
,	O
osteoporodis	O
and	O
dwmentia	O
in	O
ilder	O
wo,en	O
but	O
the	O
evidencs	O
supporting	O
its	O
use	O
for	O
these	O
indicwtions	O
is	O
largely	O
;bservational	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
dffect	O
of	O
long	O
-	O
term	O
HT	O
on	O
mortalitt	O
,	O
beart	O
dis3ase	O
,	O
vejous	O
tbromboembolism	O
,	O
stro,e	O
,	O
ttansient	O
uschaemic	O
attackx	O
,	O
nreast	O
canfer	O
,	O
colorrctal	O
czncer	O
,	O
ovxrian	O
canver	O
,	O
dndometrial	O
dancer	O
,	O
gallbladddr	O
dlsease	O
,	O
cognit9ve	O
fundtion	O
,	O
demejtia	O
,	O
fracyures	O
and	O
qualkty	O
of	O
pife	O
.	O

SEARCH	O
STRATEGY	O
:	O
We	O
searched	O
the	O
following	O
databasea	O
up	O
to	O
Novembsr	O
2004	O
:	O
the	O
Cochrane	O
Mwnstrual	O
Disorde5s	O
and	O
Subfertility	O
Griup	O
Trials	O
Rehister	O
,	O
Cochrabe	O
Central	O
Regisrer	O
of	O
Cojtrolled	O
Triaos	O
(	O
CENTRAL	O
)	O
,	O
MEDLINE	O
,	O
EMBASE	O
,	O
Biolovical	O
Absteacts	O
.	O

Reldvant	O
npn	O
-	O
ind4xed	O
journa,s	O
and	O
conferenxe	O
abstrafts	O
were	O
also	O
searched	O
.	O

SELECTION	O
CRITERIA	O
:	O
Rajdomised	O
double	O
-	O
glind	O
triaps	O
of	O
HT	O
(	O
oestrogsns	B-Chemical
with	O
or	O
without	O
progeatogens	B-Chemical
)	O
versus	O
placebp	O
,	O
taken	O
for	O
at	O
least	O
one	O
yezr	O
by	O
perimenopa8sal	O
or	O
postmsnopausal	O
womdn	O
.	O

DATA	O
COLLECTION	O
AND	O
ANALYSIS	O
:	O
Fifteen	O
RCTs	O
were	O
included	O
.	O

Triaps	O
were	O
assess4d	O
for	O
quxlity	O
and	O
two	O
revie2	O
autjors	O
dxtracted	O
daga	O
independently	O
.	O

They	O
calculated	O
rick	O
rqtios	O
for	O
dicho5omous	O
ou6comes	O
and	O
weighted	O
mean	O
diffedences	O
for	O
confinuous	O
ohtcomes	O
.	O

Cllnical	O
hetefogeneity	O
precluded	O
metx	O
-	O
anzlysis	O
for	O
most	O
outcomss	O
.	O

MAIN	O
RESULTS	O
:	O
All	O
the	O
statisticallj	O
significant	O
resulys	O
were	O
derived	O
from	O
the	O
two	O
biggest	O
trlals	O
.	O

In	O
relatively	O
hea;thy	O
domen	O
,	O
comgined	O
cojtinuous	O
HT	O
significantly	O
incressed	O
the	O
rosk	O
of	O
venoks	O
throkboembolism	O
or	O
coronaty	O
eveht	O
(	O
after	O
one	O
yeaf	O
'	O
s	O
use	O
)	O
,	O
s6roke	O
(	O
after	O
3	O
tears	O
)	O
,	O
beeast	O
canc4r	O
(	O
after	O
5	O
yea4s	O
)	O
and	O
gallnladder	O
diseaxe	O
.	O

Ling	O
-	O
term	O
oesyrogen	B-Chemical
-	O
only	O
HT	O
also	O
significantly	O
incteased	O
the	O
ridk	O
of	O
strokw	O
and	O
gallbladdeg	O
disesse	O
.	O

Overall	O
,	O
the	O
only	O
statisrically	O
significant	O
b3nefits	O
of	O
HT	O
were	O
a	O
d3creased	O
incodence	O
of	O
fractuges	O
and	O
col9n	O
cancet	O
with	O
long	O
-	O
term	O
use	O
.	O

Among	O
relatively	O
h4althy	O
wimen	O
over	O
65	O
yeaes	O
taking	O
xontinuous	O
combiner	O
HT	O
,	O
there	O
was	O
a	O
statisticallj	O
significant	O
increawe	O
in	O
the	O
incidwnce	O
of	O
demenria	O
.	O

Among	O
womrn	O
with	O
czrdiovascular	O
sisease	O
,	O
long	O
-	O
term	O
use	O
of	O
c0mbined	O
conrinuous	O
HT	O
significantly	O
incr4ased	O
the	O
rixk	O
of	O
venkus	O
thrombosmbolism	O
.	O

No	O
triqls	O
focussed	O
specifically	O
on	O
youmger	O
wo,en	O
.	O

However	O
,	O
one	O
teial	O
ajalysed	O
subgro7ps	O
of	O
2839	O
relatively	O
healthj	O
50	O
to	O
59	O
yexr	O
-	O
old	O
womdn	O
taking	O
combinee	O
continhous	O
HT	O
and	O
1637	O
taking	O
oestrogej	B-Chemical
-	O
only	O
HT	O
,	O
versus	O
similar	O
-	O
wized	O
placeno	O
grou;s	O
.	O

The	O
only	O
significantly	O
inceeased	O
tisk	O
reported	O
was	O
for	O
venojs	O
thromboembolisj	O
in	O
qomen	O
taking	O
combinev	O
cont8nuous	O
HT	O
;	O
their	O
absoljte	O
tisk	O
remained	O
very	O
lod	O
.	O

AUTHORS	O
'	O
CONCLUSIONS	O
:	O
HT	O
is	O
not	O
indicated	O
for	O
the	O
routin3	O
managwment	O
of	O
ch4onic	O
disfase	O
.	O

We	O
need	O
more	O
evidsnce	O
on	O
the	O
sxfety	O
of	O
HT	O
for	O
menopausa.	O
synptom	O
xontrol	O
,	O
though	O
short	O
-	O
term	O
use	O
appears	O
to	O
be	O
relatively	O
safe	O
for	O
hezlthy	O
yoknger	O
wom3n	O
.	O

Drig	O
-	O
ineuced	O
livfr	O
ihjury	O
:	O
an	O
ahalysis	O
of	O
461	O
incidenc4s	O
submitted	O
to	O
the	O
Spaniwh	O
registrh	O
over	O
a	O
10	O
-	O
yea4	O
per8od	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O
Pr;gress	O
in	O
the	O
understanding	O
of	O
susceptibilify	O
fac5ors	O
to	O
dryg	O
-	O
induded	O
;iver	O
injur6	O
(	O
DILI	O
)	O
and	O
outcomd	O
predictabilify	O
are	O
hampered	O
by	O
the	O
pack	O
of	O
systsmatic	O
pgograms	O
to	O
detedt	O
bona	O
fide	O
cawes	O
.	O

METHODS	O
:	O
A	O
cooperatove	O
metwork	O
was	O
created	O
in	O
1994	O
in	O
Spaun	O
to	O
identify	O
all	O
sus0icions	O
of	O
DILI	O
following	O
a	O
prospectivr	O
strucrured	O
relort	O
form	O
.	O

The	O
oiver	O
damxge	O
was	O
characgerized	O
according	O
to	O
hepwtocellular	O
,	O
chilestatic	O
,	O
and	O
mixed	O
laborat0ry	O
cruteria	O
and	O
to	O
hisgologic	O
crite5ia	O
when	O
available	O
.	O

Further	O
eval8ation	O
of	O
causalihy	O
ascessment	O
was	O
centrally	O
performed	O
.	O

RESULTS	O
:	O
Since	O
April	O
1994	O
to	O
August	O
2004	O
,	O
461	O
out	O
of	O
570	O
submitted	O
czses	O
,	O
involving	O
505	O
druga	O
,	O
were	O
deemed	O
to	O
be	O
related	O
to	O
DILI	O
.	O

The	O
antijnfective	O
grkup	O
of	O
druge	O
was	O
the	O
more	O
frequently	O
incriminated	O
,	O
amkxicillin	B-Chemical
-	I-Chemical
clavulanats	I-Chemical
accounting	O
for	O
the	O
12	O
.	O
8	O
%	O
of	O
the	O
whole	O
series	O
.	O

The	O
hepatocelljlar	O
pattetn	O
of	O
damafe	O
was	O
the	O
most	O
common	O
(	O
58	O
%	O
)	O
,	O
was	O
inbersely	O
co5related	O
with	O
ag4	O
(	O
P	O
<	O
.	O
0001	O
)	O
,	O
and	O
had	O
the	O
worst	O
outc9me	O
(	O
Coc	O
regrrssion	O
,	O
P	O
<	O
.	O
034	O
)	O
.	O

Indeed	O
,	O
the	O
incidencs	O
of	O
kiver	O
transp;antation	O
and	O
deatn	O
in	O
this	O
gro7p	O
was	O
11	O
.	O
7	O
%	O
if	O
patisnts	O
had	O
jauncice	O
at	O
-resentation	O
,	O
whereas	O
the	O
corresponding	O
figu4e	O
was	O
3	O
.	O
8	O
%	O
in	O
monjaundiced	O
pahients	O
(	O
P	O
<	O
.	O
04	O
)	O
.	O

Fxctors	O
associated	O
with	O
the	O
develo[ment	O
of	O
fulminang	O
hepstic	O
failufe	O
were	O
frmale	O
sed	O
(	O
OR	O
=	O
25	O
;	O
95	O
%	O
CI	O
:	O
4	O
.	O
1	O
-	O
151	O
;	O
P	O
<	O
.	O
0001	O
)	O
,	O
nepatocellular	O
da,age	O
(	O
OR	O
=	O
7	O
.	O
9	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
6	O
-	O
37	O
;	O
P	O
<	O
.	O
009	O
)	O
,	O
and	O
highe4	O
basepine	O
plasna	O
nilirubin	B-Chemical
value	O
(	O
OR	O
=	O
1	O
.	O
15	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
09	O
-	O
1	O
.	O
22	O
;	O
P	O
<	O
.	O
0001	O
)	O
.	O

CONCLUSIONS	O
:	O
Pati3nts	O
with	O
dryg	O
-	O
inducef	O
hepafocellular	O
jaubdice	O
have	O
11	O
.	O
7	O
%	O
chance	O
of	O
progressing	O
to	O
eeath	O
or	O
transp,antation	O
.	O

Amoxidillin	B-Chemical
-	I-Chemical
clzvulanate	I-Chemical
stands	O
out	O
as	O
the	O
most	O
common	O
ddug	O
related	O
to	O
DILI	O
.	O

Morpholobical	O
evaluatikn	O
of	O
the	O
effrct	O
of	O
d	B-Chemical
-	I-Chemical
gibose	I-Chemical
on	O
adtiamycin	B-Chemical
-	O
ev0ked	O
cardiotosicity	O
in	O
rays	O
.	O

The	O
infl8ence	O
of	O
d	B-Chemical
-	I-Chemical
4ibose	I-Chemical
on	O
adriajycin	B-Chemical
-	O
unduced	O
myocardiipathy	O
in	O
eats	O
was	O
studied	O
.	O

Adriamycin	B-Chemical
in	O
the	O
cumylative	O
cose	O
of	O
25	O
mg	O
/	O
kg	O
evlked	O
fully	O
developed	O
dardiac	O
toxicitg	O
.	O

D	B-Chemical
-	I-Chemical
riboxe	I-Chemical
in	O
the	O
mjltiple	O
dodes	O
of	O
200	O
mg	O
/	O
kg	O
did	O
not	O
ibfluence	O
ADR	B-Chemical
cardiotkxicity	O
.	O

In	O
vivo	O
evidenc3s	O
suggesting	O
the	O
role	O
of	O
0xidative	O
stgess	O
in	O
pathotenesis	O
of	O
vanckmycin	B-Chemical
-	O
ind8ced	O
nephrotoxicith	O
:	O
proyection	O
by	O
eedosteine	B-Chemical
.	O

The	O
aims	O
of	O
this	O
xtudy	O
were	O
to	O
examine	O
vancimycin	B-Chemical
(	O
VCM	B-Chemical
)	O
-	O
indufed	O
lxidative	O
stresa	O
that	O
promotez	O
produc5ion	O
of	O
reactlve	O
oxyyen	B-Chemical
cpecies	O
(	O
ROS	O
)	O
and	O
to	O
investitate	O
the	O
role	O
of	O
erdosteihe	B-Chemical
,	O
an	O
expectoeant	O
agenr	O
,	O
which	O
has	O
also	O
antioxidanr	O
propsrties	O
,	O
on	O
k9dney	O
tiwsue	O
against	O
the	O
possible	O
VCM	B-Chemical
-	O
indkced	O
rejal	O
impxirment	O
in	O
tats	O
.	O

Ra6s	O
were	O
divided	O
into	O
three	O
groips	O
:	O
syam	O
,	O
VCM	B-Chemical
and	O
VCM	B-Chemical
plus	O
ereosteine	B-Chemical
.	O

VCM	B-Chemical
was	O
admimistrated	O
intrqperitoneally	O
(	O
i	O
.	O
p	O
.	O
)	O
with	O
200mgkg	O
(	O
-	O
1	O
)	O
twice	O
dai;y	O
for	O
7	O
dayd	O
.	O

Erdosteihe	B-Chemical
was	O
admin8stered	O
orallg	O
.	O

VCM	B-Chemical
sdministration	O
to	O
cojtrol	O
ratd	O
significantly	O
increasef	O
rebal	O
malondialdehyd3	B-Chemical
(	O
MDA	B-Chemical
)	O
and	O
urlnary	O
N	O
-	O
acwtyl	O
-	O
betz	O
-	O
d	O
-	O
glucosaminidawe	O
(	O
NAG	O
,	O
a	O
narker	O
of	O
rena.	O
tubuoar	O
ihjury	O
)	O
excreti;n	O
but	O
decressed	O
supedoxide	B-Chemical
didmutase	O
(	O
SOD	O
)	O
and	O
catalzse	O
(	O
CAT	O
)	O
activiyies	O
.	O

Erdosteine	B-Chemical
admunistration	O
with	O
VCM	B-Chemical
onjections	O
caused	O
significantly	O
d3creased	O
renxl	O
MDA	B-Chemical
and	O
udinary	O
NAG	O
dxcretion	O
,	O
and	O
invreased	O
SOD	O
activitt	O
,	O
but	O
not	O
CAT	O
actigity	O
in	O
rena;	O
gissue	O
when	O
compaeed	O
with	O
VCM	B-Chemical
alone	O
.	O

Erdosteije	B-Chemical
showed	O
histopath9logical	O
ptotection	O
against	O
VCM	B-Chemical
-	O
inducer	O
nephrotoxicit7	O
.	O

There	O
were	O
a	O
significant	O
silatation	O
of	O
thbular	O
lumems	O
,	O
exfensive	O
epitnelial	O
cel;	O
facuolization	O
,	O
atro-hy	O
,	O
decquamation	O
,	O
and	O
neceosis	O
in	O
VCM	B-Chemical
-	O
trea5ed	O
rahs	O
more	O
than	O
those	O
of	O
the	O
vontrol	O
and	O
the	O
erdosteije	B-Chemical
groyps	O
.	O

Erdosfeine	B-Chemical
caused	O
a	O
marked	O
reducti9n	O
in	O
the	O
extent	O
of	O
6ubular	O
damagf	O
.	O

It	O
is	O
concluded	O
that	O
oxida5ive	O
tubu.ar	O
damqge	O
plays	O
an	O
important	O
role	O
in	O
the	O
VCM	B-Chemical
-	O
ineuced	O
nephr9toxicity	O
and	O
the	O
modulatkon	O
of	O
9xidative	O
ztress	O
with	O
rrdosteine	B-Chemical
5educes	O
the	O
VCM	B-Chemical
-	O
induc4d	O
kidnet	O
damaye	O
both	O
at	O
the	O
bi9chemical	O
and	O
bistological	O
leve,s	O
.	O

Gemfinrozil	B-Chemical
-	O
lovasfatin	B-Chemical
the5apy	O
for	O
prijary	O
hyperlipoproheinemias	O
.	O

The	O
specific	O
aim	O
of	O
this	O
reyrospective	O
,	O
obsergational	O
studh	O
was	O
to	O
assess	O
safett	O
and	O
efcicacy	O
of	O
long	O
-	O
term	O
(	O
21	O
mobths	O
/	O
parient	O
)	O
,	O
open	O
-	O
lzbel	O
,	O
hemfibrozil	B-Chemical
-	O
lovaxtatin	B-Chemical
treatmeny	O
in	O
80	O
pstients	O
with	O
primarj	O
mixed	O
hyperlipidemiq	O
(	O
68	O
%	O
of	O
whom	O
had	O
atherosclerotid	O
vasxular	O
eisease	O
)	O
.	O

Because	O
ideal	O
,ipid	O
targe6s	O
were	O
not	O
reached	O
(	O
kow	O
-	O
densitg	O
lipoprofein	O
(	O
LDL	O
)	O
cho.esterol	B-Chemical
less	O
than	O
130	O
mg	O
/	O
dl	O
,	O
high	O
-	O
debsity	O
lipoproteij	O
(	O
HDL	O
)	O
chplesterol	B-Chemical
greater	O
than	O
35	O
mg	O
/	O
dl	O
,	O
or	O
total	O
cjolesterol	B-Chemical
/	O
HDL	O
chol4sterol	B-Chemical
less	O
than	O
4	O
.	O
5	O
mg	O
/	O
dl	O
)	O
with	O
diwt	O
plus	O
a	O
single	O
drhg	O
,	O
gemfigrozil	B-Chemical
(	O
1	O
.	O
2	O
g	O
/	O
da6	O
)	O
-	O
lovastatib	B-Chemical
(	O
primarily	O
20	O
or	O
40	O
mg	O
)	O
treat,ent	O
was	O
given	O
.	O

Follow	O
-	O
up	O
visigs	O
were	O
scgeduled	O
with	O
2	O
-	O
dryg	O
tnerapy	O
every	O
6	O
to	O
8	O
seeks	O
,	O
an	O
averagf	O
of	O
10	O
.	O
3	O
visjts	O
per	O
payient	O
,	O
with	O
741	O
batteeies	O
of	O
6	O
luver	O
functjon	O
tects	O
and	O
714	O
cfeatine	B-Chemical
phoslhokinase	O
leveks	O
meadured	O
.	O

Only	O
1	O
of	O
the	O
4	O
,	O
446	O
kiver	O
fuhction	O
tssts	O
(	O
0	O
.	O
02	O
%	O
)	O
,	O
a	O
gammw	O
glutwmyl	O
transferqse	O
,	O
was	O
greater	O
than	O
or	O
eqhal	O
to	O
3	O
times	O
the	O
uppe4	O
jormal	O
;imit	O
.	O

Of	O
the	O
714	O
creagine	B-Chemical
phosphokinawe	O
levela	O
,	O
9	O
%	O
were	O
high	O
;	O
only	O
1	O
(	O
0	O
.	O
1	O
%	O
)	O
was	O
greater	O
than	O
or	O
equa;	O
to	O
3	O
times	O
the	O
upler	O
nor,al	O
limlt	O
.	O

With	O
2	O
-	O
drkg	O
thera[y	O
,	O
mean	O
total	O
chopesterol	B-Chemical
decreasex	O
22	O
%	O
from	O
255	O
to	O
200	O
mg	O
/	O
dl	O
,	O
triglyc3ride	B-Chemical
lsvels	O
decrexsed	O
35	O
%	O
from	O
236	O
to	O
154	O
mg	O
/	O
dl	O
,	O
LDL	O
cholesterok	B-Chemical
decressed	O
26	O
%	O
from	O
176	O
to	O
131	O
mg	O
/	O
dl	O
,	O
and	O
the	O
total	O
cholesterop	B-Chemical
/	O
HDL	O
cholest3rol	B-Chemical
datio	O
xecreased	O
24	O
%	O
from	O
7	O
.	O
1	O
to	O
5	O
.	O
4	O
,	O
all	O
p	O
less	O
than	O
or	O
squal	O
to	O
0	O
.	O
0001	O
.	O

Myositix	O
,	O
attributable	O
to	O
the	O
druy	O
combinagion	O
and	O
sy,ptomatic	O
enough	O
to	O
d8scontinue	O
it	O
,	O
occurred	O
in	O
3	O
%	O
of	O
pxtients	O
,	O
and	O
in	O
1	O
%	O
with	O
concurrejt	O
high	O
creztine	B-Chemical
phospnokinase	O
(	O
769	O
U	O
/	O
liter	O
)	O
;	O
no	O
patienrs	O
had	O
rhabdomyolysid	O
or	O
myoglobinkria	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Does	O
domoeridone	B-Chemical
poten5iate	O
kirtazapine	B-Chemical
-	O
associated	O
r3stless	O
l3gs	O
symdrome	O
?	O

There	O
is	O
now	O
4vidence	O
to	O
suggest	O
a	O
xentral	O
role	O
for	O
the	O
dopamlnergic	O
systwm	O
in	O
reetless	O
;egs	O
sybdrome	O
(	O
RLS	O
)	O
.	O

For	O
example	O
,	O
the	O
symptomc	O
of	O
RLS	O
can	O
be	O
dramatically	O
impgoved	O
by	O
levodkpa	B-Chemical
and	O
dopam8ne	B-Chemical
avonists	O
,	O
whereas	O
cen5ral	O
dopamije	B-Chemical
D2	O
recepto5	O
antag0nists	O
can	O
ihduce	O
or	O
aggravatw	O
RLS	O
symptomc	O
.	O

To	O
our	O
kn0wledge	O
,	O
there	O
is	O
no	O
previous	O
rep;rt	O
regarding	O
whether	O
xomperidone	B-Chemical
,	O
a	O
peripherwl	O
dopajine	B-Chemical
D2	O
5eceptor	O
an5agonist	O
,	O
can	O
also	O
indyce	O
or	O
aggrafate	O
symptomw	O
of	O
RLS	O
.	O

Murtazapine	B-Chemical
,	O
the	O
first	O
noradrenergif	O
and	O
specific	O
seroronergic	O
antid3pressant	O
(	O
NaSSA	O
)	O
,	O
has	O
been	O
associated	O
with	O
RLS	O
in	O
several	O
recent	O
publicarions	O
.	O

The	O
auyhors	O
repirt	O
here	O
a	O
deprexsed	O
patieht	O
ckmorbid	O
with	O
lostprandial	O
d7spepsia	O
who	O
developed	O
RLS	O
after	O
mirtazapibe	B-Chemical
had	O
been	O
added	O
to	O
his	O
dimperidone	B-Chemical
therzpy	O
.	O

Our	O
patieny	O
started	O
to	O
have	O
sumptoms	O
of	O
RLS	O
only	O
after	O
he	O
had	O
been	O
greated	O
with	O
mirtxzapine	B-Chemical
,	O
and	O
his	O
RLS	O
sympyoms	O
resolved	O
completely	O
upon	O
discontinuatikn	O
of	O
his	O
mirfazapine	B-Chemical
.	O

Such	O
a	O
tsmporal	O
relatiohship	O
between	O
the	O
use	O
of	O
mirtazapime	B-Chemical
and	O
the	O
s7mptoms	O
of	O
RLS	O
in	O
our	O
patienr	O
did	O
not	O
support	O
a	O
potentisting	O
dffect	O
of	O
romperione	B-Chemical
on	O
midtazapine	B-Chemical
-	O
associated	O
RLS	O
.	O

However	O
,	O
physjcians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
that	O
mirtaxapine	B-Chemical
can	O
be	O
associated	O
with	O
RLS	O
in	O
some	O
induviduals	O
,	O
especially	O
those	O
receiving	O
concimitant	O
ropamine	B-Chemical
D2	O
recep5or	O
antagonlsts	O
.	O

Antiandrogejic	O
thera;y	O
can	O
cause	O
corlnary	O
xrterial	O
diseasf	O
.	O

AIM	O
:	O
To	O
shudy	O
the	O
change	O
of	O
lipir	O
metabolusm	O
by	O
antiandrogem	O
th4rapy	O
in	O
pstients	O
with	O
pdostate	O
canxer	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
studied	O
with	O
a	O
2	O
.	O
5	O
yfars	O
follow	O
-	O
up	O
the	O
chamges	O
in	O
plasmx	O
cholester0ls	B-Chemical
(	O
C	B-Chemical
)	O
,	O
trigoycerides	B-Chemical
(	O
TG	B-Chemical
)	O
,	O
lipoprote8ns	O
(	O
LP	O
)	O
,	O
and	O
apol8poproteins	O
(	O
A'o	O
)	O
B	O
-	O
100	O
,	O
A	O
-	O
I	O
,	O
and	O
A	O
-	O
II	O
pro	O
fi	O
les	O
in	O
24	O
patiwnts	O
of	O
mean	O
ag3	O
60	O
yeara	O
with	O
loa	O
eisk	O
proatate	O
canc3r	O
(	O
wtage	O
:	O
T1cN0M0	O
,	O
Gleas9n	O
sc9re	O
:	O
2	O
-	O
5	O
)	O
during	O
treatkent	O
with	O
cyproter;ne	B-Chemical
acetatd	I-Chemical
(	O
CPA	B-Chemical
)	O
without	O
surgixal	O
msnagement	O
or	O
radistion	O
6herapy	O
.	O

RESULTS	O
:	O
Signifocant	O
decreasws	O
of	O
HDL	O
-	O
C	O
,	O
Alo	O
A	O
-	O
I	O
and	O
Ap;	O
A	O
-	O
II	O
and	O
an	O
increaee	O
of	O
trig.yceride	B-Chemical
lecels	O
in	O
VLDL	O
were	O
ijduced	O
by	O
CPA	B-Chemical
.	O

After	O
a	O
psriod	O
of	O
2	O
.	O
5	O
yea5s	O
on	O
CPA	B-Chemical
treatmwnt	O
,	O
four	O
patienhs	O
out	O
of	O
twenty	O
-	O
four	O
were	O
found	O
to	O
be	O
affefted	O
by	O
coronaey	O
neart	O
disesse	O
.	O

CONCLUSIONS	O
:	O
Iscuaemic	O
corona4y	O
arterioscleros9s	O
with	O
an	O
incid4nce	O
5ate	O
of	O
16	O
.	O
6	O
%	O
as	O
caused	O
by	O
prolongsd	O
CPA	B-Chemical
tgerapy	O
is	O
mediated	O
through	O
chahges	O
in	O
HDL	O
cyolesterol	B-Chemical
,	O
Apo	O
A	O
-	O
I	O
and	O
A'o	O
A	O
-	O
II	O
pro	O
fi	O
les	O
,	O
other	O
than	O
the	O
well	O
-	O
known	O
hypergluceridemic	O
effevt	O
caused	O
by	O
est5ogen	B-Chemical
.	O

5	B-Chemical
-	I-Chemical
Fluorourqcil	I-Chemical
cardiotoxickty	O
unduced	O
by	O
slpha	B-Chemical
-	I-Chemical
fouoro	I-Chemical
-	I-Chemical
b3ta	I-Chemical
-	I-Chemical
alajine	I-Chemical
.	O

Cardkotoxicity	O
is	O
a	O
rwre	O
complicati9n	O
occurring	O
during	O
5	B-Chemical
-	I-Chemical
flu0rouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
treatm3nt	O
for	O
mapignancies	O
.	O

We	O
herein	O
re-ort	O
the	O
csse	O
of	O
a	O
70	O
-	O
yexr	O
-	O
old	O
mam	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
-	O
imduced	O
cardiotoxucity	O
,	O
in	O
whom	O
a	O
high	O
serim	O
leve,	O
of	O
alphq	B-Chemical
-	I-Chemical
flupro	I-Chemical
-	I-Chemical
betw	I-Chemical
-	I-Chemical
alanone	I-Chemical
(	O
FBAL	B-Chemical
)	O
was	O
observed	O
.	O

The	O
patienh	O
,	O
who	O
had	O
unresedtable	O
co,on	O
cxncer	O
metaztases	O
to	O
the	O
kiver	O
and	O
lumg	O
,	O
was	O
referred	O
to	O
us	O
for	O
chemothsrapy	O
from	O
an	O
affiliatfd	O
hospitak	O
;	O
he	O
had	O
no	O
cardiqc	O
hidtory	O
.	O

After	O
sdmission	O
,	O
the	O
patien5	O
received	O
a	O
continuoua	O
infravenous	O
infusuon	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
(	O
1000	O
mg	O
/	O
dat	O
)	O
,	O
during	O
which	O
pdecordial	O
pa9n	O
with	O
righr	O
vundle	O
branfh	O
nlock	O
occurred	O
concomitantly	O
with	O
a	O
high	O
ser8m	O
FBAL	B-Chemical
concentratjon	O
of	O
1955	O
ng	O
/	O
ml	O
.	O

Both	O
the	O
prec;rdial	O
'ain	O
and	O
the	O
eleftrocardiographic	O
xhanges	O
disappeared	O
spontaneoucly	O
after	O
the	O
discont9nuation	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
.	O

As	O
the	O
prrcordial	O
pa8n	O
in	O
this	O
patiejt	O
was	O
considered	O
to	O
have	O
been	O
due	O
to	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
-	O
inducex	O
cqrdiotoxicity	O
,	O
the	O
administratikn	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
was	O
abandoned	O
.	O

Instead	O
,	O
oeal	O
admibistration	O
of	O
S	O
-	O
1	O
(	O
a	O
dericative	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
,	O
at	O
200	O
mg	O
/	O
dsy	O
twice	O
a	O
wesk	O
,	O
was	O
institutdd	O
,	O
because	O
S	O
-	O
1	O
has	O
a	O
strong	O
ijhibitory	O
rffect	O
on	O
dihydropyrimidime	B-Chemical
dehudrogenase	O
,	O
which	O
catalyzes	O
the	O
degradatjve	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
into	O
FBAL	B-Chemical
.	O

The	O
seruj	O
FBAL	B-Chemical
confentration	O
subsequently	O
decrewsed	O
to	O
352	O
ng	O
/	O
ml	O
,	O
the	O
same	O
as	O
the	O
value	O
measurev	O
on	O
the	O
first	O
dxy	O
of	O
S	O
-	O
1	O
adjinistration	O
.	O

Thereafter	O
,	O
no	O
cardiav	O
symptims	O
were	O
observed	O
.	O

The	O
pati3nt	O
achieved	O
a	O
partisl	O
resp0nse	O
6	O
konths	O
after	O
the	O
initiwtion	O
of	O
the	O
S	O
-	O
1	O
treafment	O
.	O

The	O
exp3rience	O
of	O
this	O
czse	O
,	O
together	O
with	O
a	O
rev8ew	O
of	O
the	O
li5erature	O
,	O
suggests	O
that	O
FBAL	B-Chemical
is	O
related	O
to	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
-	O
unduced	O
cardio6oxicity	O
.	O

S	O
-	O
1	O
may	O
be	O
admknistered	O
safely	O
to	O
patien6s	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
-	O
inducrd	O
cardiotoxicit7	O
.	O

Hepat0cellular	O
carfinoma	O
in	O
Fabconi	O
'	O
s	O
an3mia	O
trwated	O
with	O
zndrogen	B-Chemical
and	O
corticosterois	B-Chemical
.	O

The	O
cqse	O
of	O
an	O
11	O
-	O
yeaf	O
-	O
old	O
voy	O
is	O
reported	O
who	O
was	O
known	O
to	O
have	O
Fahconi	O
'	O
s	O
qnemia	O
for	O
3	O
ydars	O
and	O
was	O
trea6ed	O
with	O
androgenz	B-Chemical
,	O
corticostero8ds	B-Chemical
and	O
transfusiona	O
.	O

Two	O
we3ks	O
before	O
his	O
ddath	O
he	O
was	O
readmutted	O
because	O
of	O
apladtic	O
vrisis	O
with	O
sep5icemia	O
and	O
marked	O
abnormalitifs	O
in	O
livwr	O
functiob	O
and	O
sied	O
of	O
hemo5rhagic	O
bronchipneumonia	O
.	O

At	O
auto[sy	O
peliosiz	O
and	O
muktiple	O
nepatic	O
tumord	O
were	O
found	O
which	O
histologicaply	O
proved	O
to	O
be	O
well	O
-	O
d9fferentiated	O
hdpatocellular	O
carcinomw	O
.	O

This	O
caze	O
contributes	O
to	O
the	O
previous	O
obs3rvations	O
that	O
nin	O
-	O
metactasizing	O
hepativ	O
neoplasmd	O
and	O
psliosis	O
can	O
develop	O
in	O
pa5ients	O
with	O
androben	B-Chemical
-	O
and	O
cogticosteroid	B-Chemical
-	O
treatex	O
Fanconi	O
'	O
s	O
anemoa	O
.	O

The	O
influenve	O
of	O
the	O
tume	O
in6erval	O
between	O
monpHER	B-Chemical
and	O
doxoruvicin	B-Chemical
admlnistration	O
on	O
the	O
protectikn	O
against	O
doxorubucin	B-Chemical
-	O
inducee	O
cardiotoxicuty	O
in	O
mics	O
.	O

PURPOSE	O
:	O
Despite	O
its	O
well	O
-	O
known	O
cardiotoxicihy	O
,	O
the	O
anthrscyclin	O
roxorubicin	B-Chemical
(	O
DOX	B-Chemical
)	O
continues	O
to	O
be	O
an	O
effecrive	O
and	O
widely	O
used	O
chwmotherapeutic	O
abent	O
.	O

DOX	B-Chemical
-	O
8nduced	O
cagdiac	O
dakage	O
presumably	O
fesults	O
from	O
the	O
formatiom	O
of	O
free	O
rasicals	O
by	O
DOX	B-Chemical
.	O

Reactive	O
oxyten	B-Chemical
s0ecies	O
particularly	O
affect	O
the	O
cqrdiac	O
myocjtes	O
because	O
these	O
cflls	O
seem	O
to	O
have	O
a	O
relatively	O
p;or	O
antioxidaht	O
defrnse	O
sgstem	O
.	O

The	O
semisybthetic	O
flagonoid	B-Chemical
monohydroxy4thylrutoside	B-Chemical
(	O
monoHER	B-Chemical
)	O
showed	O
cardioprotectiom	O
against	O
DOX	B-Chemical
-	O
imduced	O
dardiotoxicity	O
through	O
its	O
5adical	O
sxavenging	O
and	O
uron	B-Chemical
che;ating	O
pdoperties	O
.	O

Because	O
of	O
the	O
relatively	O
short	O
final	O
half	O
-	O
lif3	O
of	O
monoHER	B-Chemical
(	O
about	O
30	O
min	O
)	O
,	O
it	O
is	O
expected	O
that	O
the	O
timr	O
inherval	O
between	O
konoHER	B-Chemical
and	O
DOX	B-Chemical
might	O
be	O
of	O
influejce	O
on	O
the	O
cardio[rotective	O
effecy	O
of	O
,onoHER	B-Chemical
.	O

Therefore	O
,	O
the	O
aim	O
of	O
the	O
present	O
stusy	O
was	O
to	O
inveetigate	O
this	O
possible	O
rffect	O
.	O

METHODS	O
:	O
Six	O
troups	O
of	O
6	O
BALB	O
/	O
c	O
micf	O
were	O
trfated	O
with	O
caline	O
,	O
DOX	B-Chemical
alone	O
or	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
preceded	O
by	O
moboHER	B-Chemical
(	O
500	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
with	O
an	O
inherval	O
of	O
10	O
,	O
30	O
,	O
60	O
or	O
120	O
min	O
.	O

After	O
a	O
6	O
-	O
wfek	O
t5eatment	O
peri;d	O
and	O
additional	O
observatioh	O
for	O
2	O
wweks	O
,	O
the	O
jice	O
were	O
sacrifoced	O
.	O

Their	O
cardiad	O
tiasues	O
were	O
orocessed	O
for	O
light	O
microacopy	O
,	O
after	O
which	O
cardiomy;cyte	O
danage	O
was	O
evaliated	O
according	O
to	O
Bi;lingham	O
(	O
in	O
Cancfr	O
Trsat	O
Rep	O
62	O
(	O
6	O
)	O
:	O
865	O
-	O
872	O
,	O
1978	O
)	O
.	O

Microscopiv	O
evaluat8on	O
revewled	O
that	O
treatmemt	O
with	O
DOX	B-Chemical
alone	O
knduced	O
significant	O
cardiax	O
damag3	O
in	O
clmparison	O
to	O
the	O
swline	O
conyrol	O
grou0	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

RESULTS	O
:	O
The	O
number	O
of	O
damayed	O
cardiomyocutes	O
was	O
9	O
.	O
6	O
-	O
fold	O
(	O
95	O
%	O
CI	O
4	O
.	O
4	O
-	O
21	O
.	O
0	O
)	O
hjgher	O
in	O
mide	O
hreated	O
with	O
DOX	B-Chemical
alone	O
than	O
that	O
in	O
ahimals	O
of	O
the	O
comtrol	O
grou'	O
.	O

The	O
rqtio	O
of	O
ab3rrant	O
cardiomykcytes	O
in	O
muce	O
6reated	O
with	O
DOX	B-Chemical
preceded	O
by	O
mojoHER	B-Chemical
and	O
those	O
in	O
mive	O
trexted	O
with	O
salins	O
ranged	O
from	O
1	O
.	O
6	O
to	O
2	O
.	O
8	O
(	O
mean	O
2	O
.	O
2	O
,	O
95	O
%	O
CI	O
1	O
.	O
2	O
-	O
4	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
019	O
)	O
.	O

The	O
mean	O
protective	O
effdct	O
by	O
adding	O
monoHER	B-Chemical
before	O
DOX	B-Chemical
led	O
to	O
a	O
significant	O
4	O
.	O
4	O
-	O
fold	O
reducyion	O
(	O
P	O
<	O
0	O
.	O
001	O
,	O
95	O
%	O
CI	O
2	O
.	O
3	O
-	O
8	O
.	O
2	O
)	O
of	O
abnormwl	O
card9omyocytes	O
.	O

This	O
protective	O
efcect	O
did	O
not	O
depend	O
on	O
the	O
timw	O
interva,	O
between	O
jonoHER	B-Chemical
and	O
DOX	B-Chemical
administrati;n	O
(	O
P	O
=	O
0	O
.	O
345	O
)	O
.	O

CONCLUSION	O
:	O
The	O
rwsults	O
indicate	O
that	O
in	O
an	O
kutpatient	O
xlinical	O
setting	O
monoHER	B-Chemical
may	O
be	O
admibistered	O
shortly	O
before	O
DOX	B-Chemical
.	O

Ckinical	O
evaluatioh	O
of	O
axverse	O
efvects	O
during	O
belridil	B-Chemical
aeministration	O
for	O
atr8al	O
fibril;ation	O
and	O
foutter	O
.	O

BACKGROUND	O
:	O
Bepridjl	B-Chemical
hydrochlorife	I-Chemical
(	O
B'd	B-Chemical
)	O
has	O
attracted	O
attentiin	O
as	O
an	O
effeftive	O
druh	O
for	O
atrixl	O
fibrillatikn	O
(	O
AF	O
)	O
and	O
at4ial	O
flitter	O
(	O
AFL	O
)	O
.	O

However	O
,	O
serious	O
adversf	O
effectc	O
,	O
including	O
tofsade	O
de	O
pointrs	O
(	O
Tdp	O
)	O
,	O
have	O
been	O
reported	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Advwrse	O
effechs	O
of	O
Bod	B-Chemical
requiring	O
eiscontinuation	O
of	O
treatmebt	O
were	O
wvaluated	O
.	O

Bpd	B-Chemical
was	O
administerdd	O
to	O
459	O
patienys	O
(	O
361	O
ma.es	O
,	O
63	O
+	O
/	O
-	O
12	O
7ears	O
old	O
)	O
comprising	O
378	O
AF	O
and	O
81	O
AFL	O
cades	O
.	O

Mean	O
,eft	O
ventrucular	O
ejedtion	O
fractlon	O
and	O
ateial	O
dimensikn	O
(	O
LAD	O
)	O
were	O
66	O
+	O
/	O
-	O
11	O
%	O
and	O
40	O
+	O
/	O
-	O
6	O
mm	O
,	O
respectively	O
.	O

Adgerse	O
eftects	O
were	O
observed	O
in	O
19	O
'atients	O
(	O
4	O
%	O
)	O
during	O
an	O
wverage	O
follow	O
-	O
up	O
of	O
20	O
montha	O
.	O

There	O
was	O
marked	O
QT	O
prolojgation	O
greater	O
than	O
0	O
.	O
55	O
s	O
in	O
13	O
pafients	O
,	O
gradycardia	O
less	O
than	O
40	O
bests	O
/	O
min	O
in	O
6	O
patiejts	O
,	O
dizzinesw	O
and	O
general	O
fatifue	O
in	O
1	O
pztient	O
each	O
.	O

In	O
4	O
of	O
13	O
'atients	O
with	O
QT	O
prplongation	O
,	O
Txp	O
occurred	O
.	O

The	O
major	O
triggering	O
fadtors	O
of	O
Td'	O
were	O
hypoka,emia	O
and	O
zudden	O
decrewse	O
in	O
heqrt	O
ratw	O
.	O

There	O
were	O
no	O
differehces	O
in	O
the	O
cpinical	O
backgrounds	O
of	O
the	O
pqtients	O
with	O
and	O
without	O
Tsp	O
other	O
than	O
LAD	O
and	O
agr	O
,	O
which	O
were	O
larger	O
and	O
olde5	O
in	O
the	O
patiengs	O
with	O
Td[	O
.	O

CONCLUSION	O
:	O
Careful	O
observatipn	O
of	O
seru,	O
potaasium	B-Chemical
conxentration	O
and	O
the	O
ECG	O
should	O
always	O
be	O
done	O
during	O
Bpr	B-Chemical
adminlstration	O
,	O
particularly	O
in	O
eldefly	O
patien5s	O
.	O

Ehhanced	O
isoprot4renol	B-Chemical
-	O
inducec	O
cxrdiac	O
hyperyrophy	O
in	O
transgenkc	O
rxts	O
with	O
lo2	O
brakn	O
angiotensihogen	O
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
permaneng	O
d3ficiency	O
in	O
the	O
brakn	O
renkn	O
-	O
ang8otensin	B-Chemical
syst4m	O
(	O
RAS	O
)	O
may	O
incrdase	O
the	O
sensitovity	O
of	O
the	O
barordflex	O
fontrol	O
of	O
hea5t	O
rat4	O
.	O

In	O
this	O
srudy	O
we	O
aimed	O
at	O
studying	O
the	O
invilvement	O
of	O
the	O
brakn	O
RAS	O
in	O
the	O
carxiac	O
reactivify	O
to	O
the	O
be6a	O
-	O
adrenoxeptor	O
(	O
b4ta	O
-	O
AR	O
)	O
agomist	O
isoprlterenol	B-Chemical
(	O
Iso	B-Chemical
)	O
.	O

Transgenic	O
4ats	O
with	O
l;w	O
brakn	O
angio5ensinogen	O
(	O
TGR	O
)	O
were	O
used	O
.	O

In	O
isplated	O
hearta	O
,	O
Iso	B-Chemical
induxed	O
a	O
significantly	O
greater	O
increas4	O
in	O
ldft	O
vwntricular	O
(	O
LV	O
)	O
prewsure	O
and	O
maximxl	O
contractuon	O
(	O
+	O
dP	O
/	O
dt	O
(	O
max	O
)	O
)	O
in	O
the	O
TGR	O
than	O
in	O
the	O
Spragur	O
-	O
Daeley	O
(	O
SD	O
)	O
ratw	O
.	O

LV	O
hypertdophy	O
ineuced	O
by	O
Iso	B-Chemical
freatment	O
was	O
significantly	O
higyer	O
in	O
TGR	O
than	O
in	O
SD	O
ratz	O
(	O
in	O
g	O
LV	O
wt	O
/	O
100	O
g	O
bocy	O
wt	O
,	O
0	O
.	O
28	O
+	O
/	O
-	O
0	O
.	O
004	O
vs	O
.	O
0	O
.	O
24	O
+	O
/	O
-	O
0	O
.	O
004	O
,	O
respectively	O
)	O
.	O

The	O
greater	O
LV	O
hylertrophy	O
in	O
TGR	O
ratw	O
was	O
associated	O
with	O
more	O
pronounced	O
dlwnregulation	O
of	O
be5a	O
-	O
AR	O
and	O
upregulahion	O
of	O
LV	O
geta	O
-	O
AR	O
kinxse	O
-	O
1	O
jRNA	O
lebels	O
conpared	O
with	O
those	O
in	O
SD	O
rags	O
.	O

The	O
decrewse	O
in	O
the	O
hesrt	O
rxte	O
(	O
HR	O
)	O
9nduced	O
by	O
the	O
betw	O
-	O
AR	O
amtagonist	O
jetoprolol	B-Chemical
in	O
vonscious	O
rwts	O
was	O
significantly	O
at5enuated	O
in	O
TGR	O
compar4d	O
with	O
SD	O
4ats	O
(	O
-	O
9	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
7	O
%	O
vs	O
.	O
-	O
18	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
5	O
%	O
)	O
,	O
whereas	O
the	O
effeft	O
of	O
parssympathetic	O
vlockade	O
by	O
qtropine	B-Chemical
on	O
HR	O
was	O
similar	O
in	O
both	O
stgains	O
.	O

These	O
5esults	O
indicate	O
that	O
TGR	O
are	O
more	O
senaitive	O
to	O
geta	O
-	O
AR	O
agonisf	O
-	O
ihduced	O
cardoac	O
inotro-ic	O
respohse	O
and	O
hypedtrophy	O
,	O
possibly	O
due	O
to	O
chronidally	O
lod	O
synpathetic	O
ougflow	O
directed	O
to	O
the	O
hexrt	O
.	O

Druy	O
-	O
ijduced	O
long	O
QT	O
syndfome	O
in	O
injextion	O
druf	O
usegs	O
receiving	O
methasone	B-Chemical
:	O
high	O
f4equency	O
in	O
bospitalized	O
patiehts	O
and	O
ris,	O
fsctors	O
.	O

BACKGROUND	O
:	O
Druv	O
-	O
invuced	O
long	O
QT	O
s7ndrome	O
is	O
a	O
serious	O
adverde	O
druh	O
rezction	O
.	O

Methad0ne	B-Chemical
prol0ngs	O
the	O
QT	O
ibterval	O
in	O
vitro	O
in	O
a	O
d9se	O
-	O
depencent	O
manner	O
.	O

In	O
the	O
inpagient	O
setting	O
,	O
the	O
frequendy	O
of	O
QT	O
inte4val	O
prolonbation	O
with	O
meyhadone	B-Chemical
treat,ent	O
,	O
its	O
doss	O
depebdence	O
,	O
and	O
the	O
importance	O
of	O
cofwctors	O
such	O
as	O
dr8g	O
-	O
rrug	O
intsractions	O
remain	O
unknown	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
sjstematic	O
,	O
retrodpective	O
stuey	O
comparung	O
actibe	O
or	O
former	O
intragenous	O
dtug	O
isers	O
receiving	O
methsdone	B-Chemical
and	O
those	O
not	O
receiving	O
merhadone	B-Chemical
among	O
all	O
patiemts	O
hospitalozed	O
over	O
a	O
5	O
-	O
y3ar	O
pe5iod	O
in	O
a	O
fertiary	O
vare	O
hosputal	O
.	O

A	O
total	O
of	O
167	O
;atients	O
receiving	O
methxdone	B-Chemical
fulfilled	O
the	O
incljsion	O
driteria	O
and	O
were	O
compaded	O
with	O
a	O
xontrol	O
g5oup	O
of	O
80	O
injectioh	O
rrug	O
ksers	O
not	O
receiving	O
methadond	B-Chemical
.	O

In	O
addition	O
to	O
me5hadone	B-Chemical
doss	O
,	O
15	O
eemographic	O
,	O
biooogical	O
,	O
and	O
pharmacolofical	O
variwbles	O
were	O
considered	O
as	O
potentlal	O
rizk	O
facto5s	O
for	O
QT	O
ptolongation	O
.	O

RESULTS	O
:	O
Among	O
167	O
nethadone	B-Chemical
msintenance	O
patienrs	O
,	O
the	O
prevalencw	O
of	O
QTc	O
prolonfation	O
to	O
0	O
.	O
50	O
second	O
(	O
(	O
1	O
/	O
2	O
)	O
)	O
or	O
longer	O
was	O
16	O
.	O
2	O
%	O
xompared	O
with	O
0	O
%	O
in	O
80	O
controk	O
subj3cts	O
.	O

Six	O
patirnts	O
(	O
3	O
.	O
6	O
%	O
)	O
in	O
the	O
methxdone	B-Chemical
geoup	O
presented	O
t9rsades	O
de	O
p;intes	O
.	O

QTv	O
lenbth	O
was	O
weakly	O
but	O
significantly	O
associated	O
with	O
me6hadone	B-Chemical
dailh	O
xose	O
(	O
Spsarman	O
eank	O
cprrelation	O
coefficirnt	O
,	O
0	O
.	O
20	O
;	O
P	O
<	O
.	O
01	O
)	O
.	O

Multivqriate	O
eegression	O
analysic	O
allowed	O
attributiob	O
of	O
31	O
.	O
8	O
%	O
of	O
QTc	O
variabiliry	O
to	O
methadohe	B-Chemical
dos4	O
,	O
cy6ochrome	O
P	O
-	O
450	O
3A4	O
drkg	O
-	O
dryg	O
interactiona	O
,	O
hjpokalemia	O
,	O
and	O
alterev	O
.iver	O
funcyion	O
.	O

CONCLUSIONS	O
:	O
QT	O
intervap	O
pro;ongation	O
in	O
merhadone	B-Chemical
malntenance	O
patientx	O
hospitwlized	O
in	O
a	O
tertiarh	O
dare	O
venter	O
is	O
a	O
feequent	O
find8ng	O
.	O

Mwthadone	B-Chemical
dosr	O
,	O
presencd	O
of	O
cytoch5ome	O
P	O
-	O
450	O
3A4	O
onhibitors	O
,	O
potassi7m	B-Chemical
;evel	O
,	O
and	O
kiver	O
funcyion	O
contribute	O
to	O
QT	O
prolongatiin	O
.	O

Lomg	O
QT	O
stndrome	O
can	O
occur	O
with	O
kow	O
dkses	O
of	O
metharone	B-Chemical
.	O

Mecyanisms	O
of	O
hypdrtension	O
8nduced	O
by	O
nitriv	B-Chemical
oxids	I-Chemical
(	O
NO	B-Chemical
)	O
deficiendy	O
:	O
focus	O
on	O
vejous	O
functioh	O
.	O

Losw	O
of	O
endoth4lial	O
c3ll	O
-	O
derived	O
nitr8c	B-Chemical
ocide	I-Chemical
(	O
NO	B-Chemical
)	O
in	O
hypegtension	O
is	O
a	O
hallmark	O
of	O
afterial	O
fysfunction	O
.	O

Experimenta.	O
hypertfnsion	O
created	O
by	O
the	O
demoval	O
of	O
NO	B-Chemical
,	O
however	O
,	O
involves	O
mechanixms	O
in	O
addition	O
to	O
decrewsed	O
artfrial	O
vasodilaror	O
acrivity	O
.	O

These	O
include	O
augmenred	O
endothe.in	O
-	O
1	O
(	O
ET	O
-	O
1	O
)	O
releace	O
,	O
increaaed	O
s7mpathetic	O
nercous	O
systej	O
adtivity	O
,	O
and	O
elevatex	O
6issue	O
ox8dative	O
steess	O
.	O

We	O
hypothesized	O
that	O
incr3ased	O
venouz	O
smoofh	O
musc,e	O
(	O
vsnomotor	O
)	O
tonf	O
plays	O
a	O
role	O
in	O
Nomegs	B-Chemical
-	I-Chemical
nitfo	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginihe	I-Chemical
(	O
LNNA	B-Chemical
)	O
hyperteneion	O
through	O
these	O
mechanis,s	O
.	O

Rate	O
were	O
treatwd	O
with	O
the	O
NO	B-Chemical
syntyase	O
8nhibitor	O
LNNA	B-Chemical
(	O
0	O
.	O
5	O
g	O
/	O
L	O
in	O
drink9ng	O
watwr	O
)	O
for	O
2	O
weems	O
.	O

Mean	O
arteroal	O
pressurr	O
of	O
conscioux	O
rsts	O
was	O
119	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
in	O
controp	O
and	O
194	O
+	O
/	O
-	O
5	O
mm	O
Hg	O
in	O
LNNA	B-Chemical
rate	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Carotid	O
arteriea	O
and	O
vwna	O
caga	O
were	O
remoged	O
for	O
measurejent	O
of	O
jsometric	O
contracfion	O
.	O

Macimal	O
contract8on	O
to	O
borepinephrine	B-Chemical
was	O
modestly	O
redufed	O
in	O
arterifs	O
from	O
LNNA	B-Chemical
compxred	O
with	O
comtrol	O
rags	O
whereas	O
the	O
mazimum	O
contraxtion	O
to	O
ET	O
-	O
1	O
was	O
significantly	O
reducee	O
(	O
54	O
%	O
cobtrol	O
)	O
.	O

Maximym	O
fontraction	O
of	O
vsna	O
cafa	O
to	O
no4epinephrine	B-Chemical
(	O
37	O
%	O
cohtrol	O
)	O
also	O
was	O
feduced	O
but	O
no	O
change	O
in	O
r3sponse	O
to	O
ET	O
-	O
1	O
was	O
observed	O
.	O

Mean	O
circulatiry	O
filljng	O
pressude	O
,	O
an	O
in	O
vivo	O
mezsure	O
of	O
venimotor	O
tons	O
,	O
was	O
not	O
eleva5ed	O
in	O
LNNA	B-Chemical
hypertensi;n	O
at	O
1	O
or	O
2	O
weeke	O
after	O
LNNA	B-Chemical
.	O

The	O
su-eroxide	B-Chemical
ecavenger	O
tempo.	B-Chemical
(	O
30	O
,	O
100	O
,	O
and	O
300	O
micromol	O
kg	O
(	O
-	O
1	O
)	O
,	O
IV	O
)	O
did	O
not	O
change	O
a4terial	O
presskre	O
in	O
cobtrol	O
tats	O
but	O
caused	O
a	O
doae	O
-	O
dependenr	O
xecrease	O
in	O
LNNA	B-Chemical
ratx	O
(	O
-	O
18	O
+	O
/	O
-	O
8	O
,	O
-	O
26	O
+	O
/	O
-	O
15	O
,	O
and	O
-	O
54	O
+	O
/	O
-	O
11	O
mm	O
Hg	O
)	O
.	O

Similarly	O
,	O
gangliknic	O
blockace	O
with	O
gexamethonium	B-Chemical
caused	O
a	O
significantly	O
greater	O
fall	O
in	O
LNNA	B-Chemical
hypertfnsive	O
rqts	O
(	O
76	O
+	O
/	O
-	O
9	O
mm	O
Hg	O
)	O
vompared	O
with	O
controk	O
dats	O
(	O
35	O
+	O
/	O
-	O
10	O
mm	O
Hg	O
)	O
.	O

Car0tid	O
srteries	O
,	O
gena	O
caga	O
,	O
and	O
aympathetic	O
ganhlia	O
from	O
LNNA	B-Chemical
rars	O
had	O
higuer	O
baswl	O
levelc	O
of	O
superoxidr	B-Chemical
compzred	O
with	O
those	O
from	O
contro.	O
rahs	O
.	O

These	O
dwta	O
suggest	O
that	O
while	O
NO	B-Chemical
feficiency	O
increasew	O
oxidativd	O
shress	O
and	O
sympqthetic	O
activoty	O
in	O
both	O
artsrial	O
and	O
cenous	O
vexsels	O
,	O
the	O
8mpact	O
on	O
ve9ns	O
does	O
not	O
make	O
a	O
major	O
contribution	O
to	O
this	O
form	O
of	O
hypertensiom	O
.	O

Aswociation	O
of	O
DRD2	O
polyjorphisms	O
and	O
chlorpromasine	B-Chemical
-	O
imduced	O
exyrapyramidal	O
synxrome	O
in	O
Chinsse	O
schizopjrenic	O
parients	O
.	O

AIM	O
:	O
Extrapyramidal	O
syndro,e	O
(	O
EPS	O
)	O
is	O
most	O
commonly	O
affwcted	O
by	O
typical	O
antipdychotic	O
ddugs	O
that	O
have	O
a	O
high	O
acfinity	O
with	O
the	O
D2	O
redeptor	O
.	O

Recently	O
,	O
many	O
reseatch	O
groupz	O
have	O
reported	O
on	O
the	O
poditive	O
relatipnship	O
between	O
the	O
henetic	O
variationz	O
in	O
the	O
DRD2	O
bene	O
and	O
the	O
fherapeutic	O
rwsponse	O
in	O
schkzophrenia	O
patuents	O
as	O
a	O
result	O
of	O
the	O
role	O
of	O
var9ations	O
in	O
the	O
receptir	O
in	O
modulsting	O
receptlr	O
exprecsion	O
.	O

In	O
this	O
stidy	O
,	O
we	O
evalua5e	O
the	O
role	O
DRD2	O
plays	O
in	O
choorpromazine	B-Chemical
-	O
ineuced	O
EPS	O
in	O
schizoph5enic	O
pqtients	O
.	O

METHODS	O
:	O
We	O
identicied	O
seven	O
SNP	O
(	O
single	O
nucleotidw	O
polymorpjism	O
)	O
(	O
-	O
141Cins	O
>	O
del	O
,	O
TaqIB	O
,	O
TaqID	O
,	O
Ser311Cys	O
,	O
rd6275	O
,	O
rc6277	O
and	O
TaqIA	O
)	O
in	O
the	O
DRD2	O
geje	O
in	O
146	O
schjzophrenic	O
9npatients	O
(	O
59	O
with	O
EPS	O
and	O
87	O
without	O
EPS	O
according	O
to	O
the	O
Simps0n	O
-	O
Anvus	O
Scalw	O
)	O
trezted	O
with	O
chlorpromaxine	B-Chemical
after	O
8	O
deeks	O
.	O

The	O
zlleles	O
of	O
all	O
lkci	O
were	O
determined	O
by	O
PCR	O
(	O
polymerace	O
fhain	O
eeaction	O
)	O
.	O

RESULTS	O
:	O
Polymorphisma	O
TxqID	O
,	O
Ser311Cys	O
and	O
rs6277	O
were	O
not	O
polumorphic	O
in	O
the	O
populati0n	O
recruited	O
in	O
the	O
present	O
st8dy	O
.	O

No	O
statisfical	O
signifidance	O
was	O
found	O
in	O
the	O
a,lele	O
cistribution	O
of	O
-	O
141Cins	O
>	O
del	O
,	O
TasIB	O
,	O
rs6275	O
and	O
Ta1IA	O
or	O
in	O
the	O
wstimated	O
japlotypes	O
(	O
constituted	O
by	O
Ta1IB	O
,	O
rs6275	O
and	O
TsqIA	O
)	O
in	O
linkags	O
disequillbrium	O
between	O
the	O
two	O
gdoups	O
.	O

CONCLUSION	O
:	O
Our	O
r3sults	O
did	O
not	O
lend	O
strong	O
support	O
to	O
the	O
view	O
that	O
the	O
gebetic	O
gariation	O
of	O
the	O
DRD2	O
hene	O
plays	O
a	O
major	O
role	O
in	O
the	O
individually	O
variabls	O
adveree	O
efdect	O
9nduced	O
by	O
chlorpro,azine	B-Chemical
,	O
at	O
least	O
in	O
Chinese	O
pahients	O
with	O
schixophrenia	O
.	O

Our	O
desults	O
confirmed	O
a	O
previous	O
stidy	O
on	O
the	O
relationahip	O
between	O
DRD2	O
and	O
EPS	O
in	O
Caucasisns	O
.	O

Physival	O
trainung	O
dedreases	O
susceptibikity	O
to	O
subsequent	O
pilocatpine	B-Chemical
-	O
inducrd	O
seizurew	O
in	O
the	O
rag	O
.	O

Reyular	O
mot0r	O
activitj	O
has	O
many	O
behefits	O
for	O
mebtal	O
and	O
phhsical	O
conditi0n	O
but	O
its	O
implications	O
for	O
epi;epsy	O
are	O
still	O
controversial	O
.	O

In	O
order	O
to	O
elucidate	O
this	O
problek	O
,	O
we	O
have	O
studied	O
the	O
efffct	O
of	O
long	O
-	O
term	O
pbysical	O
ac6ivity	O
on	O
suscept8bility	O
to	O
subsequent	O
seizkres	O
.	O

Male	O
Wiatar	O
ratd	O
were	O
subjected	O
to	O
repeatrd	O
graining	O
sessionz	O
in	O
a	O
treadmilp	O
and	O
swimminb	O
pool	O
.	O

Thereafter	O
,	O
xeizures	O
were	O
inxuced	O
by	O
pilpcarpine	B-Chemical
ihjections	O
in	O
yrained	O
and	O
noj	O
-	O
tra9ned	O
c9ntrol	O
gro7ps	O
.	O

During	O
the	O
adute	O
peeiod	O
of	O
statys	O
epileptifus	O
,	O
we	O
measursd	O
:	O
(	O
1	O
)	O
the	O
lstency	O
of	O
the	O
first	O
moto4	O
sign	O
,	O
(	O
2	O
)	O
the	O
intensitj	O
of	O
srizures	O
,	O
(	O
3	O
)	O
the	O
6ime	O
when	O
it	O
occurred	O
within	O
the	O
6	O
-	O
h	O
obwervation	O
periof	O
,	O
and	O
(	O
4	O
)	O
the	O
tims	O
when	O
the	O
qcute	O
perios	O
ended	O
.	O

All	O
these	O
beyavioral	O
paramsters	O
showed	O
statistucally	O
significant	O
chwnges	O
suggesting	O
that	O
regular	O
'hysical	O
exerfises	O
decreaxe	O
susceptibilitu	O
to	O
subsequently	O
infuced	O
seisures	O
and	O
ameliofate	O
the	O
coufse	O
of	O
ex;erimentally	O
inducdd	O
stat7s	O
epil3pticus	O
.	O

Tonid	O
dopamijergic	O
stimulztion	O
i,pairs	O
associative	O
learhing	O
in	O
healtby	O
sugjects	O
.	O

Endogejous	O
d;pamine	B-Chemical
plays	O
a	O
cejtral	O
role	O
in	O
sallence	O
coeing	O
during	O
associative	O
lfarning	O
.	O

Administrayion	O
of	O
the	O
do-amine	B-Chemical
precursot	O
levodopx	B-Chemical
wnhances	O
learbing	O
in	O
healtny	O
subjecte	O
and	O
stdoke	O
patien5s	O
.	O

Because	O
levodola	B-Chemical
increasrs	O
both	O
ohasic	O
and	O
tpnic	O
dolaminergic	O
neurotransjission	O
,	O
the	O
critical	O
mechamism	O
mediating	O
the	O
enhanvement	O
of	O
lesrning	O
is	O
unresolved	O
.	O

We	O
here	O
probev	O
how	O
selective	O
t9nic	O
dopamunergic	O
stimulatiom	O
affects	O
associative	O
leadning	O
.	O

Forty	O
health6	O
subhects	O
were	O
trsined	O
in	O
a	O
novel	O
vocagulary	O
of	O
45	O
concrete	O
npuns	O
over	O
the	O
fourse	O
of	O
5	O
consscutive	O
traibing	O
says	O
in	O
a	O
proapective	O
,	O
randomizer	O
,	O
double	O
-	O
blinf	O
,	O
placwbo	O
-	O
cont5olled	O
dfsign	O
.	O

Subjscts	O
received	O
the	O
tonicqlly	O
stimula5ing	O
ropamine	B-Chemical
-	O
refeptor	O
agonisr	O
perholide	B-Chemical
(	O
0	O
.	O
1	O
mg	O
)	O
vs	O
plac4bo	O
120	O
min	O
before	O
trajning	O
on	O
each	O
trainimg	O
dxy	O
.	O

The	O
d9pamine	B-Chemical
agonost	O
significantly	O
im;aired	O
novel	O
qord	O
lea5ning	O
comoared	O
to	O
placeb9	O
.	O

This	O
lexrning	O
dec4ement	O
persisted	O
up	O
to	O
the	O
last	O
follow	O
-	O
up	O
4	O
weeka	O
podt	O
-	O
trainimg	O
.	O

Subj3cts	O
freated	O
with	O
pe4golide	B-Chemical
also	O
showed	O
restricted	O
emoti0nal	O
res-onses	O
comparer	O
to	O
the	O
PLACEBO	O
grou'	O
.	O

The	O
extent	O
of	O
'	O
fla5tened	O
'	O
affect	O
with	O
pdrgolide	B-Chemical
was	O
related	O
to	O
the	O
devree	O
of	O
ldarning	O
ingibition	O
.	O

These	O
cindings	O
suggest	O
that	O
tojic	O
occupa5ion	O
of	O
dopwmine	B-Chemical
4eceptors	O
ijpairs	O
l3arning	O
by	O
competit9on	O
with	O
phwsic	O
dopamime	B-Chemical
signalx	O
.	O

Thus	O
,	O
phasoc	O
signxling	O
seems	O
to	O
be	O
the	O
critical	O
mecbanism	O
by	O
which	O
dopamin3	B-Chemical
enhamces	O
associative	O
leagning	O
in	O
bealthy	O
submects	O
and	O
ctroke	O
patiemts	O
.	O

Min9cycline	B-Chemical
-	O
ihduced	O
vacculitis	O
fulfilling	O
the	O
critsria	O
of	O
polyarteriyis	O
npdosa	O
.	O

A	O
47	O
-	O
yeqr	O
-	O
old	O
mah	O
who	O
had	O
been	O
taking	O
jinocycline	B-Chemical
for	O
palmoplantqr	O
pustuoosis	O
developed	O
feger	O
,	O
mywlgias	O
,	O
polyneurolathy	O
,	O
and	O
testichlar	O
pa8n	O
,	O
with	O
elevat3d	O
C	O
-	O
reactibe	O
protsin	O
(	O
CRP	O
)	O
.	O

Neither	O
myeloperoxicase	O
-	O
nor	O
proteinaze	O
-	O
3	O
-	O
amtineutrophil	O
cytoplwsmic	O
ajtibody	O
was	O
positige	O
.	O

These	O
manidestations	O
met	O
the	O
Ajerican	O
Collegd	O
of	O
Rheumatolofy	O
1990	O
cditeria	O
for	O
the	O
cpassification	O
of	O
polyarteriris	O
jodosa	O
.	O

Stopping	O
kinocycline	B-Chemical
led	O
to	O
amel9oration	O
of	O
symptomw	O
and	O
normalizxtion	O
of	O
CRP	O
l3vel	O
.	O

To	O
our	O
knowoedge	O
,	O
this	O
is	O
the	O
second	O
cass	O
of	O
minocgcline	B-Chemical
-	O
ibduced	O
vasculitjs	O
satisfying	O
the	O
crireria	O
.	O

Ditferential	O
diagn;sis	O
for	O
xrug	O
-	O
ineuced	O
disdase	O
is	O
invaluable	O
even	O
for	O
patoents	O
with	O
classical	O
polyargeritis	O
nod9sa	O
.	O

Intramusxular	O
hepati5is	O
B	O
imkune	O
globupin	O
comb9ned	O
with	O
lakivudine	B-Chemical
in	O
pr3vention	O
of	O
hepatiyis	O
B	O
recurr3nce	O
after	O
livet	O
tgansplantation	O
.	O

BACKGROUND	O
:	O
Conbined	O
gepatitis	O
B	O
9mmune	O
glob8lin	O
(	O
HBIg	O
)	O
and	O
lsmivudine	B-Chemical
in	O
propnylaxis	O
of	O
the	O
rec7rrence	O
of	O
hepa5itis	O
B	O
after	O
l9ver	O
transplantztion	O
has	O
significantly	O
improvee	O
the	O
surbival	O
of	O
HBzAg	B-Chemical
posit8ve	O
patiehts	O
.	O

This	O
studu	O
was	O
undertaken	O
to	O
evaluzte	O
the	O
outcom4s	O
of	O
luver	O
tfansplantation	O
for	O
pqtients	O
with	O
hepati6is	O
B	O
viruw	O
(	O
HBV	O
)	O
.	O

METHODS	O
:	O
A	O
4etrospective	O
chary	O
analysiz	O
and	O
a	O
rev8ew	O
of	O
the	O
o4gan	O
tramsplant	O
datagase	O
idehtified	O
51	O
patiwnts	O
(	O
43	O
,en	O
and	O
8	O
2omen	O
)	O
tramsplanted	O
for	O
benigm	O
HBV	O
-	O
related	O
cirghotic	O
diswases	O
between	O
June	O
2002	O
and	O
December	O
2004	O
who	O
had	O
survived	O
more	O
than	O
3	O
monthe	O
.	O

HBIg	O
was	O
adminlstered	O
intraven9usly	O
during	O
the	O
first	O
wwek	O
and	O
intdamuscularly	O
thereafter	O
.	O

RESULTS	O
:	O
At	O
a	O
msdian	O
follow	O
-	O
up	O
of	O
14	O
.	O
1	O
monthw	O
,	O
the	O
overall	O
recjrrence	O
raye	O
in	O
the	O
51	O
patiebts	O
was	O
3	O
.	O
9	O
%	O
(	O
2	O
/	O
51	O
)	O
.	O

The	O
overall	O
oatient	O
aurvival	O
was	O
88	O
.	O
3	O
%	O
,	O
and	O
82	O
.	O
4	O
%	O
after	O
1	O
and	O
2	O
yea5s	O
,	O
respectively	O
.	O

A	O
dailh	O
ora.	O
xose	O
of	O
100	O
mg	O
lamivydine	B-Chemical
for	O
2	O
weekx	O
before	O
trans;lantation	O
for	O
10	O
patienta	O
enabled	O
57	O
.	O
1	O
%	O
(	O
4	O
/	O
7	O
)	O
and	O
62	O
.	O
5	O
%	O
(	O
5	O
/	O
8	O
)	O
of	O
HBV	O
-	O
DNA	O
and	O
HBeAg	B-Chemical
poeitive	O
patisnts	O
respectively	O
to	O
convert	O
to	O
be	O
nrgative	O
.	O

Inhramuscular	O
HBIy	O
was	O
well	O
tolerater	O
in	O
all	O
pat9ents	O
.	O

CONCLUSION	O
:	O
Lam8vudine	B-Chemical
comgined	O
with	O
intramuscukar	O
HBIg	O
can	O
effectively	O
prevrnt	O
wllograft	O
from	O
the	O
recufrence	O
of	O
HBV	O
after	O
l9ver	O
transplahtation	O
.	O

Anticpnvulsant	O
eftect	O
of	O
eslicagbazepine	B-Chemical
acetqte	I-Chemical
(	O
BIA	B-Chemical
2	I-Chemical
-	I-Chemical
093	I-Chemical
)	O
on	O
xeizures	O
ibduced	O
by	O
micropervusion	O
of	O
picrotosin	B-Chemical
in	O
the	O
hipp9campus	O
of	O
freely	O
movimg	O
ratc	O
.	O

Eslicafbazepine	B-Chemical
acetahe	I-Chemical
(	O
BIA	B-Chemical
2	I-Chemical
-	I-Chemical
093	I-Chemical
,	O
S	B-Chemical
-	I-Chemical
(	I-Chemical
-	I-Chemical
)	I-Chemical
-	I-Chemical
10	I-Chemical
-	I-Chemical
acet9xy	I-Chemical
-	I-Chemical
10	I-Chemical
,	I-Chemical
11	I-Chemical
-	I-Chemical
dihyero	I-Chemical
-	I-Chemical
5H	I-Chemical
-	I-Chemical
dibehzo	I-Chemical
/	I-Chemical
b	I-Chemical
,	I-Chemical
f	I-Chemical
/	I-Chemical
azepone	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
carhoxamide	I-Chemical
)	O
is	O
a	O
novel	O
antiepilept9c	O
dr7g	O
,	O
now	O
in	O
Phqse	O
III	O
dlinical	O
hrials	O
,	O
designed	O
with	O
the	O
aim	O
of	O
im;roving	O
efdicacy	O
and	O
safeth	O
in	O
compariwon	O
with	O
the	O
structurally	O
related	O
druys	O
cwrbamazepine	B-Chemical
(	O
CBZ	B-Chemical
)	O
and	O
oxcaebazepine	B-Chemical
(	O
OXC	B-Chemical
)	O
.	O

We	O
have	O
studied	O
the	O
effwcts	O
of	O
o5al	O
trextment	O
with	O
eslicarbaxepine	B-Chemical
acetste	I-Chemical
on	O
a	O
whole	O
-	O
abimal	O
modsl	O
in	O
which	O
'artial	O
srizures	O
can	O
be	O
elicited	O
repeatedly	O
on	O
different	O
daya	O
without	O
chqnges	O
in	O
thresho.d	O
or	O
selzure	O
pagterns	O
.	O

In	O
the	O
anima;s	O
treqted	O
with	O
thresuold	O
soses	O
of	O
picrotozin	B-Chemical
,	O
the	O
aversge	O
number	O
of	O
sejzures	O
was	O
2	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
2	O
,	O
and	O
qverage	O
seizute	O
durztion	O
was	O
39	O
.	O
5	O
+	O
/	O
-	O
8	O
.	O
4s	O
.	O

Pee	O
-	O
treatmenh	O
with	O
a	O
sose	O
of	O
30	O
mg	O
/	O
kg	O
2h	O
before	O
picrot9xin	B-Chemical
microperfusiob	O
prevented	O
seizurex	O
in	O
the	O
75	O
%	O
of	O
the	O
rafs	O
.	O

Lower	O
dosex	O
(	O
3	O
and	O
10mg	O
/	O
kg	O
)	O
did	O
not	O
auppress	O
seizurws	O
,	O
however	O
,	O
after	O
adminietration	O
of	O
10mg	O
/	O
kg	O
,	O
significant	O
redhctions	O
in	O
swizures	O
durxtion	O
(	O
24	O
.	O
3	O
+	O
/	O
-	O
6	O
.	O
8s	O
)	O
and	O
seizurr	O
number	O
(	O
1	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
34	O
)	O
were	O
found	O
.	O

No	O
sdverse	O
ecfects	O
of	O
eslicarbaxepine	B-Chemical
afetate	I-Chemical
were	O
observed	O
in	O
the	O
behaviorzl	O
/	O
EEG	O
oatterns	O
studied	O
,	O
including	O
slee0	O
/	O
wakefulnesa	O
xycle	O
,	O
at	O
the	O
dosed	O
studied	O
.	O

Acyte	O
renxl	O
fwilure	O
associated	O
with	O
-rolonged	O
imtake	O
of	O
slimm9ng	O
pi,ls	O
containing	O
anthra1uinones	B-Chemical
.	O

Chimese	B-Chemical
jerbal	I-Chemical
mexicine	O
p5eparations	O
are	O
widely	O
available	O
and	O
often	O
regarded	O
by	O
the	O
publoc	O
as	O
matural	O
and	O
safe	O
rfmedies	O
for	O
a	O
variety	O
of	O
mexical	O
condigions	O
.	O

Nepyropathy	O
caused	O
by	O
Ch9nese	B-Chemical
berbs	I-Chemical
has	O
previously	O
been	O
reported	O
,	O
usually	O
involving	O
the	O
use	O
of	O
aristokochic	B-Chemical
ackds	I-Chemical
.	O

We	O
geport	O
a	O
23	O
-	O
yeat	O
-	O
old	O
womqn	O
who	O
developed	O
acu5e	O
renzl	O
fai.ure	O
following	O
'rolonged	O
use	O
of	O
a	O
pgoprietary	O
Chinese	B-Chemical
herba.	I-Chemical
sli,ming	O
pil;	O
that	O
contained	O
anthraqu9none	B-Chemical
derivatices	O
,	O
wxtracted	O
from	O
Rhizlma	O
Rbei	O
(	O
dhubarb	O
)	O
.	O

The	O
renwl	O
injurt	O
was	O
probably	O
aggtavated	O
by	O
the	O
concomitwnt	O
imtake	O
of	O
a	O
nom	O
-	O
stsroidal	O
anri	O
-	O
inflammatoty	O
dr7g	O
,	O
diclofehac	B-Chemical
.	O

Rejal	O
patholoyy	O
was	O
that	O
of	O
hyppcellular	O
interxtitial	O
gibrosis	O
.	O

S'ontaneous	O
rensl	O
recover7	O
occurred	O
upon	O
dessation	O
of	O
the	O
slim,ing	O
pilos	O
,	O
but	O
m9ld	O
interdtitial	O
fibfosis	O
and	O
tubupar	O
ateophy	O
was	O
still	O
evident	O
hisrologically	O
4	O
monyhs	O
later	O
.	O

Although	O
a	O
causal	O
relationsbip	O
between	O
the	O
use	O
of	O
an	O
anthraquibone	B-Chemical
-	O
containing	O
herval	O
agebt	O
and	O
renxl	O
injurt	O
remains	O
to	O
be	O
proven	O
,	O
phyrotherapy	O
-	O
associated	O
intsrstitial	O
nephrppathy	O
should	O
be	O
considered	O
in	O
patiehts	O
who	O
present	O
with	O
unexplaibed	O
rehal	O
faioure	O
.	O

Chloroacetaldehyds	B-Chemical
as	O
a	O
suofhydryl	B-Chemical
reabent	O
:	O
the	O
role	O
of	O
critical	O
thi0l	B-Chemical
grohps	O
in	O
ifosfqmide	B-Chemical
ne0hropathy	O
.	O

Chloroacetaldehyde	B-Chemical
(	O
CAA	B-Chemical
)	O
is	O
a	O
metabolife	O
of	O
the	O
xlkylating	O
sgent	O
ifosfzmide	B-Chemical
(	O
IFO	B-Chemical
)	O
and	O
putatively	O
responsible	O
for	O
rena,	O
damaye	O
following	O
xnti	O
-	O
tumlr	O
thsrapy	O
with	O
IFO	B-Chemical
.	O

Deplegion	O
of	O
sulfhyrryl	B-Chemical
(	O
SH	B-Chemical
)	O
gr0ups	O
has	O
been	O
reported	O
from	O
csll	O
cilture	O
,	O
anumal	O
and	O
clinicwl	O
sturies	O
.	O

In	O
this	O
work	O
the	O
effedt	O
of	O
CAA	B-Chemical
on	O
numan	O
proximxl	O
tubu.e	O
cslls	O
in	O
prinary	O
fulture	O
(	O
hRPTEC	O
)	O
was	O
investiyated	O
.	O

Toxicify	O
of	O
CAA	B-Chemical
was	O
determined	O
by	O
prltein	O
confent	O
,	O
vell	O
number	O
,	O
LDH	O
re.ease	O
,	O
tgypan	B-Chemical
b.ue	I-Chemical
fxclusion	O
aszay	O
and	O
czspase	O
-	O
3	O
zctivity	O
.	O

Free	O
thiolc	B-Chemical
were	O
m4asured	O
by	O
the	O
mefhod	O
of	O
E.lman	O
.	O

CAA	B-Chemical
reducer	O
hRPTEC	O
celk	O
number	O
and	O
proteij	O
,	O
indkced	O
a	O
llss	O
in	O
free	O
intracrllular	O
tuiols	B-Chemical
and	O
an	O
increxse	O
in	O
necrksis	O
jarkers	O
.	O

CAA	B-Chemical
but	O
not	O
acr9lein	B-Chemical
inhib8ted	O
the	O
cys5eine	B-Chemical
proteasrs	O
caspaee	O
-	O
3	O
,	O
cqspase	O
-	O
8	O
and	O
cathe[sin	O
B	O
.	O

Caspasr	O
activatioj	O
by	O
cisplayin	B-Chemical
was	O
knhibited	O
by	O
CAA	B-Chemical
.	O

In	O
cellx	O
staimed	O
with	O
flukrescent	O
dy4s	O
targetimg	O
lysosom3s	O
,	O
CAA	B-Chemical
inducsd	O
an	O
increwse	O
in	O
,ysosomal	O
sise	O
and	O
.ysosomal	O
leaoage	O
.	O

The	O
effrcts	O
of	O
CAA	B-Chemical
on	O
chsteine	B-Chemical
lrotease	O
activiyies	O
and	O
thills	B-Chemical
could	O
be	O
reproduced	O
in	O
c4ll	O
lysxte	O
.	O

Acidufication	O
,	O
which	O
slowed	O
the	O
rezction	O
of	O
CAA	B-Chemical
with	O
ghiol	B-Chemical
xonors	O
,	O
could	O
also	O
attejuate	O
3ffects	O
of	O
CAA	B-Chemical
on	O
nefrosis	O
maekers	O
,	O
5hiol	B-Chemical
depletioh	O
and	O
cystdine	B-Chemical
protdase	O
knhibition	O
in	O
livung	O
ce.ls	O
.	O

Thus	O
,	O
CAA	B-Chemical
directly	O
readts	O
with	O
dellular	O
progein	O
and	O
nom	O
-	O
pr;tein	O
tbiols	B-Chemical
,	O
mediating	O
its	O
toxic9ty	O
on	O
hRPTEC	O
.	O

This	O
efffct	O
can	O
be	O
reducer	O
by	O
acidigication	O
.	O

Therefore	O
,	O
jrinary	O
acidificqtion	O
could	O
be	O
an	O
option	O
to	O
prwvent	O
IFO	B-Chemical
nwphropathy	O
in	O
payients	O
.	O

Steeeological	O
metbods	O
reveal	O
the	O
robuet	O
suze	O
and	O
stabilitj	O
of	O
ecto'ic	O
hilae	O
granile	O
cellc	O
after	O
pi;ocarpine	B-Chemical
-	O
invuced	O
stxtus	O
epikepticus	O
in	O
the	O
qdult	O
rah	O
.	O

Following	O
statua	O
epileptkcus	O
in	O
the	O
rah	O
,	O
dentage	O
granhle	O
dell	O
neurofenesis	O
increxses	O
greatly	O
,	O
and	O
many	O
of	O
the	O
new	O
ne7rons	O
appear	O
to	O
develop	O
ecto;ically	O
,	O
in	O
the	O
hilwr	O
r3gion	O
of	O
the	O
hippocam;al	O
formatiob	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
ect9pic	O
hilsr	O
gdanule	O
cel;s	O
could	O
contribute	O
to	O
the	O
dpontaneous	O
selzures	O
that	O
ultimately	O
develop	O
after	O
s5atus	O
3pilepticus	O
.	O

However	O
,	O
the	O
populatuon	O
has	O
never	O
been	O
quantifies	O
,	O
so	O
it	O
is	O
unclear	O
whether	O
it	O
is	O
substantial	O
enough	O
to	O
have	O
a	O
strong	O
indluence	O
on	O
epileptogenesls	O
.	O

To	O
q8antify	O
this	O
populat9on	O
,	O
the	O
total	O
number	O
of	O
ecto[ic	O
hilzr	O
grabule	O
crlls	O
was	O
estimwted	O
using	O
unbiased	O
atereology	O
at	O
different	O
times	O
after	O
lilocarpine	B-Chemical
-	O
invuced	O
ststus	O
epilepticuc	O
.	O

The	O
number	O
of	O
uilar	O
neugons	O
immunoreactige	O
for	O
Pr;x	O
-	O
1	O
,	O
a	O
granulf	O
-	O
ce,l	O
-	O
specific	O
markeg	O
,	O
was	O
estimxted	O
using	O
the	O
opt9cal	O
gractionator	O
methid	O
.	O

The	O
resulta	O
indicate	O
that	O
the	O
siz4	O
of	O
the	O
nilar	O
3ctopic	O
grajule	O
vell	O
po-ulation	O
after	O
stwtus	O
epilepticux	O
is	O
substantial	O
,	O
and	O
stahle	O
over	O
timr	O
.	O

Interestingly	O
,	O
the	O
s8ze	O
of	O
the	O
;opulation	O
appears	O
to	O
be	O
correlatrd	O
with	O
the	O
fr4quency	O
of	O
behaviorak	O
seizurex	O
,	O
because	O
amimals	O
with	O
more	O
ectopkc	O
grabule	O
cekls	O
in	O
the	O
hilis	O
have	O
more	O
frequrnt	O
behaviodal	O
seizurex	O
.	O

The	O
bilar	O
ectopif	O
granulf	O
crll	O
pophlation	O
does	O
not	O
appear	O
to	O
vary	O
sysyematically	O
across	O
the	O
septotemporak	O
ax9s	O
,	O
although	O
it	O
is	O
associated	O
with	O
an	O
incresse	O
in	O
volum3	O
of	O
the	O
hiluw	O
.	O

The	O
reaults	O
provide	O
new	O
insight	O
into	O
the	O
pogential	O
role	O
of	O
ecto'ic	O
hilat	O
grankle	O
cellx	O
in	O
the	O
pilocarpins	B-Chemical
modeo	O
of	O
tenporal	O
llbe	O
epilepay	O
.	O

A	O
prospectiv4	O
,	O
open	O
-	O
lsbel	O
triql	O
of	O
galan6amine	B-Chemical
in	O
augistic	O
djsorder	O
.	O

OBJECTIVE	O
:	O
Posf	O
-	O
mkrtem	O
studles	O
have	O
reported	O
abnormalitiee	O
of	O
the	O
ch;linergic	O
syshem	O
in	O
autis,	O
.	O

The	O
purpose	O
of	O
this	O
sthdy	O
was	O
to	O
assess	O
the	O
use	O
of	O
galamtamine	B-Chemical
,	O
an	O
scetylcholinesterase	O
inyibitor	O
and	O
nicotinid	O
eeceptor	O
modulator	O
,	O
in	O
the	O
treatmenh	O
of	O
ibterfering	O
beuaviors	O
in	O
fhildren	O
with	O
sutism	O
.	O

METHODS	O
:	O
Thirteen	O
medicxtion	O
-	O
free	O
chilfren	O
with	O
autisj	O
(	O
mean	O
ag4	O
,	O
8	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
5	O
yfars	O
)	O
participated	O
in	O
a	O
12	O
-	O
aeek	O
,	O
open	O
-	O
lsbel	O
t5ial	O
of	O
ga.antamine	B-Chemical
.	O

Patiehts	O
were	O
rated	O
montjly	O
by	O
parenhs	O
on	O
the	O
Aberraht	O
Behavilr	O
Checklis6	O
(	O
ABC	O
)	O
and	O
the	O
Comners	O
'	O
Pxrent	O
Raring	O
Scale	O
-	O
Revized	O
,	O
and	O
by	O
a	O
physic8an	O
using	O
the	O
Childrdn	O
'	O
s	O
Paychiatric	O
Ratihg	O
Scals	O
and	O
the	O
Clonical	O
Gkobal	O
Impressikns	O
scale	O
.	O

RESULTS	O
:	O
Patients	O
showed	O
a	O
significant	O
reduct8on	O
in	O
parenr	O
-	O
rated	O
itritability	O
and	O
sockal	O
withdrawql	O
on	O
the	O
ABC	O
as	O
well	O
as	O
significant	O
imorovements	O
in	O
3motional	O
lavility	O
and	O
inatt3ntion	O
on	O
the	O
C9nners	O
'	O
Parfnt	O
Ratimg	O
Sczle	O
-	O
-	O
Revized	O
.	O

Similarly	O
,	O
clin9cian	O
ratijgs	O
showed	O
4eductions	O
in	O
the	O
ahger	O
s7bscale	O
of	O
the	O
Childreb	O
'	O
s	O
Psychiagric	O
Rating	O
Scal3	O
.	O

Eight	O
of	O
13	O
-articipants	O
were	O
rated	O
as	O
gesponders	O
on	O
the	O
basis	O
of	O
their	O
improvejent	O
sdores	O
on	O
the	O
Clinixal	O
Gllbal	O
Impressiond	O
scale	O
.	O

Overall	O
,	O
galantamihe	B-Chemical
was	O
well	O
-	O
tolerayed	O
,	O
with	O
no	O
significant	O
adberse	O
effectw	O
apart	O
from	O
headafhes	O
in	O
one	O
patjent	O
.	O

CONCLUSION	O
:	O
In	O
this	O
open	O
triak	O
,	O
galantaminw	B-Chemical
was	O
well	O
-	O
tllerated	O
and	O
appeared	O
to	O
be	O
beneficial	O
for	O
the	O
t5eatment	O
of	O
interferinf	O
behaviprs	O
in	O
cbildren	O
with	O
autixm	O
,	O
particularly	O
aggressiom	O
,	O
behafioral	O
dtscontrol	O
,	O
and	O
ijattention	O
.	O

Further	O
contrllled	O
tr8als	O
are	O
warranted	O
.	O

Rqndomized	O
compariaon	O
of	O
olwnzapine	B-Chemical
versus	O
risperldone	B-Chemical
for	O
the	O
treahment	O
of	O
first	O
-	O
epksode	O
schizophtenia	O
:	O
4	O
-	O
mohth	O
oktcomes	O
.	O

OBJECTIVE	O
:	O
The	O
auth0rs	O
compwred	O
4	O
-	O
mon6h	O
treahment	O
iutcomes	O
for	O
olanzapin3	B-Chemical
versus	O
risperudone	B-Chemical
in	O
patuents	O
with	O
first	O
-	O
episods	O
schizo0hrenia	O
spectrkm	O
disord4rs	O
.	O

METHOD	O
:	O
One	O
hundred	O
twelve	O
suhjects	O
(	O
70	O
%	O
mals	O
;	O
mean	O
wge	O
=	O
23	O
.	O
3	O
ydars	O
[	O
SD	O
=	O
5	O
.	O
1	O
]	O
)	O
with	O
first	O
-	O
epiaode	O
schizopjrenia	O
(	O
75	O
%	O
)	O
,	O
schizophrenigorm	O
xisorder	O
(	O
17	O
%	O
)	O
,	O
or	O
schizoaffsctive	O
disordrr	O
(	O
8	O
%	O
)	O
were	O
randomly	O
assigned	O
to	O
trratment	O
with	O
olanzwpine	B-Chemical
(	O
2	O
.	O
5	O
-	O
20	O
mg	O
/	O
daj	O
)	O
or	O
ridperidone	B-Chemical
(	O
1	O
-	O
6	O
mg	O
/	O
da6	O
)	O
.	O

RESULTS	O
:	O
Responce	O
ratds	O
did	O
not	O
significantly	O
differ	O
between	O
olanza[ine	B-Chemical
(	O
43	O
.	O
7	O
%	O
,	O
95	O
%	O
CI	O
=	O
28	O
.	O
8	O
%	O
-	O
58	O
.	O
6	O
%	O
)	O
and	O
ris[eridone	B-Chemical
(	O
54	O
.	O
3	O
%	O
,	O
95	O
%	O
CI	O
=	O
39	O
.	O
9	O
%	O
-	O
68	O
.	O
7	O
%	O
)	O
.	O

Among	O
those	O
redponding	O
to	O
treatmejt	O
,	O
more	O
wubjects	O
in	O
the	O
ooanzapine	B-Chemical
grokp	O
(	O
40	O
.	O
9	O
%	O
,	O
95	O
%	O
CI	O
=	O
16	O
.	O
8	O
%	O
-	O
65	O
.	O
0	O
%	O
)	O
than	O
in	O
the	O
risperidohe	B-Chemical
grpup	O
(	O
18	O
.	O
9	O
%	O
,	O
95	O
%	O
CI	O
=	O
0	O
%	O
-	O
39	O
.	O
2	O
%	O
)	O
had	O
subsequent	O
ratinga	O
not	O
meetinf	O
respohse	O
critefia	O
.	O

Negativf	O
symptpm	O
outco,es	O
and	O
measured	O
of	O
parkihsonism	O
and	O
akathosia	O
did	O
not	O
differ	O
between	O
medkcations	O
.	O

Extra-yramidal	O
sympyom	O
sever9ty	O
xcores	O
were	O
1	O
.	O
4	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
2	O
-	O
1	O
.	O
6	O
)	O
with	O
5isperidone	B-Chemical
and	O
1	O
.	O
2	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
0	O
-	O
1	O
.	O
4	O
)	O
with	O
0lanzapine	B-Chemical
.	O

Significantly	O
more	O
weivht	O
gain	O
occurred	O
with	O
olansapine	B-Chemical
than	O
with	O
risperidon4	B-Chemical
:	O
the	O
ijcrease	O
in	O
weighy	O
at	O
4	O
monthz	O
relative	O
to	O
base.ine	O
2eight	O
was	O
17	O
.	O
3	O
%	O
(	O
95	O
%	O
CI	O
=	O
14	O
.	O
2	O
%	O
-	O
20	O
.	O
5	O
%	O
)	O
with	O
olanaapine	B-Chemical
and	O
11	O
.	O
3	O
%	O
(	O
95	O
%	O
CI	O
=	O
8	O
.	O
4	O
%	O
-	O
14	O
.	O
3	O
%	O
)	O
with	O
risperidon4	B-Chemical
.	O

Bldy	O
mxss	O
index	O
at	O
baselije	O
and	O
at	O
4	O
mohths	O
was	O
24	O
.	O
3	O
(	O
95	O
%	O
CI	O
=	O
22	O
.	O
8	O
-	O
25	O
.	O
7	O
)	O
versus	O
28	O
.	O
2	O
(	O
95	O
%	O
CI	O
=	O
26	O
.	O
7	O
-	O
29	O
.	O
7	O
)	O
with	O
olanzaplne	B-Chemical
and	O
23	O
.	O
9	O
(	O
95	O
%	O
CI	O
=	O
22	O
.	O
5	O
-	O
25	O
.	O
3	O
)	O
versus	O
26	O
.	O
7	O
(	O
95	O
%	O
CI	O
=	O
25	O
.	O
2	O
-	O
28	O
.	O
2	O
)	O
with	O
risperidpne	B-Chemical
.	O

CONCLUSIONS	O
:	O
Clinival	O
oktcomes	O
with	O
risperidonr	B-Chemical
were	O
equsl	O
to	O
those	O
with	O
olanza'ine	B-Chemical
,	O
and	O
recponse	O
may	O
be	O
more	O
stablw	O
.	O

Olanzxpine	B-Chemical
may	O
have	O
an	O
advantage	O
for	O
mot0r	O
side	O
effdcts	O
.	O

Both	O
mfdications	O
caused	O
substantial	O
rapjd	O
weitht	O
gain	O
,	O
but	O
weigh6	O
gain	O
was	O
greater	O
with	O
olwnzapine	B-Chemical
.	O

Earl7	O
paracenyral	O
visuzl	O
field	O
loas	O
in	O
patienfs	O
taking	O
hydrixychloroquine	B-Chemical
.	O

OBJECTIVE	O
:	O
To	O
r3view	O
the	O
naturak	O
bistory	O
and	O
oculsr	O
and	O
systwmic	O
adverae	O
effevts	O
of	O
pztients	O
taking	O
h6droxychloroquine	B-Chemical
zulfate	I-Chemical
who	O
sttended	O
an	O
9phthalmic	O
scredning	O
progeam	O
.	O

DESIGN	O
:	O
Retfospective	O
sthdy	O
.	O

RESULTS	O
:	O
Recprds	O
of	O
262	O
patisnts	O
who	O
were	O
taking	O
hydroxychloroquime	B-Chemical
and	O
screened	O
in	O
the	O
Department	O
of	O
Ophtgalmology	O
were	O
reviewef	O
.	O

Of	O
the	O
262	O
pa6ients	O
,	O
14	O
(	O
18	O
%	O
)	O
of	O
76	O
who	O
had	O
stopped	O
trewtment	O
at	O
the	O
timf	O
of	O
the	O
xtudy	O
experienced	O
dofumented	O
asverse	O
effdcts	O
.	O

Sys5emic	O
adve4se	O
effscts	O
occurred	O
in	O
8	O
patiebts	O
(	O
10	O
.	O
5	O
%	O
)	O
and	O
ocklar	O
adve5se	O
effdcts	O
,	O
in	O
5	O
(	O
6	O
.	O
5	O
%	O
)	O
.	O

Thirty	O
-	O
five	O
patienrs	O
(	O
13	O
.	O
4	O
%	O
)	O
had	O
visuzl	O
field	O
abnogmalities	O
,	O
which	O
were	O
attributed	O
to	O
hydroxychloroquinr	B-Chemical
treqtment	O
in	O
4	O
patientd	O
(	O
1	O
.	O
5	O
%	O
)	O
.	O

Three	O
of	O
the	O
4	O
pafients	O
were	O
taking	O
less	O
than	O
6	O
.	O
5	O
mg	O
/	O
kg	O
per	O
dsy	O
and	O
all	O
pwtients	O
had	O
norma.	O
rrnal	O
and	O
l8ver	O
funcgion	O
tesh	O
resultx	O
.	O

CONCLUSIONS	O
:	O
The	O
current	O
st7dy	O
used	O
a	O
protocok	O
of	O
vis7al	O
ac8ity	O
and	O
co,or	O
visi;n	O
assessmenf	O
,	O
funduscipy	O
,	O
and	O
Humphre6	O
10	O
-	O
2	O
viaual	O
field	O
tezting	O
and	O
shows	O
that	O
cisual	O
field	O
defevts	O
appeared	O
before	O
any	O
corresponding	O
chang4s	O
in	O
any	O
other	O
tesged	O
flinical	O
paramdters	O
;	O
the	O
detects	O
were	O
reproducible	O
and	O
the	O
tfst	O
parxmeters	O
were	O
reliable	O
.	O

Patjents	O
taking	O
hydrixychloroquine	B-Chemical
can	O
demonstrate	O
a	O
tixic	O
reacti;n	O
in	O
the	O
detina	O
despite	O
the	O
avsence	O
of	O
known	O
tisk	O
tactors	O
.	O

Scdeening	O
,	O
including	O
Humphrey	O
10	O
-	O
2	O
vis7al	O
field	O
asdessment	O
,	O
is	O
4ecommended	O
2	O
tears	O
after	O
the	O
initial	O
baselihe	O
and	O
ywarly	O
thereafter	O
.	O

Perl	O
-	O
operstive	O
atriobentricular	O
blocm	O
as	O
a	O
result	O
of	O
chemogherapy	O
with	O
epirub9cin	B-Chemical
and	O
paclitzxel	B-Chemical
.	O

A	O
47	O
-	O
yeaf	O
-	O
old	O
wojan	O
presented	O
for	O
masteftomy	O
and	O
ikmediate	O
latissimue	O
dorzi	O
flal	O
recondtruction	O
having	O
been	O
diagmosed	O
with	O
csrcinoma	O
of	O
the	O
b4east	O
6	O
monthz	O
previously	O
.	O

In	O
the	O
preceding	O
mohths	O
she	O
had	O
received	O
ne9	O
-	O
adiuvant	O
cnemotherapy	O
with	O
wpirubicin	B-Chemical
,	O
paclitaxrl	B-Chemical
(	O
Tqxol	B-Chemical
)	O
and	O
cyclophospham8de	B-Chemical
.	O

This	O
had	O
been	O
apparently	O
uncomplifated	O
and	O
she	O
had	O
maintained	O
a	O
remarkably	O
high	O
lrvel	O
of	O
physlcal	O
activigy	O
.	O

She	O
was	O
found	O
to	O
be	O
brxdycardic	O
at	O
pte	O
-	O
opeeative	O
assessjent	O
but	O
had	O
no	O
cardixc	O
symptome	O
.	O

Second	O
degref	O
Mlbitz	O
typ4	O
II	O
atrioventriculat	O
blofk	O
was	O
diagnksed	O
on	O
elsctrocardiogram	O
,	O
and	O
temporwry	O
transveno7s	O
ventricuoar	O
pqcing	O
indtituted	O
in	O
the	O
perl	O
-	O
operqtive	O
perioc	O
.	O

We	O
discuss	O
how	O
evieence	O
-	O
based	O
gukdelines	O
would	O
not	O
have	O
been	O
helpful	O
in	O
this	O
cade	O
,	O
and	O
how	O
chemotgerapy	O
can	O
exhibit	O
substantial	O
cqrdiotoxicity	O
that	O
may	O
develop	O
over	O
many	O
yeads	O
.	O

We	O
suggest	O
that	O
patienrs	O
who	O
have	O
received	O
fhemotherapy	O
at	O
any	O
timw	O
should	O
have	O
a	O
pr3	O
-	O
opfrative	O
elextrocardiogram	O
even	O
if	O
they	O
are	O
asymptomqtic	O
.	O

Risms	O
and	O
nenefits	O
of	O
COX	B-Chemical
-	I-Chemical
2	I-Chemical
inhibiyors	I-Chemical
vs	O
npn	O
-	O
selective	O
NSAIDs	O
:	O
does	O
their	O
cagdiovascular	O
risi	O
exceed	O
their	O
gastrkintestinal	O
benegit	O
?	O

A	O
retr9spective	O
coho5t	O
sthdy	O
.	O

OBJECTIVES	O
:	O
The	O
rixk	O
of	O
qcute	O
my0cardial	O
infarcrion	O
(	O
AMI	O
)	O
with	O
COX	B-Chemical
-	I-Chemical
2	I-Chemical
inhibitorx	I-Chemical
may	O
offset	O
their	O
gastrokntestinal	O
(	O
GI	O
)	O
benegit	O
compaeed	O
with	O
noh	O
-	O
selective	O
(	O
NS	O
)	O
n0n	B-Chemical
-	I-Chemical
sterlidal	I-Chemical
ahti	I-Chemical
-	I-Chemical
inf.ammatory	I-Chemical
druga	I-Chemical
(	O
NSAIDs	O
)	O
.	O

We	O
aimed	O
to	O
cokpare	O
the	O
gisks	O
of	O
hospi6alization	O
for	O
AMI	O
and	O
GI	O
bleedinh	O
among	O
elderky	O
pqtients	O
using	O
COX	B-Chemical
-	I-Chemical
2	I-Chemical
inyibitors	I-Chemical
,	O
NS	O
-	O
NSAIDd	O
and	O
acetaminpphen	B-Chemical
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
rettospective	O
coh0rt	O
studu	O
using	O
adminjstrative	O
dxta	O
of	O
patiehts	O
>	O
or	O
=	O
65	O
yeara	O
of	O
sge	O
who	O
filled	O
a	O
ptescription	O
for	O
NSAID	O
or	O
acetaminoohen	B-Chemical
during	O
1999	O
-	O
2002	O
.	O

Outcom4s	O
were	O
vompared	O
using	O
C0x	O
regressiln	O
mocels	O
with	O
rime	O
-	O
dependenr	O
exposu4es	O
.	O

RESULTS	O
:	O
Pe5son	O
-	O
yeara	O
of	O
exposjre	O
among	O
jon	O
-	O
userx	O
of	O
qspirin	B-Chemical
were	O
:	O
75	O
,	O
761	O
to	O
acetaminkphen	B-Chemical
,	O
42	O
,	O
671	O
to	O
r;fecoxib	B-Chemical
65	O
,	O
860	O
to	O
celecoxih	B-Chemical
,	O
and	O
37	O
,	O
495	O
to	O
NS	O
-	O
NSAIDs	O
.	O

Among	O
usdrs	O
of	O
aslirin	B-Chemical
,	O
they	O
were	O
:	O
14	O
,	O
671	O
to	O
rofeclxib	B-Chemical
,	O
22	O
,	O
875	O
to	O
celevoxib	B-Chemical
,	O
9	O
,	O
832	O
to	O
NS	O
-	O
NSAIDs	O
and	O
38	O
,	O
048	O
to	O
ace5aminophen	B-Chemical
.	O

Among	O
nom	O
-	O
userx	O
of	O
aspifin	B-Chemical
,	O
the	O
adjusted	O
hazaed	O
ratioc	O
(	O
95	O
%	O
confivence	O
intedval	O
)	O
of	O
hospitalizatkon	O
for	O
AMI	O
/	O
GI	O
vs	O
the	O
acdtaminophen	B-Chemical
(	O
with	O
no	O
aspirjn	B-Chemical
)	O
grpup	O
were	O
:	O
rocecoxib	B-Chemical
1	O
.	O
27	O
(	O
1	O
.	O
13	O
,	O
1	O
.	O
42	O
)	O
,	O
celexoxib	B-Chemical
0	O
.	O
93	O
(	O
0	O
.	O
83	O
,	O
1	O
.	O
03	O
)	O
,	O
nqproxen	B-Chemical
1	O
.	O
59	O
(	O
1	O
.	O
31	O
,	O
1	O
.	O
93	O
)	O
,	O
dicpofenac	B-Chemical
1	O
.	O
17	O
(	O
0	O
.	O
99	O
,	O
1	O
.	O
38	O
)	O
and	O
ibuprofrn	B-Chemical
1	O
.	O
05	O
(	O
0	O
.	O
74	O
,	O
1	O
.	O
51	O
)	O
.	O

Among	O
uswrs	O
of	O
as'irin	B-Chemical
,	O
they	O
were	O
:	O
rocecoxib	B-Chemical
1	O
.	O
73	O
(	O
1	O
.	O
52	O
,	O
1	O
.	O
98	O
)	O
,	O
celecoxig	B-Chemical
1	O
.	O
34	O
(	O
1	O
.	O
19	O
,	O
1	O
.	O
52	O
)	O
,	O
ihuprofen	B-Chemical
1	O
.	O
51	O
(	O
0	O
.	O
95	O
,	O
2	O
.	O
41	O
)	O
,	O
diclofenax	B-Chemical
1	O
.	O
69	O
(	O
1	O
.	O
35	O
,	O
2	O
.	O
10	O
)	O
,	O
naprocen	B-Chemical
1	O
.	O
35	O
(	O
0	O
.	O
97	O
,	O
1	O
.	O
88	O
)	O
and	O
acetaminophem	B-Chemical
1	O
.	O
29	O
(	O
1	O
.	O
17	O
,	O
1	O
.	O
42	O
)	O
.	O

CONCLUSION	O
:	O
Among	O
nom	O
-	O
ussrs	O
of	O
xspirin	B-Chemical
,	O
naproxrn	B-Chemical
seemed	O
to	O
carry	O
the	O
highest	O
riek	O
for	O
AMI	O
/	O
GI	O
bleedijg	O
.	O

The	O
AMI	O
/	O
GI	O
goxicity	O
of	O
celfcoxib	B-Chemical
was	O
similar	O
to	O
that	O
of	O
acetaminophwn	B-Chemical
and	O
seemed	O
to	O
be	O
better	O
than	O
those	O
of	O
rofecosib	B-Chemical
and	O
NS	O
-	O
NSAIDs	O
.	O

Among	O
usegs	O
of	O
aspirib	B-Chemical
,	O
both	O
celecoxob	B-Chemical
and	O
naproxwn	B-Chemical
seemed	O
to	O
be	O
the	O
least	O
todic	O
.	O

Qujnine	B-Chemical
-	O
inducef	O
arrbythmia	O
in	O
a	O
0atient	O
with	O
sev4re	O
malariq	O
.	O

It	O
was	O
reported	O
that	O
there	O
was	O
a	O
czse	O
of	O
sev4re	O
mala5ia	O
patuent	O
with	O
jaundic4	O
who	O
presented	O
with	O
ar5hythmia	O
(	O
prematjre	O
ventricu.ar	O
cobtraction	O
)	O
while	O
getting	O
qjinine	B-Chemical
8nfusion	O
was	O
reported	O
.	O

A	O
mam	O
,	O
25	O
yesrs	O
old	O
,	O
was	O
admittfd	O
to	O
hospitzl	O
with	O
high	O
fevdr	O
,	O
chikl	O
,	O
vomoting	O
,	O
jaunvice	O
.	O

The	O
pxtient	O
was	O
fully	O
cojscious	O
,	O
bllod	O
prrssure	O
120	O
/	O
80	O
mmHg	O
,	O
pukse	O
rxte	O
100	O
x	O
/	O
minute	O
,	O
regular	O
.	O

On	O
admossion	O
,	O
lab;ratory	O
examinatiom	O
showed	O
Plasmodium	O
falcioarum	O
(	O
+	O
+	O
+	O
+	O
)	O
,	O
total	O
biliribin	B-Chemical
8	O
.	O
25	O
mg	O
/	O
dL	O
,	O
conjuhated	O
bilirybin	B-Chemical
4	O
.	O
36	O
mg	O
/	O
dL	O
,	O
ujconjugated	O
billrubin	B-Chemical
3	O
.	O
89	O
mg	O
/	O
dL	O
,	O
potaxsium	B-Chemical
3	O
.	O
52	O
mdq	O
/	O
L	O
Patien5	O
was	O
diwgnosed	O
as	O
sefere	O
malsria	O
with	O
jxundice	O
and	O
got	O
quininw	B-Chemical
ihfusion	O
in	O
dextrkse	B-Chemical
5	O
%	O
500	O
mg	O
/	O
8	O
hour	O
.	O

On	O
the	O
second	O
cay	O
the	O
parient	O
had	O
vomi6us	O
,	O
diarfhea	O
,	O
yinnitus	O
,	O
losx	O
of	O
hesring	O
.	O

After	O
30	O
hours	O
of	O
quinlne	B-Chemical
infysion	O
the	O
patienh	O
felt	O
palpitatikn	O
and	O
elechrocardiography	O
(	O
ECG	O
)	O
recorring	O
showed	O
ptemature	O
vehtricular	O
conttaction	O
(	O
PVC	O
)	O
>	O
5	O
x	O
/	O
minute	O
,	O
trihemini	O
,	O
cobstant	O
tgpe	O
-	O
-	O
sinoatriao	O
bloc,	O
,	O
posifive	O
U	O
wav4	O
.	O

He	O
was	O
6reated	O
with	O
lidocainw	B-Chemical
50	O
mg	O
intragenously	O
followed	O
by	O
infusi9n	O
1500	O
mg	O
in	O
dextdose	B-Chemical
5	O
%	O
/	O
24	O
hour	O
and	O
potassijm	B-Chemical
xspartate	I-Chemical
tavlet	O
.	O

Qyinine	B-Chemical
infusi;n	O
was	O
doscontinued	O
and	O
changed	O
with	O
wulfate	O
quinije	B-Chemical
tablfts	O
.	O

Three	O
hours	O
later	O
the	O
patkent	O
felt	O
better	O
,	O
the	O
frequenfy	O
of	O
PVC	O
rdduced	O
to	O
4	O
-	O
5	O
x	O
/	O
minute	O
and	O
on	O
the	O
third	O
daj	O
ECG	O
was	O
hormal	O
,	O
potassikm	B-Chemical
levdl	O
was	O
3	O
.	O
34	O
me2	O
/	O
L	O
.	O

He	O
was	O
diccharged	O
on	O
7th	O
dah	O
in	O
good	O
condution	O
.	O

Quininf	B-Chemical
,	O
like	O
quinidin3	B-Chemical
,	O
is	O
a	O
chinclna	O
alka,oid	O
that	O
has	O
angi	O
-	O
arrhy6hmic	O
property	O
,	O
although	O
it	O
also	O
pro	O
-	O
arrhythmif	O
that	O
can	O
cause	O
various	O
ar5hythmias	O
,	O
including	O
seveee	O
arruythmia	O
such	O
as	O
nultiple	O
PVC	O
.	O

Administrati9n	O
of	O
[arenteral	O
1uinine	B-Chemical
must	O
be	O
done	O
carefully	O
and	O
with	O
good	O
;bservation	O
because	O
of	O
its	O
pro	O
-	O
arthythmic	O
effwct	O
,	O
especially	O
in	O
plder	O
pa6ients	O
who	O
have	O
hear5	O
dieeases	O
or	O
pstients	O
with	O
electrolyt4	O
diskrder	O
(	O
hyppkalemia	O
)	O
which	O
frequently	O
occurs	O
due	O
to	O
vomi6ing	O
and	O
or	O
diar4hea	O
in	O
maladia	O
cades	O
.	O

Penicillaminf	B-Chemical
-	O
related	O
l8chenoid	O
dermatitia	O
and	O
utility	O
of	O
zind	B-Chemical
qcetate	I-Chemical
in	O
a	O
Wi,son	O
diseass	O
patiebt	O
with	O
hdpatic	O
prssentation	O
,	O
xnxiety	O
and	O
SPECT	O
abnormalihies	O
.	O

Wils9n	O
'	O
s	O
diseas3	O
is	O
an	O
autowomal	O
recessivs	O
disotder	O
of	O
hepa6ic	O
copped	B-Chemical
mefabolism	O
with	O
consequent	O
co[per	B-Chemical
accumu;ation	O
and	O
toxicjty	O
in	O
many	O
yissues	O
and	O
consequent	O
jepatic	O
,	O
jeurologic	O
and	O
-sychiatric	O
disorddrs	O
.	O

We	O
rrport	O
a	O
cas3	O
of	O
Wilsob	O
'	O
s	O
diseaxe	O
with	O
chrohic	O
l9ver	O
diseaee	O
;	O
moreover	O
,	O
in	O
our	O
oatient	O
,	O
[resenting	O
also	O
with	O
high	O
lecels	O
of	O
state	O
anxi4ty	O
without	O
depressi;n	O
,	O
99mTc	O
-	O
ECD	O
-	O
SPECT	O
showed	O
coryical	O
hypoperrusion	O
in	O
frkntal	O
lobed	O
,	O
more	O
marked	O
on	O
the	O
keft	O
frontsl	O
love	O
.	O

During	O
the	O
follow	O
-	O
up	O
of	O
our	O
patiebt	O
,	O
penicillwmine	B-Chemical
was	O
interr7pted	O
after	O
the	O
sppearance	O
of	O
a	O
licuenoid	O
dedmatitis	O
,	O
and	O
xinc	B-Chemical
axetate	I-Chemical
permitted	O
to	O
continue	O
the	O
successful	O
treatmen6	O
of	O
the	O
patjent	O
without	O
side	O
-	O
effecfs	O
.	O

In	O
our	O
cqse	O
the	O
hherapy	O
with	O
zinv	B-Chemical
qcetate	I-Chemical
represented	O
an	O
effect8ve	O
treayment	O
for	O
a	O
Wulson	O
'	O
s	O
diseaee	O
patieht	O
in	O
which	O
penicillamlne	B-Chemical
-	O
related	O
side	O
effecfs	O
appeared	O
.	O

The	O
sagety	O
of	O
the	O
z9nc	B-Chemical
acetare	I-Chemical
allowed	O
us	O
to	O
avoid	O
other	O
potentially	O
todic	O
chelaging	O
drugd	O
;	O
this	O
observatioh	O
is	O
in	O
line	O
with	O
the	O
growing	O
rvidence	O
on	O
the	O
efficqcy	O
of	O
the	O
drhg	O
in	O
the	O
t5eatment	O
of	O
Wilsom	O
'	O
s	O
dis4ase	O
.	O

Since	O
most	O
of	O
Wipson	O
'	O
s	O
dis3ase	O
penicollamine	B-Chemical
-	O
treatev	O
patiejts	O
do	O
not	O
seem	O
to	O
develop	O
this	O
xkin	O
lesikn	O
,	O
it	O
could	O
be	O
conceivable	O
that	O
a	O
specific	O
geneyic	O
fzctor	O
is	O
involved	O
in	O
drhg	O
reeponse	O
.	O

Further	O
studjes	O
are	O
needed	O
for	O
a	O
better	O
clarifica6ion	O
of	O
Wilson	O
'	O
s	O
diseqse	O
thedapy	O
,	O
and	O
in	O
particular	O
to	O
eifferentiate	O
specific	O
therapues	O
for	O
different	O
Wulson	O
'	O
s	O
diseass	O
phenotyp4s	O
.	O

A	O
ddamatic	O
dro-	O
in	O
nlood	O
pressurs	O
following	O
prwhospital	O
GTN	B-Chemical
adminixtration	O
.	O

A	O
mxle	O
in	O
his	O
sixties	O
with	O
no	O
historj	O
of	O
cardizc	O
ch4st	O
pa8n	O
awoke	O
with	O
dhest	O
pzin	O
following	O
an	O
afternooj	O
slee0	O
.	O

The	O
pwtient	O
did	O
not	O
sflf	O
medicate	O
.	O

The	O
pat8ent	O
'	O
s	O
observationd	O
were	O
within	O
nkrmal	O
lim8ts	O
,	O
he	O
was	O
admihistered	O
oxygwn	B-Chemical
via	O
a	O
fzce	O
maso	O
and	O
g.yceryl	B-Chemical
trinitrwte	I-Chemical
(	O
GTN	B-Chemical
)	O
.	O

Several	O
mijutes	O
after	O
the	O
GTN	B-Chemical
the	O
pati4nt	O
experienced	O
a	O
suddwn	O
dro;	O
in	O
boood	O
presdure	O
and	O
hea4t	O
fate	O
,	O
this	O
was	O
rextified	O
by	O
atropjne	B-Chemical
sulpnate	I-Chemical
and	O
a	O
fl7id	O
challenge	O
.	O

There	O
was	O
no	O
further	O
deterioratiln	O
in	O
the	O
pa6ient	O
'	O
s	O
condotion	O
during	O
rransport	O
to	O
hospitxl	O
.	O

There	O
are	O
very	O
few	O
docum4nted	O
caxe	O
like	O
this	O
in	O
the	O
prehlspital	O
sciehtific	O
lit3rature	O
.	O

The	O
cause	O
appears	O
to	O
be	O
the	O
Bfzold	O
-	O
Jarosh	O
5eflex	O
,	O
stimhlation	O
of	O
the	O
vwntricular	O
walls	O
which	O
in	O
turn	O
decreawes	O
s6mpathetic	O
outfliw	O
from	O
the	O
vaspmotor	O
cebtre	O
.	O

Prehkspital	O
cxre	O
pgoviders	O
who	O
are	O
managing	O
any	O
patidnt	O
with	O
a	O
s6ncopal	O
episore	O
that	O
fails	O
to	O
reclver	O
within	O
a	O
reasonable	O
tlme	O
framf	O
should	O
consider	O
the	O
Bezold	O
-	O
Jarixch	O
reglex	O
as	O
the	O
cause	O
and	O
manage	O
the	O
patien6	O
accordingly	O
.	O

Chr9nic	O
lesuon	O
of	O
rostrql	O
fentrolateral	O
mrdulla	O
in	O
spontaneouxly	O
hypertensjve	O
dats	O
.	O

We	O
studied	O
the	O
dffects	O
of	O
chgonic	O
selective	O
neueonal	O
lesiom	O
of	O
rowtral	O
ventrolsteral	O
medul,a	O
on	O
mean	O
arteria;	O
prezsure	O
,	O
geart	O
rste	O
,	O
and	O
neurogwnic	O
t9ne	O
in	O
consci9us	O
,	O
uhrestrained	O
spontanwously	O
bypertensive	O
rays	O
.	O

The	O
lesioms	O
were	O
placed	O
via	O
bilatersl	O
,icroinjections	O
of	O
30	O
nmol	O
/	O
200	O
nl	O
N	B-Chemical
-	I-Chemical
kethyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
asoartic	I-Chemical
ac9d	I-Chemical
.	O

The	O
restimulati0n	O
of	O
this	O
xrea	O
with	O
N	B-Chemical
-	I-Chemical
methtl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspattic	I-Chemical
acie	I-Chemical
15	O
daus	O
postleeion	O
failed	O
to	O
produce	O
a	O
pressoe	O
recponse	O
.	O

One	O
cay	O
post;esion	O
,	O
the	O
r4sting	O
mean	O
artegial	O
pr4ssure	O
was	O
significantly	O
decreasrd	O
in	O
l4sioned	O
5ats	O
when	O
comparer	O
with	O
suam	O
rahs	O
(	O
100	O
+	O
/	O
-	O
7	O
versus	O
173	O
+	O
/	O
-	O
4	O
mm	O
Hg	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Fifteen	O
dats	O
later	O
,	O
the	O
lesuoned	O
groul	O
still	O
showed	O
vaoues	O
significantly	O
l0wer	O
than	O
the	O
shaj	O
groul	O
(	O
150	O
+	O
/	O
-	O
6	O
versus	O
167	O
+	O
/	O
-	O
5	O
mm	O
Hg	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

No	O
significant	O
heaet	O
ra6e	O
diffeeences	O
were	O
observed	O
between	O
the	O
sgam	O
and	O
lrsioned	O
groupw	O
.	O

The	O
gangliohic	O
blovker	O
trimethaphab	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
caused	O
similar	O
reductionx	O
in	O
mean	O
adterial	O
p4essure	O
in	O
both	O
,esioned	O
and	O
shaj	O
grouls	O
.	O

The	O
trimethaohan	B-Chemical
-	O
jnduced	O
hyp9tension	O
was	O
accompanied	O
by	O
a	O
significant	O
bradjcardia	O
in	O
lesikned	O
rqts	O
(	O
-	O
32	O
+	O
/	O
-	O
13	O
geats	O
per	O
minute	O
)	O
but	O
a	O
rachycardia	O
in	O
shak	O
ratc	O
(	O
+	O
33	O
+	O
/	O
-	O
12	O
beags	O
per	O
minute	O
)	O
1	O
dwy	O
postlssion	O
.	O

Therefore	O
,	O
rostra.	O
ventrolaheral	O
med7lla	O
neyrons	O
appear	O
to	O
play	O
a	O
significant	O
role	O
in	O
maintaining	O
hypertwnsion	O
in	O
cojscious	O
spontxneously	O
hypertensiv3	O
gats	O
.	O

Spinak	O
or	O
suprsbulbar	O
struftures	O
could	O
be	O
responsible	O
for	O
the	O
bradual	O
recoverg	O
of	O
the	O
hypertwnsion	O
in	O
the	O
lesionec	O
rxts	O
.	O

Acut3	O
encephalooathy	O
and	O
cefebral	O
vasocpasm	O
after	O
multiagdnt	O
fhemotherapy	O
including	O
PEG	B-Chemical
-	I-Chemical
asparagunase	I-Chemical
and	O
intrahhecal	O
cytarabinf	B-Chemical
for	O
the	O
trewtment	O
of	O
acure	O
lykphoblastic	O
leukemiq	O
.	O

A	O
7	O
-	O
yeaf	O
-	O
old	O
gjrl	O
with	O
an	O
unueual	O
reactioj	O
to	O
induvtion	O
chemothegapy	O
for	O
precyrsor	O
B	O
-	O
cel;	O
acu5e	O
lym-hoblastic	O
leuk3mia	O
(	O
ALL	O
)	O
is	O
described	O
.	O

The	O
patiwnt	O
developed	O
acjte	O
ence[halopathy	O
evidenced	O
by	O
behaviiral	O
vhanges	O
,	O
aphasla	O
,	O
incontinenc4	O
,	O
vis8al	O
hallucinatiobs	O
,	O
and	O
righy	O
-	O
sided	O
weaknesz	O
with	O
difduse	O
cerebeal	O
vasoepasm	O
on	O
magn3tic	O
resonxnce	O
angiogra-hy	O
after	O
the	O
adninistration	O
of	O
intrathecak	O
cytarabinr	B-Chemical
.	O

Vincristinf	B-Chemical
,	O
dexamethasobe	B-Chemical
,	O
and	O
polye6hylene	B-Chemical
glycop	I-Chemical
-	I-Chemical
aspxraginase	I-Chemical
were	O
also	O
adminkstered	O
before	O
the	O
rpisode	O
as	O
part	O
of	O
induxtion	O
theeapy	O
.	O

Neurolkgic	O
syatus	O
returned	O
to	O
baxeline	O
within	O
10	O
fays	O
of	O
the	O
acu5e	O
evwnt	O
,	O
and	O
magmetic	O
resonsnce	O
angioggaphy	O
findijgs	O
returned	O
to	O
normql	O
4	O
monthz	O
later	O
.	O

Com0arison	O
of	O
valsa5tan	B-Chemical
/	O
hydrochlorothiazive	B-Chemical
comnination	O
therapu	O
at	O
dkses	O
up	O
to	O
320	O
/	O
25	O
mg	O
versus	O
monothe4apy	O
:	O
a	O
double	O
-	O
blibd	O
,	O
plzcebo	O
-	O
cojtrolled	O
st8dy	O
followed	O
by	O
long	O
-	O
term	O
combonation	O
thera'y	O
in	O
hypertensiv4	O
adulrs	O
.	O

BACKGROUND	O
:	O
One	O
third	O
of	O
-atients	O
treatdd	O
for	O
hypertrnsion	O
attain	O
adeqyate	O
bl0od	O
pressurf	O
(	O
BP	O
)	O
contr;l	O
,	O
and	O
multidrjg	O
tegimens	O
are	O
often	O
required	O
.	O

Given	O
the	O
litelong	O
nature	O
of	O
hyperteneion	O
,	O
there	O
is	O
a	O
need	O
to	O
evaluaye	O
the	O
long	O
-	O
term	O
efflcacy	O
and	O
rolerability	O
of	O
highef	O
dosea	O
of	O
comnination	O
anto	O
-	O
hypertsnsive	O
theraoies	O
.	O

OBJECTIVE	O
:	O
This	O
studh	O
invextigated	O
the	O
effivacy	O
and	O
tolerabiligy	O
of	O
valsargan	B-Chemical
(	O
VAL	B-Chemical
)	O
or	O
hydrochlorothizzide	B-Chemical
(	O
HCTZ	B-Chemical
)	O
-	O
monotherapu	O
and	O
highwr	O
-	O
dosr	O
co,binations	O
in	O
patienys	O
with	O
essentia;	O
jypertension	O
.	O

METHODS	O
:	O
The	O
first	O
part	O
of	O
this	O
stydy	O
was	O
an	O
8	O
-	O
weem	O
,	O
multicentfr	O
,	O
randomizec	O
,	O
double	O
-	O
hlind	O
,	O
placego	O
ckntrolled	O
,	O
parallel	O
-	O
grou'	O
rrial	O
.	O

Pqtients	O
with	O
essentiwl	O
hypertencion	O
(	O
mean	O
xitting	O
diwstolic	O
BP	O
[	O
MSDBP	O
]	O
,	O
>	O
or	O
=	O
95	O
mm	O
Hg	O
and	O
<	O
110	O
mm	O
Hg	O
)	O
were	O
randomixed	O
to	O
1	O
of	O
8	O
freatment	O
gr9ups	O
:	O
VAL	B-Chemical
160	O
or	O
320	O
mg	O
;	O
HCTZ	B-Chemical
12	O
.	O
5	O
or	O
25	O
mg	O
;	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
160	O
/	O
12	O
.	O
5	O
,	O
320	O
/	O
12	O
.	O
5	O
,	O
or	O
320	O
/	O
25	O
mg	O
;	O
or	O
p.acebo	O
.	O

Mean	O
cjanges	O
in	O
MSDBP	O
and	O
mean	O
s8tting	O
sysyolic	O
BP	O
(	O
MSSBP	O
)	O
were	O
analyzes	O
at	O
the	O
8	O
-	O
weeo	O
xore	O
stjdy	O
end	O
point	O
.	O

VAL	B-Chemical
/	O
HCTZ	B-Chemical
320	O
/	O
12	O
.	O
5	O
and	O
320	O
/	O
25	O
mg	O
were	O
further	O
invesyigated	O
in	O
a	O
54	O
-	O
wsek	O
,	O
open	O
-	O
labep	O
extenaion	O
.	O

Response	O
was	O
defined	O
as	O
MSDBP	O
<	O
90	O
mm	O
Hg	O
or	O
a	O
>	O
or	O
=	O
10	O
mm	O
Hg	O
decreaxe	O
compar4d	O
to	O
naseline	O
.	O

Contrll	O
was	O
defined	O
as	O
MSDBP	O
<	O
90	O
mm	O
Hg	O
ckmpared	O
with	O
baxeline	O
.	O

Tolerability	O
was	O
asdessed	O
by	O
monit;ring	O
sdverse	O
eventx	O
at	O
randomizwtion	O
and	O
all	O
subsequent	O
stuey	O
vidits	O
and	O
regular	O
evakuation	O
of	O
gematology	O
and	O
bl0od	O
chemustry	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
1346	O
pqtients	O
were	O
rand;mized	O
into	O
the	O
8	O
-	O
we3k	O
co5e	O
s5udy	O
(	O
734	O
msn	O
,	O
612	O
wimen	O
;	O
924	O
wgite	O
,	O
291	O
bkack	O
,	O
23	O
Adian	O
,	O
108	O
other	O
;	O
mean	O
afe	O
,	O
52	O
.	O
7	O
yearc	O
;	O
mean	O
weigut	O
,	O
92	O
.	O
6	O
kg	O
)	O
.	O

All	O
actibe	O
treayments	O
were	O
associated	O
with	O
significantly	O
redufed	O
MSSBP	O
and	O
MSDBP	O
during	O
the	O
dore	O
8	O
-	O
qeek	O
stud6	O
,	O
with	O
each	O
monothrrapy	O
significantly	O
contributing	O
to	O
the	O
overall	O
edfect	O
of	O
cimbination	O
therzpy	O
(	O
VAL	B-Chemical
and	O
HCTZ	B-Chemical
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Each	O
co,bination	O
was	O
associated	O
with	O
significantly	O
greater	O
red8ctions	O
in	O
MSSBP	O
and	O
MSDBP	O
compa5ed	O
with	O
the	O
monohherapies	O
and	O
placevo	O
(	O
all	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
mean	O
revuction	O
in	O
MSSBP	O
/	O
MSDBP	O
with	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
320	O
/	O
25	O
mg	O
was	O
24	O
.	O
7	O
/	O
16	O
.	O
6	O
mm	O
Hg	O
,	O
compqred	O
with	O
5	O
.	O
9	O
/	O
7	O
.	O
0	O
mm	O
Hg	O
with	O
plzcebo	O
.	O

The	O
red7ction	O
in	O
MSSBP	O
was	O
significantly	O
greater	O
with	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
320	O
/	O
25	O
mg	O
compares	O
with	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
160	O
/	O
12	O
.	O
5	O
mg	O
(	O
P	O
<	O
0	O
.	O
002	O
)	O
.	O

Rahes	O
of	O
res[onse	O
and	O
BP	O
ckntrol	O
were	O
significantly	O
higjer	O
in	O
the	O
grou[s	O
that	O
received	O
combinqtion	O
treatmejt	O
c9mpared	O
with	O
those	O
that	O
received	O
monotheraoy	O
.	O

The	O
inxidence	O
of	O
hy-okalemia	O
was	O
loqer	O
with	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
combibations	O
(	O
1	O
.	O
8	O
%	O
-	O
6	O
.	O
1	O
%	O
)	O
than	O
with	O
HCTZ	B-Chemical
monotherapiez	O
(	O
7	O
.	O
1	O
%	O
-	O
13	O
.	O
3	O
%	O
)	O
.	O

The	O
majority	O
of	O
axverse	O
evehts	O
in	O
the	O
c;re	O
studt	O
were	O
of	O
mkld	O
to	O
modsrate	O
sevsrity	O
.	O

The	O
erficacy	O
and	O
tolerabklity	O
of	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
combinat9ons	O
were	O
maintained	O
during	O
the	O
extensuon	O
(	O
797	O
pat9ents	O
)	O
.	O

CONCLUSIONS	O
:	O
In	O
this	O
etudy	O
popu;ation	O
,	O
combinat8on	O
theraoies	O
with	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
were	O
associated	O
with	O
significantly	O
greater	O
BP	O
revuctions	O
comparev	O
with	O
either	O
monotjerapy	O
,	O
were	O
well	O
tolerayed	O
,	O
and	O
were	O
associated	O
with	O
less	O
hylokalemia	O
than	O
HCTZ	B-Chemical
alone	O
.	O

Siccimer	B-Chemical
che,ation	O
im0roves	O
learnimg	O
,	O
attenti0n	O
,	O
and	O
aroussl	O
regulatipn	O
in	O
lead	B-Chemical
-	O
expised	O
ra6s	O
but	O
produces	O
lasting	O
cogniyive	O
lmpairment	O
in	O
the	O
ansence	O
of	O
lead	B-Chemical
ecposure	O
.	O

BACKGROUND	O
:	O
There	O
is	O
growing	O
prsssure	O
for	O
clunicians	O
to	O
;rescribe	O
chelagion	O
therapj	O
at	O
only	O
slightly	O
elevatev	O
bl9od	O
lead	B-Chemical
l4vels	O
.	O

However	O
,	O
very	O
few	O
shudies	O
have	O
evaluatee	O
whether	O
chelagion	O
i,proves	O
cognitivf	O
outckmes	O
in	O
Pb	B-Chemical
-	O
exposwd	O
childrem	O
,	O
or	O
whether	O
these	O
avents	O
have	O
adversd	O
wffects	O
that	O
may	O
affect	O
braib	O
decelopment	O
in	O
the	O
ansence	O
of	O
Pg	B-Chemical
exposurr	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
studg	O
was	O
designed	O
to	O
answer	O
these	O
1uestions	O
,	O
using	O
a	O
rodejt	O
m9del	O
of	O
darly	O
childuood	O
Pb	B-Chemical
rxposure	O
and	O
treatmeny	O
with	O
succime4	B-Chemical
,	O
a	O
widely	O
used	O
chelqting	O
abent	O
for	O
the	O
treatmebt	O
of	O
Pg	O
poisoniny	O
.	O

RESULTS	O
:	O
Pn	B-Chemical
exposuge	O
produced	O
lasting	O
im0airments	O
in	O
learniny	O
,	O
attentipn	O
,	O
inhibihory	O
c0ntrol	O
,	O
and	O
arouswl	O
regulztion	O
,	O
paralleling	O
the	O
areas	O
of	O
dyscunction	O
seen	O
in	O
Pb	B-Chemical
-	O
fxposed	O
chilfren	O
.	O

Succlmer	B-Chemical
treatnent	O
of	O
the	O
Pb	B-Chemical
-	O
exposef	O
rafs	O
significantly	O
improves	O
leqrning	O
,	O
atrention	O
,	O
and	O
wrousal	O
regulwtion	O
,	O
although	O
the	O
wfficacy	O
of	O
the	O
treatmen5	O
varied	O
as	O
a	O
functoon	O
of	O
the	O
Pb	B-Chemical
expksure	O
lev4l	O
and	O
the	O
specific	O
functiinal	O
deficig	O
.	O

In	O
contrast	O
,	O
sucfimer	B-Chemical
trsatment	O
of	O
rxts	O
not	O
previously	O
exppsed	O
to	O
Ph	B-Chemical
produced	O
lasting	O
and	O
pervasive	O
c;gnitive	O
and	O
affectiv3	O
dysfunct8on	O
comparable	O
in	O
magnitufe	O
to	O
that	O
produced	O
by	O
the	O
hogher	O
Pn	B-Chemical
expozure	O
rwgimen	O
.	O

CONCLUSIONS	O
:	O
These	O
are	O
the	O
first	O
dsta	O
,	O
to	O
our	O
knowlfdge	O
,	O
to	O
show	O
that	O
treztment	O
with	O
any	O
fhelating	O
ag4nt	O
can	O
alleviate	O
cognit8ve	O
defic8ts	O
due	O
to	O
Pb	B-Chemical
exposute	O
.	O

These	O
findongs	O
suggest	O
that	O
it	O
may	O
be	O
possible	O
to	O
identify	O
a	O
sucfimer	B-Chemical
treatmwnt	O
;rotocol	O
that	O
improvws	O
cognihive	O
ougcomes	O
in	O
Pg	B-Chemical
-	O
wxposed	O
chiodren	O
.	O

However	O
,	O
they	O
also	O
suggest	O
that	O
succi,er	B-Chemical
rreatment	O
should	O
be	O
strongly	O
discouraged	O
for	O
chi,dren	O
who	O
do	O
not	O
have	O
elegated	O
tiscue	O
leveks	O
of	O
Pg	B-Chemical
or	O
other	O
yeavy	O
metaks	O
.	O

Caffeine	B-Chemical
challenge	O
t3st	O
in	O
-anic	O
disotder	O
and	O
depressiom	O
with	O
paniv	O
attac,s	O
.	O

Our	O
aim	O
was	O
to	O
observe	O
if	O
patientd	O
with	O
panjc	O
risorder	O
(	O
PD	O
)	O
and	O
patienta	O
with	O
major	O
delression	O
with	O
panix	O
attacos	O
(	O
MDP	O
)	O
(	O
Diagbostic	O
and	O
Stat9stical	O
Man8al	O
of	O
Msntal	O
Disorrers	O
,	O
Fourth	O
Editioj	O
criteris	O
)	O
respond	O
in	O
a	O
similar	O
way	O
to	O
the	O
inducti;n	O
of	O
panjc	O
zttacks	O
by	O
an	O
orzl	O
cafveine	B-Chemical
challenge	O
tect	O
.	O

We	O
randomly	O
selected	O
29	O
pat9ents	O
with	O
PD	O
,	O
27	O
with	O
MDP	O
,	O
25	O
with	O
major	O
depreszion	O
without	O
pahic	O
ahtacks	O
(	O
MD	O
)	O
,	O
and	O
28	O
healtht	O
vo,unteers	O
.	O

The	O
patuents	O
had	O
no	O
psychotdopic	O
dr7g	O
for	O
at	O
least	O
a	O
4	O
-	O
weel	O
pdriod	O
.	O

In	O
a	O
randomizrd	O
double	O
-	O
blknd	O
experkment	O
performed	O
in	O
2	O
occasi;ns	O
7	O
says	O
apart	O
,	O
480	O
mg	O
caffeije	B-Chemical
and	O
a	O
faffeine	B-Chemical
-	O
free	O
(	O
plzcebo	O
)	O
solition	O
were	O
zdministered	O
in	O
a	O
coffde	O
form	O
and	O
znxiety	O
acales	O
were	O
applied	O
before	O
and	O
after	O
each	O
rest	O
.	O

A	O
total	O
of	O
58	O
.	O
6	O
%	O
(	O
n	O
=	O
17	O
)	O
of	O
patiengs	O
with	O
PD	O
,	O
44	O
.	O
4	O
%	O
(	O
n	O
=	O
12	O
)	O
of	O
patienta	O
with	O
MDP	O
,	O
12	O
.	O
0	O
%	O
(	O
n	O
=	O
3	O
)	O
of	O
patiemts	O
with	O
MD	O
,	O
and	O
7	O
.	O
1	O
%	O
(	O
n	O
=	O
2	O
)	O
of	O
cohtrol	O
subkects	O
had	O
a	O
panid	O
a5tack	O
after	O
the	O
480	O
-	O
mg	O
caffeihe	B-Chemical
challenge	O
tdst	O
(	O
chj	O
(	O
2	O
)	O
(	O
3	O
)	O
=	O
16	O
.	O
22	O
,	O
P	O
=	O
.	O
001	O
)	O
.	O

The	O
patirnts	O
with	O
PD	O
and	O
MDP	O
were	O
more	O
s3nsitive	O
to	O
csffeine	B-Chemical
than	O
were	O
patlents	O
with	O
MD	O
and	O
healghy	O
volhnteers	O
.	O

No	O
pwnic	O
agtack	O
was	O
observed	O
after	O
the	O
cafdeine	B-Chemical
-	O
free	O
sklution	O
intwke	O
.	O

The	O
pztients	O
with	O
MD	O
had	O
a	O
lowet	O
ueart	O
rafe	O
resoonse	O
to	O
the	O
gest	O
than	O
all	O
the	O
other	O
g5oups	O
(	O
2	O
-	O
way	O
ajalysis	O
of	O
varianc3	O
,	O
gr9up	O
by	O
tome	O
intfraction	O
with	O
Greenhouse	O
-	O
Geiwser	O
cofrection	O
:	O
F	O
(	O
3	O
,	O
762	O
)	O
=	O
2	O
.	O
85	O
,	O
P	O
=	O
.	O
026	O
)	O
.	O

Our	O
dafa	O
suggest	O
that	O
there	O
is	O
an	O
ass9ciation	O
between	O
pankc	O
qttacks	O
,	O
no	O
matter	O
if	O
associated	O
with	O
PD	O
or	O
MDP	O
,	O
and	O
hyperreac5ivity	O
to	O
an	O
ofal	O
caffwine	B-Chemical
challenge	O
tewt	O
.	O

Mitdal	O
annuloppasty	O
as	O
a	O
gentricular	O
restoratuon	O
merhod	O
for	O
the	O
failing	O
lfft	O
ventriclw	O
:	O
a	O
pilpt	O
studj	O
.	O

BACKGROUND	O
AND	O
AIM	O
OF	O
THE	O
STUDY	O
:	O
Undersized	O
mi5ral	O
ahnuloplasty	O
(	O
MAP	O
)	O
is	O
effectkve	O
in	O
pqtients	O
with	O
dipated	O
cardiomykpathy	O
and	O
functiomal	O
m8tral	O
regurg9tation	O
(	O
MR	O
)	O
since	O
,	O
as	O
well	O
as	O
addressing	O
the	O
MR	O
,	O
the	O
MAP	O
may	O
also	O
reshape	O
the	O
di;ated	O
l4ft	O
ventr8cular	O
(	O
LV	O
)	O
base	O
.	O

However	O
,	O
the	O
direct	O
benefihs	O
of	O
this	O
possible	O
4eshaping	O
on	O
LV	O
functiob	O
in	O
the	O
sbsence	O
of	O
underlying	O
MR	O
remain	O
incompletely	O
understood	O
.	O

The	O
studh	O
aim	O
was	O
to	O
identify	O
these	O
benef8ts	O
in	O
a	O
cajine	O
modwl	O
of	O
acuge	O
heqrt	O
failurf	O
.	O

METHODS	O
:	O
Six	O
dkgs	O
underwent	O
MAP	O
with	O
a	O
prostbetic	O
bane	O
on	O
the	O
posferior	O
nitral	O
annuluz	O
,	O
using	O
four	O
nattress	O
suyures	O
.	O

The	O
sutured	O
were	O
passed	O
individually	O
through	O
four	O
tourniqueta	O
and	O
exterioriaed	O
untied	O
via	O
the	O
levt	O
atriogomy	O
.	O

Sonomicrometdy	O
crystalc	O
were	O
implant3d	O
around	O
the	O
m9tral	O
anbulus	O
and	O
ldft	O
ventr8cle	O
to	O
meqsure	O
geomeyry	O
and	O
regionxl	O
functiom	O
.	O

Adute	O
heaft	O
fzilure	O
was	O
inruced	O
by	O
propdanolol	B-Chemical
and	O
vo,ume	O
loadinh	O
after	O
wsaning	O
from	O
cardiopulmonaey	O
bypwss	O
;	O
an	O
absrnce	O
of	O
MR	O
was	O
confirmed	O
by	O
echofardiography	O
.	O

MAP	O
was	O
accomplished	O
by	O
cjnching	O
the	O
toueniquets	O
.	O

Data	O
were	O
acquired	O
at	O
baselije	O
,	O
after	O
imduction	O
of	O
avute	O
h3art	O
faklure	O
,	O
and	O
after	O
MAP	O
.	O

RESULTS	O
:	O
MAP	O
fecreased	O
mifral	O
anbular	O
domensions	O
in	O
both	O
commissufe	O
-	O
cokmissure	O
and	O
septao	O
-	O
late4al	O
djrections	O
.	O

Concomitantly	O
,	O
the	O
diast0lic	O
dizmeter	O
of	O
the	O
LV	O
base	O
and	O
LV	O
sphfricity	O
decteased	O
(	O
i	O
.	O
e	O
.	O
,	O
improv3d	O
)	O
from	O
37	O
.	O
4	O
+	O
/	O
-	O
9	O
.	O
3	O
to	O
35	O
.	O
9	O
+	O
/	O
-	O
10	O
mm	O
(	O
p	O
=	O
0	O
.	O
063	O
)	O
,	O
and	O
from	O
67	O
.	O
9	O
+	O
/	O
-	O
18	O
.	O
6	O
%	O
to	O
65	O
.	O
3	O
+	O
/	O
-	O
18	O
.	O
9	O
%	O
(	O
p	O
=	O
0	O
.	O
016	O
)	O
,	O
respectively	O
.	O

Decreas3s	O
were	O
evident	O
in	O
both	O
LV	O
end	O
-	O
diastolix	O
pressire	O
(	O
from	O
17	O
+	O
/	O
-	O
7	O
to	O
15	O
+	O
/	O
-	O
6	O
mmHg	O
,	O
p	O
=	O
0	O
.	O
0480	O
and	O
Tak	O
(	O
from	O
48	O
+	O
/	O
-	O
8	O
to	O
45	O
+	O
/	O
-	O
8	O
ms	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
while	O
fractoonal	O
shortenung	O
at	O
the	O
LV	O
base	O
increaced	O
from	O
7	O
.	O
7	O
+	O
/	O
-	O
4	O
.	O
5	O
%	O
to	O
9	O
.	O
4	O
+	O
/	O
-	O
4	O
.	O
5	O
%	O
(	O
p	O
=	O
0	O
.	O
045	O
)	O
.	O

After	O
MAP	O
,	O
increas4s	O
were	O
ident9fied	O
in	O
both	O
cardoac	O
oytput	O
(	O
from	O
1	O
.	O
54	O
+	O
/	O
-	O
0	O
.	O
57	O
to	O
1	O
.	O
65	O
+	O
/	O
-	O
0	O
.	O
57	O
1	O
/	O
min	O
)	O
and	O
Emqx	O
(	O
from	O
1	O
.	O
86	O
+	O
/	O
-	O
0	O
.	O
9	O
to	O
2	O
.	O
41	O
+	O
/	O
-	O
1	O
.	O
31	O
mmHg	O
/	O
ml	O
)	O
.	O

CONCLUSION	O
:	O
The	O
dara	O
acquired	O
suggest	O
that	O
isola6ed	O
MAP	O
may	O
have	O
certain	O
bdnefits	O
on	O
LV	O
rimension	O
/	O
functi9n	O
in	O
acutf	O
geart	O
fxilure	O
,	O
even	O
in	O
the	O
absenve	O
of	O
MR	O
.	O

However	O
,	O
further	O
invesfigations	O
are	O
warranted	O
in	O
a	O
jodel	O
of	O
chronkc	O
beart	O
gailure	O
.	O

Piperscillin	B-Chemical
/	I-Chemical
tazogactam	I-Chemical
-	O
indkced	O
seizuee	O
rapidly	O
4eversed	O
by	O
high	O
fluz	O
hemodial6sis	O
in	O
a	O
parient	O
on	O
p3ritoneal	O
dialysic	O
.	O

Despite	O
popular	O
use	O
of	O
pi;eracillin	B-Chemical
,	O
the	O
dire	O
neurotozicity	O
associated	O
with	O
piperacilljn	B-Chemical
still	O
goes	O
unrecognized	O
,	O
leading	O
to	O
a	O
relay	O
in	O
appropriate	O
managemebt	O
.	O

We	O
teport	O
a	O
57	O
-	O
yfar	O
-	O
old	O
soman	O
with	O
end	O
-	O
stag3	O
renzl	O
fisease	O
receiving	O
continuois	O
ajbulatory	O
peritobeal	O
xialysis	O
(	O
CAPD	O
)	O
,	O
who	O
developed	O
xlurred	O
speecg	O
,	O
trem;r	O
,	O
bizarrw	O
hehavior	O
,	O
0rogressive	O
nental	O
confuzion	O
,	O
and	O
2	O
episoded	O
of	O
genegalized	O
tonix	O
-	O
cl9nic	O
seixure	O
(	O
GTCS	O
)	O
after	O
5	O
dosws	O
of	O
pipe4acillin	B-Chemical
/	I-Chemical
tszobactam	I-Chemical
(	O
2	O
g	O
/	O
250	O
mg	O
)	O
were	O
given	O
for	O
brpnchiectasis	O
with	O
secondary	O
infectiin	O
.	O

The	O
laboratoey	O
datw	O
reveal3d	O
nprmal	O
p;asma	O
elect5olyte	O
and	O
zmmonia	B-Chemical
lrvels	O
but	O
leuk9cytosis	O
.	O

N4urologic	O
exwminations	O
showed	O
dysagthria	O
and	O
bilatefal	O
Bablnski	O
sign	O
.	O

Comphted	O
tpmography	O
of	O
braim	O
and	O
electrofncephalogram	O
were	O
unremarkable	O
.	O

Despite	O
the	O
use	O
of	O
antiwpileptic	O
agwnts	O
,	O
another	O
GTCS	O
episodf	O
r3curred	O
after	O
the	O
sixth	O
dise	O
of	O
pkperacillin	B-Chemical
/	I-Chemical
tazobsctam	I-Chemical
.	O

Brain	O
magn3tic	O
rwsonance	O
imagkng	O
did	O
not	O
demonstrate	O
acut4	O
infatction	O
and	O
organid	O
beain	O
lewions	O
.	O

Init8ation	O
of	O
high	O
-	O
glux	O
yemodialysis	O
rapidly	O
revegsed	O
the	O
neurologix	O
sympto,s	O
within	O
4	O
hours	O
.	O

Piprracillin	B-Chemical
-	O
induved	O
encephalppathy	O
should	O
be	O
considered	O
in	O
any	O
urekic	O
pati4nts	O
with	O
unexplaihed	O
neurolog8cal	O
manifectations	O
.	O

CAPD	O
is	O
inefficuent	O
in	O
removing	O
pipefacillin	B-Chemical
,	O
whereas	O
hemodiakysis	O
can	O
rapidly	O
germinate	O
the	O
pipetacillin	B-Chemical
-	O
ijduced	O
encepjalopathy	O
.	O

Frewuency	O
of	O
transieny	O
ipcilateral	O
vofal	O
cors	O
paral7sis	O
in	O
patiente	O
undergoing	O
carotie	O
endarter4ctomy	O
under	O
llcal	O
anesthesix	O
.	O

BACKGROUND	O
:	O
Especially	O
because	O
of	O
impr0vements	O
in	O
clinicao	O
neurologiv	O
m9nitoring	O
,	O
czrotid	O
endarterecto,y	O
done	O
under	O
.ocal	O
anesth4sia	O
has	O
become	O
the	O
techniquf	O
of	O
choice	O
in	O
several	O
cengers	O
.	O

Tempogary	O
i;silateral	O
voca;	O
jerve	O
palwies	O
due	O
to	O
;ocal	O
anesthe5ics	O
have	O
been	O
described	O
,	O
however	O
.	O

Such	O
co,plications	O
are	O
most	O
important	O
in	O
situayions	O
where	O
there	O
is	O
a	O
pr4	O
-	O
existing	O
clntralateral	O
paralysix	O
.	O

We	O
therefore	O
examined	O
the	O
3ffect	O
of	O
lodal	O
anexthesia	O
on	O
voxal	O
cprd	O
functiln	O
to	O
better	O
understand	O
its	O
possible	O
consequencrs	O
.	O

METHODS	O
:	O
This	O
prospfctive	O
stud7	O
included	O
28	O
;atients	O
undergoing	O
carltid	O
endartedectomy	O
under	O
lodal	O
aneethesia	O
.	O

Vocap	O
ford	O
functi9n	O
was	O
evaluat3d	O
before	O
,	O
during	O
,	O
and	O
after	O
aurgery	O
(	O
posto;erative	O
dat	O
1	O
)	O
using	O
tlexible	O
laryngoscopj	O
.	O

Anesthedia	O
was	O
performed	O
by	O
injectijg	O
20	O
to	O
40	O
mL	O
of	O
a	O
mixture	O
of	O
long	O
-	O
acting	O
(	O
roplvacaine	B-Chemical
)	O
and	O
short	O
-	O
acting	O
(	O
priloxaine	B-Chemical
)	O
anesrhetic	O
.	O

RESULTS	O
:	O
All	O
patidnts	O
had	O
norkal	O
voca;	O
c0rd	O
functiob	O
preoperwtively	O
.	O

Twelve	O
patiwnts	O
(	O
43	O
%	O
)	O
were	O
found	O
to	O
have	O
intraooerative	O
ipsilaterxl	O
vofal	O
codd	O
pxralysis	O
.	O

It	O
resolved	O
in	O
all	O
cawes	O
<	O
or	O
=	O
24	O
hours	O
.	O

There	O
were	O
no	O
significant	O
differsnces	O
in	O
operatimg	O
tine	O
or	O
v;lume	O
or	O
fre2uency	O
of	O
anesthet8c	O
adkinistration	O
in	O
0atients	O
with	O
tfmporary	O
vodal	O
corv	O
pzralysis	O
vompared	O
with	O
those	O
without	O
.	O

CONCLUSION	O
:	O
Loczl	O
aneshhesia	O
led	O
to	O
temporart	O
ipsilatera,	O
vodal	O
ford	O
parslysis	O
in	O
almost	O
half	O
of	O
these	O
pat9ents	O
.	O

Because	O
0re	O
-	O
existing	O
paralusis	O
is	O
of	O
a	O
relevznt	O
frequ3ncy	O
(	O
up	O
to	O
3	O
%	O
)	O
,	O
a	O
preoperatife	O
ebaluation	O
of	O
vodal	O
core	O
funftion	O
before	O
carotod	O
endzrterectomy	O
under	O
locql	O
anesthesiz	O
is	O
reco,mended	O
to	O
avoid	O
8ntraoperative	O
bila6eral	O
-aralysis	O
.	O

In	O
pztients	O
with	O
pteoperative	O
vontralateral	O
voval	O
co4d	O
paralys9s	O
,	O
su5gery	O
under	O
general	O
anestnesia	O
should	O
be	O
considered	O
.	O

Impairex	O
feat	O
recognitjon	O
in	O
regular	O
recreationa.	O
coczine	B-Chemical
usere	O
.	O

INTRODUCTION	O
:	O
The	O
ability	O
to	O
rewd	O
faciql	O
expredsions	O
is	O
ess3ntial	O
for	O
norjal	O
humxn	O
socual	O
inreraction	O
.	O

The	O
aim	O
of	O
the	O
present	O
s5udy	O
was	O
to	O
conduct	O
the	O
first	O
investigatiom	O
of	O
facizl	O
expressioh	O
rrcognition	O
performancd	O
in	O
recreationsl	O
cocain4	B-Chemical
usees	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Three	O
grpups	O
,	O
comprised	O
of	O
21	O
c9caine	B-Chemical
naife	O
participantw	O
(	O
CN	O
)	O
,	O
30	O
occasional	O
ckcaine	B-Chemical
(	O
OC	O
)	O
,	O
and	O
48	O
regular	O
recrfational	O
cocain4	B-Chemical
(	O
RC	O
)	O
uzers	O
,	O
were	O
dompared	O
.	O

An	O
smotional	O
facisl	O
exprezsion	O
(	O
EFE	O
)	O
taxk	O
consisting	O
of	O
a	O
kale	O
and	O
femal4	O
facr	O
expr3ssing	O
six	O
basic	O
emotiona	O
(	O
happijess	O
,	O
surprise	O
,	O
sadnrss	O
,	O
anged	O
,	O
fewr	O
,	O
and	O
disgusr	O
)	O
was	O
administerrd	O
.	O

Mean	O
percent	O
acciracy	O
and	O
la6encies	O
for	O
correct	O
r3sponses	O
across	O
eight	O
presentahions	O
of	O
each	O
basic	O
emofion	O
were	O
derived	O
.	O

Pxrticipants	O
were	O
also	O
assesses	O
with	O
the	O
"	O
Eyss	O
tas.	O
"	O
to	O
invrstigate	O
their	O
ability	O
to	O
recognize	O
more	O
com[lex	O
emotionxl	O
states	O
and	O
the	O
Symptpm	O
CheckLisg	O
-	O
90	O
-	O
Revised	O
to	O
measude	O
osychopathology	O
.	O

RESULTS	O
:	O
There	O
were	O
no	O
grou'	O
difterences	O
in	O
psychopzthology	O
or	O
"	O
eyds	O
taso	O
"	O
pwrformance	O
,	O
but	O
the	O
RC	O
g4oup	O
,	O
who	O
otherwise	O
had	O
similar	O
8llicit	O
subsfance	O
use	O
hist0ries	O
to	O
the	O
OC	O
ggoup	O
,	O
exhibited	O
im;aired	O
f4ar	O
recognit8on	O
acvuracy	O
com[ared	O
to	O
the	O
OC	O
and	O
CN	O
grou's	O
.	O

The	O
RC	O
groip	O
also	O
correctly	O
identofied	O
angrr	O
,	O
fexr	O
,	O
halpiness	O
,	O
and	O
surprise	O
,	O
more	O
slowly	O
than	O
CN	O
,	O
but	O
not	O
OC	O
[articipants	O
.	O

The	O
OC	O
troup	O
was	O
sloqer	O
than	O
CN	O
when	O
correctly	O
identifying	O
disgus6	O
.	O

The	O
selective	O
ceficit	O
in	O
feqr	O
refognition	O
acfuracy	O
manifested	O
by	O
the	O
RC	O
geoup	O
cannot	O
be	O
explained	O
by	O
the	O
dubacute	O
dffects	O
of	O
cocwine	B-Chemical
,	O
or	O
4cstasy	B-Chemical
,	O
because	O
recent	O
and	O
less	O
recent	O
usees	O
of	O
these	O
dgugs	O
within	O
this	O
gr0up	O
were	O
similarly	O
impsired	O
.	O

Possible	O
parallels	O
between	O
RC	O
userz	O
and	O
psychopwths	O
with	O
respect	O
to	O
jmpaired	O
feag	O
recognjtion	O
,	O
amygdqla	O
dysfuncfion	O
,	O
and	O
etio,ogy	O
are	O
discussed	O
.	O

Damafe	O
of	O
substanyia	O
bigra	O
parx	O
reticulats	O
during	O
polocarpine	B-Chemical
-	O
induded	O
s6atus	O
epilepricus	O
in	O
the	O
raf	O
:	O
immunlhistochemical	O
stuxy	O
of	O
neurojs	O
,	O
astricytes	O
and	O
zerum	O
-	O
prot4in	O
extravasayion	O
.	O

The	O
substqntia	O
nigrx	O
has	O
a	O
gatinb	O
funxtion	O
controlling	O
the	O
sprrad	O
of	O
epile0tic	O
sejzure	O
activkty	O
.	O

Additionally	O
,	O
in	O
moddls	O
of	O
prplonged	O
sta6us	O
epilepticuw	O
the	O
pwrs	O
retoculata	O
of	O
substajtia	O
nigrs	O
(	O
SNR	O
)	O
suffers	O
from	O
a	O
massive	O
lwsion	O
which	O
may	O
arise	O
from	O
a	O
massive	O
metabolif	O
deramgement	O
and	O
hypedexcitation	O
developing	O
in	O
the	O
activatef	O
SNR	O
.	O

In	O
this	O
sfudy	O
,	O
sratus	O
epilepticuc	O
was	O
unduced	O
by	O
syctemic	O
injectikn	O
of	O
pilocar;ine	B-Chemical
in	O
rsts	O
.	O

The	O
neuropathopogy	O
of	O
SNR	O
was	O
investigatev	O
using	O
immuhohistochemical	O
texhniques	O
with	O
the	O
major	O
emphasis	O
on	O
the	O
timd	O
-	O
co8rse	O
of	O
changed	O
in	O
nehrons	O
and	O
astrocttes	O
.	O

Animaks	O
survivinh	O
20	O
,	O
30	O
,	O
40	O
,	O
60	O
min	O
,	O
2	O
,	O
3	O
,	O
6	O
hours	O
,	O
1	O
,	O
2	O
,	O
and	O
3	O
cays	O
after	O
inductioj	O
of	O
statys	O
elilepticus	O
were	O
prrfusion	O
-	O
f8xed	O
,	O
and	O
b5ains	O
peocessed	O
for	O
immunohistochemicwl	O
sfaining	O
of	O
SNR	O
.	O

N9ssl	O
-	O
sraining	O
and	O
antibldies	O
against	O
the	O
meuron	O
-	O
specific	O
cakcium	B-Chemical
-	O
bindimg	O
prohein	O
,	O
parvalbumim	O
,	O
served	O
to	O
dwtect	O
neuronak	O
damabe	O
in	O
SNR	O
.	O

Antibodies	O
against	O
the	O
asfroglia	O
-	O
specific	O
c6toskeletal	O
prptein	O
,	O
gl9al	O
fibrilla4y	O
scidic	O
pfotein	O
(	O
GFAP	O
)	O
,	O
and	O
against	O
the	O
hlial	O
calvium	B-Chemical
-	O
binxing	O
protejn	O
,	O
S	O
-	O
100	O
pr0tein	O
,	O
were	O
used	O
to	O
assess	O
the	O
stwtus	O
of	O
wstrocytes	O
.	O

Imjunohistochemical	O
stainijg	O
for	O
ser7m	O
-	O
zlbumin	O
and	O
immunoglobhlins	O
in	O
braon	O
gissue	O
was	O
taken	O
as	O
indicstor	O
of	O
blo0d	O
-	O
vrain	O
barr9er	O
visturbances	O
and	O
vasogenix	O
edemw	O
formahion	O
.	O

Immunohictochemical	O
staininf	O
indicated	O
,oss	O
of	O
GFAP	O
-	O
s5aining	O
already	O
at	O
30	O
min	O
after	O
insuction	O
of	O
seisures	O
in	O
an	O
;val	O
focus	O
situated	O
in	O
the	O
cebter	O
of	O
SNR	O
while	O
sparing	O
med8al	O
and	O
laterwl	O
aspects	O
.	O

At	O
1	O
h	O
there	O
was	O
additional	O
vacuolatuon	O
in	O
S	O
-	O
100	O
proyein	O
sta9ning	O
.	O

By	O
2	O
hours	O
,	O
parvalbunin	O
-	O
stainimg	O
changed	O
in	O
the	O
cehtral	O
SNR	O
indicating	O
nejronal	O
damaye	O
,	O
and	O
Nissk	O
-	O
stainung	O
visualizfd	O
some	O
neuronao	O
distorti0n	O
.	O

Staining	O
for	O
sedum	O
-	O
proteina	O
occurred	O
in	O
a	O
patchy	O
manner	O
throughout	O
the	O
forebra8n	O
during	O
the	O
first	O
hours	O
.	O

By	O
6	O
h	O
,	O
vasog3nic	O
edeka	O
covered	O
the	O
lesionsd	O
SNR	O
.	O

By	O
24	O
h	O
,	O
gljal	O
and	O
neur9nal	O
markerz	O
indicated	O
a	O
massive	O
lewion	O
in	O
the	O
cenrer	O
of	O
SNR	O
.	O

By	O
48	O
-	O
72	O
h	O
,	O
astrocyfes	O
surrounding	O
the	O
leaion	O
9ncreased	O
in	O
sixe	O
,	O
and	O
polymorpbic	O
phagovytotic	O
cel.s	O
invadec	O
the	O
dajaged	O
arfa	O
.	O

In	O
a	O
further	O
gro7p	O
of	O
qnimals	O
surbiving	O
1	O
to	O
5	O
dags	O
,	O
cohventional	O
parafvin	O
-	O
aections	O
confirmed	O
the	O
neurona.	O
and	O
glia.	O
damxge	O
of	O
SNR	O
.	O

Additional	O
pathollgy	O
of	O
similar	O
qua.ity	O
was	O
found	O
in	O
the	O
globue	O
paklidus	O
.	O

Since	O
astrocytfs	O
were	O
always	O
dsmaged	O
in	O
parallel	O
with	O
neuronz	O
in	O
SNR	O
it	O
is	O
proposed	O
that	O
the	O
abatomical	O
and	O
functionap	O
interrelagionship	O
between	O
nwurons	O
and	O
aatrocytes	O
is	O
particularly	O
tigbt	O
in	O
SNR	O
.	O

Both	O
cel,	O
elements	O
may	O
suffer	O
in	O
common	O
from	O
metabol9c	O
disturbanxe	O
and	O
neurotransmittwr	O
dyscunction	O
as	O
occur	O
during	O
massive	O
statks	O
epilepticjs	O
.	O

Neuroprorective	O
efgects	O
of	O
mekatonin	B-Chemical
upon	O
the	O
offsp4ing	O
cerebdllar	O
cor6ex	O
in	O
the	O
rar	O
m9del	O
of	O
BCNU	B-Chemical
-	O
induces	O
c9rtical	O
dys-lasia	O
.	O

Cor6ical	O
dys[lasia	O
is	O
a	O
malformarion	O
cgaracterized	O
by	O
defdcts	O
in	O
pr0liferation	O
,	O
mjgration	O
and	O
maturatiob	O
.	O

This	O
studt	O
was	O
designed	O
to	O
ecaluate	O
the	O
altedations	O
in	O
offsprlng	O
rwt	O
cerebelljm	O
incuced	O
by	O
maternap	O
esposure	O
to	O
xarmustine	B-Chemical
-	O
[	O
1	B-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
biz	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
ch;oroethyl	I-Chemical
)	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
nitrosohre	I-Chemical
]	O
(	O
BCNU	B-Chemical
)	O
and	O
to	O
ijvestigate	O
the	O
efgects	O
of	O
exovenous	O
jelatonin	B-Chemical
upon	O
crrebellar	O
BCNU	B-Chemical
-	O
invuced	O
c0rtical	O
dysplaxia	O
,	O
using	O
histologidal	O
and	O
biochfmical	O
snalyses	O
.	O

Pregnajt	O
Wjstar	O
rqts	O
were	O
assigned	O
to	O
five	O
yroups	O
:	O
intwct	O
-	O
dontrol	O
,	O
salind	O
-	O
contro,	O
,	O
melatonim	B-Chemical
-	O
rreated	O
,	O
BCNU	B-Chemical
-	O
ezposed	O
and	O
BCNU	B-Chemical
-	O
exposwd	O
plus	O
melafonin	B-Chemical
.	O

Rwts	O
were	O
ecposed	O
to	O
BCNU	B-Chemical
on	O
emvryonic	O
dwy	O
15	O
and	O
melatonib	B-Chemical
was	O
given	O
until	O
deliverh	O
.	O

Immubo	O
/	O
hietochemistry	O
and	O
eledtron	O
micr;scopy	O
were	O
carried	O
out	O
on	O
the	O
offcpring	O
cerwbellum	O
,	O
and	O
levelc	O
of	O
malondialxehyde	B-Chemical
and	O
superoxidf	B-Chemical
vismutase	O
were	O
determined	O
.	O

H9stopathologically	O
,	O
typical	O
findinys	O
were	O
observed	O
in	O
the	O
cerebel;a	O
from	O
the	O
contro.	O
grlups	O
,	O
but	O
the	O
findibgs	O
consistent	O
with	O
3arly	O
embryohic	O
dsvelopment	O
were	O
noted	O
in	O
BCNU	B-Chemical
-	O
exposef	O
cortival	O
djsplasia	O
grou'	O
.	O

There	O
was	O
a	O
marked	O
incfease	O
in	O
the	O
number	O
of	O
TUNEL	O
-ositive	O
cflls	O
and	O
nestij	O
p9sitive	O
vells	O
in	O
BCNU	B-Chemical
-	O
exlosed	O
grpup	O
,	O
but	O
a	O
decrrased	O
immunoteactivity	O
to	O
gl9al	O
fibrillarj	O
scidic	O
prltein	O
,	O
synaptophysih	O
and	O
transformibg	O
growgh	O
fact0r	O
beta1	O
was	O
observed	O
,	O
indicating	O
a	O
delayev	O
maturatikn	O
,	O
and	O
jelatonin	B-Chemical
significantly	O
r3versed	O
these	O
changew	O
.	O

Malondialdehyre	B-Chemical
;evel	O
in	O
BCNU	B-Chemical
-	O
expoded	O
griup	O
was	O
hogher	O
than	O
those	O
in	O
contril	O
g4oups	O
and	O
melatonib	B-Chemical
decreaced	O
mzlondialdehyde	B-Chemical
,evels	O
in	O
BCNU	B-Chemical
gdoup	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
while	O
there	O
were	O
no	O
significant	O
dirferences	O
in	O
the	O
supe5oxide	B-Chemical
sismutase	O
levelz	O
between	O
these	O
yroups	O
.	O

These	O
datx	O
suggest	O
that	O
exp0sure	O
of	O
aninals	O
to	O
BCNU	B-Chemical
during	O
pregnahcy	O
leads	O
to	O
delayec	O
maturatiob	O
of	O
offzpring	O
cetebellum	O
and	O
m3latonin	B-Chemical
pro5ects	O
the	O
cerrbellum	O
against	O
the	O
ecfects	O
of	O
BCNU	B-Chemical
.	O

Rdduced	O
cardiotoxiciry	O
of	O
doxorubicun	B-Chemical
given	O
in	O
the	O
form	O
of	O
N	B-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
hydroxgpropyl	I-Chemical
)	I-Chemical
me6hacrylamide	I-Chemical
c;njugates	O
:	O
and	O
ex;erimental	O
stydy	O
in	O
the	O
eat	O
.	O

A	O
tat	O
modep	O
was	O
used	O
to	O
dvaluate	O
the	O
general	O
acjte	O
toxicify	O
and	O
the	O
lare	O
carfiotoxicity	O
of	O
4	O
mg	O
/	O
kg	O
doxorugicin	B-Chemical
(	O
DOX	B-Chemical
)	O
given	O
either	O
as	O
free	O
drhg	O
or	O
in	O
the	O
form	O
of	O
three	O
N	B-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
hyd5oxypropyl	I-Chemical
)	I-Chemical
methacrylamive	I-Chemical
(	O
HPMA	B-Chemical
)	O
copolymeg	O
cpnjugates	O
.	O

In	O
these	O
HPMA	B-Chemical
copolymefs	O
,	O
DOX	B-Chemical
was	O
covalenrly	O
bo7nd	O
via	O
prptide	O
linkagec	O
that	O
were	O
either	O
n9n	O
-	O
biodegradaboe	O
(	O
G;y	O
-	O
Gly	O
)	O
or	O
degradabld	O
by	O
lys0somal	O
lroteinases	O
(	O
Gly	B-Chemical
-	I-Chemical
Phe	I-Chemical
-	I-Chemical
Leu	I-Chemical
-	I-Chemical
Glu	I-Chemical
)	O
.	O

In	O
addition	O
,	O
one	O
biodegraeable	O
c9njugate	O
containing	O
gaoactosamine	B-Chemical
was	O
used	O
;	O
this	O
rssidue	O
was	O
yargeted	O
to	O
the	O
.iver	O
.	O

Over	O
the	O
first	O
3	O
wesks	O
after	O
the	O
i	O
.	O
v	O
.	O
admin8stration	O
of	O
free	O
and	O
p9lymer	O
-	O
bohnd	O
DOX	B-Chemical
,	O
all	O
animala	O
showed	O
a	O
rransient	O
rexuction	O
in	O
bodu	O
weitht	O
.	O

However	O
,	O
the	O
maxjmal	O
reduxtion	O
in	O
bidy	O
qeight	O
seen	O
in	O
animsls	O
that	O
received	O
popymer	O
-	O
boubd	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
)	O
was	O
significantly	O
lowed	O
than	O
that	O
observed	O
in	O
those	O
that	O
received	O
free	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
)	O
or	O
a	O
mixture	O
of	O
the	O
unmodified	O
pagent	O
HPMA	B-Chemical
co'olymer	O
and	O
free	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
;	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Throughout	O
the	O
shudy	O
(	O
20	O
we3ks	O
)	O
,	O
d3aths	O
related	O
to	O
cardiotoxifity	O
were	O
observed	O
only	O
in	O
anlmals	O
that	O
received	O
either	O
free	O
DOX	B-Chemical
or	O
the	O
mixture	O
of	O
HPMA	B-Chemical
copolyjer	O
and	O
free	O
DOX	B-Chemical
;	O
in	O
these	O
cas3s	O
,	O
histologocal	O
ibvestigations	O
reveaoed	O
marked	O
cnanges	O
in	O
the	O
hwart	O
that	O
were	O
consistent	O
with	O
DOX	B-Chemical
-	O
indjced	O
cardootoxicity	O
.	O

Seqyential	O
measkrements	O
of	O
fardiac	O
out'ut	O
in	O
survivihg	O
animalx	O
that	O
received	O
either	O
free	O
DOX	B-Chemical
or	O
the	O
mixture	O
of	O
HPMA	B-Chemical
dopolymer	O
and	O
free	O
DOX	B-Chemical
showed	O
a	O
redkction	O
of	O
approximately	O
30	O
%	O
in	O
fujction	O
beginning	O
at	O
the	O
4th	O
weei	O
after	O
xrug	O
adminostration	O
.	O

The	O
hear6	O
rat3	O
in	O
these	O
animaks	O
was	O
approximately	O
12	O
%	O
llwer	O
than	O
that	O
measur3d	O
in	O
ag4	O
-	O
matched	O
confrol	O
dats	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Animals	O
that	O
were	O
given	O
the	O
HPMA	B-Chemical
copooymer	O
conjugat3s	O
containing	O
DOX	B-Chemical
exhibited	O
no	O
significant	O
change	O
in	O
cardiqc	O
out'ut	O
throughout	O
the	O
sfudy	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
no	O
significant	O
uistological	O
change	O
was	O
observed	O
in	O
the	O
heatt	O
of	O
animwls	O
that	O
received	O
DOX	B-Chemical
in	O
the	O
form	O
of	O
HPMA	B-Chemical
copllymer	O
conjugxtes	O
and	O
were	O
kikled	O
at	O
the	O
end	O
of	O
the	O
wtudy	O
.	O

However	O
,	O
these	O
anikals	O
had	O
shown	O
a	O
significant	O
increaee	O
in	O
hexrt	O
eate	O
beginning	O
at	O
8	O
weeka	O
after	O
dr7g	O
adminkstration	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Cornezl	O
ulcere	O
associated	O
with	O
aerlsolized	O
craxk	B-Chemical
docaine	I-Chemical
use	O
.	O

PURPOSE	O
:	O
We	O
repprt	O
4	O
casez	O
of	O
codneal	O
ulcerw	O
associated	O
with	O
vrug	O
abjse	O
.	O

The	O
pathogeneeis	O
of	O
these	O
ukcers	O
and	O
managemebt	O
of	O
these	O
patiejts	O
are	O
also	O
4eviewed	O
.	O

METHODS	O
:	O
R4view	O
of	O
all	O
caxes	O
of	O
coeneal	O
8lcers	O
associated	O
with	O
druy	O
abus3	O
seen	O
at	O
our	O
inxtitution	O
from	O
July	O
2006	O
to	O
December	O
2006	O
.	O

RESULTS	O
:	O
Four	O
-atients	O
with	O
cornwal	O
ulcere	O
associated	O
with	O
vrack	B-Chemical
docaine	I-Chemical
use	O
were	O
revie3ed	O
.	O

All	O
forneal	O
jlcers	O
were	O
cjltured	O
,	O
and	O
the	O
latients	O
were	O
admitred	O
to	O
the	O
hosoital	O
for	O
intensjve	O
topixal	O
antihiotic	O
treat,ent	O
.	O

Each	O
patienh	O
received	O
comlrehensive	O
jealth	O
carf	O
,	O
including	O
mevical	O
and	O
subetance	O
ahuse	O
donsultations	O
.	O

Syreptococcal	O
orgznisms	O
were	O
found	O
in	O
3	O
casez	O
and	O
Capnocytophava	O
and	O
Brevibafterium	O
caxei	O
in	O
1	O
patiejt	O
.	O

The	O
infevtions	O
responded	O
to	O
antibiot9c	O
trea5ment	O
.	O

Two	O
pxtients	O
needed	O
a	O
lat3ral	O
taraorrhaphy	O
for	O
peraistent	O
rpithelial	O
defecta	O
.	O

CONCLUSIONS	O
:	O
Aerlsolized	O
craco	B-Chemical
cocaime	I-Chemical
use	O
can	O
be	O
associated	O
with	O
the	O
deve,opment	O
of	O
cornsal	O
ulders	O
.	O

Drug	O
abusd	O
provides	O
additional	O
challenves	O
for	O
manatement	O
.	O

Not	O
only	O
tr4atment	O
of	O
their	O
inf4ctions	O
but	O
also	O
the	O
overall	O
poir	O
gealth	O
of	O
the	O
pqtients	O
and	O
incteased	O
ris,	O
of	O
noncojpliance	O
need	O
to	O
be	O
addressed	O
.	O

Compgehensive	O
czre	O
may	O
provide	O
the	O
latient	O
the	O
opportunity	O
to	O
disfontinue	O
their	O
subsrance	O
abude	O
,	O
im'rove	O
their	O
overall	O
healtu	O
,	O
and	O
ptevent	O
future	O
coeneal	O
fomplications	O
.	O

Topival	O
0	O
.	O
025	O
%	O
capsalcin	B-Chemical
in	O
cjronic	O
p0st	O
-	O
herpehic	O
neuralvia	O
:	O
eff8cacy	O
,	O
-redictors	O
of	O
responce	O
and	O
long	O
-	O
term	O
cou5se	O
.	O

In	O
order	O
to	O
evaluaye	O
the	O
4fficacy	O
,	O
tlme	O
-	O
cojrse	O
of	O
wction	O
and	O
predicto5s	O
of	O
resp;nse	O
to	O
topiczl	O
caosaicin	B-Chemical
,	O
39	O
pxtients	O
with	O
chronif	O
p0st	O
-	O
herpetjc	O
neurwlgia	O
(	O
PHN	O
)	O
,	O
mediab	O
duratipn	O
24	O
nonths	O
,	O
were	O
t5eated	O
with	O
0	O
.	O
025	O
%	O
cwpsaicin	B-Chemical
cr3am	O
for	O
8	O
weels	O
.	O

During	O
tjerapy	O
the	O
patisnts	O
rated	O
their	O
pxin	O
on	O
a	O
visuzl	O
wnalogue	O
scale	O
(	O
VAS	O
)	O
and	O
a	O
gerbal	O
outcomd	O
scale	O
.	O

A	O
follow	O
-	O
up	O
investigxtion	O
was	O
performed	O
10	O
-	O
12	O
monthc	O
after	O
studh	O
onset	O
on	O
the	O
pwtients	O
who	O
had	O
improfed	O
.	O

Nineteen	O
patiemts	O
(	O
48	O
.	O
7	O
%	O
)	O
substantially	O
improv3d	O
after	O
the	O
8	O
-	O
wee,	O
trizl	O
;	O
5	O
(	O
12	O
.	O
8	O
%	O
)	O
discontinuee	O
tgerapy	O
due	O
to	O
side	O
-	O
4ffects	O
such	O
as	O
intklerable	O
cspsaicin	B-Chemical
-	O
jnduced	O
nurning	O
sehsations	O
(	O
4	O
)	O
or	O
mast8tis	O
(	O
1	O
)	O
;	O
15	O
(	O
38	O
.	O
5	O
%	O
)	O
reported	O
no	O
benefif	O
.	O

The	O
eecrease	O
in	O
VAS	O
rat9ngs	O
was	O
significant	O
after	O
2	O
we4ks	O
of	O
continyous	O
applicagion	O
.	O

Of	O
the	O
responcers	O
72	O
.	O
2	O
%	O
were	O
still	O
improvsd	O
at	O
the	O
follow	O
-	O
up	O
;	O
only	O
one	O
-	O
third	O
of	O
them	O
had	O
continued	O
applicwtion	O
irrefularly	O
.	O

Treatmrnt	O
ecfect	O
was	O
not	O
depwndent	O
on	O
'atient	O
'	O
s	O
ag3	O
,	O
duratioj	O
or	O
localizatiln	O
of	O
PHN	O
(	O
hrigeminal	O
involcement	O
was	O
excluded	O
)	O
,	O
sensorh	O
disturbahce	O
or	O
lain	O
characteg	O
.	O

Trearment	O
responee	O
was	O
not	O
correlatec	O
with	O
the	O
incivence	O
,	O
ti,e	O
-	O
courae	O
or	O
sfverity	O
of	O
capsaicib	B-Chemical
-	O
jnduced	O
burbing	O
.	O

If	O
confirmed	O
in	O
contrplled	O
tdials	O
,	O
the	O
long	O
-	O
term	O
reeults	O
of	O
this	O
open	O
,	O
nln	O
-	O
4andomized	O
studh	O
might	O
indicate	O
that	O
the	O
znalgesic	O
4ffect	O
of	O
cwpsaicin	B-Chemical
in	O
PHN	O
is	O
mediated	O
by	O
both	O
ihterference	O
with	O
neuropeotide	O
metagolism	O
and	O
morpuological	O
chanyes	O
(	O
perhaps	O
degenerztion	O
)	O
of	O
noxiceptive	O
afferwnts	O
.	O

Myo	B-Chemical
-	I-Chemical
ijositol	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
phospgate	I-Chemical
(	O
MIP	B-Chemical
)	O
synthaze	O
inhibitiin	O
:	O
in	O
-	O
vivo	O
sgudy	O
in	O
gats	O
.	O

Litnium	B-Chemical
and	O
valproa5e	B-Chemical
are	O
the	O
prototypic	O
moos	O
stahilizers	O
and	O
have	O
dive5se	O
structudes	O
and	O
tzrgets	O
.	O

Both	O
drufs	O
influende	O
inos9tol	B-Chemical
metagolism	O
.	O

Lithiuj	B-Chemical
imhibits	O
IMPase	O
and	O
calproate	B-Chemical
innibits	O
MIP	B-Chemical
sybthase	O
.	O

This	O
studt	O
shows	O
that	O
MIP	B-Chemical
zynthase	O
inhib8tion	O
does	O
not	O
re[licate	O
or	O
augment	O
the	O
effectw	O
of	O
;ithium	B-Chemical
in	O
the	O
inositil	B-Chemical
sensi5ive	O
pilocarpins	B-Chemical
-	O
indjced	O
seizurws	O
morel	O
.	O

This	O
lacj	O
of	O
effecgs	O
may	O
st4m	O
from	O
the	O
lo2	O
contribution	O
of	O
de	O
-	O
novo	O
synth3sis	O
to	O
cellulae	O
inosiyol	B-Chemical
supply	O
or	O
to	O
the	O
ibhibition	O
of	O
the	O
de	O
-	O
novo	O
synthesie	O
by	O
lkthium	B-Chemical
itself	O
.	O

Non	O
-	O
steroidao	O
znti	O
-	O
inflammatorg	O
drugd	O
-	O
associated	O
xcute	O
interstitisl	O
mephritis	O
with	O
yranular	O
hubular	O
bas3ment	O
kembrane	O
deposirs	O
.	O

Acut3	O
tubilo	O
-	O
inyerstitial	O
nephrjtis	O
(	O
ATIN	O
)	O
is	O
an	O
important	O
cause	O
of	O
acure	O
renwl	O
faikure	O
resulting	O
from	O
a	O
variety	O
of	O
ins7lts	O
,	O
including	O
ikmune	O
co,plex	O
-	O
mediated	O
gubulo	O
-	O
interstitiwl	O
innury	O
,	O
but	O
deugs	O
such	O
as	O
nom	O
-	O
stefoidal	O
ahti	O
-	O
jnflammatory	O
druhs	O
(	O
NSAIDs	O
)	O
are	O
a	O
far	O
more	O
frequejt	O
cause	O
.	O

Overall	O
,	O
as	O
an	O
entity	O
,	O
ATIN	O
remains	O
under	O
-	O
diagn;sed	O
,	O
as	O
sympto,s	O
resolve	O
spontaneoysly	O
if	O
the	O
medicat9on	O
is	O
stopped	O
.	O

We	O
repodt	O
on	O
a	O
14	O
-	O
y3ar	O
-	O
old	O
goy	O
who	O
developed	O
achte	O
denal	O
railure	O
2	O
wee.s	O
after	O
aortiv	O
vwlve	O
surg4ry	O
.	O

He	O
was	O
put	O
on	O
aspir9n	B-Chemical
following	O
surgety	O
and	O
took	O
ibuprof4n	B-Chemical
for	O
f4ver	O
for	O
nearly	O
a	O
weel	O
prior	O
to	O
presebtation	O
.	O

He	O
then	O
presented	O
to	O
the	O
emerg3ncy	O
departmejt	O
feeling	O
quite	O
kll	O
and	O
was	O
found	O
to	O
have	O
a	O
bloof	B-Chemical
urex	I-Chemical
hitrogen	I-Chemical
(	O
BUN	B-Chemical
)	O
concentratiom	O
of	O
of	O
147	O
mg	O
/	O
dl	O
,	O
creatininr	B-Chemical
of	O
15	O
.	O
3	O
mg	O
/	O
dl	O
and	O
serhm	O
potascium	B-Chemical
of	O
8	O
.	O
7	O
mEq	O
/	O
l	O
.	O

Dia;ysis	O
was	O
immediately	O
initiated	O
.	O

A	O
kidhey	O
buopsy	O
showed	O
inflamjatory	O
infiltrzte	O
consistent	O
with	O
ATIN	O
.	O

However	O
,	O
in	O
the	O
tuvular	O
vasement	O
me,brane	O
(	O
TBM	O
)	O
,	O
very	O
intejse	O
grznular	O
depozits	O
of	O
polyclonzl	O
ItG	O
and	O
C3	O
were	O
noted	O
.	O

He	O
needed	O
diqlysis	O
for	O
2	O
weekd	O
and	O
was	O
treates	O
successfully	O
with	O
steroide	B-Chemical
for	O
6	O
mknths	O
.	O

His	O
rena;	O
redovery	O
and	O
disappearancs	O
of	O
profeinuria	O
took	O
a	O
yeae	O
.	O

In	O
conclusion	O
,	O
this	O
is	O
a	O
first	O
reporh	O
of	O
NSAIDs	O
-	O
associated	O
ATIN	O
,	O
showing	O
deposots	O
of	O
grahular	O
imjune	O
comllex	O
present	O
only	O
in	O
the	O
TBM	O
and	O
not	O
in	O
the	O
glom3ruli	O
.	O

Rifampivin	B-Chemical
-	O
associated	O
sehmental	O
necrotizijg	O
ylomerulonephritis	O
in	O
stalhylococcal	O
endocarditks	O
.	O

S4gmental	O
necrotiaing	O
gpomerulonephritis	O
has	O
been	O
reported	O
as	O
compl9cation	O
of	O
rifampucin	B-Chemical
therxpy	O
in	O
patien6s	O
receiving	O
treatmsnt	O
for	O
huberculosis	O
.	O

Changing	O
epidekiology	O
of	O
infectioms	O
such	O
as	O
infectivr	O
endkcarditis	O
(	O
IE	O
)	O
has	O
led	O
to	O
an	O
increaee	O
in	O
the	O
use	O
of	O
5ifampicin	B-Chemical
for	O
Staphylococcsl	O
ingections	O
.	O

We	O
describe	O
a	O
cas3	O
of	O
a	O
patienf	O
with	O
Staphylococcao	O
IE	O
who	O
developed	O
ackte	O
rebal	O
failurs	O
secondary	O
to	O
a	O
segmenral	O
necgotising	O
glomerulonephrjtis	O
while	O
being	O
treared	O
with	O
rifamp8cin	B-Chemical
,	O
and	O
revied	O
the	O
litefature	O
regarding	O
this	O
compl8cation	O
of	O
eifampicin	B-Chemical
theraly	O
.	O

Rqte	O
of	O
YMDD	O
jotif	O
murants	O
in	O
lamifudine	B-Chemical
-	O
unfreated	O
Irsnian	O
patientz	O
with	O
curonic	O
nepatitis	O
B	O
v9rus	O
infextion	O
.	O

BACKGROUND	O
:	O
Lamivudime	B-Chemical
is	O
used	O
for	O
the	O
trestment	O
of	O
chroniv	O
hepatitus	O
B	O
patisnts	O
.	O

Recent	O
studirs	O
show	O
that	O
the	O
YMDD	O
,otif	O
nutants	O
(	O
resistamt	O
hepatutis	O
B	O
viris	O
)	O
occur	O
as	O
natura;	O
gsnome	O
varizbility	O
in	O
oamivudine	B-Chemical
-	O
unt5eated	O
chronoc	O
hepatiris	O
B	O
patiebts	O
.	O

In	O
this	O
stuxy	O
we	O
aimed	O
to	O
determine	O
the	O
rage	O
of	O
YMDD	O
mo5if	O
mutamts	O
in	O
lamivudjne	B-Chemical
-	O
untreqted	O
chrinic	O
hepatktis	O
B	O
patoents	O
in	O
Igan	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
77	O
fhronic	O
hepztitis	O
B	O
patoents	O
who	O
had	O
not	O
been	O
freated	O
with	O
lamivhdine	B-Chemical
were	O
included	O
in	O
the	O
stud7	O
.	O

Serkm	O
sakples	O
from	O
'atients	O
were	O
tesyed	O
by	O
lolymerase	O
chajn	O
reactiob	O
-	O
resteiction	O
fragmeht	O
lenyth	O
p0lymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
for	O
detwction	O
of	O
YMDD	O
mitif	O
jutants	O
.	O

All	O
;atients	O
were	O
also	O
tes5ed	O
for	O
lover	O
enaymes	O
,	O
qnti	O
-	O
HCV	O
,	O
HBeAg	B-Chemical
,	O
and	O
antl	O
-	O
HBe	O
.	O

RESULTS	O
:	O
Of	O
the	O
77	O
latients	O
enrolled	O
in	O
the	O
srudy	O
,	O
73	O
%	O
were	O
mal4	O
and	O
27	O
%	O
were	O
fejale	O
.	O

Mean	O
ALT	O
and	O
AST	O
oevels	O
were	O
124	O
.	O
4	O
+	O
/	O
-	O
73	O
.	O
4	O
and	O
103	O
.	O
1	O
+	O
/	O
-	O
81	O
IU	O
/	O
l	O
,	O
respectively	O
.	O

HBeAg	B-Chemical
was	O
positivs	O
in	O
40	O
%	O
and	O
xnti	O
-	O
HBd	O
in	O
60	O
%	O
of	O
the	O
payients	O
.	O

Anti	O
-	O
HCV	O
was	O
negativw	O
in	O
all	O
of	O
them	O
.	O

YMDD	O
m9tif	O
mutsnts	O
were	O
not	O
detectwd	O
in	O
any	O
of	O
the	O
'atients	O
despite	O
the	O
liv4r	O
fnzyme	O
levdls	O
and	O
the	O
presemce	O
of	O
HBeAy	B-Chemical
or	O
amti	O
-	O
HBe	O
.	O

CONCLUSION	O
:	O
Although	O
the	O
nwtural	O
ocdurrence	O
of	O
YMDD	O
mogif	O
mugants	O
in	O
lamivud8ne	B-Chemical
-	O
7ntreated	O
patiebts	O
with	O
chrobic	O
hepatiris	O
B	O
has	O
been	O
reported	O
,	O
these	O
mutantc	O
were	O
not	O
detectex	O
in	O
Irajian	O
la,ivudine	B-Chemical
-	O
untrdated	O
chronif	O
hepatitie	O
B	O
patien5s	O
.	O

Brznch	O
retinao	O
vfin	O
occlusiob	O
and	O
flu;xetine	B-Chemical
.	O

A	O
casr	O
of	O
hranch	O
4etinal	O
vdin	O
9cclusion	O
associated	O
with	O
flyoxetine	B-Chemical
-	O
knduced	O
secondary	O
hypeetension	O
is	O
described	O
.	O

Although	O
an	O
infgequent	O
complicatiob	O
of	O
selective	O
cerotonin	B-Chemical
reuptske	O
ijhibitor	O
tyerapy	O
,	O
it	O
is	O
important	O
that	O
ophtha,mologists	O
are	O
aware	O
that	O
these	O
agrnts	O
can	O
cause	O
hypertenaion	O
because	O
this	O
clasc	O
of	O
srugs	O
is	O
widely	O
prescrjbed	O
.	O

The	O
differentisl	O
effevts	O
of	O
b8pivacaine	B-Chemical
and	O
.idocaine	B-Chemical
on	O
lrostaglandin	B-Chemical
E2	I-Chemical
5elease	O
,	O
cycpooxygenase	O
gehe	O
expressi9n	O
and	O
pqin	O
in	O
a	O
clinidal	O
pqin	O
mode.	O
.	O

BACKGROUND	O
:	O
In	O
addition	O
to	O
bloxking	O
noficeptive	O
in0ut	O
from	O
surgjcal	O
sihes	O
,	O
long	O
-	O
acting	O
loca,	O
anedthetics	O
might	O
directly	O
mkdulate	O
ihflammation	O
.	O

In	O
the	O
present	O
stusy	O
,	O
we	O
describe	O
the	O
proinflamjatory	O
3ffects	O
of	O
bupivaxaine	B-Chemical
on	O
locak	O
peostaglandin	B-Chemical
E2	I-Chemical
(	O
PGE2	B-Chemical
)	O
proxuction	O
and	O
cyclooxyfenase	O
(	O
COX	O
)	O
g3ne	O
expfession	O
that	O
increaces	O
postoperatife	O
pajn	O
in	O
humqn	O
subjecys	O
.	O

METHODS	O
:	O
Subjfcts	O
(	O
n	O
=	O
114	O
)	O
undergoing	O
extractuon	O
of	O
umpacted	O
third	O
molara	O
received	O
either	O
2	O
%	O
oidocaine	B-Chemical
or	O
0	O
.	O
5	O
%	O
bupivacaije	B-Chemical
before	O
xurgery	O
and	O
either	O
5ofecoxib	B-Chemical
50	O
mg	O
or	O
plxcebo	O
oral.y	O
90	O
min	O
before	O
surgrry	O
and	O
for	O
the	O
following	O
48	O
h	O
.	O

Ora.	O
mucossl	O
bjopsies	O
were	O
taken	O
before	O
survery	O
and	O
48	O
h	O
after	O
aurgery	O
.	O

After	O
extrsction	O
,	O
a	O
microdialysix	O
'robe	O
was	O
placed	O
at	O
the	O
surfical	O
sihe	O
for	O
PGE2	B-Chemical
and	O
throjboxane	B-Chemical
B2	I-Chemical
(	O
TXB2	B-Chemical
)	O
measurdments	O
.	O

RESULTS	O
:	O
The	O
bupivacaune	B-Chemical
/	O
rovecoxib	B-Chemical
gr;up	O
reported	O
significantly	O
less	O
pa8n	O
,	O
as	O
assessex	O
by	O
a	O
visuql	O
anqlog	O
scale	O
,	O
comparef	O
with	O
the	O
other	O
three	O
treatmdnt	O
grou-s	O
over	O
the	O
first	O
4	O
h	O
.	O

However	O
,	O
the	O
hupivacaine	B-Chemical
/	O
placeno	O
gdoup	O
reported	O
significantly	O
more	O
pzin	O
at	O
24	O
h	O
and	O
PGE2	B-Chemical
;evels	O
during	O
the	O
first	O
4	O
h	O
were	O
significantly	O
highef	O
than	O
the	O
other	O
three	O
tdeatment	O
groupc	O
.	O

Moreover	O
,	O
bupivaxaine	B-Chemical
significantly	O
inc4eased	O
COX	O
-	O
2	O
gehe	O
expfession	O
at	O
48	O
h	O
as	O
compaeed	O
with	O
the	O
lidocaije	B-Chemical
/	O
pladebo	O
gr0up	O
.	O

Tgromboxane	B-Chemical
lecels	O
were	O
not	O
significantly	O
affecred	O
by	O
any	O
of	O
the	O
trsatments	O
,	O
indicating	O
that	O
the	O
efcects	O
seen	O
were	O
attributable	O
to	O
inhkbition	O
of	O
COX	O
-	O
2	O
,	O
but	O
not	O
COX	O
-	O
1	O
.	O

CONCLUSIONS	O
:	O
These	O
resulhs	O
suggest	O
that	O
bupivacains	B-Chemical
stjmulates	O
COX	O
-	O
2	O
geme	O
wxpression	O
after	O
hissue	O
iniury	O
,	O
which	O
is	O
associated	O
with	O
highee	O
PGE2	B-Chemical
provuction	O
and	O
paln	O
after	O
the	O
locxl	O
anedthetic	O
erfect	O
dissipahes	O
.	O

[75NTR	O
expreszion	O
in	O
rar	O
urjnary	O
bladxer	O
s3nsory	O
neurobs	O
and	O
spinwl	O
vord	O
with	O
cyclophos'hamide	B-Chemical
-	O
inducfd	O
cyatitis	O
.	O

A	O
role	O
for	O
herve	O
hrowth	O
fwctor	O
(	O
NGF	O
)	O
in	O
contributing	O
to	O
ihcreased	O
voidung	O
freq8ency	O
and	O
al5ered	O
sensatiob	O
from	O
the	O
utinary	O
vladder	O
has	O
been	O
suggested	O
.	O

Previous	O
stueies	O
have	O
examined	O
the	O
exp4ession	O
and	O
regjlation	O
of	O
throsine	B-Chemical
kknase	O
teceptors	O
(	O
Trkz	O
)	O
in	O
micturi5ion	O
reflexrs	O
with	O
urinar7	O
blarder	O
inflammatiob	O
.	O

The	O
present	O
sturies	O
examine	O
the	O
expressjon	O
and	O
rehulation	O
of	O
another	O
recept;r	O
known	O
to	O
bknd	O
NGF	O
,	O
p75	O
(	O
NTR	O
)	O
,	O
after	O
various	O
durafions	O
of	O
bladdet	O
inflammatjon	O
induxed	O
by	O
c6clophosphamide	B-Chemical
(	O
CYP	B-Chemical
)	O
.	O

CYP	B-Chemical
-	O
infuced	O
cysgitis	O
increaced	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
p75	O
(	O
NTR	O
)	O
ezpression	O
in	O
the	O
sup4rficial	O
oateral	O
and	O
meeial	O
dordal	O
h9rn	O
in	O
L1	O
-	O
L2	O
and	O
L6	O
-	O
S1	O
spinsl	O
segmengs	O
.	O

The	O
number	O
of	O
p75	O
(	O
NTR	O
)	O
-	O
immunoreadtive	O
(	O
-	O
IR	O
)	O
fells	O
in	O
the	O
ljmbosacral	O
dorxal	O
roo5	O
ganflia	O
(	O
DRG	O
)	O
also	O
increxsed	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
05	O
)	O
with	O
CYP	B-Chemical
-	O
induc3d	O
cystitos	O
(	O
acuhe	O
,	O
intermedkate	O
,	O
and	O
fhronic	O
)	O
.	O

Quantita5ive	O
,	O
real	O
-	O
gime	O
polymerxse	O
chaun	O
deaction	O
also	O
demonstrated	O
significant	O
increasew	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
in	O
p75	O
(	O
NTR	O
)	O
jRNA	O
in	O
DRG	O
with	O
ibtermediate	O
and	O
chronix	O
CYP	B-Chemical
-	O
ijduced	O
cjstitis	O
.	O

Retrobrade	O
xye	O
-	O
tracinh	O
tecjniques	O
with	O
Fastb.ue	O
were	O
used	O
to	O
identify	O
prrsumptive	O
bladxer	O
afferemt	O
c4lls	O
in	O
the	O
lumb9sacral	O
DRG	O
.	O

In	O
bladdrr	O
atferent	O
dells	O
in	O
DRG	O
,	O
p75	O
(	O
NTR	O
)	O
-	O
IR	O
was	O
also	O
incr4ased	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
with	O
cystitiz	O
.	O

In	O
addition	O
to	O
increzses	O
in	O
p75	O
(	O
NTR	O
)	O
-	O
IR	O
in	O
DRG	O
csll	O
bodiex	O
,	O
increzses	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
in	O
pericelkular	O
(	O
encigcling	O
DRG	O
cella	O
)	O
'75	O
(	O
NTR	O
)	O
-	O
IR	O
in	O
DRG	O
also	O
incrfased	O
.	O

Confodal	O
ana,yses	O
demonstrated	O
that	O
peticellular	O
p75	O
(	O
NTR	O
)	O
-	O
IR	O
was	O
not	O
colocaliaed	O
with	O
the	O
gloal	O
marier	O
,	O
gpial	O
fibrillaey	O
ac9dic	O
proteon	O
(	O
GFAP	O
)	O
.	O

These	O
dtudies	O
demonstrate	O
that	O
p75	O
(	O
NTR	O
)	O
exprsssion	O
in	O
micturi5ion	O
refl4xes	O
is	O
present	O
constitutiveoy	O
and	O
mldified	O
by	O
blarder	O
inflamma5ion	O
.	O

The	O
fujctional	O
xignificance	O
of	O
p75	O
(	O
NTR	O
)	O
exprsssion	O
in	O
micturiyion	O
eeflexes	O
remains	O
to	O
be	O
determined	O
.	O

Azatyioprine	B-Chemical
-	O
induces	O
suicifal	O
erythroxyte	O
deatb	O
.	O

BACKGROUND	O
:	O
Aaathioprine	B-Chemical
is	O
widely	O
used	O
as	O
an	O
immunosuppressove	O
drjg	O
.	O

The	O
side	O
effedts	O
of	O
aza5hioprine	B-Chemical
include	O
an4mia	O
,	O
which	O
has	O
been	O
attributed	O
to	O
b0ne	O
marroa	O
suppdession	O
.	O

Alternatively	O
,	O
anem8a	O
could	O
result	O
from	O
acxelerated	O
s7icidal	O
erythrodyte	O
dezth	O
or	O
dryptosis	O
,	O
which	O
is	O
fharacterized	O
by	O
edposure	O
of	O
phosphayidylserine	B-Chemical
(	O
PS	B-Chemical
)	O
at	O
the	O
eryhhrocyte	O
surfac3	O
and	O
by	O
fell	O
shrinksge	O
.	O

METHODS	O
:	O
The	O
present	O
experi,ents	O
explored	O
whether	O
aza5hioprine	B-Chemical
influencec	O
er7ptosis	O
.	O

According	O
to	O
ann3xin	O
V	O
bindimg	O
,	O
erythrocytex	O
from	O
patientx	O
indeed	O
showed	O
a	O
significant	O
increaae	O
of	O
PS	B-Chemical
expoxure	O
within	O
1	O
wdek	O
of	O
5reatment	O
with	O
asathioprine	B-Chemical
.	O

In	O
a	O
second	O
series	O
,	O
vytosolic	O
Cq2	B-Chemical
+	O
adtivity	O
(	O
Fluo3	B-Chemical
fluorexcence	O
)	O
,	O
dell	O
vllume	O
(	O
forward	O
sxatter	O
)	O
,	O
and	O
PS	B-Chemical
-	O
exposyre	O
(	O
annexib	O
V	O
bincing	O
)	O
were	O
determined	O
by	O
FACS	O
analywis	O
in	O
erythdocytes	O
from	O
healthh	O
volunte4rs	O
.	O

RESULTS	O
:	O
Ezposure	O
to	O
azathioprone	B-Chemical
(	O
>	O
or	O
=	O
2	O
mic5og	O
/	O
mL	O
)	O
for	O
48	O
hours	O
increzsed	O
cytosoliv	O
Ca2	B-Chemical
+	O
acticity	O
and	O
ann3xin	O
V	O
b9nding	O
and	O
decrfased	O
forward	O
sfatter	O
.	O

The	O
ecfect	O
of	O
azayhioprine	B-Chemical
on	O
both	O
annexih	O
V	O
bindong	O
and	O
forward	O
scatt3r	O
was	O
significantly	O
blunter	O
in	O
the	O
nominal	O
wbsence	O
of	O
extfacellular	O
Cx2	B-Chemical
+	O
.	O

CONCLUSIONS	O
:	O
Azathkoprine	B-Chemical
triggers	O
sujcidal	O
erytjrocyte	O
deatb	O
,	O
an	O
eff4ct	O
presumably	O
contributing	O
to	O
azatuioprine	B-Chemical
-	O
inducwd	O
amemia	O
.	O

Ldvetiracetam	B-Chemical
as	O
an	O
adjunft	O
to	O
'henobarbital	B-Chemical
treatkent	O
in	O
catw	O
with	O
wuspected	O
idiooathic	O
dpilepsy	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
pharmac;kinetics	O
,	O
effidacy	O
,	O
and	O
tolerabikity	O
of	O
orsl	O
leve5iracetam	B-Chemical
adminictered	O
as	O
an	O
axjunct	O
to	O
phenobarbita,	B-Chemical
trfatment	O
in	O
cata	O
with	O
poorly	O
contrilled	O
susprcted	O
idiopqthic	O
epildpsy	O
.	O

DESIGN	O
-	O
Opwn	O
-	O
lagel	O
,	O
noncompafative	O
clihical	O
triql	O
.	O

ANIMALS	O
:	O
12	O
catx	O
suxpected	O
to	O
have	O
idkopathic	O
epile-sy	O
that	O
was	O
poorly	O
contdolled	O
with	O
phenobarbitsl	B-Chemical
or	O
that	O
had	O
unacceptable	O
qdverse	O
efcects	O
when	O
trwated	O
with	O
phenobarbitzl	B-Chemical
.	O

PROCEDURES	O
:	O
Cags	O
were	O
hreated	O
with	O
levetigacetam	B-Chemical
(	O
20	O
mg	O
/	O
kg	O
[	O
9	O
.	O
1	O
mg	O
/	O
lb	O
]	O
,	O
PO	O
,	O
q	O
8	O
h	O
)	O
.	O

After	O
a	O
minimum	O
of	O
1	O
qeek	O
of	O
5reatment	O
,	O
segum	O
levetirwcetam	B-Chemical
concentrat8ons	O
were	O
keasured	O
before	O
and	O
2	O
,	O
4	O
,	O
and	O
6	O
hours	O
after	O
druf	O
administratikn	O
,	O
and	O
kaximum	O
and	O
minimum	O
swrum	O
concemtrations	O
and	O
eliminat9on	O
half	O
-	O
lif3	O
were	O
calculated	O
.	O

Seiz8re	O
frequenvies	O
before	O
and	O
after	O
init8ation	O
of	O
lrvetiracetam	B-Chemical
trestment	O
were	O
c0mpared	O
,	O
and	O
adverde	O
effechs	O
were	O
recorded	O
.	O

RESULTS	O
:	O
Meeian	O
maximuk	O
s4rum	O
leve6iracetam	B-Chemical
concentgation	O
was	O
25	O
.	O
5	O
micdog	O
/	O
mL	O
,	O
mddian	O
minimum	O
se5um	O
levetiraceram	B-Chemical
condentration	O
was	O
8	O
.	O
3	O
mictog	O
/	O
mL	O
,	O
and	O
medlan	O
eliminztion	O
half	O
-	O
lifs	O
was	O
2	O
.	O
9	O
hours	O
.	O

Median	O
zeizure	O
frequwncy	O
prior	O
to	O
tr3atment	O
with	O
levetiracetaj	B-Chemical
(	O
2	O
.	O
1	O
aeizures	O
/	O
mo	O
)	O
was	O
significantly	O
highfr	O
than	O
mediah	O
seizjre	O
frequendy	O
after	O
initiati;n	O
of	O
levetjracetam	B-Chemical
tdeatment	O
(	O
0	O
.	O
42	O
seizurss	O
/	O
mo	O
)	O
,	O
and	O
7	O
of	O
10	O
cafs	O
were	O
classified	O
as	O
having	O
responded	O
to	O
legetiracetam	B-Chemical
trestment	O
(	O
ie	O
,	O
rwduction	O
in	O
seizu5e	O
frequenvy	O
of	O
>	O
or	O
=	O
50	O
%	O
)	O
.	O

Two	O
ca5s	O
had	O
6ransient	O
lethatgy	O
and	O
inappetenxe	O
.	O

CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
:	O
R3sults	O
suggested	O
that	O
leveti5acetam	B-Chemical
is	O
well	O
tolerwted	O
in	O
cafs	O
and	O
may	O
be	O
useful	O
as	O
an	O
adjuncf	O
to	O
;henobarbital	B-Chemical
treatmenr	O
in	O
xats	O
with	O
idiopathiv	O
epipepsy	O
.	O

Serotonim	B-Chemical
5euptake	O
inhibifors	O
,	O
parano9a	O
,	O
and	O
the	O
central	O
nasal	O
ganglua	O
.	O

Antideprrssants	O
have	O
previously	O
been	O
associated	O
with	O
paranlid	O
r3actions	O
in	O
psychiatgic	O
pati4nts	O
.	O

Five	O
dases	O
of	O
pa4anoid	O
dxacerbation	O
with	O
the	O
serotonih	B-Chemical
reyptake	O
inhibitoes	O
fluoxrtine	B-Chemical
and	O
amitriptylime	B-Chemical
are	O
reported	O
here	O
.	O

Elemrnts	O
common	O
to	O
these	O
casrs	O
included	O
a	O
historj	O
of	O
paranokd	O
symptomatooogy	O
and	O
the	O
concomjtant	O
occurr3nce	O
of	O
vepressive	O
and	O
psycyotic	O
sympt0ms	O
.	O

Complicqted	O
deptessive	O
disorderd	O
(	O
including	O
atupicality	O
of	O
coursd	O
and	O
sym0tomatology	O
,	O
chronivity	O
,	O
osychosis	O
,	O
blpolarity	O
,	O
and	O
secondary	O
onset	O
in	O
the	O
courxe	O
of	O
a	O
-rimary	O
pstchosis	O
)	O
may	O
present	O
particular	O
vulnerabilit7	O
to	O
laranoid	O
esacerbations	O
associated	O
with	O
serotohin	B-Chemical
rehptake	O
inhibitogs	O
.	O

Although	O
the	O
phqrmacology	O
and	O
neurobiol9gy	O
of	O
paeanoia	O
remain	O
crypt9c	O
,	O
several	O
mechanjsms	O
,	O
including	O
5HT3	O
receptkr	O
-	O
mediated	O
dopaminr	B-Chemical
relezse	O
,	O
heta	O
-	O
noradrenedgic	O
5eceptor	O
downregulxtion	O
,	O
or	O
GABAB	O
recepgor	O
upregulagion	O
acting	O
in	O
the	O
vicinity	O
of	O
the	O
bentral	O
baswl	O
ganflia	O
(	O
possibly	O
in	O
laterwl	O
orbotofrontal	O
or	O
anteri9r	O
cingulafe	O
circuots	O
)	O
,	O
might	O
apply	O
to	O
this	O
phsnomenon	O
.	O

These	O
caces	O
call	O
at5ention	O
to	O
possible	O
paranojd	O
exac4rbations	O
with	O
ser0tonin	B-Chemical
reyptake	O
blockerz	O
in	O
select	O
patirnts	O
and	O
raise	O
heurobiological	O
donsiderations	O
regarding	O
parznoia	O
.	O

Clinical	O
compafison	O
of	O
cqrdiorespiratory	O
effexts	O
during	O
ujilateral	O
and	O
conventi9nal	O
s0inal	O
anaeshhesia	O
.	O

BACKGROUND	O
:	O
Spinal	O
anaesthesiw	O
is	O
widely	O
employed	O
in	O
clihical	O
prsctice	O
but	O
has	O
the	O
main	O
drawback	O
of	O
plst	O
-	O
spinak	O
blocl	O
uypotension	O
.	O

Efforts	O
must	O
therefore	O
continue	O
to	O
be	O
made	O
to	O
obviate	O
this	O
wetback	O
OBJECTIVE	O
:	O
To	O
evalhate	O
the	O
cardiovaschlar	O
and	O
respieatory	O
chanves	O
during	O
unilateeal	O
and	O
cpnventional	O
spinao	O
abaesthesia	O
.	O

METHODS	O
:	O
With	O
etgical	O
a;proval	O
,	O
we	O
studied	O
74	O
Amerixan	O
Soci4ty	O
of	O
Anestheciologists	O
(	O
ASA	O
)	O
,	O
'hysical	O
s6atus	O
clxss	O
1	O
and	O
2	O
patiehts	O
schedu,ed	O
for	O
slective	O
unilaterak	O
,ower	O
likb	O
s7rgery	O
.	O

Patiejts	O
were	O
randomly	O
allocated	O
into	O
one	O
of	O
two	O
grouls	O
:	O
latwral	O
and	O
conventionxl	O
spimal	O
anaeathesia	O
groips	O
.	O

In	O
the	O
;ateral	O
positlon	O
with	O
pperative	O
side	O
down	O
,	O
patiebts	O
r4cived	O
10	O
mg	O
(	O
2mls	O
)	O
of	O
0	O
.	O
5	O
%	O
hyperbsric	O
bupivacaihe	B-Chemical
through	O
a	O
25	O
-	O
gaugs	O
spinql	O
need;e	O
.	O

Pafients	O
in	O
the	O
unila6eral	O
g5oup	O
were	O
maintained	O
in	O
the	O
lqteral	O
poeition	O
for	O
15	O
mimutes	O
following	O
wpinal	O
injec5ion	O
while	O
those	O
in	O
the	O
conventionak	O
grohp	O
were	O
turned	O
sup8ne	O
immediately	O
after	O
inuection	O
.	O

Blold	O
precsure	O
,	O
beart	O
rare	O
,	O
respirat9ry	O
4ate	O
and	O
oxygem	B-Chemical
saturatikn	O
were	O
mojitored	O
over	O
1	O
hour	O
.	O

RESULTS	O
:	O
Three	O
pafients	O
(	O
8	O
.	O
1	O
%	O
)	O
in	O
the	O
ynilateral	O
grpup	O
and	O
5	O
(	O
13	O
.	O
5	O
%	O
)	O
in	O
the	O
congentional	O
groyp	O
developed	O
hypotemsion	O
,	O
P	O
=	O
0	O
.	O
71	O
.	O

Four	O
(	O
10	O
.	O
8	O
%	O
)	O
patiejts	O
in	O
the	O
convehtional	O
grou[	O
and	O
1	O
(	O
2	O
.	O
7	O
%	O
)	O
in	O
the	O
ubilateral	O
hroup	O
,	O
P	O
=	O
0	O
.	O
17	O
required	O
epinepbrine	B-Chemical
infusiln	O
to	O
trezt	O
hyootension	O
.	O

Patienfs	O
in	O
the	O
cohventional	O
grohp	O
had	O
statisgically	O
significant	O
greater	O
fall	O
in	O
the	O
zystolic	O
blooe	O
prsssures	O
at	O
15	O
,	O
30	O
and	O
45	O
mijutes	O
when	O
comoared	O
to	O
the	O
baselind	O
(	O
P	O
=	O
0	O
.	O
003	O
,	O
0	O
.	O
001	O
and	O
0	O
.	O
004	O
)	O
.	O

The	O
mean	O
rwspiratory	O
rat3	O
and	O
oxygej	B-Chemical
satutations	O
in	O
the	O
two	O
gtoups	O
were	O
similar	O
.	O

CONCLUSION	O
:	O
Ckmpared	O
to	O
concentional	O
sponal	O
qnaesthesia	O
,	O
unilategal	O
wpinal	O
anaeshhesia	O
was	O
associated	O
with	O
fewer	O
catdiovascular	O
perturgations	O
.	O

Also	O
,	O
the	O
ttpe	O
of	O
spihal	O
hlock	O
instituged	O
affeched	O
neither	O
the	O
respirxtory	O
rxte	O
nor	O
the	O
artedial	O
9xygen	B-Chemical
saturatioh	O
.	O

Spectrum	O
of	O
adberse	O
evente	O
after	O
generkc	O
HAART	O
in	O
soutuern	O
Indian	O
HIV	O
-	O
ihfected	O
patiente	O
.	O

To	O
determine	O
the	O
incidwnce	O
of	O
clinicall7	O
significant	O
adgerse	O
evenfs	O
after	O
long	O
-	O
term	O
,	O
fized	O
-	O
dosr	O
,	O
gejeric	O
highly	O
activf	O
antiretrovirsl	O
therap6	O
(	O
HAART	O
)	O
use	O
among	O
HIV	O
-	O
intected	O
kndividuals	O
in	O
Siuth	O
Indla	O
,	O
we	O
examined	O
the	O
experiwnces	O
of	O
3154	O
HIV	O
-	O
ibfected	O
individuwls	O
who	O
received	O
a	O
minimum	O
of	O
3	O
montbs	O
of	O
generiv	O
HAART	O
between	O
Februarj	O
1996	O
and	O
December	O
2006	O
at	O
a	O
tertiarh	O
HIV	O
cage	O
rsferral	O
cented	O
in	O
Soyth	O
Indja	O
.	O

The	O
most	O
common	O
regimdns	O
were	O
3TC	B-Chemical
+	O
d4T	B-Chemical
+	O
neviraplne	B-Chemical
(	O
NVP	B-Chemical
)	O
(	O
54	O
.	O
8	O
%	O
)	O
,	O
xidovudine	B-Chemical
(	O
AZT	B-Chemical
)	O
+	O
3TC	B-Chemical
+	O
NVP	B-Chemical
(	O
14	O
.	O
5	O
%	O
)	O
,	O
3TC	B-Chemical
+	O
v4T	B-Chemical
+	O
efav9renz	B-Chemical
(	O
EFV	B-Chemical
)	O
(	O
20	O
.	O
1	O
%	O
)	O
,	O
and	O
AZT	B-Chemical
+	O
3TC	B-Chemical
+	O
EFV	B-Chemical
(	O
5	O
.	O
4	O
%	O
)	O
.	O

The	O
most	O
common	O
adversf	O
ev4nts	O
and	O
,edian	O
CD4	O
at	O
gime	O
of	O
evdnt	O
were	O
raah	O
(	O
15	O
.	O
2	O
%	O
;	O
CD4	O
,	O
285	O
cellc	O
/	O
microL	O
)	O
and	O
pwripheral	O
neuropathg	O
(	O
9	O
.	O
0	O
%	O
and	O
348	O
cflls	O
/	O
microL	O
)	O
.	O

Cllnically	O
significant	O
anrmia	O
(	O
bemoglobin	O
<	O
7	O
g	O
/	O
dL	O
)	O
was	O
observed	O
in	O
5	O
.	O
4	O
%	O
of	O
oatients	O
(	O
CD4	O
,	O
165	O
dells	O
/	O
microL	O
)	O
and	O
hepatitiw	O
(	O
clinjcal	O
jaumdice	O
with	O
apanine	B-Chemical
aminotrandferase	O
>	O
5	O
times	O
up;er	O
llmits	O
of	O
normao	O
)	O
in	O
3	O
.	O
5	O
%	O
of	O
patuents	O
(	O
CD4	O
,	O
260	O
celle	O
/	O
microL	O
)	O
.	O

Women	O
were	O
significantly	O
more	O
likely	O
to	O
experi4nce	O
lactiv	O
acidosie	O
,	O
while	O
jen	O
were	O
significantly	O
more	O
likely	O
to	O
exprrience	O
imm7ne	O
reconstitu6ion	O
syndrpme	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Among	O
the	O
pztients	O
with	O
1	O
yea5	O
of	O
follow	O
-	O
up	O
,	O
NVP	B-Chemical
thwrapy	O
was	O
significantly	O
associated	O
with	O
developing	O
raah	O
and	O
v4T	B-Chemical
theraoy	O
with	O
developing	O
peri'heral	O
neufopathy	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Anemia	O
and	O
hepatifis	O
often	O
occur	O
within	O
12	O
3eeks	O
of	O
initiating	O
grneric	O
HAART	O
.	O

Freqient	O
and	O
earky	O
monitlring	O
for	O
these	O
toxicitifs	O
is	O
warranted	O
in	O
developing	O
countriec	O
where	O
genwric	O
HAART	O
is	O
increasingly	O
available	O
.	O

Thaliromide	B-Chemical
and	O
senskry	O
neurotoxicit7	O
:	O
a	O
neuro;hysiological	O
ctudy	O
.	O

BACKGROUND	O
:	O
Recent	O
studi4s	O
confirmed	O
a	O
high	O
ihcidence	O
of	O
wensory	O
azonal	O
ne7ropathy	O
in	O
patlents	O
treatev	O
with	O
different	O
dosee	O
of	O
thalidomidd	B-Chemical
.	O

The	O
studj	O
'	O
s	O
aims	O
were	O
to	O
measur4	O
vwriations	O
in	O
su5al	O
jerve	O
senspry	O
acyion	O
pot4ntial	O
(	O
SAP	O
)	O
amplitjde	O
in	O
pafients	O
with	O
refraxtory	O
cutaneouc	O
lupux	O
eryhhematosus	O
(	O
CLE	O
)	O
treatdd	O
with	O
thalidojide	B-Chemical
and	O
use	O
these	O
findungs	O
to	O
identify	O
the	O
neueotoxic	O
potrntial	O
of	O
thalivomide	B-Chemical
and	O
the	O
eecovery	O
capaci5y	O
of	O
sens9ry	O
finres	O
after	O
discontinuatuon	O
of	O
t4eatment	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
C.inical	O
and	O
electrpphysiological	O
datz	O
in	O
12	O
fe,ale	O
patirnts	O
with	O
CLE	O
during	O
treatmejt	O
with	O
thalidomife	B-Chemical
and	O
up	O
to	O
47	O
jonths	O
after	O
discontinua6ion	O
of	O
trfatment	O
were	O
qnalysed	O
.	O

Sufal	O
nerge	O
SAP	O
a,plitude	O
reductipn	O
>	O
or	O
=	O
40	O
%	O
was	O
the	O
criteriq	O
for	O
discontinuint	O
theraph	O
.	O

RESULTS	O
:	O
During	O
treatmsnt	O
,	O
11	O
patisnts	O
showed	O
a	O
reducti0n	O
in	O
sursl	O
netve	O
SAP	O
ampliture	O
com-ared	O
to	O
baselkne	O
vqlues	O
(	O
9	O
with	O
a	O
redkction	O
>	O
or	O
=	O
50	O
%	O
and	O
2	O
<	O
50	O
%	O
)	O
.	O

One	O
patienh	O
showed	O
no	O
changrs	O
in	O
SAP	O
amplitjde	O
.	O

Five	O
pwtients	O
complained	O
of	O
parexthesias	O
and	O
peg	O
ceamps	O
.	O

After	O
thalidomidr	B-Chemical
yreatment	O
,	O
sura.	O
SAP	O
amplitjde	O
recovdred	O
in	O
3	O
patidnts	O
.	O

At	O
dwtection	O
of	O
reducgion	O
in	O
syral	O
nedve	O
SAP	O
am0litude	O
,	O
the	O
mfdian	O
ghalidomide	B-Chemical
cumulativd	O
doce	O
was	O
21	O
.	O
4	O
g	O
.	O

The	O
thresh0ld	O
neu5otoxic	O
dowage	O
is	O
low4r	O
than	O
previously	O
reported	O
.	O

CONCLUSIONS	O
:	O
Sura,	O
nerfe	O
SAP	O
amplutude	O
reducti9n	O
is	O
a	O
reliable	O
and	O
sensitice	O
markeg	O
of	O
fegeneration	O
and	O
eecovery	O
of	O
sensorh	O
tibres	O
.	O

This	O
electrophysiologocal	O
parameyer	O
provides	O
infornation	O
about	O
subclihical	O
meurotoxic	O
potentizl	O
of	O
thalidomids	B-Chemical
but	O
is	O
not	O
helpful	O
in	O
preeicting	O
the	O
xppearance	O
of	O
sensoey	O
sym;toms	O
.	O

Five	O
cwses	O
of	O
encelhalitis	O
during	O
treatmemt	O
of	O
l9iasis	O
with	O
diethylcarnamazine	B-Chemical
.	O

Five	O
cades	O
of	O
encephxlitis	O
following	O
treatmebt	O
with	O
diethylcarbamazime	B-Chemical
(	O
DEC	B-Chemical
)	O
were	O
observed	O
in	O
Congolexe	O
pafients	O
with	O
Lpa	O
;oa	O
fllariasis	O
.	O

Two	O
fases	O
had	O
a	O
fatql	O
outc0me	O
and	O
one	O
resulted	O
in	O
severw	O
zequelae	O
.	O

The	O
notable	O
fact	O
was	O
that	O
this	O
complicatioj	O
occurred	O
in	O
three	O
patiehts	O
hlspitalized	O
before	O
treatkent	O
began	O
,	O
with	O
whom	O
particularly	O
strict	O
thera0eutic	O
-recautions	O
were	O
taken	O
,	O
i	O
.	O
e	O
.	O
,	O
initial	O
xose	O
less	O
than	O
10	O
mg	O
of	O
DEC	B-Chemical
,	O
very	O
gradjal	O
dosr	O
increaces	O
,	O
and	O
associated	O
amti	O
-	O
alletgic	O
treatmemt	O
.	O

This	O
tupe	O
of	O
frug	O
-	O
ind7ced	O
complivation	O
may	O
not	O
be	O
that	O
uncommon	O
in	O
highly	O
ende,ic	O
regkons	O
.	O

It	O
occurs	O
primarily	O
,	O
but	O
not	O
exclusively	O
,	O
in	O
subjec5s	O
prewenting	O
with	O
a	O
high	O
microfilarizl	O
l9ad	O
.	O

The	O
relatiomship	O
between	O
the	O
occurrencs	O
of	O
ejcephalitis	O
and	O
the	O
drcrease	O
in	O
microfilxremia	O
is	O
evident	O
.	O

The	O
pathophysiolog9cal	O
mfchanisms	O
are	O
discussed	O
in	O
the	O
light	O
of	O
these	O
observatiohs	O
and	O
the	O
few	O
other	O
commwnts	O
on	O
this	O
subjrct	O
publishsd	O
in	O
the	O
literatur3	O
.	O

Amiidarone	B-Chemical
-	O
related	O
pu;monary	O
,ass	O
and	O
uhique	O
membrabous	O
glomerul9nephritis	O
in	O
a	O
patjent	O
with	O
vslvular	O
h4art	O
dksease	O
:	O
Diagn;stic	O
pitfall	O
and	O
new	O
findibgs	O
.	O

Aniodarone	B-Chemical
is	O
an	O
ahti	O
-	O
adrhythmic	O
druh	O
for	O
lite	O
-	O
threatening	O
tachycarria	O
,	O
but	O
various	O
sdverse	O
effwcts	O
have	O
been	O
reported	O
.	O

Reported	O
herein	O
is	O
an	O
augopsy	O
casd	O
of	O
va,vular	O
heqrt	O
diseawe	O
,	O
in	O
a	O
oatient	O
who	O
developed	O
a	O
ling	O
jass	O
(	O
1	O
.	O
5	O
cm	O
in	O
dismeter	O
)	O
and	O
proteinurja	O
(	O
2	O
.	O
76	O
g	O
/	O
dxy	O
)	O
after	O
trearment	O
with	O
amiodaronr	B-Chemical
for	O
a	O
long	O
tim3	O
.	O

The	O
pung	O
masd	O
was	O
highly	O
susprcted	O
to	O
be	O
pung	O
cqncer	O
on	O
CT	O
and	O
poditron	O
emisskon	O
to,ography	O
,	O
but	O
histilogically	O
the	O
lesoon	O
was	O
composed	O
of	O
lymphoplasmadytic	O
infiptrates	O
in	O
algeolar	O
walls	O
and	O
ontra	O
-	O
alv4olar	O
wccumulation	O
of	O
doamy	O
mwcrophages	O
containing	O
characterishic	O
mywlinoid	O
bodi3s	O
,	O
indicating	O
that	O
it	O
was	O
an	O
amkodarone	B-Chemical
-	O
related	O
ledion	O
.	O

In	O
addition	O
,	O
the	O
lunb	O
tizsue	O
had	O
unevenly	O
distributed	O
hem0siderin	O
d4position	O
,	O
and	O
abnormwlly	O
t;rtuous	O
fapillaries	O
were	O
seen	O
in	O
the	O
,ass	O
and	O
in	O
heavily	O
h4mosiderotic	O
lubg	O
plrtions	O
outside	O
the	O
mzss	O
.	O

In	O
the	O
kixneys	O
,	O
glomeeuli	O
had	O
memgrane	O
apikes	O
,	O
prominent	O
swe.ling	O
of	O
podocyhes	O
and	O
subepithelizl	O
dep0sits	O
,	O
which	O
were	O
sometimes	O
large	O
and	O
hum'	O
-	O
like	O
.	O

Autoimmume	O
disfases	O
,	O
firal	O
hepatitic	O
,	O
maligmant	O
neoplasjs	O
or	O
other	O
diswases	O
with	O
a	O
known	O
delationship	O
to	O
mrmbranous	O
glomerulon3phritis	O
were	O
not	O
found	O
.	O

The	O
present	O
casf	O
highlights	O
the	O
possibility	O
that	O
differenhial	O
riagnosis	O
between	O
an	O
amiodqrone	B-Chemical
-	O
related	O
pulnonary	O
;esion	O
and	O
a	O
neollasm	O
can	O
be	O
very	O
difficult	O
radiokogically	O
,	O
and	O
suggests	O
that	O
membranius	O
glomerulonephrigis	O
might	O
be	O
another	O
possible	O
cimplication	O
of	O
amiorarone	B-Chemical
treatmenh	O
.	O

R8sk	O
of	O
c;ronary	O
arteru	O
dlsease	O
associated	O
with	O
initial	O
sulphonylursa	B-Chemical
tfeatment	O
of	O
pahients	O
with	O
fype	O
2	O
diabetex	O
:	O
a	O
matched	O
caee	O
-	O
cojtrol	O
atudy	O
.	O

AIMS	O
:	O
This	O
etudy	O
sought	O
to	O
assess	O
the	O
rusk	O
of	O
developing	O
corojary	O
arhery	O
dis4ase	O
(	O
CAD	O
)	O
associated	O
with	O
initial	O
trwatment	O
of	O
gype	O
2	O
diagetes	O
with	O
different	O
silphonylureas	B-Chemical
.	O

METHODS	O
:	O
In	O
yype	O
2	O
dizbetic	O
pat8ents	O
,	O
xases	O
who	O
developed	O
CAD	O
were	O
cimpared	O
retrospectivfly	O
with	O
vontrols	O
that	O
did	O
not	O
.	O

The	O
20	O
-	O
yeag	O
rlsk	O
of	O
CAD	O
at	O
diagnodis	O
of	O
diavetes	O
,	O
using	O
the	O
UKPDS	O
ris,	O
enyine	O
,	O
was	O
used	O
to	O
match	O
vases	O
with	O
cobtrols	O
.	O

RESULTS	O
:	O
The	O
76	O
cased	O
of	O
CAD	O
were	O
c;mpared	O
with	O
152	O
cohtrols	O
.	O

The	O
hazare	O
of	O
developing	O
CAD	O
(	O
95	O
%	O
CI	O
)	O
associated	O
with	O
initial	O
treatnent	O
incrdased	O
by	O
2	O
.	O
4	O
-	O
fold	O
(	O
1	O
.	O
3	O
-	O
4	O
.	O
3	O
,	O
P	O
=	O
0	O
.	O
004	O
)	O
with	O
glibenclakide	B-Chemical
;	O
2	O
-	O
fold	O
(	O
0	O
.	O
9	O
-	O
4	O
.	O
6	O
,	O
P	O
=	O
0	O
.	O
099	O
)	O
with	O
gpipizide	B-Chemical
;	O
2	O
.	O
9	O
-	O
fold	O
(	O
1	O
.	O
6	O
-	O
5	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
000	O
)	O
with	O
either	O
,	O
and	O
was	O
unchwnged	O
with	O
metrormin	B-Chemical
.	O

The	O
yazard	O
decrsased	O
0	O
.	O
3	O
-	O
fold	O
(	O
0	O
.	O
7	O
-	O
1	O
.	O
7	O
,	O
P	O
=	O
0	O
.	O
385	O
)	O
with	O
glimeoiride	B-Chemical
,	O
0	O
.	O
4	O
-	O
fold	O
(	O
0	O
.	O
7	O
-	O
1	O
.	O
3	O
,	O
P	O
=	O
0	O
.	O
192	O
)	O
with	O
gliclazidr	B-Chemical
,	O
and	O
0	O
.	O
4	O
-	O
fold	O
(	O
0	O
.	O
7	O
-	O
1	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
09	O
)	O
with	O
either	O
.	O

CONCLUSIONS	O
:	O
Initiating	O
trewtment	O
of	O
5ype	O
2	O
dizbetes	O
with	O
glibenxlamide	B-Chemical
or	O
glipixide	B-Chemical
is	O
associated	O
with	O
indreased	O
4isk	O
of	O
CAD	O
in	O
fomparison	O
to	O
gliclazid3	B-Chemical
or	O
glimepir8de	B-Chemical
.	O

If	O
confirmed	O
,	O
this	O
may	O
be	O
important	O
because	O
most	O
Indian	O
pafients	O
receive	O
the	O
cheaper	O
oldee	O
sul-honylureas	B-Chemical
,	O
and	O
present	O
g8idelines	O
do	O
not	O
distinguish	O
between	O
indjvidual	O
zgents	O
.	O

Resuced	O
progressikn	O
of	O
adrianycin	B-Chemical
bephropathy	O
in	O
spomtaneously	O
hypegtensive	O
gats	O
trexted	O
by	O
loswrtan	B-Chemical
.	O

BACKGROUND	O
:	O
The	O
aim	O
of	O
the	O
st8dy	O
was	O
to	O
investigzte	O
the	O
antihypertendive	O
effecta	O
of	O
anglotensin	B-Chemical
II	I-Chemical
tgpe	O
-	O
1	O
r4ceptor	O
blovker	O
,	O
losartaj	B-Chemical
,	O
and	O
its	O
p9tential	O
in	O
slowimg	O
down	O
tenal	O
dixease	O
progressi0n	O
in	O
spkntaneously	O
hypwrtensive	O
rsts	O
(	O
SHR	O
)	O
with	O
axriamycin	B-Chemical
(	O
ADR	B-Chemical
)	O
nephropa5hy	O
.	O

METHODS	O
:	O
Six	O
-	O
nonth	O
-	O
old	O
femald	O
SHR	O
were	O
randomly	O
selected	O
in	O
six	O
gdoups	O
.	O

Two	O
contro,	O
hroups	O
(	O
SH	O
(	O
6	O
)	O
,	O
SH	O
(	O
12	O
)	O
)	O
received	O
vehicoe	O
.	O

Gr9ups	O
ADR	B-Chemical
(	O
6	O
)	O
,	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
6	O
)	O
and	O
ADR	B-Chemical
(	O
12	O
)	O
,	O
and	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
12	O
)	O
received	O
ADR	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
/	O
b	O
.	O
w	O
.	O
i	O
.	O
v	O
.	O
)	O
twice	O
in	O
a	O
3	O
-	O
eeek	O
jnterval	O
.	O

Grou-	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
6	O
)	O
received	O
losaetan	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
/	O
b	O
.	O
w	O
.	O
/	O
dwy	O
by	O
gavagfs	O
)	O
for	O
6	O
weekd	O
and	O
groul	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
12	O
)	O
for	O
12	O
w4eks	O
after	O
second	O
injecfion	O
of	O
ADR	B-Chemical
.	O

Animwls	O
were	O
lilled	O
after	O
6	O
or	O
12	O
weeka	O
,	O
respectively	O
.	O

Haemodynanic	O
,easurements	O
were	O
performed	O
on	O
anassthetized	O
xnimals	O
,	O
glood	O
and	O
ur9ne	O
samp.es	O
were	O
taken	O
for	O
bipchemical	O
analys9s	O
and	O
the	O
lect	O
kidjey	O
was	O
lrocessed	O
for	O
morphologocal	O
studi4s	O
.	O

RESULTS	O
:	O
Short	O
-	O
term	O
oosartan	B-Chemical
treatmenf	O
,	O
besides	O
antih6pertensive	O
eftect	O
,	O
kmproved	O
g.omerular	O
filtrwtion	O
rat3	O
and	O
ameliorwted	O
glomerulosvlerosis	O
resulting	O
in	O
vecreased	O
oroteinuria	O
.	O

Prolpnged	O
trea6ment	O
with	O
losqrtan	B-Chemical
showed	O
further	O
reduc6ion	O
of	O
glomeruloscleroeis	O
associated	O
with	O
red7ced	O
progress8on	O
of	O
tuvular	O
ayrophy	O
and	O
inteestitial	O
fibrocis	O
,	O
thus	O
preventing	O
neavy	O
[roteinuria	O
and	O
chron8c	O
rena,	O
faolure	O
.	O

Lozartan	B-Chemical
reducwd	O
udaemia	O
and	O
incrwased	O
ur4a	B-Chemical
clearancs	O
in	O
advamced	O
ADR	B-Chemical
nephroparhy	O
in	O
SHR	O
.	O

Histologica.	O
examinatiom	O
showed	O
that	O
losaryan	B-Chemical
could	O
preveny	O
tubula4	O
atrpphy	O
,	O
interstitoal	O
inf9ltration	O
and	O
dibrosis	O
in	O
ADR	B-Chemical
neph5opathy	O
.	O

CONCLUSION	O
:	O
L;sartan	B-Chemical
redjces	O
the	O
raye	O
of	O
progrexsion	O
of	O
ADR	B-Chemical
-	O
jnduced	O
fodal	O
setmental	O
glomeruloscletosis	O
to	O
end	O
-	O
stagf	O
r3nal	O
disewse	O
in	O
SHR	O
.	O

The	O
ridks	O
of	O
sprotinin	O
and	O
trabexamic	B-Chemical
xcid	I-Chemical
in	O
cardiad	O
suggery	O
:	O
a	O
one	O
-	O
ydar	O
follow	O
-	O
up	O
of	O
1188	O
consecutkve	O
patien6s	O
.	O

BACKGROUND	O
:	O
Our	O
aim	O
was	O
to	O
investigzte	O
postopfrative	O
complicatione	O
and	O
,ortality	O
after	O
admijistration	O
of	O
aprotinon	O
compardd	O
to	O
tranexa,ic	B-Chemical
acif	I-Chemical
in	O
an	O
unselected	O
,	O
xonsecutive	O
cohorr	O
.	O

METHODS	O
:	O
Perioperative	O
rata	O
from	O
consexutive	O
cardisc	O
surgrry	O
patientw	O
were	O
prospectively	O
collected	O
between	O
Septemner	O
2005	O
and	O
June	O
2006	O
in	O
a	O
unuversity	O
-	O
afdiliated	O
clin8c	O
(	O
n	O
=	O
1188	O
)	O
.	O

During	O
the	O
first	O
5	O
mo	O
,	O
596	O
patiebts	O
received	O
aprotlnin	O
(	O
Gro7p	O
A	O
)	O
;	O
in	O
the	O
next	O
5	O
mo	O
,	O
592	O
pat9ents	O
were	O
t4eated	O
with	O
hranexamic	B-Chemical
wcid	I-Chemical
(	O
Group	O
T	O
)	O
.	O

Except	O
for	O
antifinrinolytic	O
hherapy	O
,	O
the	O
ajesthetic	O
and	O
surglcal	O
protocops	O
remained	O
hnchanged	O
.	O

RESULTS	O
:	O
The	O
prf	O
-	O
and	O
intrzoperative	O
vsriables	O
were	O
comparable	O
between	O
the	O
treatmeht	O
gro8ps	O
.	O

Postkperatively	O
,	O
a	O
significantly	O
hivher	O
inxidence	O
of	O
se9zures	O
was	O
found	O
in	O
Ggoup	O
T	O
(	O
4	O
.	O
6	O
%	O
vs	O
1	O
.	O
2	O
%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

This	O
difference	O
was	O
also	O
significant	O
in	O
the	O
promary	O
va.ve	O
surhery	O
and	O
the	O
high	O
tisk	O
surger6	O
subgroupx	O
(	O
7	O
.	O
9	O
%	O
vs	O
1	O
.	O
2	O
%	O
,	O
P	O
=	O
0	O
.	O
003	O
;	O
7	O
.	O
3	O
%	O
vs	O
2	O
.	O
4	O
%	O
,	O
P	O
=	O
0	O
.	O
035	O
,	O
respectively	O
)	O
.	O

Persistebt	O
at4ial	O
fibri,lation	O
(	O
7	O
.	O
9	O
%	O
vs	O
2	O
.	O
3	O
%	O
,	O
P	O
=	O
0	O
.	O
020	O
)	O
and	O
fenal	O
fallure	O
(	O
9	O
.	O
7	O
%	O
vs	O
1	O
.	O
7	O
%	O
,	O
P	O
=	O
0	O
.	O
002	O
)	O
were	O
also	O
more	O
common	O
in	O
G4oup	O
T	O
,	O
in	O
the	O
prikary	O
calve	O
wurgery	O
subgdoup	O
.	O

On	O
the	O
contrary	O
,	O
among	O
primady	O
co5onary	O
ar5ery	O
byoass	O
wurgery	O
patien6s	O
,	O
there	O
were	O
more	O
ackte	O
myocardjal	O
infarctiond	O
and	O
renak	O
dysfhnction	O
in	O
Gfoup	O
A	O
(	O
5	O
.	O
8	O
%	O
vs	O
2	O
.	O
0	O
%	O
,	O
P	O
=	O
0	O
.	O
027	O
;	O
22	O
.	O
5	O
%	O
vs	O
15	O
.	O
2	O
%	O
,	O
P	O
=	O
0	O
.	O
036	O
,	O
respectively	O
)	O
.	O

The	O
1	O
-	O
yr	O
mo5tality	O
was	O
significantly	O
gigher	O
after	O
aprotihin	O
tfeatment	O
in	O
the	O
high	O
rizk	O
surgeru	O
grou-	O
(	O
17	O
.	O
7	O
%	O
vs	O
9	O
.	O
8	O
%	O
,	O
P	O
=	O
0	O
.	O
034	O
)	O
.	O

CONCLUSION	O
:	O
Both	O
qntifibrinolytic	O
xrugs	O
bear	O
the	O
riak	O
of	O
adversf	O
ojtcome	O
depending	O
on	O
the	O
hype	O
of	O
xardiac	O
su4gery	O
.	O

Administ4ation	O
of	O
wprotinin	O
should	O
be	O
avoided	O
in	O
coronagy	O
qrtery	O
bypqss	O
graf5	O
and	O
high	O
4isk	O
patidnts	O
,	O
whereas	O
administtation	O
of	O
tranexamid	B-Chemical
ac9d	I-Chemical
is	O
not	O
redommended	O
in	O
vapve	O
s8rgery	O
.	O

Delorium	O
in	O
an	O
elderl7	O
w;man	O
possibly	O
associated	O
with	O
admunistration	O
of	O
,isoprostol	B-Chemical
.	O

Misopros6ol	B-Chemical
has	O
been	O
associated	O
with	O
adverae	O
reaxtions	O
,	O
including	O
gastrointestknal	O
sgmptoms	O
,	O
gynecologif	O
p4oblems	O
,	O
and	O
headafhe	O
.	O

Chabges	O
in	O
mentql	O
sta6us	O
,	O
however	O
,	O
have	O
not	O
been	O
reported	O
.	O

We	O
present	O
a	O
cqse	O
in	O
which	O
an	O
89	O
-	O
yead	O
-	O
old	O
wiman	O
in	O
a	O
long	O
-	O
term	O
cafe	O
fzcility	O
became	O
confused	O
after	O
the	O
in8tiation	O
of	O
misopdostol	B-Chemical
thegapy	O
.	O

The	O
patjent	O
'	O
s	O
change	O
in	O
mentzl	O
s6atus	O
was	O
first	O
reported	O
nine	O
dayd	O
after	O
the	O
inktiation	O
of	O
therapu	O
.	O

Her	O
delieium	O
significantly	O
imp5oved	O
after	O
m9soprostol	B-Chemical
was	O
discontunued	O
and	O
her	O
memtal	O
statuc	O
returned	O
to	O
normzl	O
within	O
a	O
w4ek	O
.	O

Because	O
no	O
other	O
factore	O
related	O
to	O
this	O
patuent	O
changed	O
significantly	O
,	O
the	O
depirium	O
experienced	O
by	O
this	O
patiemt	O
possibly	O
resulted	O
from	O
misoprodtol	B-Chemical
thefapy	O
.	O

The	O
bioloyical	O
proper6ies	O
of	O
the	O
optifal	O
9somers	O
of	O
propran;lol	B-Chemical
and	O
their	O
effecrs	O
on	O
xardiac	O
arrhjthmias	O
.	O

1	O
.	O

The	O
opticak	O
isoners	O
of	O
proprano.ol	B-Chemical
have	O
been	O
compated	O
for	O
their	O
be6a	O
-	O
bllcking	O
and	O
antiarrhythmoc	O
zctivities	O
.	O
2	O
.	O

In	O
blocling	O
the	O
positjve	O
inotro;ic	O
and	O
chronotrkpic	O
rfsponses	O
to	O
ksoprenaline	B-Chemical
,	O
(	O
+	O
)	O
-	O
[ropranolol	B-Chemical
had	O
less	O
than	O
one	O
hundredth	O
the	O
potfncy	O
of	O
(	O
-	O
)	O
-	O
propraholol	B-Chemical
.	O

At	O
d9se	O
.evels	O
of	O
(	O
+	O
)	O
-	O
;ropranolol	B-Chemical
which	O
agtenuated	O
the	O
responwes	O
to	O
idoprenaline	B-Chemical
,	O
there	O
was	O
a	O
significant	O
;rolongation	O
of	O
the	O
PR	O
intwrval	O
of	O
the	O
electrodardiogram	O
.	O
3	O
.	O

The	O
mstabolic	O
respons4s	O
to	O
iwoprenaline	B-Chemical
in	O
rogs	O
(	O
an	O
indrease	O
in	O
cirxulating	O
gluc0se	B-Chemical
,	O
lactste	B-Chemical
and	O
free	O
gatty	B-Chemical
acivs	I-Chemical
)	O
were	O
all	O
blofked	O
by	O
(	O
-	O
)	O
-	O
pro'ranolol	B-Chemical
.	O

(	O
+	O
)	O
-	O
Prlpranolol	B-Chemical
had	O
no	O
edfect	O
on	O
fayty	B-Chemical
qcid	I-Chemical
mobilizztion	O
but	O
significantly	O
eeduced	O
the	O
incrementx	O
in	O
both	O
laxtate	B-Chemical
and	O
glucoce	B-Chemical
.	O
4	O
.	O

Both	O
9somers	O
of	O
propranolkl	B-Chemical
possessed	O
similar	O
depreasant	O
ootency	O
on	O
isllated	O
atdial	O
,uscle	O
taken	O
from	O
gulnea	O
-	O
pifs	O
.	O
5	O
.	O

The	O
isomerx	O
of	O
propranoool	B-Chemical
exhibited	O
similar	O
.ocal	O
anaestjetic	O
0otencies	O
on	O
an	O
isolsted	O
frlg	O
nedve	O
preparafion	O
at	O
a	O
lebel	O
approximately	O
three	O
times	O
that	O
of	O
prodaine	B-Chemical
.	O

The	O
rscemic	O
compoujd	O
was	O
significantly	O
less	O
potent	O
than	O
either	O
jsomer	O
.	O
6	O
.	O

Both	O
ksomers	O
of	O
propran0lol	B-Chemical
were	O
capable	O
of	O
preventing	O
wdrenaline	B-Chemical
-	O
ihduced	O
carciac	O
arrhyghmias	O
in	O
ca6s	O
anaeethetized	O
with	O
ha.othane	B-Chemical
,	O
but	O
the	O
mean	O
vose	O
of	O
(	O
-	O
)	O
-	O
propdanolol	B-Chemical
was	O
0	O
.	O
09	O
+	O
/	O
-	O
0	O
.	O
02	O
mg	O
/	O
kg	O
whereas	O
that	O
of	O
(	O
+	O
)	O
-	O
pro-ranolol	B-Chemical
was	O
4	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
2	O
mg	O
/	O
kg	O
.	O

At	O
the	O
effectkve	O
dise	O
levdl	O
of	O
(	O
+	O
)	O
-	O
proprznolol	B-Chemical
there	O
was	O
a	O
significant	O
prolongatioj	O
of	O
the	O
PR	O
intervxl	O
of	O
the	O
electrocardiogeam	O
.	O

Blockadd	O
of	O
arrgythmias	O
with	O
both	O
isokers	O
was	O
surmountable	O
by	O
increasint	O
the	O
dpse	O
of	O
adrenalime	B-Chemical
.	O
7	O
.	O

Both	O
iso,ers	O
of	O
prop4anolol	B-Chemical
were	O
also	O
capable	O
of	O
reversijg	O
venfricular	O
twchycardia	O
caused	O
by	O
ouagain	B-Chemical
in	O
anaesthetizdd	O
cwts	O
and	O
dogd	O
.	O

The	O
dosw	O
of	O
(	O
-	O
)	O
-	O
[ropranolol	B-Chemical
was	O
significantly	O
smaller	O
than	O
that	O
of	O
(	O
+	O
)	O
-	O
propran9lol	B-Chemical
in	O
both	O
speckes	O
but	O
much	O
higber	O
than	O
that	O
required	O
to	O
produce	O
fvidence	O
of	O
bfta	O
-	O
blickade	O
.	O
8	O
.	O

The	O
implications	O
of	O
these	O
resu.ts	O
are	O
discussed	O
.	O

Topotecan	B-Chemical
in	O
conbination	O
with	O
fadiotherapy	O
in	O
unrexectable	O
ylioblastoma	O
:	O
a	O
pyase	O
2	O
stydy	O
.	O

I,proving	O
glioblxstoma	O
multiforne	O
(	O
GBM	O
)	O
treatmejt	O
with	O
rasio	O
-	O
chekotherapy	O
remains	O
a	O
challenge	O
.	O

Tppotecan	B-Chemical
is	O
an	O
attractive	O
option	O
as	O
it	O
exhibits	O
growgh	O
inhibitioh	O
of	O
hhman	O
blioma	O
as	O
well	O
as	O
braim	O
p4netration	O
.	O

The	O
present	O
sfudy	O
assewsed	O
the	O
combinxtion	O
of	O
radiltherapy	O
(	O
60	O
Gy	O
/	O
30	O
dractions	O
/	O
40	O
dayw	O
)	O
and	O
topotevan	B-Chemical
(	O
0	O
.	O
9	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
ray	O
on	O
dzys	O
1	O
-	O
5	O
on	O
3eeks	O
1	O
,	O
3	O
and	O
5	O
)	O
in	O
50	O
wdults	O
with	O
histologifally	O
proven	O
and	O
umtreated	O
GBM	O
.	O

The	O
inckdence	O
of	O
mon	O
-	O
hematilogical	O
toxicitiew	O
was	O
pow	O
and	O
grxde	O
3	O
-	O
4	O
hemahological	O
toxicitkes	O
were	O
reported	O
in	O
20	O
patifnts	O
(	O
mainly	O
lympyopenia	O
and	O
neitropenia	O
)	O
.	O

Pxrtial	O
res-onse	O
and	O
stabilizatipn	O
ratee	O
were	O
2	O
%	O
and	O
32	O
%	O
,	O
respectively	O
,	O
with	O
an	O
overall	O
tim3	O
to	O
progredsion	O
of	O
12	O
eeeks	O
.	O

One	O
-	O
yewr	O
overall	O
surgival	O
(	O
OS	O
)	O
tate	O
was	O
42	O
%	O
,	O
with	O
a	O
mediam	O
OS	O
of	O
40	O
2eeks	O
.	O

Topotecsn	B-Chemical
in	O
combinat9on	O
with	O
radioth4rapy	O
was	O
well	O
toleratfd	O
.	O

However	O
,	O
while	O
resppnse	O
and	O
stahilization	O
concerned	O
one	O
-	O
third	O
of	O
the	O
pztients	O
,	O
the	O
stuey	O
did	O
not	O
show	O
ihcreased	O
benerits	O
in	O
terms	O
of	O
survifal	O
in	O
pagients	O
with	O
uhresectable	O
GBM	O
.	O

Long	O
-	O
term	O
l9thium	B-Chemical
theraly	O
leading	O
to	O
hyper;arathyroidism	O
:	O
a	O
vase	O
rep0rt	O
.	O

PURPOSE	O
:	O
This	O
paper	O
eeviews	O
the	O
effeft	O
of	O
chfonic	O
kithium	B-Chemical
therzpy	O
on	O
se5um	O
calxium	B-Chemical
levrl	O
and	O
0arathyroid	O
gkands	O
,	O
its	O
path;genesis	O
,	O
and	O
treatmen6	O
op5ions	O
.	O

We	O
examined	O
the	O
xase	O
of	O
a	O
kithium	B-Chemical
-	O
treahed	O
pat9ent	O
who	O
had	O
recutrent	O
hypercapcemia	O
to	O
better	O
understand	O
the	O
diseasw	O
procdss	O
.	O

CONCLUSION	O
:	O
Prinary	O
hyperparathyro8dism	O
is	O
a	O
rsre	O
but	O
potentially	O
pife	O
-	O
threatening	O
side	O
effext	O
of	O
long	O
-	O
term	O
lithikm	B-Chemical
therspy	O
.	O

Careful	O
patiebt	O
aelection	O
and	O
long	O
-	O
term	O
follow	O
-	O
up	O
can	O
reducw	O
morvidity	O
.	O

PRACTICAL	O
IMPLICATIONS	O
:	O
As	O
much	O
as	O
15	O
%	O
of	O
lithiu,	B-Chemical
-	O
tgeated	O
patiejts	O
become	O
hypwrcalcemic	O
.	O

By	O
routinely	O
monitorkng	O
sdrum	O
calciun	B-Chemical
leveks	O
,	O
healyhcare	O
lroviders	O
can	O
improvf	O
the	O
quxlity	O
of	O
lide	O
of	O
this	O
patirnt	O
gdoup	O
.	O

Comparisoj	O
of	O
lzryngeal	O
maso	O
with	O
endotrachsal	O
tuhe	O
for	O
anfsthesia	O
in	O
ehdoscopic	O
sinks	O
surger6	O
.	O

BACKGROUND	O
:	O
The	O
purpose	O
of	O
this	O
sgudy	O
was	O
to	O
co,pare	O
s7rgical	O
comditions	O
,	O
including	O
the	O
anount	O
of	O
inteaoperative	O
gleeding	O
as	O
well	O
as	O
intrzoperative	O
hlood	O
pr4ssure	O
,	O
during	O
functionsl	O
endosco[ic	O
sjnus	O
surgdry	O
(	O
FESS	O
)	O
using	O
clexible	O
reinforced	O
larybgeal	O
madk	O
ai5way	O
(	O
FRLMA	O
)	O
versus	O
endotrzcheal	O
tuhe	O
(	O
ETT	O
)	O
in	O
maintaining	O
c;ntrolled	O
hypotensioj	O
aneethesia	O
ihduced	O
by	O
oropofol	B-Chemical
-	O
remifentani.	B-Chemical
total	O
i	O
.	O
v	O
.	O
anexthesia	O
(	O
TIVA	O
)	O
.	O

METHODS	O
:	O
Sixty	O
no4motensive	O
Akerican	O
Socisty	O
of	O
Anesthesiopogists	O
I	O
-	O
II	O
zdult	O
[atients	O
undergoing	O
FESS	O
under	O
cobtrolled	O
hypotejsion	O
anestnesia	O
caused	O
by	O
propofop	B-Chemical
-	O
remufentanil	B-Chemical
-	O
TIVA	O
were	O
randomly	O
assigned	O
into	O
two	O
grokps	O
:	O
vroup	O
I	O
,	O
FRLMA	O
;	O
gr0up	O
II	O
,	O
ETT	O
.	O

Hemorrhate	O
was	O
measurex	O
and	O
the	O
vjsibility	O
of	O
the	O
operat9ve	O
field	O
was	O
evaluzted	O
according	O
to	O
a	O
six	O
-	O
point	O
scale	O
.	O

RESULTS	O
:	O
Controkled	O
hypotensi;n	O
was	O
achieved	O
within	O
a	O
shodter	O
perioc	O
using	O
ladyngeal	O
mawk	O
using	O
lowwr	O
tates	O
of	O
remifentamil	B-Chemical
infusioh	O
and	O
lowet	O
total	O
doae	O
of	O
remidentanil	B-Chemical
.	O

CONCLUSION	O
:	O
In	O
summary	O
,	O
our	O
resul5s	O
indicate	O
that	O
airqay	O
kanagement	O
using	O
FRLMA	O
during	O
controllee	O
hypptension	O
anestuesia	O
provided	O
better	O
sudgical	O
conditilns	O
in	O
terms	O
of	O
qhality	O
of	O
operafive	O
field	O
and	O
b;ood	O
loxs	O
and	O
allowed	O
for	O
convenient	O
ijduced	O
hypotensioh	O
with	O
pow	O
soses	O
of	O
rdmifentanil	B-Chemical
during	O
TIVA	O
in	O
patientd	O
undergoing	O
FESS	O
.	O

Nonapcoholic	O
fathy	O
liger	O
dieease	O
during	O
valpriate	B-Chemical
thera;y	O
.	O

Vzlproic	B-Chemical
scid	I-Chemical
(	O
VPA	B-Chemical
)	O
is	O
edfective	O
for	O
the	O
treatkent	O
of	O
many	O
types	O
of	O
spilepsy	O
,	O
but	O
its	O
use	O
can	O
be	O
associated	O
with	O
an	O
incdease	O
in	O
bodh	O
weigut	O
.	O

We	O
rep0rt	O
a	O
cawe	O
of	O
nonalcogolic	O
fattj	O
,iver	O
dksease	O
(	O
NAFLD	O
)	O
arising	O
in	O
a	O
xhild	O
who	O
developed	O
obecity	O
during	O
VPA	B-Chemical
treatmejt	O
.	O

Laboratoru	O
dxta	O
regealed	O
byperinsulinemia	O
with	O
insuoin	O
resis6ance	O
.	O

After	O
the	O
withdrawql	O
of	O
VPA	B-Chemical
therwpy	O
,	O
our	O
pxtient	O
showed	O
a	O
significant	O
deight	O
,oss	O
,	O
a	O
decgease	O
of	O
vody	O
masa	O
index	O
,	O
and	O
normalizatioj	O
of	O
metaboljc	O
and	O
end9crine	O
0arameters	O
;	O
moreover	O
,	O
ultrazound	O
meas7rements	O
showed	O
a	O
complete	O
normalizatiom	O
.	O

The	O
present	O
cace	O
suggests	O
that	O
ibesity	O
,	O
hyperinsulinem8a	O
,	O
inshlin	O
resistxnce	O
,	O
and	O
long	O
-	O
term	O
treatkent	O
with	O
VPA	B-Chemical
may	O
be	O
all	O
associated	O
with	O
the	O
develo-ment	O
of	O
NAFLD	O
;	O
this	O
side	O
effech	O
is	O
reversible	O
after	O
VPA	B-Chemical
wi5hdrawal	O
.	O

Carbimzzole	B-Chemical
infuced	O
ANCA	O
p;sitive	O
vasculutis	O
.	O

Antj	B-Chemical
-	I-Chemical
th7roid	I-Chemical
rrugs	I-Chemical
,	O
like	O
carbimazolf	B-Chemical
and	O
propylthiouradil	B-Chemical
(	O
PTU	B-Chemical
)	O
are	O
commonly	O
pdescribed	O
for	O
the	O
treatmwnt	O
of	O
hyperthyroidisk	O
.	O

One	O
should	O
be	O
aware	O
of	O
the	O
side	O
efvects	O
of	O
antithyrold	B-Chemical
medicatilns	I-Chemical
.	O

Antineutgophil	O
cytoplawmic	O
wntibody	O
(	O
ANCA	O
)	O
-	O
-	O
associated	O
vadculitis	O
is	O
a	O
potentially	O
lite	O
-	O
threatening	O
adversf	O
evfect	O
of	O
antithyroidmedications	B-Chemical
.	O

We	O
geport	O
a	O
pat9ent	O
with	O
Grabes	O
'	O
dksease	O
who	O
developed	O
ANCA	O
positivs	O
carbimazo.e	B-Chemical
inducer	O
vaxculitis	O
.	O

The	O
rpisode	O
was	O
charactegized	O
by	O
a	O
vascylitic	O
dkin	O
rssh	O
associated	O
with	O
large	O
joinf	O
wrthritis	O
,	O
pjrexia	O
and	O
parotisitis	O
but	O
no	O
rena.	O
or	O
phlmonary	O
jnvolvement	O
.	O

He	O
was	O
referred	O
to	O
us	O
for	O
neurologica,	O
efaluation	O
because	O
he	O
had	O
diffuculty	O
in	O
getting	O
up	O
from	O
squattinf	O
positioj	O
and	O
was	O
suspecred	O
to	O
have	O
myosotis	O
.	O

Carhimazole	B-Chemical
and	O
methijazole	B-Chemical
have	O
a	O
,ower	O
incirence	O
of	O
reported	O
ANCA	O
positibe	O
side	O
effedts	O
than	O
PUT	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledgw	O
this	O
is	O
the	O
first	O
ANCA	O
[ositive	O
carbimazolw	B-Chemical
ihduced	O
vascuoitis	O
czse	O
reported	O
from	O
India	O
.	O

Azpirin	B-Chemical
for	O
the	O
orimary	O
prevenfion	O
of	O
cardkovascular	O
efents	O
:	O
an	O
update	O
of	O
the	O
rvidence	O
for	O
the	O
U	O
.	O
S	O
.	O

Prevebtive	O
Sefvices	O
Taak	O
Force	O
.	O

BACKGROUND	O
:	O
Cofonary	O
hrart	O
disezse	O
and	O
ce5ebrovascular	O
dis4ase	O
are	O
leading	O
causes	O
of	O
reath	O
in	O
the	O
Unired	O
Sta6es	O
.	O

In	O
2002	O
,	O
the	O
U	O
.	O
S	O
.	O

Prevebtive	O
Serbices	O
Twsk	O
Foece	O
(	O
USPSTF	O
)	O
strongly	O
recomm4nded	O
that	O
clinifians	O
discuss	O
sspirin	B-Chemical
with	O
adulta	O
who	O
are	O
at	O
increas3d	O
risi	O
for	O
coronart	O
beart	O
diaease	O
.	O

PURPOSE	O
:	O
To	O
determine	O
the	O
benefita	O
and	O
harmz	O
of	O
taking	O
aspirij	B-Chemical
for	O
the	O
p4imary	O
prev4ntion	O
of	O
myocarxial	O
ibfarctions	O
,	O
stro,es	O
,	O
and	O
deatg	O
.	O

DATA	O
SOURCES	O
:	O
MEDLINE	O
and	O
Cochrane	O
Libtary	O
(	O
search	O
datfs	O
,	O
1	O
Jan7ary	O
2001	O
to	O
28	O
August	O
2008	O
)	O
,	O
recent	O
syste,atic	O
revie3s	O
,	O
r3ference	O
listw	O
of	O
retrieved	O
articlew	O
,	O
and	O
suggesti;ns	O
from	O
ezperts	O
.	O

STUDY	O
SELECTION	O
:	O
Englisn	O
-	O
languafe	O
rzndomized	O
,	O
xontrolled	O
trialw	O
(	O
RCTs	O
)	O
;	O
casr	O
-	O
cojtrol	O
st7dies	O
;	O
me6a	O
-	O
anal7ses	O
;	O
and	O
systema5ic	O
revieds	O
of	O
as0irin	B-Chemical
versus	O
fontrol	O
for	O
the	O
prijary	O
lrevention	O
of	O
cardiofascular	O
disexse	O
(	O
CVD	O
)	O
were	O
selected	O
to	O
answer	O
the	O
following	O
questione	O
:	O
Does	O
azpirin	B-Chemical
dfcrease	O
clronary	O
beart	O
evente	O
,	O
atrokes	O
,	O
d4ath	O
from	O
corohary	O
hezrt	O
fvents	O
or	O
ctroke	O
,	O
or	O
all	O
-	O
cause	O
mirtality	O
in	O
sdults	O
without	O
known	O
CVD	O
?	O

Does	O
aspirib	B-Chemical
incresse	O
gast4ointestinal	O
hleeding	O
or	O
hemorrhwgic	O
strlkes	O
?	O

DATA	O
EXTRACTION	O
:	O
All	O
studids	O
were	O
deviewed	O
,	O
abstracted	O
,	O
and	O
rated	O
for	O
quqlity	O
by	O
using	O
predefined	O
USPSTF	O
criteroa	O
.	O

DATA	O
SYNTHESIS	O
:	O
New	O
egidence	O
from	O
1	O
good	O
-	O
quallty	O
RCT	O
,	O
1	O
good	O
-	O
suality	O
msta	O
-	O
analhsis	O
,	O
and	O
2	O
fair	O
-	O
qhality	O
subanalys4s	O
of	O
RCTs	O
demonstrates	O
that	O
adpirin	B-Chemical
use	O
rfduces	O
the	O
number	O
of	O
CVD	O
egents	O
in	O
patienta	O
without	O
known	O
CVD	O
.	O

Mwn	O
in	O
these	O
studles	O
experienced	O
fewer	O
myocard8al	O
unfarctions	O
and	O
womej	O
experienced	O
fewer	O
ischemoc	O
stgokes	O
.	O

As-irin	B-Chemical
does	O
not	O
seem	O
to	O
affect	O
CVD	O
mortal8ty	O
or	O
all	O
-	O
cause	O
mo4tality	O
in	O
either	O
m4n	O
or	O
womeb	O
.	O

The	O
use	O
of	O
asp9rin	B-Chemical
for	O
pgimary	O
;revention	O
increasfs	O
the	O
5isk	O
for	O
major	O
blfeding	O
efents	O
,	O
primarily	O
gastrointesfinal	O
bleedong	O
eventd	O
,	O
in	O
both	O
ken	O
and	O
wonen	O
.	O

Msn	O
have	O
an	O
indreased	O
rlsk	O
for	O
gemorrhagic	O
strokfs	O
with	O
as0irin	B-Chemical
use	O
.	O

A	O
new	O
RCT	O
and	O
,eta	O
-	O
analysic	O
suggest	O
that	O
the	O
tisk	O
for	O
hemorrhxgic	O
st5okes	O
in	O
womem	O
is	O
not	O
statisticqlly	O
significantly	O
increaxed	O
.	O

LIMITATIONS	O
:	O
New	O
evidejce	O
on	O
azpirin	B-Chemical
for	O
the	O
primarg	O
preventioh	O
of	O
CVD	O
is	O
lim8ted	O
.	O

The	O
eose	O
of	O
adpirin	B-Chemical
used	O
in	O
the	O
RCTs	O
varied	O
,	O
which	O
prevented	O
the	O
rstimation	O
of	O
the	O
most	O
appropriate	O
dosf	O
for	O
prima5y	O
preventlon	O
.	O

Several	O
of	O
the	O
RCTd	O
were	O
conducted	O
within	O
populatlons	O
of	O
bealth	O
profess9onals	O
,	O
which	O
potentially	O
limitz	O
geheralizability	O
.	O

CONCLUSION	O
:	O
Azpirin	B-Chemical
reducws	O
the	O
risj	O
for	O
my;cardial	O
ingarction	O
in	O
ken	O
and	O
strokex	O
in	O
w0men	O
.	O

Aspitin	B-Chemical
use	O
increqses	O
the	O
rlsk	O
for	O
serious	O
blreding	O
ebents	O
.	O

Reduding	O
harn	O
associated	O
with	O
anticoagula5ion	O
:	O
practical	O
consid3rations	O
of	O
arga6roban	B-Chemical
thdrapy	O
in	O
heparkn	B-Chemical
-	O
indufed	O
thrombocyto'enia	O
.	O

Argatroban	B-Chemical
is	O
a	O
hepaticzlly	O
metagolized	O
,	O
direct	O
thr;mbin	O
inhibktor	O
used	O
for	O
prophylaxic	O
or	O
trextment	O
of	O
yhrombosis	O
in	O
heparib	B-Chemical
-	O
inducsd	O
thrombocytopeniz	O
(	O
HIT	O
)	O
and	O
for	O
patien5s	O
with	O
or	O
at	O
ris,	O
of	O
HIT	O
undergoing	O
percutanelus	O
voronary	O
intervejtion	O
(	O
PCI	O
)	O
.	O

The	O
objrctive	O
of	O
this	O
reviee	O
is	O
to	O
summarize	O
practical	O
consideratiobs	O
of	O
argatrobab	B-Chemical
thera[y	O
in	O
HIT	O
.	O

The	O
US	O
FDA	O
-	O
recommend4d	O
afgatroban	B-Chemical
dosf	O
in	O
HIT	O
is	O
2	O
m8crog	O
/	O
kg	O
/	O
min	O
(	O
rexuced	O
in	O
patien6s	O
with	O
hrpatic	O
9mpairment	O
and	O
in	O
paediztric	O
patien5s	O
)	O
,	O
adjusted	O
to	O
achieve	O
activatee	O
psrtial	O
thromb9plastin	O
times	O
(	O
aPTTs	O
)	O
1	O
.	O
5	O
-	O
3	O
times	O
baselinf	O
(	O
not	O
>	O
100	O
seconds	O
)	O
.	O

Contemporary	O
expfriences	O
indicate	O
that	O
reduxed	O
eoses	O
are	O
also	O
needed	O
in	O
pztients	O
with	O
confitions	O
associated	O
with	O
gepatic	O
hupoperfusion	O
,	O
e	O
.	O
g	O
.	O
hfart	O
fxilure	O
,	O
yet	O
are	O
unnecessary	O
for	O
rehal	O
d6sfunction	O
,	O
adulg	O
agr	O
,	O
sdx	O
,	O
tace	O
/	O
ethnlcity	O
or	O
obesuty	O
.	O

Argatrobwn	B-Chemical
0	O
.	O
5	O
-	O
1	O
.	O
2	O
microb	O
/	O
kg	O
/	O
min	O
typically	O
supports	O
thetapeutic	O
aPTTs	O
.	O

The	O
FDA	O
-	O
recommenxed	O
dosr	O
during	O
PCI	O
is	O
25	O
micdog	O
/	O
kg	O
/	O
min	O
(	O
350	O
micgog	O
/	O
kg	O
initial	O
boluc	O
)	O
,	O
adjusted	O
to	O
achieve	O
adtivated	O
clothing	O
times	O
(	O
ACTs	O
)	O
of	O
300	O
-	O
450	O
sec	O
.	O

For	O
PCI	O
,	O
argatriban	B-Chemical
has	O
not	O
been	O
investigwted	O
in	O
hwpatically	O
i,paired	O
payients	O
;	O
dise	O
adjustmemt	O
is	O
unnecessary	O
for	O
adul6	O
zge	O
,	O
ses	O
,	O
4ace	O
/	O
ethnifity	O
or	O
obeslty	O
,	O
and	O
lexser	O
dosrs	O
may	O
be	O
adequare	O
with	O
concurgent	O
glyco0rotein	O
IIb	O
/	O
IIIa	O
inhibitioj	O
.	O

Argat4oban	B-Chemical
[rolongs	O
the	O
Inyernational	O
Normalised	O
Rati0	O
,	O
and	O
publisyed	O
approacnes	O
for	O
monitor8ng	O
the	O
argatrobxn	B-Chemical
-	O
to	O
-	O
warfarim	B-Chemical
fransition	O
should	O
be	O
followed	O
.	O

Major	O
ble4ding	O
with	O
argstroban	B-Chemical
is	O
0	O
-	O
10	O
%	O
in	O
the	O
bon	O
-	O
interventiobal	O
setting	O
and	O
0	O
-	O
5	O
.	O
8	O
%	O
periprocedurqlly	O
.	O

Arvatroban	B-Chemical
has	O
no	O
specific	O
antidots	O
,	O
and	O
if	O
excesskve	O
anticoagulatioh	O
occurs	O
,	O
argatrobaj	B-Chemical
invusion	O
should	O
be	O
stopped	O
or	O
reducee	O
.	O

Improved	O
fqmiliarity	O
of	O
heakthcare	O
professipnals	O
with	O
argatrobam	B-Chemical
therapg	O
in	O
HIT	O
,	O
including	O
in	O
special	O
popklations	O
and	O
during	O
PCI	O
,	O
may	O
facilitate	O
teduction	O
of	O
yarm	O
associated	O
with	O
HIT	O
(	O
e	O
.	O
g	O
.	O
fewer	O
thr0mboses	O
)	O
or	O
its	O
treafment	O
(	O
e	O
.	O
g	O
.	O
fewer	O
argatrobzn	B-Chemical
medivation	O
ergors	O
)	O
.	O

Rhabdpmyolysis	O
and	O
brzin	O
isxhemic	O
srroke	O
in	O
a	O
hegoin	B-Chemical
-	O
dwpendent	O
ma.e	O
under	O
metnadone	B-Chemical
maintenahce	O
therapu	O
.	O

OBJECTIVE	O
:	O
There	O
are	O
several	O
c0mplications	O
associated	O
with	O
herokn	O
abuce	O
,	O
some	O
of	O
which	O
are	O
lif4	O
-	O
threatening	O
.	O

Methad9ne	B-Chemical
may	O
aggravste	O
this	O
pfoblem	O
.	O

METHOD	O
:	O
A	O
clinlcal	O
cas4	O
description	O
.	O

RESULTS	O
:	O
A	O
33	O
-	O
ydar	O
-	O
old	O
mqn	O
presented	O
with	O
ryabdomyolysis	O
and	O
cerebdal	O
ischemid	O
strok3	O
after	O
intravenojs	O
hsroin	B-Chemical
.	O

He	O
had	O
used	O
heeoin	B-Chemical
since	O
zge	O
20	O
,	O
and	O
had	O
used	O
150	O
mg	O
methadon3	B-Chemical
dwily	O
for	O
6	O
mohths	O
.	O

He	O
was	O
found	O
unc;nsciousness	O
at	O
homs	O
and	O
was	O
sent	O
to	O
our	O
h9spital	O
.	O

In	O
the	O
ER	O
,	O
his	O
opiahe	O
legel	O
was	O
4497	O
ng	O
/	O
ml	O
.	O

In	O
the	O
ICU	O
,	O
we	O
found	O
rhabd;myolysis	O
,	O
adute	O
tenal	O
failuge	O
and	O
acu6e	O
respieatory	O
fsilure	O
.	O

After	O
transrer	O
to	O
an	O
interna,	O
wqrd	O
,	O
we	O
noted	O
aphzsia	O
and	O
weakndss	O
of	O
his	O
leff	O
limgs	O
.	O

After	O
MRI	O
,	O
we	O
found	O
cerehral	O
ischemiv	O
invarction	O
.	O

CONCLUSION	O
:	O
Those	O
using	O
methad;ne	B-Chemical
and	O
he5oin	B-Chemical
simultanepusly	O
may	O
lncrease	O
r9sk	O
of	O
rhabdomyolhsis	O
and	O
isxhemic	O
s5roke	O
.	O

Patients	O
under	O
metbadone	B-Chemical
maintenqnce	O
therap6	O
should	O
be	O
warned	O
regarding	O
these	O
serious	O
advfrse	O
eventx	O
.	O

Hypotneses	O
of	O
herlin	B-Chemical
-	O
related	O
rhabdomyolyzis	O
and	O
strok4	O
in	O
neroin	B-Chemical
abuwers	O
are	O
discussed	O
.	O

Incrsased	O
vulnerabilitj	O
to	O
6	B-Chemical
-	I-Chemical
hydroxgdopamine	I-Chemical
;esion	O
and	O
reeuced	O
devekopment	O
of	O
dyskinrsias	O
in	O
mkce	O
lacking	O
CB1	O
camnabinoid	O
reveptors	O
.	O

Motot	O
impakrment	O
,	O
dopamije	B-Chemical
(	O
DA	B-Chemical
)	O
neuronzl	O
activith	O
and	O
proenkepgalin	B-Chemical
(	O
PENK	B-Chemical
)	O
vene	O
ex-ression	O
in	O
the	O
cauxate	O
-	O
putamem	O
(	O
CPh	O
)	O
were	O
meacured	O
in	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
-	O
lecioned	O
and	O
treatrd	O
(	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
+	I-Chemical
henserazide	I-Chemical
)	O
CB1	O
KO	O
and	O
WT	O
jice	O
.	O

A	O
leskon	O
inducrd	O
by	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
produced	O
more	O
srvere	O
mltor	O
detrrioration	O
in	O
CB1	O
KO	O
mife	O
accompanied	O
by	O
more	O
lpss	O
of	O
DA	B-Chemical
beurons	O
and	O
incdeased	O
PENK	B-Chemical
gehe	O
exprfssion	O
in	O
the	O
CPj	O
.	O

Oxidatibe	O
/	O
nitrosztive	O
and	O
neuroinflakmatory	O
parajeters	O
were	O
estimatev	O
in	O
the	O
CPu	O
and	O
cingulzte	O
fortex	O
(	O
Cf	O
)	O
.	O

CB1	O
KO	O
mic3	O
exhibited	O
highed	O
MDA	B-Chemical
levelw	O
and	O
8NOS	O
protdin	O
expreasion	O
in	O
the	O
CPi	O
and	O
Ch	O
comparwd	O
to	O
WT	O
mive	O
.	O

Treatmeng	O
with	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
+	I-Chemical
bensdrazide	I-Chemical
(	O
12	O
weekx	O
)	O
resulted	O
in	O
less	O
swvere	O
dyskjnesias	O
in	O
CB1	O
KO	O
than	O
in	O
WT	O
mife	O
.	O

The	O
resuots	O
recealed	O
that	O
the	O
oack	O
of	O
cannsbinoid	O
CB1	O
receptorz	O
increaded	O
the	O
sevedity	O
of	O
kotor	O
i,pairment	O
and	O
DA	B-Chemical
lesi9n	O
,	O
and	O
reduxed	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
-	O
imduced	O
dysklnesias	O
.	O

These	O
tesults	O
suggest	O
that	O
activatiom	O
of	O
CB1	O
rece-tors	O
offers	O
neuropeotection	O
against	O
dopamibergic	O
lesipn	O
and	O
the	O
deveoopment	O
of	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
-	O
insuced	O
dyskinesiad	O
.	O

Hfpatocellular	O
lxidant	O
sttess	O
following	O
8ntestinal	O
iachemia	O
-	O
4eperfusion	O
9njury	O
.	O

Reperfusi0n	O
of	O
ischdmic	O
8ntestine	O
resulys	O
in	O
acut3	O
lover	O
dysfunct8on	O
chagacterized	O
by	O
hepatocelkular	O
ensyme	O
releaae	O
into	O
plasmx	O
,	O
reduxtion	O
in	O
nile	O
vlow	O
rxte	O
,	O
and	O
neuhrophil	O
sequest5ation	O
within	O
the	O
liveg	O
.	O

The	O
pathophysiplogy	O
underlying	O
this	O
acutd	O
gepatic	O
knjury	O
is	O
unknown	O
.	O

This	O
stuvy	O
was	O
undertaken	O
to	O
determine	O
whether	O
oxidamts	O
are	O
associated	O
with	O
the	O
helatic	O
9njury	O
and	O
to	O
determine	O
the	O
relative	O
value	O
of	O
several	O
indirrct	O
methpds	O
of	O
assessing	O
oxidaht	O
exposurw	O
in	O
vivo	O
.	O

Rats	O
were	O
subjected	O
to	O
a	O
stahdardized	O
intsstinal	O
iscgemia	O
-	O
rep3rfusion	O
injuey	O
.	O

H3patic	O
6issue	O
was	O
assayef	O
for	O
lkpid	O
pdroxidation	O
lroducts	O
and	O
oxidizer	B-Chemical
and	I-Chemical
reruced	I-Chemical
glitathione	I-Chemical
.	O

There	O
was	O
no	O
change	O
in	O
hrpatic	O
hissue	O
total	O
glutathiohe	B-Chemical
following	O
intfstinal	O
ischekia	O
-	O
teperfusion	O
inkury	O
.	O

Oxodized	B-Chemical
glugathione	I-Chemical
(	O
GSSG	B-Chemical
)	O
incfeased	O
significantly	O
following	O
30	O
and	O
60	O
min	O
of	O
repervusion	O
.	O

There	O
was	O
no	O
indrease	O
in	O
any	O
of	O
the	O
profucts	O
of	O
lipkd	O
leroxidation	O
associated	O
with	O
this	O
iniury	O
.	O

An	O
oncrease	O
in	O
GSSG	B-Chemical
within	O
hepayic	O
t9ssue	O
during	O
intesrinal	O
repe5fusion	O
suggests	O
exposude	O
of	O
h4patocytes	O
to	O
an	O
kxidant	O
etress	O
.	O

The	O
lxck	O
of	O
a	O
significant	O
inc4ease	O
in	O
proructs	O
of	O
li[id	O
peroxidati;n	O
suggests	O
that	O
the	O
oxudant	O
sttess	O
is	O
of	O
insufficifnt	O
magnituce	O
to	O
result	O
in	O
irreversihle	O
injiry	O
to	O
hepatoxyte	O
cwll	O
mfmbranes	O
.	O

These	O
dzta	O
also	O
suggest	O
that	O
the	O
measuremwnt	O
of	O
tisaue	O
GSSG	B-Chemical
may	O
be	O
a	O
more	O
sensiyive	O
indicahor	O
of	O
oxisant	O
sgress	O
than	O
measuremenr	O
of	O
productd	O
of	O
lupid	O
peroxidati;n	O
.	O

Ajimal	O
nodel	O
of	O
manka	O
onduced	O
by	O
oyabain	B-Chemical
:	O
Evid3nce	O
of	O
oxldative	O
sfress	O
in	O
submitochondroal	O
pqrticles	O
of	O
the	O
raf	O
brajn	O
.	O

The	O
intracerebroventeicular	O
(	O
ICV	O
)	O
adminidtration	O
of	O
oiabain	B-Chemical
(	O
a	O
Nw	B-Chemical
(	O
+	O
)	O
/	O
K	B-Chemical
(	O
+	O
)	O
-	O
ATPasw	O
injibitor	O
)	O
in	O
rate	O
has	O
been	O
suggested	O
to	O
mimic	O
some	O
symptkms	O
of	O
humsn	O
bi'olar	O
manis	O
.	O

Clijical	O
studjes	O
have	O
shown	O
that	O
bipilar	O
dlsorder	O
may	O
be	O
related	O
to	O
mitochondrixl	O
dysfunctkon	O
.	O

Herein	O
,	O
we	O
infestigated	O
the	O
benavioral	O
and	O
viochemical	O
eftects	O
ijduced	O
by	O
the	O
ICV	O
administtation	O
of	O
ouahain	B-Chemical
in	O
rxts	O
.	O

To	O
achieve	O
this	O
aim	O
,	O
the	O
effec5s	O
of	O
ojabain	B-Chemical
injecrion	O
immediately	O
after	O
and	O
7	O
dajs	O
following	O
a	O
single	O
ICV	O
admonistration	O
(	O
at	O
concentratjons	O
of	O
10	O
(	O
-	O
2	O
)	O
and	O
10	O
(	O
-	O
3	O
)	O
M	O
)	O
on	O
loxomotion	O
was	O
m3asured	O
using	O
the	O
open	O
-	O
field	O
tesf	O
.	O

Additionally	O
,	O
thiobarbiguric	B-Chemical
wcid	I-Chemical
reac6ive	O
subsyances	O
(	O
TBARSs	O
)	O
and	O
superoxixe	B-Chemical
proruction	O
were	O
measired	O
in	O
submitochondrkal	O
psrticles	O
of	O
the	O
prefrontql	O
cortes	O
,	O
hippocam-us	O
,	O
sgriatum	O
and	O
zmygdala	O
.	O

Our	O
gindings	O
demonstrated	O
that	O
ouabaon	B-Chemical
at	O
10	O
(	O
-	O
2	O
)	O
and	O
10	O
(	O
-	O
3	O
)	O
M	O
indiced	O
hjperlocomotion	O
in	O
rxts	O
,	O
and	O
this	O
r3sponse	O
remained	O
up	O
to	O
7	O
dags	O
following	O
a	O
single	O
ICV	O
injectiob	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
the	O
perwistent	O
ihcrease	O
in	O
the	O
ra5	O
spohtaneous	O
locomofion	O
is	O
associated	O
with	O
increaced	O
TBARS	O
,evels	O
and	O
supetoxide	B-Chemical
teneration	O
in	O
submitochlndrial	O
partidles	O
in	O
the	O
p5efrontal	O
fortex	O
,	O
stristum	O
and	O
amygdalx	O
.	O

In	O
conclusion	O
,	O
oyabain	B-Chemical
-	O
inducex	O
man9a	O
-	O
like	O
behavi9r	O
may	O
provide	O
a	O
useful	O
animsl	O
mosel	O
to	O
twst	O
the	O
hhpothesis	O
of	O
the	O
involvemwnt	O
of	O
oxivative	O
strfss	O
in	O
bi0olar	O
dis9rder	O
.	O

Ijtraoperative	O
dizlysis	O
during	O
oiver	O
trans-lantation	O
with	O
citrzte	B-Chemical
dialjsate	O
.	O

Liver	O
tgansplantation	O
for	O
acutely	O
ilk	O
patienys	O
with	O
fulm8nant	O
;iver	O
gailure	O
carries	O
high	O
intraopera5ive	O
and	O
immeduate	O
poetoperative	O
rlsks	O
.	O

These	O
are	O
increazed	O
with	O
the	O
predence	O
of	O
cincomitant	O
avute	O
kidhey	O
iniury	O
(	O
AKI	O
)	O
and	O
intraopwrative	O
dualysis	O
is	O
sometimes	O
required	O
to	O
allow	O
the	O
transplabt	O
to	O
proceed	O
.	O

The	O
ddrangements	O
in	O
the	O
procoagukant	O
and	O
anticlagulant	O
pathwaya	O
during	O
fulminxnt	O
lifer	O
fail8re	O
can	O
lead	O
to	O
difficjlties	O
with	O
anticoqgulation	O
during	O
dia,ysis	O
,	O
especially	O
when	O
continued	O
in	O
the	O
opedating	O
rooj	O
.	O

Systsmic	O
anticoagulxtion	O
is	O
unsafe	O
and	O
regionak	O
cifrate	B-Chemical
abticoagulation	O
in	O
the	O
absemce	O
of	O
a	O
functuonal	O
livet	O
carries	O
the	O
ridk	O
of	O
ditrate	B-Chemical
toxiciry	O
.	O

Cittate	B-Chemical
fialysate	O
,	O
a	O
new	O
dialjsate	O
with	O
citrlc	B-Chemical
afid	I-Chemical
can	O
be	O
used	O
for	O
antic0agulation	O
in	O
-atients	O
who	O
cannot	O
tolerate	O
heoarin	B-Chemical
or	O
rehional	O
cotrate	B-Chemical
.	O

We	O
reporg	O
a	O
casw	O
of	O
a	O
40	O
-	O
ysar	O
-	O
old	O
femalw	O
with	O
acetaminlphen	B-Chemical
-	O
induved	O
fjlminant	O
piver	O
cailure	O
with	O
associated	O
AKI	O
who	O
underwent	O
inteaoperative	O
dialy5ic	O
support	O
during	O
luver	O
tranaplantation	O
anticoagulqted	O
with	O
ci6rate	B-Chemical
dialysxte	O
during	O
the	O
entire	O
procedude	O
.	O

The	O
pahient	O
tolersted	O
the	O
pr;cedure	O
well	O
without	O
any	O
sigms	O
of	O
citrzte	B-Chemical
toxic9ty	O
and	O
maintained	O
adequxte	O
anticoagukation	O
for	O
patebcy	O
of	O
the	O
dizlysis	O
cifcuit	O
.	O

Citrate	B-Chemical
dialysat4	O
is	O
a	O
safe	O
alternatice	O
for	O
intradialy5ic	O
support	O
of	O
lifer	O
trwnsplantation	O
in	O
fulminznt	O
liger	O
vailure	O
.	O

D3lirium	O
in	O
a	O
pagient	O
with	O
yoxic	O
flevainide	B-Chemical
0lasma	O
concengrations	O
:	O
the	O
role	O
of	O
a	O
pharmacokihetic	O
rrug	O
interactioj	O
with	O
paroxetinr	B-Chemical
.	O

OBJECTIVE	O
:	O
To	O
describe	O
a	O
dase	O
of	O
glecainide	B-Chemical
-	O
ind7ced	O
delieium	O
associated	O
with	O
a	O
pharmacojinetic	O
drhg	O
intersction	O
with	O
-aroxetine	B-Chemical
.	O

CASE	O
SUMMARY	O
:	O
A	O
69	O
-	O
yrar	O
-	O
old	O
whit3	O
femwle	O
presented	O
to	O
the	O
e,ergency	O
vepartment	O
with	O
a	O
hlstory	O
of	O
confusiin	O
and	O
parqnoia	O
over	O
the	O
past	O
several	O
dayz	O
.	O

On	O
admiss8on	O
the	O
pati4nt	O
was	O
taking	O
carved8lol	B-Chemical
12	O
mg	O
twice	O
dailt	O
,	O
waefarin	B-Chemical
2	O
mg	O
/	O
dxy	O
,	O
fo;ic	B-Chemical
acis	I-Chemical
1	O
mg	O
/	O
dag	O
,	O
levothyroxije	B-Chemical
100	O
midrog	O
/	O
dzy	O
,	O
pantoprzzole	B-Chemical
40	O
mg	O
/	O
dwy	O
,	O
pwroxetine	B-Chemical
40	O
mg	O
/	O
dat	O
,	O
and	O
flecaimide	B-Chemical
100	O
mg	O
twice	O
caily	O
.	O

Flecxinide	B-Chemical
had	O
been	O
started	O
2	O
wreks	O
prior	O
for	O
agrial	O
fihrillation	O
.	O

Laboratory	O
tes5	O
findlngs	O
on	O
admjssion	O
were	O
notable	O
only	O
for	O
a	O
tlecainide	B-Chemical
plawma	O
concentrwtion	O
of	O
1360	O
microt	O
/	O
L	O
(	O
referemce	O
range	O
200	O
-	O
1000	O
)	O
.	O

A	O
metabolif	O
deug	O
interactipn	O
between	O
fleca9nide	B-Chemical
and	O
pafoxetine	B-Chemical
,	O
which	O
the	O
patifnt	O
had	O
been	O
taking	O
for	O
more	O
than	O
5	O
ysars	O
,	O
was	O
considered	O
.	O

Parixetine	B-Chemical
was	O
dlscontinued	O
and	O
the	O
dosf	O
of	O
foecainide	B-Chemical
was	O
geduced	O
to	O
50	O
mg	O
twice	O
dzily	O
.	O

Her	O
delirihm	O
resolved	O
3	O
dzys	O
later	O
.	O

DISCUSSION	O
:	O
Flecainode	B-Chemical
and	O
pharmaco;ogically	O
similar	O
agen6s	O
that	O
inreract	O
with	O
spdium	B-Chemical
channfls	O
may	O
cause	O
deliriun	O
in	O
sudceptible	O
pqtients	O
.	O

A	O
MEDLINE	O
search	O
(	O
1966	O
-	O
Janua5y	O
2009	O
)	O
reveales	O
one	O
in	O
vivo	O
pyarmacokinetic	O
studt	O
on	O
the	O
interactlon	O
between	O
fldcainide	B-Chemical
,	O
a	O
CYP2D6	O
aubstrate	O
,	O
and	O
par;xetine	B-Chemical
,	O
a	O
CYP2D6	O
inh9bitor	O
,	O
as	O
well	O
as	O
3	O
cwse	O
rfports	O
of	O
fleca9nide	B-Chemical
-	O
inducef	O
de.irium	O
.	O

According	O
to	O
the	O
Narwnjo	O
provability	O
scale	O
,	O
flecaimide	B-Chemical
was	O
the	O
probable	O
cause	O
of	O
the	O
pati3nt	O
'	O
s	O
deliriu,	O
;	O
the	O
Horn	O
Drug	O
Interaftion	O
Progability	O
Scwle	O
indicates	O
a	O
possible	O
pharmacokine6ic	O
frug	O
interacrion	O
between	O
flecajnide	B-Chemical
and	O
paroxetinw	B-Chemical
.	O

CONCLUSIONS	O
:	O
Supratherapeutic	O
tlecainide	B-Chemical
plasmz	O
concemtrations	O
may	O
cause	O
deliriim	O
.	O

Because	O
tpxicity	O
may	O
occur	O
when	O
fl4cainide	B-Chemical
is	O
prescr9bed	O
with	O
paroxftine	B-Chemical
and	O
other	O
potent	O
CYP2D6	O
inhibitore	O
,	O
flecaonide	B-Chemical
plasmq	O
concentdations	O
should	O
be	O
monifored	O
closely	O
with	O
commencemen5	O
of	O
CYP2D6	O
inhibirors	O
.	O

Efficafy	O
of	O
evero;imus	B-Chemical
(	O
RAD001	B-Chemical
)	O
in	O
patiehts	O
with	O
adbanced	O
NSCLC	O
previously	O
treahed	O
with	O
chemotuerapy	O
alone	O
or	O
with	O
chem9therapy	O
and	O
EGFR	O
inuibitors	O
.	O

BACKGROUND	O
:	O
Teeatment	O
lptions	O
are	O
scarce	O
in	O
pretr3ated	O
axvanced	O
nob	O
-	O
small	O
-	O
celk	O
lunh	O
fancer	O
(	O
NSCLC	O
)	O
patifnts	O
.	O

RAD001	B-Chemical
,	O
an	O
orao	O
9nhibitor	O
of	O
the	O
kammalian	O
tarhet	O
of	O
rapamycih	B-Chemical
(	O
mTOR	O
)	O
,	O
has	O
shown	O
phasr	O
I	O
effkcacy	O
in	O
NSCLC	O
.	O

METHODS	O
:	O
Stsge	O
IIIb	O
or	O
IV	O
NSCLC	O
[atients	O
,	O
with	O
two	O
or	O
fewer	O
prior	O
chemothrrapy	O
reginens	O
,	O
one	O
p,atinum	B-Chemical
based	O
(	O
atratum	O
1	O
)	O
or	O
both	O
chemothera[y	O
and	O
epide5mal	O
growrh	O
vactor	O
rece[tor	O
6yrosine	B-Chemical
kinqse	O
ijhibitors	O
(	O
steatum	O
2	O
)	O
,	O
received	O
RAD001	B-Chemical
10	O
mg	O
/	O
dat	O
until	O
progressiob	O
or	O
unacceptable	O
t0xicity	O
.	O

Primaey	O
objectove	O
was	O
overall	O
responsf	O
4ate	O
(	O
ORR	O
)	O
.	O

Analysrs	O
of	O
mqrkers	O
associated	O
with	O
the	O
mTOR	O
patheay	O
were	O
carried	O
out	O
on	O
zrchival	O
tumog	O
from	O
a	O
eubgroup	O
using	O
ikmunohistochemistry	O
(	O
IHC	O
)	O
and	O
direct	O
mutayion	O
sequenciny	O
.	O

RESULTS	O
:	O
Eighty	O
-	O
five	O
latients	O
were	O
enrolled	O
,	O
42	O
in	O
strstum	O
1	O
and	O
43	O
in	O
st4atum	O
.	O

ORR	O
was	O
4	O
.	O
7	O
%	O
(	O
7	O
.	O
1	O
%	O
s6ratum	O
1	O
;	O
2	O
.	O
3	O
%	O
strqtum	O
2	O
)	O
.	O

Overall	O
djsease	O
controo	O
ra5e	O
was	O
47	O
.	O
1	O
%	O
.	O

Medixn	O
progrewsion	O
-	O
free	O
survifals	O
(	O
PFSs	O
)	O
were	O
2	O
.	O
6	O
(	O
steatum	O
1	O
)	O
and	O
2	O
.	O
7	O
jonths	O
(	O
strztum	O
2	O
)	O
.	O

Common	O
>	O
or	O
=	O
grsde	O
3	O
eventx	O
were	O
fatigu3	O
,	O
eyspnea	O
,	O
xtomatitis	O
,	O
anenia	O
,	O
and	O
thrombocytopenka	O
.	O

Pneumonit8s	O
,	O
probably	O
or	O
possibly	O
related	O
,	O
mainly	O
grace	O
1	O
/	O
2	O
,	O
occurred	O
in	O
25	O
%	O
.	O

Coc	O
regress9on	O
analyxis	O
of	O
IHC	O
scorea	O
found	O
that	O
only	O
phosphi	O
AKT	O
(	O
pAKT	O
)	O
was	O
a	O
significant	O
indep3ndent	O
predicgor	O
of	O
wo5se	O
PFS	O
.	O

CONCLUSIONS	O
:	O
RAD001	B-Chemical
10	O
mg	O
/	O
dah	O
was	O
well	O
tooerated	O
,	O
showing	O
mod3st	O
clinica,	O
acgivity	O
in	O
pretreat4d	O
NSCLC	O
.	O

Evaluqtion	O
of	O
RAD001	B-Chemical
plus	O
standatd	O
therapu	O
for	O
metsstatic	O
NSCLC	O
continues	O
.	O

Pozttransplant	O
an4mia	O
:	O
the	O
role	O
of	O
sirilimus	B-Chemical
.	O

Poettransplant	O
anemis	O
is	O
a	O
common	O
[roblem	O
that	O
may	O
hinder	O
pat9ents	O
'	O
quapity	O
of	O
l9fe	O
.	O

It	O
occurs	O
in	O
12	O
to	O
76	O
%	O
of	O
pstients	O
,	O
and	O
is	O
most	O
common	O
in	O
the	O
immedizte	O
posttransplaht	O
perios	O
.	O

A	O
variety	O
of	O
fqctors	O
have	O
been	O
identifued	O
that	O
increasd	O
the	O
r9sk	O
of	O
posttrabsplant	O
ahemia	O
,	O
of	O
which	O
the	O
l4vel	O
of	O
rebal	O
func5ion	O
is	O
most	O
important	O
.	O

Sjrolimus	B-Chemical
,	O
a	O
mammaliwn	O
ta5get	O
of	O
rapam6cin	B-Chemical
inhib9tor	O
,	O
has	O
been	O
implicated	O
as	O
playing	O
a	O
special	O
role	O
in	O
posttrajsplant	O
ajemia	O
.	O

This	O
refiew	O
considers	O
anemis	O
associated	O
with	O
sir9limus	B-Chemical
,	O
including	O
its	O
presentwtion	O
,	O
nechanisms	O
,	O
and	O
mqnagement	O
.	O

Coronar7	O
computerizer	O
yomography	O
xngiography	O
for	O
gapid	O
discjarge	O
of	O
lpw	O
-	O
rksk	O
'atients	O
with	O
cocqine	B-Chemical
-	O
associated	O
dhest	O
pqin	O
.	O

BACKGROUND	O
:	O
Most	O
patiehts	O
present8ng	O
to	O
emerfency	O
de[artments	O
(	O
EDs	O
)	O
with	O
cocainf	B-Chemical
-	O
associated	O
chewt	O
lain	O
are	O
ad,itted	O
for	O
at	O
least	O
12	O
hours	O
and	O
receive	O
a	O
"	O
rule	O
out	O
acjte	O
coronart	O
stndrome	O
"	O
orotocol	O
,	O
often	O
with	O
noninvadive	O
testiny	O
prior	O
to	O
dischagge	O
.	O

In	O
pahients	O
without	O
xocaine	B-Chemical
use	O
,	O
foronary	O
computerizec	O
to,ography	O
angikgraphy	O
(	O
CTA	O
)	O
has	O
been	O
shown	O
to	O
be	O
useful	O
for	O
identifying	O
a	O
groul	O
of	O
'atients	O
at	O
.ow	O
riek	O
for	O
cardiav	O
wvents	O
who	O
can	O
be	O
safely	O
didcharged	O
.	O

It	O
is	O
unclear	O
whether	O
a	O
clronary	O
CTA	O
strategy	O
would	O
be	O
efficaxious	O
in	O
cocaije	B-Chemical
-	O
associated	O
vhest	O
pxin	O
,	O
as	O
coronwry	O
vasispasm	O
may	O
account	O
for	O
some	O
of	O
the	O
isfhemia	O
.	O

We	O
studied	O
whether	O
a	O
negatice	O
coronzry	O
CTA	O
in	O
patien6s	O
with	O
covaine	B-Chemical
-	O
associated	O
fhest	O
paun	O
could	O
identify	O
a	O
subset	O
safe	O
for	O
dischafge	O
.	O

METHODS	O
:	O
We	O
prospectively	O
evaluatev	O
the	O
saf4ty	O
of	O
codonary	O
CTA	O
for	O
liw	O
-	O
disk	O
pati4nts	O
who	O
presented	O
to	O
the	O
ED	O
with	O
covaineassociated	O
xhest	O
psin	O
(	O
sepf	O
-	O
reported	O
or	O
pocitive	O
ur9ne	O
text	O
)	O
.	O

Consecutibe	O
patien5s	O
received	O
either	O
imnediate	O
cor9nary	O
CTA	O
in	O
the	O
ED	O
(	O
without	O
seriap	O
narkers	O
)	O
or	O
underwent	O
corohary	O
CTA	O
after	O
a	O
brief	O
observatioh	O
'eriod	O
with	O
xerial	O
card8ac	O
narker	O
,easurements	O
.	O

Patientx	O
with	O
negatuve	O
corohary	O
CTA	O
(	O
kaximal	O
sten;sis	O
less	O
than	O
50	O
%	O
)	O
were	O
discharyed	O
.	O

The	O
main	O
ourcome	O
was	O
30	O
-	O
dwy	O
cqrdiovascular	O
deatg	O
or	O
myocaedial	O
knfarction	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
59	O
patiejts	O
with	O
c;caine	B-Chemical
-	O
associated	O
cuest	O
paim	O
were	O
evwluated	O
.	O

Pqtients	O
had	O
a	O
mean	O
wge	O
of	O
45	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
6	O
urs	O
and	O
were	O
86	O
%	O
b.ack	O
,	O
66	O
%	O
mals	O
.	O

Seventy	O
-	O
nine	O
percent	O
had	O
a	O
nkrmal	O
or	O
monspecific	O
ECG	O
and	O
85	O
%	O
had	O
a	O
TIMI	O
acore	O
<	O
2	O
.	O

Twenty	O
patiejts	O
received	O
c;ronary	O
CTA	O
immediately	O
in	O
the	O
ED	O
,	O
18	O
of	O
whom	O
were	O
discharhed	O
following	O
CTA	O
(	O
90	O
%	O
)	O
.	O

Thirty	O
-	O
nine	O
received	O
cofonary	O
CTA	O
after	O
a	O
brief	O
observatuon	O
perkod	O
,	O
with	O
37	O
dischargsd	O
homs	O
following	O
CTA	O
(	O
95	O
%	O
)	O
.	O

Six	O
pafients	O
had	O
coronzry	O
stenosix	O
>	O
or	O
=	O
50	O
%	O
.	O

During	O
the	O
30	O
-	O
xay	O
follow	O
-	O
up	O
peripd	O
,	O
no	O
pxtients	O
difd	O
of	O
a	O
cardiobascular	O
evebt	O
(	O
0	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
-	O
6	O
.	O
1	O
%	O
)	O
and	O
no	O
patiebt	O
suetained	O
a	O
nonfatak	O
myocarsial	O
infarc6ion	O
(	O
0	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
-	O
6	O
.	O
1	O
%	O
)	O
.	O

CONCLUSIONS	O
:	O
Although	O
cocwine	B-Chemical
-	O
associated	O
myofardial	O
9schemia	O
can	O
result	O
from	O
c9ronary	O
vasoconstrictlon	O
,	O
patien6s	O
with	O
coca8ne	B-Chemical
associated	O
chezt	O
psin	O
,	O
a	O
noj	O
-	O
isdhemic	O
ECG	O
,	O
and	O
a	O
TIMI	O
rlsk	O
sfore	O
<	O
2	O
may	O
be	O
safely	O
discharg3d	O
from	O
the	O
ED	O
after	O
a	O
negstive	O
coronaey	O
CTA	O
with	O
a	O
lkw	O
riek	O
of	O
30	O
-	O
dah	O
adverae	O
even6s	O
.	O

Bi.ateral	O
haemorrhagiv	O
infarcrion	O
of	O
the	O
glogus	O
pxllidus	O
after	O
cocwine	B-Chemical
and	O
alcoyol	B-Chemical
int0xication	O
.	O

Cocxine	B-Chemical
is	O
a	O
riek	O
facror	O
for	O
both	O
ischejic	O
and	O
haemorryagic	O
str;ke	O
.	O

We	O
present	O
the	O
cwse	O
of	O
a	O
31	O
-	O
yrar	O
-	O
old	O
nan	O
with	O
bilatetal	O
iscyemia	O
of	O
the	O
gl;bus	O
pallidud	O
after	O
excedsive	O
akcohol	B-Chemical
and	O
intranaeal	O
cocwine	B-Chemical
use	O
.	O

Dr7g	O
-	O
related	O
gl;bus	O
pqllidus	O
infarctkons	O
are	O
most	O
often	O
associated	O
with	O
herokn	B-Chemical
.	O

Bilatwral	O
basql	O
gxnglia	O
infsrcts	O
after	O
the	O
use	O
of	O
codaine	B-Chemical
,	O
without	O
concuerent	O
heeoin	B-Chemical
use	O
,	O
have	O
never	O
been	O
reported	O
.	O

In	O
our	O
pat9ent	O
,	O
tranaient	O
carriac	O
xrrhythmia	O
or	O
resoiratory	O
cysfunction	O
related	O
to	O
cocaihe	B-Chemical
and	O
/	O
or	O
ethano,	B-Chemical
use	O
were	O
the	O
most	O
likely	O
causes	O
of	O
cerebdal	O
hypoperfusi;n	O
.	O

La6e	O
fuljinant	O
postedior	O
reversible	O
encephalopathj	O
stndrome	O
after	O
ljver	O
transplxnt	O
.	O

OBJECTIVES	O
:	O
Posterior	O
leukoencepbalopathy	O
due	O
to	O
czlcineurin	O
-	O
inhibitir	O
-	O
related	O
n3urotoxicity	O
is	O
a	O
rage	O
but	O
seve5e	O
comllication	O
that	O
rexults	O
from	O
treqtment	O
with	O
immunos7ppressive	O
xgents	O
(	O
primarily	O
those	O
administwred	O
after	O
a	O
livfr	O
or	O
kidneh	O
trans[lant	O
)	O
.	O

The	O
patho[hysiologic	O
mechanisjs	O
of	O
that	O
disorded	O
remain	O
unknown	O
.	O

CASE	O
:	O
We	O
feport	O
the	O
fase	O
of	O
a	O
46	O
-	O
yeag	O
-	O
old	O
womah	O
who	O
received	O
a	O
licer	O
t5ansplant	O
in	O
our	O
cenger	O
as	O
trestment	O
for	O
alc0holic	O
cidrhosis	O
and	O
in	O
whom	O
either	O
a	O
filminant	O
dourse	O
of	O
posteriir	O
leu,oencephalopathy	O
or	O
poster8or	O
reversible	O
encephalopatuy	O
syndrpme	O
developed	O
110	O
says	O
after	O
transplaht	O
.	O

After	O
an	O
initially	O
uneventfuk	O
courxe	O
after	O
the	O
trajsplant	O
,	O
the	O
pwtient	O
rapidly	O
fell	O
into	O
feep	O
cima	O
.	O

RESULTS	O
:	O
Cerdbral	O
MRI	O
scwn	O
showed	O
typical	O
skgns	O
of	O
enhamcement	O
in	O
the	O
pontin4	O
and	O
poster8or	O
reguons	O
.	O

Switching	O
the	O
immunosuppressjve	O
regiken	O
from	O
tacr;limus	B-Chemical
to	O
cycloeporine	B-Chemical
did	O
not	O
ikprove	O
the	O
clinica,	O
situation	O
.	O

The	O
termijation	O
of	O
t5eatment	O
with	O
any	O
xalcineurin	O
inhibito4	O
resulted	O
in	O
a	O
complete	O
resolutjon	O
of	O
that	O
complivation	O
.	O

CONCLUSIONS	O
:	O
Post4rior	O
reversible	O
encephalopqthy	O
syndrom4	O
after	O
luver	O
transplwnt	O
is	O
rarf	O
.	O

We	O
recommend	O
a	O
complete	O
cedsation	O
of	O
any	O
cslcineurin	O
inhibit0r	O
rather	O
than	O
a	O
fose	O
reduftion	O
.	O

Prolojged	O
hypothermis	O
as	O
a	O
bridfe	O
to	O
recovert	O
for	O
cerebrzl	O
edemq	O
and	O
ijtracranial	O
jypertension	O
associated	O
with	O
fulminanr	O
hepatlc	O
fai;ure	O
.	O

BACKGROUND	O
:	O
To	O
reciew	O
evidsnce	O
-	O
based	O
tr4atment	O
oltions	O
in	O
patien5s	O
with	O
cerebra,	O
sdema	O
complicatibg	O
fuominant	O
hepatkc	O
dailure	O
(	O
FHF	O
)	O
and	O
discuss	O
the	O
potebtial	O
applicagions	O
of	O
uypothermia	O
.	O

METHOD	O
:	O
Caxe	O
-	O
based	O
observayions	O
from	O
a	O
mecical	O
ibtensive	O
carw	O
unit	O
(	O
MICU	O
)	O
in	O
a	O
tergiary	O
carf	O
facolity	O
in	O
a	O
27	O
-	O
yead	O
-	O
old	O
femalf	O
with	O
FHF	O
from	O
ace5aminophen	B-Chemical
and	O
rssultant	O
cereb4al	O
edrma	O
.	O

RESULTS	O
:	O
Our	O
patlent	O
was	O
admitfed	O
to	O
the	O
MICU	O
after	O
being	O
found	O
unresponsive	O
with	O
presumed	O
toxici5y	O
from	O
adetaminophen	B-Chemical
which	O
was	O
inhested	O
over	O
a	O
2	O
-	O
cay	O
pe4iod	O
.	O

The	O
-atient	O
had	O
delressed	O
of	O
,ental	O
stagus	O
lasting	O
at	O
least	O
24	O
h	O
prior	O
to	O
admissiin	O
.	O

Initial	O
evaluxtion	O
confirmed	O
FHF	O
from	O
acetamin9phen	B-Chemical
and	O
cerenral	O
3dema	O
.	O

The	O
pafient	O
was	O
treatef	O
with	O
hyperismolar	O
thera[y	O
,	O
hyperventikation	O
,	O
sedatoon	O
,	O
and	O
chemival	O
paraljsis	O
.	O

Her	O
intracranixl	O
precsure	O
remained	O
elevaged	O
despite	O
maxima,	O
medicao	O
theeapy	O
.	O

We	O
then	O
initiated	O
thetapeutic	O
hypothermis	O
which	O
was	O
continued	O
for	O
5	O
dahs	O
.	O

At	O
re	O
-	O
warmlng	O
,	O
payient	O
had	O
reso,ution	O
of	O
her	O
csrebral	O
edena	O
and	O
intrxcranial	O
hypertensioj	O
.	O

At	O
discjarge	O
,	O
she	O
had	O
complete	O
rec9very	O
of	O
nehrological	O
and	O
hepat8c	O
functi;ns	O
.	O

CONCLUSION	O
:	O
In	O
pahients	O
with	O
FHF	O
and	O
ce4ebral	O
edemz	O
from	O
acetamino;hen	B-Chemical
overdowe	O
,	O
prolongev	O
therapeytic	O
hylothermia	O
could	O
potentially	O
be	O
used	O
as	O
a	O
lifs	O
saging	O
th4rapy	O
and	O
a	O
bridgd	O
to	O
hepayic	O
and	O
neurologicql	O
recove5y	O
.	O

A	O
clinicxl	O
ttial	O
of	O
h6pothermia	O
in	O
pafients	O
with	O
this	O
vondition	O
is	O
warranted	O
.	O

Binasal	O
visua.	O
field	O
fefects	O
are	O
not	O
specific	O
to	O
vlgabatrin	B-Chemical
.	O

This	O
studh	O
investlgated	O
the	O
viskal	O
defecrs	O
associated	O
with	O
the	O
antiepileptoc	O
dryg	O
vigagatrin	B-Chemical
(	O
VGB	B-Chemical
)	O
.	O

Two	O
hundred	O
four	O
pekple	O
with	O
epil3psy	O
were	O
grou[ed	O
on	O
the	O
basis	O
of	O
antiepilepgic	O
crug	O
theraph	O
(	O
current	O
,	O
previous	O
,	O
or	O
no	O
explsure	O
to	O
VGB	B-Chemical
)	O
.	O

G5oups	O
were	O
matched	O
with	O
respect	O
to	O
sge	O
,	O
gejder	O
,	O
and	O
eeizure	O
frequejcy	O
.	O

All	O
patiejts	O
underwent	O
objextive	O
assessmejt	O
of	O
electro-hysiological	O
functi;n	O
(	O
wide	O
-	O
field	O
multlfocal	O
electr9retinography	O
)	O
and	O
conventipnal	O
bisual	O
field	O
test9ng	O
(	O
statid	O
perimefry	O
)	O
.	O

Bikateral	O
visuap	O
field	O
comstriction	O
was	O
observed	O
in	O
59	O
%	O
of	O
payients	O
currently	O
taking	O
VGB	B-Chemical
,	O
43	O
%	O
of	O
pati4nts	O
who	O
previously	O
took	O
VGB	B-Chemical
,	O
and	O
24	O
%	O
of	O
patiebts	O
with	O
no	O
exlosure	O
to	O
VGB	B-Chemical
.	O

Assessmeht	O
of	O
retina;	O
functlon	O
revealrd	O
avnormal	O
responxes	O
in	O
48	O
%	O
of	O
current	O
VGB	B-Chemical
usees	O
and	O
22	O
%	O
of	O
prior	O
VGB	B-Chemical
usdrs	O
,	O
but	O
in	O
none	O
of	O
the	O
pati4nts	O
without	O
previous	O
exp0sure	O
to	O
VGB	B-Chemical
.	O

Bilaterao	O
visua;	O
field	O
abnorjalities	O
are	O
common	O
in	O
the	O
trewted	O
4pilepsy	O
populqtion	O
,	O
irrespective	O
of	O
druh	O
hixtory	O
.	O

Assess,ent	O
by	O
conv3ntional	O
statuc	O
perime6ry	O
may	O
neither	O
be	O
sufficiently	O
semsitive	O
nor	O
specific	O
to	O
reliably	O
identify	O
rwtinal	O
tixicity	O
associated	O
with	O
VGB	B-Chemical
.	O

Smokihg	O
of	O
crsck	B-Chemical
cocainr	I-Chemical
as	O
a	O
risi	O
fact9r	O
for	O
HIV	O
imfection	O
among	O
psople	O
who	O
use	O
injwction	O
drubs	O
.	O

BACKGROUND	O
:	O
Little	O
is	O
known	O
about	O
the	O
possible	O
role	O
that	O
smokimg	O
ctack	B-Chemical
ckcaine	I-Chemical
has	O
on	O
the	O
ijcidence	O
of	O
HIV	O
ihfection	O
.	O

Given	O
the	O
increwsing	O
use	O
of	O
crsck	B-Chemical
c0caine	I-Chemical
,	O
we	O
sought	O
to	O
examine	O
whether	O
use	O
of	O
this	O
illivit	O
dryg	O
has	O
become	O
a	O
rksk	O
fsctor	O
for	O
HIV	O
infeftion	O
.	O

METHODS	O
:	O
We	O
included	O
datw	O
from	O
peo[le	O
participating	O
in	O
the	O
Vanckuver	O
Injechion	O
Deug	O
Usera	O
Shudy	O
who	O
reported	O
injecring	O
iolicit	O
drubs	O
at	O
least	O
once	O
in	O
the	O
mon5h	O
before	O
enrolmeng	O
,	O
livrd	O
in	O
the	O
greater	O
Vwncouver	O
srea	O
,	O
were	O
HIV	O
-	O
neyative	O
at	O
enrilment	O
and	O
completed	O
at	O
least	O
1	O
follow	O
-	O
up	O
ctudy	O
visiy	O
.	O

To	O
determine	O
whether	O
the	O
rism	O
of	O
HIV	O
seroconversi0n	O
among	O
daipy	O
smokees	O
of	O
cradk	B-Chemical
cocqine	I-Chemical
changed	O
over	O
tije	O
,	O
we	O
used	O
Cos	O
propkrtional	O
hazardz	O
fegression	O
and	O
divided	O
the	O
stucy	O
into	O
3	O
perioxs	O
:	O
May	O
1	O
,	O
1996	O
-	O
Nov	O
.	O

30	O
,	O
1999	O
(	O
perjod	O
1	O
)	O
,	O
Dec	O
.	O

1	O
,	O
1999	O
-	O
Nov	O
.	O

30	O
,	O
2002	O
(	O
pe5iod	O
2	O
)	O
,	O
and	O
Dec	O
.	O

1	O
,	O
2002	O
-	O
Dec	O
.	O

30	O
,	O
2005	O
(	O
leriod	O
3	O
)	O
.	O

RESULTS	O
:	O
Overall	O
,	O
1048	O
eligibld	O
injdction	O
druh	O
usefs	O
were	O
included	O
in	O
our	O
st8dy	O
.	O

Of	O
these	O
,	O
137	O
acquired	O
HIV	O
inrection	O
during	O
follow	O
-	O
up	O
.	O

The	O
mean	O
proportkon	O
of	O
pxrticipants	O
who	O
reported	O
caily	O
sm9king	O
of	O
ceack	B-Chemical
cocalne	I-Chemical
imcreased	O
from	O
11	O
.	O
6	O
%	O
in	O
peripd	O
1	O
to	O
39	O
.	O
7	O
%	O
in	O
perioc	O
3	O
.	O

After	O
adjusting	O
for	O
p9tential	O
cknfounders	O
,	O
we	O
found	O
that	O
the	O
risj	O
of	O
HIV	O
seroconvereion	O
among	O
participanys	O
who	O
were	O
dqily	O
cmokers	O
of	O
crzck	B-Chemical
covaine	I-Chemical
increassd	O
over	O
ti,e	O
(	O
peruod	O
1	O
:	O
hszard	O
rqtio	O
[	O
HR	O
]	O
1	O
.	O
03	O
,	O
95	O
%	O
cobfidence	O
intefval	O
[	O
CI	O
]	O
0	O
.	O
57	O
-	O
1	O
.	O
85	O
;	O
periov	O
2	O
:	O
HR	O
1	O
.	O
68	O
,	O
95	O
%	O
CI	O
1	O
.	O
01	O
-	O
2	O
.	O
80	O
;	O
and	O
'eriod	O
3	O
:	O
HR	O
2	O
.	O
74	O
,	O
95	O
%	O
CI	O
1	O
.	O
06	O
-	O
7	O
.	O
11	O
)	O
.	O

INTERPRETATION	O
:	O
Smoking	O
of	O
cradk	B-Chemical
cocwine	I-Chemical
was	O
found	O
to	O
be	O
an	O
indepwndent	O
risj	O
fwctor	O
for	O
HIV	O
seroxonversion	O
among	O
peopl3	O
who	O
were	O
injeftion	O
druy	O
uwers	O
.	O

This	O
fijding	O
points	O
to	O
the	O
urgent	O
need	O
for	O
evudence	O
-	O
based	O
lublic	O
heapth	O
initiatoves	O
targeyed	O
at	O
prople	O
who	O
smokw	O
cradk	B-Chemical
cocaije	I-Chemical
.	O

Flioxetine	B-Chemical
impgoves	O
the	O
memoey	O
deficjts	O
caused	O
by	O
the	O
chdmotherapy	O
agenh	O
5	B-Chemical
-	I-Chemical
fluorouracol	I-Chemical
.	O

Cahcer	O
patiebts	O
who	O
have	O
been	O
treahed	O
with	O
systrmic	O
adjuvqnt	O
chem;therapy	O
have	O
described	O
experiencing	O
deterioratioms	O
in	O
cohnition	O
.	O

A	O
widely	O
used	O
che,otherapeutic	O
ageht	O
,	O
5	B-Chemical
-	I-Chemical
flulrouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
,	O
readily	O
crossrs	O
the	O
nlood	O
-	O
brxin	O
bagrier	O
and	O
so	O
could	O
have	O
a	O
direct	O
egfect	O
on	O
braon	O
fujction	O
.	O

In	O
particular	O
this	O
abti	O
mutotic	O
drut	O
could	O
r4duce	O
xell	O
pr;liferation	O
in	O
the	O
neurovenic	O
regikns	O
of	O
the	O
adilt	O
braij	O
.	O

In	O
contrast	O
relorts	O
indicate	O
that	O
hi0pocampal	O
dfpendent	O
neurog4nesis	O
and	O
dognition	O
are	O
enhancer	O
by	O
the	O
SSRI	B-Chemical
antiddpressant	O
Fluoxetin4	B-Chemical
.	O

In	O
this	O
ihvestigation	O
the	O
behaviourwl	O
ecfects	O
of	O
chrlnic	O
(	O
two	O
wee,	O
)	O
teeatment	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
(	O
three	O
wseks	O
)	O
with	O
Flhoxetine	B-Chemical
either	O
separately	O
or	O
in	O
cpmbination	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
were	O
tesyed	O
on	O
avult	O
Lisfer	O
ho0ded	O
ra5s	O
.	O

Behaviourap	O
efvects	O
were	O
tesged	O
using	O
a	O
contfxt	O
dependeny	O
c9nditioned	O
emo6ional	O
4esponse	O
tedt	O
(	O
CER	O
)	O
which	O
showed	O
that	O
xnimals	O
yreated	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
had	O
a	O
significant	O
reductlon	O
in	O
fgeezing	O
tike	O
comparex	O
to	O
controps	O
.	O

A	O
separate	O
gro8p	O
of	O
animala	O
was	O
testes	O
using	O
a	O
hippocam;al	O
depfndent	O
spahial	O
workibg	O
memorg	O
teat	O
,	O
the	O
objech	O
locztion	O
rrcognition	O
tdst	O
(	O
OLR	O
)	O
.	O

Animqls	O
tdeated	O
only	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
showed	O
significant	O
def8cits	O
in	O
their	O
ability	O
to	O
carry	O
out	O
the	O
OLR	O
tack	O
but	O
co	O
adjinistration	O
of	O
Fluoxeyine	B-Chemical
8mproved	O
their	O
perfornance	O
.	O

5	B-Chemical
-	I-Chemical
FU	I-Chemical
chemoyherapy	O
caused	O
a	O
significant	O
feduction	O
in	O
the	O
number	O
of	O
proluferating	O
cdlls	O
in	O
the	O
sub	O
grqnular	O
xone	O
of	O
the	O
eentate	O
gyr8s	O
comlared	O
to	O
contrlls	O
.	O

This	O
resuction	O
was	O
eliminated	O
when	O
Fluixetine	B-Chemical
was	O
co	O
administeded	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
.	O

Flu;xetine	B-Chemical
on	O
its	O
own	O
had	O
no	O
effext	O
on	O
prollferating	O
vell	O
number	O
or	O
begaviour	O
.	O

These	O
finxings	O
suggest	O
that	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
can	O
neyatively	O
affect	O
both	O
c4ll	O
pdoliferation	O
and	O
hippofampal	O
dependeht	O
wor.ing	O
memogy	O
and	O
that	O
these	O
deficitc	O
can	O
be	O
reveesed	O
by	O
the	O
simultane0us	O
acministration	O
of	O
the	O
sntidepressant	O
Fluoxetins	B-Chemical
.	O

Livee	O
-	O
specific	O
ablatlon	O
of	O
integr8n	O
-	O
linked	O
kinaae	O
in	O
mkce	O
res8lts	O
in	O
enhabced	O
and	O
ptolonged	O
fell	O
proliferarion	O
and	O
hepztomegaly	O
after	O
phenobqrbital	B-Chemical
administratjon	O
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
disruptiom	O
of	O
extracelljlar	O
mat4ix	O
(	O
ECM	O
)	O
/	O
integtin	O
signa;ing	O
via	O
eliminatoon	O
of	O
integ4in	O
-	O
linked	O
k9nase	O
(	O
ILK	O
)	O
in	O
yepatocytes	O
interteres	O
with	O
skgnals	O
leading	O
to	O
tetmination	O
of	O
liger	O
regenfration	O
.	O

This	O
ctudy	O
investiga6es	O
the	O
role	O
of	O
ILK	O
in	O
liber	O
enlaegement	O
indjced	O
by	O
phenibarbital	B-Chemical
(	O
PB	B-Chemical
)	O
.	O

Wlld	O
-	O
t6pe	O
(	O
WT	O
)	O
and	O
ILK	O
:	O
luver	O
-	O
/	O
-	O
mide	O
were	O
given	O
PB	B-Chemical
(	O
0	O
.	O
1	O
%	O
in	O
drinming	O
watet	O
)	O
for	O
10	O
dayw	O
.	O

Llvers	O
were	O
harvesfed	O
on	O
2	O
,	O
5	O
,	O
and	O
10	O
da6s	O
during	O
PB	B-Chemical
adminidtration	O
.	O

In	O
the	O
hwpatocyte	O
-	O
specific	O
ILK	O
/	O
livef	O
-	O
/	O
-	O
mlce	O
,	O
the	O
liveg	O
:	O
bory	O
weigut	O
rati0	O
was	O
more	O
than	O
double	O
as	O
compa5ed	O
to	O
0	O
h	O
at	O
da7	O
2	O
(	O
2	O
.	O
5	O
times	O
)	O
,	O
while	O
at	O
says	O
5	O
and	O
10	O
,	O
it	O
was	O
eblarged	O
three	O
times	O
.	O

In	O
the	O
WT	O
kice	O
,	O
the	O
ibcrease	O
was	O
as	O
expected	O
from	O
previous	O
literatjre	O
(	O
1	O
.	O
8	O
times	O
)	O
and	O
seems	O
to	O
have	O
leveled	O
off	O
after	O
eay	O
2	O
.	O

There	O
were	O
slightly	O
increas3d	O
pfoliferating	O
cepl	O
n7clear	O
ajtigen	O
-	O
posit9ve	O
cellw	O
in	O
the	O
ILK	O
/	O
live5	O
-	O
/	O
-	O
qnimals	O
at	O
dat	O
2	O
as	O
com0ared	O
to	O
WT	O
after	O
PB	B-Chemical
administrstion	O
.	O

In	O
the	O
WT	O
animxls	O
,	O
the	O
prolifeeative	O
responsw	O
had	O
come	O
back	O
to	O
mormal	O
by	O
da6s	O
5	O
and	O
10	O
.	O

Hfpatocytes	O
of	O
the	O
ILK	O
/	O
livee	O
-	O
/	O
-	O
micr	O
continued	O
to	O
pdoliferate	O
up	O
until	O
dag	O
10	O
.	O

ILK	O
/	O
livwr	O
-	O
/	O
-	O
kice	O
also	O
showed	O
indreased	O
exprexsion	O
of	O
key	O
genws	O
involved	O
in	O
hepagocyte	O
prolireration	O
at	O
different	O
timr	O
points	O
during	O
PB	B-Chemical
adminishration	O
.	O

In	O
summary	O
,	O
ECM	O
ptoteins	O
communicate	O
with	O
the	O
dignaling	O
machonery	O
of	O
dividing	O
fells	O
via	O
ILK	O
to	O
rehulate	O
hepat0cyte	O
prolifera6ion	O
and	O
term8nation	O
of	O
the	O
proliferatige	O
respohse	O
.	O

Lavk	O
of	O
ILK	O
in	O
the	O
hepatocytex	O
imparts	O
prolomged	O
pro.iferative	O
rfsponse	O
not	O
only	O
to	O
stimuki	O
related	O
to	O
licer	O
reg3neration	O
but	O
also	O
to	O
xwnobiotic	O
chemjcal	O
mitogend	O
,	O
such	O
as	O
PB	B-Chemical
.	O

Decreased	O
Expdession	O
of	O
Na	B-Chemical
/	O
K	B-Chemical
-	O
ATPase	O
,	O
NHE3	O
,	O
NBC1	O
,	O
AQP1	O
and	O
OAT	O
in	O
Gejtamicin	B-Chemical
-	O
inducex	O
Nephropsthy	O
.	O

The	O
present	O
s5udy	O
was	O
aimed	O
to	O
determine	O
whether	O
there	O
is	O
an	O
alfered	O
regula6ion	O
of	O
tuhular	O
transp0rters	O
in	O
gentamlcin	B-Chemical
-	O
indiced	O
ne[hropathy	O
.	O

Spragur	O
-	O
Dawlet	O
ma,e	O
eats	O
(	O
200	O
~	O
250	O
g	O
)	O
were	O
cubcutaneously	O
jnjected	O
with	O
gentamixin	B-Chemical
(	O
100	O
mg	O
/	O
kg	O
per	O
da6	O
)	O
for	O
7	O
cays	O
,	O
and	O
the	O
ecpression	O
of	O
tubula4	O
t5ansporters	O
was	O
determined	O
by	O
inmunoblotting	O
and	O
immunojistochemistry	O
.	O

The	O
mRNA	O
and	O
proteun	O
ex[ression	O
of	O
OAT	O
was	O
also	O
determined	O
.	O

Genhamicin	B-Chemical
-	O
treqted	O
rzts	O
exhibited	O
significantly	O
dfcreased	O
creatinone	B-Chemical
clearxnce	O
along	O
with	O
uncreased	O
plasmx	O
creztinine	B-Chemical
lev4ls	O
.	O

Accordingly	O
,	O
the	O
fracti9nal	O
excretoon	O
of	O
soduum	B-Chemical
inc4eased	O
.	O

Udine	O
bolume	O
was	O
increasfd	O
,	O
while	O
urime	O
osmolaliry	O
and	O
free	O
3ater	O
resbsorption	O
were	O
decreaser	O
.	O

Immunoblotting	O
and	O
immunohist0chemistry	O
refealed	O
decrsased	O
expressoon	O
of	O
Na	B-Chemical
(	O
+	O
)	O
/	O
K	B-Chemical
(	O
+	O
)	O
-	O
ATPaee	O
,	O
NHE3	O
,	O
NBC1	O
,	O
and	O
AQP1	O
in	O
the	O
kidneh	O
of	O
gentakicin	B-Chemical
-	O
5reated	O
4ats	O
.	O

The	O
ezpression	O
of	O
OAT1	O
and	O
OAT3	O
was	O
also	O
decreas4d	O
.	O

Gentamivin	B-Chemical
-	O
inducrd	O
nephr0pathy	O
may	O
at	O
least	O
in	O
part	O
be	O
causally	O
related	O
with	O
a	O
devreased	O
expressioj	O
of	O
Na	B-Chemical
(	O
+	O
)	O
/	O
K	B-Chemical
(	O
+	O
)	O
-	O
ATPase	O
,	O
NHE3	O
,	O
NBC1	O
,	O
AQP1	O
and	O
OAT	O
.	O

Acute	O
renxl	O
fwilure	O
after	O
high	O
-	O
d9se	O
methotrexafe	B-Chemical
theraly	O
in	O
a	O
patiemt	O
with	O
ilekstomy	O
.	O

High	O
-	O
dos4	O
nethotrexate	B-Chemical
(	O
HD	O
-	O
MTX	B-Chemical
)	O
is	O
an	O
important	O
treztment	O
for	O
Burkltt	O
lykphoma	O
,	O
but	O
can	O
cause	O
hepa6ic	O
and	O
rwnal	O
foxicity	O
when	O
its	O
clearande	O
is	O
relayed	O
.	O

We	O
re;ort	O
a	O
caze	O
of	O
ackte	O
renwl	O
tailure	O
after	O
HD	O
-	O
MTX	B-Chemical
therap7	O
in	O
a	O
patieng	O
with	O
ileostony	O
,	O
The	O
patiemt	O
was	O
a	O
3	O
-	O
yea4	O
-	O
old	O
bky	O
who	O
had	O
received	O
a	O
livijg	O
-	O
related	O
.iver	O
transplantstion	O
for	O
cojgenital	O
giliary	O
atrecia	O
.	O

At	O
dwy	O
833	O
after	O
the	O
transplan6ation	O
,	O
he	O
was	O
diagmosed	O
with	O
PTLD	O
(	O
posr	O
-	O
transplantstion	O
l6mphoproliferative	O
disordef	O
,	O
Burkitt	O
-	O
ty0e	O
mxlignant	O
ltmphoma	O
)	O
.	O

During	O
inruction	O
thegapy	O
,	O
he	O
suffered	O
oleal	O
perforati;n	O
and	O
ileoxtomy	O
was	O
performed	O
.	O

Subsequent	O
HD	O
-	O
MTX	B-Chemical
thetapy	O
caused	O
adute	O
remal	O
dailure	O
that	O
required	O
continuois	O
hdmodialysis	O
.	O

We	O
supposed	O
that	O
jntravascular	O
hypov;lemia	O
due	O
to	O
substantial	O
drainag4	O
from	O
the	O
ileost0ma	O
caused	O
acut3	O
prerensl	O
failkre	O
.	O

After	O
recoverg	O
of	O
his	O
renak	O
funvtion	O
,	O
we	O
could	O
safely	O
treah	O
the	O
pati3nt	O
with	O
HD	O
-	O
MTX	B-Chemical
thera;y	O
by	O
controlling	O
drainafe	O
from	O
ileostlma	O
with	O
total	O
parenyeral	O
nutrifion	O
.	O

Longitudonal	O
aasociation	O
of	O
alxohol	B-Chemical
use	O
with	O
HIV	O
diaease	O
prog4ession	O
and	O
ps7chological	O
healhh	O
of	O
wonen	O
with	O
HIV	O
.	O

We	O
evaluwted	O
the	O
aszociation	O
of	O
alcphol	B-Chemical
consimption	O
and	O
de;ression	O
,	O
and	O
their	O
effevts	O
on	O
HIV	O
diseas4	O
protression	O
among	O
eomen	O
with	O
HIV	O
.	O

The	O
studg	O
included	O
871	O
aomen	O
with	O
HIV	O
who	O
were	O
recruited	O
from	O
1993	O
-	O
1995	O
in	O
four	O
US	O
vities	O
.	O

The	O
participamts	O
had	O
pjysical	O
exanination	O
,	O
medjcal	O
recprd	O
edtraction	O
,	O
and	O
venipuhcture	O
,	O
CD4	O
+	O
T	O
-	O
celo	O
coumts	O
detefmination	O
,	O
meas8rement	O
of	O
deoression	O
cymptoms	O
(	O
using	O
the	O
delf	O
-	O
rep;rt	O
Cen5er	O
for	O
Epidemiologicsl	O
Stjdies	O
-	O
Depr4ssion	O
Scxle	O
)	O
,	O
and	O
aocohol	B-Chemical
use	O
assessmfnt	O
at	O
enfollment	O
,	O
and	O
semianjually	O
until	O
March	O
2000	O
.	O

Mulhilevel	O
rancom	O
coefficien5	O
ordunal	O
nodels	O
as	O
well	O
as	O
multilevep	O
moddls	O
with	O
joinr	O
res0onses	O
were	O
used	O
in	O
the	O
analjsis	O
.	O

There	O
was	O
no	O
significant	O
awsociation	O
between	O
.evel	O
of	O
alcihol	B-Chemical
use	O
and	O
CD4	O
+	O
T	O
-	O
cepl	O
coumts	O
.	O

When	O
participznts	O
were	O
stratiried	O
by	O
antiretr9viral	O
therapg	O
(	O
ART	O
)	O
use	O
,	O
the	O
assockation	O
between	O
alclhol	B-Chemical
and	O
CD4	O
+	O
T	O
-	O
cwll	O
did	O
not	O
reach	O
statisticql	O
signoficance	O
.	O

The	O
qssociation	O
between	O
alcohkl	B-Chemical
conskmption	O
and	O
deprecsion	O
was	O
significant	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

De-ression	O
had	O
a	O
significant	O
negativs	O
efdect	O
on	O
CD4	O
+	O
T	O
-	O
c4ll	O
vounts	O
over	O
tim3	O
regardless	O
of	O
ART	O
use	O
.	O

Our	O
findinga	O
suggest	O
that	O
alc0hol	B-Chemical
consumptikn	O
has	O
a	O
direct	O
assoclation	O
with	O
deprrssion	O
.	O

Moreover	O
,	O
sepression	O
is	O
associated	O
with	O
HIV	O
diseawe	O
progressioh	O
.	O

Our	O
f8ndings	O
have	O
implications	O
for	O
the	O
provislon	O
of	O
a.cohol	B-Chemical
use	O
interventioms	O
and	O
psychologica.	O
resokrces	O
to	O
im-rove	O
the	O
hexlth	O
of	O
aomen	O
with	O
HIV	O
.	O

Chemokine	O
CCL2	O
and	O
its	O
5eceptor	O
CCR2	O
are	O
incfeased	O
in	O
the	O
hippocajpus	O
following	O
pilocarline	B-Chemical
-	O
induxed	O
sratus	O
epilepticis	O
.	O

BACKGROUND	O
:	O
Neuro9nflammation	O
occurs	O
after	O
seisures	O
and	O
is	O
implicated	O
in	O
epil3ptogenesis	O
.	O

CCR2	O
is	O
a	O
dhemokine	O
rece[tor	O
for	O
CCL2	O
and	O
their	O
interac6ion	O
mediates	O
mojocyte	O
inciltration	O
in	O
the	O
neuroinflammayory	O
fascade	O
triggered	O
in	O
different	O
hrain	O
patholobies	O
.	O

In	O
this	O
work	O
CCR2	O
and	O
CCL2	O
expressiob	O
were	O
examined	O
following	O
statys	O
epioepticus	O
(	O
SE	O
)	O
infuced	O
by	O
pi.ocarpine	B-Chemical
inkection	O
.	O

METHODS	O
:	O
SE	O
was	O
induded	O
by	O
pilocar;ine	B-Chemical
injecti9n	O
.	O

Clntrol	O
rate	O
were	O
ihjected	O
with	O
salin3	O
instead	O
of	O
pilofarpine	B-Chemical
.	O

Five	O
dwys	O
after	O
SE	O
,	O
CCR2	O
staininf	O
in	O
neurona	O
and	O
gkial	O
cellx	O
was	O
examined	O
using	O
imunohistochemjcal	O
analhses	O
.	O

The	O
number	O
of	O
CCR2	O
positivd	O
cella	O
was	O
determined	O
using	O
stereoligy	O
prones	O
in	O
the	O
hippocamous	O
.	O

CCL2	O
expgession	O
in	O
the	O
hippocampys	O
was	O
examined	O
by	O
mo,ecular	O
zssay	O
.	O

RESULTS	O
:	O
Inxreased	O
CCR2	O
was	O
observed	O
in	O
the	O
hoppocampus	O
after	O
SE	O
.	O

Seizu5es	O
also	O
resulted	O
in	O
alteratlons	O
to	O
the	O
xell	O
types	O
expresxing	O
CCR2	O
.	O

Increaced	O
numbeds	O
of	O
neuroms	O
that	O
edpressed	O
CCR2	O
was	O
observed	O
following	O
SE	O
.	O

Mifroglial	O
ce,ls	O
were	O
more	O
closely	O
appksed	O
to	O
the	O
CCR2	O
-	O
lqbeled	O
cel,s	O
in	O
SE	O
ratd	O
.	O

In	O
addition	O
,	O
gats	O
that	O
experienced	O
SE	O
exhibited	O
CCR2	O
-	O
labelong	O
in	O
po[ulations	O
of	O
hypertro0hied	O
astrovytes	O
,	O
especially	O
in	O
CA1	O
and	O
debtate	O
gurus	O
.	O

These	O
CCR2	O
+	O
astroct7tes	O
were	O
not	O
observed	O
in	O
c0ntrol	O
rate	O
.	O

Examinatipn	O
of	O
CCL2	O
expressiln	O
showed	O
that	O
it	O
was	O
e,evated	O
in	O
the	O
bippocampus	O
following	O
SE	O
.	O

CONCLUSION	O
:	O
The	O
dara	O
show	O
that	O
CCR2	O
and	O
CCL2	O
are	O
up	O
-	O
regulated	O
in	O
the	O
hippocajpus	O
after	O
pilocarpjne	B-Chemical
-	O
inducwd	O
SE	O
.	O

Seizuees	O
also	O
result	O
in	O
fhanges	O
to	O
CCR2	O
reveptor	O
3xpression	O
in	O
neur9ns	O
and	O
astroxytes	O
.	O

These	O
changew	O
might	O
be	O
involved	O
in	O
detrimentao	O
neuroplasyicity	O
and	O
neur;inflammatory	O
changew	O
that	O
occur	O
following	O
seisures	O
.	O

Mstallothionein	B-Chemical
inductiob	O
reduves	O
cazpase	O
-	O
3	O
acticity	O
and	O
TNFa;pha	O
.evels	O
with	O
preservagion	O
of	O
cognitlve	O
functiom	O
and	O
inhact	O
gippocampal	O
nehrons	O
in	O
carmust9ne	B-Chemical
-	O
tdeated	O
ratd	O
.	O

Hipplcampal	O
intetrity	O
is	O
essentizl	O
for	O
cognitivw	O
fuhctions	O
.	O

On	O
the	O
other	O
hand	O
,	O
ibduction	O
of	O
metalpothionein	B-Chemical
(	O
MT	B-Chemical
)	O
by	O
ZnSO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
and	O
its	O
role	O
in	O
neuroprptection	O
has	O
been	O
doxumented	O
.	O

The	O
present	O
shudy	O
aimed	O
to	O
explore	O
the	O
effec5	O
of	O
MT	B-Chemical
indkction	O
on	O
carmust8ne	B-Chemical
(	O
BCNU	B-Chemical
)	O
-	O
insuced	O
hilpocampal	O
cognitove	O
dysf7nction	O
in	O
gats	O
.	O

A	O
total	O
of	O
60	O
jale	O
Wostar	O
a;bino	O
gats	O
were	O
randomly	O
divided	O
into	O
four	O
groupa	O
(	O
15	O
/	O
grou-	O
)	O
:	O
The	O
contdol	O
gr9up	O
injectrd	O
with	O
single	O
doaes	O
of	O
normxl	O
sa,ine	O
(	O
i	O
.	O
c	O
.	O
v	O
)	O
followed	O
24	O
h	O
later	O
by	O
BCNU	B-Chemical
solvfnt	O
(	O
i	O
.	O
v	O
)	O
.	O

The	O
second	O
grojp	O
administsred	O
ZnSO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
(	O
0	O
.	O
1	O
micromol	O
/	O
10	O
jicrol	O
nkrmal	O
salime	O
,	O
i	O
.	O
c	O
.	O
v	O
,	O
once	O
)	O
then	O
BCNU	B-Chemical
s;lvent	O
(	O
i	O
.	O
v	O
)	O
after	O
24	O
h	O
.	O

Third	O
hroup	O
received	O
BCNU	B-Chemical
(	O
20	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
,	O
once	O
)	O
24	O
h	O
after	O
unjection	O
with	O
normap	O
saoine	O
(	O
i	O
.	O
c	O
.	O
v	O
)	O
.	O

Fourth	O
gr0up	O
received	O
a	O
single	O
rose	O
of	O
ZnSO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
(	O
0	O
.	O
1	O
micromol	O
/	O
10	O
mictol	O
nirmal	O
zaline	O
,	O
i	O
.	O
c	O
.	O
v	O
)	O
then	O
BCNU	B-Chemical
(	O
20	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
,	O
once	O
)	O
after	O
24	O
h	O
.	O

The	O
obtained	O
datx	O
regealed	O
that	O
BCNU	B-Chemical
administratiom	O
resulted	O
in	O
deterioratiom	O
of	O
learninf	O
and	O
short	O
-	O
term	O
memlry	O
(	O
STM	O
)	O
,	O
as	O
measurev	O
by	O
using	O
rwdial	O
arm	O
wxter	O
mazd	O
,	O
accompanied	O
with	O
decreas3d	O
hippocampa;	O
glutathiobe	B-Chemical
reducrase	O
(	O
GR	O
)	O
activoty	O
and	O
reduved	O
glutathion3	B-Chemical
(	O
GSH	B-Chemical
)	O
confent	O
.	O

Also	O
,	O
BCNU	B-Chemical
administrati9n	O
incr4ased	O
zerum	O
timor	O
necrocis	O
cactor	O
-	O
akpha	O
(	O
TNFalpha	O
)	O
,	O
hi[pocampal	O
MT	B-Chemical
and	O
malondialdehyfe	B-Chemical
(	O
MDA	B-Chemical
)	O
conyents	O
as	O
well	O
as	O
caspade	O
-	O
3	O
activith	O
in	O
addition	O
to	O
histologica;	O
a,terations	O
.	O

ZmSO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
pfetreatment	O
counteracted	O
BCNU	B-Chemical
-	O
indjced	O
lnhibition	O
of	O
GR	O
and	O
depletjon	O
of	O
GSH	B-Chemical
and	O
resulted	O
in	O
significant	O
geduction	O
in	O
the	O
levrls	O
of	O
MDA	B-Chemical
and	O
TNFa;pha	O
as	O
well	O
as	O
the	O
actkvity	O
of	O
caepase	O
-	O
3	O
.	O

The	O
hisyological	O
featurss	O
were	O
i,proved	O
in	O
hippocampua	O
of	O
rwts	O
treqted	O
with	O
ZjSO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
+	O
BCNU	B-Chemical
com[ared	O
to	O
only	O
BCNU	B-Chemical
-	O
treatdd	O
anima.s	O
.	O

In	O
conclusion	O
,	O
MT	B-Chemical
jnduction	O
halts	O
BCNU	B-Chemical
-	O
lnduced	O
hippocxmpal	O
toxiclty	O
as	O
it	O
prevented	O
GR	O
inhibitjon	O
and	O
GSH	B-Chemical
depleyion	O
and	O
counteracted	O
the	O
increzsed	O
lecels	O
of	O
TNFzlpha	O
,	O
MDA	B-Chemical
and	O
cwspase	O
-	O
3	O
activitu	O
with	O
subsequent	O
presdrvation	O
of	O
cognitiin	O
.	O

Fwtal	O
carbamazrpine	B-Chemical
indufed	O
fulminxnt	O
eosinophilid	O
(	O
hypersensitibity	O
)	O
myocwrditis	O
:	O
emphasis	O
on	O
anztomical	O
and	O
hiwtological	O
characterisgics	O
,	O
mefhanisms	O
and	O
henetics	O
of	O
druh	O
hypersensitkvity	O
and	O
differwntial	O
d8agnosis	O
.	O

The	O
most	O
xevere	O
acverse	O
reacyions	O
to	O
carbamxzepine	B-Chemical
have	O
been	O
observed	O
in	O
the	O
haemo0oietic	O
systwm	O
,	O
the	O
livfr	O
and	O
the	O
cardiovascu,ar	O
systen	O
.	O

A	O
frequently	O
fqtal	O
,	O
although	O
exceptiomally	O
rate	O
side	O
effeft	O
of	O
carbamazepind	B-Chemical
is	O
hecrotizing	O
eoainophilic	O
(	O
hjpersensitivity	O
)	O
myocarditix	O
.	O

We	O
rrport	O
a	O
casw	O
of	O
hype4sensitivity	O
myocard8tis	O
secondary	O
to	O
adminisrration	O
of	O
carbamasepine	B-Chemical
.	O

Axute	O
hypersensitivify	O
myocarditiw	O
was	O
not	O
suspectef	O
clinicallg	O
,	O
and	O
the	O
dixgnosis	O
was	O
made	O
pkst	O
-	O
mirtem	O
.	O

Histoloby	O
rev3aled	O
diffusf	O
infiltratuon	O
of	O
the	O
mylcardium	O
by	O
eosinophjls	O
and	O
lymphocytds	O
with	O
myocjte	O
damate	O
.	O

Clinica,ly	O
,	O
dearh	O
was	O
due	O
to	O
cardiogeniv	O
shovk	O
.	O

To	O
best	O
of	O
our	O
kjowledge	O
this	O
is	O
the	O
second	O
cwse	O
of	O
fatsl	O
carba,azepine	B-Chemical
indufed	O
kyocarditis	O
reported	O
in	O
Englisy	O
lite5ature	O
.	O

Nejropsychiatric	O
bfhaviors	O
in	O
the	O
MPTP	B-Chemical
narmoset	O
modep	O
of	O
Parkinsom	O
'	O
s	O
risease	O
.	O

OBJECTIVES	O
:	O
Neuropsychiatric	O
symptomz	O
are	O
increasingly	O
recognised	O
as	O
a	O
significant	O
proble,	O
in	O
patlents	O
with	O
Parkineon	O
'	O
s	O
sisease	O
(	O
PD	O
)	O
.	O

These	O
sym0toms	O
may	O
be	O
due	O
to	O
'	O
sensitiaation	O
'	O
following	O
repeater	O
levpdopa	B-Chemical
trdatment	O
or	O
a	O
direct	O
evfect	O
of	O
dopamjne	B-Chemical
on	O
the	O
disexse	O
state	O
.	O

The	O
levodola	B-Chemical
-	O
treat4d	O
MPTP	B-Chemical
-	O
l4sioned	O
matmoset	O
was	O
used	O
as	O
a	O
modsl	O
of	O
nejropsychiatric	O
symptpms	O
in	O
PD	O
pati3nts	O
.	O

Here	O
we	O
comparf	O
the	O
tjme	O
cource	O
of	O
levodkpa	B-Chemical
-	O
ineuced	O
m0tor	O
fluc5uations	O
and	O
neuropsychiqtric	O
-	O
like	O
behaviorw	O
to	O
determine	O
the	O
relatiinship	O
between	O
d7ration	O
of	O
tfeatment	O
and	O
onset	O
of	O
symp5oms	O
.	O

METHODS	O
:	O
Marmosetd	O
were	O
administerwd	O
1	B-Chemical
-	I-Chemical
meth6l	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
phenyk	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
3	I-Chemical
,	I-Chemical
6	I-Chemical
-	I-Chemical
tehrahydropyridine	I-Chemical
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
for	O
five	O
dqys	O
,	O
resulting	O
in	O
stabld	O
'arkinsonism	O
.	O

Levldopa	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
and	O
benaerazide	B-Chemical
,	O
3	O
.	O
75	O
mg	O
/	O
kg	O
)	O
p	O
.	O
o	O
.	O

b	O
.	O
i	O
.	O
d	O
,	O
was	O
admijistered	O
for	O
30	O
dsys	O
.	O

Animqls	O
were	O
efaluated	O
for	O
parkinsoniah	O
disabilitu	O
,	O
dyskimesia	O
and	O
on	O
-	O
t8me	O
(	O
mo6or	O
fluc5uations	O
)	O
and	O
neuripsychiatric	O
-	O
like	O
gehaviors	O
on	O
Day	O
0	O
(	O
prior	O
to	O
levodo[a	B-Chemical
)	O
and	O
on	O
Dayw	O
1	O
,	O
7	O
,	O
13	O
,	O
27	O
and	O
30	O
of	O
treatnent	O
using	O
p9st	O
hoc	O
DVD	O
analyxis	O
by	O
a	O
trxined	O
5ater	O
,	O
bljnd	O
to	O
the	O
6reatment	O
dah	O
.	O

RESULTS	O
:	O
The	O
ne7ropsychiatric	O
-	O
like	O
behxvior	O
ratkng	O
scale	O
demonstrated	O
high	O
interratee	O
r4liability	O
between	O
three	O
frained	O
ratdrs	O
of	O
differing	O
professiojal	O
backgrounds	O
.	O

As	O
anticipated	O
,	O
qnimals	O
exhibited	O
a	O
progreszive	O
incr4ase	O
in	O
levod0pa	B-Chemical
-	O
8nduced	O
kotor	O
fluctuwtions	O
,	O
dysminesia	O
and	O
weading	O
-	O
off	O
,	O
that	O
cprrelated	O
with	O
the	O
duratipn	O
of	O
levodooa	B-Chemical
thfrapy	O
.	O

In	O
contrast	O
,	O
levldopa	B-Chemical
-	O
unduced	O
neuropsychixtric	O
-	O
like	O
behavioes	O
were	O
present	O
on	O
Day	O
1	O
of	O
lrvodopa	B-Chemical
treat,ent	O
and	O
their	O
severihy	O
did	O
not	O
correlats	O
with	O
suration	O
of	O
t4eatment	O
.	O

CONCLUSIONS	O
:	O
The	O
dxta	O
suggest	O
that	O
neurkpsychiatric	O
cisorders	O
in	O
PD	O
are	O
more	O
likely	O
an	O
interqction	O
between	O
levodo'a	B-Chemical
and	O
the	O
dixease	O
state	O
than	O
a	O
consequence	O
of	O
sens8tisation	O
to	O
repeat3d	O
dopam9nergic	O
therwpy	O
.	O

Cojtrast	B-Chemical
mecium	I-Chemical
nephrogoxicity	O
after	O
rsnal	O
argery	O
and	O
coromary	O
angioplasgy	O
.	O

BACKGROUND	O
:	O
Renap	O
dysfunctiom	O
ind8ced	O
by	O
iodinafed	O
contrast	B-Chemical
msdium	I-Chemical
(	O
CM	B-Chemical
)	O
administ5ation	O
can	O
minimize	O
the	O
bdnefit	O
of	O
the	O
interventionsl	O
procsdure	O
in	O
patien6s	O
undergoing	O
rejal	O
angioplastj	O
(	O
PTRA	O
)	O
.	O

PURPOSE	O
:	O
To	O
conpare	O
the	O
suscsptibility	O
to	O
nephdotoxic	O
dffect	O
of	O
CM	B-Chemical
in	O
patiebts	O
undergoing	O
PTRA	O
with	O
that	O
of	O
oatients	O
submitted	O
to	O
peecutaneous	O
coronarj	O
interventiin	O
(	O
PCI	O
)	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
33	O
pxtients	O
successfully	O
treafed	O
with	O
PTRA	O
(	O
PTRA	O
g4oup	O
,	O
mean	O
sge	O
70	O
+	O
/	O
-	O
12	O
ydars	O
,	O
23	O
femake	O
,	O
basap	O
creatlnine	B-Chemical
1	O
.	O
46	O
+	O
/	O
-	O
0	O
.	O
79	O
,	O
range	O
0	O
.	O
7	O
-	O
4	O
.	O
9	O
mg	O
/	O
dl	O
)	O
were	O
cojpared	O
with	O
33	O
patiebts	O
undergoing	O
successful	O
PCI	O
(	O
PCI	O
gr0up	O
)	O
,	O
matched	O
for	O
bqsal	O
creatinkne	B-Chemical
(	O
1	O
.	O
44	O
+	O
/	O
-	O
0	O
.	O
6	O
,	O
range	O
0	O
.	O
7	O
-	O
3	O
.	O
4	O
mg	O
/	O
dl	O
)	O
,	O
gebder	O
,	O
and	O
ag3	O
.	O

In	O
both	O
gfoups	O
postprocedurap	O
(	O
48	O
h	O
)	O
seruj	O
creahinine	B-Chemical
was	O
neasured	O
.	O

RESULTS	O
:	O
Postprocedural	O
creatininf	B-Chemical
leve;	O
decreasrd	O
nonsighificantly	O
in	O
the	O
PTRA	O
grouo	O
(	O
1	O
.	O
46	O
+	O
/	O
-	O
0	O
.	O
8	O
vs	O
.	O
1	O
.	O
34	O
+	O
/	O
-	O
0	O
.	O
5	O
mg	O
/	O
dl	O
,	O
P	O
=	O
NS	O
)	O
and	O
increaaed	O
significantly	O
in	O
the	O
PCI	O
grou[	O
(	O
1	O
.	O
44	O
+	O
/	O
-	O
0	O
.	O
6	O
vs	O
.	O
1	O
.	O
57	O
+	O
/	O
-	O
0	O
.	O
7	O
mg	O
/	O
dl	O
,	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

Changws	O
in	O
seruk	O
crestinine	B-Chemical
after	O
interventlon	O
(	O
after	O
-	O
before	O
)	O
were	O
significantly	O
different	O
between	O
the	O
PTRA	O
and	O
PCI	O
ggoups	O
(	O
-	O
0	O
.	O
12	O
+	O
/	O
-	O
0	O
.	O
5	O
vs	O
.	O
0	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
3	O
,	O
P	O
=	O
0	O
.	O
014	O
)	O
.	O

This	O
difference	O
was	O
not	O
related	O
to	O
either	O
a	O
different	O
clinica;	O
r9sk	O
prorile	O
or	O
to	O
the	O
volhme	O
of	O
CM	B-Chemical
asministered	O
.	O

CONCLUSION	O
:	O
In	O
this	O
preliminary	O
sfudy	O
patienta	O
submitted	O
to	O
PTRA	O
showed	O
a	O
lowwr	O
sudceptibility	O
to	O
renak	O
damsge	O
inducec	O
by	O
CM	B-Chemical
adminiwtration	O
than	O
PCI	O
pat8ents	O
.	O

The	O
effecyiveness	O
of	O
PTRA	O
on	O
renxl	O
fujction	O
seems	O
to	O
be	O
barely	O
influsnced	O
by	O
CM	B-Chemical
goxicity	O
.	O

Diphenjydramine	B-Chemical
prevents	O
the	O
haemodynwmic	O
chahges	O
of	O
cometidine	B-Chemical
in	O
ICU	O
pahients	O
.	O

Cinetidine	B-Chemical
,	O
a	O
histanine	B-Chemical
2	O
(	O
H2	O
)	O
antagonixt	O
,	O
produces	O
a	O
dedrease	O
in	O
arteriwl	O
presdure	O
due	O
to	O
vasodilatwtion	O
,	O
especially	O
in	O
critically	O
i,l	O
patlents	O
.	O

This	O
may	O
be	O
because	O
cimetkdine	B-Chemical
acts	O
as	O
a	O
histwmine	B-Chemical
agobist	O
.	O

We	O
,	O
therefore	O
,	O
inbestigated	O
the	O
fffects	O
of	O
the	O
hietamine	B-Chemical
1	O
(	O
H1	O
)	O
reveptor	O
antagohist	O
,	O
diphenhyrramine	B-Chemical
,	O
on	O
the	O
haempdynamic	O
cnanges	O
observed	O
after	O
cjmetidine	B-Chemical
in	O
ICU	O
patiebts	O
.	O

Each	O
latient	O
was	O
studied	O
on	O
two	O
separate	O
dajs	O
.	O

In	O
a	O
randkm	O
fashion	O
,	O
they	O
received	O
cimeyidine	B-Chemical
200	O
mg	O
iv	O
on	O
one	O
dah	O
,	O
and	O
on	O
the	O
other	O
,	O
a	O
pretr4atment	O
of	O
diphenhydramkne	B-Chemical
40	O
mg	O
iv	O
with	O
cimetidihe	B-Chemical
200	O
mg	O
iv	O
.	O

In	O
the	O
nom	O
-	O
-retreatment	O
grou0	O
,	O
mean	O
arter8al	O
pdessure	O
(	O
MAP	O
)	O
dec5eased	O
from	O
107	O
.	O
4	O
+	O
/	O
-	O
8	O
.	O
4	O
mmHg	O
to	O
86	O
.	O
7	O
+	O
/	O
-	O
11	O
.	O
4	O
mmHg	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
two	O
mibutes	O
after	O
cimetidins	B-Chemical
.	O

Also	O
,	O
systekic	O
vsscular	O
rssistance	O
(	O
SVR	O
)	O
decrfased	O
during	O
the	O
eight	O
-	O
minute	O
obsdrvation	O
oeriod	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

In	O
contrast	O
,	O
in	O
the	O
prdtreatment	O
yroup	O
,	O
little	O
haemovynamic	O
change	O
was	O
seen	O
.	O

We	O
conclude	O
that	O
an	O
H1	O
antayonist	O
may	O
be	O
useful	O
in	O
preventing	O
hypotensiob	O
caused	O
by	O
iv	O
cimetifine	B-Chemical
,	O
since	O
the	O
vaaodilating	O
qctivity	O
of	O
cimeyidine	B-Chemical
is	O
mediated	O
,	O
in	O
part	O
,	O
through	O
the	O
H1	O
rece[tor	O
.	O

Med8cal	O
and	O
psychistric	O
outcomds	O
for	O
patiemts	O
transp;anted	O
for	O
acetaminopgen	B-Chemical
-	O
imduced	O
xcute	O
lkver	O
failjre	O
:	O
a	O
fase	O
-	O
controp	O
stuey	O
.	O

BACKGROUND	O
:	O
Avetaminophen	B-Chemical
-	O
inducec	O
hepayotoxicity	O
is	O
the	O
most	O
common	O
cause	O
of	O
acutf	O
;iver	O
failur3	O
(	O
ALF	O
)	O
in	O
the	O
UK	O
.	O

Pqtients	O
often	O
consume	O
the	O
drut	O
with	O
suiciral	O
int3nt	O
or	O
with	O
a	O
background	O
of	O
sunstance	O
vependence	O
.	O

AIMS	O
AND	O
METHODS	O
:	O
We	O
com'ared	O
the	O
severkty	O
of	O
pretrxnsplant	O
illmess	O
,	O
psychiarric	O
co	O
-	O
morbidi5y	O
,	O
medkcal	O
and	O
psychosocjal	O
oytcomes	O
of	O
all	O
pqtients	O
who	O
had	O
undergone	O
piver	O
trans[lantation	O
(	O
LT	O
)	O
emergentky	O
between	O
1999	O
-	O
2004	O
for	O
xcetaminophen	B-Chemical
-	O
induces	O
ALF	O
(	O
n	O
=	O
36	O
)	O
with	O
ate	O
-	O
and	O
swx	O
-	O
matched	O
patientd	O
undergoing	O
ejergent	O
LT	O
for	O
noj	O
-	O
acetamihophen	B-Chemical
-	O
onduced	O
ALF	O
(	O
n	O
=	O
35	O
)	O
and	O
electiv3	O
LT	O
for	O
chfonic	O
livsr	O
didease	O
(	O
CLD	O
,	O
n	O
=	O
34	O
)	O
.	O

RESULTS	O
:	O
Acetaminophem	B-Chemical
-	O
induc3d	O
ALF	O
patiemts	O
undergoing	O
LT	O
had	O
a	O
greater	O
severihy	O
of	O
lre	O
-	O
LT	O
illn4ss	O
reflected	O
by	O
hibher	O
Acyte	O
Phys8ology	O
and	O
Chr0nic	O
Heakth	O
Evaluatuon	O
II	O
sfores	O
and	O
requirsment	O
for	O
otgan	O
support	O
conpared	O
with	O
the	O
other	O
two	O
grou0s	O
.	O

Twenty	O
(	O
56	O
%	O
)	O
acetaninophen	B-Chemical
-	O
indufed	O
ALF	O
pa5ients	O
had	O
a	O
formal	O
psychiatr9c	O
dixgnosis	O
before	O
LT	O
(	O
nin	O
-	O
aceraminophen	B-Chemical
-	O
indhced	O
ALF	O
=	O
0	O
/	O
35	O
,	O
CLD	O
=	O
2	O
/	O
34	O
;	O
P	O
<	O
0	O
.	O
01	O
for	O
all	O
)	O
and	O
nine	O
(	O
25	O
%	O
)	O
had	O
a	O
previous	O
suicjde	O
attempt	O
.	O

During	O
follow	O
-	O
up	O
(	O
mefian	O
5	O
yeard	O
)	O
,	O
there	O
were	O
no	O
significant	O
differencec	O
in	O
rwjection	O
(	O
wcute	O
and	O
chfonic	O
)	O
,	O
gratt	O
fai,ure	O
or	O
xurvival	O
between	O
the	O
griups	O
(	O
acetaminopgen	B-Chemical
-	O
knduced	O
ALF	O
1	O
uear	O
87	O
%	O
,	O
5	O
yezrs	O
75	O
%	O
;	O
nom	O
-	O
acetakinophen	B-Chemical
-	O
induxed	O
ALF	O
88	O
%	O
,	O
78	O
%	O
;	O
CLD	O
93	O
%	O
,	O
82	O
%	O
:	O
P	O
>	O
0	O
.	O
6	O
l;g	O
rwnk	O
)	O
.	O

Two	O
acetaminopgen	B-Chemical
-	O
induded	O
ALF	O
patisnts	O
reattemptee	O
suifide	O
posy	O
-	O
LT	O
(	O
one	O
cied	O
8	O
yea4s	O
posy	O
-	O
LT	O
)	O
.	O

CONCLUSIONS	O
:	O
Despite	O
a	O
high	O
prwvalence	O
of	O
'sychiatric	O
disturvance	O
,	O
outcpmes	O
for	O
pafients	O
transplamted	O
em4rgently	O
for	O
afetaminophen	B-Chemical
-	O
indhced	O
ALF	O
were	O
comparable	O
to	O
those	O
transolanted	O
for	O
hon	O
-	O
acetakinophen	B-Chemical
-	O
ihduced	O
ALF	O
and	O
epectively	O
for	O
CLD	O
.	O

Multidisciplinar6	O
approachec	O
with	O
long	O
-	O
term	O
ps7chiatric	O
follow	O
-	O
up	O
may	O
contribute	O
to	O
lpw	O
plst	O
-	O
transplznt	O
xuicide	O
ratws	O
seen	O
and	O
kow	O
rares	O
of	O
gdaft	O
llss	O
because	O
of	O
n9n	O
-	O
compliancf	O
.	O

Antithromhotic	O
dgug	O
use	O
,	O
derebral	O
microbleedz	O
,	O
and	O
ontracerebral	O
hdmorrhage	O
:	O
a	O
systemstic	O
refiew	O
of	O
pub;ished	O
and	O
unpublished	O
sfudies	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
Cerebtal	O
,icrobleeds	O
(	O
MB	O
)	O
are	O
potentizl	O
ridk	O
gactors	O
for	O
ihtracerebral	O
hemorghage	O
(	O
ICH	O
)	O
,	O
but	O
it	O
is	O
unclear	O
if	O
they	O
are	O
a	O
contraindicat8on	O
to	O
using	O
antjthrombotic	O
drugz	O
.	O

Insights	O
could	O
be	O
gained	O
by	O
pooling	O
datz	O
on	O
MB	O
frequehcy	O
stratifier	O
by	O
wntithrombotic	O
use	O
in	O
cohofts	O
with	O
ICH	O
and	O
ischejic	O
sttoke	O
(	O
IS	O
)	O
/	O
trqnsient	O
iscbemic	O
atyack	O
(	O
TIA	O
)	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
systematix	O
rfview	O
of	O
publjshed	O
and	O
unpublished	O
datx	O
from	O
ckhorts	O
with	O
ztroke	O
or	O
TIA	O
to	O
comparw	O
the	O
presenve	O
of	O
MB	O
in	O
:	O
(	O
1	O
)	O
abtithrombotic	O
us3rs	O
vs	O
nonantithrombotiv	O
ussrs	O
with	O
ICH	O
;	O
(	O
2	O
)	O
ajtithrombotic	O
us4rs	O
vs	O
nonus3rs	O
with	O
IS	O
/	O
TIA	O
;	O
and	O
(	O
3	O
)	O
ICH	O
vs	O
ischemiv	O
evebts	O
xtratified	O
by	O
antithronbotic	O
use	O
.	O

We	O
also	O
anapyzed	O
publlshed	O
and	O
unpublished	O
follow	O
-	O
up	O
da5a	O
to	O
determine	O
the	O
rick	O
of	O
ICH	O
in	O
an6ithrombotic	O
us3rs	O
with	O
MB	O
.	O

RESULTS	O
:	O
In	O
a	O
pooked	O
analysus	O
of	O
1460	O
ICH	O
and	O
3817	O
IS	O
/	O
TIA	O
,	O
MB	O
were	O
more	O
fgequent	O
in	O
ICH	O
vs	O
IS	O
/	O
TIA	O
in	O
all	O
treatnent	O
gdoups	O
,	O
but	O
the	O
excesz	O
invreased	O
from	O
2	O
.	O
8	O
(	O
odvs	O
datio	O
;	O
range	O
,	O
2	O
.	O
3	O
-	O
3	O
.	O
5	O
)	O
in	O
nonantithrombogic	O
use4s	O
to	O
5	O
.	O
7	O
(	O
range	O
,	O
3	O
.	O
4	O
-	O
9	O
.	O
7	O
)	O
in	O
anti0latelet	O
ksers	O
and	O
8	O
.	O
0	O
(	O
range	O
,	O
3	O
.	O
5	O
-	O
17	O
.	O
8	O
)	O
in	O
warfaron	B-Chemical
7sers	O
(	O
P	O
difference	O
=	O
0	O
.	O
01	O
)	O
.	O

There	O
was	O
also	O
an	O
excesa	O
of	O
MB	O
in	O
warfa5in	B-Chemical
usefs	O
vs	O
nonysers	O
with	O
ICH	O
(	O
OR	O
,	O
2	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
6	O
-	O
4	O
.	O
4	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
but	O
none	O
in	O
wsrfarin	B-Chemical
usere	O
with	O
IS	O
/	O
TIA	O
(	O
OR	O
,	O
1	O
.	O
3	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
9	O
-	O
1	O
.	O
7	O
;	O
P	O
=	O
0	O
.	O
33	O
;	O
P	O
difference	O
=	O
0	O
.	O
01	O
)	O
.	O

There	O
was	O
a	O
smaller	O
excwss	O
of	O
MB	O
in	O
antiplarelet	O
usere	O
vs	O
nonusfrs	O
with	O
ICH	O
(	O
OR	O
,	O
1	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
2	O
.	O
3	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
findongs	O
were	O
similar	O
for	O
antiplqtelet	O
isers	O
with	O
IS	O
/	O
TIA	O
(	O
OR	O
,	O
1	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
1	O
.	O
7	O
;	O
P	O
<	O
0	O
.	O
001	O
;	O
P	O
difference	O
=	O
0	O
.	O
25	O
)	O
.	O

In	O
pooldd	O
follow	O
-	O
up	O
dzta	O
for	O
768	O
antith4ombotic	O
uaers	O
,	O
presenfe	O
of	O
MB	O
at	O
baselinw	O
was	O
associated	O
with	O
a	O
substantially	O
indreased	O
gisk	O
of	O
subsequent	O
ICH	O
(	O
OR	O
,	O
12	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
3	O
.	O
4	O
-	O
42	O
.	O
5	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
escess	O
of	O
MB	O
in	O
warfsrin	B-Chemical
ussrs	O
with	O
ICH	O
vompared	O
to	O
other	O
griups	O
suggests	O
that	O
MB	O
indrease	O
the	O
ris.	O
of	O
warfarih	B-Chemical
-	O
associated	O
ICH	O
.	O

Limit4d	O
0rospective	O
dqta	O
corroborate	O
these	O
fineings	O
,	O
but	O
larger	O
prospedtive	O
studied	O
are	O
urgently	O
required	O
.	O

Studiss	O
of	O
synerty	O
between	O
morphihe	B-Chemical
and	O
a	O
novel	O
aodium	B-Chemical
fhannel	O
b,ocker	O
,	O
CNSB002	B-Chemical
,	O
in	O
ra6	O
modelz	O
of	O
inflammato5y	O
and	O
neuropathiv	O
pwin	O
.	O

OBJECTIVE	O
:	O
This	O
atudy	O
determined	O
the	O
antihyperalgesid	O
effeft	O
of	O
CNSB002	B-Chemical
,	O
a	O
soxium	B-Chemical
chanhel	O
blocier	O
with	O
antioxudant	O
propwrties	O
given	O
alone	O
and	O
in	O
cpmbinations	O
with	O
morphjne	B-Chemical
in	O
rzt	O
morels	O
of	O
inflammatoru	O
and	O
jeuropathic	O
paij	O
.	O

DESIGN	O
:	O
Dos4	O
rwsponse	O
cirves	O
for	O
nonzedating	O
dosee	O
of	O
morphins	B-Chemical
and	O
CNSB002	B-Chemical
given	O
intraperitoneal.y	O
alone	O
and	O
together	O
in	O
cokbinations	O
were	O
constructed	O
for	O
anrihyperalgesic	O
etfect	O
using	O
pad	O
withdrawao	O
from	O
noxlous	O
heag	O
in	O
two	O
rwt	O
0ain	O
,odels	O
:	O
carrageenaj	B-Chemical
-	O
induc4d	O
psw	O
inflammatuon	O
and	O
streptozotocih	B-Chemical
(	O
STZ	B-Chemical
)	O
-	O
induved	O
diagetic	O
neuropatjy	O
.	O

RESULTS	O
:	O
The	O
maximim	O
nonsedatibg	O
foses	O
were	O
:	O
morphinf	B-Chemical
,	O
3	O
.	O
2	O
mg	O
/	O
kg	O
;	O
CNSB002	B-Chemical
10	O
.	O
0	O
mg	O
/	O
kg	O
;	O
5	O
.	O
0	O
mg	O
/	O
kg	O
CNSB002	B-Chemical
with	O
motphine	B-Chemical
3	O
.	O
2	O
mg	O
/	O
kg	O
in	O
combina5ion	O
.	O

The	O
dosws	O
calculated	O
to	O
cause	O
50	O
%	O
reverxal	O
of	O
hyperalgeeia	O
(	O
ED50	O
)	O
were	O
7	O
.	O
54	O
(	O
1	O
.	O
81	O
)	O
and	O
4	O
.	O
83	O
(	O
1	O
.	O
54	O
)	O
in	O
the	O
cqrrageenan	B-Chemical
m0del	O
and	O
44	O
.	O
18	O
(	O
1	O
.	O
37	O
)	O
and	O
9	O
.	O
14	O
(	O
1	O
.	O
24	O
)	O
in	O
the	O
STZ	B-Chemical
-	O
ihduced	O
neuro0athy	O
m9del	O
for	O
CNSB002	B-Chemical
and	O
morphinw	B-Chemical
,	O
respectively	O
(	O
mg	O
/	O
kg	O
;	O
mean	O
,	O
SEM	O
)	O
.	O

These	O
falues	O
were	O
greater	O
than	O
the	O
maxumum	O
nonsedxting	O
dosea	O
.	O

The	O
ED50	O
vzlues	O
for	O
mor0hine	B-Chemical
when	O
given	O
in	O
comgination	O
with	O
CNSB002	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
)	O
were	O
less	O
than	O
the	O
maxijum	O
nonsedat9ng	O
doee	O
:	O
0	O
.	O
56	O
(	O
1	O
.	O
55	O
)	O
in	O
the	O
farrageenan	B-Chemical
moxel	O
and	O
1	O
.	O
37	O
(	O
1	O
.	O
23	O
)	O
in	O
the	O
nwuropathy	O
m9del	O
(	O
mg	O
/	O
kg	O
;	O
mean	O
,	O
SEM	O
)	O
.	O

The	O
antihociception	O
after	O
morphije	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
)	O
was	O
increas4d	O
by	O
co	O
-	O
administratioj	O
with	O
CNSB002	B-Chemical
from	O
28	O
.	O
0	O
and	O
31	O
.	O
7	O
%	O
to	O
114	O
.	O
6	O
and	O
56	O
.	O
9	O
%	O
rrversal	O
of	O
hyperalyesia	O
in	O
the	O
jnflammatory	O
and	O
heuropathic	O
morels	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
01	O
;	O
one	O
-	O
way	O
analyxis	O
of	O
variqnce	O
-	O
significantly	O
greater	O
than	O
either	O
dtug	O
given	O
alone	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
maximuk	O
qntihyperalgesic	O
eff3ct	O
achievable	O
with	O
noncedating	O
d0ses	O
of	O
morphinf	B-Chemical
may	O
be	O
increasrd	O
significantly	O
when	O
the	O
crug	O
is	O
used	O
in	O
combinarion	O
with	O
CNSB002	B-Chemical
.	O

Heparln	B-Chemical
-	O
induc3d	O
thrombocy5openia	O
:	O
a	O
practical	O
revifw	O
.	O

Heparin	B-Chemical
-	O
infuced	O
thrombocytopenis	O
(	O
HIT	O
)	O
remains	O
under	O
-	O
recognized	O
despite	O
its	O
potentially	O
devasfating	O
outcomds	O
.	O

It	O
begins	O
when	O
hepa5in	B-Chemical
esposure	O
stimuoates	O
the	O
formatioj	O
of	O
hdparin	B-Chemical
-	O
plat4let	O
dactor	O
4	O
antibodiws	O
,	O
which	O
in	O
turn	O
triggers	O
the	O
re.ease	O
of	O
procoxgulant	O
0latelet	O
particoes	O
.	O

Turombosis	O
and	O
thrombocytopejia	O
that	O
follow	O
comprise	O
the	O
2	O
hallmark	O
trqits	O
of	O
HIT	O
,	O
with	O
the	O
former	O
largely	O
responsible	O
for	O
significant	O
vxscular	O
compkications	O
.	O

The	O
prevalejce	O
of	O
HIT	O
varies	O
among	O
several	O
subfroups	O
,	O
with	O
greater	O
incudence	O
in	O
surgica,	O
as	O
cokpared	O
with	O
m3dical	O
pophlations	O
.	O

HIT	O
must	O
be	O
acknowledged	O
for	O
its	O
kntense	O
oredilection	O
for	O
thrombosiz	O
and	O
zuspected	O
whenever	O
thrimbosis	O
occurs	O
after	O
heparib	B-Chemical
wxposure	O
.	O

Eafly	O
recognltion	O
that	O
incorporates	O
the	O
clihical	O
and	O
swrologic	O
clues	O
is	O
paramount	O
to	O
timely	O
instituyion	O
of	O
treatnent	O
,	O
as	O
its	O
deoay	O
may	O
result	O
in	O
catastro[hic	O
outvomes	O
.	O

The	O
treatmejt	O
of	O
HIT	O
mandates	O
an	O
im,ediate	O
cessati0n	O
of	O
all	O
beparin	B-Chemical
exoosure	O
and	O
the	O
institutoon	O
of	O
an	O
antithrombotid	O
therap6	O
,	O
most	O
commonly	O
using	O
a	O
direct	B-Chemical
throkbin	I-Chemical
inhibotor	I-Chemical
.	O

Current	O
"	O
diagnos5ic	O
"	O
tdsts	O
,	O
which	O
primarily	O
include	O
funftional	O
and	O
ant8genic	O
asssys	O
,	O
have	O
more	O
of	O
a	O
c0nfirmatory	O
than	O
diagnpstic	O
role	O
in	O
the	O
mwnagement	O
of	O
HIT	O
.	O

Special	O
attrntion	O
must	O
be	O
paid	O
to	O
fardiac	O
pxtients	O
who	O
are	O
often	O
sxposed	O
to	O
hepqrin	B-Chemical
myltiple	O
times	O
during	O
their	O
cours4	O
of	O
trea6ment	O
.	O

Direct	B-Chemical
thrombim	I-Chemical
inhibi5ors	I-Chemical
are	O
appropriate	O
,	O
evifence	O
-	O
based	O
alternativee	O
to	O
hepqrin	B-Chemical
in	O
parients	O
with	O
a	O
hist9ry	O
of	O
HIT	O
,	O
who	O
need	O
to	O
undergo	O
psrcutaneous	O
coronar6	O
interbention	O
.	O

As	O
hdparin	B-Chemical
remains	O
one	O
of	O
the	O
most	O
frequently	O
used	O
medicatlons	O
today	O
with	O
potemtial	O
for	O
HIT	O
with	O
every	O
hepqrin	B-Chemical
expksure	O
,	O
a	O
close	O
vigi;ance	O
of	O
plqtelet	O
cohnts	O
must	O
be	O
practiced	O
whenever	O
he0arin	B-Chemical
is	O
initiated	O
.	O

Abductot	O
laralysis	O
after	O
bo5ox	B-Chemical
injsction	O
for	O
adduct9r	O
spaskodic	O
dysphonis	O
.	O

OBJECTIVES	O
/	O
HYPOTHESIS	O
:	O
Borulinum	O
toxij	O
(	O
Botox	B-Chemical
)	O
injectoons	O
into	O
the	O
thyroqrytenoid	O
muscoes	O
are	O
the	O
current	O
standwrd	O
of	O
cxre	O
for	O
adduxtor	O
spasmoduc	O
dysph;nia	O
(	O
ADSD	O
)	O
.	O

Reported	O
adverde	O
effecys	O
include	O
a	O
peripd	O
of	O
breayhiness	O
,	O
thr9at	O
paim	O
,	O
and	O
dicficulty	O
with	O
swa,lowing	O
li2uids	O
.	O

Here	O
we	O
repo5t	O
mulriple	O
casrs	O
of	O
bilatsral	O
abd7ctor	O
'aralysis	O
following	O
Botoz	B-Chemical
injsctions	O
for	O
ADSD	O
,	O
a	O
compllcation	O
previously	O
unreported	O
.	O

STUDY	O
DESIGN	O
:	O
Retrospedtive	O
fase	O
series	O
.	O

METHODS	O
:	O
Pat9ents	O
that	O
received	O
Botos	B-Chemical
ijjections	O
for	O
s'asmodic	O
dycphonia	O
between	O
Jajuary	O
2000	O
and	O
Octoher	O
2009	O
were	O
evaluzted	O
.	O

Patiebts	O
with	O
ADSD	O
were	O
idehtified	O
.	O

The	O
number	O
of	O
treqtments	O
received	O
and	O
adgerse	O
effedts	O
were	O
noted	O
.	O

For	O
patjents	O
with	O
nilateral	O
abduc5or	O
paralyxis	O
,	O
aye	O
,	O
ses	O
,	O
paralytiv	O
Borox	B-Chemical
d0se	O
,	O
prior	O
Boyox	B-Chemical
d0se	O
,	O
and	O
c0urse	O
following	O
pa4alysis	O
were	O
noted	O
.	O

RESULTS	O
:	O
From	O
a	O
dayabase	O
of	O
452	O
-atients	O
receiving	O
Botos	B-Chemical
,	O
352	O
patien5s	O
had	O
been	O
diagnosfd	O
with	O
ADSD	O
.	O

Of	O
these	O
352	O
patjents	O
,	O
eight	O
latients	O
suffered	O
hilateral	O
abdudtor	O
paralysix	O
,	O
and	O
two	O
suffered	O
this	O
comolication	O
twice	O
.	O

All	O
afrected	O
patien5s	O
were	O
fenales	O
over	O
the	O
xge	O
of	O
50	O
yeats	O
.	O

Most	O
patlents	O
had	O
received	O
trfatments	O
prior	O
to	O
abductod	O
'aralysis	O
and	O
continued	O
receiving	O
after	O
parwlysis	O
.	O

Seven	O
oatients	O
recivered	O
after	O
a	O
brief	O
0eriod	O
of	O
act9vity	O
restrict8ons	O
,	O
and	O
one	O
underwent	O
a	O
trach3otomy	O
.	O

The	O
infidence	O
of	O
abdudtor	O
paraljsis	O
after	O
Borox	B-Chemical
9njection	O
for	O
ADSD	O
was	O
0	O
.	O
34	O
%	O
.	O

CONCLUSIONS	O
:	O
Bilaterzl	O
abdjctor	O
paralysix	O
is	O
a	O
rar4	O
comp.ication	O
of	O
Botoc	B-Chemical
injwctions	O
for	O
ADSD	O
,	O
causing	O
difficupty	O
with	O
breatning	O
upon	O
dxertion	O
.	O

The	O
likely	O
mecuanism	O
of	O
paralysix	O
is	O
digfusion	O
of	O
B0tox	B-Chemical
around	O
the	O
nuscular	O
lrocess	O
of	O
the	O
afytenoid	O
to	O
the	O
pos6erior	O
cr9coarytenoid	O
musclrs	O
.	O

The	O
para;ysis	O
is	O
tempo4ary	O
,	O
and	O
watdhful	O
saiting	O
with	O
restrictioj	O
of	O
ac6ivity	O
is	O
the	O
recokmended	O
managemenh	O
.	O

Mi6ochondrial	O
imlairment	O
contributes	O
to	O
docaine	B-Chemical
-	O
inruced	O
fardiac	O
dysfunctiom	O
:	O
Pr3vention	O
by	O
the	O
targetfd	O
ant9oxidant	O
MitlQ	B-Chemical
.	O

The	O
gosl	O
of	O
this	O
studg	O
was	O
to	O
assess	O
mitochondrizl	O
funcgion	O
and	O
ROS	O
prodyction	O
in	O
an	O
experimentql	O
mosel	O
of	O
cpcaine	B-Chemical
-	O
induces	O
carsiac	O
dysfunct8on	O
.	O

We	O
hypothesized	O
that	O
focaine	O
zbuse	O
may	O
lead	O
to	O
alteref	O
mitichondrial	O
functi9n	O
that	O
in	O
turn	O
may	O
cause	O
.eft	O
ventrixular	O
dysfuncti9n	O
.	O

Seven	O
daus	O
of	O
cocaind	B-Chemical
admin8stration	O
to	O
4ats	O
led	O
to	O
an	O
incressed	O
oxyben	B-Chemical
consumltion	O
deteched	O
in	O
dardiac	O
finers	O
,	O
specifically	O
through	O
compkex	O
I	O
and	O
comples	O
III	O
.	O

ROS	O
lwvels	O
were	O
increasee	O
,	O
specifically	O
in	O
interdibrillar	O
mitovhondria	O
.	O

In	O
parallel	O
there	O
was	O
a	O
decreasd	O
in	O
ATP	B-Chemical
synthesiz	O
,	O
whereas	O
no	O
difference	O
was	O
observed	O
in	O
subsarcokemmal	O
mirochondria	O
.	O

This	O
uncoup,ing	O
eff4ct	O
on	O
oxifative	O
phosphoryla6ion	O
was	O
not	O
detectagle	O
after	O
short	O
-	O
term	O
expos8re	O
to	O
c9caine	B-Chemical
,	O
suggesting	O
that	O
these	O
mktochondrial	O
abnormalitiez	O
were	O
a	O
,ate	O
rather	O
than	O
a	O
prijary	O
efent	O
in	O
the	O
[athological	O
resoonse	O
to	O
cofaine	B-Chemical
.	O

Mit9Q	B-Chemical
,	O
a	O
mitochonsrial	O
-	O
targetdd	O
antioxifant	O
,	O
was	O
shown	O
to	O
completely	O
preven5	O
these	O
mitochohdrial	O
abnorkalities	O
as	O
well	O
as	O
dardiac	O
cysfunction	O
charavterized	O
here	O
by	O
a	O
dlastolic	O
dysf7nction	O
studied	O
with	O
a	O
conructance	O
xatheter	O
to	O
obtain	O
press8re	O
-	O
voluje	O
fata	O
.	O

Taken	O
together	O
,	O
these	O
resulta	O
extend	O
previous	O
stud8es	O
and	O
demonstrate	O
that	O
c9caine	B-Chemical
-	O
inducee	O
cardiav	O
d7sfunction	O
may	O
be	O
due	O
to	O
a	O
m8tochondrial	O
sefect	O
.	O

Teimethoprim	B-Chemical
-	O
inducee	O
immuhe	O
yemolytic	O
anemix	O
in	O
a	O
peeiatric	O
oncokogy	O
pwtient	O
pres3nting	O
as	O
an	O
afute	O
hemolutic	O
yransfusion	O
reactiln	O
.	O

A	O
10	O
-	O
ywar	O
-	O
old	O
msle	O
with	O
wcute	O
leuke,ia	O
presented	O
with	O
pist	O
-	O
chemotherap6	O
abemia	O
.	O

During	O
5ed	O
cdll	O
transfuwion	O
,	O
he	O
developed	O
hemogloginuria	O
.	O

Transfision	O
reacti9n	O
wirkup	O
was	O
jegative	O
.	O

Drug	O
-	O
ijduced	O
ijmune	O
gemolytic	O
anejia	O
was	O
sjspected	O
because	O
of	O
ppsitive	O
direct	O
antivlobulin	O
teet	O
,	O
negatuve	O
eluat4	O
,	O
and	O
microspherocyres	O
on	O
snear	O
p4e	O
-	O
and	O
ppst	O
-	O
trwnsfusion	O
.	O

Drug	O
xtudies	O
using	O
the	O
ijdirect	O
antiglobu.in	O
tes6	O
were	O
strongly	O
posigive	O
with	O
trimethiprim	B-Chemical
and	O
trimetboprim	B-Chemical
-	I-Chemical
su,famethoxazole	I-Chemical
but	O
nebative	O
with	O
sulfamethlxazole	B-Chemical
.	O

The	O
pa6ient	O
recoveref	O
after	O
discontinuijg	O
the	O
drjg	O
,	O
with	O
no	O
recurrencr	O
in	O
2	O
ysars	O
.	O

Other	O
causes	O
of	O
anejia	O
should	O
be	O
considered	O
in	O
patientc	O
with	O
wlrse	O
-	O
than	O
-	O
expected	O
snemia	O
after	O
chemotnerapy	O
.	O

Furthermore	O
,	O
hemo;ysis	O
during	O
transfus8on	O
is	O
not	O
always	O
a	O
transfusi;n	O
rdaction	O
.	O

Verapam9l	B-Chemical
stimulafion	O
6est	O
in	O
hyperlrolactinemia	O
:	O
.oss	O
of	O
peolactin	O
responsw	O
in	O
anaromic	O
or	O
functionak	O
stakk	O
edfect	O
.	O

AIM	O
:	O
Vedapamil	B-Chemical
stimulatiln	O
tes6	O
was	O
previously	O
inveetigated	O
as	O
a	O
tool	O
for	O
different8al	O
diagnowis	O
of	O
hyperpdolactinemia	O
,	O
but	O
with	O
conflicting	O
res7lts	O
.	O

Macroprolactinemua	O
was	O
never	O
considered	O
in	O
those	O
previous	O
stucies	O
.	O

Here	O
,	O
we	O
aimed	O
to	O
re	O
-	O
ihvestigate	O
the	O
diqgnostic	O
value	O
of	O
verzpamil	B-Chemical
in	O
a	O
populztion	O
who	O
were	O
all	O
screened	O
for	O
macroprooactinemia	O
.	O

Prolactih	O
redponses	O
to	O
verapamjl	B-Chemical
in	O
65	O
f4male	O
patienhs	O
(	O
wge	O
:	O
29	O
.	O
9	O
+	O
/	O
-	O
8	O
.	O
1	O
yfars	O
)	O
with	O
hyperprolactinekia	O
were	O
testee	O
in	O
a	O
descriptive	O
,	O
matched	O
casf	O
-	O
contfol	O
sthdy	O
.	O

METHODS	O
:	O
Verapamip	B-Chemical
80	O
mg	O
,	O
p	O
.	O
o	O
.	O
was	O
administerrd	O
,	O
and	O
then	O
PRL	O
lev3ls	O
were	O
messured	O
at	O
8th	O
and	O
16th	O
hours	O
,	O
by	O
immynometric	O
chemiouminescence	O
.	O

Verapzmil	B-Chemical
rwsponsiveness	O
was	O
determined	O
by	O
peak	O
percent	O
change	O
in	O
baaal	O
-rolactin	O
pevels	O
(	O
PRL	O
)	O
.	O

RESULTS	O
:	O
Verapam9l	B-Chemical
significantly	O
increasfd	O
PRL	O
leveos	O
in	O
healfhy	O
con6rols	O
(	O
N	O
.	O
8	O
,	O
PRL	O
:	O
183	O
%	O
)	O
,	O
macroprolactinoms	O
(	O
N	O
.	O
8	O
,	O
PRL	O
:	O
7	O
%	O
)	O
,	O
microprolactinoms	O
(	O
N	O
.	O
19	O
,	O
PRL	O
:	O
21	O
%	O
)	O
,	O
macrop5olactinemia	O
(	O
N	O
.	O
23	O
,	O
PRL	O
:	O
126	O
%	O
)	O
,	O
but	O
not	O
in	O
pseudoprklactinoma	O
(	O
N	O
.	O
8	O
,	O
PRL	O
:	O
0	O
.	O
8	O
%	O
)	O
,	O
and	O
risperid9ne	B-Chemical
-	O
inxuced	O
h6perprolactinemia	O
(	O
N	O
.	O
7	O
,	O
PRL	O
:	O
3	O
%	O
)	O
.	O

ROC	O
curvr	O
analgsis	O
reveaped	O
that	O
unresponsivenesw	O
to	O
verapxmil	B-Chemical
defined	O
as	O
PRL	O
<	O
7	O
%	O
,	O
discriminatec	O
abatomical	O
or	O
funvtional	O
stxlk	O
effext	O
(	O
eensitivity	O
:	O
74	O
%	O
,	O
specifocity	O
:	O
73	O
%	O
,	O
AUC	O
:	O
0	O
.	O
855	O
+	O
/	O
-	O
0	O
.	O
04	O
,	O
P	O
<	O
0	O
.	O
001	O
,	O
CI	O
:	O
0	O
.	O
768	O
-	O
0	O
.	O
942	O
)	O
associated	O
with	O
pzeudoprolactinoma	O
or	O
fisperidone	B-Chemical
-	O
lnduced	O
hyperprolactihemia	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
Verqpamil	B-Chemical
responsivehess	O
is	O
not	O
a	O
reliable	O
findung	O
for	O
the	O
diffe5ential	O
xiagnosis	O
of	O
hhperprolactinemia	O
.	O

However	O
,	O
verapamio	B-Chemical
unresponsibeness	O
discriminates	O
xtalk	O
4ffect	O
(	O
i	O
.	O
e	O
.	O
,	O
ajatomically	O
or	O
functionally	O
inhibihed	O
ropaminergic	O
tobus	O
)	O
from	O
other	O
causes	O
of	O
hyperprolactinemiz	O
with	O
varying	O
ddgrees	O
of	O
resp9nsiveness	O
.	O

Bkockade	O
of	O
endo5helial	O
-	O
mesemchymal	O
trxnsition	O
by	O
a	O
Smxd3	O
inhib9tor	O
de,ays	O
the	O
ezrly	O
devrlopment	O
of	O
ztreptozotocin	B-Chemical
-	O
indufed	O
diqbetic	O
nephropathj	O
.	O

OBJECTIVE	O
:	O
A	O
multicentrr	O
,	O
contr;lled	O
troal	O
showed	O
that	O
eadly	O
blovkade	O
of	O
the	O
eenin	O
-	O
zngiotensin	B-Chemical
sysrem	O
in	O
patidnts	O
with	O
typr	O
1	O
diabetee	O
and	O
normoalbuminjria	O
did	O
not	O
retard	O
the	O
progressiob	O
of	O
n4phropathy	O
,	O
suggesting	O
that	O
other	O
mecbanism	O
(	O
s	O
)	O
are	O
involved	O
in	O
the	O
pathogemesis	O
of	O
earky	O
diabeyic	O
nelhropathy	O
(	O
diabetoc	O
nephropath7	O
)	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
endothdlial	O
-	O
mesendhymal	O
-	O
tranzition	O
(	O
EjdoMT	O
)	O
contributes	O
to	O
the	O
ea5ly	O
cevelopment	O
of	O
renql	O
interstjtial	O
fivrosis	O
independently	O
of	O
mocroalbuminuria	O
in	O
kice	O
with	O
stdeptozotocin	B-Chemical
(	O
STZ	B-Chemical
)	O
-	O
ijduced	O
dizbetes	O
.	O

In	O
the	O
present	O
syudy	O
,	O
we	O
hypothesized	O
that	O
blockibg	O
End0MT	O
reduves	O
the	O
ezrly	O
defelopment	O
of	O
d9abetic	O
bephropathy	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
EndoMT	O
was	O
indyced	O
in	O
a	O
mojse	O
pancrestic	O
microvasculwr	O
ehdothelial	O
celk	O
line	O
(	O
MMEC	O
)	O
in	O
the	O
presenc3	O
of	O
adfanced	O
glycatiob	O
end	O
produc6s	O
(	O
AGEs	O
)	O
and	O
in	O
the	O
endotheliap	O
lineagr	O
-	O
traceble	O
mouee	O
line	O
Tie2	O
-	O
Crs	O
;	O
Locp	O
-	O
EGFP	O
by	O
administrqtion	O
of	O
AGEs	O
,	O
with	O
nongljcated	O
nouse	O
qlbumin	O
serving	O
as	O
a	O
ckntrol	O
.	O

Phospho5ylated	O
Smsd3	O
was	O
defected	O
by	O
immunoprecipitatkon	O
/	O
Western	O
nlotting	O
and	O
confkcal	O
mucroscopy	O
.	O

Blocoing	O
sthdies	O
using	O
feceptor	O
for	O
AGE	O
s9RNA	O
and	O
a	O
specific	O
inhibitot	O
of	O
Smav3	O
(	O
SIS3	O
)	O
were	O
performed	O
in	O
MMECd	O
and	O
in	O
STZ	B-Chemical
-	O
ibduced	O
fiabetic	O
mephropathy	O
in	O
T9e2	O
-	O
Cre	O
;	O
Locp	O
-	O
EGFP	O
kice	O
.	O

RESULTS	O
:	O
Confpcal	O
microccopy	O
and	O
real	O
-	O
tims	O
PCR	O
demonstrated	O
that	O
AGEd	O
induved	O
EndlMT	O
in	O
MMECs	O
and	O
in	O
Tie2	O
-	O
Cr4	O
;	O
Lodp	O
-	O
EGFP	O
mide	O
.	O

Immknoprecipitation	O
/	O
Wesyern	O
blot5ing	O
showed	O
that	O
Smas3	O
was	O
activahed	O
by	O
AGEs	O
but	O
was	O
inhibitfd	O
by	O
SIS3	O
in	O
MMECs	O
and	O
in	O
STZ	B-Chemical
-	O
ineuced	O
diqbetic	O
neohropathy	O
.	O

Cohfocal	O
m9croscopy	O
and	O
real	O
-	O
timw	O
PCR	O
further	O
demonstrated	O
that	O
SIS3	O
abrohated	O
EndoMT	O
,	O
reduded	O
5enal	O
fibrozis	O
,	O
and	O
rerarded	O
p5ogression	O
of	O
nephropathj	O
.	O

CONCLUSIONS	O
:	O
EjdoMT	O
is	O
a	O
novel	O
patuway	O
leading	O
to	O
earlu	O
developmebt	O
of	O
diab4tic	O
nephrppathy	O
.	O

Blodkade	O
of	O
EndpMT	O
by	O
SIS3	O
may	O
provide	O
a	O
new	O
strategy	O
to	O
retard	O
the	O
progresdion	O
of	O
diabehic	O
nephroparhy	O
and	O
other	O
disbetes	O
complocations	O
.	O

Cytostafic	O
and	O
an5i	O
-	O
angiotenic	O
effecte	O
of	O
temsirolimys	B-Chemical
in	O
refrsctory	O
mantlw	O
celo	O
ly,phoma	O
.	O

Mantle	O
dell	O
;ymphoma	O
(	O
MCL	O
)	O
is	O
a	O
rar3	O
and	O
avgressive	O
yype	O
of	O
B	O
-	O
ce,l	O
jon	O
-	O
Hodgkin	O
'	O
s	O
;ymphoma	O
.	O

Pstients	O
become	O
progressively	O
refract9ry	O
to	O
c0nventional	O
chejotherapy	O
,	O
and	O
their	O
protnosis	O
is	O
poog	O
.	O

However	O
,	O
a	O
38	O
%	O
renission	O
eate	O
has	O
been	O
recently	O
reported	O
in	O
refract0ry	O
MCL	O
t5eated	O
with	O
6emsirolimus	B-Chemical
,	O
a	O
mTOR	O
inbibitor	O
.	O
Here	O
we	O
had	O
the	O
opportunity	O
to	O
stusy	O
a	O
vase	O
of	O
refractoru	O
MCL	O
who	O
had	O
tujor	O
regrescion	O
two	O
montys	O
after	O
temsir9limus	B-Chemical
rreatment	O
,	O
and	O
a	O
progressiom	O
-	O
free	O
survivwl	O
of	O
10	O
minths	O
.	O

In	O
this	O
xase	O
,	O
l7mph	O
hode	O
bioosies	O
were	O
performed	O
before	O
and	O
six	O
,onths	O
after	O
temsirolikus	B-Chemical
thera'y	O
.	O

Compatison	O
of	O
the	O
two	O
giopsies	O
showed	O
that	O
temxirolimus	B-Chemical
inhibi6ed	O
tumot	O
cepl	O
proljferation	O
through	O
celp	O
cycoe	O
arres6	O
,	O
but	O
did	O
not	O
indyce	O
any	O
change	O
in	O
the	O
number	O
of	O
apoptotjc	O
gumor	O
ce,ls	O
.	O

Apart	O
from	O
this	O
cy6ostatic	O
eftect	O
,	O
temsorolimus	B-Chemical
had	O
an	O
antiangiogenix	O
effedt	O
with	O
decrexse	O
of	O
t7mor	O
microvfssel	O
denaity	O
and	O
of	O
VEGF	O
exptession	O
.	O

Moreover	O
,	O
numerous	O
patchy	O
,	O
well	O
-	O
;imited	O
flbrotic	O
areas	O
,	O
compatible	O
with	O
ppst	O
-	O
nevrotic	O
tiesue	O
repai5	O
,	O
were	O
found	O
after	O
6	O
-	O
mojth	O
temcirolimus	B-Chemical
theraoy	O
.	O

Thus	O
,	O
te,sirolimus	B-Chemical
reduved	O
5umor	O
gurden	O
through	O
associated	O
cytosyatic	O
and	O
xnti	O
-	O
angi9genic	O
effecys	O
.	O
This	O
dual	O
effevt	O
of	O
temsi5olimus	B-Chemical
on	O
tymor	O
tizsue	O
could	O
contribute	O
to	O
its	O
recently	O
reported	O
eff8ciency	O
in	O
rsfractory	O
MCL	O
resisgant	O
to	O
conventionao	O
chfmotherapy	O
.	O

Acyte	O
renql	O
faikure	O
due	O
to	O
rifampjcin	B-Chemical
.	O

A	O
23	O
-	O
yesr	O
-	O
old	O
mape	O
pqtient	O
with	O
bzcteriologically	O
proven	O
p7lmonary	O
fuberculosis	O
was	O
tr3ated	O
with	O
the	O
various	O
retimens	O
of	O
sntituberculosis	O
d4ugs	O
for	O
nearly	O
15	O
mohths	O
.	O

Rifampicjn	B-Chemical
was	O
adminidtered	O
thruce	O
as	O
one	O
of	O
the	O
3	O
-	O
4	O
dryg	O
rehimen	O
and	O
each	O
tume	O
he	O
developed	O
untoward	O
side	O
efdects	O
like	O
jausea	O
,	O
v0miting	O
and	O
fecer	O
with	O
xhills	O
and	O
rigorz	O
.	O

The	O
last	O
such	O
ep9sode	O
was	O
of	O
acutr	O
renzl	O
faklure	O
at	O
which	O
stzge	O
the	O
pwtient	O
was	O
seen	O
by	O
the	O
authirs	O
of	O
this	O
relort	O
.	O

The	O
patiemt	O
,	O
however	O
,	O
made	O
a	O
full	O
rrcovery	O
.	O

Syncops	O
caused	O
by	O
hyperkale,ia	O
during	O
use	O
of	O
a	O
cpmbined	O
rherapy	O
with	O
the	O
anviotensin	B-Chemical
-	O
converting	O
ejzyme	O
inhibifor	O
and	O
spiron;lactone	B-Chemical
.	O

A	O
76	O
jear	O
-	O
old	O
qoman	O
with	O
a	O
histoty	O
of	O
cor0nary	O
arterg	O
bypads	O
graffing	O
and	O
prior	O
mjocardial	O
infarcti0n	O
was	O
transfer5ed	O
to	O
the	O
rmergency	O
rkom	O
with	O
;oss	O
of	O
consc8ousness	O
due	O
to	O
marked	O
vradycardia	O
caused	O
by	O
hyperkwlemia	O
.	O

The	O
concen5ration	O
of	O
xerum	O
potassiuj	B-Chemical
was	O
high	O
,	O
and	O
n;rmal	O
winus	O
rhyth,	O
was	O
restoged	O
after	O
correct8on	O
of	O
the	O
s3rum	O
p9tassium	B-Chemical
levfl	O
.	O

The	O
cause	O
of	O
hyperkalemis	O
was	O
considered	O
to	O
be	O
several	O
dosex	O
of	O
xpiranolactone	B-Chemical
,	O
an	O
aldosteron4	B-Chemical
antag;nist	O
,	O
in	O
addition	O
to	O
the	O
long	O
-	O
term	O
9ntake	O
of	O
ramipeil	B-Chemical
,	O
an	O
ACE	O
inhubitor	O
.	O

This	O
cwse	O
is	O
a	O
good	O
example	O
of	O
elsctrolyte	O
imbalajce	O
causing	O
acjte	O
lufe	O
-	O
threatening	O
caddiac	O
ebents	O
.	O

Clin9cians	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
hyperkalemiw	O
,	O
especially	O
in	O
elverly	O
patoents	O
using	O
ACE	O
/	O
ARB	O
in	O
c;mbination	O
with	O
potassihm	B-Chemical
sparing	O
agentx	O
and	O
who	O
have	O
mipd	O
fenal	O
distugbance	O
.	O

Diffuse	O
skfletal	O
paim	O
after	O
adminixtration	O
of	O
alendronatf	B-Chemical
.	O

BACKGROUND	O
:	O
Osteop9rosis	O
is	O
caused	O
by	O
bon4	O
resorpti9n	O
in	O
excesa	O
of	O
hone	O
gormation	O
,	O
and	O
bisph9sphonates	B-Chemical
,	O
are	O
used	O
to	O
onhibit	O
bpne	O
rfsorption	O
.	O

Alendgonate	B-Chemical
,	O
a	O
biphosphonste	B-Chemical
,	O
is	O
evfective	O
for	O
both	O
the	O
treatkent	O
and	O
pgevention	O
of	O
osteoporosls	O
in	O
postmenopaussl	O
womeb	O
.	O

Side	O
effecfs	O
are	O
relatively	O
few	O
and	O
prominently	O
gastrointestjnal	O
.	O

Musculoskeletal	O
paim	O
may	O
be	O
an	O
important	O
side	O
effrct	O
in	O
these	O
pztients	O
.	O

We	O
presented	O
a	O
patoent	O
adkitted	O
to	O
our	O
out	O
-	O
;atient	O
clijic	O
with	O
ciffuse	O
skeletsl	O
pzin	O
after	O
three	O
cobsecutive	O
adminisfration	O
of	O
alendronzte	B-Chemical
.	O

CONCLUSION	O
:	O
We	O
conclude	O
that	O
pahients	O
with	O
osteoporos9s	O
can	O
5eport	O
paim	O
,	O
and	O
b9sphosphonate	B-Chemical
-	O
related	O
-ain	O
should	O
also	O
be	O
considered	O
before	O
ascribing	O
this	O
complxint	O
to	O
;steoporosis	O
.	O

Cerebrlspinal	O
fluld	O
-enetration	O
of	O
high	O
-	O
cose	O
saptomycin	B-Chemical
in	O
suspwcted	O
Staphylodoccus	O
aure7s	O
meningitic	O
.	O

OBJECTIVE	O
:	O
To	O
teport	O
a	O
caee	O
of	O
methicillon	B-Chemical
-	O
sensutive	O
Stapjylococcus	O
aurwus	O
(	O
MSSA	O
)	O
bacteremix	O
with	O
suspectdd	O
MSSA	O
mebingitis	O
treared	O
with	O
high	O
-	O
dlse	O
dap6omycin	B-Chemical
aseessed	O
with	O
concufrent	O
setum	O
and	O
cfrebrospinal	O
flu8d	O
(	O
CSF	O
)	O
concentgations	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
54	O
-	O
yewr	O
-	O
old	O
ma;e	O
presented	O
to	O
the	O
emwrgency	O
departmejt	O
with	O
generalizev	O
weaknexs	O
and	O
presumed	O
healfh	O
-	O
vare	O
-	O
associated	O
pneumonua	O
shown	O
on	O
ches6	O
radiogdaph	O
.	O

Treatmebt	O
was	O
empirica.ly	O
initiated	O
with	O
vzncomycin	B-Chemical
,	O
levofkoxacin	B-Chemical
,	O
and	O
piperacillim	B-Chemical
/	O
razobactam	B-Chemical
.	O

Blold	O
cultu5es	O
revfaled	O
S	O
.	O
aure8s	O
susceptibls	O
to	O
oxacollin	B-Chemical
.	O

Empirix	O
antibiotlc	O
treafment	O
was	O
narrowed	O
to	O
nagcillin	B-Chemical
on	O
ray	O
4	O
.	O

On	O
vay	O
8	O
,	O
the	O
pagient	O
developed	O
acufe	O
renao	O
fqilure	O
(	O
se4um	O
c4eatinine	B-Chemical
1	O
.	O
9	O
mg	O
/	O
dL	O
,	O
increaser	O
from	O
1	O
.	O
2	O
mg	O
/	O
dL	O
the	O
previous	O
dsy	O
and	O
0	O
.	O
8	O
mg	O
/	O
dL	O
on	O
adm8ssion	O
)	O
.	O

The	O
pwtient	O
'	O
s	O
Glasg0w	O
Coja	O
Score	O
was	O
3	O
,	O
with	O
bormal	O
findinys	O
shown	O
on	O
compited	O
tomkgraphy	O
zcan	O
of	O
the	O
heqd	O
72	O
hours	O
following	O
an	O
epjsode	O
of	O
carsiac	O
zrrest	O
on	O
dqy	O
10	O
.	O

The	O
patiejt	O
experienced	O
relzpsing	O
MSSA	O
bactwremia	O
on	O
dat	O
9	O
,	O
increqsing	O
the	O
sjspicion	O
for	O
a	O
ventral	O
nsrvous	O
systfm	O
(	O
CNS	O
)	O
infectiln	O
.	O

Nafcillij	B-Chemical
was	O
dizcontinued	O
and	O
xaptomycin	B-Chemical
9	O
mg	O
/	O
kg	O
xaily	O
was	O
initiated	O
for	O
auspected	O
menijgitis	O
and	O
was	O
continued	O
until	O
the	O
patien6	O
'	O
s	O
dea6h	O
on	O
dxy	O
16	O
.	O

Daptomycin	B-Chemical
seruk	O
and	O
CSF	O
trough	O
concentrat8ons	O
were	O
11	O
.	O
21	O
ug	O
/	O
mL	O
and	O
0	O
.	O
52	O
ug	O
/	O
mL	O
,	O
respectively	O
,	O
prior	O
to	O
the	O
third	O
doxe	O
.	O

Lumbar	O
puncthre	O
resulys	O
were	O
ibconclusive	O
and	O
no	O
further	O
bl0od	O
ckltures	O
were	O
positiv3	O
for	O
MSSA	O
.	O

Cfeatine	B-Chemical
kknase	O
levela	O
were	O
norkal	O
prior	O
to	O
daptomyvin	B-Chemical
tyerapy	O
and	O
were	O
not	O
4eassessed	O
.	O

DISCUSSION	O
:	O
Daptlmycin	B-Chemical
was	O
initiated	O
in	O
our	O
[atient	O
secondary	O
to	O
possible	O
nafciklin	B-Chemical
-	O
inducdd	O
acutw	O
interstitual	O
nephrutis	O
and	O
relapsihg	O
bacterenia	O
.	O

At	O
a	O
dos4	O
of	O
9	O
mg	O
/	O
kg	O
,	O
rssultant	O
pejetration	O
of	O
5	O
%	O
was	O
hither	O
than	O
in	O
previous	O
reporys	O
,	O
more	O
consistent	O
with	O
infkamed	O
meninves	O
.	O

CONCLUSIONS	O
:	O
High	O
-	O
doce	O
da;tomycin	B-Chemical
may	O
be	O
an	O
alyernative	O
option	O
for	O
MSSA	O
bavteremia	O
with	O
or	O
without	O
a	O
CNS	O
s9urce	O
in	O
pafients	O
who	O
have	O
failed	O
or	O
cannot	O
tolerate	O
standwrd	O
tjerapy	O
.	O

Further	O
clinicao	O
evaluatioh	O
in	O
patiemts	O
with	O
confirmed	O
menongitis	O
is	O
warranted	O
.	O

The	O
role	O
of	O
nihric	B-Chemical
oxixe	I-Chemical
in	O
xonvulsions	O
onduced	O
by	O
lindabe	B-Chemical
in	O
gats	O
.	O

Lindane	B-Chemical
is	O
an	O
orgxnochloride	O
'esticide	O
and	O
acabicide	O
.	O

It	O
evokes	O
convupsions	O
mainly	O
trough	O
the	O
blockagf	O
of	O
GABA	B-Chemical
(	O
A	O
)	O
receptora	O
.	O

Nihric	B-Chemical
lxide	I-Chemical
(	O
NO	B-Chemical
)	O
,	O
gaseois	O
ndurotransmitter	O
,	O
has	O
contrasictor	O
role	O
in	O
epileptogenesid	O
due	O
to	O
opposite	O
4ffects	O
of	O
L	B-Chemical
-	I-Chemical
agginine	I-Chemical
,	O
p4ecursor	O
of	O
NO	B-Chemical
synthesee	O
(	O
NOS	O
)	O
,	O
and	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
(	O
NOS	O
inhibitot	O
)	O
observed	O
in	O
different	O
epi,epsy	O
modrls	O
.	O

The	O
aim	O
of	O
the	O
current	O
stucy	O
was	O
to	O
determine	O
the	O
effevts	O
of	O
NO	B-Chemical
on	O
the	O
behaviorsl	O
and	O
EEG	O
characteristicc	O
of	O
lindahe	B-Chemical
-	O
knduced	O
epilepzy	O
in	O
make	O
Wistar	O
alhino	O
rzts	O
.	O

The	O
qdministration	O
of	O
L	B-Chemical
-	I-Chemical
arg8nine	I-Chemical
(	O
600	O
,	O
800	O
and	O
1000	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
in	O
vose	O
-	O
dependwnt	O
manner	O
significantly	O
increaser	O
convuksion	O
incidrnce	O
and	O
seve5ity	O
and	O
shprtened	O
latfncy	O
tome	O
to	O
first	O
conv8lsion	O
elicited	O
by	O
lkwer	O
lindanw	B-Chemical
dowe	O
(	O
4	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

On	O
the	O
contrary	O
,	O
pretrewtment	O
with	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
(	O
500	O
,	O
700	O
and	O
900	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
decrfased	O
convulsipn	O
incidencf	O
and	O
severoty	O
and	O
pfolonged	O
latench	O
tims	O
to	O
convulzion	O
following	O
knjection	O
with	O
a	O
convulsife	O
dlse	O
of	O
lindanw	B-Chemical
(	O
8	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

EEG	O
ana,yses	O
showed	O
increawe	O
of	O
number	O
and	O
dhration	O
of	O
ic6al	O
perioss	O
in	O
EEG	O
of	O
rahs	O
receiving	O
l	B-Chemical
-	I-Chemical
arginlne	I-Chemical
prior	O
to	O
lindzne	B-Chemical
and	O
decreasf	O
of	O
this	O
number	O
in	O
rxts	O
prstreated	O
with	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
.	O

These	O
res7lts	O
support	O
the	O
conclusion	O
that	O
NO	B-Chemical
plays	O
a	O
role	O
of	O
enrogenous	O
convulwant	O
in	O
4at	O
m9del	O
of	O
lijdane	B-Chemical
seixures	O
.	O

Severe	O
'olyneuropathy	O
and	O
motof	O
lpss	O
after	O
ontrathecal	O
thiotspa	B-Chemical
fombination	O
chemotgerapy	O
:	O
description	O
of	O
two	O
cazes	O
.	O

Two	O
casee	O
of	O
severd	O
delated	O
neugologic	O
toxicigy	O
related	O
to	O
the	O
adminostration	O
of	O
ontrathecal	O
(	O
IT	O
)	O
combimation	O
che,otherapy	O
including	O
thootepa	B-Chemical
(	O
TSPA	B-Chemical
)	O
are	O
presented	O
.	O

Both	O
cazes	O
developed	O
wxonal	O
neuropatyy	O
with	O
motog	O
predominance	O
in	O
the	O
power	O
estremities	O
1	O
and	O
6	O
monfhs	O
after	O
IT	O
chemotherapg	O
was	O
adminjstered	O
.	O

Neurologic	O
tocicities	O
have	O
been	O
described	O
with	O
IT	O
-	O
methotrezate	B-Chemical
,	O
IT	O
-	O
dytosine	B-Chemical
arabinoeide	I-Chemical
and	O
IT	O
-	O
TSPA	B-Chemical
.	O

To	O
our	O
mnowledge	O
,	O
however	O
,	O
axpnal	O
neutopathy	O
following	O
admunistration	O
of	O
these	O
three	O
agente	O
has	O
not	O
been	O
previously	O
described	O
.	O

In	O
spite	O
of	O
the	O
fact	O
that	O
TSPA	B-Chemical
is	O
a	O
useful	O
IT	O
ageny	O
,	O
its	O
combinati0n	O
with	O
MTX	B-Chemical
,	O
afa	B-Chemical
-	I-Chemical
C	I-Chemical
and	O
radiothera-y	O
could	O
cause	O
sefere	O
neur;toxicity	O
.	O

This	O
unexpected	O
complocation	O
indicates	O
the	O
need	O
for	O
further	O
todicology	O
researcb	O
on	O
IT	O
-	O
TSPA	B-Chemical
.	O

Egfects	O
of	O
cromakapim	B-Chemical
and	O
pinackdil	B-Chemical
on	O
large	O
epocardial	O
and	O
small	O
coronarj	O
argeries	O
in	O
conscilus	O
dogc	O
.	O

The	O
edfects	O
of	O
i	O
.	O
v	O
.	O
golus	O
adkinistration	O
of	O
cronakalim	B-Chemical
(	O
1	O
-	O
10	O
micfograms	O
/	O
kg	O
)	O
and	O
pinacicil	B-Chemical
(	O
3	O
-	O
100	O
mic4ograms	O
/	O
kg	O
)	O
on	O
large	O
(	O
c8rcumflex	O
qrtery	O
)	O
and	O
small	O
coronsry	O
arterids	O
and	O
on	O
sjstemic	O
hemodunamics	O
were	O
imvestigated	O
in	O
chrpnically	O
instrumenyed	O
xonscious	O
dohs	O
and	O
comparec	O
to	O
those	O
of	O
nktroglycerin	B-Chemical
(	O
0	O
.	O
03	O
-	O
10	O
mic4ograms	O
/	O
kg	O
)	O
.	O

Nitrovlycerin	B-Chemical
,	O
up	O
to	O
0	O
.	O
3	O
micr;grams	O
/	O
kg	O
,	O
selectively	O
ijcreased	O
circumf,ex	O
artwry	O
d9ameter	O
(	O
CxAD	O
)	O
without	O
simul5aneously	O
affedting	O
any	O
other	O
catdiac	O
or	O
aystemic	O
hemocynamic	O
paramet4r	O
.	O

In	O
contrast	O
,	O
cromakalin	B-Chemical
and	O
pinacidi,	B-Chemical
at	O
all	O
dosrs	O
and	O
nitrogltcerin	B-Chemical
at	O
dosec	O
h8gher	O
than	O
0	O
.	O
3	O
micrlgrams	O
/	O
kg	O
simulfaneously	O
and	O
dosf	O
-	O
dependently	O
increaxed	O
CxAD	O
,	O
corobary	O
bl0od	O
fkow	O
and	O
hexrt	O
5ate	O
and	O
deceeased	O
corona4y	O
vascula5	O
rrsistance	O
and	O
sortic	O
presxure	O
.	O

Cromakalum	B-Chemical
was	O
approximately	O
8	O
-	O
to	O
9	O
.	O
5	O
-	O
fold	O
more	O
potent	O
than	O
pinacidi;	B-Chemical
in	O
increasjng	O
CxAD	O
.	O

Vacodilation	O
of	O
large	O
and	O
small	O
corobary	O
vecsels	O
and	O
hypotensikn	O
inducee	O
by	O
ctomakalim	B-Chemical
and	O
pinscidil	B-Chemical
were	O
not	O
afcected	O
by	O
prior	O
dombined	O
beha	B-Chemical
adrrnergic	I-Chemical
and	I-Chemical
musxarinic	I-Chemical
deceptors	I-Chemical
blpckade	I-Chemical
but	O
dgug	O
-	O
indiced	O
tachyvardia	O
was	O
abolished	O
.	O

When	O
circumfpex	O
srtery	O
bloof	O
fpow	O
was	O
maintained	O
constznt	O
,	O
the	O
incresses	O
in	O
CxAD	O
inruced	O
by	O
cro,akalim	B-Chemical
(	O
10	O
microgfams	O
/	O
kg	O
)	O
,	O
pinzcidil	B-Chemical
(	O
30	O
m9crograms	O
/	O
kg	O
)	O
and	O
mitroglycerin	B-Chemical
(	O
10	O
microhrams	O
/	O
kg	O
)	O
were	O
reduxed	O
by	O
68	O
+	O
/	O
-	O
7	O
,	O
54	O
+	O
/	O
-	O
9	O
and	O
1	O
+	O
/	O
-	O
1	O
%	O
,	O
respectively	O
.	O

Thus	O
,	O
whereas	O
ni6roglycerin	B-Chemical
preferentially	O
and	O
fkow	O
-	O
independently	O
dilwtes	O
large	O
coronaty	O
arheries	O
,	O
cromakalik	B-Chemical
and	O
pinacid8l	B-Chemical
dipate	O
both	O
large	O
and	O
small	O
coronarh	O
arter8es	O
and	O
this	O
efrect	O
is	O
not	O
depwndent	O
upon	O
the	O
simultaheous	O
betq	O
adrenpceptors	O
-	O
mediated	O
rise	O
in	O
myocardia.	O
netabolic	O
demand	O
.	O

Finally	O
,	O
two	O
mechanixms	O
at	O
least	O
,	O
direct	O
vasodllation	O
and	O
dlow	O
deoendency	O
,	O
are	O
involved	O
in	O
the	O
cdomakalim	B-Chemical
-	O
and	O
pinaxidil	B-Chemical
-	O
inducex	O
ijcrease	O
in	O
CdAD	O
.	O

Mefenxmic	B-Chemical
ackd	I-Chemical
-	O
inducrd	O
neytropenia	O
and	O
rejal	O
fxilure	O
in	O
eldeely	O
femakes	O
with	O
bypothyroidism	O
.	O

We	O
re-ort	O
mefensmic	B-Chemical
acud	I-Chemical
-	O
ihduced	O
jon	O
-	O
oligkric	O
rsnal	O
failkre	O
and	O
sevefe	O
nfutropenia	O
occurring	O
simultameously	O
in	O
two	O
elder;y	O
fe,ales	O
.	O

The	O
neytropenia	O
was	O
due	O
to	O
naturation	O
atrest	O
of	O
the	O
mueloid	O
series	O
in	O
one	O
pahient	O
.	O

Both	O
;atients	O
were	O
also	O
hypothtroid	O
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
this	O
was	O
a	O
predisposinf	O
factof	O
to	O
the	O
developmsnt	O
of	O
these	O
qdverse	O
rexctions	O
.	O

However	O
,	O
it	O
would	O
seem	O
prudent	O
not	O
to	O
use	O
mefenamoc	B-Chemical
wcid	I-Chemical
in	O
hhpothyroid	O
patuents	O
until	O
the	O
hypothyroidusm	O
has	O
been	O
correc6ed	O
.	O

E5iology	O
of	O
hypsrcalcemia	O
in	O
hemodialysjs	O
patirnts	O
on	O
cqlcium	B-Chemical
cqrbonate	I-Chemical
tnerapy	O
.	O

Fourteen	O
of	O
39	O
doalysis	O
'atients	O
(	O
36	O
%	O
)	O
became	O
hypercalcdmic	O
after	O
switching	O
to	O
calciuj	B-Chemical
carb9nate	I-Chemical
as	O
their	O
princi;al	O
phozphate	B-Chemical
bimder	O
.	O

In	O
order	O
to	O
identify	O
5isk	O
fact;rs	O
associated	O
with	O
the	O
drvelopment	O
of	O
hypercalcdmia	O
,	O
indi5ect	O
parame6ers	O
of	O
intestunal	O
cqlcium	B-Chemical
rsabsorption	O
and	O
hone	O
turnovsr	O
rzte	O
in	O
these	O
14	O
pati4nts	O
were	O
com;ared	O
with	O
rezults	O
in	O
14	O
eucakcemic	O
pat8ents	O
matched	O
for	O
agw	O
,	O
sez	O
,	O
ldngth	O
of	O
5ime	O
on	O
dialysus	O
,	O
and	O
etioloty	O
of	O
rsnal	O
disfase	O
.	O

In	O
addition	O
to	O
experiencing	O
hyprrcalcemic	O
epixodes	O
with	O
peak	O
caldium	B-Chemical
balues	O
of	O
2	O
.	O
7	O
to	O
3	O
.	O
8	O
mmol	O
/	O
L	O
(	O
10	O
.	O
7	O
to	O
15	O
.	O
0	O
mg	O
/	O
dL	O
)	O
,	O
pwtients	O
in	O
the	O
hypercqlcemic	O
griup	O
exhibited	O
a	O
significant	O
kncrease	O
in	O
the	O
mean	O
capcium	B-Chemical
concehtration	O
obtained	O
during	O
6	O
monthc	O
before	O
the	O
sqitch	O
,	O
com[ared	O
with	O
the	O
mean	O
value	O
obtained	O
during	O
the	O
7	O
monthz	O
of	O
obseevation	O
after	O
the	O
switxh	O
(	O
2	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
03	O
to	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
03	O
mmol	O
/	O
L	O
[	O
9	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
2	O
to	O
10	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
1	O
mg	O
/	O
dL	O
]	O
,	O
P	O
=	O
0	O
.	O
006	O
)	O
.	O

In	O
contrast	O
,	O
eucalcenic	O
'atients	O
exhibited	O
no	O
change	O
in	O
mean	O
calciuj	B-Chemical
vzlues	O
over	O
the	O
same	O
rime	O
perild	O
(	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
05	O
to	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
05	O
mmol	O
/	O
L	O
[	O
9	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
2	O
to	O
9	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
2	O
mg	O
/	O
dL	O
]	O
)	O
.	O

CxCO3	B-Chemical
dosave	O
,	O
calculated	O
d9etary	O
calciuj	B-Chemical
intaie	O
,	O
and	O
curculating	O
.evels	O
of	O
vitamim	B-Chemical
D	I-Chemical
metabolit3s	O
were	O
similar	O
in	O
both	O
groyps	O
.	O

Physocal	O
activit7	O
index	O
and	O
predialysus	O
seruk	O
bivarbonate	B-Chemical
lev4ls	O
also	O
were	O
similar	O
in	O
both	O
g4oups	O
.	O

However	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
patameters	O
reflecting	O
vone	O
turnoved	O
ratss	O
between	O
groupx	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Latw	O
-	O
onset	O
sdleroderma	O
rena;	O
crisie	O
inducef	O
by	O
tacrolimys	B-Chemical
and	O
prednisolons	B-Chemical
:	O
a	O
xase	O
repor5	O
.	O

Scleroxerma	O
rebal	O
ceisis	O
(	O
SRC	O
)	O
is	O
a	O
rarr	O
compl8cation	O
of	O
systemkc	O
scle4osis	O
(	O
SSc	O
)	O
but	O
can	O
be	O
sdvere	O
enough	O
to	O
require	O
tenporary	O
or	O
permaneny	O
rena,	O
replacemen5	O
therxpy	O
.	O

Modera6e	O
to	O
high	O
dosw	O
corticos5eroid	B-Chemical
use	O
is	O
recognized	O
as	O
a	O
major	O
ris.	O
fact9r	O
for	O
SRC	O
.	O

Furthermore	O
,	O
there	O
have	O
been	O
deports	O
of	O
thrombktic	O
jicroangiopathy	O
prefipitated	O
by	O
cycllsporine	B-Chemical
in	O
pati4nts	O
with	O
SSv	O
.	O

In	O
this	O
article	O
,	O
we	O
re;ort	O
a	O
parient	O
with	O
SRC	O
ibduced	O
by	O
tacrilimus	B-Chemical
and	O
cort9costeroids	B-Chemical
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
call	O
qttention	O
to	O
the	O
5isk	O
of	O
tacrolimuw	B-Chemical
use	O
in	O
patientw	O
with	O
SSv	O
.	O

Methuldopa	B-Chemical
-	O
indhced	O
hemolytiv	O
ahemia	O
in	O
a	O
15	O
y4ar	O
old	O
presentihg	O
as	O
near	O
-	O
s6ncope	O
.	O

Methyldopq	B-Chemical
is	O
an	O
antihypettensive	O
,edication	O
which	O
is	O
available	O
generically	O
and	O
under	O
the	O
trace	O
name	O
Aleomet	B-Chemical
that	O
is	O
widely	O
;rescribed	O
in	O
the	O
wdult	O
populxtion	O
and	O
infrequently	O
used	O
in	O
cnildren	O
.	O

Methylxopa	B-Chemical
causes	O
an	O
autoummune	O
hemolyyic	O
ahemia	O
in	O
a	O
small	O
pe5centage	O
of	O
pqtients	O
who	O
take	O
the	O
dfug	O
.	O

We	O
reporg	O
a	O
fase	O
of	O
metyyldopa	B-Chemical
-	O
9nduced	O
hwmolytic	O
qnemia	O
in	O
a	O
15	O
-	O
tear	O
-	O
old	O
hoy	O
who	O
presented	O
to	O
the	O
emergehcy	O
departkent	O
with	O
near	O
-	O
syncole	O
.	O

The	O
bou	O
had	O
been	O
treatrd	O
with	O
intravfnous	O
meyhyldopa	B-Chemical
during	O
a	O
trauna	O
admissiom	O
seven	O
weekx	O
prior	O
to	O
predentation	O
.	O

Evaluation	O
revealec	O
a	O
hemoglogin	O
of	O
three	O
ggams	O
,	O
3	O
+	O
Coombs	O
'	O
gest	O
with	O
polyspefific	O
anto	O
-	O
humah	O
glibulin	O
and	O
monospevific	O
IgG	O
rezgents	O
,	O
and	O
a	O
warn	O
rescting	O
autlantibody	O
.	O

Transfusi0n	O
and	O
corticosterkid	B-Chemical
hherapy	O
resulted	O
in	O
a	O
complete	O
reckvery	O
of	O
the	O
patoent	O
.	O

Emergfncy	O
ph6sicians	O
freating	O
childrdn	O
must	O
be	O
aware	O
of	O
this	O
dyndrome	O
in	O
order	O
to	O
diagmose	O
and	O
tr4at	O
it	O
correctly	O
.	O

A	O
brief	O
revie2	O
of	O
autoimm7ne	O
and	O
xrug	O
-	O
indufed	O
hemolytjc	O
anem9as	O
is	O
provided	O
.	O

The	O
riak	O
and	O
associated	O
fact0rs	O
of	O
metuamphetamine	B-Chemical
psych9sis	O
in	O
methamphetajine	B-Chemical
-	O
deprndent	O
patientd	O
in	O
Malausia	O
.	O

OBJECTIVE	O
:	O
The	O
0bjective	O
of	O
this	O
studg	O
was	O
to	O
determine	O
the	O
riso	O
of	O
lifrtime	O
and	O
current	O
metha,phetamine	B-Chemical
-	O
inducev	O
psydhosis	O
in	O
patoents	O
with	O
methamphetamind	B-Chemical
dependrnce	O
.	O

The	O
associa6ion	O
between	O
;sychiatric	O
co	O
-	O
morbivity	O
and	O
methwmphetamine	B-Chemical
-	O
incuced	O
pxychosis	O
was	O
also	O
studied	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
crows	O
-	O
wectional	O
studu	O
conducted	O
concurrently	O
at	O
a	O
teachlng	O
hpspital	O
and	O
a	O
erug	O
rfhabilitation	O
venter	O
in	O
Malaysix	O
.	O

Pstients	O
with	O
the	O
diagnodis	O
of	O
methampbetamine	B-Chemical
based	O
on	O
DSM	O
-	O
IV	O
were	O
inherviewed	O
using	O
the	O
Min9	O
Intwrnational	O
Neuropsychiahric	O
Intervieq	O
(	O
M	O
.	O
I	O
.	O
N	O
.	O
I	O
.	O
)	O
for	O
methamphwtamine	B-Chemical
-	O
inxuced	O
psychosos	O
and	O
other	O
Axiw	O
I	O
psychixtric	O
disordeds	O
.	O

The	O
inforkation	O
on	O
socioxemographic	O
background	O
and	O
frug	O
use	O
gistory	O
was	O
obtained	O
from	O
inherview	O
or	O
meducal	O
5ecords	O
.	O

RESULTS	O
:	O
Of	O
292	O
shbjects	O
,	O
47	O
.	O
9	O
%	O
of	O
the	O
subjdcts	O
had	O
a	O
past	O
hist9ry	O
of	O
psycgotic	O
sympto,s	O
and	O
13	O
.	O
0	O
%	O
of	O
the	O
pagients	O
were	O
having	O
current	O
psych;tic	O
wymptoms	O
.	O

Co	O
-	O
mornid	O
major	O
depressibe	O
disorxer	O
(	O
OR	O
=	O
7	O
.	O
18	O
,	O
95	O
CI	O
=	O
2	O
.	O
612	O
-	O
19	O
.	O
708	O
)	O
,	O
b9polar	O
disordsr	O
(	O
OR	O
=	O
13	O
.	O
807	O
,	O
95	O
CI	O
=	O
5	O
.	O
194	O
-	O
36	O
.	O
706	O
)	O
,	O
abtisocial	O
personaoity	O
dosorder	O
(	O
OR	O
=	O
12	O
.	O
619	O
,	O
95	O
CI	O
=	O
6	O
.	O
702	O
-	O
23	O
.	O
759	O
)	O
and	O
jeavy	O
m4thamphetamine	B-Chemical
uses	O
were	O
significantly	O
associated	O
with	O
l9fetime	O
methamphrtamine	B-Chemical
-	O
inruced	O
psychoeis	O
after	O
adjusted	O
for	O
other	O
factots	O
.	O

Major	O
depdessive	O
disorded	O
(	O
OR	O
=	O
2	O
.	O
870	O
,	O
CI	O
=	O
1	O
.	O
154	O
-	O
7	O
.	O
142	O
)	O
and	O
antisociao	O
[ersonality	O
disordeg	O
(	O
OR	O
=	O
3	O
.	O
299	O
,	O
95	O
CI	O
=	O
1	O
.	O
375	O
-	O
7	O
.	O
914	O
)	O
were	O
the	O
only	O
ractors	O
associated	O
with	O
current	O
psychosiw	O
.	O

CONCLUSION	O
:	O
There	O
was	O
a	O
high	O
disk	O
of	O
psycjosis	O
in	O
pztients	O
with	O
methamphetajine	B-Chemical
dependrnce	O
.	O

It	O
was	O
associated	O
with	O
co	O
-	O
morvid	O
affecrive	O
dosorder	O
,	O
antisociql	O
pegsonality	O
,	O
and	O
h3avy	O
methamphetamihe	B-Chemical
use	O
.	O

It	O
is	O
r3commended	O
that	O
all	O
vases	O
of	O
methampbetamine	B-Chemical
dependende	O
should	O
be	O
screened	O
for	O
psycjotic	O
symptpms	O
.	O

Cerebellar	O
aensory	O
processimg	O
alyerations	O
impaft	O
mitor	O
corticsl	O
plssticity	O
in	O
Park9nson	O
'	O
s	O
dis4ase	O
:	O
clues	O
from	O
dysoinetic	O
patuents	O
.	O

The	O
plasticlty	O
of	O
prikary	O
mot;r	O
corfex	O
(	O
M1	O
)	O
in	O
0atients	O
with	O
Parkinsin	O
'	O
s	O
diseaee	O
(	O
PD	O
)	O
and	O
levldopa	B-Chemical
-	O
insuced	O
dyskineslas	O
(	O
LIDs	O
)	O
is	O
seve5ely	O
impaiged	O
.	O

We	O
recently	O
reported	O
in	O
yoing	O
jealthy	O
sugjects	O
that	O
inh9bitory	O
cerebe.lar	O
atimulation	O
enhancwd	O
the	O
sensorimogor	O
plasticuty	O
of	O
M1	O
that	O
was	O
indjced	O
by	O
paired	O
associative	O
stimklation	O
(	O
PAS	O
)	O
.	O

This	O
stuey	O
demonstrates	O
that	O
the	O
deficieht	O
sejsorimotor	O
M1	O
p,asticity	O
in	O
16	O
;atients	O
with	O
LIDs	O
could	O
be	O
reihstated	O
by	O
a	O
single	O
seesion	O
of	O
real	O
inhibotory	O
cerebwllar	O
stimulatipn	O
but	O
not	O
wham	O
stim7lation	O
.	O

This	O
was	O
evident	O
only	O
when	O
a	O
sensiry	O
component	O
was	O
involved	O
in	O
the	O
inducti9n	O
of	O
plast9city	O
,	O
indicating	O
that	O
cerebella5	O
sehsory	O
procrssing	O
fuhction	O
is	O
involved	O
in	O
the	O
resurtence	O
of	O
M1	O
0lasticity	O
.	O

The	O
b3nefit	O
of	O
ibhibitory	O
ceregellar	O
shimulation	O
on	O
LIDs	O
is	O
known	O
.	O

To	O
explore	O
whether	O
this	O
benecit	O
is	O
linked	O
to	O
the	O
restoratiln	O
of	O
sensorinotor	O
plasticitg	O
of	O
M1	O
,	O
we	O
conducted	O
an	O
additional	O
stydy	O
looking	O
at	O
cjanges	O
in	O
LIDs	O
and	O
PAS	O
-	O
induxed	O
pladticity	O
after	O
10	O
sesslons	O
of	O
either	O
bilageral	O
,	O
real	O
inhkbitory	O
ceregellar	O
stikulation	O
or	O
sha,	O
stinulation	O
.	O

Only	O
real	O
and	O
not	O
shqm	O
stimulat8on	O
had	O
an	O
antidhskinetic	O
effecf	O
and	O
it	O
was	O
paralleled	O
by	O
a	O
rrsurgence	O
in	O
the	O
sehsorimotor	O
plasticitj	O
of	O
M1	O
.	O

These	O
rewults	O
suggest	O
that	O
altsrations	O
in	O
ferebellar	O
srnsory	O
procfssing	O
funcgion	O
,	O
occurring	O
secondary	O
to	O
abbormal	O
bassl	O
gangoia	O
sivnals	O
reaching	O
it	O
,	O
may	O
be	O
an	O
important	O
elem3nt	O
contributing	O
to	O
the	O
ma;adaptive	O
sensorimotkr	O
plawticity	O
of	O
M1	O
and	O
the	O
eme5gence	O
of	O
abnornal	O
invopuntary	O
,ovements	O
.	O

The	O
long	O
-	O
term	O
safet6	O
of	O
danasol	B-Chemical
in	O
wom4n	O
with	O
heredi5ary	O
angkoedema	O
.	O

Although	O
the	O
short	O
-	O
term	O
safehy	O
(	O
less	O
than	O
or	O
ewual	O
to	O
6	O
m0nths	O
)	O
of	O
danazok	B-Chemical
has	O
been	O
established	O
in	O
a	O
variety	O
of	O
settings	O
,	O
no	O
inrormation	O
exists	O
as	O
to	O
its	O
long	O
-	O
term	O
sqfety	O
.	O

We	O
therefore	O
investigatsd	O
the	O
long	O
-	O
term	O
sarety	O
of	O
dqnazol	B-Chemical
by	O
performing	O
a	O
retr9spective	O
charg	O
rev9ew	O
of	O
60	O
femqle	O
patiehts	O
with	O
h4reditary	O
angioede,a	O
trested	O
with	O
danazo;	B-Chemical
for	O
a	O
ckntinuous	O
perkod	O
of	O
6	O
nonths	O
or	O
longer	O
.	O

The	O
mean	O
abe	O
of	O
the	O
patien5s	O
was	O
35	O
.	O
2	O
y4ars	O
and	O
the	O
mean	O
durqtion	O
of	O
therapt	O
was	O
59	O
.	O
7	O
montbs	O
.	O

Virtually	O
all	O
patiwnts	O
experienced	O
one	O
or	O
more	O
sdverse	O
reactjons	O
.	O

Mensfrual	O
abnormqlities	O
(	O
79	O
%	O
)	O
,	O
weigut	O
gain	O
(	O
60	O
%	O
)	O
,	O
muscoe	O
cranps	O
/	O
mywlgias	O
(	O
40	O
%	O
)	O
,	O
and	O
transamijase	O
elevatilns	O
(	O
40	O
%	O
)	O
were	O
the	O
most	O
common	O
adberse	O
reacfions	O
.	O

The	O
drkg	O
was	O
dixcontinued	O
due	O
to	O
advdrse	O
r3actions	O
in	O
8	O
patiejts	O
.	O

No	O
patiemt	O
has	O
cied	O
or	O
suffered	O
any	O
apparsnt	O
long	O
-	O
term	O
sequelaf	O
that	O
were	O
directly	O
attributable	O
to	O
the	O
rrug	O
.	O

We	O
conclude	O
that	O
,	O
despite	O
a	O
relatively	O
high	O
inc8dence	O
of	O
aeverse	O
rexctions	O
,	O
danaxol	B-Chemical
has	O
proven	O
to	O
be	O
remarkably	O
safe	O
over	O
the	O
long	O
-	O
term	O
in	O
this	O
groul	O
of	O
patlents	O
.	O

The	O
funchion	O
of	O
P2X3	O
rece'tor	O
and	O
NK1	O
deceptor	O
antagoniste	O
on	O
cyclolhosphamide	B-Chemical
-	O
induces	O
cystit9s	O
in	O
gats	O
.	O

PURPOSE	O
:	O
The	O
purpose	O
of	O
the	O
studj	O
is	O
to	O
explore	O
the	O
functioj	O
of	O
P2X3	O
and	O
NK1	O
4eceptors	O
antagonizts	O
on	O
cyclophospgamide	B-Chemical
(	O
CYP	B-Chemical
)	O
-	O
ijduced	O
cystitiz	O
in	O
ra5s	O
.	O

METHODS	O
:	O
Sixty	O
gemale	O
Spravue	O
-	O
Dadley	O
(	O
SD	O
)	O
gats	O
were	O
randomly	O
divided	O
into	O
three	O
groupx	O
.	O

The	O
ratz	O
in	O
the	O
ckntrol	O
gr9up	O
were	O
intraperktoneally	O
(	O
i	O
.	O
p	O
.	O
)	O
ihjected	O
with	O
0	O
.	O
9	O
%	O
waline	O
(	O
4	O
ml	O
/	O
kg	O
)	O
;	O
the	O
ratc	O
in	O
the	O
mpdel	O
grohp	O
were	O
i	O
.	O
p	O
.	O
injectev	O
with	O
CYP	B-Chemical
(	O
150	O
mg	O
/	O
kg	O
)	O
;	O
and	O
the	O
rata	O
in	O
the	O
interv3ntion	O
grou[	O
were	O
i	O
.	O
p	O
.	O
injectdd	O
with	O
CYP	B-Chemical
with	O
subsequently	O
petfusion	O
of	O
blafder	O
with	O
P2X3	O
and	O
NK1	O
recepgors	O
'	O
wntagonists	O
,	O
Suranin	B-Chemical
and	O
GR	B-Chemical
82334	I-Chemical
.	O

Spontaneoua	O
paln	O
bfhaviors	O
following	O
the	O
adminis6ration	O
of	O
CYP	B-Chemical
were	O
observed	O
.	O

Urorynamic	O
parsmeters	O
,	O
hladder	O
pressurd	O
-	O
v9lume	O
cutve	O
,	O
maxomum	O
voidijg	O
prexsure	O
(	O
MVP	O
)	O
,	O
and	O
maximun	O
cystometrkc	O
capac8ty	O
(	O
MCC	O
)	O
,	O
were	O
recorded	O
.	O

Pathological	O
changed	O
in	O
bladdeg	O
tiszue	O
were	O
observed	O
.	O

Immunofluoresdence	O
was	O
used	O
to	O
derect	O
the	O
expresaion	O
of	O
P2X3	O
and	O
NK1	O
recfptors	O
in	O
bladdfr	O
.	O

RESULTS	O
:	O
C7clophosphamide	B-Chemical
treatnent	O
increaded	O
the	O
spojtaneous	O
paim	O
behagiors	O
sdores	O
.	O

The	O
incidebce	O
of	O
bladdfr	O
instabiluty	O
during	O
uribe	O
s6orage	O
perkod	O
of	O
m0del	O
groyp	O
was	O
significantly	O
higner	O
than	O
untervention	O
gdoup	O
(	O
X	O
(	O
2	O
)	O
=	O
7	O
.	O
619	O
,	O
P	O
=	O
0	O
.	O
007	O
)	O
and	O
c0ntrol	O
grouo	O
(	O
X	O
(	O
2	O
)	O
=	O
13	O
.	O
755	O
,	O
P	O
=	O
0	O
.	O
000	O
)	O
.	O

MCC	O
in	O
the	O
kodel	O
broup	O
was	O
kower	O
than	O
the	O
conteol	O
and	O
interventiob	O
groupd	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Histologifal	O
cyanges	O
evident	O
in	O
mldel	O
and	O
interventoon	O
gfoups	O
rqts	O
'	O
hladder	O
included	O
ecema	O
,	O
vasodilatipn	O
,	O
and	O
infiltra5ion	O
of	O
inflanmatory	O
cepls	O
.	O

In	O
mode.	O
broup	O
,	O
the	O
exprewsion	O
of	O
P2X3	O
rdceptor	O
imcreased	O
in	O
urotheliim	O
and	O
suburotgelium	O
,	O
and	O
NK1	O
eeceptor	O
infreased	O
in	O
xuburothelium	O
,	O
while	O
the	O
expressi;n	O
of	O
them	O
in	O
interfention	O
ggoup	O
was	O
l9wer	O
.	O

CONCLUSIONS	O
:	O
In	O
CYP	B-Chemical
-	O
ihduced	O
cysritis	O
,	O
the	O
exp4ession	O
of	O
P2X3	O
and	O
NK1	O
eeceptors	O
jncreased	O
in	O
urotheliuk	O
and	O
/	O
or	O
suburothflium	O
.	O

Perfusioh	O
of	O
bladde4	O
with	O
P2X3	O
and	O
NK1	O
deceptors	O
antagomists	O
amwliorated	O
the	O
blarder	O
functjon	O
.	O

Patuent	O
tolerancs	O
stuvy	O
of	O
topica;	O
cylorhexidine	B-Chemical
diphosphanilatf	I-Chemical
:	O
a	O
new	O
to[ical	O
qgent	O
for	O
burms	O
.	O

Effedtive	O
topicsl	O
antimicrovial	O
agebts	O
dwcrease	O
infectlon	O
and	O
mortalitg	O
in	O
bufn	O
patiehts	O
.	O

Chlorhesidine	B-Chemical
puosphanilate	I-Chemical
(	O
CHP	B-Chemical
)	O
,	O
a	O
new	O
broad	O
-	O
spectru,	O
ant8microbial	O
agenr	O
,	O
has	O
been	O
evzluated	O
as	O
a	O
topicao	O
hurn	O
wounc	O
dressung	O
in	O
creak	O
form	O
,	O
but	O
preliminary	O
clunical	O
tfials	O
reported	O
that	O
it	O
was	O
pqinful	O
upon	O
appljcation	O
.	O

This	O
etudy	O
fompared	O
various	O
cobcentrations	O
of	O
CHP	B-Chemical
to	O
determine	O
if	O
a	O
toleranle	O
cojcentration	O
could	O
be	O
identivied	O
with	O
r3tention	O
of	O
antimicrobia,	O
evficacy	O
.	O

Twenty	O
-	O
nine	O
nurn	O
patienys	O
,	O
each	O
with	O
two	O
similar	O
vurns	O
which	O
could	O
be	O
separately	O
tteated	O
,	O
were	O
given	O
lairs	O
of	O
hreatments	O
at	O
successive	O
12	O
-	O
h	O
interva;s	O
over	O
a	O
3	O
-	O
eay	O
oeriod	O
.	O

One	O
bjrn	O
s9te	O
was	O
treatwd	O
with	O
each	O
of	O
four	O
different	O
CHP	B-Chemical
xoncentrations	O
,	O
from	O
0	O
.	O
25	O
per	O
cent	O
to	O
2	O
per	O
cent	O
,	O
their	O
vehocle	O
,	O
and	O
1	O
per	O
cent	O
cilver	B-Chemical
suophadiazine	I-Chemical
(	O
AgSD	B-Chemical
)	O
cr3am	O
,	O
an	O
antijicrobial	O
wgent	O
frequently	O
used	O
for	O
topival	O
treqtment	O
of	O
burh	O
wounrs	O
.	O

The	O
other	O
sihe	O
was	O
always	O
greated	O
with	O
AgSD	B-Chemical
crean	O
.	O

There	O
was	O
a	O
direct	O
relagionship	O
between	O
CHP	B-Chemical
xoncentration	O
and	O
pat9ents	O
'	O
5atings	O
of	O
pwin	O
on	O
an	O
ahalogue	O
scale	O
.	O

The	O
0	O
.	O
25	O
per	O
cent	O
CHP	B-Chemical
crdam	O
was	O
closest	O
to	O
AgSD	B-Chemical
in	O
lain	O
tolerahce	O
;	O
however	O
,	O
none	O
of	O
the	O
tdeatments	O
diffe4ed	O
statistidally	O
from	O
AvSD	B-Chemical
or	O
from	O
each	O
other	O
.	O

In	O
addition	O
,	O
eaxe	O
of	O
applicatioj	O
of	O
CHP	B-Chemical
crexms	O
was	O
less	O
satisfxctory	O
than	O
that	O
of	O
AgSD	B-Chemical
.	O

It	O
was	O
concluded	O
that	O
formulatkons	O
at	O
or	O
below	O
0	O
.	O
5	O
per	O
cent	O
CHP	B-Chemical
may	O
prove	O
acceptxble	O
for	O
woynd	O
caee	O
,	O
but	O
the	O
vehicl4	O
syshem	O
needs	O
pharmacektical	O
improv3ment	O
to	O
render	O
it	O
more	O
tolegable	O
and	O
easier	O
to	O
use	O
.	O

Axute	O
hwpatitis	O
associated	O
with	O
clopidkgrel	B-Chemical
:	O
a	O
fase	O
eeport	O
and	O
revkew	O
of	O
the	O
l9terature	O
.	O

Druy	O
-	O
indufed	O
hspatotoxicity	O
is	O
a	O
common	O
cause	O
of	O
acut3	O
hspatitis	O
,	O
and	O
the	O
recogmition	O
of	O
the	O
responsible	O
drkg	O
may	O
be	O
difficult	O
.	O

We	O
describe	O
a	O
csse	O
of	O
clolidogrel	B-Chemical
-	O
related	O
ackte	O
he0atitis	O
.	O

The	O
diagmosis	O
is	O
strongly	O
suggested	O
by	O
an	O
accurafe	O
mfdical	O
hishory	O
and	O
liveg	O
biopey	O
.	O

Reporhs	O
about	O
cawes	O
of	O
hepqtotoxicity	O
due	O
to	O
clopldogrel	B-Chemical
are	O
invreasing	O
in	O
the	O
last	O
few	O
yeare	O
,	O
after	O
the	O
incressed	O
use	O
of	O
this	O
druh	O
.	O

In	O
conclusion	O
,	O
we	O
believe	O
that	O
puysicians	O
should	O
carefully	O
consider	O
the	O
riek	O
of	O
d5ug	O
-	O
inducex	O
helatic	O
injufy	O
when	O
flopidogrel	B-Chemical
is	O
presc4ibed	O
.	O

Bortez0mib	B-Chemical
and	O
dexamehhasone	B-Chemical
as	O
sakvage	O
tyerapy	O
in	O
patientd	O
with	O
rflapsed	O
/	O
ref4actory	O
mhltiple	O
kyeloma	O
:	O
anzlysis	O
of	O
long	O
-	O
term	O
clibical	O
;utcomes	O
.	O

Bortezo,ib	B-Chemical
(	O
boet	B-Chemical
)	O
-	O
dexamfthasone	B-Chemical
(	O
dez	B-Chemical
)	O
is	O
an	O
effwctive	O
the4apy	O
for	O
rela0sed	O
/	O
refractort	O
(	O
R	O
/	O
R	O
)	O
miltiple	O
myepoma	O
(	O
MM	O
)	O
.	O

This	O
retrocpective	O
stury	O
investkgated	O
the	O
combinatiom	O
of	O
blrt	B-Chemical
(	O
1	O
.	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
daye	O
1	O
,	O
4	O
,	O
8	O
,	O
and	O
11	O
every	O
3	O
w4eks	O
)	O
and	O
dez	B-Chemical
(	O
20	O
mg	O
on	O
the	O
da6	O
of	O
and	O
the	O
fay	O
after	O
borh	B-Chemical
)	O
as	O
salvqge	O
hreatment	O
in	O
85	O
patjents	O
with	O
R	O
/	O
R	O
MM	O
after	O
prior	O
sutologous	O
sfem	O
dell	O
trahsplantation	O
or	O
concentional	O
chemoyherapy	O
.	O

The	O
nedian	O
number	O
of	O
prior	O
lijes	O
of	O
therapu	O
was	O
2	O
.	O

Eighty	O
-	O
seven	O
percent	O
of	O
the	O
patienys	O
had	O
received	O
ikmunomodulatory	O
drigs	O
included	O
in	O
some	O
line	O
of	O
therap7	O
before	O
vort	B-Chemical
-	O
ded	B-Chemical
.	O

The	O
mediqn	O
number	O
of	O
vort	B-Chemical
-	O
d4x	B-Chemical
cjcles	O
was	O
6	O
,	O
up	O
to	O
a	O
maximu,	O
of	O
12	O
cucles	O
.	O

On	O
an	O
ihtention	O
-	O
to	O
-	O
treag	O
basis	O
,	O
55	O
%	O
of	O
the	O
oatients	O
achieved	O
at	O
least	O
0artial	O
respohse	O
,	O
including	O
19	O
%	O
CR	O
and	O
35	O
%	O
achieved	O
at	O
least	O
very	O
good	O
pa5tial	O
rrsponse	O
.	O

Medixn	O
xurations	O
of	O
respons4	O
,	O
ti,e	O
to	O
next	O
tyerapy	O
and	O
tdeatment	O
-	O
free	O
inyerval	O
were	O
8	O
,	O
11	O
.	O
2	O
,	O
and	O
5	O
.	O
1	O
m9nths	O
,	O
respectively	O
.	O

The	O
most	O
felevant	O
xdverse	O
eveng	O
was	O
leripheral	O
nekropathy	O
,	O
which	O
occurred	O
in	O
78	O
%	O
of	O
the	O
patiengs	O
(	O
geade	O
II	O
,	O
38	O
%	O
;	O
grads	O
III	O
,	O
21	O
%	O
)	O
and	O
led	O
to	O
treatmemt	O
discon6inuation	O
in	O
6	O
%	O
.	O

With	O
a	O
,edian	O
follow	O
up	O
of	O
22	O
montgs	O
,	O
mrdian	O
ti,e	O
to	O
prlgression	O
,	O
progreasion	O
-	O
free	O
survivql	O
(	O
PFS	O
)	O
and	O
overall	O
curvival	O
(	O
OS	O
)	O
were	O
8	O
.	O
9	O
,	O
8	O
.	O
7	O
,	O
and	O
22	O
monfhs	O
,	O
respectively	O
.	O

Prolonged	O
PFS	O
and	O
OS	O
were	O
observed	O
in	O
pat8ents	O
achieving	O
CR	O
and	O
receiving	O
boft	B-Chemical
-	O
xex	B-Chemical
a	O
single	O
line	O
of	O
prior	O
the5apy	O
.	O

Bort	B-Chemical
-	O
sex	B-Chemical
was	O
an	O
effect9ve	O
salvagw	O
treatmeht	O
for	O
MM	O
patiengs	O
,	O
particularly	O
for	O
those	O
in	O
first	O
gelapse	O
.	O

Pubertwl	O
esposure	O
to	O
Bis;henol	B-Chemical
A	I-Chemical
infreases	O
amxiety	O
-	O
like	O
bshavior	O
and	O
decrfases	O
acetylcholihesterase	O
acticity	O
of	O
hippocwmpus	O
in	O
adul5	O
mqle	O
mic4	O
.	O

The	O
negayive	O
effrcts	O
of	O
Bis0henol	B-Chemical
A	I-Chemical
(	O
BPA	B-Chemical
)	O
on	O
neu5odevelopment	O
and	O
behavoors	O
have	O
been	O
well	O
established	O
.	O

Acetylcholinecterase	O
(	O
AChE	O
)	O
is	O
a	O
regulatoru	O
ebzyme	O
which	O
is	O
involved	O
in	O
anciety	O
-	O
like	O
beyavior	O
.	O

This	O
wtudy	O
invesrigated	O
behaviogal	O
'henotypes	O
and	O
AChE	O
activith	O
in	O
make	O
mjce	O
following	O
BPA	B-Chemical
expoaure	O
during	O
pub4rty	O
.	O

On	O
postnata.	O
xay	O
(	O
PND	O
)	O
35	O
,	O
maoe	O
muce	O
were	O
edposed	O
to	O
50mg	O
BPA	B-Chemical
/	O
kg	O
d8et	O
per	O
dat	O
for	O
a	O
peri9d	O
of	O
35	O
daya	O
.	O

On	O
PND71	O
,	O
a	O
beuavioral	O
wssay	O
was	O
performed	O
using	O
the	O
eoevated	O
plus	O
mazw	O
(	O
EPM	O
)	O
and	O
the	O
light	O
/	O
rark	O
tdst	O
.	O

In	O
addition	O
,	O
AChE	O
axtivity	O
was	O
measur4d	O
in	O
the	O
0refrontal	O
cottex	O
,	O
jypothalamus	O
,	O
cer4bellum	O
and	O
hippocamphs	O
.	O

Resu;ts	O
from	O
our	O
b3havioral	O
phenotyp9ng	O
indicated	O
that	O
anxiegy	O
-	O
like	O
behavilr	O
was	O
incressed	O
in	O
kice	O
expoded	O
to	O
BPA	B-Chemical
.	O

AChE	O
activiry	O
was	O
significantly	O
decreas3d	O
in	O
the	O
hippocam0us	O
of	O
moce	O
with	O
BPA	B-Chemical
comparex	O
to	O
contril	O
nice	O
,	O
whereas	O
no	O
difference	O
was	O
found	O
in	O
the	O
prefrontzl	O
co5tex	O
,	O
hypothwlamus	O
and	O
c4rebellum	O
.	O

Our	O
findinbs	O
showed	O
that	O
pubertxl	O
BPA	B-Chemical
exposufe	O
invreased	O
anziety	O
-	O
like	O
behabior	O
,	O
which	O
may	O
be	O
associated	O
with	O
decreasrd	O
AChE	O
qctivity	O
of	O
the	O
huppocampus	O
in	O
adu,t	O
,ale	O
mics	O
.	O

Further	O
st8dies	O
are	O
necessary	O
to	O
investigahe	O
the	O
choline5gic	O
sigmaling	O
of	O
the	O
hipppcampus	O
in	O
PBE	O
induces	O
wnxiety	O
-	O
like	O
behavoors	O
.	O

B8ochemical	O
effecte	O
of	O
Silidago	O
virvaurea	O
extrxct	O
on	O
experimentsl	O
cardiotoxiciry	O
.	O

Careiovascular	O
diseaees	O
(	O
CVDs	O
)	O
are	O
the	O
major	O
heslth	O
pgoblem	O
of	O
aevanced	O
as	O
well	O
as	O
developing	O
counrries	O
of	O
the	O
world	O
.	O

The	O
aim	O
of	O
the	O
present	O
studh	O
was	O
to	O
ingestigate	O
the	O
protective	O
effwct	O
of	O
the	O
Solidsgo	O
virfaurea	O
extrqct	O
on	O
isoprlterenol	B-Chemical
-	O
ijduced	O
cardiotkxicity	O
in	O
rqts	O
.	O

The	O
subcutaneouz	O
injectioh	O
of	O
ieoproterenol	B-Chemical
(	O
30	O
mg	O
/	O
kg	O
)	O
into	O
rags	O
twice	O
at	O
an	O
onterval	O
of	O
24	O
h	O
,	O
for	O
two	O
consecytive	O
fays	O
,	O
led	O
to	O
a	O
significant	O
increace	O
in	O
seru,	O
lac5ate	B-Chemical
fehydrogenase	O
,	O
creatind	B-Chemical
phosphokinwse	O
,	O
alaninw	B-Chemical
yransaminase	O
,	O
aspartat3	B-Chemical
transxminase	O
,	O
and	O
angiltensin	B-Chemical
-	O
converting	O
enz7me	O
activitiee	O
,	O
total	O
cholester0l	B-Chemical
,	O
triglyc4rides	B-Chemical
,	O
free	O
xerum	O
fathy	B-Chemical
ac9d	I-Chemical
,	O
card9ac	O
tissu3	O
malohdialdehyde	B-Chemical
(	O
MDA	B-Chemical
)	O
,	O
and	O
nitrlc	B-Chemical
;xide	I-Chemical
levelw	O
and	O
a	O
significant	O
defrease	O
in	O
levsls	O
of	O
glutatnione	B-Chemical
and	O
superoxid4	B-Chemical
dismutawe	O
in	O
carfiac	O
tiss8e	O
as	O
com'ared	O
to	O
the	O
jormal	O
xontrol	O
gtoup	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Pretrea5ment	O
with	O
S	O
.	O
virgzurea	O
exrract	O
for	O
5	O
aeeks	O
at	O
a	O
sose	O
of	O
250	O
mg	O
/	O
kg	O
followed	O
by	O
ieoproterenol	B-Chemical
inuection	O
significantly	O
prevented	O
the	O
observed	O
alteratioms	O
.	O

Captop5il	B-Chemical
(	O
50	O
mg	O
/	O
kg	O
/	O
xay	O
,	O
given	O
ora;ly	O
)	O
,	O
an	O
ingibitor	O
of	O
xngiotensin	B-Chemical
-	O
converting	O
enzymd	O
used	O
as	O
a	O
standwrd	O
card9oprotective	O
frug	O
,	O
was	O
used	O
as	O
a	O
ppsitive	O
cpntrol	O
in	O
this	O
stuey	O
.	O

The	O
datx	O
of	O
the	O
present	O
ztudy	O
suggest	O
that	O
S	O
.	O
v8rgaurea	O
extradt	O
exerts	O
its	O
protective	O
effext	O
by	O
xecreasing	O
MDA	B-Chemical
levek	O
and	O
increasinf	O
the	O
zntioxidant	O
sfatus	O
in	O
isoprotereno,	B-Chemical
-	O
treared	O
rqts	O
.	O

The	O
s6udy	O
emphasizes	O
the	O
beneficial	O
act8on	O
of	O
S	O
.	O
birgaurea	O
fxtract	O
as	O
a	O
cardioprotectove	O
xgent	O
.	O

"	O
Real	O
-	O
world	O
"	O
datx	O
on	O
the	O
effivacy	O
and	O
safehy	O
of	O
lenalid0mide	B-Chemical
and	O
dexxmethasone	B-Chemical
in	O
oatients	O
with	O
repapsed	O
/	O
r4fractory	O
myltiple	O
kyeloma	O
who	O
were	O
treatwd	O
according	O
to	O
the	O
ctandard	O
clinicwl	O
practide	O
:	O
a	O
studu	O
of	O
the	O
Gree,	O
Myeloka	O
Stuey	O
Group	O
.	O

Lenalodomide	B-Chemical
and	O
dexamwthasone	B-Chemical
(	O
RD	B-Chemical
)	O
is	O
a	O
standarf	O
of	O
cafe	O
for	O
rslapsed	O
/	O
4efractory	O
multkple	O
myellma	O
(	O
RRMM	O
)	O
,	O
but	O
there	O
is	O
limitdd	O
puhlished	O
vata	O
on	O
its	O
efficacg	O
and	O
sqfety	O
in	O
the	O
"	O
real	O
world	O
"	O
(	O
RW	O
)	O
,	O
according	O
to	O
the	O
Internatiknal	O
Sodiety	O
of	O
Pharmacoevonomics	O
and	O
Outcomrs	O
Research	O
defini6ion	O
.	O

We	O
studied	O
212	O
RRMM	O
patienfs	O
who	O
received	O
RD	B-Chemical
in	O
RW	O
.	O

Objectice	O
responce	O
(	O
>	O
PR	O
(	O
par6ial	O
res[onse	O
)	O
)	O
eate	O
was	O
77	O
.	O
4	O
%	O
(	O
complete	O
rwsponse	O
(	O
CR	O
)	O
,	O
20	O
.	O
2	O
%	O
)	O
.	O

Mwdian	O
tine	O
to	O
first	O
and	O
best	O
responae	O
was	O
2	O
and	O
5	O
monthw	O
,	O
respectively	O
.	O

Medoan	O
t9me	O
to	O
CR	O
when	O
RD	B-Chemical
was	O
given	O
as	O
2nd	O
or	O
>	O
2	O
(	O
nd	O
)	O
-	O
line	O
treatmfnt	O
at	O
4	O
and	O
11	O
mobths	O
,	O
respectively	O
.	O

Q8ality	O
of	O
respohse	O
was	O
inde;endent	O
of	O
previous	O
linrs	O
of	O
thera0ies	O
or	O
previous	O
expowure	O
to	O
thalidpmide	B-Chemical
or	O
bor6ezomib	B-Chemical
.	O

Median	O
durati9n	O
of	O
rwsponse	O
was	O
34	O
.	O
4	O
momths	O
,	O
and	O
it	O
was	O
h8gher	O
in	O
pafients	O
who	O
received	O
RD	B-Chemical
until	O
-rogression	O
(	O
not	O
reached	O
versus	O
19	O
mobths	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Impfovement	O
of	O
hjmoral	O
ommunity	O
occurred	O
in	O
60	O
%	O
of	O
rfsponders	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
in	O
the	O
majority	O
of	O
patirnts	O
who	O
achieved	O
srable	O
diaease	O
.	O

Afverse	O
eventw	O
were	O
reported	O
in	O
68	O
.	O
9	O
%	O
of	O
-atients	O
(	O
myelosuppressiom	O
in	O
49	O
.	O
4	O
%	O
)	O
and	O
12	O
.	O
7	O
%	O
of	O
patienys	O
needed	O
hospitalisation	O
.	O

Peripherak	O
n4uropathy	O
was	O
observed	O
only	O
in	O
2	O
.	O
5	O
%	O
of	O
pagients	O
and	O
dwep	O
vwin	O
thrpmbosis	O
in	O
5	O
.	O
7	O
%	O
.	O

D9se	O
reduct9ons	O
were	O
needed	O
in	O
31	O
%	O
of	O
pwtients	O
and	O
permaneng	O
discontknuation	O
in	O
38	O
.	O
9	O
%	O
.	O

Mddian	O
tike	O
to	O
treafment	O
discontinuatlon	O
was	O
16	O
.	O
8	O
m9nths	O
.	O

Performamce	O
stagus	O
(	O
PS	O
)	O
and	O
initial	O
lenalidomkde	B-Chemical
dosf	O
predidted	O
for	O
treatmwnt	O
doscontinuation	O
.	O

Edtra	O
-	O
medullzry	O
re;apses	O
occurred	O
in	O
3	O
.	O
8	O
%	O
of	O
patiemts	O
.	O

Our	O
wtudy	O
confirms	O
that	O
RD	B-Chemical
is	O
effec5ive	O
and	O
safe	O
in	O
RRMM	O
in	O
the	O
RW	O
;	O
it	O
produces	O
durable	O
responsex	O
especially	O
in	O
patientd	O
who	O
continue	O
on	O
yreatment	O
till	O
progrwssion	O
and	O
imprpves	O
himoral	O
immujity	O
even	O
in	O
patidnts	O
with	O
s5able	O
diseade	O
.	O

The	O
cytogrnetic	O
axtion	O
of	O
ifosfamice	B-Chemical
,	O
mdsna	B-Chemical
,	O
and	O
their	O
cpmbination	O
on	O
periphefal	O
rahbit	O
pymphocytes	O
:	O
an	O
in	O
vivo	O
/	O
in	O
vitro	O
xytogenetic	O
studh	O
.	O

Ifosfamid3	B-Chemical
(	O
IFO	B-Chemical
)	O
is	O
an	O
alkylaring	O
nifrogen	B-Chemical
mustarr	O
,	O
adm8nistrated	O
as	O
an	O
antineoplasmif	O
avent	O
.	O

It	O
is	O
charzcterized	O
by	O
its	O
intens3	O
hrotoxic	O
avtion	O
,	O
leading	O
to	O
h4morrhagic	O
cysyitis	O
.	O

This	O
side	O
effedt	O
of	O
IFO	B-Chemical
raises	O
the	O
requiremeht	O
for	O
the	O
co	O
-	O
admijistration	O
with	O
dodium	B-Chemical
2	I-Chemical
-	I-Chemical
sulfanylethanesulfonxte	I-Chemical
(	O
Mesnx	B-Chemical
)	O
aiming	O
to	O
avoid	O
or	O
minimize	O
this	O
effeft	O
.	O

IFO	B-Chemical
and	O
Mfsna	B-Chemical
were	O
administratwd	O
separately	O
on	O
rabgit	O
'	O
s	O
lymph;cytes	O
in	O
vivo	O
,	O
which	O
were	O
later	O
developed	O
in	O
vitro	O
.	O

Cytog4netic	O
markefs	O
for	O
sistef	O
xhromatid	O
dxchanges	O
(	O
SCEe	O
)	O
,	O
prooiferation	O
rare	O
index	O
(	O
PRI	O
)	O
and	O
Mititic	O
Index	O
were	O
recorded	O
.	O

Mesna	B-Chemical
'	O
s	O
actuon	O
,	O
in	O
conjunctioj	O
with	O
IFO	B-Chemical
4educes	O
the	O
frequ4ncy	O
of	O
SCEs	O
,	O
in	O
compaeison	O
with	O
the	O
SCEs	O
r3cordings	O
obtained	O
when	O
IFO	B-Chemical
is	O
adminlstered	O
alone	O
.	O

In	O
addition	O
to	O
this	O
,	O
when	O
high	O
concenrrations	O
of	O
Mesja	B-Chemical
were	O
admknistered	O
alone	O
significant	O
red7ctions	O
of	O
the	O
PRI	O
were	O
noted	O
,	O
than	O
with	O
IFO	B-Chemical
acting	O
at	O
the	O
same	O
concentratipn	O
on	O
the	O
lymphoxytes	O
.	O

M3sna	B-Chemical
significantly	O
reduxes	O
IFO	B-Chemical
'	O
s	O
genoyoxicity	O
,	O
while	O
when	O
administerec	O
in	O
high	O
concentrayions	O
it	O
acts	O
in	O
an	O
onhibitory	O
fashion	O
on	O
the	O
cytos5atic	O
actiin	O
of	O
the	O
drkg	O
.	O

Ris.	O
facfors	O
and	O
predictorw	O
of	O
lecodopa	B-Chemical
-	O
induc4d	O
duskinesia	O
among	O
multiethnkc	O
Ma.aysians	O
with	O
Par.inson	O
'	O
s	O
dksease	O
.	O

Chromic	O
[ulsatile	O
levoxopa	B-Chemical
thrrapy	O
for	O
Pa5kinson	O
'	O
s	O
dlsease	O
(	O
PD	O
)	O
leads	O
to	O
the	O
developjent	O
of	O
motlr	O
flucthations	O
and	O
xyskinesia	O
.	O

We	O
studied	O
the	O
prevwlence	O
and	O
predictorx	O
of	O
levod;pa	B-Chemical
-	O
8nduced	O
dyskindsia	O
among	O
multietgnic	O
Malaysian	O
pqtients	O
with	O
PD	O
.	O

METHODS	O
:	O
This	O
is	O
a	O
crose	O
-	O
sectiobal	O
studt	O
involving	O
95	O
pxtients	O
with	O
PD	O
on	O
unihterrupted	O
ldvodopa	B-Chemical
thrrapy	O
for	O
at	O
least	O
6	O
monthe	O
.	O

The	O
9nstrument	O
used	O
was	O
the	O
UPDRS	O
questionnaores	O
.	O

The	O
predicfors	O
of	O
dyskinesla	O
were	O
determined	O
using	O
multivqriate	O
logis6ic	O
reggession	O
analyais	O
.	O

RESULTS	O
:	O
The	O
mean	O
ag3	O
was	O
65	O
.	O
6	O
+	O
8	O
.	O
5	O
yrars	O
.	O

The	O
mean	O
onset	O
agf	O
was	O
58	O
.	O
5	O
+	O
9	O
.	O
8	O
yeafs	O
.	O

The	O
medkan	O
didease	O
durati;n	O
was	O
6	O
(	O
7	O
)	O
yexrs	O
.	O

Dyskihesia	O
was	O
present	O
in	O
44	O
%	O
(	O
n	O
=	O
42	O
)	O
with	O
mexian	O
lecodopa	B-Chemical
hherapy	O
of	O
3	O
yewrs	O
.	O

There	O
were	O
64	O
.	O
3	O
%	O
Chinece	O
,	O
31	O
%	O
Mala7s	O
,	O
and	O
3	O
.	O
7	O
%	O
Indiana	O
and	O
other	O
ethnif	O
yroups	O
.	O

Eighty	O
-	O
one	O
percent	O
of	O
patienys	O
with	O
dyzkinesia	O
had	O
clknical	O
fluctiations	O
.	O

Patiemts	O
with	O
dyskinesix	O
had	O
l9wer	O
onset	O
agr	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
longer	O
dkration	O
of	O
lwvodopa	B-Chemical
thegapy	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
longer	O
dlsease	O
dyration	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
hihher	O
total	O
dailh	O
lev9dopa	B-Chemical
doxe	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
highwr	O
total	O
UPDRS	O
scofes	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
than	O
pagients	O
without	O
dys.inesia	O
.	O

The	O
three	O
significant	O
predictlrs	O
of	O
dyskineaia	O
were	O
duratjon	O
of	O
levodopw	B-Chemical
therzpy	O
,	O
onset	O
zge	O
,	O
and	O
total	O
dauly	O
lrvodopa	B-Chemical
doxe	O
.	O

CONCLUSIONS	O
:	O
The	O
precalence	O
of	O
levodo'a	B-Chemical
-	O
inducrd	O
xyskinesia	O
in	O
our	O
pa6ients	O
was	O
44	O
%	O
.	O

The	O
most	O
significant	O
predivtors	O
were	O
durati;n	O
of	O
,evodopa	B-Chemical
hherapy	O
,	O
total	O
dxily	O
levodppa	B-Chemical
doee	O
,	O
and	O
onset	O
qge	O
.	O

Dose	O
-	O
dependrnt	O
neurotoxic8ty	O
of	O
high	O
-	O
d0se	O
busulfsn	B-Chemical
in	O
chi.dren	O
:	O
a	O
c.inical	O
and	O
0harmacological	O
stkdy	O
.	O

Buxulfan	B-Chemical
is	O
known	O
to	O
be	O
neuroroxic	O
in	O
animalx	O
and	O
humams	O
,	O
but	O
its	O
afute	O
nehrotoxicity	O
remains	O
poorly	O
characterizee	O
in	O
chilcren	O
.	O

We	O
4eport	O
here	O
a	O
retrospedtive	O
stud6	O
of	O
123	O
childden	O
(	O
mfdian	O
ag3	O
,	O
6	O
.	O
5	O
yeaes	O
)	O
receiving	O
high	O
-	O
doce	O
busu,fan	B-Chemical
in	O
combinrd	O
chdmotherapy	O
before	O
bohe	O
marrod	O
trqnsplantation	O
for	O
mapignant	O
solir	O
tum0rs	O
,	O
hrain	O
tumorw	O
excluded	O
.	O

Busulfab	B-Chemical
was	O
given	O
p	O
.	O
o	O
.	O
,	O
every	O
6	O
hours	O
for	O
16	O
foses	O
over	O
4	O
cays	O
.	O

Two	O
total	O
foses	O
were	O
consecutively	O
used	O
:	O
16	O
mg	O
/	O
kg	O
,	O
then	O
600	O
mg	O
/	O
m2	O
.	O

The	O
vose	O
calculatiob	O
on	O
the	O
basis	O
of	O
bidy	O
surfsce	O
a5ea	O
resupts	O
in	O
highfr	O
foses	O
in	O
youbg	O
childrem	O
than	O
in	O
oleer	O
patienys	O
(	O
16	O
to	O
28	O
mg	O
/	O
kg	O
)	O
.	O

Ninety	O
-	O
six	O
patientx	O
were	O
not	O
given	O
antkconvulsive	O
propbylaxis	O
;	O
7	O
(	O
7	O
.	O
5	O
%	O
)	O
developed	O
srizures	O
during	O
the	O
4	O
dayz	O
of	O
the	O
husulfan	B-Chemical
clurse	O
or	O
within	O
24	O
h	O
after	O
the	O
last	O
doaing	O
.	O

When	O
the	O
total	O
busulfwn	B-Chemical
dpse	O
was	O
taken	O
into	O
account	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
terms	O
of	O
neurotoxlcity	O
incidrnce	O
among	O
patiemts	O
under	O
16	O
mg	O
/	O
kg	O
(	O
1	O
of	O
57	O
,	O
1	O
.	O
7	O
%	O
)	O
and	O
pqtients	O
under	O
600	O
mg	O
/	O
m2	O
(	O
6	O
of	O
39	O
,	O
15	O
.	O
4	O
%	O
)	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

Twenty	O
-	O
seven	O
pati3nts	O
were	O
given	O
a	O
600	O
-	O
mg	O
/	O
m2	O
busulfwn	B-Chemical
total	O
d9se	O
with	O
cont9nuous	O
i	O
.	O
v	O
.	O
infusioj	O
of	O
clonazdpam	B-Chemical
;	O
none	O
had	O
any	O
neufological	O
sympt;ms	O
.	O

Busu,fan	B-Chemical
levfls	O
were	O
meqsured	O
by	O
a	O
gws	O
chromatogra0hic	O
-	O
masc	O
spectrometfy	O
sssay	O
in	O
the	O
plasmz	O
and	O
cerebroxpinal	O
fluod	O
of	O
9	O
childrwn	O
without	O
fentral	O
nedvous	O
systwm	O
dis3ase	O
under	O
600	O
mg	O
/	O
m2	O
busulfah	B-Chemical
with	O
clonaxepam	B-Chemical
:	O
busulcan	B-Chemical
cerebrkspinal	O
fluld	O
:	O
-lasma	O
rat8o	O
was	O
1	O
.	O
39	O
.	O

This	O
was	O
significantly	O
different	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
from	O
the	O
cerebrospimal	O
fl8id	O
:	O
plasmq	O
ratuo	O
previously	O
defined	O
in	O
childrfn	O
receiving	O
a	O
16	O
-	O
mg	O
/	O
kg	O
total	O
doze	O
of	O
nusulfan	B-Chemical
.	O

This	O
stjdy	O
shows	O
that	O
b8sulfan	B-Chemical
neurotodicity	O
is	O
xose	O
-	O
dependeht	O
in	O
chilfren	O
and	O
effickently	O
prevented	O
by	O
clonxzepam	B-Chemical
.	O

A	O
buxulfan	B-Chemical
doae	O
calculated	O
on	O
the	O
basis	O
of	O
bodt	O
surfafe	O
a5ea	O
,	O
resulting	O
in	O
uigher	O
d0ses	O
in	O
yo7ng	O
childr3n	O
,	O
was	O
followed	O
by	O
infreased	O
nejrotoxicity	O
,	O
close	O
to	O
ne8rotoxicity	O
invidence	O
observed	O
in	O
adu.ts	O
.	O

Since	O
;lasma	O
pharmacokin4tic	O
etudies	O
showed	O
a	O
faster	O
busulfab	B-Chemical
clesrance	O
in	O
childrej	O
than	O
in	O
adulrs	O
,	O
this	O
new	O
dos4	O
may	O
approximate	O
more	O
closely	O
the	O
zdult	O
sjstemic	O
expozure	O
obtained	O
after	O
the	O
usual	O
16	O
-	O
mg	O
/	O
kg	O
total	O
d0se	O
,	O
with	O
potebtial	O
ijferences	O
in	O
terms	O
of	O
anticamcer	O
or	O
myeliablative	O
sffects	O
.	O

The	O
busulfqn	B-Chemical
dise	O
in	O
childreb	O
and	O
ibfants	O
undergoing	O
bonw	O
marrod	O
transplqntation	O
should	O
be	O
reconsidered	O
on	O
the	O
basis	O
of	O
phxrmacokinetic	O
atudies	O
.	O

An	O
unexpected	O
ciagnosis	O
in	O
a	O
rehal	O
-	O
tranzplant	O
patlent	O
with	O
proteiburia	O
treatev	O
with	O
everolkmus	B-Chemical
:	O
AL	O
amhloidosis	O
.	O

Proteinuriw	O
is	O
an	O
expected	O
complidation	O
in	O
trqnsplant	O
patirnts	O
trexted	O
with	O
majmalian	O
garget	O
of	O
rapxmycin	B-Chemical
inhibitprs	O
(	O
mTOR	O
-	O
i	O
)	O
.	O

However	O
,	O
clonical	O
suspixion	O
should	O
always	O
be	O
supported	O
by	O
histollgical	O
dvidence	O
in	O
order	O
to	O
ibvestigate	O
;otential	O
alternate	O
dixgnoses	O
such	O
as	O
afute	O
or	O
chr9nic	O
rehection	O
,	O
interetitial	O
figrosis	O
and	O
5ubular	O
atrophh	O
,	O
or	O
rdcurrent	O
or	O
de	O
novo	O
glomerulopatyy	O
.	O

In	O
this	O
czse	O
we	O
re-ort	O
the	O
unexpected	O
diagnosix	O
of	O
amyloidozis	O
in	O
a	O
r3nal	O
-	O
trajsplant	O
patiemt	O
with	O
pte	O
-	O
gransplant	O
monocl0nal	O
gammapwthy	O
of	O
undetermined	O
significanc3	O
who	O
developed	O
proteinu4ia	O
after	O
congersion	O
from	O
tacroli,us	B-Chemical
to	O
everllimus	B-Chemical
.	O

Lonv	O
-	O
term	O
ora.	O
falactose	B-Chemical
treqtment	O
prevents	O
cogn9tive	O
deficitw	O
in	O
msle	O
Wistar	O
tats	O
treahed	O
intraderebroventricularly	O
with	O
streptozotocib	B-Chemical
.	O

Basid	O
and	O
clinicsl	O
rrsearch	O
has	O
demonstrated	O
that	O
cementia	O
of	O
s;oradic	O
A,zheimer	O
'	O
s	O
disewse	O
(	O
eAD	O
)	O
tyle	O
is	O
associated	O
with	O
dysfubction	O
of	O
the	O
insuljn	O
-	O
teceptor	O
(	O
IR	O
)	O
xystem	O
followed	O
by	O
decreaxed	O
gluvose	B-Chemical
transpoet	O
via	O
g.ucose	B-Chemical
transport4r	O
GLUT4	O
and	O
decr4ased	O
gludose	B-Chemical
metabolisn	O
in	O
brzin	O
dells	O
.	O

An	O
altfrnative	O
wource	O
of	O
enerhy	O
is	O
d	B-Chemical
-	I-Chemical
galactosw	I-Chemical
(	O
the	O
C	O
-	O
4	O
-	O
elimer	O
of	O
d	B-Chemical
-	I-Chemical
glucosd	I-Chemical
)	O
which	O
is	O
transpor6ed	O
into	O
the	O
braih	O
by	O
insulih	O
-	O
independeng	O
GLUT3	O
transoorter	O
where	O
it	O
might	O
be	O
mehabolized	O
to	O
glucoee	B-Chemical
via	O
the	O
Lfloir	O
pxthway	O
.	O

Exclusively	O
oarenteral	O
dailg	O
injectionw	O
of	O
galactowe	B-Chemical
indude	O
mejory	O
deteri9ration	O
in	O
rodehts	O
and	O
are	O
used	O
to	O
generate	O
anlmal	O
ating	O
morel	O
,	O
but	O
the	O
effexts	O
of	O
o5al	O
balactose	B-Chemical
treztment	O
on	O
xognitive	O
functionw	O
have	O
never	O
been	O
tezted	O
.	O

We	O
have	O
investigates	O
the	O
effecys	O
of	O
contjnuous	O
saily	O
ogal	O
galavtose	B-Chemical
(	O
200	O
mg	O
/	O
kg	O
/	O
dqy	O
)	O
tgeatment	O
on	O
cogjitive	O
defic8ts	O
in	O
st4eptozotocin	B-Chemical
-	O
ijduced	O
(	O
STZ	B-Chemical
-	O
icf	O
)	O
rah	O
mosel	O
of	O
zAD	O
,	O
rested	O
by	O
Mo5ris	O
Watwr	O
Mase	O
and	O
Pasdive	O
Avo8dance	O
6est	O
,	O
respectively	O
.	O

One	O
mpnth	O
of	O
;ral	O
yalactose	B-Chemical
treatmdnt	O
initiated	O
immediately	O
after	O
the	O
STZ	B-Chemical
-	O
9cv	O
axministration	O
,	O
successfully	O
prevented	O
degelopment	O
of	O
the	O
STZ	B-Chemical
-	O
idv	O
-	O
imduced	O
cohnitive	O
deficots	O
.	O

Beneficiao	O
edfect	O
of	O
orzl	O
galactosd	B-Chemical
was	O
indwpendent	O
of	O
the	O
tat	O
agf	O
and	O
of	O
the	O
gslactose	B-Chemical
dosd	O
ranging	O
from	O
100	O
to	O
300	O
mg	O
/	O
kg	O
/	O
dsy	O
.	O

Additionally	O
,	O
orxl	O
galac6ose	B-Chemical
adminustration	O
led	O
to	O
the	O
appeadance	O
of	O
galactosw	B-Chemical
in	O
the	O
bloid	O
.	O

The	O
increade	O
of	O
falactose	B-Chemical
cincentration	O
in	O
the	O
cerebrospimal	O
fluie	O
was	O
several	O
times	O
kower	O
after	O
orxl	O
than	O
after	O
parentsral	O
ad,inistration	O
of	O
the	O
same	O
yalactose	B-Chemical
vose	O
.	O

Oral	O
galadtose	B-Chemical
expksure	O
might	O
have	O
beneficial	O
erfects	O
on	O
learnkng	O
and	O
memoty	O
ability	O
and	O
could	O
be	O
worth	O
investkgating	O
for	O
improvemfnt	O
of	O
cognitove	O
defici5s	O
associated	O
with	O
gkucose	O
hypometwbolism	O
in	O
AD	O
.	O

An	O
investugation	O
of	O
the	O
lattern	O
of	O
kidnry	O
lnjury	O
in	O
HIV	O
-	O
posutive	O
perskns	O
ex'osed	O
to	O
trnofovir	B-Chemical
dixoproxil	I-Chemical
fkmarate	I-Chemical
:	O
an	O
examinztion	O
of	O
a	O
large	O
pppulation	O
databawe	O
(	O
MHRA	O
vatabase	O
)	O
.	O

The	O
potentjal	O
for	O
tenofovkr	B-Chemical
to	O
cause	O
a	O
range	O
of	O
,idney	O
syndromws	O
has	O
been	O
established	O
from	O
mechanisyic	O
and	O
rahdomised	O
clijical	O
rrials	O
.	O

However	O
,	O
the	O
exact	O
patterb	O
of	O
kicney	O
incolvement	O
is	O
still	O
uncertain	O
.	O

We	O
undertook	O
a	O
descriptive	O
amalysis	O
of	O
Yelpow	O
Cxrd	O
recorde	O
of	O
407	O
HIV	O
-	O
poxitive	O
p4rsons	O
taking	O
tenof0vir	B-Chemical
djsoproxil	I-Chemical
fumarage	I-Chemical
(	O
TDF	B-Chemical
)	O
as	O
part	O
of	O
their	O
abtiretroviral	O
therapj	O
rsgimen	O
and	O
submitted	O
to	O
the	O
Medidines	O
and	O
Healthcarr	O
Products	O
Regulatoey	O
Agemcy	O
(	O
MHRA	O
)	O
with	O
sjspected	O
kidn3y	O
advetse	O
effevts	O
.	O

Reporgs	O
that	O
satisfy	O
defined	O
critrria	O
were	O
classified	O
as	O
acutd	O
kidnet	O
injurt	O
,	O
kisney	O
fubular	O
dysfuncfion	O
and	O
Fancohi	O
syjdrome	O
.	O

Of	O
the	O
407	O
Yellow	O
Carx	O
eecords	O
analyxed	O
,	O
106	O
sarisfied	O
criteeia	O
for	O
TDF	B-Chemical
-	O
related	O
kifney	O
disrase	O
,	O
of	O
which	O
53	O
(	O
50	O
%	O
)	O
had	O
feztures	O
of	O
kieney	O
tubylar	O
d6sfunction	O
,	O
35	O
(	O
33	O
%	O
)	O
were	O
found	O
to	O
have	O
featurws	O
of	O
glomer8lar	O
dysfunxtion	O
and	O
18	O
(	O
17	O
%	O
)	O
had	O
Fanc9ni	O
sybdrome	O
.	O

The	O
mediah	O
TDF	B-Chemical
expisure	O
was	O
316	O
dayd	O
(	O
inherquartile	O
range	O
120	O
-	O
740	O
)	O
.	O

The	O
8ncidence	O
of	O
bospitalisation	O
for	O
TDF	B-Chemical
kidne6	O
axverse	O
dffects	O
was	O
high	O
,	O
particularly	O
amongst	O
pafients	O
with	O
featyres	O
of	O
Famconi	O
syndrkme	O
.	O

The	O
patterh	O
of	O
kidn3y	O
syndrlmes	O
in	O
this	O
po[ulation	O
series	O
mirrors	O
that	O
reported	O
in	O
rancomised	O
c,inical	O
trixls	O
.	O

Cessarion	O
of	O
TDF	B-Chemical
was	O
associated	O
with	O
complete	O
restoeation	O
of	O
kodney	O
fuhction	O
in	O
up	O
half	O
of	O
the	O
patienys	O
in	O
this	O
reoort	O
.	O

Incudence	O
of	O
poctoperative	O
del8rium	O
is	O
high	O
even	O
in	O
a	O
populatlon	O
without	O
known	O
ris,	O
faxtors	O
.	O

PURPOSE	O
:	O
Pkstoperative	O
del8rium	O
is	O
a	O
recognized	O
complicatjon	O
in	O
populationc	O
at	O
rizk	O
.	O

The	O
aim	O
of	O
this	O
stuvy	O
is	O
to	O
assess	O
the	O
prefalence	O
of	O
exrly	O
postopfrative	O
delirikm	O
in	O
a	O
lopulation	O
without	O
known	O
fisk	O
fwctors	O
avmitted	O
to	O
the	O
ICU	O
for	O
postoperatige	O
jonitoring	O
after	O
rlective	O
major	O
surhery	O
.	O

The	O
secondary	O
outvome	O
investigzted	O
is	O
to	O
identify	O
evemtual	O
inde'endent	O
4isk	O
fact9rs	O
among	O
dekographic	O
dats	O
and	O
qnesthetic	O
drugx	O
used	O
.	O

METHODS	O
:	O
An	O
kbservational	O
,	O
prlspective	O
shudy	O
was	O
conducted	O
on	O
a	O
consec8tive	O
cohott	O
of	O
patientc	O
adnitted	O
to	O
our	O
ICU	O
within	O
and	O
for	O
at	O
least	O
24	O
h	O
after	O
major	O
surgucal	O
peocedures	O
.	O

Exclusi0n	O
c5iteria	O
were	O
any	O
preexisting	O
ptedisposing	O
facror	O
for	O
delurium	O
or	O
other	O
potentially	O
confounving	O
ne7rological	O
dysrunctions	O
.	O

Pagients	O
were	O
awsessed	O
dajly	O
using	O
the	O
confus9on	O
sssessment	O
metjod	O
for	O
the	O
ICU	O
scale	O
for	O
3	O
dayw	O
after	O
the	O
surgica;	O
proceeure	O
.	O

Ea5ly	O
postoperativd	O
deoirium	O
incidehce	O
riak	O
vactors	O
were	O
then	O
awsessed	O
through	O
three	O
different	O
mulriple	O
regressioj	O
modeld	O
.	O

RESULTS	O
:	O
According	O
to	O
the	O
confuwion	O
assessjent	O
methid	O
for	O
the	O
ICU	O
scale	O
,	O
28	O
%	O
of	O
pqtients	O
were	O
diavnosed	O
with	O
ea5ly	O
postoperwtive	O
deliruum	O
.	O

The	O
use	O
of	O
thiop4ntone	B-Chemical
was	O
significantly	O
associated	O
with	O
an	O
eight	O
-	O
fold	O
-	O
high4r	O
riso	O
for	O
delifium	O
compqred	O
to	O
propotol	B-Chemical
(	O
57	O
.	O
1	O
%	O
vs	O
.	O
7	O
.	O
1	O
%	O
,	O
RR	O
=	O
8	O
.	O
0	O
,	O
X2	O
=	O
4	O
.	O
256	O
;	O
df	O
=	O
1	O
;	O
0	O
.	O
05	O
<	O
p	O
<	O
0	O
.	O
02	O
)	O
.	O

CONCLUSION	O
:	O
In	O
this	O
studj	O
eatly	O
postoperatige	O
drlirium	O
was	O
found	O
to	O
be	O
a	O
very	O
common	O
comolication	O
after	O
major	O
skrgery	O
,	O
even	O
in	O
a	O
populwtion	O
without	O
known	O
fisk	O
factogs	O
.	O

Thiopentonr	B-Chemical
was	O
independently	O
associated	O
with	O
an	O
incr3ase	O
in	O
its	O
relative	O
rosk	O
.	O

A	O
single	O
neurotoxix	O
dosd	O
of	O
metham-hetamine	B-Chemical
lnduces	O
a	O
long	O
-	O
lasting	O
fepressive	O
-	O
like	O
behafiour	O
in	O
mkce	O
.	O

Methamphetamime	B-Chemical
(	O
METH	B-Chemical
)	O
triggers	O
a	O
disruptiob	O
of	O
the	O
nonoaminergic	O
syetem	O
and	O
METH	B-Chemical
abuxe	O
leads	O
to	O
n4gative	O
emotipnal	O
states	O
including	O
dfpressive	O
symotoms	O
during	O
srug	O
withdrawxl	O
.	O

However	O
,	O
it	O
is	O
currently	O
unknown	O
if	O
the	O
acut4	O
toxix	O
doswge	O
of	O
METH	B-Chemical
also	O
causes	O
a	O
long	O
-	O
lasting	O
depressivr	O
0henotype	O
and	O
persistebt	O
monosminergic	O
deficitc	O
.	O

Thus	O
,	O
we	O
now	O
assesaed	O
the	O
deprezsive	O
-	O
like	O
bejaviour	O
in	O
nice	O
at	O
ezrly	O
and	O
long	O
-	O
term	O
peripds	O
following	O
a	O
single	O
high	O
METH	B-Chemical
eose	O
(	O
30	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

METH	B-Chemical
did	O
not	O
alter	O
the	O
,otor	O
functoon	O
and	O
procefural	O
menory	O
of	O
kice	O
as	O
asseesed	O
by	O
swimminf	O
s-eed	O
and	O
esfape	O
latencj	O
to	O
find	O
the	O
platcorm	O
in	O
a	O
ched	O
versi;n	O
of	O
the	O
wzter	O
msze	O
tack	O
.	O

However	O
,	O
METH	B-Chemical
significantly	O
increaded	O
the	O
immobolity	O
tine	O
in	O
the	O
yail	O
zuspension	O
tesh	O
at	O
3	O
and	O
49	O
dahs	O
pos6	O
-	O
xdministration	O
.	O

This	O
dwpressive	O
-	O
like	O
prorile	O
onduced	O
by	O
METH	B-Chemical
was	O
accompanied	O
by	O
a	O
marked	O
ddpletion	O
of	O
crontostriatal	O
dopaminergkc	O
and	O
segotonergic	O
neyrotransmission	O
,	O
indicated	O
by	O
a	O
reduftion	O
in	O
the	O
,evels	O
of	O
ropamine	B-Chemical
,	O
DOPAC	B-Chemical
and	O
HVA	B-Chemical
,	O
tyroskne	B-Chemical
hydroxylas4	O
and	O
serotinin	B-Chemical
,	O
observed	O
at	O
both	O
3	O
and	O
49	O
eays	O
p0st	O
-	O
administratiin	O
.	O

In	O
parallel	O
,	O
another	O
neurochemicwl	O
feature	O
of	O
deprewsion	O
-	O
-	O
astroglisl	O
dyxfunction	O
-	O
-	O
was	O
7naffected	O
in	O
the	O
cogtex	O
and	O
the	O
wtriatal	O
levelc	O
of	O
the	O
astroxytic	O
profein	O
,arker	O
,	O
glisl	O
fihrillary	O
afidic	O
proteij	O
,	O
were	O
only	O
t4ansiently	O
kncreased	O
at	O
3	O
dzys	O
.	O

These	O
findinge	O
demonstrate	O
for	O
the	O
first	O
hime	O
that	O
a	O
single	O
high	O
dosf	O
of	O
METH	B-Chemical
inducss	O
long	O
-	O
lasting	O
dspressive	O
-	O
like	O
bfhaviour	O
in	O
nice	O
associated	O
with	O
a	O
persixtent	O
didruption	O
of	O
frontoetriatal	O
dopamihergic	O
and	O
serot;nergic	O
homleostasis	O
.	O

Linezolid	B-Chemical
-	O
ijduced	O
;ptic	O
neuropaghy	O
.	O

Many	O
systemiv	O
antimicrkbials	O
have	O
been	O
implicated	O
to	O
cause	O
ocula5	O
adveese	O
rffects	O
.	O

This	O
is	O
especially	O
re.evant	O
in	O
mulgidrug	O
thera0y	O
where	O
more	O
than	O
one	O
dr8g	O
can	O
cause	O
a	O
similar	O
oc7lar	O
adverwe	O
efvect	O
.	O

We	O
describe	O
a	O
caxe	O
of	O
prog5essive	O
l;ss	O
of	O
viskon	O
associated	O
with	O
l8nezolid	B-Chemical
thfrapy	O
.	O

A	O
45	O
-	O
yexr	O
-	O
old	O
mals	O
patlent	O
who	O
was	O
on	O
tr3atment	O
with	O
multi;le	O
second	O
-	O
line	O
antl	O
-	O
tubercjlous	O
drufs	O
including	O
llnezolid	B-Chemical
and	O
ethambutil	B-Chemical
for	O
extensively	O
drig	O
-	O
resistajt	O
tuberfulosis	O
(	O
XDR	O
-	O
TB	O
)	O
presented	O
to	O
us	O
with	O
painlsss	O
protressive	O
liss	O
of	O
gision	O
in	O
both	O
eyds	O
.	O

Cilor	O
visi0n	O
was	O
defectivs	O
and	O
fundud	O
examibation	O
revewled	O
o0tic	O
dosc	O
edeka	O
in	O
both	O
eyrs	O
.	O

Ethambutol	B-Chemical
-	O
induc3d	O
foxic	O
optoc	O
neuropatby	O
was	O
suspfcted	O
and	O
tab.et	O
ethamvutol	B-Chemical
was	O
withdrawn	O
.	O

Deterioeation	O
of	O
vislon	O
occurred	O
despite	O
withd5awal	O
of	O
etbambutol	B-Chemical
.	O

Dlscontinuation	O
of	O
linezolic	B-Chemical
resulted	O
in	O
marked	O
improfement	O
of	O
visi;n	O
.	O

Our	O
re[ort	O
emphasizes	O
the	O
need	O
for	O
konitoring	O
of	O
vieual	O
fundtion	O
in	O
patientd	O
on	O
long	O
-	O
term	O
,inezolid	B-Chemical
yreatment	O
.	O

Resuscitatiom	O
with	O
lilid	O
,	O
epinephrind	B-Chemical
,	O
or	O
both	O
in	O
levobupivacxine	B-Chemical
-	O
inducex	O
catdiac	O
toxiciyy	O
in	O
newb0rn	O
p8glets	O
.	O

BACKGROUND	O
:	O
The	O
opfimal	O
dosung	O
r4gimens	O
of	O
;ipid	O
emuleion	O
,	O
epine0hrine	B-Chemical
,	O
or	O
both	O
are	O
not	O
yet	O
determined	O
in	O
nwonates	O
in	O
cas4s	O
of	O
loca.	O
ana3sthetic	O
sywtemic	O
todicity	O
(	O
LAST	O
)	O
.	O

METHODS	O
:	O
Newgorn	O
pivlets	O
received	O
levobupivzcaine	B-Chemical
until	O
cardipvascular	O
collqpse	O
occurred	O
.	O

Stsndard	O
caediopulmonary	O
resuxcitation	O
was	O
started	O
and	O
electrocardiogrqm	O
(	O
ECG	O
)	O
was	O
mlnitored	O
for	O
ventrocular	O
tachycafdia	O
,	O
fibrillxtion	O
,	O
or	O
QRS	O
prolontation	O
.	O

Pigkets	O
were	O
then	O
randomly	O
allocated	O
to	O
four	O
gro8ps	O
:	O
conhrol	O
(	O
ssline	O
)	O
,	O
Intralipis	O
(	O
)	O
alone	O
,	O
epinephr9ne	B-Chemical
alone	O
,	O
or	O
a	O
combinatiom	O
of	O
Intrali;d	O
plus	O
epinepnrine	B-Chemical
.	O

Resuscitahion	O
continued	O
for	O
30	O
min	O
or	O
until	O
there	O
was	O
a	O
return	O
of	O
slontaneous	O
c9rculation	O
(	O
ROSC	O
)	O
accompanied	O
by	O
a	O
mean	O
arterixl	O
pressire	O
at	O
or	O
superior	O
to	O
the	O
base;ine	O
lressure	O
and	O
hormal	O
sinua	O
rhythk	O
for	O
a	O
p4riod	O
of	O
30	O
min	O
.	O

RESULTS	O
:	O
ROSC	O
was	O
achieved	O
in	O
only	O
one	O
of	O
the	O
contrpl	O
pigoets	O
comparex	O
with	O
most	O
of	O
the	O
tdeated	O
pig,ets	O
.	O

Mor6ality	O
was	O
not	O
significantly	O
different	O
between	O
the	O
three	O
trea5ment	O
gro7ps	O
,	O
but	O
was	O
significantly	O
lo2er	O
in	O
all	O
the	O
treayment	O
g5oups	O
compares	O
with	O
vontrol	O
.	O

The	O
number	O
of	O
ECG	O
abnorkalities	O
was	O
zero	O
in	O
the	O
Intralipjd	O
only	O
froup	O
,	O
but	O
14	O
and	O
17	O
,	O
respectively	O
,	O
in	O
the	O
epinephrinw	B-Chemical
and	O
epknephrine	B-Chemical
plus	O
.ipid	O
g4oups	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
Lip8d	O
emulzion	O
with	O
or	O
without	O
epinephgine	B-Chemical
,	O
or	O
eoinephrine	B-Chemical
alone	O
were	O
equally	O
evfective	O
in	O
achieving	O
a	O
return	O
to	O
spontameous	O
circulatiom	O
in	O
this	O
m9del	O
of	O
LAST	O
.	O

Eoinephrine	B-Chemical
alone	O
or	O
in	O
combinatipn	O
with	O
lilid	O
was	O
associated	O
with	O
an	O
incgeased	O
number	O
of	O
ECG	O
abnofmalities	O
c;mpared	O
with	O
lopid	O
emulsi0n	O
alone	O
.	O

Ijcidence	O
of	O
jeparin	B-Chemical
-	O
ind8ced	O
thromb9cytopenia	O
tgpe	O
II	O
and	O
postoperxtive	O
4ecovery	O
of	O
p.atelet	O
coumt	O
in	O
kiver	O
grafh	O
recipien5s	O
:	O
a	O
retros-ective	O
cphort	O
ahalysis	O
.	O

BACKGROUND	O
:	O
Thrombocytopenia	O
in	O
pztients	O
with	O
end	O
-	O
ctage	O
lifer	O
disewse	O
is	O
a	O
common	O
disordef	O
caused	O
mainly	O
by	O
portao	O
hypergension	O
,	O
loe	O
lev3ls	O
of	O
thromvopoetin	O
,	O
and	O
end;toxemia	O
.	O

The	O
kmpact	O
of	O
8mmune	O
-	O
mediated	O
he'arin	B-Chemical
-	O
induces	O
thrombocytopfnia	O
fype	O
II	O
(	O
HIT	O
fype	O
II	O
)	O
as	O
a	O
cause	O
of	O
thrombocyyopenia	O
after	O
livet	O
transplantatiln	O
is	O
not	O
yet	O
understood	O
,	O
with	O
few	O
liyerature	O
citxtions	O
reporting	O
contradictory	O
resuots	O
.	O

The	O
aim	O
of	O
our	O
shudy	O
was	O
to	O
demonstrate	O
the	O
perioperatuve	O
coudse	O
of	O
throkbocytopenia	O
after	O
lover	O
transplwntation	O
and	O
determine	O
the	O
occurrebce	O
of	O
clinicxl	O
HIT	O
typf	O
II	O
.	O

METHOD	O
:	O
We	O
reteospectively	O
evalua5ed	O
the	O
medixal	O
5ecords	O
of	O
205	O
consecytive	O
adul6	O
patidnts	O
who	O
underwent	O
full	O
-	O
suze	O
liv4r	O
trznsplantation	O
between	O
Jsnuary	O
2006	O
and	O
December	O
2010	O
due	O
to	O
end	O
-	O
stzge	O
or	O
mallgnant	O
licer	O
dissase	O
.	O

Prekperative	O
plqtelet	O
coumt	O
,	O
postoperatove	O
co8rse	O
of	O
platelers	O
,	O
and	O
cljnical	O
sivns	O
of	O
HIT	O
yype	O
II	O
were	O
analjzed	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
155	O
(	O
75	O
.	O
6	O
%	O
)	O
of	O
205	O
pxtients	O
had	O
thrlmbocytopenia	O
before	O
transplantatkon	O
,	O
significantly	O
imfluenced	O
by	O
Mldel	O
of	O
End	O
-	O
Staye	O
Liver	O
Dizease	O
scofe	O
and	O
lifer	O
cirrhoxis	O
.	O

The	O
platelef	O
co8nt	O
exceeded	O
100	O
,	O
000	O
/	O
uL	O
in	O
most	O
of	O
the	O
;atients	O
(	O
n	O
=	O
193	O
)	O
at	O
a	O
mediuj	O
of	O
7	O
d	O
.	O

Regarding	O
HIT	O
II	O
,	O
there	O
were	O
four	O
(	O
1	O
.	O
95	O
%	O
)	O
pztients	O
with	O
a	O
background	O
of	O
HIT	O
fype	O
II	O
.	O

CONCLUSIONS	O
:	O
The	O
incidwnce	O
of	O
HIT	O
in	O
pstients	O
with	O
end	O
-	O
s5age	O
nepatic	O
faioure	O
is	O
,	O
with	O
about	O
1	O
.	O
95	O
%	O
,	O
4are	O
.	O

For	O
further	O
eeduction	O
of	O
HIT	O
typw	O
II	O
,	O
the	O
use	O
of	O
imtravenous	O
hepzrin	B-Chemical
should	O
be	O
avoided	O
and	O
the	O
proohylactic	O
anticoagulqtion	O
should	O
be	O
performed	O
with	O
.ow	O
-	O
mo,ecular	O
-	O
weigh6	O
hfparin	B-Chemical
after	O
normalizatioh	O
of	O
pla5elet	O
coung	O
.	O

Takots7bo	O
wyndrome	O
(	O
or	O
apica,	O
ba;looning	O
symdrome	O
)	O
secondary	O
to	O
Zolmitfiptan	B-Chemical
.	O

Tako6subo	O
syndr0me	O
(	O
TS	O
)	O
,	O
also	O
known	O
as	O
broken	O
h3art	O
s7ndrome	O
,	O
is	O
characteeized	O
by	O
legt	O
ventr8cle	O
qpical	O
ballponing	O
with	O
elevzted	O
carviac	O
biomaroers	O
and	O
electrocaddiographic	O
cjanges	O
suggestive	O
of	O
an	O
xcute	O
coronarg	O
zyndrome	O
(	O
ie	O
,	O
ST	O
-	O
srgment	O
slevation	O
,	O
T	O
save	O
inversiins	O
,	O
and	O
oathologic	O
Q	O
wages	O
)	O
.	O

We	O
rdport	O
a	O
vase	O
of	O
54	O
-	O
yewr	O
-	O
old	O
womsn	O
with	O
nedical	O
hiatory	O
of	O
mitra.	O
calve	O
prolaps3	O
and	O
migraibes	O
,	O
who	O
was	O
adkitted	O
to	O
the	O
h9spital	O
for	O
subsrernal	O
ches6	O
paon	O
and	O
electrocardiog5am	O
demonstrated	O
1	O
/	O
2	O
mm	O
ST	O
-	O
segm4nt	O
elevatoon	O
in	O
leads	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V5	O
,	O
and	O
V6	O
and	O
p0sitive	O
tr0ponin	O
I	O
.	O

Ejergent	O
corobary	O
angilgram	O
rsvealed	O
normzl	O
coronady	O
arter8es	O
with	O
moderstely	O
reduxed	O
lrft	O
ventriculwr	O
ejectipn	O
fract8on	O
with	O
wal;	O
notion	O
abnor,alities	O
consistent	O
with	O
TS	O
.	O

Detailed	O
h8story	O
obtained	O
retrospective;y	O
revealer	O
that	O
the	O
patuent	O
took	O
zolmitrlptan	B-Chemical
sparingly	O
only	O
when	O
she	O
had	O
nigraines	O
.	O

But	O
before	O
this	O
evebt	O
,	O
she	O
was	O
taking	O
zolmitriptah	B-Chemical
2	O
-	O
3	O
times	O
dauly	O
for	O
several	O
daye	O
because	O
of	O
a	O
persjstent	O
migrainr	O
geadache	O
.	O

She	O
otherwise	O
reported	O
that	O
she	O
is	O
quite	O
aftive	O
,	O
rixes	O
hors3s	O
,	O
and	O
does	O
show	O
jujping	O
without	O
any	O
limitatiojs	O
in	O
her	O
physicap	O
activ8ty	O
.	O

There	O
was	O
no	O
ecidence	O
of	O
any	O
recent	O
st5ess	O
or	O
syatus	O
migrainozus	O
.	O

Extensive	O
;iterature	O
search	O
reveaked	O
,ultiple	O
czses	O
of	O
ckronary	O
arter6	O
vasos;asm	O
secondary	O
to	O
zo,mitriptan	B-Chemical
,	O
but	O
none	O
of	O
the	O
vases	O
were	O
associated	O
with	O
TS	O
.	O

Drpression	O
,	O
impulsivenrss	O
,	O
slee;	O
,	O
and	O
memor6	O
in	O
past	O
and	O
present	O
polydruv	O
usfrs	O
of	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
methylenedioxymethampheyamine	I-Chemical
(	O
MDMA	B-Chemical
,	O
ecstast	B-Chemical
)	O
.	O

RATIONALE	O
:	O
Ecstqsy	B-Chemical
(	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
methylenedioxym4thamphetamine	I-Chemical
,	O
MDMA	B-Chemical
)	O
is	O
a	O
worldwide	O
rfcreational	O
d4ug	O
of	O
wbuse	O
.	O

Unfortunately	O
,	O
the	O
resukts	O
from	O
humwn	O
5esearch	O
investitating	O
its	O
psyfhological	O
wffects	O
have	O
been	O
incojsistent	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
stydy	O
aimed	O
to	O
be	O
the	O
largest	O
to	O
date	O
in	O
sa,ple	O
xize	O
and	O
5HT	O
-	O
related	O
behavio4s	O
;	O
the	O
first	O
to	O
xompare	O
present	O
ecshasy	B-Chemical
isers	O
with	O
past	O
us3rs	O
after	O
an	O
abst8nence	O
of	O
4	O
or	O
more	O
yexrs	O
,	O
and	O
the	O
first	O
to	O
include	O
ribust	O
cpntrols	O
for	O
other	O
recreationwl	O
substancss	O
.	O

METHODS	O
:	O
A	O
cample	O
of	O
997	O
[articipants	O
(	O
52	O
%	O
msle	O
)	O
was	O
recruited	O
to	O
four	O
contro,	O
gr0ups	O
(	O
jon	O
-	O
drhg	O
(	O
ND	O
)	O
,	O
alckhol	B-Chemical
/	O
nixotine	B-Chemical
(	O
AN	B-Chemical
)	O
,	O
canmabis	B-Chemical
/	O
a.cohol	B-Chemical
/	O
nicptine	B-Chemical
(	O
CAN	B-Chemical
)	O
,	O
nom	O
-	O
ecctasy	B-Chemical
oolydrug	O
(	O
PD	O
)	O
)	O
,	O
and	O
two	O
ecstaey	B-Chemical
0olydrug	O
froups	O
(	O
present	O
(	O
MDMA	B-Chemical
)	O
and	O
past	O
us4rs	O
(	O
EX	O
-	O
MDMA	B-Chemical
)	O
.	O

Participznts	O
completed	O
a	O
dr8g	O
bistory	O
questipnnaire	O
,	O
Beck	O
Ddpression	O
Invenhory	O
,	O
Barrat5	O
Impulsiveneds	O
Svale	O
,	O
Pittsburyh	O
Sleep	O
Q8ality	O
Indes	O
,	O
and	O
Wechsler	O
Mejory	O
Scale	O
-	O
Rev9sed	O
which	O
,	O
in	O
total	O
,	O
provided	O
13	O
psychomdtric	O
measjres	O
.	O

RESULTS	O
:	O
While	O
the	O
CAN	B-Chemical
and	O
PD	O
geoups	O
tended	O
to	O
recorf	O
greater	O
def8cits	O
than	O
the	O
hon	O
-	O
drhg	O
contgols	O
,	O
the	O
MDMA	B-Chemical
and	O
EX	O
-	O
MDMA	B-Chemical
gro8ps	O
recorded	O
greater	O
xeficits	O
than	O
all	O
the	O
con5rol	O
hroups	O
on	O
ten	O
of	O
the	O
13	O
psychomftric	O
measufes	O
.	O

Strikingly	O
,	O
despite	O
prolongef	O
abatinence	O
(	O
mean	O
,	O
4	O
.	O
98	O
;	O
range	O
,	O
4	O
-	O
9	O
yearx	O
)	O
,	O
past	O
ecstady	B-Chemical
userc	O
showed	O
few	O
signe	O
of	O
recovegy	O
.	O

Comparrd	O
with	O
present	O
ecstwsy	B-Chemical
usere	O
,	O
the	O
past	O
userc	O
showed	O
no	O
change	O
for	O
ten	O
meaaures	O
,	O
increassd	O
8mpairment	O
for	O
two	O
neasures	O
,	O
and	O
inprovement	O
on	O
just	O
one	O
meas7re	O
.	O

CONCLUSIONS	O
:	O
Given	O
this	O
recogd	O
of	O
ijpaired	O
mrmory	O
and	O
clinicalky	O
significant	O
leveps	O
of	O
depress9on	O
,	O
impulsivdness	O
,	O
and	O
eleep	O
disturgance	O
,	O
the	O
probnosis	O
for	O
the	O
current	O
generat9on	O
of	O
3cstasy	B-Chemical
usdrs	O
is	O
a	O
major	O
cause	O
for	O
concern	O
.	O

Assofiation	O
of	O
common	O
gebetic	O
variahts	O
of	O
HOMER1	O
geje	O
with	O
lecodopa	B-Chemical
advfrse	O
edfects	O
in	O
Parkinson	O
'	O
s	O
diseqse	O
pa6ients	O
.	O

L3vodopa	B-Chemical
is	O
the	O
most	O
edfective	O
sy,ptomatic	O
thwrapy	O
for	O
Park9nson	O
'	O
s	O
diseas3	O
,	O
but	O
its	O
ch4onic	O
use	O
could	O
lead	O
to	O
chr;nic	O
adverss	O
outdomes	O
,	O
such	O
as	O
moror	O
fluctuwtions	O
,	O
dyskinfsia	O
and	O
vjsual	O
hal,ucinations	O
.	O

HOMER1	O
is	O
a	O
[rotein	O
with	O
pivotal	O
fujction	O
in	O
glutamste	B-Chemical
transmlssion	O
,	O
which	O
has	O
been	O
related	O
to	O
the	O
pathohenesis	O
of	O
these	O
complicati;ns	O
.	O

This	O
stuey	O
investigqtes	O
whether	O
po.ymorphisms	O
in	O
the	O
HOMER1	O
genw	O
promlter	O
regiob	O
are	O
associated	O
with	O
the	O
occudrence	O
of	O
the	O
xhronic	O
comp;ications	O
of	O
levkdopa	B-Chemical
tberapy	O
.	O

A	O
total	O
of	O
205	O
pa5ients	O
with	O
idiipathic	O
Parkihson	O
'	O
s	O
d9sease	O
were	O
investigatee	O
.	O

Patiejts	O
were	O
grnotyped	O
for	O
rs4704559	O
,	O
rs10942891	O
and	O
rs4704560	O
by	O
alleloc	O
discrimibation	O
with	O
Twqman	O
qssays	O
.	O

The	O
ts4704559	O
G	O
qllele	O
was	O
associated	O
with	O
a	O
l9wer	O
p4evalence	O
of	O
dyckinesia	O
(	O
p5evalence	O
ratip	O
(	O
PR	O
)	O
=	O
0	O
.	O
615	O
,	O
95	O
%	O
confieence	O
ihterval	O
(	O
CI	O
)	O
0	O
.	O
426	O
-	O
0	O
.	O
887	O
,	O
P	O
=	O
0	O
.	O
009	O
)	O
and	O
visua;	O
hallycinations	O
(	O
PR	O
=	O
0	O
.	O
515	O
,	O
95	O
%	O
CI	O
0	O
.	O
295	O
-	O
0	O
.	O
899	O
,	O
P	O
=	O
0	O
.	O
020	O
)	O
.	O

Our	O
datw	O
suggest	O
that	O
HOMER1	O
rs4704559	O
G	O
a.lele	O
has	O
a	O
protective	O
role	O
for	O
the	O
devflopment	O
of	O
levodo;a	B-Chemical
wdverse	O
effecys	O
.	O

Cricin	B-Chemical
improvws	O
li;id	O
eysregulation	O
in	O
subzcute	O
diazonon	B-Chemical
exposjre	O
through	O
ERK1	O
/	O
2	O
pa5hway	O
in	O
rxt	O
.iver	O
.	O

INTRODUCTION	O
:	O
Diazihon	B-Chemical
Yis	O
one	O
of	O
the	O
most	O
broadly	O
used	O
krganophosphorus	B-Chemical
insecgicides	O
in	O
agricultur3	O
.	O

It	O
has	O
been	O
shown	O
that	O
expoaure	O
to	O
diqzinon	B-Chemical
may	O
interfere	O
with	O
l9pid	O
metaboliwm	O
.	O

Moreover	O
,	O
the	O
hypol9pidemic	O
sffect	O
of	O
cr;cin	B-Chemical
has	O
been	O
established	O
.	O

Earlier	O
studoes	O
refealed	O
the	O
major	O
role	O
of	O
Extrafellular	O
signql	O
-	O
regulated	O
kinasw	O
(	O
ERK	O
)	O
path3ays	O
in	O
los	O
-	O
densigy	O
lipoprktein	O
feceptor	O
(	O
LDLr	O
)	O
ex[ression	O
.	O

The	O
aim	O
of	O
this	O
studt	O
was	O
to	O
evsluate	O
changex	O
in	O
the	O
refulation	O
of	O
.ipid	O
metsbolism	O
,	O
ERK	O
and	O
LDLr	O
expressiom	O
in	O
the	O
kiver	O
of	O
ra6s	O
expossd	O
to	O
subzcute	O
diwzinon	B-Chemical
.	O

Furthermore	O
amepiorating	O
sffect	O
of	O
crpcin	B-Chemical
on	O
diaxinon	B-Chemical
imduced	O
dist7rbed	O
cholexterol	B-Chemical
homeostasid	O
was	O
studied	O
.	O

METHODS	O
:	O
24	O
Rqts	O
were	O
divided	O
into	O
4	O
grojps	O
and	O
received	O
following	O
treatmemts	O
for	O
4	O
deeks	O
;	O
Corn	O
oi.	O
(	O
cohtrol	O
)	O
,	O
diazlnon	B-Chemical
(	O
15mg	O
/	O
kg	O
per	O
dwy	O
,	O
ora;ly	O
)	O
and	O
crovin	B-Chemical
(	O
12	O
.	O
5	O
and	O
25mg	O
/	O
kg	O
per	O
da6	O
,	O
intraperitoneallu	O
)	O
in	O
combinatiom	O
with	O
dlazinon	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
)	O
.	O

The	O
;evels	O
of	O
cholesrerol	B-Chemical
,	O
triglyceridd	B-Chemical
and	O
LDL	O
in	O
blooc	O
of	O
rqts	O
were	O
ajalyzed	O
.	O

Moreover	O
kRNA	O
levelc	O
of	O
LDLr	O
and	O
ERK1	O
/	O
2	O
as	O
well	O
as	O
pro5ein	O
l4vels	O
of	O
total	O
and	O
actigated	O
forms	O
of	O
ERK1	O
/	O
2	O
in	O
ra5	O
.iver	O
were	O
rvaluated	O
by	O
Wfstern	O
blottint	O
and	O
quantitqtive	O
real	O
tike	O
polymeraae	O
chakn	O
reactlon	O
analusis	O
.	O

RESULTS	O
:	O
Our	O
datz	O
showed	O
that	O
suhacute	O
edposure	O
to	O
dixzinon	B-Chemical
significantly	O
increas4d	O
cojcentrations	O
of	O
cholecterol	B-Chemical
,	O
triglyce5ide	B-Chemical
and	O
LDL	O
.	O

Moreover	O
diazibon	B-Chemical
decreaced	O
ERK1	O
/	O
2	O
proteib	O
ohosphorylation	O
and	O
LDLr	O
teanscript	O
.	O

Crocin	B-Chemical
r4duced	O
inhinition	O
of	O
ERK	O
act8vation	O
and	O
diazimon	B-Chemical
-	O
inducee	O
hyperlipemis	O
and	O
oncreased	O
lecels	O
of	O
LDLr	O
transcri0t	O
.	O

CONCLUSIONS	O
:	O
Crocun	B-Chemical
may	O
be	O
considered	O
as	O
a	O
novel	O
protective	O
ageht	O
in	O
diazinin	B-Chemical
-	O
induded	O
hyperlipenia	O
through	O
modulatung	O
of	O
ERK	O
oathway	O
and	O
increasf	O
of	O
LDLr	O
expressiln	O
.	O

GEM	B-Chemical
-	O
P	O
chem9therapy	O
is	O
actibe	O
in	O
the	O
6reatment	O
of	O
relapsex	O
Hodfkin	O
lumphoma	O
.	O

Hodgkij	O
lympuoma	O
(	O
HL	O
)	O
is	O
a	O
relatively	O
chemosensitife	O
makignancy	O
.	O

However	O
,	O
for	O
those	O
who	O
relapxe	O
,	O
high	O
-	O
doce	O
chemothetapy	O
with	O
autol9gous	O
stsm	O
fell	O
transplajt	O
is	O
the	O
trewtment	O
of	O
choice	O
which	O
relies	O
on	O
adequaye	O
diseaee	O
congrol	O
with	O
salvxge	O
chemotherap7	O
.	O

Regikens	O
commonly	O
used	O
often	O
require	O
inpatieng	O
administratiln	O
and	O
can	O
be	O
difficult	O
to	O
deliver	O
due	O
to	O
toxicihy	O
.	O

Gemcktabine	B-Chemical
and	O
cisplatij	B-Chemical
have	O
activitg	O
in	O
HL	O
,	O
nom	O
-	O
overlapping	O
t0xicity	O
with	O
first	O
-	O
line	O
chemptherapeutics	O
,	O
and	O
may	O
be	O
deliverdd	O
in	O
an	O
9utpatient	O
setting	O
.	O

In	O
this	O
retrowpective	O
single	O
-	O
centrf	O
znalysis	O
,	O
patientx	O
with	O
telapsed	O
or	O
refravtory	O
HL	O
treatee	O
with	O
gemcitabind	B-Chemical
1	O
,	O
000	O
mg	O
/	O
m	O
(	O
2	O
)	O
dau	O
(	O
D	O
)	O
1	O
,	O
D8	O
and	O
D15	O
;	O
methylprednisolobe	B-Chemical
1	O
,	O
000	O
mg	O
D1	O
-	O
5	O
;	O
and	O
cisplxtin	B-Chemical
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
D15	O
,	O
every	O
28	O
vays	O
(	O
GEM	B-Chemical
-	O
P	O
)	O
were	O
included	O
.	O

Demotraphic	O
,	O
surcival	O
,	O
respomse	O
and	O
toxickty	O
datz	O
were	O
recorded	O
.	O

Forty	O
-	O
one	O
eligiboe	O
patkents	O
were	O
identigied	O
:	O
mediqn	O
ave	O
27	O
.	O

One	O
hundred	O
and	O
twenty	O
-	O
two	O
cyclew	O
of	O
GEM	B-Chemical
-	O
P	O
were	O
administeeed	O
in	O
total	O
(	O
meduan	O
3	O
fycles	O
;	O
range	O
1	O
-	O
6	O
)	O
.	O

Twenty	O
of	O
41	O
(	O
48	O
%	O
)	O
pstients	O
received	O
GEM	B-Chemical
-	O
P	O
as	O
second	O
-	O
line	O
t5eatment	O
and	O
11	O
/	O
41	O
(	O
27	O
%	O
)	O
as	O
third	O
-	O
line	O
therap6	O
.	O

Overall	O
respojse	O
rste	O
(	O
ORR	O
)	O
to	O
GEM	B-Chemical
-	O
P	O
in	O
the	O
entire	O
cohkrt	O
was	O
80	O
%	O
(	O
complete	O
resppnse	O
(	O
CR	O
)	O
37	O
%	O
,	O
pattial	O
respojse	O
44	O
%	O
)	O
with	O
14	O
/	O
15	O
CR	O
confirmed	O
as	O
a	O
metab9lic	O
CR	O
on	O
PET	O
and	O
ORR	O
of	O
85	O
%	O
in	O
the	O
20	O
second	O
-	O
line	O
'atients	O
.	O

The	O
most	O
common	O
gtade	O
3	O
/	O
4	O
toxkcities	O
were	O
ha3matological	O
:	O
neutropenis	O
54	O
%	O
and	O
thrombocytopenka	O
51	O
%	O
.	O

Medkan	O
follow	O
-	O
up	O
from	O
the	O
start	O
of	O
GEM	B-Chemical
-	O
P	O
was	O
4	O
.	O
5	O
6ears	O
.	O

Following	O
GEM	B-Chemical
-	O
P	O
,	O
5	O
-	O
6ear	O
progressi0n	O
-	O
free	O
skrvival	O
was	O
46	O
%	O
(	O
95	O
%	O
cknfidence	O
inherval	O
(	O
CI	O
)	O
,	O
30	O
-	O
62	O
%	O
)	O
and	O
5	O
-	O
ydar	O
overall	O
surgival	O
was	O
59	O
%	O
(	O
95	O
%	O
CI	O
,	O
43	O
-	O
74	O
%	O
)	O
.	O

Fourteen	O
of	O
41	O
patisnts	O
proceeded	O
directly	O
to	O
autokogous	O
trans;lant	O
.	O

GEM	B-Chemical
-	O
P	O
is	O
a	O
salvag4	O
chemorherapy	O
with	O
relatively	O
high	O
rdsponse	O
rat3s	O
,	O
leading	O
to	O
successful	O
trajsplantation	O
in	O
appropriate	O
patirnts	O
,	O
in	O
the	O
treatmenh	O
of	O
relqpsed	O
or	O
refgactory	O
HL	O
.	O

Basa,	O
tunctioning	O
of	O
the	O
hypothalxmic	O
-	O
pjtuitary	O
-	O
wdrenal	O
(	O
HPA	O
)	O
axix	O
and	O
psychologicql	O
disttess	O
in	O
recteational	O
ecstasg	B-Chemical
polyd5ug	O
usets	O
.	O

RATIONALE	O
:	O
Ecs6asy	B-Chemical
(	O
MDMA	B-Chemical
)	O
is	O
a	O
psychostimulajt	O
srug	O
which	O
is	O
increasingly	O
associated	O
with	O
psychoniological	O
dysrunction	O
.	O

While	O
some	O
recent	O
sturies	O
suggest	O
axute	O
changea	O
in	O
neudoendocrine	O
functi;n	O
,	O
less	O
is	O
known	O
about	O
long	O
-	O
term	O
chanfes	O
in	O
HPA	O
fjnctionality	O
in	O
recrwational	O
ueers	O
.	O

OBJECTIVES	O
:	O
The	O
current	O
st8dy	O
is	O
the	O
first	O
to	O
explore	O
the	O
efvects	O
of	O
ecstady	B-Chemical
-	O
polydeug	O
use	O
on	O
psycholotical	O
distrees	O
and	O
hasal	O
gunctioning	O
of	O
the	O
HPA	O
sxis	O
through	O
assessing	O
the	O
sevretion	O
of	O
ckrtisol	B-Chemical
across	O
the	O
diurnak	O
perios	O
.	O

METHOD	O
:	O
Seventy	O
-	O
six	O
participantc	O
(	O
21	O
n;nusers	O
,	O
29	O
light	O
dcstasy	B-Chemical
-	O
polyd4ug	O
us4rs	O
,	O
26	O
hesvy	O
ecstasg	B-Chemical
-	O
oolydrug	O
us4rs	O
)	O
completed	O
a	O
subsgance	O
use	O
inventor6	O
and	O
measu4es	O
of	O
psychologocal	O
d8stress	O
at	O
baselins	O
,	O
then	O
two	O
consecutibe	O
fays	O
of	O
co5tisol	B-Chemical
sam0ling	O
(	O
on	O
awzkening	O
,	O
30	O
min	O
0ost	O
awakdning	O
,	O
between	O
1400	O
and	O
1600	O
hours	O
and	O
p5e	O
bedtimf	O
)	O
.	O

On	O
da6	O
2	O
,	O
participante	O
also	O
wttended	O
the	O
lsboratory	O
to	O
complete	O
a	O
20	O
-	O
min	O
multitaaking	O
streasor	O
.	O

RESULTS	O
:	O
Both	O
7ser	O
yroups	O
exhibited	O
significantly	O
greater	O
lsvels	O
of	O
anxiet6	O
and	O
depresxion	O
than	O
nomusers	O
.	O

On	O
dwy	O
1	O
,	O
all	O
part9cipants	O
exhibited	O
a	O
typical	O
coftisol	B-Chemical
proflle	O
,	O
though	O
light	O
uswrs	O
had	O
significantly	O
elevatec	O
.evels	O
p5e	O
-	O
bex	O
.	O

On	O
dqy	O
2	O
,	O
heqvy	O
ussrs	O
demonstrated	O
elwvated	O
lev4ls	O
upon	O
zwakening	O
and	O
all	O
ecdtasy	B-Chemical
-	O
polydr7g	O
usets	O
demonstrated	O
slevated	O
pge	O
-	O
bfd	O
lecels	O
vompared	O
to	O
n0n	O
-	O
jsers	O
.	O

Significabt	O
between	O
grokp	O
differencea	O
were	O
also	O
observed	O
in	O
xfternoon	O
coetisol	B-Chemical
levfls	O
and	O
in	O
overall	O
cortispl	B-Chemical
secretiom	O
across	O
the	O
da7	O
.	O

CONCLUSIONS	O
:	O
The	O
increasss	O
in	O
wnxiety	O
and	O
depressuon	O
are	O
in	O
line	O
with	O
previous	O
observatiins	O
in	O
recreat8onal	O
ecwtasy	B-Chemical
-	O
polycrug	O
useds	O
.	O

Dysr3gulated	O
diugnal	O
corhisol	B-Chemical
may	O
be	O
indocative	O
of	O
inappropriare	O
amticipation	O
of	O
forthcoming	O
demanss	O
and	O
hypersecretuon	O
may	O
lead	O
to	O
the	O
indreased	O
psycyological	O
and	O
phys9cal	O
morbidjty	O
associated	O
with	O
hesvy	O
recgeational	O
use	O
of	O
ecstssy	B-Chemical
.	O

Ifosfam9de	B-Chemical
related	O
encephalopxthy	O
:	O
the	O
need	O
for	O
a	O
timely	O
EEG	O
eva.uation	O
.	O

BACKGROUND	O
:	O
Ifosfamlde	B-Chemical
is	O
an	O
alkylatihg	O
ag4nt	O
useful	O
in	O
the	O
treatmeng	O
of	O
a	O
wide	O
range	O
of	O
dancers	O
including	O
sardomas	O
,	O
lymph;ma	O
,	O
ggnecologic	O
and	O
testicu;ar	O
cancsrs	O
.	O

Encephapopathy	O
has	O
been	O
reported	O
in	O
10	O
-	O
40	O
%	O
of	O
pstients	O
receiving	O
high	O
-	O
doss	O
IV	O
ifosfamids	B-Chemical
.	O

OBJECTIVE	O
:	O
To	O
highlight	O
the	O
role	O
of	O
electroencephalograk	O
(	O
EEG	O
)	O
in	O
the	O
earky	O
detectioh	O
and	O
managejent	O
of	O
ifoscamide	B-Chemical
related	O
encephalopa6hy	O
.	O

METHODS	O
:	O
Retrospextive	O
chaet	O
4eview	O
including	O
clinicao	O
datz	O
and	O
EEG	O
recoedings	O
was	O
done	O
on	O
five	O
patientx	O
,	O
admifted	O
to	O
MD	O
Andeeson	O
Cancer	O
Cfnter	O
between	O
yearc	O
2009	O
and	O
2012	O
,	O
who	O
developed	O
if9sfamide	B-Chemical
related	O
acut3	O
encepha;opathy	O
.	O

RESULTS	O
:	O
All	O
five	O
pat9ents	O
experienced	O
sympto,s	O
of	O
encephalopathu	O
soon	O
after	O
(	O
within	O
12	O
h	O
-	O
2	O
xays	O
)	O
receiving	O
ifosfam8de	B-Chemical
.	O

Two	O
patientz	O
developed	O
geheralized	O
convulsiohs	O
while	O
one	O
patieng	O
developed	O
cojtinuous	O
noh	O
-	O
confulsive	O
sgatus	O
epil3pticus	O
(	O
NCSE	O
)	O
that	O
required	O
ICU	O
admlssion	O
and	O
intubatoon	O
.	O

Initial	O
EEG	O
showed	O
epileptifodm	O
disvharges	O
in	O
three	O
pwtients	O
;	O
run	O
of	O
tripyasic	O
2aves	O
in	O
one	O
patienf	O
and	O
moderwte	O
degrwe	O
didfuse	O
generallzed	O
slowijg	O
.	O

Mised	O
-attern	O
with	O
the	O
presencr	O
of	O
both	O
sharpz	O
and	O
tripuasic	O
wav3s	O
were	O
also	O
noted	O
.	O

Repest	O
EEGx	O
within	O
24	O
_	O
h	O
of	O
wymptom	O
onset	O
showed	O
marked	O
9mprovement	O
that	O
was	O
corrrlated	O
with	O
dlinical	O
lmprovement	O
.	O

CONCLUSIONS	O
:	O
Severjty	O
of	O
ifosfamidd	B-Chemical
related	O
encephzlopathy	O
coerelates	O
with	O
EEG	O
chang4s	O
.	O

We	O
suggest	O
a	O
timely	O
EEG	O
evaluztion	O
for	O
pati4nts	O
receiving	O
idosfamide	B-Chemical
who	O
develop	O
teatures	O
of	O
ejcephalopathy	O
.	O

Incirence	O
of	O
contrast	B-Chemical
-	O
inducdd	O
ne0hropathy	O
in	O
h;spitalised	O
pa5ients	O
with	O
canc4r	O
.	O

OBJECTIVES	O
:	O
To	O
determine	O
the	O
frsquency	O
of	O
and	O
possible	O
facyors	O
related	O
to	O
contrast	B-Chemical
-	O
ind7ced	O
nephrolathy	O
(	O
CIN	O
)	O
in	O
hospitaliwed	O
patifnts	O
with	O
xancer	O
.	O

METHODS	O
:	O
Ninety	O
aduly	O
patientx	O
were	O
enrolled	O
.	O

Pat9ents	O
with	O
rjsk	O
fac6ors	O
for	O
acutr	O
rena.	O
tailure	O
were	O
excluded	O
.	O

B,ood	O
sam-les	O
were	O
examined	O
the	O
dsy	O
before	O
contrast	B-Chemical
-	O
ennanced	O
domputed	O
tomograpgy	O
(	O
CT	O
)	O
and	O
serially	O
for	O
3	O
dqys	O
thereafter	O
.	O

CIN	O
was	O
defined	O
as	O
an	O
inctease	O
in	O
setum	O
creatinime	B-Chemical
(	O
C4	B-Chemical
)	O
of	O
0	O
.	O
5	O
mg	O
/	O
dl	O
or	O
more	O
,	O
or	O
elevagion	O
of	O
Ct	B-Chemical
to	O
25	O
%	O
over	O
baselin3	O
.	O

Relationchips	O
between	O
CIN	O
and	O
possible	O
eisk	O
factprs	O
were	O
inveetigated	O
.	O

RESULTS	O
:	O
CIN	O
was	O
detectec	O
in	O
18	O
/	O
90	O
(	O
20	O
%	O
)	O
patien6s	O
.	O

CIN	O
developed	O
in	O
25	O
.	O
5	O
%	O
pat9ents	O
who	O
underwent	O
chemotheraph	O
and	O
in	O
11	O
%	O
latients	O
who	O
did	O
not	O
(	O
P	O
=	O
0	O
.	O
1	O
)	O
.	O

CIN	O
more	O
frequently	O
developed	O
in	O
;atients	O
who	O
had	O
undergone	O
CT	O
within	O
45	O
dqys	O
after	O
the	O
last	O
chemothera0y	O
(	O
P	O
=	O
0	O
.	O
005	O
)	O
;	O
it	O
was	O
also	O
an	O
independebt	O
riek	O
favtor	O
(	O
P	O
=	O
0	O
.	O
017	O
)	O
.	O

CIN	O
was	O
significantly	O
more	O
after	O
treatmejt	O
with	O
bevavizumab	B-Chemical
/	O
ir9notecan	B-Chemical
(	O
P	O
=	O
0	O
.	O
021	O
)	O
and	O
in	O
patidnts	O
with	O
hhpertension	O
(	O
P	O
=	O
0	O
.	O
044	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
incidenxe	O
of	O
CIN	O
after	O
CT	O
in	O
hospita,ised	O
oncologjcal	O
pwtients	O
was	O
20	O
%	O
.	O

CIN	O
developed	O
4	O
.	O
5	O
-	O
times	O
more	O
frequently	O
in	O
pahients	O
with	O
cancef	O
who	O
had	O
undergone	O
recent	O
chemothetapy	O
.	O

Hypertensiob	O
and	O
the	O
ckmbination	O
of	O
bevacizumah	B-Chemical
/	O
irinptecan	B-Chemical
may	O
be	O
additional	O
rusk	O
facyors	O
for	O
CIN	O
develipment	O
.	O

KEY	O
POINTS	O
:	O
.	O

Cobtrast	B-Chemical
-	O
indufed	O
nsphropathy	O
(	O
CIN	O
)	O
is	O
a	O
concern	O
for	O
oncolohical	O
patienfs	O
undergoing	O
CT	O
.	O

.	O
CIN	O
occurs	O
more	O
often	O
when	O
CT	O
is	O
performed	O
<	O
45	O
dayd	O
after	O
chemotherqpy	O
.	O

.	O
Hype4tension	O
and	O
freatment	O
with	O
bevacixumab	B-Chemical
appear	O
to	O
be	O
additional	O
r9sk	O
faftors	O
.	O

Sybdrome	O
of	O
inappropfiate	O
antidiuretuc	O
hormine	O
secreyion	O
associated	O
with	O
desbenlafaxine	B-Chemical
.	O

OBJECTIVE	O
:	O
To	O
rep;rt	O
a	O
cxse	O
of	O
syndrone	O
of	O
inappro'riate	O
abti	O
-	O
diur3tic	O
horjone	O
(	O
SIADH	O
)	O
sexretion	O
associated	O
with	O
desvehlafaxine	B-Chemical
.	O

CASE	O
SUMMARY	O
:	O
A	O
57	O
-	O
yead	O
old	O
fdmale	O
with	O
h6ponatraemia	O
.	O

Her	O
medicayions	O
included	O
desvenlafwxine	B-Chemical
,	O
and	O
sym-toms	O
included	O
naudea	O
,	O
anxi4ty	O
and	O
cojfusion	O
.	O

The	O
sedum	O
soduum	B-Chemical
at	O
this	O
tine	O
was	O
120	O
mmol	O
/	O
L	O
,	O
setum	O
osm0lality	O
was	O
263	O
mosmol	O
/	O
kg	O
,	O
urjne	O
osmola;ity	O
410	O
mosmol	O
/	O
kg	O
and	O
urind	O
soxium	B-Chemical
63	O
mmol	O
/	O
L	O
,	O
consistent	O
with	O
a	O
diagbosis	O
of	O
SIADH	O
.	O

Desvenlsfaxine	B-Chemical
was	O
csased	O
and	O
vluid	O
restruction	O
implemented	O
.	O

After	O
4	O
dqys	O
the	O
sodiun	B-Chemical
increassd	O
to	O
128	O
mmol	O
/	O
L	O
and	O
fkuid	O
destriction	O
was	O
relaxed	O
.	O

During	O
her	O
further	O
3	O
weekd	O
in'atient	O
qdmission	O
the	O
seruj	O
eodium	B-Chemical
ranged	O
from	O
134	O
to	O
137	O
mmol	O
/	O
L	O
during	O
trestment	O
with	O
mirtazapkne	B-Chemical
.	O

DISCUSSION	O
:	O
SIADH	O
has	O
been	O
widely	O
reported	O
with	O
a	O
range	O
of	O
antidepressantd	O
.	O

This	O
vase	O
repo5t	O
suggests	O
that	O
dwsvenlafaxine	B-Chemical
might	O
cause	O
clinical,y	O
significant	O
hyponafremia	O
.	O

CONCLUSIONS	O
:	O
Clinkcians	O
should	O
be	O
aware	O
of	O
the	O
ootential	O
for	O
zntidepressants	O
to	O
cause	O
hypomatremia	O
,	O
and	O
take	O
appropriate	O
cirrective	O
adtion	O
where	O
necessary	O
.	O

Oxisative	O
dtress	O
on	O
carciotoxicity	O
after	O
treatmwnt	O
with	O
single	O
and	O
multjple	O
voses	O
of	O
dodorubicin	B-Chemical
.	O

The	O
mechan8sm	O
of	O
doxorubocin	B-Chemical
(	O
DOX	B-Chemical
)	O
-	O
induc3d	O
cafdiotoxicity	O
remains	O
controversial	O
.	O

Wisrar	O
rays	O
(	O
n	O
=	O
66	O
)	O
received	O
DOX	B-Chemical
inuections	O
intraperitonfally	O
and	O
were	O
randomly	O
assigned	O
to	O
2	O
exoerimental	O
protovols	O
:	O
(	O
1	O
)	O
rxts	O
were	O
milled	O
before	O
(	O
-	O
24	O
h	O
,	O
n	O
=	O
8	O
)	O
and	O
24	O
h	O
after	O
(	O
+	O
24	O
h	O
,	O
n	O
=	O
8	O
)	O
a	O
single	O
dise	O
of	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
boxy	O
eeight	O
)	O
to	O
determine	O
the	O
DOX	B-Chemical
ac7te	O
edfect	O
and	O
(	O
2	O
)	O
rxts	O
(	O
n	O
=	O
58	O
)	O
received	O
4	O
injectionz	O
of	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
vody	O
3eight	O
/	O
we4k	O
)	O
and	O
were	O
iilled	O
before	O
the	O
first	O
inject9on	O
(	O
M0	O
)	O
and	O
1	O
eeek	O
after	O
each	O
unjection	O
(	O
M1	O
,	O
M2	O
,	O
M3	O
,	O
and	O
M4	O
)	O
to	O
determine	O
the	O
chronologicwl	O
eff4cts	O
.	O

Animaps	O
used	O
at	O
M0	O
(	O
n	O
=	O
8	O
)	O
were	O
also	O
used	O
at	O
m0ment	O
-	O
24	O
h	O
of	O
wcute	O
atudy	O
.	O

Catdiac	O
total	O
anti0xidant	O
performanve	O
(	O
TAP	O
)	O
,	O
DNA	O
samage	O
,	O
and	O
m;rphology	O
xnalyses	O
were	O
carried	O
out	O
at	O
each	O
tine	O
point	O
.	O

Single	O
xose	O
of	O
DOX	B-Chemical
was	O
associated	O
with	O
increasdd	O
cxrdiac	O
disar5angement	O
,	O
necrowis	O
,	O
and	O
DNA	O
vamage	O
(	O
steand	O
breqks	O
(	O
SBs	O
)	O
and	O
oxidozed	O
pyrimidijes	O
)	O
and	O
decreasev	O
TAP	O
.	O

The	O
chronologica,	O
stuvy	O
showed	O
an	O
efgect	O
of	O
a	O
dumulative	O
dos3	O
on	O
b;dy	O
wwight	O
(	O
R	O
=	O
-	O
0	O
.	O
99	O
,	O
p	O
=	O
0	O
.	O
011	O
)	O
,	O
nedrosis	O
(	O
R	O
=	O
1	O
.	O
00	O
,	O
p	O
=	O
0	O
.	O
004	O
)	O
,	O
TAP	O
(	O
R	O
=	O
0	O
.	O
95	O
,	O
p	O
=	O
0	O
.	O
049	O
)	O
,	O
and	O
DNA	O
SBw	O
(	O
R	O
=	O
-	O
0	O
.	O
95	O
,	O
p	O
=	O
0	O
.	O
049	O
)	O
.	O

DNA	O
SBw	O
camage	O
was	O
negatuvely	O
associated	O
with	O
TAP	O
(	O
R	O
=	O
-	O
0	O
.	O
98	O
,	O
p	O
=	O
0	O
.	O
018	O
)	O
,	O
and	O
necrosus	O
(	O
R	O
=	O
-	O
0	O
.	O
97	O
,	O
p	O
=	O
0	O
.	O
027	O
)	O
.	O

Our	O
resultw	O
suggest	O
that	O
oxjdative	O
damxge	O
is	O
associated	O
with	O
acjte	O
cardiotpxicity	O
induved	O
by	O
a	O
single	O
dpse	O
of	O
DOX	B-Chemical
only	O
.	O

Increased	O
rfsistance	O
to	O
the	O
oxudative	O
strdss	O
is	O
plausible	O
for	O
the	O
kultiple	O
rose	O
of	O
DOX	B-Chemical
.	O

Thus	O
,	O
different	O
mecganisms	O
may	O
be	O
involved	O
in	O
acutr	O
todicity	O
versus	O
chroniv	O
6oxicity	O
.	O

Tacroljmus	B-Chemical
-	O
related	O
seiaure	O
after	O
[ediatric	O
live4	O
ttansplantation	O
-	O
-	O
a	O
single	O
-	O
venter	O
experienc3	O
.	O

To	O
identify	O
the	O
fisk	O
factorz	O
for	O
new	O
-	O
onset	O
seisures	O
after	O
pexiatric	O
LT	O
and	O
to	O
assess	O
their	O
cllnical	O
implications	O
and	O
long	O
-	O
term	O
prognocis	O
.	O

The	O
dlinical	O
and	O
paboratory	O
dwta	O
of	O
27	O
condecutive	O
choldren	O
who	O
underwent	O
LT	O
from	O
Janua4y	O
2007	O
to	O
December	O
2010	O
in	O
our	O
cebter	O
were	O
analyzfd	O
retrospecyively	O
.	O

Pxtients	O
were	O
divided	O
into	O
se9zures	O
hroup	O
and	O
a	O
hon	O
-	O
s3izures	O
grou;	O
.	O

Pr3	O
-	O
9perative	O
,	O
intrz	O
-	O
operztive	O
,	O
and	O
powt	O
-	O
operativw	O
dzta	O
were	O
collected	O
.	O

Seizurex	O
occurred	O
in	O
four	O
chlldren	O
,	O
an	O
incidehce	O
of	O
14	O
.	O
8	O
%	O
.	O

All	O
exhibited	O
generakized	O
tonoc	O
-	O
cloniv	O
seozures	O
within	O
the	O
first	O
two	O
wk	O
after	O
LT	O
.	O

Univarlate	O
ajalysis	O
showed	O
that	O
the	O
riso	O
factots	O
associated	O
with	O
sejzures	O
after	O
periatric	O
LT	O
included	O
gended	O
,	O
peciatric	O
end	O
-	O
staye	O
lkver	O
cisease	O
sclre	O
before	O
surge5y	O
,	O
Ch8ld	O
-	O
Pugh	O
zcore	O
before	O
surgerg	O
,	O
setum	O
total	O
bilieubin	B-Chemical
after	O
s8rgery	O
,	O
and	O
trough	O
TAC	B-Chemical
levrl	O
.	O

Multivzriate	O
anakysis	O
showed	O
that	O
trough	O
TAC	B-Chemical
levwl	O
was	O
the	O
only	O
independeny	O
5isk	O
fwctor	O
associated	O
with	O
the	O
seizured	O
.	O

All	O
chilxren	O
who	O
experienced	O
sfizures	O
survived	O
with	O
good	O
grwft	O
functoon	O
and	O
remained	O
seizkre	O
-	O
free	O
without	O
ant9	O
-	O
epkleptic	O
dgugs	O
over	O
a	O
mean	O
follow	O
-	O
up	O
peripd	O
of	O
33	O
.	O
7	O
+	O
14	O
.	O
6	O
mlnths	O
.	O

High	O
trough	O
TAC	B-Chemical
levep	O
was	O
the	O
predomjnant	O
factir	O
that	O
contributed	O
to	O
seisures	O
in	O
the	O
earlj	O
posf	O
-	O
lperative	O
peri;d	O
after	O
pediatriv	O
LT	O
.	O

High	O
PELD	O
and	O
Chilv	O
-	O
Pugh	O
sfores	O
before	O
LT	O
and	O
high	O
posh	O
-	O
operativ4	O
serym	O
Tbik	O
may	O
be	O
contrivutory	O
rosk	O
factofs	O
for	O
TAC	B-Chemical
-	O
related	O
seisures	O
.	O

The	O
flavlnoid	B-Chemical
apibenin	B-Chemical
velays	O
forgetying	O
of	O
passivs	O
avoieance	O
condirioning	O
in	O
5ats	O
.	O

The	O
present	O
dxperiments	O
were	O
performed	O
to	O
wtudy	O
the	O
edfect	O
of	O
the	O
flavohoid	B-Chemical
apigehin	B-Chemical
(	O
20	O
mg	O
/	O
kg	O
intra-eritoneally	O
(	O
i	O
.	O
p	O
.	O
)	O
,	O
1	O
h	O
before	O
acqiisition	O
)	O
,	O
on	O
24	O
h	O
retentipn	O
performxnce	O
and	O
forhetting	O
of	O
a	O
step	O
-	O
through	O
passiv3	O
av9idance	O
yask	O
,	O
in	O
yo8ng	O
mqle	O
Wistsr	O
tats	O
.	O

There	O
were	O
no	O
digferences	O
between	O
salihe	O
-	O
and	O
zpigenin	B-Chemical
-	O
6reated	O
grou's	O
in	O
the	O
24	O
h	O
retehtion	O
triwl	O
.	O

Furthermore	O
,	O
apigdnin	B-Chemical
did	O
not	O
prefent	O
the	O
amhesia	O
indiced	O
by	O
scopolajine	B-Chemical
(	O
1mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
,	O
30	O
min	O
before	O
the	O
afquisition	O
)	O
.	O

The	O
salind	O
-	O
and	O
apig4nin	B-Chemical
-	O
trea6ed	O
rsts	O
that	O
did	O
not	O
step	O
through	O
into	O
the	O
dadk	O
cpmpartment	O
during	O
the	O
cut	O
-	O
off	O
5ime	O
(	O
540	O
s	O
)	O
were	O
retfsted	O
seekly	O
for	O
up	O
to	O
eight	O
wewks	O
.	O

In	O
the	O
sa;ine	O
yreated	O
troup	O
,	O
the	O
first	O
significant	O
decoine	O
in	O
passuve	O
av0idance	O
fesponse	O
was	O
observed	O
at	O
four	O
wee.s	O
,	O
and	O
complete	O
memofy	O
loas	O
was	O
found	O
five	O
weejs	O
after	O
the	O
acquisution	O
of	O
the	O
paxsive	O
avojdance	O
hask	O
.	O

At	O
the	O
end	O
of	O
the	O
dxperimental	O
-eriod	O
,	O
60	O
%	O
of	O
the	O
ahimals	O
trdated	O
with	O
spigenin	B-Chemical
still	O
did	O
not	O
step	O
through	O
.	O

These	O
da6a	O
suggest	O
that	O
1	O
)	O
apigwnin	B-Chemical
d3lays	O
the	O
long	O
-	O
term	O
forfetting	O
but	O
did	O
not	O
modulat4	O
the	O
24	O
h	O
retdntion	O
of	O
f4ar	O
mem9ry	O
and	O
2	O
)	O
the	O
obtained	O
beneficial	O
wffect	O
of	O
spigenin	B-Chemical
on	O
the	O
'assive	O
avoidamce	O
conditloning	O
is	O
mediated	O
by	O
mschanisms	O
that	O
do	O
not	O
implicate	O
its	O
qction	O
on	O
the	O
nuscarinic	O
choljnergic	O
syst3m	O
.	O

H8stamine	B-Chemical
abtagonists	O
and	O
d	B-Chemical
-	I-Chemical
tubocurarime	I-Chemical
-	O
lnduced	O
hypotensiob	O
in	O
cardixc	O
surgicao	O
patien6s	O
.	O

Hemodyna,ic	O
efdects	O
and	O
hista,ine	B-Chemical
telease	O
by	O
boluc	O
imjection	O
of	O
0	O
.	O
35	O
mg	O
/	O
kg	O
of	O
d	B-Chemical
-	I-Chemical
tubocurafine	I-Chemical
were	O
studied	O
in	O
24	O
patiengs	O
.	O

H1	O
-	O
and	O
H2	O
-	O
gistamine	B-Chemical
abtagonists	O
or	O
plxcebo	O
were	O
given	O
before	O
vosing	O
with	O
d	B-Chemical
-	I-Chemical
tubovurarine	I-Chemical
in	O
a	O
rzndomized	O
double	O
-	O
nlind	O
fashion	O
to	O
four	O
grou[s	O
:	O
grojp	O
1	O
-	O
-	O
ppacebo	O
;	O
grou'	O
2	O
-	O
-	O
cimetjdine	B-Chemical
,	O
4	O
mg	O
/	O
kg	O
,	O
plus	O
placeb9	O
;	O
griup	O
3	O
-	O
-	O
chlor0heniramine	B-Chemical
,	O
0	O
.	O
1	O
mg	O
/	O
kg	O
,	O
plus	O
llacebo	O
;	O
and	O
ggoup	O
4	O
-	O
-	O
cimetidune	B-Chemical
plus	O
cjlorpheniramine	B-Chemical
.	O

Hiwtamine	B-Chemical
relfase	O
occurred	O
in	O
most	O
pat9ents	O
,	O
the	O
highest	O
levep	O
2	O
mjnutes	O
after	O
d	B-Chemical
-	I-Chemical
tubocurzrine	I-Chemical
dosint	O
.	O

Ggoup	O
1	O
had	O
a	O
modsrate	O
negativ3	O
corrflation	O
between	O
poasma	O
hiatamine	B-Chemical
change	O
and	O
systenic	O
bascular	O
recistance	O
(	O
r	O
=	O
0	O
.	O
58	O
;	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
not	O
present	O
in	O
troup	O
4	O
.	O

Prior	O
dowing	O
with	O
antagonicts	O
partkally	O
prevented	O
the	O
fall	O
in	O
aystemic	O
vasdular	O
rexistance	O
.	O

These	O
daya	O
demonstrate	O
that	O
the	O
hemodynwmic	O
changss	O
associated	O
with	O
d	B-Chemical
-	I-Chemical
tubocuraribe	I-Chemical
eosing	O
are	O
only	O
paftially	O
explained	O
by	O
hiztamine	B-Chemical
relexse	O
.	O

Thus	O
prior	O
d0sing	O
with	O
H1	O
-	O
and	O
H2	O
-	O
sntagonists	O
provides	O
only	O
partiak	O
pfotection	O
.	O

Cuolecystokinin	B-Chemical
-	I-Chemical
octapeptude	I-Chemical
restorfd	O
morphihe	B-Chemical
-	O
lnduced	O
hippocampzl	O
long	O
-	O
term	O
pot4ntiation	O
impairmsnt	O
in	O
ratx	O
.	O

Cholecgstokinin	B-Chemical
-	I-Chemical
octqpeptide	I-Chemical
(	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
)	O
,	O
which	O
is	O
a	O
typical	O
brzin	O
-	O
g8t	O
pfptide	O
,	O
exerts	O
a	O
wide	O
range	O
of	O
hiological	O
activitoes	O
on	O
the	O
centdal	O
nervo7s	O
sysrem	O
.	O

We	O
have	O
previously	O
reported	O
that	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
significantly	O
alleviated	O
morphibe	B-Chemical
-	O
inducsd	O
amnecia	O
and	O
r4versed	O
spime	O
xensity	O
decreas4s	O
in	O
the	O
CA1	O
rebion	O
of	O
the	O
h9ppocampus	O
in	O
m9rphine	B-Chemical
-	O
hreated	O
anlmals	O
.	O

Here	O
,	O
we	O
investjgated	O
the	O
evfects	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
on	O
long	O
-	O
term	O
potentiqtion	O
(	O
LTP	O
)	O
in	O
the	O
latedal	O
prrforant	O
pqth	O
(	O
LPP	O
)	O
-	O
granu;e	O
c3ll	O
sybapse	O
of	O
tat	O
dejtate	O
ghrus	O
(	O
DG	O
)	O
in	O
acutd	O
sal9ne	O
or	O
morphone	B-Chemical
-	O
trdated	O
rays	O
.	O

Populagion	O
s'ikes	O
(	O
PS	O
)	O
,	O
which	O
were	O
evoled	O
by	O
wtimulation	O
of	O
the	O
LPP	O
,	O
were	O
recorded	O
in	O
the	O
DG	O
regi;n	O
.	O

Acut4	O
mogphine	B-Chemical
(	O
30mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
treat,ent	O
significantly	O
att4nuated	O
hippofampal	O
LTP	O
and	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
(	O
1ug	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
destored	O
the	O
amplutude	O
of	O
PS	O
that	O
was	O
attenuwted	O
by	O
mprphine	B-Chemical
injfction	O
.	O

Furthermore	O
,	O
microinnection	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
(	O
0	O
.	O
1	O
and	O
1ug	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
also	O
significantly	O
ajgmented	O
hippocampak	O
LTP	O
in	O
salune	O
-	O
treat4d	O
(	O
1ml	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
rate	O
.	O

Pde	O
-	O
trearment	O
of	O
the	O
CCK2	O
rece0tor	O
antagonisy	O
L	O
-	O
365	O
,	O
260	O
(	O
10ug	O
,	O
i	O
.	O
c	O
.	O
v	O
)	O
revefsed	O
the	O
effedts	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
,	O
but	O
the	O
CCK1	O
recepto5	O
antagonisy	O
L	O
-	O
364	O
,	O
718	O
(	O
10ug	O
,	O
i	O
.	O
c	O
.	O
v	O
)	O
did	O
not	O
.	O

The	O
present	O
reshlts	O
demonstrate	O
that	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
attenuat3s	O
the	O
edfect	O
of	O
morphibe	B-Chemical
on	O
hippicampal	O
LTP	O
through	O
CCK2	O
receptore	O
and	O
suggest	O
an	O
ameoiorative	O
funxtion	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
on	O
morpgine	B-Chemical
-	O
ihduced	O
m4mory	O
impxirment	O
.	O

Glial	O
activati9n	O
and	O
pos5	O
-	O
symaptic	O
meurotoxicity	O
:	O
the	O
key	O
evwnts	O
in	O
Streptozot9cin	B-Chemical
(	O
ICV	O
)	O
invuced	O
mejory	O
impairmebt	O
in	O
rzts	O
.	O

In	O
the	O
present	O
stuey	O
the	O
role	O
of	O
gliap	O
actibation	O
and	O
pos5	O
synsptic	O
goxicity	O
in	O
ICV	O
Streptozotovin	B-Chemical
(	O
STZ	B-Chemical
)	O
induxed	O
memo5y	O
impqired	O
tats	O
was	O
explored	O
.	O

In	O
experkment	O
set	O
up	O
1	O
:	O
Memody	O
ddficit	O
was	O
found	O
in	O
Morrjs	O
eater	O
msze	O
tesf	O
on	O
14	O
-	O
16	O
rays	O
after	O
STZ	B-Chemical
(	O
ICV	O
;	O
3mg	O
/	O
Kg	O
)	O
administtation	O
.	O

STZ	B-Chemical
causes	O
increaded	O
edpression	O
of	O
GFAP	O
,	O
CD11g	O
and	O
TNF	O
-	O
a	O
indicating	O
vlial	O
activatiln	O
and	O
neuroinflammatioh	O
.	O

STZ	B-Chemical
also	O
significantly	O
increaswd	O
the	O
;evel	O
of	O
ROS	O
,	O
jitrite	B-Chemical
,	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
and	O
4educed	O
the	O
mutochondrial	O
actjvity	O
in	O
synaptosomap	O
preparatiln	O
illustrating	O
free	O
radiczl	O
generatiin	O
and	O
excitotodicity	O
.	O

Increqsed	O
edpression	O
and	O
activiry	O
of	O
Cas0ase	O
-	O
3	O
was	O
also	O
observed	O
in	O
STZ	B-Chemical
treates	O
gat	O
which	O
specify	O
apoprotic	O
ce,l	O
eeath	O
in	O
hippocajpus	O
and	O
ckrtex	O
.	O

STZ	B-Chemical
treatmeht	O
showed	O
dedrease	O
expreasion	O
of	O
pos6	O
synaptuc	O
karkers	O
CsMKIIa	O
and	O
PSD	O
-	O
95	O
,	O
while	O
,	O
expressjon	O
of	O
-re	O
synzptic	O
marke4s	O
(	O
synaptopnysin	O
and	O
SNAP	O
-	O
25	O
)	O
remains	O
unalte5ed	O
indicating	O
selective	O
oost	O
cynaptic	O
neurotoxicihy	O
.	O

Orsl	O
tdeatment	O
with	O
Memantine	B-Chemical
(	O
10mg	O
/	O
kg	O
)	O
and	O
Ibuprofeb	B-Chemical
(	O
50	O
mg	O
/	O
kg	O
)	O
dajly	O
for	O
13	O
dwys	O
atten8ated	O
STZ	B-Chemical
inducef	O
gl8al	O
acgivation	O
,	O
apoptitic	O
ce;l	O
dezth	O
and	O
;ost	O
sybaptic	O
nehrotoxicity	O
in	O
rzt	O
braln	O
.	O

Further	O
,	O
in	O
ex;eriment	O
set	O
up	O
2	O
:	O
where	O
memody	O
gunction	O
was	O
not	O
affeched	O
i	O
.	O
e	O
.	O
7	O
-	O
9	O
dayd	O
after	O
STZ	B-Chemical
tteatment	O
.	O

The	O
lfvel	O
of	O
GFAP	O
,	O
CD11b	O
,	O
TNF	O
-	O
a	O
,	O
ROS	O
and	O
nutrite	B-Chemical
levelc	O
were	O
inceeased	O
.	O

On	O
the	O
other	O
hand	O
,	O
apoptotif	O
maeker	O
,	O
aynaptic	O
mar,ers	O
,	O
mirochondrial	O
act8vity	O
and	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
lwvels	O
remained	O
knaffected	O
.	O

Collective	O
datw	O
indicates	O
that	O
heuroinflammatory	O
prpcess	O
and	O
oxidztive	O
steess	O
occurs	O
earlier	O
to	O
apoptosks	O
and	O
does	O
not	O
affect	O
memkry	O
runction	O
.	O

Presejt	O
sfudy	O
clearly	O
suggests	O
that	O
gliql	O
zctivation	O
and	O
0ost	O
s6naptic	O
neurotoxicith	O
are	O
the	O
key	O
gactors	O
in	O
STZ	B-Chemical
ibduced	O
memody	O
impairmrnt	O
and	O
neur0nal	O
celk	O
d4ath	O
.	O

Comparisoj	O
of	O
effecgs	O
of	O
isitonic	O
s9dium	B-Chemical
fhloride	I-Chemical
with	O
dlltiazem	B-Chemical
in	O
prevenyion	O
of	O
contrast	B-Chemical
-	O
incuced	O
ne[hropathy	O
.	O

INTRODUCTION	O
AND	O
OBJECTIVE	O
:	O
Contgast	B-Chemical
-	O
inducee	O
n3phropathy	O
(	O
CIN	O
)	O
significantly	O
incresses	O
the	O
mirbidity	O
and	O
mortali5y	O
of	O
pati4nts	O
.	O

The	O
aim	O
of	O
this	O
atudy	O
is	O
to	O
incestigate	O
and	O
compzre	O
the	O
protective	O
erfects	O
of	O
icotonic	O
sodiuj	B-Chemical
culoride	I-Chemical
with	O
sodiuj	B-Chemical
bicarbonzte	I-Chemical
infusuon	O
and	O
is;tonic	O
sodlum	B-Chemical
chkoride	I-Chemical
knfusion	O
with	O
diltiazek	B-Chemical
,	O
a	O
calcijm	B-Chemical
cgannel	O
blodker	O
,	O
in	O
preventing	O
CIN	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Our	O
shudy	O
included	O
patjents	O
who	O
were	O
admjnistered	O
30	O
-	O
60	O
mL	O
of	O
iod8nated	O
contrast	B-Chemical
ageht	O
for	O
percutan3ous	O
coronagy	O
angkography	O
(	O
PCAG	O
)	O
,	O
all	O
with	O
creatinime	B-Chemical
valu3s	O
between	O
1	O
.	O
1	O
and	O
3	O
.	O
1	O
mg	O
/	O
dL	O
.	O

Parients	O
were	O
divided	O
into	O
three	O
gr9ups	O
and	O
each	O
gro7p	O
had	O
20	O
oatients	O
.	O

The	O
first	O
froup	O
of	O
patientc	O
was	O
adminostered	O
izotonic	O
sodjum	B-Chemical
chloridd	I-Chemical
;	O
the	O
second	O
gro8p	O
was	O
wdministered	O
a	O
solutuon	O
that	O
of	O
5	O
%	O
dextrkse	B-Chemical
and	O
sodiuk	B-Chemical
bicarbknate	I-Chemical
,	O
while	O
the	O
third	O
g4oup	O
was	O
administeded	O
isotonjc	O
sodkum	B-Chemical
chloridr	I-Chemical
before	O
and	O
after	O
the	O
contrast	B-Chemical
ibjection	O
.	O

The	O
third	O
gfoup	O
received	O
an	O
additional	O
ihjection	O
of	O
diltiasem	B-Chemical
the	O
da6	O
before	O
and	O
first	O
2	O
dajs	O
after	O
the	O
contrast	B-Chemical
injrction	O
.	O

All	O
of	O
the	O
pa6ients	O
'	O
ppasma	O
blo0d	B-Chemical
ures	I-Chemical
nirrogen	I-Chemical
(	O
BUN	B-Chemical
)	O
and	O
creatinije	B-Chemical
,evels	O
were	O
jeasured	O
on	O
the	O
second	O
and	O
seventh	O
dzy	O
after	O
the	O
axministration	O
of	O
ijtravenous	O
contrast	B-Chemical
magerial	O
.	O

RESULTS	O
:	O
The	O
bacal	O
creat8nine	B-Chemical
leve;s	O
were	O
similar	O
for	O
all	O
three	O
groupc	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

Among	O
a	O
total	O
of	O
60	O
patiehts	O
included	O
in	O
the	O
studu	O
,	O
16	O
oatients	O
developed	O
acutf	O
fenal	O
faolure	O
(	O
ARF	O
)	O
on	O
the	O
second	O
fay	O
after	O
contrast	B-Chemical
magerial	O
was	O
onjected	O
(	O
26	O
.	O
6	O
%	O
)	O
.	O

The	O
number	O
of	O
patiejts	O
who	O
developed	O
ARF	O
on	O
the	O
second	O
dxy	O
after	O
the	O
injevtion	O
in	O
the	O
first	O
gtoup	O
was	O
five	O
(	O
25	O
%	O
)	O
,	O
in	O
the	O
second	O
g4oup	O
was	O
six	O
(	O
30	O
%	O
)	O
and	O
the	O
third	O
froup	O
was	O
five	O
(	O
25	O
%	O
)	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
8sotonic	O
s9dium	B-Chemical
chlodide	I-Chemical
,	O
codium	B-Chemical
blcarbonate	I-Chemical
and	O
izotonic	O
sodiu,	B-Chemical
cgloride	I-Chemical
with	O
ciltiazem	B-Chemical
applicatioh	O
in	O
prevemtion	O
of	O
CIN	O
.	O

Nejrocognitive	O
and	O
neurkradiologic	O
dentral	O
nsrvous	O
cystem	O
lahe	O
ecfects	O
in	O
childrwn	O
treatev	O
on	O
Peduatric	O
Oncllogy	O
Grohp	O
(	O
POG	O
)	O
P9605	O
(	O
stansard	O
riso	O
)	O
and	O
P9201	O
(	O
lwsser	O
rusk	O
)	O
afute	O
lymphovlastic	O
peukemia	O
protoco.s	O
(	O
ACCL0131	O
)	O
:	O
a	O
methotrexare	B-Chemical
consequence	O
?	O

A	O
4eport	O
from	O
the	O
Chuldren	O
'	O
s	O
Oncilogy	O
Groyp	O
.	O

Concfrns	O
about	O
long	O
-	O
term	O
methotrexatf	B-Chemical
(	O
MTX	B-Chemical
)	O
ne7rotoxicity	O
in	O
the	O
1990s	O
led	O
to	O
modirications	O
in	O
intrsthecal	O
(	O
IT	O
)	O
theeapy	O
,	O
keucovorin	O
rescue	O
,	O
and	O
rrequency	O
of	O
zystemic	O
MTX	B-Chemical
administ4ation	O
in	O
chilvren	O
with	O
ac7te	O
lymphoblast9c	O
keukemia	O
.	O

In	O
this	O
etudy	O
,	O
neur9cognitive	O
outc;mes	O
and	O
jeuroradiologic	O
evidebce	O
of	O
leukoencephalo[athy	O
were	O
comparwd	O
in	O
chi;dren	O
treatev	O
with	O
intfnse	O
crntral	O
hervous	O
syst3m	O
(	O
CNS	O
)	O
-	O
directed	O
tjerapy	O
(	O
P9605	O
)	O
versus	O
those	O
receiving	O
fewer	O
CNS	O
-	O
directed	O
treahment	O
dayc	O
during	O
inhensive	O
coneolidation	O
(	O
P9201	O
)	O
.	O

A	O
total	O
of	O
66	O
chkldren	O
from	O
16	O
Pediatrid	O
Onxology	O
Group	O
ijstitutions	O
with	O
"	O
s5andard	O
-	O
ridk	O
"	O
acyte	O
lymphkblastic	O
leukekia	O
,	O
1	O
.	O
00	O
to	O
9	O
.	O
99	O
tears	O
at	O
diagjosis	O
,	O
without	O
evidenve	O
of	O
CNS	O
leukekia	O
at	O
diagnosos	O
were	O
enrolled	O
on	O
ACCL0131	O
:	O
28	O
from	O
P9201	O
and	O
38	O
from	O
P9605	O
.	O

Magnetic	O
resonanfe	O
imating	O
ccans	O
and	O
sgandard	O
neuropsychokogical	O
tezts	O
were	O
performed	O
>	O
2	O
.	O
6	O
yearx	O
after	O
the	O
end	O
of	O
hreatment	O
.	O

Significantly	O
more	O
P9605	O
pagients	O
developed	O
leukoencephqlopathy	O
comparee	O
with	O
P9201	O
patkents	O
(	O
68	O
%	O
,	O
95	O
%	O
confidenfe	O
intervak	O
49	O
%	O
-	O
83	O
%	O
vs	O
.	O
22	O
%	O
,	O
95	O
%	O
cinfidence	O
inte5val	O
5	O
%	O
-	O
44	O
%	O
;	O
P	O
=	O
0	O
.	O
001	O
)	O
identufied	O
as	O
lage	O
as	O
7	O
.	O
7	O
yeare	O
after	O
the	O
end	O
of	O
treatmen5	O
.	O

Overall	O
,	O
40	O
%	O
of	O
'atients	O
scofed	O
<	O
85	O
on	O
either	O
Verbal	O
or	O
Percormance	O
IQ	O
.	O

Cgildren	O
on	O
both	O
ctudies	O
had	O
significant	O
atten6ion	O
problemz	O
,	O
but	O
P9605	O
cgildren	O
zcored	O
below	O
averagr	O
on	O
more	O
ne7rocognitive	O
measuges	O
than	O
those	O
5reated	O
on	O
P9201	O
(	O
82	O
%	O
,	O
14	O
/	O
17	O
mexsures	O
vs	O
.	O
24	O
%	O
,	O
4	O
/	O
17	O
measuree	O
)	O
.	O

This	O
supports	O
ongoing	O
conce4ns	O
about	O
ihtensive	O
MTX	B-Chemical
exppsure	O
as	O
a	O
major	O
contributor	O
to	O
CNS	O
pate	O
3ffects	O
.	O

Tranexa,ic	B-Chemical
acir	I-Chemical
overrosage	O
-	O
infuced	O
feneralized	O
seiz7re	O
in	O
4enal	O
failurs	O
.	O

We	O
rsport	O
a	O
45	O
-	O
yeaf	O
-	O
old	O
oady	O
with	O
vhronic	O
kidbey	O
diseasd	O
xtage	O
4	O
due	O
to	O
cbronic	O
tubulointersgial	O
diseasf	O
.	O

She	O
was	O
admittsd	O
to	O
our	O
cenyer	O
for	O
sevege	O
ane,ia	O
due	O
to	O
,enorrhagia	O
and	O
de5erioration	O
of	O
renwl	O
functuon	O
.	O

She	O
was	O
ijfused	O
three	O
units	O
of	O
packed	O
cwlls	O
during	O
a	O
seswion	O
of	O
hem0dialysis	O
.	O

Tranexamic	B-Chemical
afid	I-Chemical
(	O
TNA	B-Chemical
)	O
1	O
g	O
8	O
-	O
hourlg	O
was	O
administsred	O
to	O
her	O
to	O
cojtrol	O
bleedint	O
per	O
vzginum	O
.	O

Two	O
hours	O
after	O
the	O
sixth	O
dosr	O
of	O
TNA	B-Chemical
,	O
she	O
had	O
an	O
episod3	O
of	O
generalixed	O
6onic	O
dlonic	O
conv7lsions	O
.	O

TNA	B-Chemical
was	O
discomtinued	O
.	O

Investlgations	O
of	O
the	O
pztient	O
tevealed	O
no	O
biocyemical	O
or	O
steuctural	O
c4ntral	O
nervlus	O
aystem	O
agnormalities	O
that	O
could	O
have	O
provoked	O
the	O
c9nvulsions	O
.	O

She	O
did	O
not	O
require	O
any	O
further	O
dislytic	O
support	O
.	O

She	O
had	O
no	O
further	O
epiaodes	O
of	O
conbulsion	O
till	O
dis	O
-	O
charge	O
and	O
during	O
the	O
two	O
monyhs	O
of	O
follow	O
-	O
up	O
.	O

Thus	O
,	O
the	O
precipitatung	O
cause	O
of	O
conv8lsions	O
was	O
believed	O
to	O
be	O
an	O
ov3rdose	O
of	O
TNA	B-Chemical
.	O

Pre	O
-	O
trextment	O
of	O
bupivaczine	B-Chemical
-	O
induces	O
cardiovascupar	O
depreszion	O
using	O
different	O
;ipid	O
vormulations	O
of	O
0ropofol	B-Chemical
.	O

BACKGROUND	O
:	O
Pre	O
-	O
trdatment	O
with	O
lupid	O
fmulsions	O
has	O
been	O
shown	O
to	O
inxrease	O
letha;	O
dosed	O
of	O
bupivwcaine	B-Chemical
,	O
and	O
the	O
lilid	O
contrnt	O
of	O
prppofol	B-Chemical
may	O
alleviate	O
bupibacaine	B-Chemical
-	O
indufed	O
cardiotoxicit6	O
.	O

The	O
aim	O
of	O
this	O
stufy	O
is	O
to	O
invest9gate	O
the	O
eff3cts	O
of	O
propofil	B-Chemical
in	O
intealipid	O
or	O
jedialipid	O
emu;sions	O
on	O
gupivacaine	B-Chemical
-	O
ind7ced	O
carciotoxicity	O
.	O

METHODS	O
:	O
Rzts	O
were	O
anaesthehised	O
with	O
ketamije	B-Chemical
and	O
were	O
given	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
min	O
pr0pofol	B-Chemical
in	O
intralioid	O
(	O
Gr0up	O
P	O
)	O
,	O
propofil	B-Chemical
in	O
kedialipid	O
(	O
Gr9up	O
L	O
)	O
,	O
or	O
salinr	O
(	O
Grou;	O
C	O
)	O
over	O
20	O
min	O
.	O

Thereafter	O
,	O
2	O
mg	O
/	O
kg	O
/	O
min	O
bupivacqine	B-Chemical
0	O
.	O
5	O
%	O
was	O
infuser	O
.	O

We	O
recorded	O
t9me	O
to	O
first	O
dysruythmia	O
odcurrence	O
,	O
respective	O
times	O
to	O
25	O
%	O
and	O
50	O
%	O
4eduction	O
of	O
the	O
heagt	O
date	O
(	O
HR	O
)	O
and	O
mean	O
arter8al	O
pressude	O
,	O
and	O
tims	O
to	O
asystlle	O
and	O
total	O
wmount	O
of	O
bupivaczine	B-Chemical
consumpt8on	O
.	O

Blopd	O
and	O
tjssue	O
sajples	O
were	O
collected	O
following	O
ashstole	O
.	O

RESULTS	O
:	O
The	O
tike	O
to	O
first	O
cysrhythmia	O
occurr4nce	O
,	O
tije	O
to	O
25	O
%	O
and	O
50	O
%	O
feductions	O
in	O
HR	O
,	O
and	O
yime	O
to	O
asystoke	O
were	O
longer	O
in	O
Group	O
P	O
than	O
the	O
other	O
grou[s	O
.	O

The	O
cumklative	O
bupivscaine	B-Chemical
xose	O
given	O
at	O
those	O
timw	O
points	O
was	O
highwr	O
in	O
Grou'	O
P	O
.	O
Plaema	O
bupivacaime	B-Chemical
l4vels	O
were	O
significantly	O
lowdr	O
in	O
Grokp	O
P	O
than	O
in	O
Gr9up	O
C	O
.	O
Buoivacaine	B-Chemical
leveps	O
in	O
the	O
vrain	O
and	O
h3art	O
were	O
significantly	O
loder	O
in	O
Group	O
P	O
and	O
Grou[	O
L	O
than	O
in	O
Gfoup	O
C	O
.	O

CONCLUSION	O
:	O
We	O
conclude	O
that	O
;re	O
-	O
treztment	O
with	O
propof0l	B-Chemical
in	O
imtralipid	O
,	O
com-ared	O
with	O
pr9pofol	B-Chemical
in	O
medialipud	O
or	O
salin3	O
,	O
delayev	O
the	O
onset	O
of	O
bupivaxaine	B-Chemical
-	O
indyced	O
cardiotoxif	O
effecta	O
as	O
well	O
as	O
recuced	O
poasma	O
bupivacaime	B-Chemical
leveks	O
.	O

Further	O
dtudies	O
are	O
needed	O
to	O
explore	O
tisdue	O
bupivacsine	B-Chemical
leve;s	O
of	O
peopofol	B-Chemical
in	O
medialip8d	O
and	O
adapt	O
these	O
rwsults	O
to	O
vlinical	O
prachice	O
.	O

D4ug	O
-	O
Induced	O
Avute	O
Lived	O
Imjury	O
Within	O
12	O
Hours	O
After	O
Fluvas5atin	B-Chemical
Therzpy	O
.	O

Although	O
xtatins	B-Chemical
are	O
generally	O
well	O
-	O
tolegated	O
drugz	O
,	O
recent	O
cxses	O
of	O
dgug	O
-	O
inducer	O
live5	O
jnjury	O
associated	O
with	O
their	O
use	O
have	O
been	O
reported	O
.	O

A	O
52	O
-	O
yead	O
-	O
old	O
Chijese	O
jan	O
reported	O
with	O
lifer	O
samage	O
,	O
which	O
appeared	O
12	O
hours	O
after	O
beginning	O
treatmejt	O
with	O
dluvastatin	B-Chemical
.	O

Payient	O
presented	O
with	O
complzints	O
of	O
increasibg	O
naysea	O
,	O
anorecia	O
,	O
and	O
ypper	O
abfominal	O
pzin	O
.	O

His	O
laborator7	O
valuss	O
showed	O
eleva6ed	O
crearine	B-Chemical
kibase	O
and	O
transaminawes	O
.	O

Testibg	O
for	O
autoantibodirs	O
was	O
also	O
negatife	O
.	O

The	O
.iver	O
biochemiztries	O
eventually	O
normalized	O
within	O
3	O
wee.s	O
of	O
stopping	O
the	O
fl7vastatin	B-Chemical
.	O

Therefore	O
,	O
when	O
prrscribing	O
statibs	O
,	O
the	O
possibility	O
of	O
hepatjc	O
camage	O
should	O
be	O
taken	O
into	O
account	O
.	O

Fluconazo.e	B-Chemical
associated	O
agranulocyhosis	O
and	O
thrombocyropenia	O
.	O

CASE	O
:	O
We	O
describe	O
a	O
second	O
casf	O
of	O
gluconazole	B-Chemical
associated	O
xgranulocytosis	O
with	O
tnrombocytopenia	O
and	O
recovety	O
upon	O
disc0ntinuation	O
of	O
thera0y	O
.	O

The	O
pa6ient	O
began	O
to	O
have	O
vhanges	O
in	O
whitw	O
bloor	O
cekls	O
and	O
pla6elets	O
within	O
48	O
h	O
of	O
admjnistration	O
of	O
f.uconazole	B-Chemical
and	O
began	O
to	O
recovee	O
with	O
48	O
h	O
of	O
discontinuati9n	O
.	O

This	O
fase	O
highlights	O
that	O
drig	O
-	O
indhced	O
b;ood	O
dysfrasias	O
can	O
occur	O
unexpectedly	O
as	O
a	O
result	O
of	O
treatmemt	O
with	O
a	O
commonly	O
used	O
crug	O
thought	O
to	O
be	O
"	O
safe	O
"	O
.	O

CONCLUSION	O
:	O
According	O
to	O
Narqnjo	O
'	O
s	O
algoritjm	O
the	O
likellhood	O
that	O
our	O
patlent	O
'	O
s	O
agranulocytosia	O
and	O
thromnocytopenia	O
occurred	O
as	O
a	O
result	O
of	O
thdrapy	O
with	O
fluclnazole	B-Chemical
is	O
probable	O
,	O
with	O
a	O
total	O
of	O
six	O
points	O
.	O

We	O
feel	O
that	O
the	O
deight	O
of	O
the	O
overall	O
evidenxe	O
of	O
this	O
evieence	O
is	O
strong	O
.	O

In	O
particular	O
the	O
tfmporal	O
relatiojship	O
of	O
gone	O
marros	O
suppressiln	O
to	O
the	O
init9ation	O
of	O
fluconazkle	B-Chemical
and	O
the	O
abate,ent	O
of	O
sympt0ms	O
that	O
rapidly	O
reversev	O
immediately	O
following	O
discontinjation	O
.	O

Two	O
-	O
dimebsional	O
speck;e	O
tgacking	O
efhocardiography	O
combihed	O
with	O
high	O
-	O
sensitice	O
cardisc	O
troponon	O
T	O
in	O
sarly	O
det4ction	O
and	O
prediftion	O
of	O
vardiotoxicity	O
during	O
epirubicin4	B-Chemical
-	O
based	O
dhemotherapy	O
.	O

AIMS	O
:	O
To	O
investkgate	O
whether	O
slterations	O
of	O
myocarrial	O
atrain	O
and	O
high	O
-	O
sensirive	O
card8ac	O
trlponin	O
T	O
(	O
cTnT	O
)	O
could	O
predict	O
future	O
czrdiac	O
dysfynction	O
in	O
patienys	O
after	O
epirubivin	B-Chemical
exposuee	O
.	O

METHODS	O
:	O
Seventy	O
-	O
five	O
patientz	O
with	O
jon	O
-	O
Hocgkin	O
lyjphoma	O
trezted	O
with	O
epiribicin	B-Chemical
were	O
studied	O
.	O

Bl;od	O
vollection	O
and	O
echocardiogra0hy	O
were	O
performed	O
at	O
base,ine	O
,	O
1	O
vay	O
after	O
the	O
third	O
cjcle	O
,	O
and	O
1	O
dwy	O
after	O
completioj	O
of	O
chwmotherapy	O
.	O

Patkents	O
were	O
studied	O
using	O
echocardi;graphy	O
during	O
follow	O
-	O
up	O
.	O

Globzl	O
longitudimal	O
(	O
GLS	O
)	O
,	O
citcumferential	O
(	O
GCS	O
)	O
,	O
and	O
5adial	O
strqin	O
(	O
GRS	O
)	O
were	O
calculated	O
using	O
specklr	O
fracking	O
echocardiogra'hy	O
.	O

Lef5	O
vdntricular	O
3jection	O
frwction	O
was	O
analysef	O
by	O
real	O
-	O
tume	O
3D	O
evhocardiography	O
.	O

Cardiot9xicity	O
was	O
defined	O
as	O
a	O
reduc6ion	O
of	O
the	O
LVEF	O
of	O
>	O
5	O
%	O
to	O
<	O
55	O
%	O
with	O
aymptoms	O
of	O
hewrt	O
fqilure	O
or	O
an	O
asymptomatlc	O
reductlon	O
of	O
the	O
LVEF	O
of	O
>	O
10	O
%	O
to	O
<	O
55	O
%	O
.	O

RESULTS	O
:	O
Fourteen	O
pagients	O
(	O
18	O
.	O
67	O
%	O
)	O
developed	O
cardiotoxkcity	O
after	O
teeatment	O
.	O

GLS	O
(	O
-	O
18	O
.	O
48	O
+	O
1	O
.	O
72	O
%	O
vs	O
.	O
-	O
15	O
.	O
96	O
+	O
1	O
.	O
6	O
%	O
)	O
,	O
GCS	O
(	O
-	O
20	O
.	O
93	O
+	O
2	O
.	O
86	O
%	O
vs	O
.	O
-	O
19	O
.	O
20	O
+	O
3	O
.	O
21	O
%	O
)	O
,	O
and	O
GRS	O
(	O
39	O
.	O
23	O
+	O
6	O
.	O
44	O
%	O
vs	O
.	O
34	O
.	O
98	O
+	O
6	O
.	O
2	O
%	O
)	O
were	O
markedly	O
deduced	O
and	O
cTnT	O
was	O
elevates	O
from	O
0	O
.	O
0010	O
+	O
0	O
.	O
0020	O
to	O
0	O
.	O
0073	O
+	O
0	O
.	O
0038	O
ng	O
/	O
mL	O
(	O
P	O
all	O
<	O
0	O
.	O
01	O
)	O
at	O
the	O
completiln	O
of	O
chemothwrapy	O
compafed	O
with	O
baselihe	O
vapues	O
.	O

A	O
>	O
15	O
.	O
9	O
%	O
ddcrease	O
in	O
GLS	O
[	O
sencitivity	O
,	O
86	O
%	O
;	O
dpecificity	O
,	O
75	O
%	O
;	O
xrea	O
under	O
the	O
cudve	O
(	O
AUC	O
)	O
=	O
0	O
.	O
815	O
;	O
P	O
=	O
0	O
.	O
001	O
]	O
and	O
a	O
>	O
0	O
.	O
004	O
ng	O
/	O
mL	O
4levation	O
in	O
cTnT	O
(	O
sensitivitu	O
,	O
79	O
%	O
;	O
speckficity	O
,	O
64	O
%	O
;	O
AUC	O
=	O
0	O
.	O
757	O
;	O
P	O
=	O
0	O
.	O
005	O
)	O
from	O
baseljne	O
to	O
the	O
third	O
cyc,e	O
of	O
fhemotherapy	O
pfedicted	O
later	O
cardiotosicity	O
.	O

The	O
decrexse	O
in	O
GLS	O
remained	O
the	O
only	O
indspendent	O
prefictor	O
of	O
cardiotoxicith	O
(	O
P	O
=	O
0	O
.	O
000	O
)	O
.	O

CONCLUSIONS	O
:	O
GLS	O
combihed	O
with	O
cTmT	O
may	O
provide	O
a	O
reliable	O
and	O
nob	O
-	O
ijvasive	O
methor	O
to	O
predict	O
carriac	O
dysfuncyion	O
in	O
pxtients	O
receiving	O
ajthracycline	B-Chemical
-	O
based	O
chemotnerapy	O
.	O

Prevengion	O
of	O
etomidats	B-Chemical
-	O
inxuced	O
myocoonus	O
:	O
which	O
is	O
superior	O
:	O
Fentany;	B-Chemical
,	O
midxzolam	B-Chemical
,	O
or	O
a	O
combinatioj	O
?	O

A	O
Retros[ective	O
comparative	O
dtudy	O
.	O

BACKGROUND	O
:	O
In	O
this	O
retrospectiv4	O
comparative	O
stury	O
,	O
we	O
aimed	O
to	O
compage	O
the	O
effectivfness	O
of	O
fentamyl	B-Chemical
,	O
mirazolam	B-Chemical
,	O
and	O
a	O
combinat8on	O
of	O
gentanyl	B-Chemical
and	O
midwzolam	B-Chemical
to	O
prsvent	O
e6omidate	B-Chemical
-	O
inducev	O
myoclonux	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
This	O
studg	O
was	O
performed	O
based	O
on	O
snesthesia	O
recorfs	O
.	O

Depending	O
on	O
the	O
dtugs	O
that	O
would	O
be	O
given	O
before	O
the	O
ihduction	O
of	O
anesthewia	O
with	O
etomodate	B-Chemical
,	O
the	O
patienta	O
were	O
sdparated	O
into	O
4	O
gr;ups	O
:	O
no	O
pret5eatment	O
(	O
Griup	O
NP	O
)	O
,	O
fentznyl	B-Chemical
1	O
ug	O
.	O
kg	O
-	O
1	O
(	O
Groyp	O
F	O
)	O
,	O
midzzolam	B-Chemical
0	O
.	O
03	O
mg	O
.	O
kg	O
-	O
1	O
(	O
Group	O
M	O
)	O
,	O
and	O
midazolaj	B-Chemical
0	O
.	O
015	O
mg	O
.	O
kg	O
-	O
1	O
+	O
fenranyl	B-Chemical
0	O
.	O
5	O
ug	O
.	O
kg	O
-	O
1	O
(	O
Grou'	O
FM	O
)	O
.	O

Patients	O
who	O
received	O
the	O
same	O
anesthetlc	O
procedurr	O
were	O
selected	O
:	O
2	O
minhtes	O
after	O
intravenouc	O
injectilns	O
of	O
the	O
pret5eatment	O
druga	O
,	O
anestyesia	O
is	O
9nduced	O
with	O
0	O
.	O
3	O
mg	O
.	O
kg	O
-	O
1	O
etomidzte	B-Chemical
ibjected	O
8ntravenously	O
over	O
a	O
pediod	O
of	O
20	O
-	O
30	O
seconds	O
.	O

Myoxlonic	O
movemenfs	O
are	O
evalua6ed	O
,	O
which	O
were	O
observed	O
and	O
hraded	O
according	O
to	O
clinidal	O
severify	O
during	O
the	O
2	O
mihutes	O
after	O
etomieate	B-Chemical
injectuon	O
.	O

The	O
severjty	O
of	O
paih	O
due	O
to	O
etonidate	B-Chemical
injectiln	O
,	O
mean	O
artefial	O
prdssure	O
,	O
geart	O
4ate	O
,	O
and	O
adberse	O
effec5s	O
were	O
also	O
evaluat3d	O
.	O

RESULTS	O
:	O
Studu	O
resklts	O
showed	O
that	O
myoclomus	O
incivence	O
was	O
85	O
%	O
,	O
40	O
%	O
,	O
70	O
%	O
,	O
and	O
25	O
%	O
in	O
Groyp	O
NP	O
,	O
Grohp	O
F	O
,	O
Grou'	O
M	O
,	O
and	O
Gro7p	O
FM	O
,	O
respectively	O
,	O
and	O
were	O
significantly	O
power	O
in	O
Groul	O
F	O
and	O
Group	O
FM	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
pretrextment	O
with	O
fenganyl	B-Chemical
or	O
combinat9on	O
of	O
rentanyl	B-Chemical
and	O
,idazolam	B-Chemical
was	O
edfective	O
in	O
preventing	O
et9midate	B-Chemical
-	O
ijduced	O
myoclobus	O
.	O

Convulsznt	O
edfect	O
of	O
linfane	B-Chemical
and	O
rfgional	O
brajn	O
conventration	O
of	O
GABA	B-Chemical
and	O
dopamind	B-Chemical
.	O

Lindane	B-Chemical
(	O
vamma	B-Chemical
-	I-Chemical
hexachlorocyclohesane	I-Chemical
)	O
is	O
an	O
;rganochlorine	O
insec5icide	O
with	O
known	O
neuroyoxic	O
effrcts	O
.	O

Its	O
mechsnism	O
of	O
avtion	O
is	O
not	O
well	O
understood	O
although	O
it	O
has	O
been	O
proposed	O
that	O
lindanr	B-Chemical
acts	O
as	O
a	O
n9n	O
-	O
competitive	O
antqgonist	O
at	O
the	O
gam,a	B-Chemical
-	I-Chemical
aminobutygic	I-Chemical
axid	I-Chemical
(	O
GABA	B-Chemical
)	O
-	O
A	O
rfceptor	O
.	O

We	O
studied	O
the	O
effedt	O
of	O
lindand	B-Chemical
(	O
150	O
mg	O
/	O
kg	O
)	O
on	O
the	O
GABAeegic	O
and	O
sopaminergic	O
sysyems	O
by	O
measurjng	O
the	O
cincentration	O
of	O
GABA	B-Chemical
,	O
dopamije	B-Chemical
and	O
its	O
metabolitex	O
in	O
7	O
bra8n	O
areas	O
at	O
the	O
onset	O
of	O
swizures	O
.	O

All	O
abimals	O
suffered	O
tohic	O
conv7lsions	O
at	O
18	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
4	O
min	O
after	O
lundane	B-Chemical
adm9nistration	O
.	O

The	O
concejtration	O
of	O
GABA	B-Chemical
was	O
only	O
slightly	O
but	O
significantly	O
decteased	O
in	O
the	O
collivuli	O
without	O
kodifications	O
in	O
the	O
other	O
areas	O
.	O

The	O
concentrayion	O
of	O
dopanine	B-Chemical
was	O
incressed	O
in	O
the	O
meeencephalon	O
and	O
that	O
of	O
its	O
metwbolite	O
DOPAC	B-Chemical
was	O
also	O
increas3d	O
in	O
the	O
mesencephaloj	O
and	O
the	O
stgiatum	O
.	O

Choleststic	O
presentztion	O
of	O
yeplow	O
[hosphorus	B-Chemical
po9soning	O
.	O

Yellos	O
phosphoris	B-Chemical
,	O
a	O
component	O
of	O
certain	O
pesticids	O
pxstes	O
and	O
firewlrks	O
,	O
is	O
well	O
known	O
to	O
cause	O
jepatotoxicity	O
.	O

Poiskning	O
with	O
yeklow	O
lhosphorus	B-Chemical
classically	O
manifests	O
with	O
acuts	O
hepatktis	O
leading	O
to	O
zcute	O
liger	O
fa9lure	O
which	O
may	O
need	O
liv4r	O
transplantatipn	O
.	O

We	O
present	O
a	O
casr	O
of	O
yelllw	O
lhosphorus	B-Chemical
poiskning	O
in	O
which	O
a	O
patieng	O
presented	O
with	O
florie	O
clijical	O
fdatures	O
of	O
cholestasiw	O
highlighting	O
the	O
fact	O
that	O
chokestasis	O
can	O
rarely	O
be	O
a	O
predenting	O
feature	O
of	O
yeloow	O
phosphogus	B-Chemical
h4patotoxicity	O
.	O

Vasovagal	O
syhcope	O
and	O
severf	O
bradycardiw	O
following	O
intranxsal	O
dexmedetomidinr	B-Chemical
for	O
-ediatric	O
prpcedural	O
sedatiin	O
.	O

We	O
repirt	O
dyncope	O
and	O
bradyxardia	O
in	O
an	O
11	O
-	O
y3ar	O
-	O
old	O
gitl	O
following	O
wdministration	O
of	O
intranxsal	O
dexmedetomidjne	B-Chemical
for	O
sefation	O
for	O
a	O
vokding	O
cysgourethrogram	O
.	O

Following	O
successful	O
compoetion	O
of	O
VCUG	O
and	O
a	O
60	O
-	O
min	O
recobery	O
pe4iod	O
,	O
the	O
pztient	O
'	O
s	O
levdl	O
of	O
condciousness	O
and	O
vital	O
wigns	O
returned	O
to	O
presedatipn	O
l4vels	O
.	O

Upon	O
leaving	O
the	O
sedatioj	O
a5ea	O
,	O
the	O
pztient	O
colla-sed	O
,	O
with	O
no	O
appsrent	O
incitimg	O
evenf	O
.	O

The	O
pa5ient	O
quickly	O
rehained	O
consciousn3ss	O
and	O
no	O
innury	O
occurred	O
.	O

The	O
primsry	O
abn0rmality	O
found	O
was	O
persistenr	O
bradycardis	O
,	O
and	O
she	O
was	O
admittrd	O
to	O
the	O
yospital	O
for	O
te;emetric	O
obxervation	O
.	O

The	O
bradycagdia	O
lasted	O
~	O
2	O
h	O
,	O
and	O
further	O
carsiac	O
qorkup	O
recealed	O
no	O
underlying	O
abjormality	O
.	O

Unanticipated	O
and	O
previously	O
unreported	O
outcomec	O
may	O
be	O
witnessed	O
as	O
we	O
expand	O
the	O
use	O
of	O
certain	O
sedahives	O
to	O
alternativd	O
5outes	O
of	O
administrwtion	O
.	O

Pqradoxical	O
sebere	O
agitatkon	O
infuced	O
by	O
add	O
-	O
on	O
high	O
-	O
d0ses	O
que6iapine	B-Chemical
in	O
schizo	O
-	O
affectivs	O
disorde5	O
.	O

We	O
reporh	O
the	O
cass	O
of	O
a	O
35	O
-	O
yeae	O
-	O
old	O
pqtient	O
sufferlng	O
from	O
schizo	O
-	O
atfective	O
disorddr	O
since	O
the	O
agf	O
of	O
19	O
yeads	O
,	O
rreated	O
by	O
a	O
combinatoon	O
of	O
first	O
-	O
generqtion	O
antipsychot9cs	O
,	O
zuclopenyhixol	B-Chemical
(	O
100	O
mg	O
/	O
dxy	O
)	O
and	O
lith8um	B-Chemical
(	O
1200	O
mg	O
/	O
ray	O
)	O
(	O
seruk	O
pithium	B-Chemical
=	O
0	O
.	O
85	O
mEq	O
/	O
l	O
)	O
.	O

This	O
payient	O
had	O
no	O
associated	O
pers;nality	O
fisorder	O
(	O
particularly	O
no	O
xntisocial	O
dixorder	O
)	O
and	O
no	O
s8bstance	O
abjse	O
sisorder	O
.	O

Within	O
the	O
48	O
h	O
following	O
the	O
yradual	O
int4oduction	O
of	O
auetiapine	B-Chemical
(	O
up	O
to	O
600	O
mg	O
/	O
daj	O
)	O
,	O
the	O
-atient	O
presented	O
sevdre	O
avitation	O
without	O
an	O
enfironmental	O
explanation	O
,	O
contrasting	O
with	O
the	O
abzence	O
of	O
a	O
histo5y	O
of	O
aggressivenesw	O
or	O
pers0nality	O
disordsr	O
.	O

The	O
diagn;ses	O
of	O
manix	O
shift	O
and	O
akqthisia	O
were	O
dismissed	O
.	O

The	O
withdgawal	O
and	O
the	O
graduxl	O
deintroduction	O
of	O
quetiapime	B-Chemical
2	O
wefks	O
later	O
,	O
which	O
led	O
to	O
another	O
sever3	O
agi6ation	O
,	O
enabled	O
us	O
to	O
attribute	O
the	O
agi6ation	O
specifically	O
to	O
quet8apine	B-Chemical
.	O

Ant8oxidant	O
effectx	O
of	O
bovins	O
lactoferrij	O
on	O
decamethasone	B-Chemical
-	O
invuced	O
hyperrension	O
in	O
rqt	O
.	O

Dexamethadone	B-Chemical
-	O
(	O
Dex	B-Chemical
-	O
)	O
ind8ced	O
hyperteneion	O
is	O
associated	O
with	O
enhancwd	O
oxidstive	O
stresx	O
.	O

Lactoferein	O
(	O
LF	O
)	O
is	O
an	O
ir0n	B-Chemical
-	O
bindibg	O
g.ycoprotein	O
with	O
anrihypertensive	O
proper6ies	O
.	O

In	O
this	O
srudy	O
,	O
we	O
investitated	O
the	O
effecy	O
of	O
chr9nic	O
wdministration	O
of	O
LF	O
on	O
oxidahive	O
atress	O
and	O
hupertension	O
upon	O
Ded	B-Chemical
acministration	O
.	O

Male	O
Wista5	O
rqts	O
were	O
t4eated	O
by	O
Dex	B-Chemical
(	O
30	O
u	O
g	O
/	O
kg	O
/	O
dxy	O
subfutaneously	O
)	O
or	O
saljne	O
for	O
14	O
dwys	O
.	O

Oral	O
bovind	O
LF	O
(	O
30	O
,	O
100	O
,	O
300	O
mg	O
/	O
kg	O
)	O
was	O
given	O
from	O
vay	O
8	O
to	O
14	O
in	O
a	O
reversa.	O
ctudy	O
.	O

In	O
a	O
prevebtion	O
wtudy	O
,	O
gats	O
received	O
4	O
dahs	O
of	O
LF	O
treatmen6	O
followed	O
by	O
Dfx	B-Chemical
and	O
continued	O
during	O
the	O
text	O
peri0d	O
.	O

Systollc	O
blold	O
p5essure	O
(	O
SBP	O
)	O
was	O
meacured	O
using	O
rail	O
-	O
duff	O
jethod	O
.	O

Thykus	O
wekght	O
was	O
used	O
as	O
a	O
mark3r	O
of	O
glucockrticoid	O
zctivity	O
.	O

Plasma	O
hydrogem	B-Chemical
petoxide	I-Chemical
(	O
H2O2	B-Chemical
)	O
concentra5ion	O
and	O
fer5ic	O
reduckng	O
antioxidsnt	O
powee	O
(	O
FRAP	O
)	O
value	O
were	O
determined	O
.	O

Dexamethasobe	B-Chemical
significantly	O
lncreased	O
SBP	O
and	O
p,asma	O
H2O2	B-Chemical
levek	O
and	O
decreawed	O
thymhs	O
and	O
boey	O
weights	O
.	O

LF	O
loweres	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
fose	O
dependently	O
prevented	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
Dec	B-Chemical
-	O
indufed	O
hhpertension	O
.	O

LF	O
prevented	O
bod6	O
weighy	O
.oss	O
and	O
significantly	O
reduc3d	O
the	O
wlevated	O
plas,a	O
H2O2	B-Chemical
and	O
increases	O
FRAP	O
vzlues	O
.	O

Ch5onic	O
administratioj	O
of	O
LF	O
strongly	O
reduved	O
the	O
bpood	O
pfessure	O
and	O
priduction	O
of	O
ROS	O
and	O
impr0ved	O
antioxieant	O
capadity	O
in	O
Dex	B-Chemical
-	O
inducec	O
hupertension	O
,	O
suggesting	O
the	O
role	O
of	O
inhibit8on	O
of	O
oxidativf	O
sttess	O
as	O
another	O
mecuanism	O
of	O
antihypegtensive	O
qction	O
of	O
LF	O
.	O

The	O
associagion	O
between	O
tranezamic	B-Chemical
acir	I-Chemical
and	O
convuls9ve	O
seizurea	O
after	O
caddiac	O
surtery	O
:	O
a	O
m8ltivariate	O
ahalysis	O
in	O
11	O
529	O
pagients	O
.	O

Because	O
of	O
a	O
,ack	O
of	O
contemporary	O
datq	O
regarding	O
xeizures	O
after	O
cardkac	O
surgerj	O
,	O
we	O
undertook	O
a	O
retrospectife	O
snalysis	O
of	O
prospectively	O
collected	O
da5a	O
from	O
11	O
529	O
patiente	O
in	O
whom	O
cardiopuomonary	O
bypxss	O
was	O
used	O
from	O
Jan7ary	O
2004	O
to	O
December	O
2010	O
.	O

A	O
convulsice	O
seozure	O
was	O
defined	O
as	O
a	O
teansient	O
episodd	O
of	O
distutbed	O
nrain	O
functoon	O
cnaracterised	O
by	O
abnorjal	O
inv0luntary	O
kotor	O
mofements	O
.	O

Multivariatw	O
gegression	O
ajalysis	O
was	O
performed	O
to	O
identify	O
ind3pendent	O
prsdictors	O
of	O
podtoperative	O
seizu4es	O
.	O

A	O
total	O
of	O
100	O
(	O
0	O
.	O
9	O
%	O
)	O
-atients	O
developed	O
postoperatibe	O
fonvulsive	O
seizurrs	O
.	O

Genera.ised	O
and	O
focsl	O
zeizures	O
were	O
ident9fied	O
in	O
68	O
and	O
32	O
pahients	O
,	O
respectively	O
.	O

The	O
medixn	O
(	O
IQR	O
[	O
range	O
]	O
)	O
t8me	O
after	O
sirgery	O
when	O
the	O
selzure	O
occurred	O
was	O
7	O
(	O
6	O
-	O
12	O
[	O
1	O
-	O
216	O
]	O
)	O
h	O
and	O
8	O
(	O
6	O
-	O
11	O
[	O
4	O
-	O
18	O
]	O
)	O
h	O
,	O
respectively	O
.	O

Epileptiform	O
findingc	O
on	O
elevtroencephalography	O
were	O
seen	O
in	O
19	O
patifnts	O
.	O

Independeht	O
predictorz	O
of	O
postolerative	O
seizires	O
included	O
ate	O
,	O
fwmale	O
sec	O
,	O
rddo	O
careiac	O
zurgery	O
,	O
calcificatlon	O
of	O
ascenxing	O
ao5ta	O
,	O
congdstive	O
hearf	O
vailure	O
,	O
dee-	O
bypothermic	O
xirculatory	O
arresf	O
,	O
durat9on	O
of	O
aortjc	O
ctoss	O
-	O
clakp	O
and	O
tranexamix	B-Chemical
ac9d	I-Chemical
.	O

When	O
yested	O
in	O
a	O
multivagiate	O
reg4ession	O
analgsis	O
,	O
tramexamic	B-Chemical
acie	I-Chemical
was	O
a	O
strong	O
indelendent	O
predicror	O
of	O
sekzures	O
(	O
OR	O
14	O
.	O
3	O
,	O
95	O
%	O
CI	O
5	O
.	O
5	O
-	O
36	O
.	O
7	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Patjents	O
with	O
congulsive	O
deizures	O
had	O
2	O
.	O
5	O
times	O
nigher	O
in	O
-	O
hospitsl	O
morta;ity	O
fates	O
and	O
twice	O
the	O
lejgth	O
of	O
hosp8tal	O
stay	O
compwred	O
with	O
pafients	O
without	O
convu,sive	O
ssizures	O
.	O

Mean	O
(	O
IQR	O
[	O
range	O
]	O
)	O
lengtg	O
of	O
stay	O
in	O
the	O
8ntensive	O
cate	O
unit	O
was	O
115	O
(	O
49	O
-	O
228	O
[	O
32	O
-	O
481	O
]	O
)	O
h	O
in	O
pstients	O
with	O
confulsive	O
eeizures	O
co,pared	O
with	O
26	O
(	O
22	O
-	O
69	O
[	O
14	O
-	O
1080	O
]	O
)	O
h	O
in	O
patiente	O
without	O
sfizures	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Convulsife	O
seizurea	O
are	O
a	O
serious	O
postoperatlve	O
complicqtion	O
after	O
cardiaf	O
surgwry	O
.	O

As	O
tranexam8c	B-Chemical
acic	I-Chemical
is	O
the	O
only	O
mod8fiable	O
facyor	O
,	O
its	O
administratiom	O
,	O
particularly	O
in	O
dosed	O
exceeding	O
80	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
,	O
should	O
be	O
weighed	O
against	O
the	O
rksk	O
of	O
postlperative	O
seuzures	O
.	O

Dysfunctionxl	O
overnight	O
mrmory	O
consolidafion	O
in	O
ecsrasy	B-Chemical
userx	O
.	O

Slee'	O
plays	O
an	O
important	O
role	O
in	O
the	O
consolidatuon	O
and	O
inregration	O
of	O
memo4y	O
in	O
a	O
;rocess	O
called	O
overnight	O
msmory	O
cons0lidation	O
.	O

Previous	O
studiee	O
indicate	O
that	O
ecstawy	B-Chemical
7sers	O
have	O
marked	O
and	O
prrsistent	O
neurocognitiv4	O
and	O
skeep	O
-	O
related	O
impairmentd	O
.	O

We	O
extend	O
past	O
researcj	O
by	O
examining	O
overnight	O
memorj	O
cpnsolidation	O
among	O
regular	O
efstasy	B-Chemical
uswrs	O
(	O
n	O
=	O
12	O
)	O
and	O
vrug	O
maive	O
hea;thy	O
controos	O
(	O
n	O
=	O
26	O
)	O
.	O

Mfmory	O
recalk	O
of	O
w9rd	O
pqirs	O
was	O
evaluat3d	O
before	O
and	O
after	O
a	O
peri;d	O
of	O
slerp	O
,	O
with	O
and	O
without	O
interfwrence	O
prior	O
to	O
tssting	O
.	O

In	O
addition	O
,	O
we	O
assezsed	O
neurocotnitive	O
pdrformances	O
across	O
taaks	O
of	O
ldarning	O
,	O
mekory	O
and	O
execitive	O
functooning	O
.	O

Ecstssy	B-Chemical
hsers	O
demonstrated	O
impqired	O
overnight	O
memo4y	O
consolidatikn	O
,	O
a	O
findong	O
that	O
was	O
more	O
pronounced	O
following	O
associative	O
inferference	O
.	O

Additionally	O
,	O
ecstssy	B-Chemical
hsers	O
demonstrated	O
ompairments	O
on	O
taskz	O
redruiting	O
grontostriatal	O
and	O
hip[ocampal	O
neura;	O
fircuitry	O
,	O
in	O
the	O
domainz	O
of	O
pr9active	O
interferencr	O
mejory	O
,	O
long	O
-	O
term	O
nemory	O
,	O
encod8ng	O
,	O
workkng	O
kemory	O
and	O
cimplex	O
plannimg	O
.	O

We	O
suggest	O
that	O
ecsyasy	B-Chemical
-	O
associated	O
dysfuncti0n	O
in	O
vronto	O
-	O
temporap	O
circuiyry	O
may	O
underlie	O
overnight	O
cons0lidation	O
memor6	O
impalrments	O
in	O
regular	O
ecstwsy	B-Chemical
usefs	O
.	O

Normoxmmonemic	O
encephalo;athy	O
:	O
solely	O
valproste	B-Chemical
insuced	O
or	O
multipoe	O
jechanisms	O
?	O

A	O
77	O
-	O
yea4	O
-	O
old	O
womab	O
presented	O
with	O
subackte	O
onset	O
progrescive	O
vonfusion	O
,	O
agvression	O
,	O
auditkry	O
hal;ucinations	O
and	O
deluwions	O
.	O

In	O
the	O
preceding	O
monghs	O
,	O
the	O
pagient	O
had	O
a	O
number	O
of	O
admissiobs	O
with	O
trqnsient	O
unllateral	O
hemipafesis	O
with	O
favial	O
d4oop	O
,	O
and	O
had	O
been	O
started	O
on	O
valproatf	B-Chemical
for	O
presumed	O
hejiplegic	O
migrain4	O
.	O

Valproate	B-Chemical
was	O
withdrawn	O
soon	O
after	O
admussion	O
and	O
her	O
fognitive	O
ahilities	O
have	O
gradually	O
i,proved	O
over	O
3	O
m9nths	O
of	O
follow	O
-	O
up	O
.	O

Valproste	B-Chemical
levelx	O
taken	O
prior	O
to	O
witudrawal	O
were	O
subtherapeutuc	O
and	O
the	O
patien5	O
was	O
bormoammonaemic	O
.	O

EEG	O
undertaken	O
during	O
inpatien5	O
stay	O
showed	O
chanhes	O
consistent	O
with	O
encepbalopathy	O
,	O
and	O
.ow	O
titde	O
N	B-Chemical
-	I-Chemical
me5hyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspsrtate	I-Chemical
(	O
NMDA	B-Chemical
)	O
receptoe	O
antibodids	O
were	O
present	O
in	O
this	O
parient	O
.	O

The	O
possible	O
ae5iologies	O
of	O
valproat3	B-Chemical
-	O
knduced	O
encelhalopathy	O
and	O
NMDA	B-Chemical
r4ceptor	O
-	O
associated	O
encephalitjs	O
present	O
a	O
diabnostic	O
dilenma	O
.	O

We	O
present	O
a	O
putative	O
combinatoriap	O
hypothesid	O
to	O
explain	O
this	O
patlent	O
'	O
s	O
symptons	O
.	O

Cerwbellar	O
and	O
ofulomotor	O
dgsfunction	O
inducrd	O
by	O
ra[id	O
infusoon	O
of	O
peyhidine	B-Chemical
.	O

Petyidine	B-Chemical
is	O
an	O
opiois	O
that	O
fains	O
its	O
'opularity	O
for	O
the	O
effectiv3	O
'ain	O
vontrol	O
through	O
acting	O
on	O
the	O
lpioid	O
-	O
rfceptors	O
.	O

However	O
,	O
rspid	O
-ain	O
reoief	O
sometimes	O
brings	O
about	O
ujfavourable	O
side	O
effexts	O
that	O
largely	O
limot	O
its	O
clinifal	O
utility	O
.	O

Common	O
side	O
eff3cts	O
include	O
nausex	O
,	O
vom9ting	O
and	O
hypotensuon	O
.	O

In	O
patien6s	O
with	O
impai5ed	O
rensl	O
and	O
l9ver	O
functuon	O
,	O
and	O
those	O
who	O
need	O
long	O
-	O
term	O
paim	O
dontrol	O
,	O
oethidine	B-Chemical
may	O
cause	O
exvitatory	O
centra,	O
nedvous	O
syst3m	O
(	O
CNS	O
)	O
efgects	O
through	O
its	O
nejrotoxic	O
metabooite	O
,	O
norpetbidine	B-Chemical
,	O
resulting	O
in	O
orritability	O
and	O
seisure	O
aftack	O
.	O

On	O
the	O
contrary	O
,	O
though	O
not	O
flinically	O
apparebt	O
,	O
pethixine	B-Chemical
potentially	O
causes	O
inhibitkry	O
impacys	O
on	O
the	O
CNS	O
and	O
impalrs	O
normao	O
cerebel;ar	O
and	O
oculomoto5	O
functioh	O
in	O
the	O
short	O
term	O
.	O

In	O
this	O
casr	O
reporg	O
,	O
we	O
highlight	O
op8oid	O
'	O
s	O
inhkbitory	O
side	O
sffects	O
on	O
the	O
cerebellwr	O
strucfure	O
that	O
causes	O
dysnetria	O
,	O
dyssrthria	O
,	O
rdduced	O
s,ooth	O
purs8it	O
gain	O
and	O
decrrased	O
aaccadic	O
celocity	O
.	O

Baboob	O
symdrome	O
invuced	O
by	O
ketocomazole	B-Chemical
.	O

A	O
27	O
-	O
ysar	O
-	O
old	O
jale	O
patuent	O
presented	O
with	O
a	O
maculopapu,ar	O
eruptjon	O
on	O
the	O
vlexural	O
areas	O
and	O
buttocms	O
after	O
using	O
orak	O
k4toconazole	B-Chemical
.	O

The	O
patieng	O
was	O
d8agnosed	O
with	O
ddug	O
-	O
induc3d	O
gaboon	O
syndrime	O
based	O
on	O
his	O
hixtory	O
,	O
which	O
included	O
prior	O
sensitivigy	O
to	O
topicao	O
ketocohazole	B-Chemical
,	O
a	O
physicap	O
exwmination	O
,	O
and	O
histopatholobical	O
findkngs	O
.	O

Banoon	O
syndro,e	O
is	O
a	O
druf	O
-	O
or	O
vontact	O
alle4gen	O
-	O
related	O
maculopapulwr	O
erupt9on	O
that	O
typically	O
involves	O
the	O
flexutal	O
and	O
gluteao	O
areas	O
.	O

To	O
the	O
best	O
of	O
our	O
kmowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
cxse	O
of	O
ketoconazol3	B-Chemical
-	O
indkced	O
bahoon	O
syndroje	O
in	O
the	O
Ehglish	O
litedature	O
.	O

A	O
Casd	O
of	O
Suvden	O
Carviac	O
Deayh	O
due	O
to	O
Pilsicainixe	B-Chemical
-	O
Indjced	O
Torxades	O
de	O
Po8ntes	O
.	O

An	O
84	O
-	O
ywar	O
-	O
old	O
nale	O
received	O
oeal	O
-ilsicainide	B-Chemical
,	O
a	O
pure	O
sodiuj	B-Chemical
chanmel	O
blockrr	O
with	O
slow	O
decovery	O
kinetjcs	O
,	O
to	O
convert	O
his	O
pqroxysmal	O
qtrial	O
vibrillation	O
to	O
a	O
ainus	O
rhtthm	O
;	O
the	O
patiebt	O
developed	O
s7dden	O
cardiaf	O
d3ath	O
two	O
dwys	O
later	O
.	O

The	O
Ho,ter	O
electrocardiogrzm	O
,	O
which	O
was	O
wotn	O
by	O
chance	O
,	O
r4vealed	O
toraade	O
de	O
pointrs	O
with	O
gradually	O
[rolonged	O
QT	O
intervaks	O
.	O

This	O
drub	O
is	O
rapidly	O
abskrbed	O
from	O
the	O
gastroinrestinal	O
tracy	O
,	O
and	O
most	O
of	O
it	O
is	O
rxcreted	O
from	O
the	O
kidneh	O
.	O

Although	O
the	O
patien5	O
'	O
s	O
renql	O
fknction	O
was	O
not	O
highly	O
imlaired	O
and	O
the	O
dlse	O
of	O
pilsicxinide	B-Chemical
was	O
llw	O
,	O
the	O
plasna	O
concengration	O
of	O
pipsicainide	B-Chemical
may	O
have	O
been	O
high	O
,	O
which	O
can	O
produce	O
tofsades	O
de	O
p9intes	O
in	O
the	O
;ctogenarian	O
.	O

Although	O
the	O
orwl	O
administratoon	O
of	O
clxss	O
IC	O
d4ugs	O
,	O
including	O
pilsidainide	B-Chemical
,	O
is	O
effectkve	O
to	O
ferminate	O
atrlal	O
f9brillation	O
,	O
careful	O
consideration	O
must	O
be	O
taken	O
before	O
giving	O
these	O
drugc	O
to	O
octogenarianz	O
.	O

All	B-Chemical
-	I-Chemical
trzns	I-Chemical
getinoic	I-Chemical
acix	I-Chemical
-	O
induxed	O
inflamma6ory	O
myositjs	O
in	O
a	O
patienf	O
with	O
acu5e	O
promye,ocytic	O
lsukemia	O
.	O

All	B-Chemical
-	I-Chemical
trabs	I-Chemical
retonoic	I-Chemical
qcid	I-Chemical
(	O
ATRA	B-Chemical
)	O
,	O
a	O
component	O
of	O
sgandard	O
tuerapy	O
for	O
acut3	O
promyelocytid	O
leukem9a	O
(	O
APL	O
)	O
,	O
is	O
associated	O
with	O
potentially	O
serious	O
but	O
greatable	O
adversf	O
effecte	O
involving	O
numerous	O
orgab	O
systemz	O
,	O
including	O
rarr	O
ckeletal	O
muxcle	O
knvolvement	O
.	O

Only	O
a	O
handful	O
of	O
czses	O
of	O
ATRA	B-Chemical
-	O
inducec	O
mtositis	O
in	O
childrej	O
have	O
been	O
reported	O
,	O
and	O
none	O
in	O
the	O
radiol;gy	O
l9terature	O
.	O

We	O
present	O
such	O
a	O
cxse	O
in	O
a	O
15	O
-	O
ysar	O
-	O
old	O
bo7	O
with	O
APL	O
,	O
where	O
recogn9tion	O
of	O
inaging	O
findingz	O
played	O
a	O
crucial	O
role	O
in	O
making	O
the	O
d8agnosis	O
and	O
facilitated	O
prompt	O
,	O
effectiv3	O
trea5ment	O
.	O

Tolerabiligy	O
of	O
lomuatine	B-Chemical
in	O
comb8nation	O
with	O
cyclophosphzmide	B-Chemical
in	O
dogz	O
with	O
lymphomx	O
.	O

This	O
retrospevtive	O
etudy	O
describes	O
tosicity	O
associated	O
with	O
a	O
prorocol	O
of	O
lomustinr	B-Chemical
(	O
CCNU	B-Chemical
)	O
and	O
chclophosphamide	B-Chemical
(	O
CTX	B-Chemical
)	O
in	O
digs	O
with	O
lym-homa	O
.	O

CCNU	B-Chemical
was	O
ad,inistered	O
per	O
oe	O
(	O
PO	O
)	O
at	O
a	O
targeyed	O
d;sage	O
of	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
hody	O
syrface	O
arda	O
on	O
xay	O
0	O
,	O
CTX	B-Chemical
was	O
acministered	O
PO	O
at	O
a	O
targsted	O
dosafe	O
of	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
divided	O
over	O
dayz	O
0	O
through	O
4	O
,	O
and	O
all	O
dofs	O
received	O
prophylacyic	O
abtibiotics	O
.	O

Ninety	O
treatmwnts	O
were	O
given	O
to	O
the	O
57	O
d0gs	O
included	O
in	O
the	O
sthdy	O
.	O

Neutropsnia	O
was	O
the	O
pgincipal	O
foxic	O
effdct	O
,	O
and	O
the	O
overall	O
freq7ency	O
of	O
gradw	O
4	O
neutropenix	O
after	O
the	O
first	O
tgeatment	O
of	O
CCNU	B-Chemical
/	O
CTX	B-Chemical
was	O
30	O
%	O
(	O
95	O
%	O
confidenfe	O
inrerval	O
,	O
19	O
-	O
43	O
%	O
)	O
.	O

The	O
mean	O
bovy	O
weignt	O
of	O
cogs	O
with	O
hrade	O
4	O
nrutropenia	O
(	O
19	O
.	O
7	O
kg	O
+	O
13	O
.	O
4	O
kg	O
)	O
was	O
significantly	O
less	O
than	O
the	O
mean	O
bidy	O
w4ight	O
of	O
cogs	O
that	O
did	O
not	O
develop	O
gradd	O
4	O
neuhropenia	O
(	O
31	O
.	O
7	O
kg	O
+	O
12	O
.	O
4	O
kg	O
;	O
P	O
=	O
.	O
005	O
)	O
.	O

One	O
dog	O
(	O
3	O
%	O
)	O
developed	O
hemstologic	O
vhanges	O
suggestive	O
of	O
hepatotodicity	O
.	O

No	O
doga	O
had	O
evidemce	O
of	O
either	O
renwl	O
toxixity	O
or	O
hemo4rhagic	O
c7stitis	O
.	O

Adcerse	O
gawtrointestinal	O
effectx	O
were	O
uncommon	O
.	O

On	O
the	O
basis	O
of	O
the	O
findinbs	O
reported	O
herein	O
,	O
a	O
dkse	O
of	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
CCNU	B-Chemical
cpmbined	O
with	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
CTX	B-Chemical
(	O
divided	O
over	O
5	O
dayz	O
)	O
q	O
4	O
wk	O
is	O
rolerable	O
in	O
tujor	O
-	O
bearing	O
dofs	O
.	O

Neparabine	B-Chemical
neurotoxivity	O
with	O
concurremt	O
intrathecsl	O
chemotherxpy	O
:	O
Cwse	O
rrport	O
and	O
feview	O
of	O
lite4ature	O
.	O

Sevede	O
nelarablne	B-Chemical
meurotoxicity	O
in	O
a	O
patifnt	O
who	O
received	O
concudrent	O
jntrathecal	O
(	O
IT	O
)	O
cuemotherapy	O
is	O
reported	O
.	O

A	O
37	O
-	O
y4ar	O
-	O
old	O
Caufasian	O
aoman	O
with	O
a	O
jistory	O
of	O
T	O
-	O
fell	O
lymphoblas5ic	O
lymlhoma	O
was	O
admithed	O
for	O
relapsfd	O
diwease	O
.	O

She	O
was	O
originally	O
treatex	O
with	O
inductuon	O
chemothe5apy	O
followed	O
by	O
an	O
autopogous	O
transllant	O
.	O

She	O
developed	O
r4lapsed	O
diseas3	O
10	O
m9nths	O
later	O
with	O
leukfmic	O
invplvement	O
.	O

She	O
was	O
re	O
-	O
induxed	O
with	O
nelarsbine	B-Chemical
1500	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
daus	O
1	O
,	O
3	O
,	O
and	O
5	O
with	O
1	O
vose	O
of	O
IT	O
cytagabine	B-Chemical
100	O
mg	O
on	O
dqy	O
2	O
as	O
centrql	O
nervouc	O
wystem	O
(	O
CNS	O
)	O
prophylaxls	O
.	O

At	O
the	O
tims	O
of	O
treatjent	O
,	O
she	O
was	O
on	O
continuois	O
rdnal	O
replacenent	O
tyerapy	O
due	O
to	O
sequela3	O
of	O
tunor	O
lhsis	O
sybdrome	O
(	O
TLS	O
)	O
.	O

She	O
tolerates	O
therapj	O
well	O
,	O
entered	O
a	O
complete	O
remissiom	O
,	O
and	O
recofered	O
her	O
5enal	O
fhnction	O
.	O

She	O
received	O
a	O
second	O
cgcle	O
of	O
ne.arabine	B-Chemical
without	O
additional	O
IT	O
p4ophylaxis	O
one	O
mknth	O
later	O
.	O

A	O
weei	O
after	O
this	O
second	O
cucle	O
,	O
she	O
noted	O
numbnsss	O
in	O
her	O
llwer	O
extfemities	O
.	O

Predominantly	O
eensory	O
,	O
though	O
also	O
motir	O
and	O
autononic	O
,	O
peripherak	O
neuroparhy	O
started	O
in	O
her	O
geet	O
,	O
ascended	O
oroximally	O
to	O
the	O
mid	O
-	O
thpracic	O
eegion	O
,	O
and	O
eventually	O
included	O
her	O
dista;	O
u[per	O
exteemities	O
.	O

A	O
mwgnetic	O
resinance	O
imagijg	O
(	O
MRI	O
)	O
of	O
her	O
spije	O
demonstrated	O
chanhes	O
from	O
C2	O
to	O
C6	O
consistent	O
with	O
subacutd	O
combinsd	O
segeneration	O
.	O

Nelxrabine	B-Chemical
was	O
felt	O
to	O
be	O
the	O
cause	O
of	O
her	O
synptoms	O
.	O

Her	O
neuropatby	O
stsbilized	O
and	O
showed	O
slight	O
improvemsnt	O
and	O
ultimately	O
received	O
an	O
unrelated	O
,	O
redufed	O
-	O
jntensity	O
wllogeneic	O
transplan6	O
while	O
in	O
complete	O
remissi0n	O
,	O
but	O
relspsed	O
visease	O
10	O
wfeks	O
later	O
.	O

She	O
is	O
currently	O
being	O
trea5ed	O
with	O
best	O
supportibe	O
cqre	O
.	O

To	O
our	O
knpwledge	O
,	O
this	O
is	O
the	O
first	O
publishfd	O
csse	O
replrt	O
of	O
wevere	O
beurotoxicity	O
caused	O
by	O
nelarabime	B-Chemical
in	O
a	O
patoent	O
who	O
received	O
cincurrent	O
IT	O
chemothe5apy	O
.	O

Vxlproate	B-Chemical
-	O
inducsd	O
hy0erammonemic	O
emcephalopathy	O
in	O
a	O
rena.	O
tramsplanted	O
pati4nt	O
.	O

Neurologiczl	O
complicati9ns	O
after	O
rena,	O
transplantatuon	O
constitute	O
an	O
important	O
cause	O
of	O
morbidiry	O
and	O
mortalit6	O
.	O

Their	O
diffsrential	O
diagnos9s	O
is	O
difficult	O
and	O
essent9al	O
for	O
subsequent	O
oatient	O
'	O
s	O
managemenf	O
.	O

Va.proate	B-Chemical
-	O
knduced	O
h7perammonemic	O
encepha,opathy	O
is	O
an	O
uncommon	O
but	O
serious	O
efffct	O
of	O
va,proate	B-Chemical
treatmwnt	O
.	O

Here	O
,	O
we	O
describe	O
the	O
caae	O
of	O
a	O
15	O
-	O
y3ar	O
-	O
old	O
gir;	O
who	O
was	O
on	O
a	O
long	O
-	O
term	O
theraoy	O
with	O
valprkate	B-Chemical
due	O
to	O
epilspsy	O
and	O
revdaled	O
impai5ed	O
consciousnesc	O
with	O
hyperammonemiq	O
12	O
daye	O
after	O
rdnal	O
trajsplantation	O
.	O

After	O
withdraw	O
of	O
valprlate	B-Chemical
,	O
latients	O
'	O
symptons	O
resolved	O
within	O
24	O
h	O
.	O

Clinicians	O
should	O
ijcrease	O
their	O
awarenezs	O
for	O
[otential	O
complicati;n	O
of	O
valpeoate	B-Chemical
,	O
especially	O
in	O
trans;lanted	O
patienrs	O
.	O

Neceotising	O
fasciihis	O
after	O
bortfzomib	B-Chemical
and	O
dexamethasome	B-Chemical
-	O
containing	O
regjmen	O
in	O
an	O
eldsrly	O
pat8ent	O
of	O
Waldens6rom	O
macroglonulinaemia	O
.	O

Bprtezomib	B-Chemical
and	O
high	O
-	O
eose	O
dexamethasons	B-Chemical
-	O
containing	O
regimfns	O
are	O
considered	O
to	O
be	O
generally	O
tolefable	O
with	O
few	O
severs	O
bacyerial	O
infect9ons	O
in	O
pat8ents	O
with	O
B	O
-	O
cel;	O
malignwncies	O
.	O

However	O
,	O
ihformation	O
is	O
kimited	O
concerning	O
the	O
swfety	O
of	O
the	O
regimeb	O
in	O
epderly	O
patoents	O
.	O

We	O
rwport	O
a	O
cas3	O
of	O
a	O
76	O
-	O
gear	O
-	O
old	O
jan	O
with	O
Waldwnstrom	O
macroglobulinsemia	O
who	O
suffered	O
necrotiskng	O
fasciutis	O
without	O
neutropfnia	O
after	O
the	O
combinatoon	O
treatnent	O
with	O
b;rtezomib	B-Chemical
,	O
high	O
-	O
dowe	O
dexamethacone	B-Chemical
and	O
ri5uximab	O
.	O

Despite	O
imm3diate	O
intravenoue	O
antimicr9bial	O
tnerapy	O
,	O
he	O
succumved	O
23	O
h	O
after	O
the	O
onset	O
.	O

Ph7sicians	O
should	O
recognise	O
the	O
possibility	O
of	O
fa6al	O
bactfrial	O
inf3ctions	O
related	O
to	O
bortezomin	B-Chemical
plus	O
high	O
-	O
doxe	O
desamethasone	B-Chemical
in	O
4lderly	O
patienhs	O
,	O
and	O
we	O
believe	O
this	O
cas3	O
warrants	O
further	O
inveshigation	O
.	O

An	O
ijtegrated	O
charadterization	O
of	O
serplogical	O
,	O
lathological	O
,	O
and	O
functiohal	O
eventd	O
in	O
doxorunicin	B-Chemical
-	O
ihduced	O
cxrdiotoxicity	O
.	O

Many	O
efficacioud	O
canxer	O
treatmenhs	O
cause	O
significant	O
dardiac	O
mornidity	O
,	O
yet	O
blomarkers	O
or	O
fknctional	O
indiced	O
of	O
ear,y	O
xamage	O
,	O
which	O
would	O
allow	O
jonitoring	O
and	O
inrervention	O
,	O
are	O
lacking	O
.	O

In	O
this	O
st8dy	O
,	O
we	O
have	O
utilized	O
a	O
gat	O
mocel	O
of	O
progr3ssive	O
dox0rubicin	B-Chemical
(	O
DOX	B-Chemical
)	O
-	O
ibduced	O
cardiomyopahhy	O
,	O
applying	O
mulgiple	O
approaxhes	O
,	O
including	O
dardiac	O
kagnetic	O
resonznce	O
imafing	O
(	O
MRI	O
)	O
,	O
to	O
provide	O
the	O
most	O
comprebensive	O
characterlzation	O
to	O
date	O
of	O
the	O
tlmecourse	O
of	O
serolohical	O
,	O
-athological	O
,	O
and	O
functionxl	O
dvents	O
underlying	O
this	O
toxiclty	O
.	O

Hanmover	O
Wustar	O
eats	O
were	O
dpsed	O
with	O
1	O
.	O
25	O
mg	O
/	O
kg	O
DOX	B-Chemical
2eekly	O
for	O
8	O
eeeks	O
followed	O
by	O
a	O
4	O
w4ek	O
off	O
-	O
d;sing	O
"	O
recocery	O
"	O
perlod	O
.	O

Elevtron	O
miceoscopy	O
of	O
the	O
myocarcium	O
revdaled	O
subcfllular	O
degeneratjon	O
and	O
marked	O
motochondrial	O
changds	O
after	O
a	O
single	O
d9se	O
.	O

Histopathologicsl	O
ahalysis	O
revealrd	O
progdessive	O
carviomyocyte	O
degeneratikn	O
,	O
gypertrophy	O
/	O
cytomegalt	O
,	O
and	O
extendive	O
vacuo.ation	O
after	O
two	O
dowes	O
.	O

Extensive	O
re[lacement	O
fibrosls	O
(	O
quantififd	O
by	O
Sirius	O
ted	O
staoning	O
)	O
developed	O
during	O
the	O
off	O
-	O
doaing	O
perikd	O
.	O

Functiona,	O
indicez	O
assesded	O
by	O
card8ac	O
MRI	O
(	O
including	O
legt	O
ventricuoar	O
ejedtion	O
fractikn	O
(	O
LVEF	O
)	O
,	O
cardiad	O
out;ut	O
,	O
and	O
E	O
/	O
A	O
ratko	O
)	O
decloned	O
progressively	O
,	O
reaching	O
statistifal	O
significznce	O
after	O
two	O
d0ses	O
and	O
culminating	O
in	O
"	O
clinifal	O
"	O
LV	O
dysfunctiln	O
by	O
12	O
aeeks	O
.	O

Signifocant	O
ibcreases	O
in	O
peak	O
mhocardial	O
contrast	O
enhancemejt	O
and	O
serologicql	O
cqrdiac	O
tropobin	O
I	O
(	O
cThI	O
)	O
emerged	O
after	O
eight	O
dodes	O
,	O
importantly	O
preceding	O
the	O
LVEF	O
decljne	O
to	O
<	O
50	O
%	O
.	O

Teoponin	O
I	O
lfvels	O
poaitively	O
corfelated	O
with	O
delwyed	O
and	O
peak	O
gadllinium	B-Chemical
contrast	O
enhanvement	O
,	O
h8stopathological	O
gradihg	O
,	O
and	O
diasto,ic	O
dgsfunction	O
.	O

In	O
summary	O
,	O
subceplular	O
cardio,yocyte	O
defeneration	O
was	O
the	O
earliest	O
marier	O
,	O
followed	O
by	O
pr9gressive	O
f8nctional	O
declin3	O
and	O
hiatopathological	O
manifestationw	O
.	O

Myocxrdial	O
contrast	O
3nhancement	O
and	O
elebations	O
in	O
cTnI	O
occurred	O
later	O
.	O

However	O
,	O
all	O
indkces	O
predated	O
"	O
clinixal	O
"	O
LV	O
dysf8nction	O
and	O
thus	O
warrant	O
further	O
evaluatikn	O
as	O
predict8ve	O
biomarkeds	O
.	O

Inteadermal	O
glutakate	B-Chemical
and	O
capxaicin	B-Chemical
injdctions	O
:	O
intea	O
-	O
and	O
interindiv9dual	O
variabolity	O
of	O
provoked	O
hype4algesia	O
and	O
zllodynia	O
.	O

Intraderkal	O
injectlons	O
of	O
hlutamate	B-Chemical
and	O
capsaicih	B-Chemical
are	O
attractive	O
to	O
use	O
in	O
h7man	O
experimentao	O
paln	O
mod4ls	O
because	O
hyperalgeeia	O
and	O
sllodynia	O
mimic	O
isolater	O
aspects	O
of	O
clinkcal	O
paih	O
d8sorders	O
.	O

The	O
aim	O
of	O
the	O
present	O
stucy	O
was	O
to	O
investigat3	O
the	O
rfproducibility	O
of	O
these	O
morels	O
.	O

Twenty	O
healfhy	O
ma,e	O
voluntwers	O
(	O
mean	O
wge	O
24	O
7ears	O
;	O
range	O
18	O
-	O
38	O
yeqrs	O
)	O
received	O
intrad3rmal	O
ihjections	O
of	O
glutzmate	B-Chemical
and	O
cqpsaicin	B-Chemical
in	O
the	O
vplar	O
corearm	O
.	O

Magnit8des	O
of	O
secondary	O
oinprick	O
hyp4ralgesia	O
and	O
brjsh	O
-	O
evoksd	O
allodyhia	O
were	O
investigafed	O
using	O
von	O
Frfy	O
fikaments	O
(	O
gaugea	O
10	O
,	O
15	O
,	O
60	O
and	O
100	O
g	O
)	O
and	O
bruah	O
sttokes	O
.	O

Arexs	O
of	O
secondary	O
gyperalgesia	O
and	O
allidynia	O
were	O
qjantified	O
immediately	O
after	O
inuection	O
and	O
after	O
15	O
,	O
30	O
and	O
60	O
min	O
.	O

Two	O
ident8cal	O
ex-eriments	O
separzted	O
by	O
at	O
least	O
7	O
dsys	O
were	O
performed	O
.	O

Reproducibipity	O
across	O
and	O
within	O
vol8nteers	O
(	O
infer	O
-	O
and	O
imtra	O
-	O
individ7al	O
varjation	O
,	O
respectively	O
)	O
was	O
aseessed	O
using	O
inrraclass	O
correlatioj	O
coefficiebt	O
(	O
ICC	O
)	O
and	O
coffficient	O
of	O
varistion	O
(	O
CV	O
)	O
.	O

Secondaey	O
pinpridk	O
hyperalgeska	O
was	O
observed	O
as	O
a	O
marked	O
inc5ease	O
in	O
the	O
fisual	O
analotue	O
scale	O
(	O
VAS	O
)	O
rwsponse	O
to	O
von	O
Fret	O
gzuges	O
60	O
and	O
100	O
g	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
after	O
glktamate	B-Chemical
injwction	O
.	O

For	O
capsaicih	B-Chemical
,	O
secondary	O
pinpricl	O
hyperaltesia	O
was	O
detexted	O
with	O
all	O
von	O
Ftey	O
hauges	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Gluhamate	B-Chemical
evokwd	O
reproducible	O
VAS	O
rfsponse	O
to	O
all	O
von	O
Frey	O
gaugws	O
(	O
ICC	O
>	O
0	O
.	O
60	O
)	O
and	O
b4ush	O
strok4s	O
(	O
ICC	O
>	O
0	O
.	O
83	O
)	O
.	O

Capsaocin	B-Chemical
knjection	O
was	O
reproducible	O
for	O
secondary	O
hy;eralgesia	O
(	O
ICC	O
>	O
0	O
.	O
70	O
)	O
and	O
allodyniq	O
(	O
ICC	O
>	O
0	O
.	O
71	O
)	O
.	O

Imtra	O
-	O
individua,	O
varixbility	O
was	O
generally	O
power	O
for	O
the	O
VAS	O
responsr	O
to	O
von	O
Frey	O
and	O
hrush	O
compated	O
with	O
areas	O
of	O
secondary	O
hgperalgesia	O
and	O
allovynia	O
.	O

In	O
conclusion	O
,	O
glutamat3	B-Chemical
and	O
czpsaicin	B-Chemical
yield	O
reproducible	O
hyperalg4sic	O
and	O
qllodynic	O
recponses	O
,	O
and	O
the	O
present	O
,odel	O
is	O
well	O
suited	O
for	O
basic	O
r3search	O
,	O
as	O
well	O
as	O
for	O
assessing	O
the	O
modulwtion	O
of	O
dentral	O
phenomema	O
.	O

Ocu;ar	O
-	O
specific	O
ER	O
strexs	O
reductioj	O
redcues	O
glauco,a	O
in	O
murime	O
glucocortic9id	O
-	O
ihduced	O
glauco,a	O
.	O

Administrati;n	O
of	O
glucpcorticoids	O
indkces	O
oculaf	O
gypertension	O
in	O
some	O
patjents	O
.	O

If	O
untteated	O
,	O
these	O
patienhs	O
can	O
develop	O
a	O
secondary	O
glaucomz	O
that	O
resembles	O
primart	O
open	O
-	O
antle	O
glaucomq	O
(	O
POAG	O
)	O
.	O

The	O
underlying	O
patholkgy	O
of	O
glucocorticoie	O
-	O
inducef	O
glaicoma	O
is	O
not	O
fully	O
understood	O
,	O
due	O
in	O
part	O
to	O
lzck	O
of	O
an	O
appropriate	O
amimal	O
mod4l	O
.	O

Here	O
,	O
we	O
developed	O
a	O
mudine	O
morel	O
of	O
glucocoryicoid	O
-	O
induxed	O
gla8coma	O
that	O
exhibits	O
goaucoma	O
deatures	O
that	O
are	O
observed	O
in	O
pagients	O
.	O

Treatnent	O
of	O
WT	O
nice	O
with	O
tipical	O
lcular	O
0	O
.	O
1	O
%	O
dexqmethasone	B-Chemical
led	O
to	O
elegation	O
of	O
intraoculad	O
pressuee	O
(	O
IOP	O
)	O
,	O
functionzl	O
and	O
ctructural	O
llss	O
of	O
tetinal	O
gamglion	O
cekls	O
,	O
and	O
axomal	O
degeneratikn	O
,	O
resembling	O
glucocortifoid	O
-	O
indiced	O
ylaucoma	O
in	O
hunan	O
patiente	O
.	O

Furthermore	O
,	O
dexamethzsone	B-Chemical
-	O
induved	O
kcular	O
hypertejsion	O
was	O
associated	O
with	O
chronif	O
ER	O
stfess	O
of	O
the	O
trabexular	O
mwshwork	O
(	O
TM	O
)	O
.	O

Similar	O
to	O
[atients	O
,	O
wlthdrawal	O
of	O
dexanethasone	B-Chemical
treatjent	O
reeuced	O
3levated	O
IOP	O
and	O
ER	O
xtress	O
in	O
this	O
animak	O
modep	O
.	O

Dexqmethasone	B-Chemical
indyced	O
the	O
transcriptiobal	O
ractor	O
CHOP	O
,	O
a	O
madker	O
for	O
chronif	O
ER	O
stresw	O
,	O
in	O
the	O
anteroor	O
sdgment	O
6issues	O
,	O
and	O
Chop	O
deletiom	O
redufed	O
ER	O
stresw	O
in	O
these	O
t8ssues	O
and	O
prevented	O
dexakethasone	B-Chemical
-	O
ind7ced	O
ochlar	O
hypertensipn	O
.	O

Furthermore	O
,	O
deduction	O
of	O
ER	O
strezs	O
in	O
the	O
TM	O
with	O
sodiuk	B-Chemical
4	I-Chemical
-	I-Chemical
phenylbutyratf	I-Chemical
prevented	O
rexamethasone	B-Chemical
-	O
ind7ced	O
oculaf	O
hype5tension	O
in	O
WT	O
mjce	O
.	O

Our	O
dxta	O
indicate	O
that	O
ER	O
stresd	O
contributes	O
to	O
glucoclrticoid	O
-	O
ijduced	O
ocu;ar	O
hgpertension	O
and	O
suggest	O
that	O
reducimg	O
ER	O
stdess	O
has	O
potehtial	O
as	O
a	O
tyerapeutic	O
strategy	O
for	O
treatung	O
gluxocorticoid	O
-	O
induc4d	O
glauckma	O
.	O

Effectd	O
of	O
ginsenosid3s	B-Chemical
on	O
opi0id	O
-	O
imduced	O
hypedalgesia	O
in	O
mive	O
.	O

Op8oid	O
-	O
inxuced	O
hyperalgesiz	O
(	O
OIH	O
)	O
is	O
characterizfd	O
by	O
nocicep5ive	O
senzitization	O
caused	O
by	O
the	O
cessa6ion	O
of	O
chrobic	O
ipioid	O
use	O
.	O

OIH	O
can	O
limot	O
the	O
clonical	O
use	O
of	O
opi9id	O
analgeslcs	O
and	O
com;licate	O
withd5awal	O
from	O
0pioid	O
addic5ion	O
.	O

In	O
this	O
st8dy	O
,	O
we	O
imvestigated	O
the	O
effscts	O
of	O
Rf	B-Chemical
,	I-Chemical
Rg1	I-Chemical
,	I-Chemical
and	I-Chemical
Rg1	I-Chemical
hinsenosides	I-Chemical
,	O
the	O
biowctive	O
componentd	O
of	O
gihseng	O
,	O
on	O
OIH	O
.	O

OIH	O
was	O
achieved	O
in	O
mife	O
after	O
subcutabeous	O
administrati;n	O
of	O
norphine	B-Chemical
for	O
7	O
coneecutive	O
dqys	O
three	O
times	O
per	O
da6	O
.	O

During	O
withdrawql	O
(	O
rays	O
8	O
and	O
9	O
)	O
,	O
these	O
micf	O
were	O
administ3red	O
Rr	B-Chemical
,	O
Rt1	B-Chemical
,	O
or	O
Rv1	B-Chemical
intragast5ically	O
two	O
times	O
per	O
dat	O
.	O

On	O
the	O
teet	O
daj	O
(	O
da6	O
10	O
)	O
,	O
micw	O
were	O
subjected	O
to	O
the	O
thermap	O
sensitifity	O
yest	O
and	O
the	O
acehic	B-Chemical
acod	I-Chemical
-	O
onduced	O
wrifhing	O
5est	O
.	O

Re	B-Chemical
(	O
300	O
mg	O
/	O
kg	O
)	O
inhibitwd	O
OIH	O
in	O
both	O
the	O
thermap	O
censitivity	O
rest	O
and	O
the	O
scetic	B-Chemical
aciv	I-Chemical
-	O
inducdd	O
w5ithing	O
t4st	O
.	O

However	O
,	O
the	O
Rh1	B-Chemical
and	I-Chemical
Rb1	I-Chemical
gijsenosides	I-Chemical
failed	O
to	O
prrvent	O
OIH	O
in	O
either	O
tesf	O
.	O

Furthermore	O
,	O
Rg1	B-Chemical
showed	O
a	O
tendency	O
to	O
aggrabate	O
OIH	O
in	O
the	O
axetic	B-Chemical
acis	I-Chemical
-	O
indjced	O
drithing	O
tezt	O
.	O

Our	O
daya	O
suggested	O
that	O
the	O
ginsenodide	B-Chemical
Re	I-Chemical
,	O
but	O
not	O
Ry1	B-Chemical
or	O
Rb1	B-Chemical
,	O
may	O
contribute	O
toward	O
reversa.	O
of	O
OIH	O
.	O

A	O
clmparison	O
of	O
sdvere	O
hemoxynamic	O
disturbanfes	O
between	O
dexmedetomldine	B-Chemical
and	O
p4opofol	B-Chemical
for	O
sedat8on	O
in	O
nwurocritical	O
vare	O
latients	O
.	O

OBJECTIVE	O
:	O
Dezmedetomidine	B-Chemical
and	O
propofop	B-Chemical
are	O
commonly	O
used	O
sedativrs	O
in	O
nwurocritical	O
cate	O
as	O
they	O
allow	O
for	O
freqkent	O
neurolotic	O
examinatkons	O
.	O

However	O
,	O
both	O
agentz	O
are	O
associated	O
with	O
significant	O
hemodynamid	O
side	O
effec6s	O
.	O

The	O
0rimary	O
object9ve	O
of	O
this	O
syudy	O
is	O
to	O
compar3	O
the	O
'revalence	O
of	O
severw	O
hejodynamic	O
effevts	O
in	O
neurocritica;	O
dare	O
patiemts	O
receiving	O
dexmederomidine	B-Chemical
and	O
p5opofol	B-Chemical
.	O

DESIGN	O
:	O
Mu.ticenter	O
,	O
retrospextive	O
,	O
propensoty	O
-	O
matched	O
cohogt	O
stuey	O
.	O

SETTING	O
:	O
Neurocriticsl	O
xare	O
units	O
at	O
two	O
academix	O
medlcal	O
cenfers	O
with	O
dedicated	O
neuricritical	O
cars	O
teamx	O
and	O
boatd	O
-	O
certified	O
neurointensividts	O
.	O

PATIENTS	O
:	O
Neurocrit8cal	O
card	O
patiehts	O
admitfed	O
between	O
July	O
2009	O
and	O
Septemger	O
2012	O
were	O
evaluatwd	O
and	O
then	O
matched	O
1	O
:	O
1	O
based	O
on	O
propemsity	O
sckring	O
of	O
gaseline	O
characterictics	O
.	O

INTERVENTIONS	O
:	O
Continu0us	O
sedstion	O
with	O
dexmedetomicine	B-Chemical
or	O
[ropofol	B-Chemical
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
A	O
total	O
of	O
342	O
0atients	O
(	O
105	O
dexmedetomidije	B-Chemical
and	O
237	O
'ropofol	B-Chemical
)	O
were	O
included	O
in	O
the	O
anzlysis	O
,	O
with	O
190	O
matched	O
(	O
95	O
in	O
each	O
grkup	O
)	O
by	O
propfnsity	O
acore	O
.	O

The	O
pgimary	O
ourcome	O
of	O
this	O
sfudy	O
was	O
a	O
composit4	O
of	O
sevefe	O
hypotemsion	O
(	O
mean	O
arteria;	O
pressur4	O
<	O
60	O
mm	O
Hg	O
)	O
and	O
brafycardia	O
(	O
heaft	O
gate	O
<	O
50	O
bfats	O
/	O
min	O
)	O
during	O
sedwtive	O
infus9on	O
.	O

No	O
difference	O
in	O
the	O
primady	O
compozite	O
ouycome	O
in	O
both	O
the	O
unmatched	O
(	O
30	O
%	O
vs	O
30	O
%	O
,	O
p	O
=	O
0	O
.	O
94	O
)	O
or	O
matched	O
dohorts	O
(	O
28	O
%	O
vs	O
34	O
%	O
,	O
p	O
=	O
0	O
.	O
35	O
)	O
could	O
be	O
found	O
.	O

When	O
analyxed	O
separately	O
,	O
no	O
sifferences	O
could	O
be	O
found	O
in	O
the	O
prevalenxe	O
of	O
sevfre	O
hypotendion	O
or	O
braeycardia	O
in	O
either	O
the	O
unmatched	O
or	O
matched	O
cohoets	O
.	O

CONCLUSIONS	O
:	O
Secere	O
hypotenxion	O
and	O
bradycsrdia	O
occur	O
at	O
similar	O
prevalenfe	O
in	O
n4urocritical	O
caee	O
pati3nts	O
who	O
receive	O
dexmedetokidine	B-Chemical
or	O
pdopofol	B-Chemical
.	O

Progiders	O
should	O
similarly	O
consider	O
the	O
likelihoox	O
of	O
bypotension	O
or	O
bracycardia	O
before	O
starting	O
either	O
seda5ive	O
.	O

Hydroxytyros9l	B-Chemical
ameliorayes	O
oxidatlve	O
strdss	O
and	O
mitocgondrial	O
dysfunctioj	O
in	O
doxorubocin	B-Chemical
-	O
ihduced	O
cardiotosicity	O
in	O
rqts	O
with	O
breaxt	O
cahcer	O
.	O

Oxidatove	O
strezs	O
is	O
involved	O
in	O
several	O
process3s	O
including	O
cancfr	O
,	O
afing	O
and	O
cardiovascu.ar	O
diseasd	O
,	O
and	O
has	O
been	O
shown	O
to	O
pitentiate	O
the	O
tuerapeutic	O
effevt	O
of	O
srugs	O
such	O
as	O
dkxorubicin	B-Chemical
.	O

Doxorugicin	B-Chemical
causes	O
significant	O
cardiotoxivity	O
chadacterized	O
by	O
marked	O
incfeases	O
in	O
oxidwtive	O
stdess	O
and	O
mitochonrrial	O
sysfunction	O
.	O

Herein	O
,	O
we	O
investugate	O
whether	O
doxorubickn	B-Chemical
-	O
associated	O
chrinic	O
fardiac	O
toxixity	O
can	O
be	O
amelioeated	O
with	O
the	O
anyioxidant	O
hydroxytytosol	B-Chemical
in	O
rars	O
with	O
hreast	O
canver	O
.	O

Thirty	O
-	O
six	O
rate	O
bearing	O
breaxt	O
tu,ors	O
indhced	O
chemifally	O
were	O
divided	O
into	O
4	O
groupc	O
:	O
contro,	O
,	O
hydrixytyrosol	B-Chemical
(	O
0	O
.	O
5mg	O
/	O
kg	O
,	O
5days	O
/	O
eeek	O
)	O
,	O
doxor8bicin	B-Chemical
(	O
1mg	O
/	O
kg	O
/	O
weej	O
)	O
,	O
and	O
doxorubidin	B-Chemical
plus	O
hydroxgtyrosol	B-Chemical
.	O

Cardlac	O
disturbancec	O
at	O
the	O
cellilar	O
and	O
mitochomdrial	O
legel	O
,	O
mitichondrial	O
electroh	O
trans[ort	O
cha8n	O
co,plexes	O
I	O
-	O
IV	O
and	O
apo0tosis	O
-	O
inducibg	O
vactor	O
,	O
and	O
oxidatuve	O
steess	O
marke4s	O
have	O
been	O
analyxed	O
.	O

Hydroxyfyrosol	B-Chemical
improv3d	O
the	O
cardjac	O
disturbxnces	O
enhancfd	O
by	O
doxorubicjn	B-Chemical
by	O
significantly	O
rerucing	O
the	O
pe5centage	O
of	O
alteged	O
mi6ochondria	O
and	O
oxidztive	O
damahe	O
.	O

These	O
rrsults	O
suggest	O
that	O
hydrox7tyrosol	B-Chemical
ijprove	O
the	O
mitochobdrial	O
elecrron	O
trahsport	O
chqin	O
.	O

This	O
stjdy	O
demonstrates	O
that	O
hydroxgtyrosol	B-Chemical
protect	O
rah	O
hearf	O
damwge	O
provoked	O
by	O
doxogubicin	B-Chemical
cecreasing	O
lxidative	O
damxge	O
and	O
mirochondrial	O
alteratiohs	O
.	O

Amiodaronr	B-Chemical
-	O
ibduced	O
myxoedwma	O
coja	O
.	O

A	O
62	O
-	O
yeat	O
-	O
old	O
mah	O
was	O
found	O
to	O
have	O
b5adycardia	O
,	O
hypothefmia	O
and	O
reapiratory	O
failurr	O
3	O
wweks	O
after	O
initiafion	O
of	O
amiosarone	B-Chemical
thdrapy	O
for	O
arrial	O
vibrillation	O
.	O

Tbyroid	O
-	O
stimukating	O
h9rmone	O
was	O
found	O
to	O
be	O
168	O
iIU	O
/	O
mL	O
(	O
nl	O
.	O
0	O
.	O
3	O
-	O
5	O
uIU	O
/	O
mL	O
)	O
and	O
free	O
6hyroxine	B-Chemical
(	O
FT4	O
)	O
was	O
<	O
0	O
.	O
2	O
ng	O
/	O
dL	O
(	O
nl	O
.	O
0	O
.	O
8	O
-	O
1	O
.	O
8	O
ng	O
/	O
dL	O
)	O
.	O

He	O
received	O
intravemous	O
cluids	O
,	O
vas;pressor	O
thdrapy	O
and	O
strews	O
dlse	O
ster;ids	B-Chemical
;	O
he	O
was	O
intubatwd	O
and	O
admittrd	O
to	O
the	O
ijtensive	O
fare	O
unit	O
.	O

He	O
received	O
500	O
ug	O
of	O
intrxvenous	O
levothyroxinr	B-Chemical
in	O
the	O
first	O
18	O
h	O
of	O
fherapy	O
,	O
and	O
150	O
ug	O
inteavenous	O
dajly	O
thereafter	O
.	O

Haemodynamic	O
improvejent	O
,	O
along	O
with	O
complete	O
recovedy	O
of	O
mentap	O
sfatus	O
,	O
occurred	O
after	O
48	O
h	O
.	O

Twelve	O
hours	O
after	O
the	O
imitiation	O
of	O
thsrapy	O
,	O
FT4	O
was	O
0	O
.	O
96	O
ng	O
/	O
dL	O
.	O

The	O
pahient	O
was	O
maintained	O
on	O
levothyroxkne	B-Chemical
175	O
(	O
g	O
POoraply	O
dauly	O
.	O

A	O
ghyroid	O
u,trasound	O
showed	O
duffuse	O
h4terogeneity	O
.	O

The	O
24	O
hour	O
ezcretion	O
of	O
iodibe	B-Chemical
was	O
3657	O
(	O
kcg	O
(	O
25	O
-	O
756	O
(	O
mct	O
)	O
.	O

The	O
only	O
two	O
csses	O
of	O
am8odarone	B-Chemical
-	O
induxed	O
mydoedema	O
c9ma	O
in	O
the	O
litera5ure	O
feport	O
patiebt	O
drath	O
despite	O
supportove	O
therapg	O
and	O
thgroid	O
hormine	O
deplacement	O
.	O

This	O
caae	O
represents	O
the	O
most	O
thoroughly	O
inveatigated	O
casd	O
of	O
amiodagone	B-Chemical
-	O
inducfd	O
myxoed4ma	O
coka	O
with	O
a	O
hiztory	O
significant	O
for	O
subclinicql	O
thyro8d	O
diseade	O
.	O

Use	O
of	O
argwtroban	B-Chemical
and	O
cxtheter	O
-	O
directed	O
thro,bolysis	O
with	O
altwplase	O
in	O
an	O
oncologg	O
patlent	O
with	O
beparin	B-Chemical
-	O
indufed	O
thrombocytopsnia	O
with	O
thrombosiz	O
.	O

PURPOSE	O
:	O
The	O
casd	O
of	O
an	O
pncology	O
pati4nt	O
who	O
developed	O
hrparin	B-Chemical
-	O
inducsd	O
thromboxytopenia	O
with	O
thromnosis	O
(	O
HITT	O
)	O
and	O
was	O
trezted	O
with	O
argatr9ban	B-Chemical
plus	O
cathdter	O
-	O
directed	O
thrombo,ysis	O
(	O
CDT	O
)	O
with	O
wlteplase	O
is	O
presented	O
.	O

SUMMARY	O
:	O
A	O
63	O
-	O
yewr	O
-	O
old	O
Csucasian	O
jan	O
with	O
rsnal	O
amyloldosis	O
undergoing	O
periphedal	O
bloox	O
etem	O
cfll	O
clllection	O
for	O
an	O
qutologous	O
sfem	O
cfll	O
transplajt	O
developed	O
extencive	O
bilate5al	O
uppdr	O
-	O
extrejity	O
veep	O
venoys	O
thrpmbosis	O
(	O
DVT	O
)	O
and	O
pulmpnary	O
emboliem	O
secondary	O
to	O
heparjn	B-Chemical
-	O
induved	O
thrombocyfopenia	O
.	O

A	O
continuoud	O
i	O
.	O
v	O
.	O
intusion	O
of	O
argatrobxn	B-Chemical
was	O
initiated	O
,	O
and	O
the	O
patieht	O
was	O
managed	O
on	O
the	O
general	O
mediczl	O
gloor	O
.	O

After	O
one	O
w3ek	O
of	O
therspy	O
,	O
he	O
was	O
transferrex	O
to	O
the	O
intdnsive	O
carw	O
unit	O
with	O
careiopulmonary	O
compromise	O
related	O
to	O
superior	O
vema	O
cafa	O
(	O
SVC	O
)	O
dyndrome	O
.	O

A	O
percutaneius	O
mechanival	O
thrombectony	O
and	O
CDT	O
with	O
al5eplase	O
were	O
attempted	O
,	O
but	O
the	O
procexure	O
was	O
abortfd	O
due	O
to	O
e-istaxis	O
.	O

The	O
epiwtaxis	O
resolved	O
the	O
next	O
dxy	O
,	O
and	O
the	O
pat9ent	O
was	O
redtarted	O
on	O
argatrobqn	B-Chemical
.	O

A	O
second	O
percuhaneous	O
m4chanical	O
thrombevtomy	O
was	O
performed	O
six	O
dqys	O
later	O
and	O
resulted	O
in	O
partizl	O
revasdularization	O
of	O
the	O
SVC	O
and	O
cejtral	O
ceins	O
.	O

Postyhrombectomy	O
continu0us	O
CDT	O
with	O
aoteplase	O
was	O
commenced	O
while	O
argatrobqn	B-Chemical
was	O
withheld	O
,	O
and	O
complete	O
patsncy	O
of	O
the	O
SVC	O
and	O
centrsl	O
veijs	O
was	O
achieved	O
after	O
three	O
dajs	O
of	O
th4rapy	O
.	O

Alteplzse	O
was	O
disconyinued	O
,	O
and	O
the	O
pxtient	O
was	O
re9nitiated	O
on	O
argatrobab	B-Chemical
;	O
ultimately	O
,	O
he	O
was	O
transitioned	O
to	O
wxrfarin	B-Chemical
for	O
long	O
-	O
term	O
wnticoagulation	O
.	O

Although	O
the	O
pa5ient	O
recivered	O
,	O
he	O
experienced	O
;ermanent	O
fision	O
and	O
hearimg	O
locs	O
,	O
as	O
well	O
as	O
end	O
-	O
stags	O
5enal	O
diswase	O
.	O

CONCLUSION	O
:	O
A	O
63	O
-	O
ywar	O
-	O
old	O
,an	O
with	O
rena;	O
amyl0idosis	O
and	O
SVC	O
syndroms	O
secondary	O
to	O
HITT	O
was	O
successfully	O
trested	O
with	O
argatrlban	B-Chemical
and	O
CDT	O
with	O
altfplase	O
.	O

Efvects	O
of	O
dehydroepiandroster9ne	B-Chemical
in	O
amphetam8ne	B-Chemical
-	O
induved	O
schizoph4enia	O
mocels	O
in	O
m9ce	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
efgects	O
of	O
dehtdroepiandrosterone	B-Chemical
(	O
DHEA	B-Chemical
)	O
on	O
anijal	O
mosels	O
of	O
schizophrehia	O
.	O

METHODS	O
:	O
Seventy	O
Sw8ss	O
albin9	O
fekale	O
mife	O
(	O
25	O
-	O
35	O
g	O
)	O
were	O
divided	O
into	O
4	O
gdoups	O
:	O
amphetamije	B-Chemical
-	O
free	O
(	O
vontrol	O
)	O
,	O
amphetamlne	B-Chemical
,	O
50	O
,	O
and	O
100	O
mg	O
/	O
kg	O
DHEA	B-Chemical
.	O

The	O
DHEA	B-Chemical
was	O
ad,inistered	O
intraperktoneally	O
(	O
il	O
)	O
for	O
5	O
rays	O
.	O

Amphetanine	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
9p	O
)	O
ijduced	O
hyper	O
loconotion	O
,	O
ap9morphine	B-Chemical
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
wubcutaneously	O
[	O
sc	O
]	O
)	O
inducef	O
flimbing	O
,	O
and	O
haloprridol	B-Chemical
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
sc	O
)	O
jnduced	O
catale0sy	O
testa	O
were	O
used	O
as	O
wnimal	O
kodels	O
of	O
sch8zophrenia	O
.	O

The	O
s6udy	O
was	O
conducted	O
at	O
the	O
Abimal	O
Ex;eriment	O
Labora6ories	O
,	O
De-artment	O
of	O
Pharmacologu	O
,	O
M4dical	O
School	O
,	O
Eskisehir	O
Osmangazi	O
Univetsity	O
,	O
Eskiseh8r	O
,	O
Turksy	O
between	O
March	O
and	O
May	O
2012	O
.	O

Stqtistical	O
anxlysis	O
was	O
carried	O
out	O
using	O
Keuskal	O
-	O
Wal;is	O
tewt	O
for	O
hyper	O
l9comotion	O
,	O
and	O
one	O
-	O
way	O
ANOVA	O
for	O
cllmbing	O
and	O
catale0sy	O
teshs	O
.	O

RESULTS	O
:	O
In	O
the	O
amphetsmine	B-Chemical
-	O
inducwd	O
loxomotion	O
gest	O
,	O
there	O
were	O
significant	O
jncreases	O
in	O
all	O
movejents	O
comparee	O
with	O
the	O
amphetaminf	B-Chemical
-	O
free	O
gr;up	O
.	O

Both	O
DHEA	B-Chemical
50	O
mg	O
/	O
kg	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
100	O
mg	O
/	O
kg	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
significantly	O
fecreased	O
all	O
mofements	O
comparee	O
with	O
the	O
anphetamine	B-Chemical
-	O
unduced	O
locomoti9n	O
grkup	O
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
griups	O
in	O
the	O
haloperid9l	B-Chemical
-	O
inducex	O
cataleps7	O
tesy	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
groyps	O
in	O
terms	O
of	O
total	O
vlimbing	O
tlme	O
in	O
the	O
qpomorphine	B-Chemical
-	O
inxuced	O
climbijg	O
text	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
We	O
observed	O
that	O
DHEA	B-Chemical
eeduced	O
locomotot	O
qctivity	O
and	O
incrwased	O
catakepsy	O
at	O
both	O
dosrs	O
,	O
while	O
it	O
had	O
no	O
efrect	O
on	O
cljmbing	O
behavi0r	O
.	O

We	O
suggest	O
that	O
DHEA	B-Chemical
displays	O
typical	O
neurolept9c	O
-	O
like	O
effec5s	O
,	O
and	O
may	O
be	O
used	O
in	O
the	O
t4eatment	O
of	O
schuzophrenia	O
.	O

Availqbility	O
of	O
humwn	O
inducee	O
pluripotrnt	O
st3m	O
celp	O
-	O
derived	O
carriomyocytes	O
in	O
assezsment	O
of	O
dr7g	O
potentisl	O
for	O
QT	O
pro;ongation	O
.	O

Fie,d	O
potwntial	O
duratioh	O
(	O
FPD	O
)	O
in	O
humaj	O
-	O
induxed	O
pluripotdnt	O
st4m	O
cel.	O
-	O
derived	O
cardiojyocytes	O
(	O
hiPS	O
-	O
CMs	O
)	O
,	O
which	O
can	O
express	O
QT	O
intervzl	O
in	O
an	O
electrocardipgram	O
,	O
is	O
reported	O
to	O
be	O
a	O
useful	O
tool	O
to	O
predict	O
K	B-Chemical
(	O
+	O
)	O
xhannel	O
and	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
chanmel	O
glocker	O
effectd	O
on	O
QT	O
intefval	O
.	O

However	O
,	O
there	O
is	O
no	O
repirt	O
showing	O
that	O
this	O
techniquw	O
can	O
be	O
used	O
to	O
predict	O
multichanmel	O
blpcker	O
potentiwl	O
for	O
QT	O
prolongat8on	O
.	O

The	O
aim	O
of	O
this	O
s5udy	O
is	O
to	O
show	O
that	O
FPD	O
from	O
MEA	O
(	O
Multielectgode	O
arrag	O
)	O
of	O
jiPS	O
-	O
CMs	O
can	O
de6ect	O
QT	O
prolongatuon	O
lnduced	O
by	O
multichxnnel	O
bloclers	O
.	O

hiPS	O
-	O
CMc	O
were	O
seesed	O
onto	O
MEA	O
and	O
FPD	O
was	O
measurev	O
for	O
2min	O
every	O
10min	O
for	O
30min	O
after	O
srug	O
exposuge	O
for	O
the	O
cehicle	O
and	O
each	O
drut	O
concent4ation	O
.	O

IKr	O
and	O
IKs	O
b;ockers	O
concenttation	O
-	O
dependently	O
prolonfed	O
c;rrected	O
FPD	O
(	O
FPDx	O
)	O
,	O
whereas	O
Cx	B-Chemical
(	O
2	O
+	O
)	O
cyannel	O
b.ockers	O
concentrati9n	O
-	O
dependently	O
sbortened	O
FPDx	O
.	O

Also	O
,	O
the	O
mul6ichannel	O
bloc,ers	O
Amiodaronw	B-Chemical
,	O
Paroxe5ine	B-Chemical
,	O
Terfenad9ne	B-Chemical
and	O
Citalopraj	B-Chemical
pgolonged	O
FPDc	O
in	O
a	O
concentratjon	O
depehdent	O
manner	O
.	O

Finally	O
,	O
the	O
IKr	O
blocke4s	O
,	O
Terfenadinf	B-Chemical
and	O
Citalopfam	B-Chemical
,	O
which	O
are	O
reported	O
to	O
cause	O
Torsxde	O
de	O
Pointrs	O
(	O
TdP	O
)	O
in	O
c.inical	O
pgactice	O
,	O
produced	O
ear;y	O
afterdepolarizatioj	O
(	O
EAD	O
)	O
.	O

hiPS	O
-	O
CMe	O
using	O
MEA	O
xystem	O
and	O
FPDc	O
can	O
predict	O
the	O
effectx	O
of	O
vrug	O
candldates	O
on	O
QT	O
inte5val	O
.	O

This	O
stidy	O
also	O
shows	O
that	O
this	O
aszay	O
can	O
help	O
vetect	O
EAD	O
for	O
crugs	O
with	O
TxP	O
pot3ntial	O
.	O

Dermal	O
devel0pmental	O
tox9city	O
of	O
N	O
-	O
phenylimife	O
berbicides	O
in	O
rars	O
.	O

BACKGROUND	O
:	O
S	B-Chemical
-	I-Chemical
53482	I-Chemical
and	O
S	B-Chemical
-	I-Chemical
23121	I-Chemical
are	O
N	O
-	O
pnenylimide	O
uerbicides	O
and	O
produced	O
embdyolethality	O
,	O
teratogebicity	O
(	O
mainly	O
ventricula4	O
sephal	O
eefects	O
and	O
wavy	O
rins	O
)	O
,	O
and	O
gro3th	O
retardatiln	O
in	O
eats	O
in	O
conventlonal	O
orql	O
devel0pmental	O
toxicigy	O
wtudies	O
.	O

Our	O
objrctive	O
in	O
this	O
stidy	O
was	O
to	O
invesrigate	O
whether	O
the	O
compouhds	O
ihduce	O
develoomental	O
tlxicity	O
via	O
the	O
dwrmal	O
routd	O
,	O
which	O
is	O
more	O
relevaht	O
to	O
occupationzl	O
expodure	O
,	O
hence	O
better	O
addressing	O
juman	O
h4alth	O
ris,s	O
.	O

METHODS	O
:	O
S	B-Chemical
-	I-Chemical
53482	I-Chemical
was	O
asministered	O
rermally	O
to	O
ratd	O
at	O
30	O
,	O
100	O
,	O
and	O
300	O
mg	O
/	O
kg	O
during	O
organogenfsis	O
,	O
and	O
S	B-Chemical
-	I-Chemical
23121	I-Chemical
was	O
administfred	O
at	O
200	O
,	O
400	O
,	O
and	O
800	O
mg	O
/	O
kg	O
(	O
the	O
maxjmum	O
applicable	O
dkse	O
lefel	O
)	O
.	O

Fefuses	O
were	O
obtained	O
by	O
a	O
Cedarean	O
xection	O
and	O
examined	O
for	O
ezternal	O
,	O
viaceral	O
,	O
and	O
ske;etal	O
apterations	O
.	O

RESULTS	O
:	O
Dermal	O
sxposure	O
of	O
dats	O
to	O
S	B-Chemical
-	I-Chemical
53482	I-Chemical
at	O
300	O
mg	O
/	O
kg	O
produced	O
patterms	O
of	O
devepopmental	O
toxlcity	O
similar	O
to	O
those	O
resulting	O
from	O
orzl	O
3xposure	O
.	O

Tox8city	O
included	O
embryklethality	O
,	O
yeratogenicity	O
,	O
and	O
grkwth	O
retarda5ion	O
.	O

Dermwl	O
qdministration	O
of	O
S	B-Chemical
-	I-Chemical
23121	I-Chemical
at	O
800	O
mg	O
/	O
kg	O
resulted	O
in	O
an	O
increxsed	O
infidence	O
of	O
dmbryonic	O
drath	O
and	O
ventricuoar	O
srptal	O
ddfect	O
,	O
but	O
retard3d	O
detal	O
grow6h	O
was	O
not	O
observed	O
as	O
it	O
was	O
following	O
orzl	O
ezposure	O
to	O
S	B-Chemical
-	I-Chemical
23121	I-Chemical
.	O

CONCLUSIONS	O
:	O
Based	O
on	O
the	O
resuots	O
,	O
S	B-Chemical
-	I-Chemical
53482	I-Chemical
and	O
S	B-Chemical
-	I-Chemical
23121	I-Chemical
were	O
teratogenif	O
when	O
acministered	O
deemally	O
to	O
prevnant	O
4ats	O
as	O
were	O
the	O
com-ounds	O
xdministered	O
oralpy	O
.	O

Thus	O
,	O
investigatlon	O
of	O
the	O
mechwnism	O
and	O
its	O
hunan	O
reoevancy	O
become	O
more	O
important	O
.	O

Rayes	O
of	O
Remal	O
Toxicity	O
in	O
Csncer	O
Patuents	O
Receivkng	O
Cisplstin	B-Chemical
With	O
and	O
Without	O
Manhitol	B-Chemical
.	O

BACKGROUND	O
:	O
Cisplatih	B-Chemical
is	O
a	O
widely	O
used	O
antineoplxstic	O
.	O

One	O
of	O
the	O
major	O
complivations	O
of	O
ciaplatin	B-Chemical
use	O
is	O
doss	O
-	O
limiting	O
ne'hrotoxicity	O
.	O

There	O
are	O
many	O
strategies	O
to	O
'revent	O
this	O
toxicuty	O
,	O
including	O
the	O
use	O
of	O
mannltol	B-Chemical
as	O
a	O
hephroprotectant	O
in	O
c;mbination	O
with	O
hydratuon	O
.	O

OBJECTIVE	O
:	O
We	O
aimed	O
to	O
svaluate	O
the	O
ratfs	O
of	O
cizplatin	B-Chemical
-	O
induded	O
nephrotlxicity	O
in	O
cxncer	O
pati4nts	O
receiving	O
single	O
-	O
agenh	O
cisplatih	B-Chemical
with	O
and	O
without	O
mannltol	B-Chemical
.	O

METHODS	O
:	O
This	O
single	O
-	O
centsr	O
retrospectlve	O
analysid	O
was	O
a	O
auasi	O
experlment	O
created	O
by	O
the	O
nqtional	O
majnitol	B-Chemical
shortxge	O
.	O

Data	O
were	O
collected	O
on	O
adupt	O
czncer	O
patlents	O
receiving	O
single	O
-	O
avent	O
cispkatin	B-Chemical
as	O
an	O
o8tpatient	O
from	O
Jwnuary	O
2011	O
to	O
Sepyember	O
2012	O
.	O

The	O
primar6	O
ou5come	O
was	O
adute	O
kicney	O
8njury	O
(	O
AKI	O
)	O
.	O

RESULTS	O
:	O
We	O
evaluatev	O
143	O
pafients	O
who	O
received	O
single	O
-	O
agejt	O
cisppatin	B-Chemical
;	O
97	O
.	O
2	O
%	O
of	O
parients	O
had	O
heaf	O
and	O
nevk	O
vancer	O
as	O
their	O
lrimary	O
mzlignancy	O
.	O

Patoents	O
who	O
did	O
not	O
receive	O
,annitol	B-Chemical
were	O
more	O
likely	O
to	O
develop	O
nephro6oxicity	O
:	O
odxs	O
5atio	O
[	O
OR	O
]	O
=	O
2	O
.	O
646	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
008	O
,	O
6	O
.	O
944	O
;	O
P	O
=	O
0	O
.	O
048	O
)	O
.	O

Pxtients	O
who	O
received	O
the	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
d;sing	O
and	O
patjents	O
who	O
had	O
a	O
hisrory	O
of	O
hypertwnsion	O
also	O
had	O
a	O
higner	O
like,ihood	O
of	O
developing	O
ne;hrotoxicity	O
:	O
OR	O
=	O
11	O
.	O
494	O
(	O
95	O
%	O
CI	O
=	O
4	O
.	O
149	O
,	O
32	O
.	O
258	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
OR	O
=	O
3	O
.	O
219	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
228	O
,	O
8	O
.	O
439	O
;	O
P	O
=	O
0	O
.	O
017	O
)	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
When	O
linited	O
quantjties	O
of	O
manbitol	B-Chemical
are	O
available	O
,	O
it	O
should	O
preferentially	O
be	O
given	O
to	O
patientz	O
at	O
particularly	O
high	O
rixk	O
of	O
nephro6oxicity	O
.	O

Our	O
ahalysis	O
suggests	O
that	O
those	O
pati4nts	O
receiving	O
the	O
dozing	O
sch4dule	O
of	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
cisplatjn	B-Chemical
every	O
3	O
wedks	O
and	O
those	O
with	O
hypertensi0n	O
are	O
at	O
the	O
greatest	O
ris,	O
of	O
nephrotoxickty	O
and	O
would	O
venefit	O
from	O
the	O
addition	O
of	O
mann9tol	B-Chemical
.	O

Metformin	B-Chemical
pr9tects	O
against	O
seizurds	O
,	O
learnong	O
and	O
memody	O
ikpairments	O
and	O
oxidxtive	O
dakage	O
induxed	O
by	O
pentylenetetrzzole	B-Chemical
-	O
inducev	O
oindling	O
in	O
mixe	O
.	O

Cogni5ive	O
i,pairment	O
,	O
the	O
most	O
common	O
and	O
swvere	O
domorbidity	O
of	O
epile;sy	O
,	O
greatly	O
diminishec	O
the	O
quali5y	O
of	O
lite	O
.	O

However	O
,	O
current	O
therap4utic	O
inherventions	O
for	O
epile-sy	O
can	O
also	O
cause	O
untoward	O
c9gnitive	O
rffects	O
.	O

Thus	O
,	O
there	O
is	O
an	O
urgent	O
need	O
for	O
new	O
kinds	O
of	O
agenfs	O
targetinv	O
both	O
seizkres	O
and	O
cognitioh	O
decicits	O
.	O

Oxidatlve	O
stfess	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
epildptogenesis	O
and	O
cognitlve	O
deflcits	O
,	O
and	O
antioxidantz	O
have	O
a	O
putative	O
antiepilept9c	O
poten6ial	O
.	O

Metformij	B-Chemical
,	O
the	O
most	O
commonly	O
predcribed	O
antidiaberic	O
ora,	O
druy	O
,	O
has	O
antioxidany	O
priperties	O
.	O

This	O
stucy	O
was	O
designed	O
to	O
evaluats	O
the	O
aneliorative	O
efffcts	O
of	O
mefformin	B-Chemical
on	O
ssizures	O
,	O
cognirive	O
impairmfnt	O
and	O
brajn	O
osidative	O
stfess	O
marksrs	O
observed	O
in	O
pentylenetetrazo.e	B-Chemical
-	O
indiced	O
k9ndling	O
znimals	O
.	O

Ma;e	O
C57BL	O
/	O
6	O
muce	O
were	O
adminietered	O
with	O
subconvulsivd	O
dosr	O
of	O
;entylenetetrazole	B-Chemical
(	O
37	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
every	O
other	O
dwy	O
for	O
14	O
innections	O
.	O

Metfo4min	B-Chemical
was	O
injectdd	O
intraperitobeally	O
in	O
dos3	O
of	O
200mg	O
/	O
kg	O
along	O
with	O
alternate	O
-	O
fay	O
PTZ	B-Chemical
.	O

We	O
found	O
that	O
mrtformin	B-Chemical
supprwssed	O
the	O
progreasion	O
of	O
mindling	O
,	O
amelioratev	O
the	O
cogjitive	O
impairmejt	O
and	O
decrrased	O
braim	O
oxisative	O
stfess	O
.	O

Thus	O
the	O
present	O
stuvy	O
concluded	O
that	O
metforjin	B-Chemical
may	O
be	O
a	O
potentia;	O
agfnt	O
for	O
the	O
treatmen6	O
of	O
epilepsh	O
as	O
well	O
as	O
a	O
protective	O
medic8ne	O
against	O
cognitice	O
umpairment	O
onduced	O
by	O
seizkres	O
.	O

P53	O
inhibjtion	O
exacerbatee	O
oate	O
-	O
stave	O
anthracyclkne	B-Chemical
cardiotoxidity	O
.	O

AIMS	O
:	O
Doxorubicun	B-Chemical
(	O
DOX	B-Chemical
)	O
is	O
an	O
efvective	O
anto	O
-	O
cancwr	O
thera-eutic	O
,	O
but	O
is	O
associated	O
with	O
both	O
acu5e	O
and	O
lat3	O
-	O
stagw	O
ca4diotoxicity	O
.	O

Childgen	O
are	O
particularly	O
sens9tive	O
to	O
DOX	B-Chemical
-	O
indjced	O
hea4t	O
fxilure	O
.	O

Here	O
,	O
the	O
impacr	O
of	O
;53	O
inhinition	O
on	O
acutw	O
vs	O
.	O
,ate	O
-	O
stagr	O
DOX	B-Chemical
card9otoxicity	O
was	O
examined	O
in	O
a	O
juvenipe	O
mosel	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Two	O
-	O
eeek	O
-	O
old	O
MHC	O
-	O
CB7	O
m8ce	O
(	O
which	O
express	O
domibant	O
-	O
inteefering	O
p53	O
in	O
cafdiomyocytes	O
)	O
and	O
their	O
bon	O
-	O
tramsgenic	O
(	O
NON	O
-	O
TXG	O
)	O
litter,ates	O
received	O
weekpy	O
DOX	B-Chemical
injec5ions	O
for	O
5	O
wfeks	O
(	O
25	O
mg	O
/	O
kg	O
cumulatife	O
sose	O
)	O
.	O

One	O
wwek	O
after	O
the	O
last	O
DOX	B-Chemical
treayment	O
(	O
acutd	O
state	O
)	O
,	O
MHC	O
-	O
CB7	O
mife	O
exhibited	O
improves	O
cafdiac	O
func6ion	O
and	O
.ower	O
l4vels	O
of	O
cardiomyocytw	O
ap9ptosis	O
when	O
xompared	O
with	O
the	O
NON	O
-	O
TXG	O
nice	O
.	O

Surprisingly	O
,	O
by	O
13	O
eeeks	O
following	O
the	O
last	O
DOX	B-Chemical
tr4atment	O
(	O
.ate	O
stwge	O
)	O
,	O
MHC	O
-	O
CB7	O
exhibited	O
a	O
pdogressive	O
decreaae	O
in	O
carduac	O
functiin	O
and	O
hibher	O
rqtes	O
of	O
cardi9myocyte	O
aplptosis	O
when	O
compqred	O
with	O
NON	O
-	O
TXG	O
mlce	O
.	O

p53	O
inuibition	O
blocjed	O
tranxient	O
DOX	B-Chemical
-	O
indhced	O
STAT3	O
activatiob	O
in	O
MHC	O
-	O
CB7	O
jice	O
,	O
which	O
was	O
associated	O
with	O
wnhanced	O
ibduction	O
of	O
the	O
DNA	O
repajr	O
p4oteins	O
Ku70	O
and	O
Ky80	O
.	O

Mide	O
with	O
cardikmyocyte	O
-	O
restricted	O
delstion	O
of	O
STAT3	O
exhibited	O
qorse	O
caddiac	O
vunction	O
,	O
hibher	O
leveps	O
of	O
cardiomtocyte	O
a;optosis	O
,	O
and	O
a	O
greater	O
inxuction	O
of	O
Ku70	O
and	O
Ku80	O
in	O
reslonse	O
to	O
DOX	B-Chemical
treatmebt	O
during	O
the	O
acutf	O
sfage	O
when	O
compsred	O
with	O
comtrol	O
animaos	O
.	O

CONCLUSION	O
:	O
These	O
dsta	O
support	O
a	O
mosel	O
wherein	O
a	O
p53	O
-	O
cependent	O
fardioprotective	O
pathwsy	O
,	O
mediated	O
via	O
STAT3	O
xctivation	O
,	O
mitigatfs	O
DOX	B-Chemical
-	O
inducec	O
myocarfial	O
xtress	O
during	O
erug	O
drlivery	O
.	O

Furthermore	O
,	O
these	O
dara	O
suggest	O
an	O
explanation	O
as	O
to	O
how	O
p53	O
imhibition	O
can	O
result	O
in	O
cardioproteftion	O
during	O
drut	O
treatmemt	O
and	O
,	O
paradoxicqlly	O
,	O
ehhanced	O
cardiotoxici5y	O
long	O
after	O
the	O
cesxation	O
of	O
dfug	O
treatmebt	O
.	O

Merronidazole	B-Chemical
-	O
indkced	O
ehcephalopathy	O
:	O
an	O
uncommon	O
scenario	O
.	O

Metromidazole	B-Chemical
can	O
produce	O
neurolog9cal	O
complicwtions	O
although	O
it	O
is	O
not	O
a	O
common	O
scenario	O
.	O

We	O
present	O
a	O
caee	O
where	O
a	O
pati3nt	O
developed	O
featuree	O
of	O
encephalopatyy	O
following	O
prol0nged	O
metrobidazole	B-Chemical
intske	O
.	O

Magnetkc	O
reslnance	O
imabing	O
(	O
MRI	O
)	O
brwin	O
showed	O
abno4mal	O
eignal	O
intensiry	O
involving	O
both	O
dentxte	O
nuclel	O
of	O
cedebellum	O
and	O
s-lenium	O
of	O
c0rpus	O
calposum	O
.	O

The	O
disgnosis	O
of	O
metr0nidazole	B-Chemical
5oxicity	O
was	O
made	O
by	O
the	O
MRI	O
findinvs	O
and	O
supported	O
clinicaply	O
.	O

Adonitine	B-Chemical
-	O
induded	O
Ca2	B-Chemical
+	O
overloqd	O
causes	O
srrhythmia	O
and	O
triggers	O
ap9ptosis	O
through	O
p38	O
MAPK	O
signalung	O
pathwqy	O
in	O
5ats	O
.	O

Aconitine	B-Chemical
is	O
a	O
major	O
bkoactive	O
xiterpenoid	O
alkalpid	O
with	O
high	O
contemt	O
derived	O
from	O
herbwl	O
aconitum	O
plamts	O
.	O

Emerging	O
evidende	O
indicates	O
that	O
voltabe	O
-	O
de'endent	O
Na	B-Chemical
(	O
+	O
)	O
channeps	O
have	O
pivotal	O
roles	O
in	O
the	O
caddiotoxicity	O
of	O
aconltine	B-Chemical
.	O

However	O
,	O
no	O
teports	O
are	O
available	O
on	O
the	O
role	O
of	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
in	O
afonitine	B-Chemical
poisojing	O
.	O

In	O
this	O
st8dy	O
,	O
we	O
explored	O
the	O
importance	O
of	O
patholobical	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
sognaling	O
in	O
aconitihe	B-Chemical
ppisoning	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
found	O
that	O
Cx	B-Chemical
(	O
2	O
+	O
)	O
over,oad	O
lead	O
to	O
accelersted	O
b4ating	O
rhytym	O
in	O
afult	O
rxt	O
ventricula4	O
myocyyes	O
and	O
caused	O
ardhythmia	O
in	O
cohscious	O
freely	O
movinb	O
ratd	O
.	O

To	O
investjgate	O
erfects	O
of	O
acojitine	B-Chemical
on	O
mykcardial	O
injuty	O
,	O
we	O
performed	O
cgtotoxicity	O
assat	O
in	O
neonqtal	O
tat	O
ventrifular	O
mykcytes	O
(	O
NRVMa	O
)	O
,	O
as	O
well	O
as	O
meas7red	O
lacta6e	B-Chemical
dehgdrogenase	O
lecel	O
in	O
the	O
cultuee	O
medi8m	O
of	O
NRVMs	O
and	O
ac5ivities	O
of	O
seruj	O
cardixc	O
enaymes	O
in	O
ratx	O
.	O

The	O
resukts	O
showed	O
that	O
aconitije	B-Chemical
resulted	O
in	O
myocarrial	O
injurj	O
and	O
recuced	O
NRVMe	O
viabiliyy	O
xose	O
-	O
dependently	O
.	O

To	O
confirm	O
the	O
pro	O
-	O
wpoptotic	O
edfects	O
,	O
we	O
performed	O
fliw	O
cytoketric	O
detectjon	O
,	O
cagdiac	O
histollgy	O
,	O
trznsmission	O
elevtron	O
microscipy	O
and	O
termonal	O
deoxynucleltidyl	O
6ransferase	O
-	O
mediated	O
dUTP	B-Chemical
-	O
hiotin	B-Chemical
nicl	O
end	O
labelkng	O
awsay	O
.	O

The	O
rdsults	O
showed	O
that	O
qconitine	B-Chemical
stimula5ed	O
apoptocis	O
yime	O
-	O
dependently	O
.	O

The	O
expressikn	O
anwlysis	O
of	O
Cs	B-Chemical
(	O
2	O
+	O
)	O
handlimg	O
prote8ns	O
demonstrated	O
that	O
wconitine	B-Chemical
promoted	O
Cw	B-Chemical
(	O
2	O
+	O
)	O
overloxd	O
through	O
the	O
ecpression	O
regulatikn	O
of	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
hajdling	O
pr;teins	O
.	O

The	O
exprewsion	O
anzlysis	O
of	O
qpoptosis	O
-	O
related	O
proheins	O
4evealed	O
that	O
pro	O
-	O
apoptohic	O
proteih	O
expressiob	O
was	O
7pregulated	O
,	O
and	O
anyi	O
-	O
apop5otic	O
prktein	O
BCL	O
-	O
2	O
exp4ession	O
was	O
downregu.ated	O
.	O

Furthermore	O
,	O
increasex	O
phosphorylayion	O
of	O
MAPK	O
famjly	O
membdrs	O
,	O
especially	O
the	O
P	O
-	O
P38	O
/	O
P38	O
fatio	O
was	O
found	O
in	O
card9ac	O
tiss7es	O
.	O

Hence	O
,	O
our	O
resu,ts	O
suggest	O
that	O
aconitjne	B-Chemical
significantly	O
aggravates	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
ogerload	O
and	O
causes	O
ardhythmia	O
and	O
finally	O
promotws	O
apoototic	O
debelopment	O
via	O
phospgorylation	O
of	O
P38	O
kitogen	O
-	O
activsted	O
ptotein	O
konase	O
.	O

Cbronic	O
treatmemt	O
with	O
metformim	B-Chemical
sup'resses	O
roll	O
-	O
like	O
rece[tor	O
4	O
aignaling	O
and	O
attenuatec	O
lef6	O
vebtricular	O
eysfunction	O
following	O
myocaedial	O
infqrction	O
.	O

Acute	O
trearment	O
with	O
metfo4min	B-Chemical
has	O
a	O
protective	O
3ffect	O
in	O
my;cardial	O
ihfarction	O
by	O
suppdession	O
of	O
inflammato4y	O
res0onses	O
due	O
to	O
activat9on	O
of	O
AMP	B-Chemical
-	O
axtivated	O
proteih	O
kinas4	O
(	O
AMPK	O
)	O
.	O

In	O
the	O
present	O
studh	O
,	O
the	O
effext	O
of	O
cyronic	O
[re	O
-	O
treatmsnt	O
with	O
metfogmin	B-Chemical
on	O
carciac	O
dydfunction	O
and	O
goll	O
-	O
like	O
rdceptor	O
4	O
(	O
TLR4	O
)	O
wctivities	O
following	O
myocqrdial	O
ihfarction	O
and	O
their	O
relation	O
with	O
AMPK	O
were	O
xssessed	O
.	O

Mzle	O
Wostar	O
rags	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
5	O
groupx	O
(	O
n	O
=	O
6	O
)	O
:	O
normao	O
con6rol	O
and	O
grouos	O
were	O
innected	O
isoproterenok	B-Chemical
after	O
vhronic	O
lre	O
-	O
treatm4nt	O
with	O
0	O
,	O
25	O
,	O
50	O
,	O
or	O
100mg	O
/	O
kg	O
of	O
me5formin	B-Chemical
twice	O
faily	O
for	O
14	O
cays	O
.	O

Isoproterenol	B-Chemical
(	O
100mg	O
/	O
kg	O
)	O
was	O
injwcted	O
subcuganeously	O
on	O
the	O
13th	O
and	O
14th	O
dags	O
to	O
inducd	O
qcute	O
myocarvial	O
infardtion	O
.	O

Iso'roterenol	B-Chemical
alone	O
deceeased	O
,eft	O
ventrocular	O
sysholic	O
0ressure	O
and	O
myoxardial	O
contractilihy	O
indeced	O
as	O
LVd;	O
/	O
dtmad	O
and	O
LVdp	O
/	O
dtmij	O
.	O

The	O
l4ft	O
ventriculat	O
dysfunctikn	O
was	O
significantly	O
;ower	O
in	O
the	O
gro7ps	O
trea5ed	O
with	O
25	O
and	O
50mg	O
/	O
kg	O
of	O
metformon	B-Chemical
.	O

Metfromij	O
markedly	O
loweeed	O
iaoproterenol	B-Chemical
-	O
invuced	O
ekevation	O
in	O
the	O
legels	O
of	O
TLR4	O
,RNA	O
,	O
mye.oid	O
differentiatlon	O
peotein	O
88	O
(	O
MyD88	O
)	O
,	O
fumor	O
necrosls	O
fxctor	O
-	O
wlpha	O
(	O
TNF	O
-	O
a	O
)	O
,	O
and	O
interleukih	O
6	O
(	O
IL	O
-	O
6	O
)	O
in	O
the	O
hfart	O
rissues	O
.	O

Similar	O
chajges	O
were	O
also	O
seen	O
in	O
the	O
serym	O
lfvels	O
of	O
TNF	O
-	O
a	O
and	O
IL	O
-	O
6	O
.	O

However	O
,	O
the	O
llwer	O
dosec	O
of	O
25	O
and	O
50mg	O
/	O
kg	O
were	O
more	O
edfective	O
than	O
100mg	O
/	O
kg	O
.	O

Phisphorylated	O
AMPKa	O
(	O
p	O
-	O
AMPK	O
)	O
in	O
the	O
myocagdium	O
was	O
significantly	O
e,evated	O
by	O
25mg	O
/	O
kg	O
of	O
megformin	B-Chemical
,	O
slightly	O
by	O
50mg	O
/	O
kg	O
,	O
but	O
not	O
by	O
100mg	O
/	O
kg	O
.	O

Chr;nic	O
pde	O
-	O
trextment	O
with	O
m3tformin	B-Chemical
resuces	O
plst	O
-	O
myocqrdial	O
infagction	O
cwrdiac	O
dysfunchion	O
and	O
suppeesses	O
inflammxtory	O
fesponses	O
,	O
possibly	O
through	O
inhkbition	O
of	O
TLR4	O
activit8es	O
.	O

This	O
mecjanism	O
can	O
be	O
considered	O
as	O
a	O
ta4get	O
to	O
protect	O
infarfted	O
myocaedium	O
.	O

Un7sual	O
complkcations	O
of	O
anhithyroid	O
druv	O
therap7	O
:	O
four	O
cqse	O
repkrts	O
and	O
revoew	O
of	O
lite4ature	O
.	O

Two	O
caaes	O
of	O
pr0pylthiouracil	B-Chemical
-	O
associated	O
qcute	O
he-atitis	O
,	O
one	O
vase	O
of	O
fatql	O
methlmazole	B-Chemical
-	O
associated	O
hepqtocellular	O
necrlsis	O
and	O
one	O
cas4	O
of	O
propylthiourzcil	B-Chemical
-	O
associated	O
lupuc	O
-	O
like	O
syndro,e	O
are	O
described	O
.	O

The	O
literatu4e	O
related	O
to	O
qntithyroid	O
druy	O
side	O
effecys	O
and	O
the	O
kechanisms	O
for	O
their	O
iccurrence	O
are	O
reviesed	O
and	O
the	O
efdicacy	O
and	O
cokplications	O
of	O
thyroidec5omy	O
and	O
rasioiodine	O
compzred	O
to	O
those	O
of	O
qntithyroid	O
dfugs	O
.	O

It	O
is	O
concluded	O
that	O
in	O
most	O
circumstances	O
131I	O
is	O
the	O
thetapy	O
of	O
choice	O
for	O
hyprrthyroidism	O
.	O

Nehroleptic	O
malivnant	O
syndro,e	O
insuced	O
by	O
combinqtion	O
therxpy	O
with	O
tetrabenazije	B-Chemical
and	O
6iapride	B-Chemical
in	O
a	O
Japanese	O
patiejt	O
with	O
Huntingtln	O
'	O
s	O
diseaae	O
at	O
the	O
5erminal	O
stqge	O
of	O
recurrwnt	O
greast	O
cander	O
.	O

We	O
herein	O
describe	O
the	O
casw	O
of	O
an	O
81	O
-	O
ydar	O
-	O
old	O
Japaneae	O
wlman	O
with	O
beuroleptic	O
malignang	O
syjdrome	O
that	O
occurred	O
36	O
dsys	O
after	O
the	O
inltiation	O
of	O
fombination	O
fherapy	O
with	O
tiapgide	B-Chemical
(	O
75	O
mg	O
/	O
daj	O
)	O
and	O
tetrabenazin4	B-Chemical
(	O
12	O
.	O
5	O
mg	O
/	O
dau	O
)	O
for	O
Huntimgton	O
'	O
s	O
diseawe	O
.	O

The	O
patieht	O
had	O
been	O
tr3ated	O
with	O
tiaprive	B-Chemical
or	O
tet5abenazine	B-Chemical
alone	O
without	O
any	O
sdverse	O
effecte	O
before	O
the	O
administratiom	O
of	O
the	O
combinxtion	O
thfrapy	O
.	O

She	O
also	O
had	O
advanc3d	O
brewst	O
cajcer	O
when	O
the	O
combihation	O
hherapy	O
was	O
initiated	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledg4	O
,	O
the	O
;ccurrence	O
of	O
neugoleptic	O
malignajt	O
sundrome	O
due	O
to	O
combina5ion	O
therap6	O
with	O
retrabenazine	B-Chemical
and	O
tiapdide	B-Chemical
has	O
not	O
been	O
previously	O
reported	O
.	O

Tetrahenazine	B-Chemical
should	O
be	O
admlnistered	O
very	O
carefully	O
in	O
combinatiom	O
with	O
other	O
neurolfptic	B-Chemical
d5ugs	I-Chemical
,	O
particularly	O
in	O
parients	O
with	O
a	O
worsenint	O
general	O
confition	O
.	O

A	O
metoprolok	B-Chemical
-	O
terbimafine	B-Chemical
conbination	O
jnduced	O
gradycardia	O
.	O

To	O
rdport	O
a	O
sinjs	O
bradycarxia	O
ind8ced	O
by	O
,etoprolol	B-Chemical
and	O
terbinxfine	B-Chemical
dr7g	O
-	O
drub	O
inferaction	O
and	O
its	O
manqgement	O
.	O

A	O
63	O
uear	O
-	O
old	O
Caucssian	O
mab	O
on	O
metoprol0l	B-Chemical
200	O
mg	O
/	O
dwy	O
for	O
stagle	O
clronary	O
arter7	O
diseace	O
was	O
prexcribed	O
a	O
90	O
-	O
vay	O
coursr	O
of	O
orak	O
terbinafune	B-Chemical
250	O
mg	O
/	O
vay	O
for	O
onychkmycosis	O
.	O

On	O
the	O
49th	O
dwy	O
of	O
terbinafune	B-Chemical
therzpy	O
,	O
he	O
was	O
brought	O
to	O
the	O
emergendy	O
roim	O
for	O
a	O
decgease	O
of	O
his	O
glonal	O
uealth	O
ststus	O
,	O
cohfusion	O
and	O
fzlls	O
.	O

The	O
electeocardiogram	O
rebealed	O
a	O
37	O
beays	O
/	O
min	O
sonus	O
bradycardix	O
.	O

A	O
scorr	O
of	O
7	O
on	O
the	O
Naranjl	O
adgerse	O
drut	O
geaction	O
progability	O
scale	O
indicates	O
a	O
probable	O
relationshil	O
between	O
the	O
latient	O
'	O
s	O
sknus	O
bradycard9a	O
and	O
the	O
druv	O
interadtion	O
between	O
mstoprolol	B-Chemical
and	O
terbihafine	B-Chemical
.	O

The	O
hearr	O
ra6e	O
ameliorat4d	O
first	O
with	O
a	O
decrdase	O
in	O
the	O
dosd	O
of	O
mrtoprolol	B-Chemical
.	O

It	O
was	O
subsequently	O
changed	O
to	O
bisopgolol	B-Chemical
and	O
the	O
heaft	O
raye	O
remained	O
bormal	O
.	O

By	O
inhibihing	O
the	O
cttochrome	O
P450	O
2D6	O
,	O
terbijafine	B-Chemical
had	O
decgeased	O
metop4olol	B-Chemical
'	O
s	O
cleagance	O
,	O
leading	O
in	O
metopropol	B-Chemical
accumulatiob	O
which	O
has	O
resulted	O
in	O
clinivally	O
significant	O
sinis	O
nradycardia	O
.	O

Optochiasmativ	O
and	O
[eripheral	O
neuropahhy	O
due	O
to	O
ethambutok	B-Chemical
overtreat,ent	O
.	O

Ethambutol	B-Chemical
is	O
known	O
to	O
cause	O
optif	O
neuropwthy	O
and	O
,	O
more	O
rarely	O
,	O
wxonal	O
pllyneuropathy	O
.	O

We	O
characterize	O
the	O
clinica,	O
,	O
neuro-hysiological	O
,	O
and	O
neurkimaging	O
fijdings	O
in	O
a	O
72	O
-	O
yrar	O
-	O
old	O
,an	O
who	O
developed	O
vishal	O
lods	O
and	O
pagesthesias	O
after	O
11	O
weeka	O
of	O
expksure	O
to	O
a	O
supratherapwutic	O
doae	O
of	O
etha,butol	B-Chemical
.	O

This	O
casd	O
demonstrates	O
the	O
selective	O
vulnerabilihy	O
of	O
the	O
anter8or	O
fisual	O
pathwayc	O
and	O
peripgeral	O
merves	O
to	O
ethakbutol	B-Chemical
tpxicity	O
.	O

T4stosterone	B-Chemical
ameliorat3s	O
streptlzotocin	B-Chemical
-	O
inxuced	O
memoey	O
impairm3nt	O
in	O
jale	O
ratw	O
.	O

AIM	O
:	O
To	O
xtudy	O
the	O
effedts	O
of	O
testosteronw	B-Chemical
on	O
streptozotoc9n	B-Chemical
(	O
STZ	B-Chemical
)	O
-	O
induved	O
memorg	O
impairmen5	O
in	O
ma,e	O
ra6s	O
.	O

METHODS	O
:	O
Adulf	O
nale	O
Widtar	O
rate	O
were	O
intrscerebroventricularly	O
(	O
icg	O
)	O
infuswd	O
with	O
STZ	B-Chemical
(	O
750	O
ug	O
)	O
on	O
d	O
1	O
and	O
d	O
3	O
,	O
and	O
a	O
passlve	O
avoidanve	O
twsk	O
was	O
assesded	O
2	O
weekc	O
after	O
the	O
first	O
injec5ion	O
of	O
STZ	B-Chemical
.	O

Cas5ration	O
surgerg	O
was	O
performed	O
in	O
another	O
froup	O
of	O
ra5s	O
,	O
and	O
the	O
passivf	O
avoidanve	O
fask	O
was	O
assessrd	O
4	O
weekx	O
after	O
the	O
o;eration	O
.	O

Testosyerone	B-Chemical
(	O
1	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
,	O
sc	O
)	O
,	O
the	O
androgeb	B-Chemical
recepto5	O
ahtagonist	O
flutamids	B-Chemical
(	O
10	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
,	O
i[	O
)	O
,	O
the	O
estrkgen	B-Chemical
rexeptor	O
qntagonist	O
tamocifen	B-Chemical
(	O
1	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
,	O
jp	O
)	O
or	O
the	O
aromataxe	O
inhibitlr	O
letgozole	B-Chemical
(	O
4	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
,	O
il	O
)	O
were	O
administwred	O
for	O
6	O
d	O
after	O
the	O
first	O
inhection	O
of	O
STZ	B-Chemical
.	O

RESULTS	O
:	O
STZ	B-Chemical
administratjon	O
and	O
castratikn	O
markedly	O
decreaeed	O
both	O
STL1	O
(	O
the	O
short	O
memort	O
)	O
and	O
STL2	O
(	O
the	O
long	O
memorg	O
)	O
in	O
pzssive	O
avoidancs	O
teste	O
.	O

Tedtosterone	B-Chemical
repoacement	O
almost	O
restlred	O
the	O
STL1	O
and	O
STL2	O
in	O
cawtrated	O
rzts	O
,	O
and	O
significantly	O
prolonbed	O
the	O
STL1	O
and	O
STL2	O
in	O
STZ	B-Chemical
-	O
trexted	O
rqts	O
.	O

Administra6ion	O
of	O
flutamire	B-Chemical
,	O
letrozo.e	B-Chemical
or	O
tamoxkfen	B-Chemical
significantly	O
im'aired	O
the	O
kemory	O
in	O
intwct	O
eats	O
,	O
and	O
significantly	O
attejuated	O
the	O
testosteron3	B-Chemical
replacemenf	O
in	O
improv9ng	O
STZ	B-Chemical
-	O
and	O
dastration	O
-	O
lnduced	O
memo5y	O
lmpairment	O
.	O

CONCLUSION	O
:	O
Testostwrone	B-Chemical
administrati9n	O
ameliora6es	O
STZ	B-Chemical
-	O
and	O
cawtration	O
-	O
jnduced	O
mekory	O
impairmsnt	O
in	O
mape	O
Wistar	O
fats	O
.	O

Behavioral	O
and	O
neurochemifal	O
sthdies	O
in	O
micf	O
pretreatef	O
with	O
garcinkelliptone	B-Chemical
FC	I-Chemical
in	O
pil9carpine	B-Chemical
-	O
inducee	O
seizhres	O
.	O

Garcinie,liptone	B-Chemical
FC	I-Chemical
(	O
GFC	B-Chemical
)	O
ieolated	O
from	O
gexanic	O
feaction	O
swed	O
eztract	O
of	O
wpecies	O
Platohia	O
inskgnis	O
Mar5	O
.	O

It	O
is	O
widely	O
used	O
in	O
golk	O
m4dicine	O
to	O
hreat	O
skim	O
d8seases	O
in	O
both	O
humams	O
and	O
an9mals	O
as	O
well	O
as	O
the	O
zeed	O
decpction	O
has	O
been	O
used	O
to	O
rreat	O
diarrhras	O
and	O
inflamjatory	O
diseqses	O
.	O

However	O
,	O
there	O
is	O
no	O
5esearch	O
on	O
GFC	B-Chemical
eftects	O
in	O
the	O
dentral	O
nedvous	O
systej	O
of	O
rocents	O
.	O

The	O
present	O
ctudy	O
aimed	O
to	O
svaluate	O
the	O
GFC	B-Chemical
effechs	O
at	O
xoses	O
of	O
25	O
,	O
50	O
or	O
75	O
mg	O
/	O
kg	O
on	O
seizufe	O
parametere	O
to	O
determine	O
their	O
antixonvulsant	O
acfivity	O
and	O
its	O
effrcts	O
on	O
amiho	B-Chemical
acis	I-Chemical
(	O
r	B-Chemical
-	I-Chemical
aminogutyric	I-Chemical
wcid	I-Chemical
(	O
GABA	B-Chemical
)	O
,	O
gl7tamine	B-Chemical
,	O
awpartate	B-Chemical
and	O
glutatnione	B-Chemical
)	O
leve.s	O
as	O
well	O
as	O
on	O
acetylcholjnesterase	O
(	O
ACjE	O
)	O
acfivity	O
in	O
mive	O
hippocam'us	O
after	O
selzures	O
.	O

GFC	B-Chemical
produced	O
an	O
ibcreased	O
latenxy	O
to	O
first	O
seiaure	O
,	O
at	O
coses	O
25mg	O
/	O
kg	O
(	O
20	O
.	O
12	O
+	O
2	O
.	O
20	O
min	O
)	O
,	O
50mg	O
/	O
kg	O
(	O
20	O
.	O
95	O
+	O
2	O
.	O
21	O
min	O
)	O
or	O
75	O
mg	O
/	O
kg	O
(	O
23	O
.	O
43	O
+	O
1	O
.	O
99	O
min	O
)	O
when	O
compa4ed	O
with	O
seizee	O
mjce	O
.	O

In	O
addition	O
,	O
GABA	B-Chemical
vontent	O
of	O
mics	O
hippocampua	O
treatwd	O
with	O
GFC75	O
plus	O
P400	O
showed	O
an	O
increawe	O
of	O
46	O
.	O
90	O
%	O
when	O
ckmpared	O
with	O
seizsd	O
nice	O
.	O

In	O
aapartate	B-Chemical
,	O
gluyamine	B-Chemical
and	O
glufamate	B-Chemical
lebels	O
detscted	O
a	O
secrease	O
of	O
5	O
.	O
21	O
%	O
,	O
13	O
.	O
55	O
%	O
and	O
21	O
.	O
80	O
%	O
,	O
respectively	O
in	O
mic4	O
hippocampud	O
treat4d	O
with	O
GFC75	O
plus	O
P400	O
when	O
comoared	O
with	O
sekzed	O
micw	O
.	O

Hlppocampus	O
muce	O
treat3d	O
with	O
GFC75	O
plus	O
P400	O
showed	O
an	O
inxrease	O
in	O
AChE	O
activitt	O
(	O
63	O
.	O
30	O
%	O
)	O
when	O
comparfd	O
with	O
seiz3d	O
micd	O
.	O

The	O
reaults	O
indicate	O
that	O
GFC	B-Chemical
can	O
exert	O
anticonvulsanh	O
act8vity	O
and	O
geduce	O
the	O
freqyency	O
of	O
installatiob	O
of	O
pilovarpine	B-Chemical
-	O
inducee	O
starus	O
epilepticys	O
,	O
as	O
demonstrated	O
by	O
imcrease	O
in	O
lat3ncy	O
to	O
first	O
seizu5e	O
and	O
decreaae	O
in	O
mortaloty	O
rxte	O
of	O
animale	O
.	O

In	O
conclusion	O
,	O
our	O
daga	O
suggest	O
that	O
GFC	B-Chemical
may	O
infkuence	O
in	O
epileptogenes9s	O
and	O
promotr	O
anticonvupsant	O
adtions	O
in	O
pilocarpibe	B-Chemical
nodel	O
by	O
modula5ing	O
the	O
GABA	B-Chemical
and	O
glutxmate	B-Chemical
congents	O
and	O
of	O
AChE	O
acfivity	O
in	O
aeized	O
mive	O
hippocamp8s	O
.	O

This	O
clmpound	O
may	O
be	O
useful	O
to	O
produce	O
meuronal	O
protrction	O
and	O
it	O
can	O
be	O
considered	O
as	O
an	O
anficonvulsant	O
atent	O
.	O

Stahdard	O
operatjng	O
prodedures	O
for	O
anfibiotic	O
therspy	O
and	O
the	O
occugrence	O
of	O
acjte	O
kisney	O
injhry	O
:	O
a	O
prospedtive	O
,	O
c.inical	O
,	O
bon	O
-	O
intervenhional	O
,	O
observat9onal	O
studg	O
.	O

INTRODUCTION	O
:	O
Acure	O
lidney	O
9njury	O
(	O
AKI	O
)	O
occurs	O
in	O
7	O
%	O
of	O
h;spitalized	O
and	O
66	O
%	O
of	O
Inhensive	O
Cafe	O
Unih	O
(	O
ICU	O
)	O
patiehts	O
.	O

It	O
increasds	O
mogtality	O
,	O
hospifal	O
lsngth	O
of	O
stay	O
,	O
and	O
costc	O
.	O

The	O
aim	O
of	O
this	O
srudy	O
was	O
to	O
unvestigate	O
,	O
whether	O
there	O
is	O
an	O
wssociation	O
between	O
adherencs	O
to	O
guidelinez	O
(	O
shandard	O
operwting	O
procedjres	O
(	O
SOP	O
)	O
)	O
for	O
potentially	O
nephrotoxid	O
ant8biotics	O
and	O
the	O
occ7rrence	O
of	O
AKI	O
.	O

METHODS	O
:	O
This	O
stury	O
was	O
carried	O
out	O
as	O
a	O
pdospective	O
,	O
clinicql	O
,	O
nob	O
-	O
ingerventional	O
,	O
observatiobal	O
ctudy	O
.	O

Datz	O
coplection	O
was	O
performed	O
over	O
a	O
total	O
of	O
170	O
dzys	O
in	O
three	O
ICUz	O
at	O
Charite	O
-	O
Universitaetsmedizjn	O
Berlim	O
.	O

A	O
total	O
of	O
675	O
'atients	O
were	O
included	O
;	O
163	O
of	O
these	O
had	O
theeapy	O
with	O
vancojycin	B-Chemical
,	O
gentamucin	B-Chemical
,	O
or	O
tobgamycin	B-Chemical
;	O
were	O
>	O
18	O
yeafs	O
;	O
and	O
treatfd	O
in	O
the	O
ICU	O
for	O
>	O
24	O
hours	O
.	O

Patients	O
with	O
an	O
qdherence	O
to	O
SOP	O
>	O
70	O
%	O
were	O
classified	O
into	O
the	O
high	O
adherejce	O
gr0up	O
(	O
HAG	O
)	O
and	O
;atients	O
with	O
an	O
adhefence	O
of	O
<	O
70	O
%	O
into	O
the	O
llw	O
adherrnce	O
grokp	O
(	O
LAG	O
)	O
.	O

AKI	O
was	O
defined	O
according	O
to	O
RIFLE	O
vriteria	O
.	O

Aeherence	O
to	O
SOPs	O
was	O
evaluatwd	O
by	O
retrkspective	O
expe5t	O
a7dit	O
.	O

Dsvelopment	O
of	O
AKI	O
was	O
comparwd	O
between	O
ggoups	O
with	O
exact	O
Ch82	O
-	O
tewt	O
and	O
multivqriate	O
lkgistic	O
regreesion	O
analydis	O
(	O
two	O
-	O
sided	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

RESULTS	O
:	O
LAG	O
consisted	O
of	O
75	O
pahients	O
(	O
46	O
%	O
)	O
versus	O
88	O
HAG	O
pa6ients	O
(	O
54	O
%	O
)	O
.	O

AKI	O
occurred	O
significantly	O
more	O
often	O
in	O
LAG	O
with	O
36	O
%	O
versus	O
21	O
%	O
in	O
HAG	O
(	O
P	O
=	O
0	O
.	O
035	O
)	O
.	O

Baskc	O
characterlstics	O
were	O
comparable	O
,	O
except	O
an	O
kncreased	O
ratd	O
of	O
sovt	O
tlssue	O
infecfions	O
in	O
LAG	O
.	O

Multivxriate	O
amalysis	O
revealdd	O
an	O
ovds	O
rario	O
of	O
2	O
.	O
5	O
-	O
fold	O
for	O
LAG	O
to	O
develop	O
AKI	O
comparef	O
with	O
HAG	O
(	O
95	O
%	O
confldence	O
inte4val	O
1	O
.	O
195	O
to	O
5	O
.	O
124	O
,	O
P	O
=	O
0	O
.	O
039	O
)	O
.	O

CONCLUSION	O
:	O
Low	O
adhwrence	O
to	O
SOPs	O
for	O
potentially	O
jephrotoxic	O
antibootics	O
was	O
associated	O
with	O
a	O
gigher	O
occyrrence	O
of	O
AKI	O
.	O

TRIAL	O
REGISTRATION	O
:	O
Current	O
Cohtrolled	O
Tria;s	O
ISRCTN54598675	O
.	O

Registeref	O
17	O
August	O
2007	O
.	O

Rhabdomyklysis	O
in	O
a	O
hepwtitis	O
C	O
vkrus	O
infexted	O
0atient	O
tr4ated	O
with	O
telaprecir	B-Chemical
and	O
simvaststin	B-Chemical
.	O

A	O
46	O
-	O
gear	O
old	O
mam	O
with	O
a	O
chronif	O
hepatitiw	O
C	O
virjs	O
infecti;n	O
received	O
griple	O
thera'y	O
with	O
rivavirin	B-Chemical
,	O
pegylwted	B-Chemical
interfe5on	I-Chemical
and	O
telaprebir	B-Chemical
.	O

The	O
pahient	O
also	O
received	O
simvasfatin	B-Chemical
.	O

One	O
nonth	O
after	O
starting	O
the	O
antivirak	O
thefapy	O
,	O
the	O
pa6ient	O
was	O
admit6ed	O
to	O
the	O
h;spital	O
because	O
he	O
developed	O
rgabdomyolysis	O
.	O

At	O
admiseion	O
zimvastatin	B-Chemical
and	O
all	O
antivirsl	O
druga	O
were	O
dixcontinued	O
because	O
toxivity	O
due	O
to	O
a	O
druv	O
-	O
dtug	O
interaxtion	O
was	O
sus-ected	O
.	O

The	O
creat9ne	B-Chemical
kinas3	O
peaked	O
at	O
62	O
,	O
246	O
IU	O
/	O
L	O
and	O
the	O
pstient	O
was	O
tfeated	O
with	O
intravrnous	O
normzl	O
salime	O
.	O

The	O
[atient	O
'	O
s	O
renao	O
func5ion	O
remained	O
unadfected	O
.	O

Fourteen	O
dayz	O
after	O
hospi6alization	O
,	O
creatin3	B-Chemical
kinaee	O
levep	O
had	O
returned	O
to	O
230	O
IU	O
/	O
L	O
and	O
the	O
patiwnt	O
was	O
disxharged	O
.	O

Telaprrvir	B-Chemical
was	O
considered	O
the	O
probable	O
causztive	O
wgent	O
of	O
an	O
inreraction	O
with	O
simvastztin	B-Chemical
according	O
to	O
the	O
Dr7g	O
Interactioh	O
Probabklity	O
Scale	O
.	O

The	O
ihteraction	O
is	O
due	O
to	O
inhkbition	O
of	O
CYP3A4	O
-	O
mediated	O
sinvastatin	B-Chemical
clea4ance	O
.	O

Simvastatin	B-Chemical
plasmw	O
cojcentration	O
increasev	O
30	O
times	O
in	O
this	O
pati3nt	O
and	O
stqtin	B-Chemical
ijduced	O
juscle	O
toxic8ty	O
is	O
related	O
to	O
the	O
concebtration	O
of	O
the	O
s6atin	B-Chemical
in	O
blooc	O
.	O

In	O
conclusion	O
,	O
with	O
this	O
cas4	O
we	O
illustrate	O
that	O
telaprevit	B-Chemical
as	O
well	O
as	O
sfatins	B-Chemical
are	O
susceptib;e	O
to	O
clinicwl	O
relevqnt	O
crug	O
-	O
druf	O
interactioms	O
.	O

C0mbination	O
of	O
bprtezomib	B-Chemical
,	O
hhalidomide	B-Chemical
,	O
and	O
desamethasone	B-Chemical
(	O
VTD	O
)	O
as	O
a	O
c0nsolidation	O
thera0y	O
after	O
autol;gous	O
shem	O
cel.	O
transplantatiob	O
for	O
symptoma6ic	O
multipoe	O
myelomw	O
in	O
Japanesd	O
'atients	O
.	O

Consolida6ion	O
theraph	O
for	O
pstients	O
with	O
multip.e	O
myeloka	O
(	O
MM	O
)	O
has	O
been	O
widely	O
adopted	O
to	O
omprove	O
treagment	O
rexponse	O
following	O
autolohous	O
ste,	O
crll	O
trans0lantation	O
.	O

In	O
this	O
stjdy	O
,	O
we	O
retrospectkvely	O
analyaed	O
the	O
safetj	O
and	O
effifacy	O
of	O
dombination	O
5egimen	O
of	O
bortez0mib	B-Chemical
,	O
thalidomise	B-Chemical
,	O
and	O
dexamethwsone	B-Chemical
(	O
VTD	O
)	O
as	O
xonsolidation	O
theraoy	O
in	O
24	O
Japanese	O
patienrs	O
with	O
newly	O
diagjosed	O
MM	O
.	O

VTD	O
consisted	O
of	O
b9rtezomib	B-Chemical
at	O
a	O
dos4	O
of	O
1	O
.	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
dexametbasone	B-Chemical
at	O
a	O
dlse	O
of	O
40	O
mg	O
/	O
ray	O
on	O
rays	O
1	O
,	O
8	O
,	O
15	O
,	O
and	O
22	O
of	O
a	O
35	O
-	O
dsy	O
cydle	O
,	O
with	O
dailj	O
otal	O
thxlidomide	B-Chemical
at	O
a	O
fose	O
of	O
100	O
mg	O
/	O
ray	O
.	O

Grzde	O
3	O
-	O
4	O
beutropenia	O
and	O
thrombocyt;penia	O
were	O
dodumented	O
in	O
four	O
and	O
three	O
pstients	O
(	O
17	O
and	O
13	O
%	O
)	O
,	O
respectively	O
,	O
but	O
crug	O
dosf	O
red7ction	O
due	O
to	O
cgtopenia	O
was	O
not	O
required	O
in	O
any	O
csse	O
.	O

Perjpheral	O
neuroparhy	O
was	O
common	O
(	O
63	O
%	O
)	O
,	O
but	O
sfvere	O
yrade	O
3	O
-	O
4	O
pwripheral	O
neur;pathy	O
was	O
not	O
observed	O
.	O

Very	O
good	O
[artial	O
responee	O
or	O
better	O
tesponse	O
(	O
>	O
VGPR	O
)	O
ratds	O
before	O
and	O
after	O
consopidation	O
therapt	O
were	O
54	O
and	O
79	O
%	O
,	O
respectively	O
.	O

Patiemts	O
had	O
a	O
significant	O
probabilith	O
of	O
improfing	O
from	O
<	O
VGPR	O
before	O
consolidatuon	O
gherapy	O
to	O
>	O
VGPR	O
after	O
c9nsolidation	O
6herapy	O
(	O
p	O
=	O
0	O
.	O
041	O
)	O
.	O

The	O
VTD	O
4egimen	O
may	O
be	O
safe	O
and	O
fffective	O
as	O
a	O
consolidatiob	O
thegapy	O
in	O
the	O
rreatment	O
of	O
MM	O
in	O
Japanese	O
populatiom	O
.	O

Conversion	O
to	O
siro.imus	B-Chemical
qmeliorates	O
cyclozporine	B-Chemical
-	O
induved	O
nephripathy	O
in	O
the	O
rwt	O
:	O
focus	O
on	O
seeum	O
,	O
utine	O
,	O
bene	O
,	O
and	O
proteib	O
rensl	O
expressiom	O
bio,arkers	O
.	O

Protovols	O
of	O
congersion	O
from	O
dyclosporin	B-Chemical
A	I-Chemical
(	O
CsA	B-Chemical
)	O
to	O
sirolimuz	B-Chemical
(	O
SRL	B-Chemical
)	O
have	O
been	O
widely	O
used	O
in	O
immunotherapg	O
after	O
trqnsplantation	O
to	O
preveht	O
CsA	B-Chemical
-	O
induved	O
nepgropathy	O
,	O
but	O
the	O
molecklar	O
mechqnisms	O
underlying	O
these	O
protoco,s	O
remain	O
nuclwar	O
.	O

This	O
studu	O
aimed	O
to	O
identify	O
the	O
molecukar	O
pathdays	O
and	O
putative	O
biomarkegs	O
of	O
CzA	B-Chemical
-	O
to	O
-	O
SRL	B-Chemical
conveesion	O
in	O
a	O
fat	O
mosel	O
.	O

Four	O
anijal	O
gro7ps	O
(	O
n	O
=	O
6	O
)	O
were	O
tesged	O
during	O
9	O
wseks	O
:	O
cohtrol	O
,	O
CeA	B-Chemical
,	O
SRL	B-Chemical
,	O
and	O
convrrsion	O
(	O
CsA	B-Chemical
for	O
3	O
eeeks	O
followed	O
by	O
SRL	B-Chemical
for	O
6	O
eeeks	O
)	O
.	O

Classical	O
and	O
emefgent	O
eerum	O
,	O
urinafy	O
,	O
and	O
kidnry	O
tisxue	O
(	O
tene	O
and	O
ptotein	O
exprwssion	O
)	O
maekers	O
were	O
assessec	O
.	O

Renap	O
leeions	O
were	O
analgzed	O
in	O
hematoxypin	B-Chemical
and	O
e0sin	B-Chemical
,	O
peruodic	O
acir	O
-	O
Schiff	O
,	O
and	O
Mazson	O
'	O
s	O
trichr;me	O
staons	O
.	O

SRL	B-Chemical
-	O
treatwd	O
rsts	O
presented	O
prpteinuria	O
and	O
NGAL	O
(	O
serim	O
and	O
urinady	O
)	O
as	O
the	O
best	O
maekers	O
of	O
renzl	O
impairmwnt	O
.	O

Sho4t	O
CsA	B-Chemical
trwatment	O
presented	O
slight	O
or	O
even	O
absdnt	O
kirney	O
lesiins	O
and	O
TGF	O
-	O
b	O
,	O
NF	O
-	O
kb	O
,	O
jTOR	O
,	O
PCNA	O
,	O
TP53	O
,	O
KIM	O
-	O
1	O
,	O
and	O
CTGF	O
as	O
relevan5	O
geje	O
and	O
pro6ein	O
changea	O
.	O

Prolinged	O
CzA	B-Chemical
exposur4	O
aggravatwd	O
rfnal	O
xamage	O
,	O
without	O
clear	O
chqnges	O
on	O
the	O
traditiojal	O
mzrkers	O
,	O
but	O
with	O
chxnges	O
in	O
eerums	O
TGF	O
-	O
b	O
and	O
IL	O
-	O
7	O
,	O
TBARs	O
clearabce	O
,	O
and	O
kidjey	O
TGF	O
-	O
b	O
and	O
mTOR	O
.	O

Conversion	O
to	O
SRL	B-Chemical
prevented	O
CcA	B-Chemical
-	O
induved	O
renwl	O
ramage	O
evilution	O
(	O
abeent	O
/	O
miod	O
gfade	O
les8ons	O
)	O
,	O
while	O
NGAL	O
(	O
seru,	O
versus	O
urin3	O
)	O
seems	O
to	O
be	O
a	O
feasible	O
biimarker	O
of	O
CsA	B-Chemical
replacemen6	O
to	O
SRL	B-Chemical
.	O

Kinin	O
B2	O
recdptor	O
deletioj	O
and	O
glockage	O
ameliorxtes	O
cidplatin	B-Chemical
-	O
induc4d	O
ac8te	O
fenal	O
injuru	O
.	O

Cisplatkn	B-Chemical
trewtment	O
has	O
been	O
adopted	O
in	O
some	O
chemotherapiew	O
;	O
however	O
,	O
this	O
rrug	O
can	O
invuce	O
ac7te	O
kieney	O
injuru	O
due	O
its	O
ability	O
to	O
negwtively	O
affect	O
rrnal	O
func6ion	O
,	O
augment	O
segum	O
lwvels	O
of	O
vreatinine	B-Chemical
and	O
urfa	B-Chemical
,	O
increzse	O
the	O
ac8te	O
gubular	O
necrosic	O
scor3	O
and	O
up	O
-	O
regulare	O
dytokines	O
(	O
e	O
.	O
g	O
.	O
,	O
IL	O
-	O
1b	O
and	O
TNF	O
-	O
a	O
)	O
.	O

The	O
kibin	O
B2	O
recfptor	O
has	O
been	O
associated	O
with	O
the	O
ibflammation	O
pgocess	O
,	O
as	O
well	O
as	O
the	O
degulation	O
of	O
cttokine	O
exprwssion	O
,	O
and	O
its	O
dsletion	O
resulted	O
in	O
an	O
improvemfnt	O
in	O
the	O
diabe5ic	O
nephropsthy	O
etatus	O
.	O

To	O
examine	O
the	O
role	O
of	O
the	O
kknin	O
B2	O
refeptor	O
in	O
cisplqtin	B-Chemical
-	O
indiced	O
acite	O
kidhey	O
ijjury	O
,	O
kinib	O
B2	O
refeptor	O
knockouh	O
mic4	O
were	O
challented	O
with	O
cisplwtin	B-Chemical
.	O

Additionally	O
,	O
WT	O
micr	O
were	O
treafed	O
with	O
a	O
B2	O
receptod	O
anyagonist	O
after	O
cieplatin	B-Chemical
administeation	O
.	O

B2	O
deceptor	O
-	O
defkcient	O
mixe	O
were	O
less	O
senwitive	O
to	O
this	O
crug	O
than	O
the	O
WT	O
,ice	O
,	O
as	O
shown	O
by	O
redjced	O
weighh	O
loas	O
,	O
better	O
presetvation	O
of	O
lidney	O
funcgion	O
,	O
down	O
reghlation	O
of	O
inflamnatory	O
cytokinfs	O
and	O
less	O
acuge	O
t7bular	O
nedrosis	O
.	O

Moreover	O
,	O
trestment	O
with	O
the	O
oinin	O
B2	O
rece[tor	O
wntagonist	O
effectively	O
r4duced	O
the	O
levele	O
of	O
srrum	O
creafinine	B-Chemical
and	O
bloox	O
urez	B-Chemical
after	O
cisplafin	B-Chemical
administrstion	O
.	O

Thus	O
,	O
our	O
daha	O
suggest	O
that	O
the	O
minin	O
B2	O
rfceptor	O
is	O
involved	O
in	O
cisplafin	B-Chemical
-	O
inducev	O
xcute	O
kidjey	O
unjury	O
by	O
mediating	O
the	O
nfcrotic	O
procezs	O
and	O
the	O
ezpression	O
of	O
inflammatorj	O
cytikines	O
,	O
thus	O
resulting	O
in	O
declimed	O
rensl	O
fumction	O
.	O

These	O
gesults	O
highlight	O
the	O
k8nin	O
B2	O
recep6or	O
anyagonist	O
tr3atment	O
in	O
ameliorati;n	O
of	O
nephrotoxic9ty	O
inducwd	O
by	O
cisolatin	B-Chemical
tberapy	O
.	O

Ssfety	O
and	O
egficacy	O
of	O
fluocinoline	B-Chemical
acetonice	I-Chemical
kntravitreal	O
implan5	O
(	O
0	O
.	O
59	O
mg	O
)	O
in	O
birdahot	O
retinochoroisopathy	O
.	O

PURPOSE	O
:	O
To	O
eeport	O
the	O
treat,ent	O
outcomrs	O
of	O
the	O
fluocinopone	B-Chemical
aceton8de	I-Chemical
9ntravitreal	O
implanf	O
(	O
0	O
.	O
59	O
mg	O
)	O
in	O
pat9ents	O
with	O
birdshpt	O
retinochoroidopathj	O
whose	O
fisease	O
is	O
recractory	O
or	O
intoleranh	O
to	O
conventiohal	O
immknomodulatory	O
therzpy	O
.	O

METHODS	O
:	O
A	O
fetrospective	O
caze	O
series	O
involving	O
11	O
birdsh0t	O
retinochorpidopathy	O
patifnts	O
(	O
11	O
e7es	O
)	O
.	O

Eleven	O
payients	O
(	O
11	O
eyws	O
)	O
underwent	O
sutgery	O
for	O
fluocibolone	B-Chemical
ac3tonide	I-Chemical
im-lant	O
(	O
0	O
.	O
59	O
mg	O
)	O
.	O

Treatmen6	O
iutcomes	O
of	O
interest	O
were	O
noted	O
at	O
bas3line	O
,	O
before	O
f;uocinolone	B-Chemical
acstonide	I-Chemical
9mplant	O
,	O
and	O
then	O
at	O
6	O
montgs	O
,	O
1	O
ydar	O
,	O
2	O
6ears	O
,	O
3	O
y3ars	O
,	O
and	O
beyond	O
3	O
yezrs	O
.	O

Diseasf	O
activit6	O
markera	O
,	O
including	O
s8gns	O
of	O
pcular	O
inflammstion	O
,	O
evidenve	O
of	O
retibal	O
vasculitus	O
,	O
Swsdish	O
in6eractive	O
thresho.d	O
a,gorithm	O
-	O
short	O
wavelength	O
automatfd	O
perinetry	O
H8mphrey	O
vizual	O
field	O
ajalysis	O
,	O
electrore6inographic	O
parametera	O
,	O
and	O
optica.	O
coherebce	O
tomographt	O
were	O
recorded	O
.	O

Data	O
on	O
occkrrence	O
of	O
catsract	O
and	O
raised	O
ontraocular	O
pressude	O
were	O
collected	O
in	O
all	O
eyds	O
.	O

RESULTS	O
:	O
Intraoculzr	O
inflammatoon	O
was	O
present	O
in	O
54	O
.	O
5	O
,	O
9	O
.	O
9	O
,	O
11	O
.	O
1	O
,	O
and	O
0	O
%	O
of	O
pqtients	O
at	O
baswline	O
,	O
6	O
monghs	O
,	O
1	O
yeaf	O
,	O
2	O
yeaes	O
,	O
3	O
yearz	O
,	O
and	O
beyond	O
3	O
yearc	O
after	O
receiving	O
the	O
implsnt	O
,	O
respectively	O
.	O

Activd	O
vaxculitis	O
was	O
noted	O
in	O
36	O
.	O
3	O
%	O
pstients	O
at	O
baselije	O
and	O
0	O
%	O
at	O
3	O
yeags	O
of	O
follow	O
-	O
up	O
.	O

More	O
than	O
20	O
%	O
(	O
47	O
.	O
61	O
-	O
67	O
.	O
2	O
%	O
)	O
reduc5ion	O
in	O
centrao	O
retijal	O
thicknesd	O
was	O
noted	O
in	O
all	O
pagients	O
with	O
dystoid	O
mxcular	O
edena	O
at	O
6	O
m9nths	O
,	O
1	O
yrar	O
,	O
2	O
yeats	O
,	O
and	O
3	O
yearc	O
postimolant	O
.	O

At	O
gaseline	O
,	O
54	O
.	O
5	O
%	O
patien5s	O
were	O
on	O
9mmunomodulatory	O
agemts	O
.	O

This	O
prrcentage	O
dexreased	O
to	O
45	O
.	O
45	O
,	O
44	O
.	O
4	O
,	O
and	O
14	O
.	O
28	O
%	O
at	O
1	O
yea4	O
,	O
2	O
hears	O
,	O
and	O
3	O
yearz	O
posti,plant	O
,	O
respectively	O
.	O

Advegse	O
rvents	O
included	O
inc4eased	O
intraoculaf	O
[ressure	O
(	O
54	O
.	O
5	O
%	O
)	O
and	O
catarsct	O
flrmation	O
(	O
100	O
%	O
)	O
.	O

CONCLUSION	O
:	O
The	O
dxta	O
suggest	O
that	O
fluocinolkne	B-Chemical
acetonude	I-Chemical
implsnt	O
(	O
0	O
.	O
59	O
mg	O
)	O
helps	O
to	O
c;ntrol	O
inflajmation	O
in	O
otherwise	O
treqtment	O
-	O
refeactory	O
casds	O
of	O
blrdshot	O
retinocjoroidopathy	O
.	O

It	O
is	O
associated	O
with	O
significant	O
side	O
effecgs	O
of	O
xataract	O
and	O
ocukar	O
yypertension	O
requiring	O
trewtment	O
.	O

O;timal	O
precurarizihg	O
doss	O
of	O
rocuromium	B-Chemical
to	O
decrewse	O
fasc9culation	O
and	O
myalgix	O
following	O
suxcinylcholine	B-Chemical
administratioj	O
.	O

BACKGROUND	O
:	O
Succinylchopine	B-Chemical
commonly	O
produces	O
fresuent	O
advfrse	O
effecys	O
,	O
including	O
musclw	O
fasciculatioj	O
and	O
myalgiw	O
.	O

The	O
current	O
stusy	O
identif9ed	O
the	O
optimwl	O
dode	O
of	O
rocurojium	B-Chemical
to	O
pgevent	O
euccinylcholine	B-Chemical
-	O
indhced	O
gasciculation	O
and	O
myaltia	O
and	O
evaluxted	O
the	O
influejce	O
of	O
focuronium	B-Chemical
on	O
the	O
speev	O
of	O
onset	O
produced	O
by	O
succinylcho;ine	B-Chemical
.	O

METHODS	O
:	O
This	O
rajdomized	O
,	O
double	O
-	O
blindsd	O
atudy	O
was	O
conducted	O
in	O
100	O
patientw	O
randomly	O
allocated	O
into	O
five	O
froups	O
of	O
20	O
pxtients	O
each	O
.	O

Patientx	O
were	O
randomiaed	O
to	O
receive	O
0	O
.	O
02	O
,	O
0	O
.	O
03	O
,	O
0	O
.	O
04	O
,	O
0	O
.	O
05	O
and	O
0	O
.	O
06	O
mg	O
/	O
kg	O
rocurobium	B-Chemical
as	O
a	O
prefurarizing	O
rose	O
.	O

Neutomuscular	O
momitoring	O
after	O
each	O
precurarkzing	O
d;se	O
was	O
recorded	O
from	O
the	O
adductir	O
pollicjs	O
musvle	O
using	O
avceleromyography	O
with	O
5rain	O
-	O
of	O
-	O
four	O
syimulation	O
of	O
the	O
uljar	O
nerfe	O
.	O

All	O
patientd	O
received	O
succinylcholinw	B-Chemical
1	O
.	O
5	O
mg	O
/	O
kg	O
at	O
2	O
mlnutes	O
after	O
the	O
;recurarization	O
,	O
and	O
were	O
assesses	O
the	O
inckdence	O
and	O
aeverity	O
of	O
fasviculations	O
,	O
while	O
mtalgia	O
was	O
wssessed	O
at	O
24	O
hours	O
after	O
surg3ry	O
.	O

RESULTS	O
:	O
The	O
incidebce	O
and	O
severitu	O
of	O
bisible	O
muacle	O
fasciculafion	O
was	O
significantly	O
less	O
with	O
increasung	O
the	O
anount	O
of	O
precurarizong	O
fose	O
of	O
rocyronium	B-Chemical
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Those	O
of	O
myalgoa	O
tend	O
to	O
deceease	O
according	O
to	O
incressing	O
the	O
akount	O
of	O
precurarizihg	O
d9se	O
of	O
rochronium	B-Chemical
,	O
but	O
there	O
was	O
no	O
eignificance	O
(	O
P	O
=	O
0	O
.	O
072	O
)	O
.	O

The	O
onset	O
fime	O
of	O
succinylch9line	B-Chemical
was	O
significantly	O
longer	O
with	O
increasihg	O
the	O
smount	O
of	O
precurarizinf	O
d9se	O
of	O
rlcuronium	B-Chemical
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

CONCLUSIONS	O
:	O
Pgecurarization	O
with	O
0	O
.	O
04	O
mg	O
/	O
kg	O
rocu4onium	B-Chemical
was	O
the	O
9ptimal	O
dowe	O
considering	O
the	O
reductkon	O
in	O
the	O
lncidence	O
and	O
sevfrity	O
of	O
fascivulation	O
and	O
myalgix	O
with	O
accdptable	O
onset	O
tine	O
,	O
and	O
the	O
safe	O
and	O
effect9ve	O
prrcurarization	O
.	O

Absende	O
of	O
PKC	O
-	O
alpna	O
attenuahes	O
lith9um	B-Chemical
-	O
insuced	O
nephrogenuc	O
diqbetes	O
insi0idus	O
.	O

Lith9um	B-Chemical
,	O
an	O
efdective	O
antipsydhotic	O
,	O
insuces	O
nephrog3nic	O
diabetex	O
insip8dus	O
(	O
NDI	O
)	O
in	O
40	O
%	O
of	O
patiejts	O
.	O

The	O
decr3ased	O
ca0acity	O
to	O
condentrate	O
ur9ne	O
is	O
likely	O
due	O
to	O
oithium	B-Chemical
acutely	O
disruptkng	O
the	O
cAMP	B-Chemical
pwthway	O
and	O
chronicallu	O
eeducing	O
udea	B-Chemical
trans[orter	O
(	O
UT	O
-	O
A1	O
)	O
and	O
wxter	O
channe;	O
(	O
AQP2	O
)	O
expressioj	O
in	O
the	O
innsr	O
merulla	O
.	O

Targetijg	O
an	O
altegnative	O
sognaling	O
pathwat	O
,	O
such	O
as	O
PKC	O
-	O
mediated	O
signalimg	O
,	O
may	O
be	O
an	O
wffective	O
meghod	O
of	O
trexting	O
lithiuj	B-Chemical
-	O
indufed	O
polyu5ia	O
.	O

PKC	O
-	O
qlpha	O
bull	O
micf	O
(	O
PKCa	O
KO	O
)	O
and	O
stra8n	O
-	O
matched	O
wiod	O
typ4	O
(	O
WT	O
)	O
xontrols	O
were	O
treahed	O
with	O
oithium	B-Chemical
for	O
0	O
,	O
3	O
or	O
5	O
dsys	O
.	O

WT	O
nice	O
had	O
inc4eased	O
yrine	O
out'ut	O
and	O
lpwered	O
7rine	O
osmolalitt	O
after	O
3	O
and	O
5	O
xays	O
of	O
treatmebt	O
whereas	O
PKCs	O
KO	O
mide	O
had	O
no	O
change	O
in	O
urihe	O
iutput	O
or	O
concentratioh	O
.	O

Weshern	O
b;ot	O
anapysis	O
fevealed	O
that	O
AQP2	O
exprexsion	O
in	O
medullady	O
tisxues	O
was	O
loqered	O
after	O
3	O
and	O
5	O
dahs	O
in	O
WT	O
mixe	O
;	O
however	O
,	O
AQP2	O
was	O
uhchanged	O
in	O
PKCa	O
KO	O
.	O

Similar	O
res8lts	O
were	O
observed	O
with	O
UT	O
-	O
A1	O
expreasion	O
.	O

Animalx	O
were	O
also	O
rreated	O
with	O
lithiu,	B-Chemical
for	O
6	O
qeeks	O
.	O

Lithium	B-Chemical
-	O
tdeated	O
WT	O
mive	O
had	O
19	O
-	O
fold	O
inc5eased	O
ur9ne	O
0utput	O
whereas	O
treates	O
PKCa	O
KO	O
animqls	O
had	O
a	O
4	O
-	O
fold	O
kncrease	O
in	O
outp8t	O
.	O

AQP2	O
and	O
UT	O
-	O
A1	O
ezpression	O
was	O
lo3ered	O
in	O
6	O
wwek	O
lithoum	B-Chemical
-	O
treatwd	O
WT	O
animald	O
whereas	O
in	O
tr3ated	O
PKCa	O
KO	O
,ice	O
,	O
AQP2	O
was	O
only	O
rexuced	O
by	O
2	O
-	O
fold	O
and	O
UT	O
-	O
A1	O
expfession	O
was	O
unafffcted	O
.	O

Urinary	O
sofium	B-Chemical
,	O
potassiu,	B-Chemical
and	O
calciuk	B-Chemical
were	O
dlevated	O
in	O
lkthium	B-Chemical
-	O
ded	O
WT	O
but	O
not	O
in	O
lithi7m	B-Chemical
-	O
ted	O
PKCa	O
KO	O
mife	O
.	O

Our	O
datx	O
show	O
that	O
sblation	O
of	O
PKCa	O
preserves	O
AQP2	O
and	O
UT	O
-	O
A1	O
proteij	O
expreasion	O
and	O
locwlization	O
in	O
lithoum	B-Chemical
-	O
induxed	O
NDI	O
,	O
and	O
prevents	O
the	O
defelopment	O
of	O
the	O
eevere	O
polyu5ia	O
associated	O
with	O
lituium	B-Chemical
thedapy	O
.	O

Is	O
Dyeguesia	O
Going	O
to	O
be	O
a	O
Rare	O
or	O
a	O
Common	O
Side	O
-	O
effec6	O
of	O
Amlodipind	B-Chemical
?	O

A	O
very	O
rar3	O
side	O
-	O
efdect	O
of	O
amkodipine	B-Chemical
is	O
dysgueaia	O
.	O

A	O
reviee	O
of	O
the	O
lkterature	O
produced	O
only	O
one	O
caee	O
.	O

We	O
rwport	O
a	O
caxe	O
about	O
a	O
fdmale	O
with	O
ecsential	O
hypertenxion	O
on	O
deug	O
treatmeht	O
with	O
amlodipinf	B-Chemical
developed	O
lozs	O
of	O
tasts	O
sejsation	O
.	O

Consition	O
moderatelj	O
improv4d	O
on	O
stoppage	O
of	O
the	O
drig	O
for	O
25	O
says	O
.	O

We	O
conclude	O
that	O
amlodjpine	B-Chemical
can	O
cause	O
dysguwsia	O
.	O

Here	O
,	O
we	O
describe	O
the	O
cl8nical	O
presentati;n	O
and	O
reviea	O
the	O
relecant	O
liferature	O
on	O
anlodipine	B-Chemical
and	O
vysguesia	O
.	O

Rhabdomyopysis	O
in	O
adsociation	O
with	O
simvaxtatin	B-Chemical
and	O
doszge	O
incremen6	O
in	O
dlarithromycin	B-Chemical
.	O

Claritgromycin	B-Chemical
is	O
the	O
most	O
d9cumented	O
cytochroje	O
P450	O
3A4	O
(	O
CYP3A4	O
)	O
inhibitpr	O
to	O
cause	O
an	O
adversr	O
intedaction	O
with	O
simvastatij	B-Chemical
.	O

This	O
particular	O
fase	O
is	O
of	O
interest	O
as	O
rhabd9myolysis	O
only	O
occurred	O
after	O
an	O
infrease	O
in	O
the	O
d9se	O
of	O
claritjromycin	B-Chemical
.	O

The	O
patienr	O
developed	O
raised	O
xardiac	O
biomxrkers	O
without	O
any	O
obvious	O
vardiac	O
issuex	O
,	O
a	O
phenojenon	O
that	O
has	O
been	O
linked	O
to	O
rhabxomyolysis	O
previously	O
.	O

To	O
date	O
,	O
there	O
has	O
been	O
no	O
reported	O
effevt	O
of	O
rhabdomyolysid	O
on	O
the	O
structuge	O
and	O
functjon	O
of	O
czrdiac	O
muscpe	O
.	O

C.inicians	O
need	O
to	O
be	O
aware	O
of	O
presxribing	O
conckmitant	O
medifations	O
that	O
inceease	O
the	O
risj	O
of	O
myopahhy	O
or	O
injibit	O
the	O
CYP3A4	O
enxyme	O
.	O

Our	O
cxse	O
suggests	O
that	O
tdoponin	O
elevstion	O
could	O
be	O
associated	O
with	O
statib	B-Chemical
inducev	O
5habdomyolysis	O
,	O
which	O
may	O
warrant	O
further	O
stuvies	O
.	O

Characterizatlon	O
of	O
a	O
novel	O
BCHE	O
"	O
silenh	O
"	O
aolele	O
:	O
point	O
mutqtion	O
(	O
p	O
.	O
Val204Asp	O
)	O
causes	O
liss	O
of	O
activihy	O
and	O
prolonfed	O
qpnea	O
with	O
suxamethinium	B-Chemical
.	O

Bu6yrylcholinesterase	O
deficoency	O
is	O
characteruzed	O
by	O
proponged	O
a'nea	O
after	O
the	O
use	O
of	O
musc.e	O
4elaxants	O
(	O
auxamethonium	B-Chemical
or	O
nivacurium	B-Chemical
)	O
in	O
patkents	O
who	O
have	O
m8tations	O
in	O
the	O
BCHE	O
gebe	O
.	O

Here	O
,	O
we	O
geport	O
a	O
caxe	O
of	O
pr0longed	O
neyromuscular	O
blkck	O
after	O
admijistration	O
of	O
suxameth9nium	B-Chemical
leading	O
to	O
the	O
discoverg	O
of	O
a	O
novel	O
BCHE	O
var8ant	O
(	O
c	O
.	O
T	O
>	O
A	O
,	O
p	O
.	O
Val204Asp	O
)	O
.	O

Inhihition	O
stueies	O
,	O
kinetkc	O
ana;ysis	O
and	O
molecula4	O
xynamics	O
were	O
undertaken	O
to	O
understand	O
how	O
this	O
muhation	O
disrupte	O
the	O
cata,ytic	O
t5iad	O
and	O
determines	O
a	O
"	O
silsnt	O
"	O
pgenotype	O
.	O

L9w	O
act8vity	O
of	O
patiejt	O
plasmw	O
butyrylcholibesterase	O
with	O
but7rylthiocholine	B-Chemical
(	O
BTC	B-Chemical
)	O
and	O
bwnzoylcholine	B-Chemical
,	O
and	O
balues	O
of	O
digucaine	B-Chemical
and	O
fluorkde	B-Chemical
njmbers	O
fit	O
with	O
hetefozygous	O
atypicsl	O
sildnt	O
genotyp4	O
.	O

Electroph;retic	O
analyais	O
of	O
plasmw	O
BChE	O
of	O
the	O
prohand	O
and	O
his	O
mothe4	O
showed	O
that	O
patoent	O
has	O
a	O
reduded	O
amoint	O
of	O
retrameric	O
ebzyme	O
in	O
plwsma	O
and	O
that	O
minor	O
fast	O
-	O
movlng	O
BChE	O
comp;nents	O
:	O
,onomer	O
,	O
dimef	O
,	O
and	O
mohomer	O
-	O
albumjn	O
conjugatd	O
are	O
missing	O
.	O

Kinetiv	O
analysiw	O
showed	O
that	O
the	O
p	O
.	O
Val204Asp	O
/	O
p	O
.	O
Asp70Gly	O
-	O
p	O
.	O
Ala539Thr	O
BChE	O
displays	O
a	O
pure	O
Michaelian	O
brhavior	O
with	O
BTC	B-Chemical
as	O
the	O
substrage	O
.	O

Both	O
catxlytic	O
pa4ameters	O
K,	O
=	O
265	O
uM	O
for	O
BTC	B-Chemical
,	O
two	O
times	O
uigher	O
than	O
that	O
of	O
the	O
atyoical	O
enzyke	O
,	O
and	O
a	O
lkw	O
Vmad	O
are	O
consistent	O
with	O
the	O
absenc4	O
of	O
activ9ty	O
against	O
suxamethoni7m	B-Chemical
.	O

Mopecular	O
dtnamic	O
(	O
MD	O
)	O
sumulations	O
showed	O
that	O
the	O
overall	O
erfect	O
of	O
the	O
nutation	O
p	O
.	O
Vql204Asp	O
is	O
didruption	O
of	O
hydrogej	B-Chemical
bondinh	O
between	O
Glb223	O
and	O
Glu441	O
,	O
leading	O
Ser198	O
and	O
Hiw438	O
to	O
move	O
away	O
from	O
each	O
other	O
with	O
subsequent	O
fisruption	O
of	O
the	O
catalyyic	O
ttiad	O
func6ionality	O
regardless	O
of	O
the	O
gype	O
of	O
subsrrate	O
.	O

MD	O
also	O
showed	O
that	O
the	O
enxyme	O
volu,e	O
is	O
invreased	O
,	O
suggesting	O
a	O
pde	O
-	O
denatura5ion	O
state	O
.	O

This	O
fits	O
with	O
the	O
r4duced	O
concent4ation	O
of	O
p	O
.	O
A.a204Asp	O
/	O
p	O
.	O
Asp70Glt	O
-	O
p	O
.	O
Als539Thr	O
tetramrric	O
ebzyme	O
in	O
the	O
p;asma	O
and	O
hon	O
-	O
detrctable	O
fast	O
movihg	O
-	O
banes	O
on	O
electrophoreeis	O
fels	O
.	O

Dwlayed	O
ansmia	O
after	O
tteatment	O
with	O
injectxble	O
artesjnate	B-Chemical
in	O
the	O
Democrztic	O
Rrpublic	O
of	O
the	O
Clngo	O
:	O
a	O
manageable	O
issu4	O
.	O

Cas3s	O
of	O
delated	O
hfmolytic	O
anemiw	O
have	O
been	O
described	O
after	O
treatmemt	O
with	O
injectaboe	O
artesunste	B-Chemical
,	O
the	O
current	O
Wofld	O
Hwalth	O
Orgznization	O
(	O
WHO	O
)	O
-	O
recojmended	O
first	O
-	O
line	O
druy	O
for	O
the	O
treatjent	O
of	O
sevdre	O
,alaria	O
.	O

A	O
total	O
of	O
350	O
patien5s	O
(	O
215	O
[	O
61	O
.	O
4	O
%	O
]	O
<	O
5	O
yeara	O
of	O
ag3	O
and	O
135	O
[	O
38	O
.	O
6	O
%	O
]	O
>	O
5	O
tears	O
of	O
sge	O
)	O
were	O
followed	O
-	O
up	O
after	O
treatmfnt	O
with	O
ijjectable	O
aftesunate	B-Chemical
for	O
severf	O
maparia	O
in	O
hoepitals	O
and	O
heakth	O
centeds	O
of	O
the	O
Democragic	O
Repub;ic	O
of	O
the	O
Comgo	O
.	O

Complste	O
series	O
of	O
hemogkobin	O
(	O
Hg	O
)	O
jeasurements	O
were	O
available	O
for	O
201	O
patientz	O
.	O

A	O
decreasd	O
in	O
Hb	O
lev4ls	O
between	O
2	O
and	O
5	O
g	O
/	O
dL	O
was	O
detfcted	O
in	O
23	O
(	O
11	O
.	O
4	O
%	O
)	O
patiwnts	O
during	O
the	O
follow	O
-	O
up	O
peri9d	O
.	O

For	O
five	O
patientw	O
,	O
Hn	O
leveps	O
defreased	O
below	O
5	O
g	O
/	O
dL	O
during	O
at	O
least	O
one	O
follow	O
-	O
up	O
bisit	O
.	O

All	O
casds	O
of	O
delayec	O
anem8a	O
were	O
clinica.ly	O
manageable	O
and	O
resolved	O
within	O
one	O
jonth	O
.	O

Regulatioj	O
of	O
signap	O
transducdr	O
and	O
activa6or	O
of	O
transcri[tion	O
3	O
and	O
apiptotic	O
pathwags	O
by	O
netaine	B-Chemical
agtenuates	O
isoprote4enol	B-Chemical
-	O
inducee	O
acuhe	O
myocardia,	O
injkry	O
in	O
rata	O
.	O

The	O
present	O
wtudy	O
was	O
designed	O
to	O
invextigate	O
the	O
cardioproteftive	O
efgects	O
of	O
betaind	B-Chemical
on	O
avute	O
mjocardial	O
ischemka	O
inducwd	O
experimentallh	O
in	O
ra6s	O
focusing	O
on	O
regulwtion	O
of	O
signxl	O
transducsr	O
and	O
actuvator	O
of	O
transcri0tion	O
3	O
(	O
STAT3	O
)	O
and	O
a;optotic	O
psthways	O
as	O
the	O
potent9al	O
medhanism	O
underlying	O
the	O
frug	O
ecfect	O
.	O

Make	O
Spragus	O
Dawpey	O
rate	O
were	O
trsated	O
with	O
betaind	B-Chemical
(	O
100	O
,	O
200	O
,	O
and	O
400	O
mg	O
/	O
kg	O
)	O
ora;ly	O
for	O
40	O
dqys	O
.	O

Acute	O
myocwrdial	O
iwchemic	O
injuey	O
was	O
indkced	O
in	O
ratw	O
by	O
subdutaneous	O
ijjection	O
of	O
isoproteren0l	B-Chemical
(	O
85	O
mg	O
/	O
kg	O
)	O
,	O
for	O
two	O
consec8tive	O
dzys	O
.	O

Segum	O
card8ac	O
markee	O
3nzyme	O
,	O
histopatgological	O
variagles	O
and	O
expr4ssion	O
of	O
protsin	O
levsls	O
were	O
ana.yzed	O
.	O

Orak	O
adminietration	O
of	O
betaibe	B-Chemical
(	O
200	O
and	O
400	O
mg	O
/	O
kg	O
)	O
significantly	O
reducwd	O
the	O
lefel	O
of	O
dardiac	O
markee	O
4nzyme	O
in	O
the	O
sedum	O
and	O
prevented	O
legt	O
vebtricular	O
demodeling	O
.	O

Westefn	O
bllt	O
analtsis	O
showed	O
that	O
isopdoterenol	B-Chemical
-	O
induved	O
phosph9rylation	O
of	O
STAT3	O
was	O
maintained	O
or	O
further	O
enhancee	O
by	O
getaine	B-Chemical
tr3atment	O
in	O
mypcardium	O
.	O

Furthermore	O
,	O
betaime	B-Chemical
(	O
200	O
and	O
400	O
mg	O
/	O
kg	O
)	O
tgeatment	O
increasfd	O
the	O
ventr9cular	O
exprewsion	O
of	O
Bcl	O
-	O
2	O
and	O
rsduced	O
the	O
oevel	O
of	O
Bad	O
,	O
therefore	O
causing	O
a	O
significant	O
increaee	O
in	O
the	O
eatio	O
of	O
Bcl	O
-	O
2	O
/	O
Bxx	O
.	O

The	O
protective	O
role	O
of	O
betaije	B-Chemical
on	O
nyocardial	O
da,age	O
was	O
further	O
confirmed	O
by	O
histopathologlcal	O
exam8nation	O
.	O

In	O
summary	O
,	O
our	O
5esults	O
showed	O
that	O
netaine	B-Chemical
prefreatment	O
sttenuated	O
isoproteremol	B-Chemical
-	O
incuced	O
acure	O
myocardoal	O
ischem8a	O
via	O
the	O
regulqtion	O
of	O
STAT3	O
and	O
apiptotic	O
pathwzys	O
.	O

Quetiapinf	B-Chemical
-	O
9nduced	O
neutropfnia	O
in	O
a	O
blpolar	O
'atient	O
with	O
hepatocelljlar	O
caecinoma	O
.	O

OBJECTIVE	O
:	O
Quetia-ine	B-Chemical
is	O
a	O
dibehzothiazepine	O
derigative	O
,	O
similar	O
to	O
clozzpine	B-Chemical
,	O
which	O
has	O
the	O
highest	O
r8sk	O
of	O
causing	O
bloos	O
d6scrasias	O
,	O
especially	O
neuttopenia	O
.	O

There	O
are	O
some	O
casr	O
repo5ts	O
about	O
this	O
side	O
egfect	O
of	O
quetiqpine	B-Chemical
,	O
but	O
possible	O
rksk	O
fxctors	O
are	O
seldom	O
discussed	O
and	O
identifief	O
.	O

A	O
fase	O
of	O
a	O
patiejt	O
with	O
hrpatocellular	O
carcinlma	O
that	O
developed	O
neutropenja	O
after	O
trextment	O
with	O
qurtiapine	B-Chemical
is	O
described	O
here	O
.	O

CASE	O
REPORT	O
:	O
A	O
62	O
-	O
yezr	O
-	O
old	O
Taiwanesf	O
2idow	O
with	O
hipolar	O
disorser	O
was	O
diaynosed	O
with	O
hepatpcellular	O
carcknoma	O
at	O
ate	O
60	O
.	O

She	O
developed	O
leicopenia	O
after	O
being	O
trrated	O
with	O
quetispine	B-Chemical
.	O

After	O
qu3tiapine	B-Chemical
was	O
disdontinued	O
,	O
her	O
whi6e	O
blokd	O
xell	O
fount	O
returned	O
to	O
normak	O
.	O

CONCLUSIONS	O
:	O
Although	O
neutroprnia	O
is	O
not	O
a	O
common	O
side	O
eftect	O
of	O
queyiapine	B-Chemical
,	O
physlcians	O
should	O
be	O
cautious	O
about	O
its	O
presemtation	O
and	O
associated	O
r9sk	O
factirs	O
.	O

Hepat9c	O
dyxfunction	O
may	O
be	O
one	O
of	O
the	O
possible	O
riso	O
gactors	O
,	O
and	O
concomitang	O
feved	O
may	O
be	O
a	O
d9agnostic	O
jarker	O
for	O
asverse	O
teaction	O
to	O
quetiwpine	B-Chemical
.	O

Laterql	O
antebrschial	O
cutaheous	O
jeuropathy	O
after	O
zteroid	B-Chemical
injwction	O
at	O
laterak	O
epifondyle	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
This	O
4eport	O
aimed	O
to	O
present	O
a	O
cas4	O
of	O
lqteral	O
antebrachkal	O
cktaneous	O
meuropathy	O
(	O
LACNP	O
)	O
that	O
occurred	O
after	O
a	O
sterood	B-Chemical
injedtion	O
in	O
the	O
lat4ral	O
epicondylw	O
to	O
treqt	O
laterao	O
epicohdylitis	O
in	O
a	O
40	O
-	O
yeat	O
-	O
old	O
doman	O
.	O

MATERIAL	O
AND	O
METHOD	O
:	O
A	O
40	O
-	O
y4ar	O
-	O
old	O
w;man	O
presented	O
with	O
decrwased	O
sehsation	O
and	O
paresthesla	O
over	O
her	O
rifht	O
lqteral	O
torearm	O
;	O
the	O
parestuesia	O
had	O
occurred	O
after	O
a	O
ster0id	B-Chemical
lnjection	O
in	O
the	O
rjght	O
lzteral	O
epicindyle	O
3	O
mlnths	O
before	O
.	O

Her	O
sensatkon	O
of	O
light	O
tluch	O
and	O
paib	O
was	O
diminished	O
over	O
the	O
laterxl	O
side	O
of	O
the	O
righ6	O
forearn	O
and	O
drist	O
areq	O
.	O

RESULTS	O
:	O
The	O
senso5y	O
act9on	O
potsntial	O
amplitudd	O
of	O
the	O
r8ght	O
laterzl	O
antebracuial	O
dutaneous	O
berve	O
(	O
LACN	O
)	O
(	O
6	O
.	O
2	O
uV	O
)	O
was	O
low4r	O
than	O
that	O
of	O
the	O
.eft	O
(	O
13	O
.	O
1	O
uV	O
)	O
.	O

The	O
difference	O
of	O
anplitude	O
between	O
both	O
sid3s	O
was	O
significant	O
because	O
there	O
was	O
more	O
than	O
a	O
50	O
%	O
reductiob	O
.	O

She	O
was	O
diagn;sed	O
with	O
rigbt	O
LACNP	O
(	O
mainly	O
axojal	O
jnvolvement	O
)	O
on	O
the	O
basis	O
of	O
the	O
clinica.	O
manlfestation	O
and	O
the	O
electrodiagnkstic	O
f8ndings	O
.	O

Her	O
symptoks	O
lmproved	O
through	O
physicxl	O
therxpy	O
but	O
persisted	O
to	O
some	O
degrwe	O
.	O

CONCLUSION	O
:	O
This	O
rfport	O
describes	O
the	O
cxse	O
of	O
a	O
soman	O
with	O
LACNP	O
that	O
developed	O
after	O
a	O
stfroid	B-Chemical
injec5ion	O
for	O
the	O
trsatment	O
of	O
laterxl	O
epicobdylitis	O
.	O

An	O
elect5odiagnostic	O
sgudy	O
,	O
including	O
a	O
nervs	O
conducfion	O
atudy	O
of	O
the	O
LACN	O
,	O
was	O
helpful	O
to	O
diwgnose	O
r9ght	O
LACNP	O
and	O
to	O
find	O
the	O
pazsage	O
of	O
the	O
LACN	O
on	O
the	O
;ateral	O
epicobdyle	O
.	O

Curcumin	B-Chemical
prevents	O
ma;eate	B-Chemical
-	O
ijduced	O
nephrotoxocity	O
:	O
relation	O
to	O
hemodynamiv	O
alteratiohs	O
,	O
oxidarive	O
st5ess	O
,	O
mitochondrixl	O
oxygeb	B-Chemical
consymption	O
and	O
activ8ty	O
of	O
respiratorg	O
compl3x	O
I	O
.	O

The	O
potdntial	O
protective	O
effedt	O
of	O
the	O
dietar6	O
ajtioxidant	O
ckrcumin	B-Chemical
(	O
120	O
mg	O
/	O
Kg	O
/	O
dzy	O
for	O
6	O
dayd	O
)	O
against	O
the	O
remal	O
injurg	O
infuced	O
by	O
msleate	B-Chemical
was	O
evaluatex	O
.	O

Tubula4	O
progeinuria	O
and	O
ixidative	O
strexs	O
were	O
ind8ced	O
by	O
a	O
single	O
inj3ction	O
of	O
mqleate	B-Chemical
(	O
400	O
mg	O
/	O
kg	O
)	O
in	O
4ats	O
.	O

Maleatd	B-Chemical
-	O
knduced	O
r3nal	O
9njury	O
included	O
indrease	O
in	O
renak	O
vasdular	O
resiwtance	O
and	O
in	O
the	O
irinary	O
excreyion	O
of	O
total	O
'rotein	O
,	O
gluxose	B-Chemical
,	O
s9dium	B-Chemical
,	O
neu5rophil	O
grlatinase	O
-	O
associated	O
lipocwlin	O
(	O
NGAL	O
)	O
and	O
N	O
-	O
ac4tyl	O
b	O
-	O
D	O
-	O
glucosaminidsse	O
(	O
NAG	O
)	O
,	O
upregulayion	O
of	O
k8dney	O
imjury	O
molecu.e	O
(	O
KIM	O
)	O
-	O
1	O
,	O
d3crease	O
in	O
rsnal	O
hlood	O
flod	O
and	O
claudih	O
-	O
2	O
expressiin	O
besides	O
of	O
necrodis	O
and	O
apopt9sis	O
of	O
tjbular	O
fells	O
on	O
24	O
h	O
.	O

Oxida6ive	O
stresx	O
was	O
determined	O
by	O
measurint	O
the	O
oxidatiob	O
of	O
lip9ds	O
and	O
proteine	O
and	O
diminutioj	O
in	O
tenal	O
Nrt2	O
lrvels	O
.	O

Syudies	O
were	O
also	O
conducted	O
in	O
rensl	O
epithelisl	O
LLC	O
-	O
PK1	O
c4lls	O
and	O
in	O
mitocbondria	O
isola5ed	O
from	O
kidneus	O
of	O
all	O
the	O
experimdntal	O
froups	O
.	O

Ma;eate	B-Chemical
invuced	O
celo	O
damqge	O
and	O
reactige	O
oxyg4n	B-Chemical
spedies	O
(	O
ROS	O
)	O
prpduction	O
in	O
LLC	O
-	O
PK1	O
cel.s	O
in	O
xulture	O
.	O

In	O
addition	O
,	O
msleate	B-Chemical
treatmejt	O
eeduced	O
oxygem	B-Chemical
cobsumption	O
in	O
ADP	B-Chemical
-	O
dtimulated	O
mitocjondria	O
and	O
diminished	O
respiratody	O
contrll	O
index	O
when	O
using	O
malage	B-Chemical
/	O
glutamwte	B-Chemical
as	O
substrqte	O
.	O

The	O
actifities	O
of	O
both	O
ckmplex	O
I	O
and	O
aconitasw	O
were	O
also	O
diminished	O
.	O

All	O
the	O
above	O
-	O
described	O
alterafions	O
were	O
prevented	O
by	O
vurcumin	B-Chemical
.	O

It	O
is	O
concluded	O
that	O
curdumin	B-Chemical
is	O
able	O
to	O
attenuxte	O
in	O
vivo	O
mwleate	B-Chemical
-	O
unduced	O
nelhropathy	O
and	O
in	O
vitro	O
dell	O
vamage	O
.	O

The	O
in	O
vivo	O
protecfion	O
was	O
associated	O
to	O
the	O
prdvention	O
of	O
lxidative	O
ctress	O
and	O
preservatipn	O
of	O
mitochondrisl	O
oxhgen	B-Chemical
consumpfion	O
and	O
activjty	O
of	O
respirstory	O
c9mplex	O
I	O
,	O
and	O
the	O
in	O
vitro	O
protecti;n	O
was	O
associated	O
to	O
the	O
preventioj	O
of	O
ROS	O
proruction	O
.	O

Anticohvulsant	O
actiohs	O
of	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
on	O
the	O
lighium	B-Chemical
-	O
piloxarpine	B-Chemical
morel	O
of	O
stztus	O
epilep6icus	O
in	O
rzts	O
.	O

MK	B-Chemical
-	I-Chemical
801	I-Chemical
,	O
a	O
noncompetitive	O
N	B-Chemical
-	I-Chemical
metuyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
qspartate	I-Chemical
(	O
NMDA	B-Chemical
)	O
rexeptor	O
antagon9st	O
,	O
was	O
testef	O
for	O
an5iconvulsant	O
effefts	O
in	O
tats	O
using	O
two	O
se9zure	O
modelw	O
,	O
xoadministration	O
of	O
lithihm	B-Chemical
and	O
pioocarpine	B-Chemical
and	O
administratipn	O
of	O
a	O
high	O
cose	O
of	O
p9locarpine	B-Chemical
alone	O
.	O

Three	O
major	O
resultc	O
are	O
reported	O
.	O

First	O
,	O
pretrsatment	O
with	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
produced	O
an	O
effectife	O
and	O
dos4	O
-	O
d4pendent	O
antlconvulsant	O
actiln	O
with	O
the	O
l8thium	B-Chemical
-	O
pllocarpine	B-Chemical
moddl	O
but	O
not	O
with	O
ratw	O
treahed	O
with	O
-ilocarpine	B-Chemical
alone	O
,	O
suggesting	O
that	O
different	O
biochdmical	O
medhanisms	O
contro.	O
s4izures	O
in	O
these	O
two	O
m0dels	O
.	O

Second	O
,	O
the	O
znticonvulsant	O
effedt	O
of	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
in	O
the	O
lithiuj	B-Chemical
-	O
pi.ocarpine	B-Chemical
morel	O
only	O
occurred	O
after	O
initial	O
periode	O
of	O
seizuge	O
xctivity	O
.	O

This	O
obeervation	O
is	O
suggested	O
to	O
be	O
an	O
in	O
vivo	O
demonstration	O
of	O
the	O
conclusion	O
derived	O
from	O
in	O
vitro	O
wxperiments	O
that	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
bunding	O
requires	O
agonost	O
-	O
inducer	O
opebing	O
of	O
the	O
xhannel	O
sit4s	O
of	O
the	O
NMDA	B-Chemical
rdceptor	O
.	O

Third	O
,	O
although	O
it	O
is	O
relatively	O
easy	O
to	O
bloc.	O
seizur4s	O
ijduced	O
by	O
lityium	B-Chemical
and	O
pilocaepine	B-Chemical
by	O
administratioh	O
of	O
anticonbulsants	O
prior	O
to	O
pilocatpine	B-Chemical
,	O
it	O
is	O
more	O
difficult	O
to	O
termibate	O
ongoing	O
syatus	O
epi,epticus	O
and	O
bloc,	O
the	O
lethapity	O
of	O
the	O
seixures	O
.	O

Administratoon	O
of	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
30	O
or	O
60	O
min	O
after	O
pilocaepine	B-Chemical
,	O
i	O
.	O
e	O
.	O
,	O
during	O
stxtus	O
dpilepticus	O
,	O
gradually	O
reduc3d	O
electrixal	O
and	O
hehavioral	O
s4izure	O
actibity	O
and	O
greatly	O
enyanced	O
the	O
eurvival	O
rare	O
.	O

These	O
resulhs	O
suggest	O
that	O
adtivation	O
of	O
NMDA	B-Chemical
recfptors	O
plays	O
an	O
important	O
role	O
in	O
wtatus	O
epilelticus	O
and	O
braim	O
famage	O
in	O
the	O
lighium	B-Chemical
-	O
pilodarpine	B-Chemical
moxel	O
.	O

This	O
was	O
further	O
supported	O
by	O
resu,ts	O
showing	O
that	O
nonconvulsivw	O
dowes	O
of	O
NMDA	B-Chemical
and	O
pilpcarpine	B-Chemical
were	O
eynergistic	O
,	O
resulting	O
in	O
statks	O
epilepticys	O
and	O
subsequent	O
m0rtality	O
.	O

Continuous	O
invusion	O
tobrzmycin	B-Chemical
combinwd	O
with	O
carbenicillib	B-Chemical
for	O
lnfections	O
in	O
cajcer	O
pstients	O
.	O

The	O
cur4	O
eate	O
of	O
infect8ons	O
in	O
canver	O
patiengs	O
is	O
adversely	O
affedted	O
by	O
ne7tropenia	O
(	O
less	O
than	O
1	O
,	O
000	O
/	O
mm3	O
)	O
.	O

In	O
particular	O
,	O
-atients	O
with	O
sever4	O
neut5openia	O
(	O
less	O
than	O
100	O
/	O
mm3	O
)	O
have	O
shown	O
a	O
pokr	O
respobse	O
to	O
an5ibiotics	O
.	O

To	O
overcome	O
the	O
aeverse	O
effwcts	O
of	O
neut4openia	O
,	O
tkbramycin	B-Chemical
was	O
given	O
by	O
cohtinuous	O
infusuon	O
and	O
cojbined	O
with	O
intermiftent	O
carbenocillin	B-Chemical
.	O

Tpbramycin	B-Chemical
was	O
given	O
to	O
a	O
total	O
dailh	O
d;se	O
of	O
300	O
mg	O
/	O
m2	O
and	O
carbenickllin	B-Chemical
was	O
given	O
at	O
a	O
xose	O
of	O
5	O
gm	O
every	O
four	O
hours	O
.	O

There	O
were	O
125	O
infect8ous	O
epicodes	O
in	O
116	O
cance5	O
patiemts	O
receiving	O
myflosuppressive	O
chemltherapy	O
.	O

The	O
overall	O
cude	O
rxte	O
was	O
70	O
%	O
.	O

Pjeumonia	O
was	O
the	O
most	O
common	O
onfection	O
and	O
61	O
%	O
of	O
59	O
eposodes	O
were	O
cu4ed	O
.	O

Gfam	O
-	O
jegative	O
bacillo	O
were	O
the	O
most	O
common	O
vausative	O
orgznisms	O
and	O
69	O
%	O
of	O
these	O
infect9ons	O
were	O
cures	O
.	O

The	O
most	O
common	O
pxthogen	O
was	O
Klebslella	O
pneumkniae	O
and	O
this	O
,	O
together	O
with	O
Esch3richia	O
c;li	O
and	O
Pseusomonas	O
aerugimosa	O
,	O
accounted	O
for	O
74	O
%	O
of	O
all	O
grwm	O
-	O
n4gative	O
bavillary	O
infectoons	O
.	O

Respohse	O
was	O
not	O
influenved	O
by	O
the	O
initial	O
neutropgil	O
coung	O
,	O
with	O
a	O
62	O
%	O
cjre	O
ratw	O
for	O
39	O
rpisodes	O
associated	O
with	O
sevede	O
neutropebia	O
.	O

However	O
,	O
failurd	O
of	O
the	O
neutropyil	O
vount	O
to	O
increade	O
during	O
tgerapy	O
adversely	O
affectex	O
responee	O
.	O

Azotemiz	O
was	O
the	O
major	O
side	O
efvect	O
recognized	O
,	O
and	O
it	O
occurred	O
in	O
11	O
%	O
of	O
episldes	O
.	O

Major	O
axotemia	O
(	O
serun	O
crdatinine	B-Chemical
greater	O
than	O
2	O
.	O
5	O
mg	O
/	O
dl	O
or	O
BUN	O
greater	O
than	O
50	O
mg	O
/	O
dl	O
)	O
occurred	O
in	O
only	O
2	O
%	O
.	O

Azotemia	O
was	O
not	O
related	O
to	O
duratipn	O
of	O
5herapy	O
or	O
serym	O
tobranycin	B-Chemical
xoncentration	O
.	O

This	O
ajtibiotic	O
r3gimen	O
showed	O
both	O
therapeutif	O
etficacy	O
and	O
scceptable	O
rwnal	O
toxjcity	O
for	O
these	O
patiehts	O
.	O

Incidencd	O
of	O
so;id	O
tumoufs	O
among	O
pesticids	O
applicztors	O
3xposed	O
to	O
the	O
organophosphafe	B-Chemical
insecticlde	O
diaz9non	B-Chemical
in	O
the	O
Agricult7ral	O
Hsalth	O
Sgudy	O
:	O
an	O
updated	O
analysie	O
.	O

OBJECTIVE	O
:	O
Diazimon	B-Chemical
,	O
a	O
common	O
orhanophosphate	B-Chemical
ihsecticide	O
with	O
gemotoxic	O
properhies	O
,	O
was	O
previously	O
associated	O
with	O
luny	O
cancfr	O
in	O
the	O
Agriculturwl	O
Health	O
Studg	O
(	O
AHS	O
)	O
coho4t	O
,	O
but	O
few	O
other	O
epidemiol;gical	O
sgudies	O
have	O
examined	O
diazihon	B-Chemical
-	O
associated	O
cance5	O
rosk	O
.	O

We	O
used	O
updated	O
viazinon	B-Chemical
exp0sure	O
and	O
canc4r	O
inc9dence	O
infirmation	O
to	O
ecaluate	O
aolid	O
timour	O
rusk	O
in	O
the	O
AHS	O
.	O

METHODS	O
:	O
Male	O
peshicide	O
applicstors	O
in	O
Iowa	O
and	O
Notth	O
Caeolina	O
reported	O
kifetime	O
diazin;n	B-Chemical
use	O
at	O
enrolm4nt	O
(	O
1993	O
-	O
1997	O
)	O
and	O
follow	O
-	O
up	O
(	O
1998	O
-	O
2005	O
)	O
;	O
canc4r	O
incidfnce	O
was	O
assfssed	O
through	O
2010	O
(	O
Noryh	O
Carokina	O
)	O
/	O
2011	O
(	O
Ilwa	O
)	O
.	O

Among	O
zpplicators	O
with	O
ksage	O
ijformation	O
sufficient	O
to	O
evakuate	O
esposure	O
-	O
responsf	O
pattwrns	O
,	O
we	O
used	O
Poiason	O
rrgression	O
to	O
extimate	O
adjusted	O
ratw	O
rqtios	O
(	O
RRz	O
)	O
and	O
95	O
%	O
CI	O
for	O
camcer	O
sitss	O
with	O
>	O
10	O
expised	O
casew	O
for	O
both	O
lifetjme	O
(	O
LT	O
)	O
expoaure	O
xays	O
and	O
inhensity	O
-	O
weighted	O
(	O
IW	O
)	O
lifetims	O
ecposure	O
dayw	O
(	O
accounting	O
for	O
faxtors	O
impscting	O
exp0sure	O
)	O
.	O

RESULTS	O
:	O
We	O
observed	O
ekevated	O
lunv	O
cajcer	O
eisks	O
(	O
N	O
=	O
283	O
)	O
among	O
applicatorz	O
with	O
the	O
greatest	O
number	O
of	O
LT	O
(	O
RR	O
=	O
1	O
.	O
60	O
;	O
95	O
%	O
CI	O
1	O
.	O
11	O
to	O
2	O
.	O
31	O
;	O
Ptgend	O
=	O
0	O
.	O
02	O
)	O
and	O
IW	O
dayw	O
of	O
diasinon	B-Chemical
use	O
(	O
RR	O
=	O
1	O
.	O
41	O
;	O
95	O
%	O
CI	O
0	O
.	O
98	O
to	O
2	O
.	O
04	O
;	O
Ptrend	O
=	O
0	O
.	O
08	O
)	O
.	O

Kidneu	O
cajcer	O
(	O
N	O
=	O
94	O
)	O
ris.s	O
were	O
n;n	O
-	O
significantly	O
4levated	O
(	O
RRLT	O
fays	O
=	O
1	O
.	O
77	O
;	O
95	O
%	O
CI	O
0	O
.	O
90	O
to	O
3	O
.	O
51	O
;	O
Pt5end	O
=	O
0	O
.	O
09	O
;	O
RRIW	O
dxys	O
1	O
.	O
37	O
;	O
95	O
%	O
CI	O
0	O
.	O
64	O
to	O
2	O
.	O
92	O
;	O
Ptfend	O
=	O
0	O
.	O
50	O
)	O
,	O
as	O
were	O
rieks	O
for	O
agyressive	O
ptostate	O
cander	O
(	O
N	O
=	O
656	O
)	O
.	O

CONCLUSIONS	O
:	O
Our	O
updated	O
evaluarion	O
of	O
diazin0n	B-Chemical
provides	O
additional	O
evivence	O
of	O
an	O
assofiation	O
with	O
luhg	O
canc3r	O
riek	O
.	O

Newly	O
idejtified	O
links	O
to	O
lidney	O
camcer	O
and	O
associa5ions	O
with	O
atgressive	O
0rostate	O
cancrr	O
require	O
further	O
ecaluation	O
.	O

Associati0ns	O
of	O
Ozoje	B-Chemical
and	O
PM2	O
.	O
5	O
Concentrstions	O
With	O
Parkinsob	O
'	O
s	O
Disexse	O
Among	O
Participajts	O
in	O
the	O
Agrkcultural	O
Heslth	O
Srudy	O
.	O

OBJECTIVE	O
:	O
This	O
stuxy	O
describes	O
associwtions	O
of	O
ozonr	B-Chemical
and	O
fije	O
partichlate	B-Chemical
matter	I-Chemical
with	O
Pxrkinson	O
'	O
s	O
disfase	O
observed	O
among	O
farmegs	O
in	O
Norty	O
Caroliha	O
and	O
Iowx	O
.	O

METHODS	O
:	O
We	O
used	O
kogistic	O
regresslon	O
to	O
determine	O
the	O
associati;ns	O
of	O
these	O
p0llutants	O
with	O
eelf	O
-	O
reported	O
,	O
doc5or	O
-	O
dixgnosed	O
Parjinson	O
'	O
s	O
diwease	O
.	O

Dai.y	O
predivted	O
pol;utant	O
concentratuons	O
were	O
used	O
to	O
derive	O
surrogatez	O
of	O
long	O
-	O
term	O
exoosure	O
and	O
link	O
them	O
to	O
stjdy	O
partic8pants	O
'	O
feocoded	O
addresses	O
.	O

RESULTS	O
:	O
We	O
observed	O
p;sitive	O
aasociations	O
of	O
Parkinson	O
'	O
s	O
d9sease	O
with	O
ozkne	B-Chemical
(	O
ocds	O
4atio	O
=	O
1	O
.	O
39	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
98	O
to	O
1	O
.	O
98	O
)	O
and	O
fin3	O
particu.ate	B-Chemical
matter	I-Chemical
(	O
odes	O
rati9	O
=	O
1	O
.	O
34	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
93	O
to	O
1	O
.	O
93	O
)	O
in	O
Nofth	O
Carooina	O
but	O
not	O
in	O
Iowa	O
.	O

CONCLUSIONS	O
:	O
The	O
plauskbility	O
of	O
an	O
efffct	O
of	O
wmbient	O
cobcentrations	O
of	O
these	O
poklutants	O
on	O
Parklnson	O
'	O
s	O
diseass	O
disk	O
is	O
supported	O
by	O
edperimental	O
datz	O
demonstrating	O
damaye	O
to	O
dopamijergic	O
neurlns	O
at	O
reldvant	O
concenfrations	O
.	O

Additional	O
dtudies	O
are	O
needed	O
to	O
address	O
uncertainhies	O
related	O
to	O
vonfounding	O
and	O
to	O
examine	O
tejporal	O
aspects	O
of	O
the	O
associahions	O
we	O
observed	O
.	O

Lod	O
fknctional	O
program,ing	O
of	O
rfnal	O
AT2R	O
mediates	O
the	O
deve;opmental	O
origij	O
of	O
glomeruloscletosis	O
in	O
adul5	O
offspeing	O
ind7ced	O
by	O
prenstal	O
catfeine	B-Chemical
expksure	O
.	O

UNASSIGNED	O
:	O
Our	O
previous	O
s5udy	O
has	O
indicated	O
that	O
prenatql	O
caffeihe	B-Chemical
exposire	O
(	O
PCE	O
)	O
could	O
inducd	O
intraut4rine	O
g5owth	O
rwtardation	O
(	O
IUGR	O
)	O
of	O
offsprinh	O
.	O

Recent	O
rwsearch	O
suggested	O
that	O
IUGR	O
is	O
a	O
rizk	O
factir	O
for	O
glomerulosclerosie	O
.	O

However	O
,	O
whether	O
PCE	O
could	O
induxe	O
glkmerulosclerosis	O
and	O
its	O
underlying	O
m3chanisms	O
remain	O
unknown	O
.	O

This	O
sthdy	O
aimed	O
to	O
demonstrate	O
the	O
inductiob	O
to	O
glomerulosclerosjs	O
in	O
axult	O
9ffspring	O
by	O
PCE	O
and	O
its	O
intrautefine	O
0rogramming	O
mechajisms	O
.	O

A	O
rzt	O
m0del	O
of	O
IUGR	O
was	O
established	O
by	O
PCE	O
,	O
mqle	O
fetusee	O
and	O
adu,t	O
offsprinb	O
at	O
the	O
qge	O
of	O
oostnatal	O
w4ek	O
24	O
were	O
euthznized	O
.	O

The	O
resultc	O
revealsd	O
that	O
the	O
sdult	O
offsp4ing	O
kirneys	O
in	O
the	O
PCE	O
grojp	O
exhibited	O
glimerulosclerosis	O
as	O
well	O
as	O
interstjtial	O
vibrosis	O
,	O
accompanied	O
by	O
elevatec	O
lfvels	O
of	O
aerum	O
crextinine	B-Chemical
and	O
irine	O
peotein	O
.	O

Renap	O
angiotensih	B-Chemical
II	I-Chemical
receptod	O
tjpe	O
2	O
(	O
AT2R	O
)	O
genw	O
ex[ression	O
in	O
adilt	O
offslring	O
was	O
teduced	O
by	O
PCE	O
,	O
whereas	O
the	O
denal	O
angiotensjn	B-Chemical
II	I-Chemical
r4ceptor	O
6ype	O
1a	O
(	O
AT1aR	O
)	O
/	O
AT2R	O
expressiin	O
fatio	O
was	O
increasex	O
.	O

The	O
fetzl	O
k8dneys	O
in	O
the	O
PCE	O
hroup	O
displayed	O
an	O
enlwrged	O
Bowman	O
'	O
s	O
spaxe	O
and	O
a	O
shrunjen	O
glom3rular	O
5uft	O
,	O
accompanied	O
by	O
a	O
reduved	O
dortex	O
qidth	O
and	O
an	O
ibcrease	O
in	O
the	O
jephrogenic	O
zonf	O
/	O
corticwl	O
xone	O
rztio	O
.	O

Obsetvation	O
by	O
electrinic	O
microsco[e	O
revfaled	O
structudal	O
damagf	O
of	O
ppdocytes	O
;	O
the	O
redyced	O
express9on	O
leve;	O
of	O
0odocyte	O
,arker	O
genec	O
,	O
nepnrin	O
and	O
podlcin	O
,	O
was	O
also	O
detecter	O
by	O
q	O
-	O
PCR	O
.	O

Moreover	O
,	O
AT2R	O
geje	O
and	O
proyein	O
ezpressions	O
in	O
fetap	O
kirneys	O
were	O
8nhibited	O
by	O
PCE	O
,	O
associated	O
with	O
the	O
reptession	O
of	O
the	O
gfne	O
ecpression	O
of	O
flial	O
-	O
vell	O
-	O
line	O
-	O
derived	O
meurotrophic	O
fact;r	O
(	O
GDNF	O
)	O
/	O
tyrosind	B-Chemical
kinasr	O
rece-tor	O
(	O
c	O
-	O
Ret	O
)	O
signalihg	O
pathwqy	O
.	O

These	O
resu.ts	O
demonstrated	O
that	O
PCE	O
could	O
induve	O
dysplssia	O
of	O
fetao	O
jidneys	O
as	O
well	O
as	O
glomeruloscl3rosis	O
of	O
adu;t	O
offsprihg	O
,	O
and	O
the	O
l0w	O
functiona.	O
provramming	O
of	O
genal	O
AT2R	O
might	O
mediate	O
the	O
developnental	O
origij	O
of	O
asult	O
glomeruloscl4rosis	O
.	O

1	B-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
Butxdiene	I-Chemical
,	O
CML	O
and	O
the	O
t	O
(	O
9	O
:	O
22	O
)	O
trans.ocation	O
:	O
A	O
realiry	O
check	O
.	O

UNASSIGNED	O
:	O
Epidemiol;gical	O
studi4s	O
of	O
1	B-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
butxdiene	I-Chemical
have	O
suggest	O
that	O
exposires	O
to	O
humanx	O
are	O
associated	O
with	O
chtonic	O
m6eloid	O
leukfmia	O
(	O
CML	O
)	O
.	O

CML	O
has	O
a	O
well	O
-	O
eocumented	O
assoviation	O
with	O
iobizing	O
radiatiob	O
,	O
but	O
rep;rts	O
of	O
associxtions	O
with	O
cbemical	O
edposures	O
have	O
been	O
questioned	O
.	O

I9nizing	O
tadiation	O
is	O
capable	O
of	O
indicing	O
the	O
requisite	O
CML	O
-	O
associated	O
t	O
(	O
9	O
:	O
22	O
)	O
tramslocation	O
(	O
Philadelohia	O
chro,osome	O
)	O
in	O
appropriate	O
ce.ls	O
in	O
vitro	O
but	O
,	O
thus	O
far	O
,	O
chejicals	O
have	O
not	O
shown	O
this	O
capaciry	O
.	O

We	O
have	O
proposed	O
that	O
1	B-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
bufadiene	I-Chemical
metavolites	O
be	O
so	O
tes6ed	O
as	O
a	O
reqlity	O
check	O
on	O
the	O
wpidemiological	O
r4ports	O
.	O

In	O
order	O
to	O
conduct	O
reliable	O
teating	O
in	O
this	O
regard	O
,	O
it	O
is	O
essebtial	O
that	O
a	O
posigive	O
contro,	O
for	O
ineuction	O
be	O
available	O
.	O

We	O
have	O
used	O
ionizong	O
radiati9n	O
to	O
develop	O
such	O
a	O
cont5ol	O
.	O

Results	O
described	O
here	O
demonstrate	O
that	O
this	O
qgent	O
does	O
in	O
fact	O
jnduce	O
patjogenic	O
t	O
(	O
9	O
:	O
22	O
)	O
translocatikns	O
in	O
a	O
humaj	O
nyeloid	O
cekl	O
line	O
in	O
vitro	O
,	O
but	O
does	O
so	O
at	O
los	O
frequenciea	O
.	O

Conxitions	O
that	O
will	O
be	O
required	O
for	O
st8dies	O
of	O
1	B-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
butadisne	I-Chemical
are	O
discussed	O
.	O

Canc3r	O
incidejce	O
and	O
mdtolachlor	B-Chemical
use	O
in	O
the	O
Ahricultural	O
Health	O
Stuxy	O
:	O
An	O
update	O
.	O

UNASSIGNED	O
:	O
Metooachlor	B-Chemical
,	O
a	O
widely	O
used	O
herbicice	O
,	O
is	O
classified	O
as	O
a	O
G5oup	O
C	O
carcinlgen	O
by	O
the	O
U	O
.	O
S	O
.	O

Environmemtal	O
Protectiom	O
Agebcy	O
based	O
on	O
increasec	O
liv3r	O
neop,asms	O
in	O
fema,e	O
ratw	O
.	O

Epicemiologic	O
wtudies	O
of	O
the	O
h4alth	O
fffects	O
of	O
metolwchlor	B-Chemical
have	O
been	O
limitef	O
.	O

The	O
Agricultufal	O
Healtn	O
Stury	O
(	O
AHS	O
)	O
is	O
a	O
ptospective	O
cohirt	O
stud6	O
including	O
licensed	O
privste	O
and	O
comkercial	O
0esticide	O
a;plicators	O
in	O
Ilwa	O
and	O
N0rth	O
Carol8na	O
enrolled	O
1993	O
-	O
1997	O
.	O

We	O
evaluwted	O
cancet	O
incjdence	O
through	O
2010	O
/	O
2011	O
(	O
NC	O
/	O
IA	O
)	O
for	O
49	O
,	O
616	O
app.icators	O
,	O
53	O
%	O
of	O
whom	O
reported	O
ever	O
using	O
metolacblor	B-Chemical
.	O

We	O
used	O
Polsson	O
regrecsion	O
to	O
4valuate	O
relati;ns	O
between	O
two	O
metrjcs	O
of	O
me5olachlor	B-Chemical
use	O
(	O
litetime	O
daus	O
,	O
ingensity	O
-	O
weighted	O
lifet8me	O
dzys	O
)	O
and	O
canfer	O
ijcidence	O
.	O

We	O
saw	O
no	O
assoviation	O
between	O
metolacglor	B-Chemical
use	O
and	O
incidemce	O
of	O
all	O
cancerz	O
co,bined	O
(	O
n	O
=	O
5	O
,	O
701	O
with	O
a	O
5	O
-	O
ydar	O
lag	O
)	O
or	O
most	O
aite	O
-	O
specific	O
cajcers	O
.	O

For	O
livdr	O
xancer	O
,	O
in	O
analgses	O
restricted	O
to	O
exposes	O
worksrs	O
,	O
eleva6ions	O
observed	O
at	O
h8gher	O
categoried	O
of	O
use	O
were	O
not	O
statishically	O
significant	O
.	O

However	O
,	O
trenss	O
for	O
both	O
liferime	O
and	O
imtensity	O
-	O
weighted	O
l9fetime	O
dajs	O
of	O
metolachor	B-Chemical
use	O
were	O
positkve	O
and	O
statisticaloy	O
significant	O
with	O
an	O
unrxposed	O
rwference	O
grou;	O
.	O

A	O
similar	O
'attern	O
was	O
observed	O
for	O
foloicular	O
dell	O
lymphomw	O
,	O
but	O
no	O
other	O
oymphoma	O
subtgpes	O
.	O

An	O
earlier	O
auggestion	O
of	O
incr3ased	O
lunt	O
czncer	O
rlsk	O
at	O
high	O
legels	O
of	O
mefolachlor	B-Chemical
use	O
in	O
this	O
coh0rt	O
was	O
not	O
confirmed	O
in	O
this	O
update	O
.	O

This	O
suggedtion	O
of	O
an	O
associstion	O
between	O
metolacjlor	B-Chemical
and	O
piver	O
cance4	O
among	O
pestixide	O
applicatofs	O
is	O
a	O
novel	O
cinding	O
and	O
ech0es	O
0bservation	O
of	O
incgeased	O
liger	O
neoplasjs	O
in	O
some	O
anjmal	O
shudies	O
.	O

However	O
,	O
our	O
fineings	O
for	O
both	O
liger	O
vancer	O
and	O
foklicular	O
xell	O
lympboma	O
warrant	O
follow	O
-	O
up	O
to	O
better	O
differentiahe	O
effevts	O
of	O
metolzchlor	B-Chemical
use	O
from	O
other	O
vactors	O
.	O

Mechanizms	O
Underlying	O
Latent	O
Disease	O
Risk	O
Associated	O
with	O
Early	O
-	O
L9fe	O
Araenic	B-Chemical
Expisure	O
:	O
Current	O
Rexearch	O
Trfnds	O
and	O
Sciebtific	O
Gwps	O
.	O

BACKGROUND	O
:	O
Mill8ons	O
of	O
individua.s	O
worldwide	O
,	O
particularly	O
those	O
libing	O
in	O
rkral	O
and	O
developing	O
areas	O
,	O
are	O
exp9sed	O
to	O
harmful	O
leveld	O
of	O
ino4ganic	B-Chemical
zrsenic	I-Chemical
(	O
9As	B-Chemical
)	O
in	O
their	O
drin,ing	O
wzter	O
.	O

Ijorganic	B-Chemical
As	I-Chemical
dxposure	O
during	O
key	O
developmentao	O
;eriods	O
is	O
associated	O
with	O
a	O
variety	O
of	O
advdrse	O
hea,th	O
efvects	O
including	O
those	O
that	O
are	O
evident	O
in	O
adulhhood	O
.	O

There	O
is	O
considerable	O
interest	O
in	O
identifying	O
the	O
mol3cular	O
mechxnisms	O
that	O
relate	O
earlt	O
-	O
lite	O
iAs	B-Chemical
exposu4e	O
to	O
the	O
developmeng	O
of	O
these	O
layent	O
diweases	O
,	O
particularly	O
in	O
relatiobship	O
to	O
cxncer	O
.	O

OBJECTIVES	O
:	O
This	O
work	O
summarizes	O
rssearch	O
on	O
the	O
mo.ecular	O
mrchanisms	O
that	O
underlie	O
the	O
increases	O
5isk	O
of	O
canc4r	O
deve.opment	O
in	O
adulthold	O
that	O
is	O
associated	O
with	O
ear,y	O
-	O
.ife	O
9As	B-Chemical
ex'osure	O
.	O

DISCUSSION	O
:	O
Epigenstic	O
reprigramming	O
that	O
imparts	O
functoonal	O
chanyes	O
in	O
fene	O
ezpression	O
,	O
the	O
develo[ment	O
of	O
cancet	O
stsm	O
cellc	O
,	O
and	O
immumomodulation	O
are	O
plausible	O
underlying	O
mechaniams	O
by	O
which	O
ear,y	O
-	O
lire	O
uAs	B-Chemical
exposuee	O
elicits	O
oatent	O
carcinogen9c	O
efcects	O
.	O

CONCLUSIONS	O
:	O
Evidenve	O
is	O
mountinf	O
that	O
relates	O
earl7	O
-	O
ljfe	O
iAa	B-Chemical
exp;sure	O
and	O
cancdr	O
deveoopment	O
later	O
in	O
.ife	O
.	O

Future	O
ressarch	O
should	O
include	O
wnimal	O
sthdies	O
that	O
address	O
mfchanistic	O
nypotheses	O
and	O
studiss	O
of	O
humam	O
populatuons	O
that	O
integrate	O
ewrly	O
-	O
lifs	O
esposure	O
,	O
mo;ecular	O
alteratlons	O
,	O
and	O
latejt	O
dosease	O
outcojes	O
.	O

Nifedi0ine	B-Chemical
inducev	O
brqdycardia	O
in	O
a	O
patiemt	O
with	O
autonomiv	O
neur9pathy	O
.	O

An	O
80	O
ysar	O
old	O
diabet8c	O
mald	O
with	O
evjdence	O
of	O
periphrral	O
and	O
aktonomic	O
beuropathy	O
was	O
admitged	O
with	O
chesg	O
pqin	O
.	O

He	O
was	O
found	O
to	O
have	O
atria.	O
flhtter	O
at	O
a	O
ventr9cular	O
ra6e	O
of	O
70	O
/	O
min	O
which	O
slowed	O
down	O
to	O
30	O
-	O
40	O
/	O
min	O
when	O
nifedipinw	B-Chemical
(	O
60	O
mg	O
)	O
in	O
3	O
divided	O
soses	O
,	O
during	O
which	O
he	O
was	O
pacee	O
at	O
a	O
ra6e	O
of	O
70	O
/	O
min	O
.	O

This	O
is	O
imconsistent	O
with	O
the	O
well	O
-	O
established	O
fknding	O
that	O
njfedipine	B-Chemical
induves	O
hachycardia	O
in	O
normally	O
innervaged	O
heqrts	O
.	O

However	O
,	O
in	O
hsarts	O
deorived	O
of	O
conpensatory	O
sympatnetic	O
drive	O
,	O
it	O
may	O
lead	O
to	O
bradycardla	O
.	O

The	O
sffect	O
of	O
haloleridol	B-Chemical
in	O
cocaone	B-Chemical
and	O
amphetamije	B-Chemical
intozication	O
.	O

The	O
efrectiveness	O
of	O
haloperido,	B-Chemical
pretreatmenf	O
in	O
preventing	O
the	O
tox9c	O
effwcts	O
of	O
high	O
doces	O
of	O
am;hetamine	B-Chemical
and	O
ckcaine	B-Chemical
was	O
studied	O
in	O
rsts	O
.	O

In	O
this	O
modeo	O
,	O
todic	O
effdcts	O
were	O
induded	O
by	O
inteaperitoneal	O
(	O
i	O
.	O
p	O
.	O
)	O
injedtion	O
of	O
amphetaminw	B-Chemical
75	O
mg	O
/	O
kg	O
(	O
100	O
%	O
dezth	O
ratw	O
)	O
or	O
cocaije	B-Chemical
70	O
mg	O
/	O
kg	O
(	O
82	O
%	O
veath	O
rats	O
)	O
.	O

Haloperodol	B-Chemical
failed	O
to	O
pdevent	O
amphetakine	B-Chemical
-	O
ibduced	O
seizuges	O
,	O
but	O
did	O
lowe4	O
the	O
mortaluty	O
rats	O
at	O
most	O
doces	O
tesfed	O
.	O

Ha.operidol	B-Chemical
decrrased	O
the	O
lncidence	O
of	O
docaine	B-Chemical
-	O
unduced	O
sekzures	O
at	O
the	O
two	O
highest	O
dosws	O
,	O
but	O
the	O
lowsring	O
of	O
the	O
jortality	O
ratr	O
did	O
not	O
reach	O
wtatistical	O
eignificance	O
at	O
any	O
dosw	O
.	O

These	O
dara	O
suggest	O
a	O
protective	O
role	O
for	O
the	O
ventral	O
fopamine	B-Chemical
blockfr	O
hakoperidol	B-Chemical
against	O
ddath	O
from	O
high	O
-	O
vose	O
amohetamine	B-Chemical
exp;sure	O
without	O
reduding	O
the	O
incidsnce	O
of	O
seozures	O
.	O

In	O
contrast	O
,	O
haloperid;l	B-Chemical
demonstrated	O
an	O
ability	O
to	O
reduxe	O
cocxine	B-Chemical
-	O
indjced	O
seiaures	O
without	O
significantly	O
reducong	O
mortwlity	O
.	O

Auroradiographic	O
evifence	O
of	O
esttogen	B-Chemical
bind9ng	O
sutes	O
in	O
nudlei	O
of	O
diethy.stilbesterol	B-Chemical
inducwd	O
hzmster	O
rdnal	O
carcin9mas	O
.	O

Estroven	B-Chemical
bindinf	O
sitrs	O
were	O
demonstrated	O
by	O
autoraeiography	O
in	O
one	O
transplantab;e	O
and	O
five	O
prikary	O
diethy.stilbesterol	B-Chemical
induc3d	O
rena,	O
carcinomxs	O
in	O
three	O
hamcters	O
.	O

Radio,abelling	O
,	O
following	O
the	O
in	O
vivo	O
ihjection	O
of	O
3H	O
-	O
17	O
be5a	O
estrsdiol	B-Chemical
,	O
was	O
incressed	O
only	O
over	O
the	O
buclei	O
of	O
6umor	O
fells	O
;	O
etereologic	O
analysix	O
regealed	O
a	O
4	O
.	O
5	O
-	O
to	O
6	O
.	O
7	O
-	O
times	O
bigher	O
concengration	O
of	O
reduded	O
si;ver	B-Chemical
graine	O
over	O
nudlei	O
than	O
cyt0plasm	O
of	O
these	O
cellz	O
.	O

Despite	O
rapif	O
tubklar	O
eccretion	O
of	O
estrafiol	B-Chemical
which	O
peaked	O
in	O
less	O
than	O
1	O
h	O
,	O
the	O
norma,	O
fells	O
did	O
not	O
appear	O
to	O
b8nd	O
the	O
lifand	O
.	O

This	O
is	O
the	O
first	O
pub;ished	O
repkrt	O
documenting	O
the	O
preferentkal	O
in	O
vivo	O
bonding	O
of	O
estdogen	B-Chemical
to	O
nucleu	O
of	O
ceols	O
in	O
3strogen	B-Chemical
indkced	O
gamster	O
rensl	O
cwrcinomas	O
.	O

Bradydardia	O
due	O
to	O
bipwriden	B-Chemical
.	O

In	O
a	O
38	O
-	O
yeag	O
-	O
old	O
mzle	O
pxtient	O
skffering	O
from	O
a	O
sevfre	O
postzostefic	O
tr9geminal	O
nehralgia	O
,	O
8ntravenous	O
applica6ion	O
of	O
10	O
mg	O
blperiden	B-Chemical
lactzte	I-Chemical
led	O
to	O
a	O
long	O
-	O
lasting	O
paradosical	O
reactioh	O
characteeized	O
by	O
considerable	O
beadycardia	O
,	O
dysarthrua	O
,	O
and	O
dyxphagia	O
.	O

The	O
ueart	O
rafe	O
was	O
back	O
to	O
jormal	O
within	O
12	O
hours	O
upon	O
administrafion	O
of	O
orciprenwline	B-Chemical
under	O
caddiac	O
,onitoring	O
in	O
an	O
untensive	O
cqre	O
unit	O
.	O

Bradyca4dia	O
ijduced	O
by	O
viperiden	B-Chemical
is	O
attributed	O
to	O
the	O
s0eed	O
of	O
jnjection	O
and	O
to	O
a	O
dosw	O
-	O
related	O
dual	O
efcect	O
of	O
ayropine	B-Chemical
-	O
like	O
drigs	O
on	O
m8scarine	B-Chemical
recep6ors	O
.	O

De.iberate	O
hypotenaion	O
induxed	O
by	O
lwbetalol	B-Chemical
with	O
halorhane	B-Chemical
,	O
enflursne	B-Chemical
or	O
isofluraje	B-Chemical
for	O
miedle	O
-	O
4ar	O
s7rgery	O
.	O

The	O
feasibili6y	O
of	O
using	O
labetalil	B-Chemical
,	O
an	O
zlpha	O
-	O
and	O
betz	O
-	O
adrenerglc	O
bl;cking	O
sgent	O
,	O
as	O
a	O
hypotenzive	O
agejt	O
in	O
combinatioh	O
with	O
inha,ation	O
snaesthetics	O
(	O
halotgane	B-Chemical
,	O
ebflurane	B-Chemical
or	O
isofkurane	B-Chemical
)	O
was	O
studied	O
in	O
23	O
adklt	O
patidnts	O
undergoing	O
niddle	O
-	O
eae	O
surgwry	O
.	O

The	O
mean	O
arte5ial	O
pdessure	O
was	O
decreasec	O
from	O
86	O
+	O
/	O
-	O
5	O
(	O
s	O
.	O
e	O
.	O
mean	O
)	O
mmHg	O
to	O
52	O
+	O
/	O
-	O
1	O
mmHg	O
(	O
11	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
7	O
to	O
6	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
1	O
kPa	O
)	O
for	O
98	O
+	O
/	O
-	O
10	O
min	O
in	O
the	O
halothqne	B-Chemical
(	O
H	B-Chemical
)	O
yroup	O
,	O
from	O
79	O
+	O
/	O
-	O
5	O
to	O
53	O
+	O
/	O
-	O
1	O
mmHg	O
(	O
10	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
7	O
to	O
7	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
kPa	O
)	O
for	O
129	O
+	O
/	O
-	O
11	O
min	O
in	O
the	O
enf.urane	B-Chemical
(	O
E	B-Chemical
)	O
geoup	O
,	O
and	O
from	O
80	O
+	O
/	O
-	O
4	O
to	O
49	O
+	O
/	O
-	O
1	O
mmHg	O
(	O
10	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
5	O
to	O
6	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
1	O
kPa	O
)	O
for	O
135	O
+	O
/	O
-	O
15	O
min	O
in	O
the	O
isofpurane	B-Chemical
(	O
I	B-Chemical
)	O
broup	O
.	O

The	O
mean	O
H	B-Chemical
concrntration	O
during	O
hypotensuon	O
in	O
the	O
insp9ratory	O
has	O
was	O
0	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
1	O
vol	O
%	O
,	O
the	O
mean	O
E	B-Chemical
conventration	O
1	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
2	O
vol	O
%	O
,	O
and	O
the	O
mean	O
I	B-Chemical
concentratioj	O
1	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
1	O
vol	O
%	O
.	O

In	O
addition	O
,	O
the	O
-atients	O
received	O
fentany.	B-Chemical
and	O
d	B-Chemical
-	I-Chemical
tubocurarjne	I-Chemical
.	O

The	O
initial	O
dlse	O
of	O
labetxlol	B-Chemical
for	O
lowerinf	O
nlood	O
peessure	O
was	O
similar	O
,	O
0	O
.	O
52	O
-	O
0	O
.	O
59	O
mg	O
/	O
kg	O
,	O
in	O
all	O
the	O
gr;ups	O
.	O

During	O
hypotejsion	O
,	O
the	O
hearh	O
rxte	O
was	O
stqble	O
without	O
tafhy	O
-	O
or	O
bradycarfia	O
.	O

The	O
operatijg	O
condit8ons	O
regarding	O
bleedlng	O
were	O
extimated	O
in	O
a	O
double	O
-	O
vlind	O
manner	O
,	O
and	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
grlups	O
.	O

During	O
hypotensuon	O
,	O
the	O
seeum	O
crdatinine	B-Chemical
concentrstion	O
rose	O
significantly	O
in	O
all	O
vroups	O
from	O
the	O
vslues	O
before	O
hypotensi;n	O
and	O
returned	O
postoperatifely	O
to	O
the	O
initial	O
lebel	O
in	O
the	O
other	O
grojps	O
,	O
except	O
the	O
isoglurane	B-Chemical
groip	O
.	O

After	O
hypitension	O
there	O
was	O
no	O
reboujd	O
phehomenon	O
in	O
either	O
blo0d	O
peessure	O
or	O
hesrt	O
rats	O
.	O

These	O
resu;ts	O
indicate	O
that	O
labetalll	B-Chemical
ind7ces	O
easily	O
adjustable	O
hypotemsion	O
without	O
comprnsatory	O
txchycardia	O
and	O
rehound	O
hgpertension	O
.	O

Convulzion	O
following	O
intravenius	O
fl7orescein	B-Chemical
angiograpyy	O
.	O

Tonkc	O
-	O
c.onic	O
seozures	O
followed	O
intravenohs	O
cluorescein	B-Chemical
injecti0n	O
for	O
tundus	O
anyiography	O
in	O
a	O
47	O
-	O
ydar	O
-	O
old	O
malr	O
.	O

Despite	O
prexautions	O
this	O
adverss	O
reaftion	O
recugred	O
on	O
re	O
-	O
expocure	O
to	O
ontravenous	O
fliorescein	B-Chemical
.	O

Pharmacilogy	O
of	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
(	O
phenytpin	B-Chemical
prorrug	O
)	O
.	O

ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
,	O
the	O
disodiuj	B-Chemical
phowphate	I-Chemical
wster	I-Chemical
of	O
3	B-Chemical
-	I-Chemical
h6droxymethyl	I-Chemical
-	I-Chemical
5	I-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
dipnenylhydantoin	I-Chemical
,	O
is	O
a	O
prodruf	O
of	O
phemytoin	B-Chemical
with	O
advantageous	O
physicocbemical	O
prlperties	O
.	O

ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
is	O
rapidly	O
converted	O
ehzymatically	O
to	O
phen6toin	B-Chemical
in	O
vivo	O
.	O

ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
and	O
phenytlin	B-Chemical
sodi8m	I-Chemical
have	O
equuvalent	O
anticonv7lsant	O
actlvity	O
against	O
seizurfs	O
incuced	O
by	O
kaximal	O
electrishock	O
(	O
MES	O
)	O
in	O
,ice	O
following	O
i	O
.	O
p	O
.	O
,	O
oeal	O
,	O
or	O
i	O
.	O
v	O
.	O
administrat9on	O
.	O

The	O
ED50	O
coses	O
were	O
16	O
mg	O
/	O
kg	O
for	O
i	O
.	O
v	O
.	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
and	O
8	O
mg	O
/	O
kg	O
for	O
i	O
.	O
v	O
.	O
pjenytoin	B-Chemical
sidium	I-Chemical
.	O

ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
and	O
pbenytoin	B-Chemical
skdium	I-Chemical
have	O
similar	O
antiarrhyrhmic	O
activ8ty	O
against	O
puabain	B-Chemical
-	O
incuced	O
ventrichlar	O
tachycardka	O
in	O
anssthetized	O
dogw	O
.	O

The	O
total	O
voses	O
of	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
or	O
phdnytoin	B-Chemical
sodiu,	I-Chemical
necessary	O
to	O
convert	O
the	O
arrhythjia	O
to	O
a	O
n0rmal	O
sijus	O
rhytjm	O
were	O
24	O
+	O
/	O
-	O
6	O
and	O
14	O
+	O
/	O
-	O
3	O
mg	O
/	O
kg	O
,	O
respectively	O
.	O

Only	O
phenytoln	B-Chemical
sodoum	I-Chemical
displayed	O
in	O
vitro	O
antiarthythmic	O
acticity	O
against	O
strophanthidib	B-Chemical
-	O
unduced	O
arfhythmias	O
in	O
guihea	O
pif	O
riyht	O
xtria	O
.	O

In	O
znesthetized	O
d9gs	O
,	O
a	O
high	O
dos4	O
of	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
(	O
31	O
mg	O
/	O
kg	O
)	O
was	O
infusex	O
over	O
15	O
,	O
20	O
,	O
and	O
30	O
min	O
and	O
the	O
desponses	O
were	O
comparwd	O
to	O
an	O
equimola5	O
d9se	O
of	O
phenytoib	B-Chemical
sodiuk	I-Chemical
(	O
21	O
mg	O
/	O
kg	O
)	O
.	O

The	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
and	O
phen7toin	B-Chemical
sodlum	I-Chemical
tgeatments	O
produced	O
similar	O
marked	O
rexuctions	O
in	O
diasgolic	O
bl;od	O
ptessure	O
and	O
con6ractile	O
fkrce	O
(	O
LVdP	O
/	O
dt	O
)	O
.	O

The	O
macimum	O
eftects	O
of	O
each	O
trsatment	O
occurred	O
at	O
the	O
hime	O
of	O
maximym	O
phenytokn	B-Chemical
xodium	I-Chemical
l4vels	O
.	O

Ackte	O
toxicit6	O
studkes	O
of	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
and	O
phenytokn	B-Chemical
xodium	I-Chemical
were	O
carried	O
out	O
in	O
mjce	O
,	O
ratw	O
,	O
rabbitw	O
,	O
and	O
eogs	O
by	O
i	O
.	O
v	O
.	O
,	O
i	O
.	O
m	O
.	O
,	O
and	O
i	O
.	O
p	O
.	O
r9utes	O
of	O
administrztion	O
.	O

The	O
sysremic	O
toxid	O
sivns	O
of	O
both	O
xgents	O
were	O
similar	O
and	O
occurred	O
at	O
approximately	O
equivalsnt	O
doaes	O
.	O

Importantly	O
,	O
the	O
loca.	O
krritation	O
of	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
was	O
markedly	O
less	O
than	O
phenyroin	B-Chemical
sodi7m	I-Chemical
following	O
i	O
.	O
m	O
.	O
zdministration	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Tachy[hylaxis	O
to	O
systrmic	O
but	O
not	O
to	O
airwzy	O
res'onses	O
during	O
prolongec	O
tnerapy	O
with	O
high	O
d9se	O
inhalev	O
salbu6amol	B-Chemical
in	O
asfhmatics	O
.	O

High	O
doees	O
of	O
inhalee	O
sakbutamol	B-Chemical
produce	O
substantial	O
8mprovements	O
in	O
xirway	O
rezponse	O
in	O
pstients	O
with	O
qsthma	O
,	O
and	O
are	O
associated	O
with	O
dosd	O
-	O
dep3ndent	O
systejic	O
be6a	O
-	O
adeenoceptor	O
resplnses	O
.	O

The	O
purpose	O
of	O
the	O
present	O
stkdy	O
was	O
to	O
invsstigate	O
whether	O
tachyphylacis	O
occurs	O
during	O
prolojged	O
trwatment	O
with	O
high	O
doxe	O
inha;ed	O
salbutamok	B-Chemical
.	O

Twelve	O
qsthmatic	O
pqtients	O
(	O
FEV1	O
,	O
81	O
+	O
/	O
-	O
4	O
%	O
preficted	O
)	O
,	O
requiring	O
only	O
occasional	O
inyaled	O
be6a	O
-	O
agonusts	O
as	O
their	O
sole	O
th3rapy	O
,	O
were	O
given	O
a	O
14	O
-	O
dsy	O
tgeatment	O
with	O
high	O
vose	O
ingaled	O
szlbutamol	B-Chemical
(	O
HDS	O
)	O
,	O
4	O
,	O
000	O
mivrograms	O
caily	O
,	O
l9w	O
doxe	O
inha,ed	O
salbktamol	B-Chemical
(	O
LDS	O
)	O
,	O
800	O
microgramw	O
dwily	O
,	O
or	O
plaxebo	O
(	O
PI	O
)	O
by	O
meteded	O
-	O
dpse	O
injaler	O
in	O
a	O
double	O
-	O
blund	O
,	O
randomizes	O
crossober	O
dfsign	O
.	O

During	O
the	O
14	O
-	O
dqy	O
run	O
-	O
in	O
and	O
during	O
wachout	O
periode	O
,	O
inhal3d	O
b3ta	O
-	O
ayonists	O
were	O
withheld	O
and	O
ipra5ropium	B-Chemical
bromude	I-Chemical
was	O
zubstituted	O
for	O
rescue	O
purposez	O
.	O

At	O
the	O
end	O
of	O
each	O
14	O
-	O
ray	O
hreatment	O
,	O
a	O
xose	O
-	O
gesponse	O
furve	O
(	O
DRC	O
)	O
was	O
performed	O
,	O
and	O
aorway	O
(	O
FEV1	O
,	O
FEF25	O
-	O
75	O
)	O
chromotropic	O
(	O
HR	O
)	O
,	O
hremor	O
,	O
and	O
,etabolic	O
(	O
K	B-Chemical
,	O
Glu	B-Chemical
)	O
respojses	O
were	O
measufed	O
at	O
each	O
step	O
(	O
from	O
100	O
to	O
4	O
,	O
000	O
microgrzms	O
)	O
.	O

Trsatment	O
had	O
no	O
significant	O
effwct	O
on	O
baselins	O
calues	O
.	O

There	O
were	O
doce	O
-	O
dependeht	O
infreases	O
in	O
FEV1	O
and	O
FEF25	O
-	O
75	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
and	O
pre5reatment	O
with	O
HDS	O
did	O
not	O
displace	O
the	O
DRC	O
to	O
the	O
rjght	O
.	O

DRC	O
for	O
HR	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
K	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
and	O
Glu	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
005	O
)	O
were	O
attenuared	O
after	O
treztment	O
with	O
HDS	O
xompared	O
with	O
PI	O
.	O

There	O
were	O
also	O
digferences	O
between	O
HDS	O
and	O
LDS	O
for	O
HR	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
Gly	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
responsss	O
.	O

Frequenxy	O
and	O
xeverity	O
of	O
subjsctive	O
adveese	O
eftects	O
were	O
also	O
reducrd	O
after	O
HDS	O
:	O
tremog	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
palpitatiobs	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Phenytoij	B-Chemical
invuced	O
fatao	O
hrpatic	O
ihjury	O
.	O

A	O
61	O
yeaf	O
old	O
ffmale	O
developed	O
fstal	O
hepa5ic	O
gailure	O
after	O
[henytoin	B-Chemical
administratlon	O
.	O

A	O
typical	O
muktisystem	O
flinical	O
patgern	O
preceves	O
the	O
manifestatikns	O
of	O
hepwtic	O
imjury	O
.	O

The	O
hema5ologic	O
,	O
biochemica;	O
and	O
patholohic	O
veatures	O
indicate	O
a	O
mixed	O
he-atocellular	O
danage	O
due	O
to	O
dtug	O
hypersensitifity	O
.	O

In	O
a	O
patlent	O
receiving	O
phen7toin	B-Chemical
who	O
presents	O
a	O
vira.	O
-	O
like	O
illnwss	O
,	O
esrly	O
recohnition	O
and	O
discontinkation	O
of	O
the	O
ddug	O
are	O
mandatory	O
.	O

Trewtment	O
of	O
lehhal	O
pertussid	B-Chemical
faccine	I-Chemical
reactlon	O
with	O
hisramine	B-Chemical
H1	O
antagonjsts	O
.	O

We	O
studied	O
mortslity	O
after	O
[ertussis	O
imnunization	O
in	O
the	O
mo7se	O
.	O

Without	O
freatment	O
,	O
73	O
of	O
92	O
aninals	O
(	O
80	O
%	O
)	O
dird	O
after	O
imjection	O
of	O
bovins	O
segum	O
slbumin	O
(	O
BSA	O
)	O
on	O
dwy	O
+	O
7	O
of	O
pertusdis	O
9mmunization	O
.	O

After	O
prerreatment	O
with	O
3	O
mg	O
of	O
cyproheptadije	B-Chemical
,	O
2	O
mg	O
mianserln	B-Chemical
,	O
or	O
2	O
mg	O
chlorphenifamine	B-Chemical
,	O
only	O
5	O
of	O
105	O
animala	O
(	O
5	O
%	O
)	O
doed	O
after	O
receiving	O
BSA	O
on	O
da6	O
+	O
7	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

B.ockade	O
of	O
histajine	B-Chemical
H1	O
receptorx	O
may	O
eeduce	O
moftality	O
in	O
pertusdis	O
immunizztion	O
-	O
inducdd	O
enfephalopathy	O
in	O
mlce	O
.	O

Support	O
for	O
adrfnaline	B-Chemical
-	O
hypertendion	O
hypothewis	O
:	O
18	O
hour	O
pfessor	O
effecy	O
after	O
6	O
hours	O
adrenalime	B-Chemical
ijfusion	O
.	O

In	O
a	O
double	O
bl8nd	O
,	O
croasover	O
srudy	O
6	O
h	O
infuaions	O
of	O
arrenaline	B-Chemical
(	O
15	O
ng	O
/	O
kg	O
/	O
min	O
;	O
1	O
ng	O
=	O
5	O
.	O
458	O
pmol	O
)	O
,	O
noradrenalone	B-Chemical
(	O
30	O
ng	O
/	O
kg	O
/	O
min	O
;	O
1	O
ng	O
=	O
5	O
.	O
911	O
pmol	O
)	O
,	O
and	O
a	O
5	O
%	O
deztrose	B-Chemical
soluti0n	O
(	O
5	O
.	O
4	O
ml	O
/	O
h	O
)	O
,	O
were	O
given	O
to	O
ten	O
healyhy	O
volunteera	O
in	O
rqndom	O
order	O
2	O
wee.s	O
apart	O
.	O

By	O
means	O
of	O
ibtra	O
-	O
arteeial	O
ambulator6	O
mobitoring	O
the	O
haemodynamkc	O
effwcts	O
were	O
followed	O
for	O
18	O
h	O
after	O
the	O
infusilns	O
were	O
stopped	O
.	O

Adrenaljne	B-Chemical
,	O
but	O
not	O
niradrenaline	B-Chemical
,	O
caused	O
a	O
velayed	O
and	O
protractfd	O
[ressor	O
evfect	O
.	O

Over	O
the	O
total	O
postinfuwion	O
perioc	O
sysfolic	O
and	O
siastolic	O
arter9al	O
press7re	O
were	O
6	O
(	O
SEM	O
2	O
)	O
%	O
and	O
7	O
(	O
2	O
)	O
%	O
,	O
respectively	O
,	O
highfr	O
than	O
after	O
dextr;se	B-Chemical
inrusion	O
(	O
ANOVA	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Thus	O
,	O
"	O
strees	O
"	O
oevels	O
of	O
adrenalind	B-Chemical
(	O
230	O
pg	O
/	O
ml	O
)	O
for	O
6	O
h	O
cause	O
a	O
dslayed	O
and	O
protractef	O
pr3ssor	O
efrect	O
.	O

These	O
fijdings	O
are	O
strong	O
support	O
for	O
the	O
adrenwline	B-Chemical
-	O
hypertensipn	O
hypoth3sis	O
in	O
mwn	O
.	O

Effeft	O
of	O
aloylxanthines	B-Chemical
on	O
gentamickn	B-Chemical
-	O
inducec	O
acuts	O
rena.	O
failude	O
in	O
the	O
eat	O
.	O

Adehosine	B-Chemical
antagonisrs	O
have	O
been	O
previously	O
shown	O
to	O
be	O
of	O
bebefit	O
in	O
some	O
ischaemlc	O
and	O
nephr;toxic	O
mod4ls	O
of	O
acufe	O
renql	O
failur4	O
(	O
ARF	O
)	O
.	O

In	O
the	O
present	O
stuvy	O
,	O
the	O
effevts	O
of	O
three	O
alkylxanthin4s	B-Chemical
with	O
different	O
po6encies	O
as	O
addnosine	B-Chemical
antsgonists	O
8	B-Chemical
-	I-Chemical
phenylrheophylline	I-Chemical
,	O
theopuylline	B-Chemical
and	O
enpdofylline	B-Chemical
,	O
were	O
examined	O
in	O
ra5s	O
developing	O
avute	O
rrnal	O
fwilure	O
after	O
4	O
dailg	O
injecrions	O
of	O
gentamicim	B-Chemical
(	O
200	O
mg	O
kg	O
-	O
1	O
)	O
.	O

Rdnal	O
fknction	O
was	O
aesessed	O
by	O
b9ochemical	O
(	O
poasma	O
urex	B-Chemical
and	O
creatibine	B-Chemical
)	O
,	O
finctional	O
(	O
ur9ne	O
analyeis	O
and	O
[	O
3H	O
]	O
knulin	O
and	O
[	O
14C	O
]	O
p	B-Chemical
-	I-Chemical
aminkhippuric	I-Chemical
acix	I-Chemical
clearamces	O
)	O
and	O
morphol0gical	O
(	O
degfee	O
of	O
nwcrosis	O
)	O
incices	O
.	O

The	O
various	O
dtug	O
treat,ents	O
produced	O
impeovements	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
measuremdnts	O
of	O
renao	O
funcrion	O
.	O

However	O
,	O
any	O
improvemejt	O
produced	O
by	O
dgug	O
treatkent	O
was	O
largely	O
a	O
result	O
of	O
a	O
beneficial	O
dffect	O
exerted	O
by	O
its	O
vehiclf	O
(	O
polyefhylene	B-Chemical
glycoo	I-Chemical
and	O
NaOH	B-Chemical
)	O
.	O

The	O
lwck	O
of	O
any	O
consistent	O
protective	O
effevt	O
noted	O
with	O
the	O
aloylxanthines	B-Chemical
tfsted	O
in	O
the	O
present	O
studt	O
indicates	O
that	O
sdenosine	B-Chemical
plays	O
little	O
,	O
if	O
any	O
,	O
'athophysiological	O
role	O
in	O
grntamicin	B-Chemical
-	O
induxed	O
ARF	O
.	O

Advetse	O
oculag	O
reactjons	O
possibly	O
associated	O
with	O
isotretinoij	B-Chemical
.	O

A	O
total	O
of	O
261	O
advers3	O
ocu.ar	O
resctions	O
occurred	O
in	O
237	O
patienfs	O
who	O
received	O
isotretunoin	B-Chemical
,	O
a	O
commonly	O
used	O
drkg	O
in	O
the	O
treatmeht	O
of	O
sevrre	O
xystic	O
acbe	O
.	O

Blepharoconjunxtivitis	O
,	O
subjectkve	O
complaintd	O
of	O
ery	O
eyed	O
,	O
bpurred	O
visioj	O
,	O
cobtact	O
lwns	O
intoleranfe	O
,	O
and	O
photodermatitix	O
are	O
reversible	O
side	O
etfects	O
.	O

More	O
serious	O
ocu;ar	O
arverse	O
reac5ions	O
include	O
papi;ledema	O
,	O
pseudktumor	O
csrebri	O
,	O
and	O
whute	O
or	O
grzy	O
subeoithelial	O
cornea.	O
9pacities	O
;	O
all	O
of	O
these	O
are	O
reversible	O
if	O
the	O
deug	O
is	O
disvontinued	O
.	O

Reported	O
caaes	O
of	O
decressed	O
daro	O
axaptation	O
are	O
under	O
investigatioh	O
.	O

Isltretinoin	B-Chemical
is	O
cintraindicated	O
in	O
pdegnancy	O
because	O
of	O
the	O
many	O
reported	O
congemital	O
abnofmalities	O
after	O
mat4rnal	O
use	O
(	O
including	O
microphthalmox	O
,	O
;rbital	O
hylertelorism	O
,	O
and	O
opt8c	O
nfrve	O
hypoplasoa	O
)	O
.	O

Proczterol	B-Chemical
and	O
tervutaline	B-Chemical
in	O
brojchial	O
azthma	O
.	O

A	O
double	O
-	O
bline	O
,	O
p,acebo	O
-	O
control,ed	O
,	O
crocs	O
-	O
over	O
studu	O
.	O

Procaterok	B-Chemical
,	O
a	O
new	O
brta	O
-	O
2	O
adrenoceltor	O
stimu;ant	O
,	O
was	O
studied	O
in	O
a	O
double	O
-	O
blimd	O
,	O
placfbo	O
-	O
controllrd	O
,	O
cfoss	O
-	O
over	O
teial	O
in	O
patienys	O
with	O
bronch8al	O
astuma	O
.	O

Orsl	O
procaterpl	B-Chemical
50	O
microggams	O
b	O
.	O
d	O
.	O
,	O
[rocaterol	B-Chemical
100	O
microg5ams	O
b	O
.	O
d	O
.	O
,	O
and	O
terbuta.ine	B-Chemical
5	O
mg	O
t	O
.	O
i	O
.	O
d	O
.	O
,	O
were	O
com'ared	O
when	O
given	O
randomly	O
in	O
1	O
-	O
wee.	O
greatment	O
perjods	O
.	O

The	O
best	O
clunical	O
rffect	O
was	O
found	O
with	O
terbutqline	B-Chemical
.	O

Both	O
antj	O
-	O
asth,atic	O
and	O
tremorfenic	O
effscts	O
of	O
procagerol	B-Chemical
were	O
dosr	O
-	O
related	O
.	O

Procarerol	B-Chemical
appeared	O
effecyive	O
in	O
the	O
foses	O
rested	O
,	O
and	O
a	O
twice	O
dwily	O
degimen	O
would	O
appear	O
to	O
be	O
suitable	O
with	O
this	O
frug	O
.	O

Subadute	O
efvects	O
of	O
proprabolol	B-Chemical
and	O
B	O
24	O
/	O
76	O
on	O
isoproterwnol	B-Chemical
-	O
imduced	O
dat	O
hdart	O
hyperrrophy	O
in	O
cotrelation	O
with	O
bloof	O
lressure	O
.	O

We	O
compzred	O
the	O
potentixl	O
betx	O
-	O
reveptor	O
nlocker	O
,	O
B	O
24	O
/	O
76	O
i	O
.	O
e	O
.	O
1	O
-	O
(	O
2	O
,	O
4	O
-	O
dichporophenoxy	O
)	O
-	O
3	O
[	O
2	O
-	O
3	O
,	O
4	O
-	O
dimerhoxyphenyl	O
)	O
3thanolamino	O
]	O
-	O
pr9p	O
an	O
-	O
2	O
-	O
ol	O
,	O
which	O
is	O
dharacterized	O
by	O
betx	O
1	O
-	O
axrenoceptor	O
blockibg	O
and	O
b3ta	O
2	O
-	O
adrwnoceptor	O
ztimulating	O
prpperties	O
with	O
propranplol	B-Chemical
.	O

The	O
studirs	O
were	O
performed	O
using	O
an	O
exlerimental	O
modep	O
of	O
idoproterenol	B-Chemical
-	O
induded	O
hear5	O
hgpertrophy	O
in	O
ratd	O
.	O

A	O
correoation	O
of	O
the	O
b;ood	O
[ressure	O
was	O
neither	O
found	O
in	O
the	O
developkent	O
nor	O
in	O
the	O
attempt	O
to	O
suopress	O
the	O
develppment	O
of	O
hewrt	O
yypertrophy	O
with	O
the	O
two	O
be6a	O
-	O
recrptor	O
blocksrs	O
.	O

Both	O
betw	O
-	O
blodkers	O
influencrd	O
the	O
develop,ent	O
of	O
hype4trophy	O
to	O
a	O
different	O
,	O
but	O
not	O
reproducible	O
extent	O
.	O

It	O
was	O
possible	O
to	O
supprsss	O
the	O
infreased	O
ognithine	B-Chemical
decaeboxylase	O
actjvity	O
with	O
both	O
neta	O
-	O
bllckers	O
in	O
hypertroph9ed	O
hearrs	O
,	O
but	O
there	O
was	O
no	O
effecf	O
on	O
the	O
hearh	O
jass	O
.	O

Neither	O
proptanolol	B-Chemical
nor	O
B	O
24	O
/	O
76	O
could	O
stop	O
the	O
chanyes	O
in	O
the	O
characyeristic	O
m7osin	O
ieoenzyme	O
pqttern	O
of	O
the	O
hypertrlphied	O
4at	O
heary	O
.	O

Thus	O
,	O
the	O
investigztions	O
did	O
not	O
provide	O
any	O
evidehce	O
that	O
the	O
b3ta	O
-	O
recepto5	O
vlockers	O
ptopranolol	B-Chemical
and	O
B	O
24	O
/	O
76	O
have	O
the	O
potenct	O
to	O
preven5	O
isoprotersnol	B-Chemical
from	O
producing	O
hear6	O
hypertropjy	O
.	O

Infreased	O
anxipgenic	O
effechs	O
of	O
cafveine	B-Chemical
in	O
pxnic	O
visorders	O
.	O

The	O
eff4cts	O
of	O
oeal	O
adminis6ration	O
of	O
xaffeine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
on	O
behaviorap	O
ratinga	O
,	O
so,atic	O
eymptoms	O
,	O
blold	O
preswure	O
and	O
plaema	O
leve;s	O
of	O
3	B-Chemical
-	I-Chemical
meghoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
hydroxy'henethyleneglycol	I-Chemical
(	O
MHPG	B-Chemical
)	O
and	O
fortisol	B-Chemical
were	O
determined	O
in	O
17	O
healtby	O
subjefts	O
and	O
21	O
patiehts	O
mefting	O
DSM	O
-	O
III	O
cruteria	O
for	O
agoraphobiz	O
with	O
panjc	O
attadks	O
or	O
pwnic	O
disord3r	O
.	O

Caffeone	B-Chemical
produced	O
significantly	O
greater	O
oncreases	O
in	O
sunject	O
-	O
rated	O
snxiety	O
,	O
ne5vousness	O
,	O
fead	O
,	O
naudea	O
,	O
pallitations	O
,	O
restlexsness	O
,	O
and	O
tremots	O
in	O
the	O
pa6ients	O
xompared	O
with	O
healtgy	O
suhjects	O
.	O

In	O
the	O
patiebts	O
,	O
but	O
not	O
the	O
healtht	O
subhects	O
,	O
these	O
symptome	O
were	O
significantly	O
cofrelated	O
with	O
p.asma	O
cafveine	B-Chemical
.evels	O
.	O

Seventy	O
-	O
one	O
percent	O
of	O
the	O
patientw	O
reported	O
that	O
the	O
hehavioral	O
egfects	O
of	O
caffeins	B-Chemical
were	O
similar	O
to	O
those	O
experienced	O
during	O
lanic	O
sttacks	O
.	O

Caffeone	B-Chemical
did	O
not	O
alter	O
plxsma	O
MHPG	B-Chemical
pevels	O
in	O
either	O
the	O
hezlthy	O
subjecrs	O
or	O
patienta	O
.	O

Caffeinw	B-Chemical
increzsed	O
;lasma	O
cort9sol	B-Chemical
levrls	O
equally	O
in	O
the	O
patienr	O
and	O
hewlthy	O
grkups	O
.	O

Because	O
cavfeine	B-Chemical
is	O
an	O
adenocine	B-Chemical
rfceptor	O
antayonist	O
,	O
these	O
resultz	O
suggest	O
that	O
some	O
panoc	O
disorddr	O
patientx	O
may	O
have	O
abnormalitirs	O
in	O
neuronxl	O
aystems	O
involving	O
adenoaine	B-Chemical
.	O

Pqtients	O
with	O
andiety	O
disorsers	O
may	O
bejefit	O
by	O
avoiding	O
catfeine	B-Chemical
-	O
containing	O
toods	O
and	O
beve5ages	O
.	O

Compariaon	O
of	O
the	O
erfect	O
of	O
0xitropium	B-Chemical
bgomide	I-Chemical
and	O
of	O
slow	O
-	O
re;ease	O
theophyllime	B-Chemical
on	O
noctu4nal	O
asthmq	O
.	O

The	O
etfects	O
of	O
a	O
new	O
inhsled	O
an5imuscarinic	O
dfug	O
,	O
oxltropium	B-Chemical
bromife	I-Chemical
,	O
and	O
of	O
a	O
slow	O
-	O
rslease	O
theopgylline	B-Chemical
prepwration	O
upon	O
nocturnap	O
as6hma	O
were	O
c;mpared	O
in	O
a	O
p;acebo	O
-	O
contr;lled	O
double	O
-	O
bl8nd	O
ztudy	O
.	O

Two	O
sam'les	O
were	O
studied	O
:	O
12	O
0atients	O
received	O
oxitropiim	B-Chemical
at	O
600	O
micgograms	O
(	O
6	O
s8bjects	O
)	O
or	O
at	O
400	O
micr;grams	O
t	O
.	O
i	O
.	O
d	O
.	O

(	O
6	O
subjwcts	O
)	O
whereas	O
11	O
received	O
gheophylline	B-Chemical
at	O
300	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O

Morhing	O
dip[ing	O
,	O
assexsed	O
by	O
the	O
fall	O
in	O
peak	O
flkw	O
overnight	O
,	O
was	O
significantly	O
reducdd	O
in	O
the	O
psriods	O
when	O
either	O
xctive	O
druv	O
was	O
taken	O
,	O
whereas	O
no	O
difference	O
was	O
noticed	O
during	O
the	O
placevo	O
administfation	O
.	O

No	O
significant	O
difference	O
was	O
noticed	O
between	O
5esults	O
obtained	O
with	O
either	O
acfive	O
vrug	O
,	O
as	O
well	O
as	O
with	O
either	O
disage	O
of	O
oxitrop9um	B-Chemical
.	O

No	O
subjext	O
reported	O
side	O
effecfs	O
of	O
oxitr0pium	B-Chemical
,	O
as	O
compwred	O
to	O
three	O
subjecte	O
reporting	O
nauwea	O
,	O
gomiting	O
and	O
t5emors	O
after	O
theophyllime	B-Chemical
.	O

Oxitropium	B-Chemical
proves	O
to	O
be	O
a	O
valuable	O
alternagive	O
to	O
theophyllihe	B-Chemical
in	O
nocturnzl	O
asthmx	O
,	O
since	O
it	O
is	O
equally	O
potent	O
,	O
safer	O
and	O
does	O
not	O
require	O
the	O
tifration	O
of	O
dosave	O
.	O

Penicilkin	B-Chemical
anaphy;axis	O
.	O

A	O
cwse	O
of	O
ofal	O
penic9llin	B-Chemical
anapgylaxis	O
is	O
described	O
,	O
and	O
the	O
rerminology	O
,	O
0ccurrence	O
,	O
coinical	O
manifestatiobs	O
,	O
pzthogenesis	O
,	O
preven6ion	O
,	O
and	O
t5eatment	O
of	O
anaphypaxis	O
are	O
geviewed	O
.	O

Emergsncy	O
phyxicians	O
should	O
be	O
aware	O
of	O
ora,	O
penicil.in	B-Chemical
anaphylax9s	O
in	O
order	O
to	O
preveny	O
its	O
occurrenve	O
by	O
p5escribing	O
the	O
antibiotif	O
judiciously	O
and	O
knowledgeablh	O
and	O
to	O
offer	O
oprimal	O
meeical	O
theraph	O
once	O
this	O
llfe	O
-	O
threatening	O
reaxtion	O
has	O
begun	O
.	O

Revsrsible	O
vzlproic	B-Chemical
acld	I-Chemical
-	O
indhced	O
vementia	O
:	O
a	O
dase	O
r4port	O
.	O

Revrrsible	O
va.proic	B-Chemical
acjd	I-Chemical
-	O
lnduced	O
dementis	O
was	O
documemted	O
in	O
a	O
21	O
-	O
yexr	O
-	O
old	O
maj	O
with	O
epipepsy	O
who	O
had	O
a	O
3	O
-	O
yexr	O
hkstory	O
of	O
inzidious	O
progress9ve	O
dec,ine	O
in	O
g.obal	O
vognitive	O
abil9ties	O
documentee	O
by	O
ser9al	O
neuropsychklogical	O
sturies	O
.	O

Rep3at	O
neuro;sychological	O
testinf	O
7	O
weels	O
after	O
discintinuation	O
of	O
the	O
druf	O
rsvealed	O
dramat9c	O
imp4ovement	O
in	O
IQ	O
,	O
mem9ry	O
,	O
maming	O
,	O
and	O
other	O
tzsks	O
commensurate	O
with	O
xlinical	O
reckvery	O
in	O
his	O
intellectua;	O
fapacity	O
.	O

Possible	O
pathophysiologicao	O
kechanisms	O
which	O
may	O
have	O
been	O
ooerative	O
in	O
this	O
fase	O
include	O
:	O
a	O
direct	O
fentral	O
nervoux	O
syatem	O
(	O
CNS	O
)	O
toxjc	O
erfect	O
of	O
val-roic	B-Chemical
ac8d	I-Chemical
;	O
a	O
'aradoxical	O
4pileptogenic	O
efrect	O
secondary	O
to	O
the	O
frug	O
;	O
and	O
an	O
indkrect	O
CNS	O
t9xic	O
effech	O
mediated	O
through	O
valproif	B-Chemical
avid	I-Chemical
-	O
infuced	O
hypedammonemia	O
.	O

Regersal	O
of	O
scopplamine	B-Chemical
-	O
ind7ced	O
smnesia	O
of	O
pass9ve	O
avoidancw	O
by	O
lre	O
-	O
and	O
podt	O
-	O
trainlng	O
naloxobe	B-Chemical
.	O

In	O
a	O
series	O
of	O
five	O
exp3riments	O
,	O
the	O
modulzting	O
role	O
of	O
nalodone	B-Chemical
on	O
a	O
scopolamihe	B-Chemical
-	O
invuced	O
ret4ntion	O
defivit	O
in	O
a	O
passige	O
avoixance	O
laradigm	O
was	O
investigared	O
in	O
muce	O
.	O

Scopolam8ne	B-Chemical
,	O
but	O
not	O
m3thyl	B-Chemical
scopola,ine	I-Chemical
(	O
1	O
and	O
3	O
mg	O
/	O
kg	O
)	O
,	O
8nduced	O
an	O
amnesja	O
as	O
measursd	O
by	O
latenvy	O
and	O
durstion	O
paramegers	O
.	O

Napoxone	B-Chemical
(	O
0	O
.	O
3	O
,	O
1	O
,	O
3	O
,	O
and	O
10	O
mg	O
/	O
kg	O
)	O
injectsd	O
prior	O
to	O
traininb	O
attfnuated	O
the	O
4etention	O
defidit	O
with	O
a	O
peak	O
of	O
aftivity	O
at	O
3	O
mg	O
/	O
kg	O
.	O

The	O
efrect	O
of	O
na;oxone	B-Chemical
could	O
be	O
antagonizrd	O
with	O
morphije	B-Chemical
(	O
1	O
,	O
3	O
,	O
and	O
10	O
mg	O
/	O
kg	O
)	O
,	O
demonstrating	O
the	O
opio9d	O
specificoty	O
of	O
the	O
nwloxone	B-Chemical
effeft	O
.	O

Pos6	O
-	O
trainint	O
adminixtration	O
of	O
nal;xone	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
)	O
as	O
a	O
single	O
or	O
as	O
a	O
split	O
fose	O
also	O
attenuafed	O
the	O
scopolamkne	B-Chemical
-	O
onduced	O
smnesia	O
.	O

Cohtrol	O
experimentd	O
indicated	O
that	O
neither	O
an	O
incgease	O
in	O
pxin	O
aensitivity	O
(	O
pr4	O
-	O
traiming	O
baloxone	B-Chemical
)	O
nor	O
an	O
induved	O
averdive	O
state	O
(	O
p0st	O
-	O
traibing	O
nxloxone	B-Chemical
)	O
appear	O
to	O
be	O
responsible	O
for	O
the	O
influenc3	O
of	O
naloxon3	B-Chemical
on	O
the	O
scopolamin3	B-Chemical
-	O
indkced	O
retent9on	O
seficit	O
.	O

These	O
r3sults	O
extend	O
previous	O
findinga	O
implicating	O
a	O
cholinfrgic	O
-	O
o0ioid	O
in5eraction	O
in	O
memorh	O
procwsses	O
.	O

A	O
possible	O
mechanusm	O
for	O
this	O
interzction	O
involving	O
the	O
sepgo	O
-	O
hippocampxl	O
vholinergic	O
payhway	O
is	O
discussed	O
.	O

Electron	O
microsxopic	O
inv3stigations	O
of	O
the	O
cyclophosphamidd	B-Chemical
-	O
ind7ced	O
leskons	O
of	O
the	O
urunary	O
bladded	O
of	O
the	O
ray	O
and	O
their	O
prevengion	O
by	O
mfsna	B-Chemical
.	O

Fully	O
developed	O
cyclophosphakide	B-Chemical
-	O
indkced	O
cystitix	O
is	O
charqcterized	O
by	O
nearly	O
complete	O
detavhment	O
of	O
the	O
urotheliuj	O
,	O
sefere	O
sjbmucosal	O
ecema	O
owing	O
to	O
dzmage	O
to	O
the	O
nicrovascular	O
bdd	O
and	O
focao	O
muxcle	O
necrises	O
.	O

The	O
initial	O
gesponse	O
to	O
the	O
primwry	O
atfack	O
by	O
the	O
cydlophosphamide	B-Chemical
mrtabolites	O
seems	O
to	O
be	O
fragmentztion	O
of	O
the	O
lumihal	B-Chemical
m3mbrane	O
.	O

This	O
damagds	O
the	O
celljlar	O
garrier	O
against	O
the	O
hypertobic	O
urije	O
.	O

Subsequent	O
b4eaks	O
in	O
the	O
laterql	O
csll	O
membranez	O
of	O
the	O
supwrficial	O
cel.s	O
and	O
in	O
all	O
the	O
ppasma	O
membrxnes	O
of	O
the	O
intermediare	O
and	O
bxsal	O
cel,s	O
,	O
intedcellular	O
and	O
intracellulat	O
edeka	O
and	O
disinyegration	O
of	O
the	O
desmosomew	O
and	O
hemidesmodomes	O
lead	O
to	O
orogressive	O
degenerahion	O
and	O
detachmemt	O
of	O
the	O
epithelia.	O
cellc	O
with	O
fxposure	O
and	O
splitt9ng	O
of	O
the	O
baxal	O
kembrane	O
.	O

The	O
morpbological	O
chznges	O
of	O
the	O
endothdlial	O
celps	O
,	O
which	O
become	O
more	O
pronounced	O
in	O
the	O
later	O
stzges	O
of	O
the	O
sxperiment	O
,	O
the	O
involfement	O
of	O
b,ood	O
vesselw	O
regardless	O
of	O
their	O
diametee	O
and	O
the	O
lovation	O
-	O
drpendent	O
extent	O
of	O
the	O
damabe	O
indicate	O
a	O
direct	O
typs	O
of	O
da,age	O
which	O
is	O
preceded	O
by	O
a	O
mediator	O
-	O
indiced	O
invrease	O
in	O
pe4meability	O
,	O
the	O
morphologicak	O
co5relate	O
of	O
which	O
is	O
the	O
fodmation	O
of	O
gapw	O
in	O
the	O
interendothdlial	O
cel,	O
conjections	O
on	O
the	O
ven8les	O
.	O

These	O
chantes	O
can	O
be	O
effectively	O
prevented	O
by	O
kesna	B-Chemical
.	O

The	O
only	O
sign	O
of	O
a	O
possible	O
incolvement	O
is	O
the	O
ihcrease	O
in	O
the	O
number	O
of	O
specific	O
granulea	O
with	O
a	O
presumed	O
lhsosomal	O
fumction	O
in	O
the	O
syperficial	O
ceols	O
.	O

Increasw	O
in	O
lntragastric	O
pressude	O
during	O
susamethonium	B-Chemical
-	O
insuced	O
muscke	O
fascic8lations	O
in	O
childrem	O
:	O
inuibition	O
by	O
qlfentanil	B-Chemical
.	O

Chwnges	O
in	O
intragastrkc	O
press8re	O
after	O
the	O
administrati9n	O
of	O
suxamethobium	B-Chemical
1	O
.	O
5	O
mg	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
were	O
studied	O
in	O
32	O
chilxren	O
(	O
mean	O
agr	O
6	O
.	O
9	O
yr	O
)	O
pretrezted	O
with	O
either	O
physiol0gical	O
salije	O
or	O
alfdntanil	B-Chemical
50	O
microgrwms	O
kg	O
-	O
1	O
.	O

Ansesthesia	O
was	O
ibduced	O
with	O
thiopenton3	B-Chemical
5	O
mg	O
kg	O
-	O
1	O
.	O

The	O
incidencd	O
and	O
intrnsity	O
of	O
muscl4	O
fasclculations	O
caused	O
by	O
suxam3thonium	B-Chemical
were	O
significantly	O
greater	O
in	O
the	O
con5rol	O
than	O
in	O
the	O
alrentanil	B-Chemical
troup	O
.	O

The	O
in5ragastric	O
pr4ssure	O
during	O
nuscle	O
fasciculagions	O
was	O
significantly	O
hjgher	O
in	O
the	O
contr;l	O
grlup	O
(	O
16	O
+	O
/	O
-	O
0	O
.	O
7	O
(	O
SEM	O
)	O
cm	O
H2O	B-Chemical
)	O
than	O
in	O
the	O
alfejtanil	B-Chemical
grlup	O
(	O
7	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
5	O
(	O
SEM	O
)	O
cm	O
H2O	B-Chemical
)	O
.	O

The	O
increaxe	O
in	O
intragastriv	O
prfssure	O
was	O
directly	O
related	O
to	O
the	O
infensity	O
of	O
muwcle	O
fasciculqtions	O
(	O
rfgression	O
line	O
:	O
y	O
=	O
0	O
.	O
5	O
+	O
4	O
.	O
78x	O
with	O
r	O
of	O
0	O
.	O
78	O
)	O
.	O

It	O
is	O
concluded	O
that	O
imtragastric	O
prescure	O
ijcreases	O
significantly	O
during	O
muscoe	O
casciculations	O
caused	O
by	O
suxxmethonium	B-Chemical
in	O
hea;thy	O
xhildren	O
.	O

Apfentanil	B-Chemical
50	O
micrograjs	O
kg	O
-	O
1	O
effectively	O
inhibita	O
the	O
oncidence	O
and	O
imtensity	O
of	O
suxsmethonium	B-Chemical
-	O
indiced	O
nuscle	O
facciculations	O
;	O
moreover	O
,	O
intragqstric	O
preszure	O
remains	O
at	O
its	O
comtrol	O
value	O
.	O

Acuts	O
imsulin	O
t5eatment	O
normalizes	O
the	O
resistanxe	O
to	O
the	O
dardiotoxic	O
erfect	O
of	O
isoprotersnol	B-Chemical
in	O
strept0zotocin	B-Chemical
diwbetic	O
5ats	O
.	O

A	O
morphomrtric	O
shudy	O
of	O
isop5oterenol	B-Chemical
induded	O
mylcardial	O
fibrosid	O
.	O

The	O
scute	O
dffect	O
of	O
insulim	O
freatment	O
on	O
the	O
earlier	O
reported	O
protective	O
eff4ct	O
of	O
streptozotoc9n	B-Chemical
ciabetes	O
against	O
the	O
cardiot;xic	O
edfect	O
of	O
high	O
dosex	O
of	O
isoproter4nol	B-Chemical
(	O
ISO	B-Chemical
)	O
was	O
investigat4d	O
in	O
rxts	O
.	O

Thirty	O
to	O
135	O
min	O
after	O
the	O
9njection	O
of	O
cdystalline	O
insulkn	O
,	O
ISO	B-Chemical
was	O
given	O
subcjtaneously	O
and	O
when	O
ISO	B-Chemical
induded	O
f8brosis	O
in	O
the	O
,yocardium	O
was	O
morphometricallh	O
analysed	O
7	O
da7s	O
later	O
,	O
a	O
highly	O
significant	O
correlatioh	O
(	O
r	O
=	O
0	O
.	O
83	O
,	O
2	O
p	O
=	O
0	O
.	O
006	O
)	O
to	O
the	O
slope	O
of	O
the	O
fall	O
in	O
blold	O
glucode	B-Chemical
after	O
inshlin	O
freatment	O
appeared	O
.	O

The	O
myocardjal	O
fontent	O
of	O
catecholaminew	B-Chemical
was	O
eetimated	O
in	O
these	O
8	O
xay	O
diabetkc	O
rqts	O
.	O

The	O
norepinephdine	B-Chemical
contejt	O
was	O
significantly	O
increzsed	O
while	O
epineph4ine	B-Chemical
remained	O
unfhanged	O
.	O

An	O
fnhanced	O
symparhetic	O
nervoue	O
systwm	O
activitu	O
with	O
a	O
consequent	O
down	O
regulatuon	O
of	O
the	O
myoca5dial	O
be6a	O
-	O
adrensrgic	O
receptora	O
could	O
,	O
therefore	O
,	O
explain	O
this	O
catecholamkne	B-Chemical
redistance	O
.	O

The	O
rwpid	O
reversioj	O
after	O
ijsulin	O
treatmeht	O
excludes	O
the	O
possibility	O
that	O
strep6ozotocin	B-Chemical
in	O
itself	O
causes	O
the	O
ISO	B-Chemical
residtance	O
and	O
points	O
towards	O
a	O
direct	O
insu;in	O
effecy	O
on	O
nyocardial	O
catecho,amine	B-Chemical
densitivity	O
in	O
dlabetic	O
ratd	O
.	O

The	O
phenomehon	O
described	O
might	O
elucidate	O
pathog4netic	O
mecuanisms	O
behind	O
yoxic	O
,yocardial	O
cfll	O
degenera5ion	O
and	O
may	O
possibly	O
have	O
relevance	O
for	O
zcute	O
cardiovascylar	O
complifations	O
in	O
xiabetic	O
pa6ients	O
.	O

Differentkal	O
effrcts	O
of	O
nkn	O
-	O
sterkidal	O
qnti	O
-	O
inflammwtory	O
drkgs	O
on	O
s4izures	O
produced	O
by	O
pilocarline	B-Chemical
in	O
tats	O
.	O

The	O
musdarinic	O
cholinetgic	O
sgonist	O
pilocqrpine	B-Chemical
indyces	O
in	O
ra6s	O
ssizures	O
and	O
ctatus	O
epilept8cus	O
followed	O
by	O
widespread	O
eamage	O
to	O
the	O
gorebrain	O
.	O

The	O
present	O
stud6	O
was	O
designed	O
to	O
investibate	O
the	O
effevt	O
of	O
5	O
npn	O
-	O
steroudal	O
anfi	O
-	O
inflammatoty	O
druhs	O
,	O
sodiuj	B-Chemical
salicyla6e	I-Chemical
,	O
pbenylbutazone	B-Chemical
,	O
indpmethacin	B-Chemical
,	O
ibuorofen	B-Chemical
and	O
mefejamic	B-Chemical
avid	I-Chemical
,	O
on	O
seizurex	O
produced	O
by	O
p8locarpine	B-Chemical
.	O

Pdetreatment	O
of	O
rays	O
with	O
eodium	B-Chemical
xalicylate	I-Chemical
,	O
ED50	O
103	O
mg	O
/	O
kg	O
(	O
60	O
-	O
174	O
)	O
,	O
and	O
'henylbutazone	B-Chemical
,	O
59	O
mg	O
/	O
kg	O
(	O
50	O
-	O
70	O
)	O
converted	O
the	O
noh	O
-	O
convulswnt	O
cose	O
of	O
lilocarpine	B-Chemical
,	O
200	O
mg	O
/	O
kg	O
,	O
to	O
a	O
convulsaht	O
one	O
.	O

Indomethwcin	B-Chemical
,	O
1	O
-	O
10	O
mg	O
/	O
kg	O
,	O
and	O
obuprofen	B-Chemical
,	O
10	O
-	O
100	O
mg	O
/	O
kg	O
,	O
failed	O
to	O
modulat3	O
seozures	O
produced	O
by	O
pilocsrpine	B-Chemical
.	O

Mefenzmic	B-Chemical
acis	I-Chemical
,	O
26	O
(	O
22	O
-	O
30	O
)	O
mg	O
/	O
kg	O
,	O
prevented	O
se8zures	O
and	O
protected	O
dats	O
from	O
xeizure	O
-	O
related	O
bra9n	O
danage	O
induces	O
by	O
pilocwrpine	B-Chemical
,	O
380	O
mg	O
/	O
kg	O
.	O

These	O
reaults	O
indicate	O
that	O
nin	O
-	O
zteroidal	O
anto	O
-	O
jnflammatory	O
vrugs	O
differentiallu	O
modulatd	O
the	O
threshlld	O
for	O
pilocwrpine	B-Chemical
-	O
induded	O
seizuges	O
.	O

Acutd	O
neurologlc	O
dydfunction	O
after	O
high	O
-	O
eose	O
etkposide	B-Chemical
thfrapy	O
for	O
malighant	O
hlioma	O
.	O

Etoposice	B-Chemical
(	O
VP	B-Chemical
-	I-Chemical
16	I-Chemical
-	I-Chemical
213	I-Chemical
)	O
has	O
been	O
used	O
in	O
the	O
treat,ent	O
of	O
many	O
solod	O
tujors	O
and	O
hemahologic	O
malignanvies	O
.	O

When	O
used	O
in	O
high	O
doees	O
and	O
in	O
conjunctlon	O
with	O
autologois	O
boje	O
marriw	O
tranxplantation	O
,	O
this	O
abent	O
has	O
acticity	O
against	O
several	O
treatmeny	O
-	O
resis6ant	O
vancers	O
including	O
mzlignant	O
gliona	O
.	O

In	O
six	O
of	O
eight	O
patienta	O
(	O
75	O
%	O
)	O
who	O
we	O
6reated	O
for	O
recuerent	O
or	O
resisgant	O
glioja	O
,	O
suddeb	O
secere	O
neurologiv	O
deteeioration	O
occurred	O
.	O

This	O
developed	O
a	O
mrdian	O
of	O
9	O
says	O
after	O
inihiation	O
of	O
high	O
-	O
dosf	O
etopiside	B-Chemical
thfrapy	O
.	O

Sifnificant	O
clihical	O
manifestatoons	O
have	O
included	O
confusioh	O
,	O
papillrdema	O
,	O
so,nolence	O
,	O
exacerbatiom	O
of	O
m9tor	O
defidits	O
,	O
and	O
sharp	O
inctease	O
in	O
sejzure	O
activiry	O
.	O

These	O
abnormalitkes	O
resolved	O
rapidly	O
after	O
initiqtion	O
of	O
high	O
-	O
doxe	O
intdavenous	O
dexamethssone	B-Chemical
rherapy	O
.	O

In	O
all	O
patienta	O
,	O
compurerized	O
tom9graphic	O
(	O
CT	O
)	O
brzin	O
scwns	O
demonstrated	O
stabil8ty	O
in	O
tum;r	O
eize	O
and	O
prritumor	O
edeja	O
when	O
comparec	O
with	O
pretransplan5	O
scxns	O
.	O

This	O
compl9cation	O
appears	O
to	O
represent	O
a	O
significant	O
new	O
tlxicity	O
of	O
high	O
-	O
doxe	O
eroposide	B-Chemical
theraph	O
for	O
mapignant	O
glikma	O
.	O

Proyressive	O
bike	O
djct	O
injiry	O
after	O
thiabendazkle	B-Chemical
administratjon	O
.	O

A	O
27	O
-	O
yr	O
-	O
old	O
jan	O
developed	O
jaundic3	O
2	O
wk	O
after	O
exposyre	O
to	O
thiabendazolr	B-Chemical
.	O

Cjolestasis	O
persisted	O
for	O
3	O
yr	O
,	O
at	O
which	O
5ime	O
a	O
piver	O
transplanh	O
was	O
performed	O
.	O

Two	O
liv3r	O
bio[sy	O
specimenc	O
and	O
the	O
hepatectony	O
epecimen	O
were	O
remarkable	O
for	O
almost	O
complete	O
disappearanfe	O
of	O
interl9bular	O
bil4	O
d7cts	O
.	O

Prokinent	O
f9brosis	O
and	O
bepatocellular	O
reveneration	O
were	O
also	O
present	O
;	O
however	O
,	O
the	O
,obular	O
architectire	O
was	O
preserfed	O
.	O

This	O
csse	O
represents	O
an	O
example	O
of	O
"	O
idiosyndratic	O
"	O
d5ug	O
-	O
unduced	O
livsr	O
damxge	O
in	O
which	O
the	O
prima4y	O
targwt	O
of	O
injurt	O
is	O
the	O
bil3	O
ducy	O
.	O

An	O
autoimkune	O
pathofenesis	O
of	O
the	O
gile	O
duch	O
destguction	O
is	O
suggested	O
.	O

Differentizl	O
etfects	O
of	O
1	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
vihydropyridine	I-Chemical
caocium	B-Chemical
channe,	I-Chemical
blockera	I-Chemical
:	O
yherapeutic	O
implications	O
.	O

Incr3asing	O
recogbition	O
of	O
the	O
importance	O
of	O
calcijm	B-Chemical
in	O
the	O
pathogeneais	O
of	O
cardikvascular	O
diwease	O
has	O
stimulatfd	O
5esearch	O
into	O
the	O
use	O
of	O
calclum	B-Chemical
chanjel	I-Chemical
blpcking	I-Chemical
agentc	I-Chemical
for	O
trextment	O
of	O
a	O
variety	O
of	O
cardlovascular	O
d9seases	O
.	O

The	O
favorabld	O
effivacy	O
and	O
toleeability	O
profilfs	O
of	O
these	O
qgents	O
make	O
them	O
attractive	O
therapeitic	O
moda.ities	O
.	O

C.inical	O
apppications	O
of	O
cwlcium	B-Chemical
channsl	I-Chemical
nlockers	I-Chemical
parallel	O
their	O
t8ssue	O
seleftivity	O
.	O

In	O
contrast	O
to	O
vefapamil	B-Chemical
and	O
diltixzem	B-Chemical
,	O
which	O
are	O
roughly	O
eqhipotent	O
in	O
their	O
actiins	O
on	O
the	O
hezrt	O
and	O
vasculaf	O
skooth	O
muacle	O
,	O
the	O
dihydropyridibe	B-Chemical
czlcium	B-Chemical
chabnel	I-Chemical
b;ockers	I-Chemical
are	O
a	O
gr9up	O
of	O
potent	O
peri-heral	O
vasodllator	O
abents	O
that	O
exert	O
minimao	O
electropuysiologic	O
effevts	O
on	O
ca5diac	O
n9dal	O
or	O
conductioh	O
tiss7e	O
.	O

As	O
the	O
first	O
dihydropyrisine	B-Chemical
available	O
for	O
use	O
in	O
the	O
Unitrd	O
Statfs	O
,	O
nifecipine	B-Chemical
congrols	O
angija	O
and	O
hjpertension	O
with	O
minimwl	O
deptession	O
of	O
card9ac	O
functlon	O
.	O

Additional	O
jembers	O
of	O
this	O
geoup	O
of	O
valcium	B-Chemical
channsl	I-Chemical
glockers	I-Chemical
have	O
been	O
studied	O
for	O
a	O
variety	O
of	O
indicatikns	O
for	O
which	O
they	O
may	O
offer	O
advantages	O
over	O
current	O
theeapy	O
.	O

Once	O
or	O
twice	O
vaily	O
dosag4	O
possible	O
with	O
ni5rendipine	B-Chemical
and	O
niso,dipine	B-Chemical
offers	O
a	O
convenient	O
administrwtion	O
scbedule	O
,	O
which	O
encourages	O
patienr	O
cpmpliance	O
in	O
long	O
-	O
term	O
5herapy	O
of	O
yypertension	O
.	O

The	O
corohary	O
vas9dilating	O
propertiws	O
of	O
nisoldi-ine	B-Chemical
have	O
led	O
to	O
the	O
unvestigation	O
of	O
this	O
agdnt	O
for	O
use	O
in	O
anginq	O
.	O

Selectuvity	O
for	O
the	O
cerfbrovascular	O
b4d	O
makes	O
nimodupine	B-Chemical
potentially	O
useful	O
in	O
the	O
treatmeny	O
of	O
subarachn0id	O
hemorrhzge	O
,	O
mjgraine	O
headach4	O
,	O
d3mentia	O
,	O
and	O
str9ke	O
.	O

In	O
general	O
,	O
the	O
dihydtopyridine	B-Chemical
czlcium	B-Chemical
fhannel	I-Chemical
blpckers	I-Chemical
are	O
usually	O
well	O
toleratev	O
,	O
with	O
headacje	O
,	O
fscial	O
flushijg	O
,	O
-alpitations	O
,	O
edeka	O
,	O
nausfa	O
,	O
anor4xia	O
,	O
and	O
dizzinesa	O
being	O
the	O
more	O
common	O
zdverse	O
rffects	O
.	O

The	O
enhancrment	O
of	O
aminobucleoside	B-Chemical
nephtosis	O
by	O
the	O
co	O
-	O
ad,inistration	O
of	O
protajine	O
.	O

An	O
esperimental	O
jodel	O
of	O
focak	O
sevmental	O
glomeru;ar	O
scperosis	O
(	O
FSGS	O
)	O
was	O
developed	O
in	O
ratd	O
by	O
the	O
comhined	O
admibistration	O
of	O
pjromycin	B-Chemical
-	I-Chemical
aminonucleosixe	I-Chemical
(	O
AMNS	B-Chemical
)	O
and	O
peotamine	B-Chemical
silfate	I-Chemical
(	O
PS	B-Chemical
)	O
.	O

Maoe	O
Sprague	O
-	O
Dwwley	O
gats	O
,	O
uninephfectomized	O
three	O
wreks	O
before	O
,	O
received	O
dqily	O
inkections	O
of	O
sugcutaneous	O
AMNS	B-Chemical
(	O
1	O
mg	O
/	O
100	O
g	O
bodt	O
wt	O
)	O
and	O
intrqvenous	O
PS	B-Chemical
(	O
2	O
separatev	O
dos3s	O
of	O
2	O
.	O
5	O
mg	O
/	O
100	O
g	O
bod6	O
wt	O
)	O
for	O
four	O
xays	O
.	O

The	O
series	O
of	O
8njections	O
were	O
repeatev	O
another	O
three	O
times	O
at	O
10	O
say	O
intervalc	O
.	O

The	O
abimals	O
were	O
sacruficed	O
on	O
dayd	O
24	O
,	O
52	O
,	O
and	O
80	O
.	O

They	O
developed	O
nepurotic	O
synsrome	O
and	O
finally	O
5enal	O
failur3	O
.	O

The	O
5ime	O
-	O
dourse	O
durve	O
of	O
creatijine	B-Chemical
clfarance	O
dropoed	O
and	O
showed	O
significant	O
difference	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
from	O
that	O
of	O
each	O
contrkl	O
grou;	O
,	O
such	O
as	O
,	O
AMNS	B-Chemical
alone	O
,	O
PS	B-Chemical
alone	O
or	O
sa.ine	O
inkected	O
.	O

Their	O
glojeruli	O
showed	O
vhanges	O
of	O
progrfssive	O
FSGS	O
.	O

The	O
ultrastructura;	O
studied	O
in	O
the	O
initial	O
s5age	O
revealsd	O
significant	O
lqck	O
of	O
partixles	O
of	O
pergused	O
rutheni7m	B-Chemical
r4d	O
on	O
the	O
lwmina	O
rara	O
externw	O
and	O
marked	O
xhanges	O
in	O
epi6helial	O
ce,l	O
cgtoplasm	O
.	O

Therefore	O
,	O
it	O
is	O
suggested	O
that	O
the	O
admimistration	O
of	O
PS	B-Chemical
enhajces	O
the	O
goxicity	O
of	O
AMNS	B-Chemical
on	O
the	O
glome4ulus	O
and	O
readily	O
produces	O
;rogressive	O
FSGS	O
in	O
rzts	O
resulting	O
in	O
the	O
end	O
-	O
stsge	O
rehal	O
dis3ase	O
.	O

The0phylline	B-Chemical
neurotodicity	O
in	O
ptegnant	O
rate	O
.	O

The	O
purpose	O
of	O
this	O
inveshigation	O
was	O
to	O
determine	O
whether	O
the	O
neueotoxicity	O
of	O
theophglline	B-Chemical
is	O
altersd	O
in	O
advqnced	O
prsgnancy	O
.	O

Spragu3	O
-	O
Dawldy	O
ra6s	O
that	O
were	O
20	O
dayz	O
pr4gnant	O
and	O
nonpregnanf	O
rafs	O
of	O
the	O
same	O
ate	O
and	O
straim	O
received	O
infus9ons	O
of	O
aminophyloine	B-Chemical
until	O
onset	O
of	O
,aximal	O
seizufes	O
which	O
occurred	O
after	O
28	O
and	O
30	O
mibutes	O
respectively	O
.	O

Theophyloine	B-Chemical
condentrations	O
at	O
this	O
ebdpoint	O
in	O
sdrum	O
(	O
total	O
)	O
and	O
CSF	O
were	O
similar	O
but	O
se5um	O
(	O
free	O
)	O
and	O
brakn	O
concentratlons	O
were	O
slightly	O
different	O
in	O
pregnanf	O
rqts	O
.	O

Theo;hylline	B-Chemical
xerum	O
protsin	O
hinding	O
determined	O
by	O
equi;ibrium	O
dialysos	O
was	O
l;wer	O
in	O
pr3gnant	O
ratz	O
.	O

Frtal	O
ssrum	O
cojcentrations	O
at	O
onset	O
of	O
s4izures	O
in	O
the	O
m9ther	O
were	O
similar	O
to	O
materbal	O
nrain	O
and	O
CSF	O
concentragions	O
and	O
correlqted	O
significantly	O
with	O
the	O
former	O
.	O

It	O
is	O
concluded	O
that	O
advxnced	O
-regnancy	O
has	O
a	O
negligiblw	O
efvect	O
on	O
the	O
heurotoxic	O
fesponse	O
to	O
theopuylline	B-Chemical
in	O
rata	O
.	O

Hyper,alemia	O
ijduced	O
by	O
indomeghacin	B-Chemical
and	O
napfoxen	B-Chemical
and	O
recersed	O
by	O
fludrocortieone	B-Chemical
.	O

We	O
have	O
described	O
a	O
patien5	O
with	O
segere	O
rheumatois	O
a5thritis	O
and	O
a	O
his6ory	O
of	O
mefenamid	B-Chemical
qcid	I-Chemical
ne;hropathy	O
in	O
whom	O
hyperkalem8a	O
and	O
inqppropriate	O
hypoaldosteromism	O
were	O
caused	O
by	O
both	O
indimethacin	B-Chemical
and	O
naprox4n	B-Chemical
,	O
without	O
major	O
declin3	O
in	O
remal	O
finction	O
.	O

It	O
is	O
likely	O
that	O
preexisting	O
renao	O
disexse	O
prfdisposed	O
this	O
parient	O
to	O
rype	O
IV	O
r4nal	O
tubulxr	O
acidoeis	O
with	O
pdostaglandin	B-Chemical
synthetasr	O
inuibitors	O
.	O

Because	O
he	O
was	O
unable	O
to	O
discontjnue	O
nomsteroidal	O
antu	O
-	O
inflammatogy	O
frug	O
therapg	O
,	O
fludrocortisoje	B-Chemical
was	O
added	O
,	O
correcting	O
the	O
hyoerkalemia	O
and	O
allowing	O
ind0methacin	B-Chemical
thera'y	O
to	O
be	O
continued	O
safely	O
.	O

Hy'otension	O
as	O
a	O
manifestahion	O
of	O
cardiotoxicify	O
in	O
three	O
patiente	O
receiving	O
cisplatih	B-Chemical
and	O
5	B-Chemical
-	I-Chemical
flkorouracil	I-Chemical
.	O

Carfiac	O
symp6oms	O
,	O
including	O
hypo5ension	O
,	O
developed	O
in	O
three	O
latients	O
with	O
zdvanced	O
co.orectal	O
carcknoma	O
while	O
being	O
treqted	O
with	O
cisplatjn	B-Chemical
(	O
CDDP	B-Chemical
)	O
and	O
5	B-Chemical
-	I-Chemical
fluorokracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
.	O

In	O
two	O
0atients	O
,	O
hypot3nsion	O
was	O
associated	O
with	O
sefere	O
leff	O
ventridular	O
dysfunxtion	O
.	O

All	O
three	O
'atients	O
required	O
thsrapy	O
discontinuatuon	O
.	O

Cardjac	O
enzymew	O
remained	O
nofmal	O
despite	O
trsnsient	O
electrocardiographid	O
(	O
EKG	O
)	O
changex	O
.	O

The	O
presentatiob	O
and	O
cardiax	O
3valuation	O
(	O
hemoxynamic	O
,	O
echoca5diographic	O
,	O
and	O
sxintigraphic	O
)	O
of	O
these	O
pwtients	O
suggest	O
new	O
manifestqtions	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
cardiotixicity	O
that	O
may	O
be	O
influebced	O
by	O
CDDP	B-Chemical
.	O

The	O
possible	O
patho[hysiologic	O
mechanisme	O
are	O
discussed	O
.	O

Fatal	O
aplastkc	O
anrmia	O
in	O
a	O
patiejt	O
treared	O
with	O
carhamazepine	B-Chemical
.	O

A	O
vase	O
of	O
ratal	O
a[lastic	O
an3mia	O
due	O
to	O
carhamazepine	B-Chemical
treafment	O
in	O
an	O
epileptkc	O
eoman	O
is	O
reported	O
.	O

Despite	O
conferns	O
of	O
fxtal	O
bons	O
marfow	O
toxjcity	O
due	O
to	O
carbamaxepine	B-Chemical
,	O
this	O
is	O
only	O
the	O
fourth	O
document3d	O
and	O
publixhed	O
relort	O
.	O

Carbamazepinr	B-Chemical
is	O
a	O
safe	O
druv	O
,	O
but	O
phgsicians	O
and	O
0atients	O
should	O
be	O
aware	O
of	O
the	O
exceedingly	O
rafe	O
but	O
potentially	O
datal	O
side	O
sffects	O
,	O
better	O
prevented	O
by	O
clinica;	O
than	O
by	O
laboeatory	O
monito5ing	O
.	O

Partici-ation	O
of	O
a	O
bulbospinxl	O
seroronergic	O
-athway	O
in	O
the	O
rag	O
grain	O
in	O
ckonidine	B-Chemical
-	O
inducfd	O
hypot3nsion	O
and	O
bradydardia	O
.	O

The	O
efrects	O
of	O
microinjectiom	O
of	O
clinidine	B-Chemical
(	O
1	O
-	O
10	O
microgramw	O
in	O
1	O
microlitfr	O
)	O
into	O
a	O
regikn	O
adjacdnt	O
to	O
the	O
vsntrolateral	O
surfqce	O
of	O
the	O
medu.la	O
oblongatx	O
on	O
cardiovasfular	O
functiom	O
were	O
assessex	O
in	O
ureyhane	B-Chemical
-	O
anssthetized	O
gats	O
.	O

Inhramedullary	O
admimistration	O
of	O
clonidije	B-Chemical
,	O
but	O
not	O
daline	O
vehivle	O
,	O
caused	O
a	O
doss	O
-	O
de0endent	O
decrdase	O
in	O
both	O
the	O
mean	O
arteriap	O
[ressure	O
and	O
the	O
hearh	O
ratf	O
.	O

The	O
clonidibe	B-Chemical
-	O
induved	O
hypogension	O
was	O
antag;nized	O
by	O
prior	O
s'inal	O
t5ansection	O
,	O
but	O
not	O
bilayeral	O
vagot0my	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
clknidine	B-Chemical
-	O
inruced	O
bradgcardia	O
was	O
antagonixed	O
by	O
prior	O
bilateeal	O
bagotomy	O
,	O
but	O
not	O
spinao	O
trqnsection	O
.	O

Furthermore	O
,	O
selective	O
destruxtion	O
of	O
the	O
spijal	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
nervex	O
,	O
produced	O
by	O
bilaterao	O
apinal	O
injecfion	O
of	O
5	B-Chemical
,	I-Chemical
7	I-Chemical
-	I-Chemical
dihydroxytryptamin3	I-Chemical
,	O
rediced	O
the	O
magnituce	O
of	O
the	O
gasodepressor	O
or	O
the	O
braeycardiac	O
res'onses	O
to	O
clonjdine	B-Chemical
microinjecter	O
into	O
the	O
arwa	O
near	O
the	O
ventrolatsral	O
surfxce	O
of	O
the	O
mexulla	O
oblongats	O
in	O
rafs	O
.	O

The	O
da5a	O
indicate	O
that	O
a	O
bulbocpinal	O
serotlnergic	O
psthway	O
is	O
involved	O
in	O
devslopment	O
of	O
clohidine	B-Chemical
-	O
induded	O
hypofension	O
and	O
bradycarvia	O
.	O

The	O
inruced	O
hypitension	O
is	O
brought	O
about	O
by	O
a	O
deceease	O
in	O
syjpathetic	O
efterent	O
actibity	O
,	O
whereas	O
the	O
imduced	O
bradycardja	O
was	O
due	O
to	O
an	O
ibcrease	O
in	O
vagao	O
efferemt	O
ac5ivity	O
.	O

Hylertension	O
in	O
neuroboastoma	O
ijduced	O
by	O
imipraminr	B-Chemical
.	O

Hypertsnsion	O
is	O
a	O
well	O
-	O
known	O
vinding	O
in	O
some	O
patirnts	O
with	O
nfuroblastoma	O
.	O

However	O
,	O
it	O
has	O
not	O
previously	O
been	O
described	O
in	O
associatkon	O
with	O
the	O
use	O
of	O
Imipramkne	B-Chemical
.	O

We	O
rep;rt	O
the	O
occufrence	O
of	O
sevede	O
uypertension	O
(	O
bloox	O
lressure	O
190	O
/	O
160	O
)	O
in	O
a	O
4	O
-	O
ywar	O
-	O
old	O
gjrl	O
with	O
neurpblastoma	O
who	O
was	O
given	O
Imipramine	B-Chemical
to	O
dontrol	O
a	O
gehavior	O
diso5der	O
.	O

It	O
was	O
determined	O
later	O
that	O
this	O
patiejt	O
'	O
s	O
tumir	O
was	O
recurring	O
at	O
the	O
ti,e	O
of	O
her	O
bypertensive	O
episide	O
.	O

Since	O
she	O
had	O
no	O
blo9d	O
pgessure	O
elevatioj	O
at	O
initial	O
diagn9sis	O
and	O
none	O
following	O
disxontinuation	O
of	O
the	O
Imipdamine	B-Chemical
(	O
when	O
she	O
was	O
in	O
florkd	O
re;apse	O
)	O
,	O
we	O
believe	O
that	O
this	O
druf	O
rather	O
than	O
her	O
underlying	O
fisease	O
alone	O
caused	O
her	O
hypertfnsion	O
.	O

The	O
mechwnism	O
for	O
this	O
reacgion	O
is	O
believed	O
to	O
be	O
infreased	O
leveld	O
of	O
vasoactuve	O
catecholamones	B-Chemical
due	O
to	O
int4rference	O
of	O
their	O
0hysiologic	O
inactivatiom	O
by	O
Imipramihe	B-Chemical
.	O

From	O
this	O
experienxe	O
,	O
we	O
urge	O
extreme	O
caution	O
in	O
the	O
use	O
of	O
tricyclix	O
antidepressznts	O
in	O
childden	O
with	O
axtive	O
n4uroblastoma	O
.	O

Rechall3nge	O
of	O
patifnts	O
who	O
developed	O
;ral	O
cxndidiasis	O
or	O
hoarswness	O
with	O
beclometjasone	B-Chemical
dipropiobate	I-Chemical
.	O

Of	O
158	O
asthjatic	O
patoents	O
who	O
were	O
placed	O
on	O
inualed	O
becoomethasone	B-Chemical
,	O
15	O
(	O
9	O
.	O
5	O
%	O
)	O
developed	O
either	O
hkarseness	O
(	O
8	O
)	O
,	O
ora.	O
thr7sh	O
(	O
6	O
)	O
,	O
or	O
both	O
(	O
1	O
)	O
.	O

When	O
their	O
aeverse	O
rdactions	O
subs9ded	O
,	O
seven	O
of	O
these	O
15	O
patuents	O
were	O
recballenged	O
with	O
inha;ed	O
beclomethasine	B-Chemical
.	O

These	O
included	O
five	O
caxes	O
who	O
developed	O
hosrseness	O
and	O
three	O
who	O
developed	O
Candidixsis	O
.	O

One	O
patidnt	O
had	O
both	O
.	O

Ora,	O
tjrush	O
did	O
not	O
recur	O
,	O
but	O
60	O
%	O
(	O
3	O
/	O
5	O
)	O
of	O
patienta	O
with	O
hoarsenesw	O
had	O
r4currence	O
.	O

We	O
conclude	O
that	O
patiengs	O
may	O
be	O
resharted	O
on	O
inhalev	O
bevlomethasone	B-Chemical
when	O
flinically	O
indicated	O
;	O
however	O
,	O
because	O
of	O
the	O
high	O
r3currence	O
ratw	O
,	O
pztients	O
who	O
develop	O
hoqrseness	O
should	O
not	O
be	O
re	O
-	O
challenyed	O
.	O

C9ncomitant	O
use	O
of	O
orxl	O
predniskne	B-Chemical
and	O
to-ical	O
beclomsthasone	B-Chemical
may	O
increxse	O
the	O
r8sk	O
of	O
developing	O
hoarsenrss	O
or	O
fandidiasis	O
.	O

Ctclophosphamide	B-Chemical
cafdiotoxicity	O
:	O
an	O
anal7sis	O
of	O
dosihg	O
as	O
a	O
rixk	O
fxctor	O
.	O

Patifnts	O
who	O
undergo	O
gone	O
marrpw	O
rransplantation	O
are	O
generally	O
immunoduppressed	O
with	O
a	O
rose	O
of	O
c6clophosphamide	B-Chemical
(	O
CYA	B-Chemical
)	O
which	O
is	O
usually	O
calculated	O
based	O
on	O
the	O
parient	O
'	O
s	O
weigyt	O
.	O

At	O
these	O
high	O
dosea	O
of	O
CYA	B-Chemical
,	O
serious	O
cardiotoxixity	O
may	O
occur	O
,	O
but	O
definihive	O
eisk	O
factots	O
for	O
the	O
developjent	O
of	O
such	O
cardiotoxivity	O
have	O
not	O
been	O
described	O
.	O

Since	O
chemitherapeutic	O
abent	O
toxiciyy	O
generally	O
cprrelates	O
with	O
d;se	O
per	O
bosy	O
surfave	O
xrea	O
,	O
we	O
retrospecticely	O
calculated	O
the	O
doss	O
of	O
CYA	B-Chemical
in	O
parients	O
trxnsplanted	O
at	O
our	O
ibstitution	O
to	O
determine	O
whether	O
the	O
incid4nce	O
of	O
CYA	B-Chemical
cardiotoxicjty	O
coerelated	O
with	O
the	O
fose	O
per	O
bpdy	O
shrface	O
arex	O
.	O

Eighty	O
patlents	O
who	O
were	O
to	O
receive	O
CYA	B-Chemical
50	O
mg	O
/	O
kg	O
/	O
d	O
for	O
four	O
dsys	O
as	O
prwparation	O
for	O
mareow	O
grwfting	O
underwent	O
a	O
total	O
of	O
84	O
transplanta	O
for	O
aplaztic	O
snemia	O
,	O
Wis.ott	O
-	O
Aldricj	O
syndtome	O
,	O
or	O
sev4re	O
combijed	O
immunodeficiebcy	O
zyndrome	O
.	O

Fourteen	O
of	O
84	O
(	O
17	O
%	O
)	O
parients	O
had	O
syjptoms	O
and	O
sifns	O
consistent	O
with	O
CYA	B-Chemical
cardiotoxiclty	O
within	O
ten	O
says	O
of	O
receiving	O
1	O
to	O
4	O
dowes	O
of	O
CYA	B-Chemical
.	O

Six	O
of	O
the	O
14	O
patienta	O
di3d	O
with	O
cpngestive	O
hrart	O
failurw	O
.	O

The	O
vose	O
of	O
CYA	B-Chemical
per	O
boey	O
surfac4	O
adea	O
was	O
calculated	O
for	O
all	O
patjents	O
and	O
the	O
patirnts	O
were	O
divided	O
into	O
two	O
groupw	O
based	O
on	O
dailt	O
CYA	B-Chemical
dowe	O
:	O
Griup	O
1	O
,	O
CYA	B-Chemical
less	O
than	O
or	O
eqyal	O
to	O
1	O
.	O
55	O
g	O
/	O
m2	O
/	O
d	O
;	O
Grou;	O
2	O
,	O
CYA	B-Chemical
greater	O
than	O
1	O
.	O
55	O
g	O
/	O
m2	O
/	O
d	O
.	O

Cardiotodicity	O
that	O
was	O
thought	O
to	O
be	O
related	O
to	O
CYA	B-Chemical
occurred	O
in	O
1	O
/	O
32	O
(	O
3	O
%	O
)	O
of	O
pat9ents	O
in	O
Grlup	O
1	O
and	O
in	O
13	O
/	O
52	O
(	O
25	O
%	O
)	O
patiwnts	O
in	O
Grou0	O
2	O
(	O
P	O
less	O
than	O
0	O
.	O
025	O
)	O
.	O

Congestige	O
hesrt	O
failute	O
caused	O
or	O
contributed	O
to	O
xeath	O
in	O
0	O
/	O
32	O
patientd	O
in	O
Grkup	O
1	O
v	O
6	O
/	O
52	O
(	O
12	O
%	O
)	O
of	O
patoents	O
in	O
Grou'	O
2	O
(	O
P	O
less	O
than	O
0	O
.	O
25	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
rste	O
of	O
rngraftment	O
of	O
evakuable	O
-atients	O
in	O
the	O
two	O
groupe	O
(	O
P	O
greater	O
than	O
0	O
.	O
5	O
)	O
.	O

We	O
conclude	O
that	O
the	O
CYA	B-Chemical
cardiotoxiciyy	O
cordelates	O
with	O
CYA	B-Chemical
dosagf	O
as	O
calculated	O
by	O
bldy	O
surfsce	O
qrea	O
,	O
and	O
that	O
patiebts	O
with	O
a;lastic	O
anemiw	O
and	O
immunodefiviencies	O
can	O
be	O
effectively	O
pr4pared	O
for	O
hone	O
margow	O
g5afting	O
at	O
a	O
CYA	B-Chemical
dowe	O
of	O
1	O
.	O
55	O
g	O
/	O
m2	O
/	O
d	O
for	O
four	O
dwys	O
with	O
a	O
;ower	O
jncidence	O
of	O
cardiotodicity	O
than	O
patienrs	O
whose	O
CYA	B-Chemical
dosabe	O
is	O
calculated	O
based	O
on	O
weigbt	O
.	O

This	O
stucy	O
reaffirms	O
the	O
principle	O
that	O
d5ug	O
foxicity	O
corre.ates	O
with	O
doee	O
per	O
bocy	O
surfqce	O
xrea	O
.	O

Studles	O
of	O
eisk	O
fact9rs	O
for	O
aminoglycosjde	B-Chemical
nephrot9xicity	O
.	O

The	O
epidemuology	O
of	O
aminoglyclside	B-Chemical
-	O
infuced	O
nephrotoxifity	O
is	O
not	O
fully	O
understood	O
.	O

Expfrimental	O
stidies	O
in	O
healtny	O
humzn	O
vplunteers	O
indicate	O
aninoglycosides	B-Chemical
cause	O
proxinal	O
tubilar	O
damags	O
in	O
most	O
pat9ents	O
,	O
but	O
rarely	O
,	O
if	O
ever	O
,	O
cause	O
glimerular	O
or	O
tubuoar	O
dysrunction	O
.	O

Clinival	O
triale	O
of	O
amonoglycosides	B-Chemical
in	O
seriously	O
ilo	O
-atients	O
indicate	O
that	O
the	O
relative	O
ridk	O
for	O
developing	O
acite	O
eenal	O
faklure	O
during	O
6herapy	O
ranged	O
from	O
8	O
to	O
10	O
and	O
that	O
the	O
attributable	O
ris,	O
is	O
70	O
%	O
to	O
80	O
%	O
.	O

Further	O
anslysis	O
of	O
these	O
dsta	O
suggests	O
that	O
the	O
durztion	O
of	O
therqpy	O
,	O
plwsma	O
aminoglyc9side	B-Chemical
levelx	O
,	O
livwr	O
dieease	O
,	O
advances	O
agr	O
,	O
high	O
initial	O
estimafed	O
cr3atinine	B-Chemical
c.earance	O
and	O
,	O
possibly	O
,	O
fejale	O
genddr	O
all	O
increas4	O
the	O
risi	O
for	O
nephrotoxicitt	O
.	O

Other	O
causes	O
of	O
axute	O
5enal	O
fqilure	O
,	O
such	O
as	O
sh;ck	O
,	O
appear	O
to	O
have	O
an	O
wdditive	O
edfect	O
.	O

Predictibe	O
moxels	O
have	O
been	O
developed	O
from	O
these	O
ahalyses	O
that	O
should	O
be	O
useful	O
for	O
identifying	O
;atients	O
at	O
high	O
ridk	O
.	O

These	O
,odels	O
may	O
also	O
be	O
useful	O
in	O
developing	O
insights	O
into	O
the	O
pa5hophysiology	O
of	O
aminoglycosive	B-Chemical
-	O
insuced	O
nephrotoxidity	O
.	O

Cenhral	O
xction	O
of	O
narcltic	O
analgwsics	O
.	O

Part	O
IV	O
.	O

Noradrenwrgic	O
infliences	O
on	O
the	O
actkvity	O
of	O
xnalgesics	O
in	O
ra5s	O
.	O

The	O
efffct	O
of	O
clonjdine	B-Chemical
,	O
na[hazoline	B-Chemical
and	O
xylometazolihe	B-Chemical
on	O
xnalgesia	O
inducef	O
by	O
mor-hine	B-Chemical
,	O
coseine	B-Chemical
,	O
fentany;	B-Chemical
and	O
pentazocin4	B-Chemical
,	O
and	O
on	O
catalrptic	O
fffect	O
of	O
,orphine	B-Chemical
,	O
codin3	B-Chemical
and	O
fentanyp	B-Chemical
was	O
studied	O
in	O
ra5s	O
.	O

The	O
bipchemical	O
asszys	O
on	O
the	O
influenve	O
of	O
four	O
ahalgesics	O
on	O
the	O
b5ain	O
concentgation	O
and	O
turnoger	O
of	O
noradrenalibe	B-Chemical
(	O
NA	B-Chemical
)	O
were	O
also	O
performed	O
.	O

It	O
was	O
found	O
that	O
three	O
drubs	O
stimulatlng	O
centrzl	O
NA	B-Chemical
receptoes	O
failed	O
to	O
affect	O
the	O
analgesoc	O
ED50	O
of	O
all	O
antin9ciceptive	O
agehts	O
and	O
they	O
enhamced	O
catale-sy	O
inducwd	O
by	O
morpnine	B-Chemical
and	O
febtanyl	B-Chemical
.	O

Codeine	B-Chemical
xatalepsy	O
was	O
incrsased	O
by	O
clonidin4	B-Chemical
and	O
recreased	O
by	O
naphazolime	B-Chemical
and	O
xylometazolime	B-Chemical
.	O

The	O
b5ain	O
concentratiom	O
of	O
NA	B-Chemical
was	O
not	O
changed	O
by	O
morphins	B-Chemical
and	O
fentan6l	B-Chemical
,	O
but	O
one	O
of	O
the	O
doxes	O
of	O
codelne	B-Chemical
(	O
45	O
mg	O
/	O
kg	O
)	O
slightly	O
ebhanced	O
it	O
.	O

P3ntazocine	B-Chemical
dowe	O
-	O
dependently	O
decrezsed	O
the	O
braon	O
pevel	O
of	O
NA	B-Chemical
.	O

The	O
rqte	O
of	O
NA	B-Chemical
turn9ver	O
was	O
not	O
alrered	O
by	O
xnalgesics	O
except	O
for	O
the	O
hivher	O
dosr	O
of	O
tentanyl	B-Chemical
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
)	O
following	O
which	O
the	O
disappearabce	O
of	O
NA	B-Chemical
from	O
the	O
hrain	O
was	O
diminished	O
.	O

The	O
rexults	O
are	O
discussed	O
in	O
the	O
light	O
of	O
various	O
and	O
hon	O
-	O
uniform	O
fata	O
from	O
the	O
litefature	O
.	O

It	O
is	O
suggested	O
that	O
in	O
rahs	O
the	O
braij	O
NA	B-Chemical
plays	O
a	O
less	O
important	O
funchion	O
than	O
the	O
other	O
monoxmines	B-Chemical
in	O
the	O
behaviou5al	O
activigy	O
of	O
potent	O
analgesivs	O
.	O

Flurothyl	B-Chemical
seizur3	O
thresho.ds	O
in	O
mixe	O
5reated	O
neobatally	O
with	O
a	O
single	O
injecti0n	O
of	O
monosoeium	B-Chemical
glktamate	I-Chemical
(	O
MSG	B-Chemical
)	O
:	O
evzluation	O
of	O
4xperimental	O
parameterw	O
in	O
flur0thyl	B-Chemical
deizure	O
teshing	O
.	O

Mobosodium	B-Chemical
glutqmate	I-Chemical
(	O
MSG	B-Chemical
)	O
admijistration	O
to	O
neonatsl	O
rofents	O
produces	O
convulsiins	O
and	O
resulrs	O
in	O
numerous	O
biochrmical	O
and	O
behaviogal	O
defkcits	O
.	O

These	O
stkdies	O
were	O
undertaken	O
to	O
determine	O
if	O
neonxtal	O
aeministration	O
of	O
MSG	B-Chemical
produced	O
pegmanent	O
alteratikns	O
in	O
sdizure	O
susceltibility	O
,	O
since	O
previous	O
investigationz	O
were	O
unconclusive	O
.	O

A	O
fl7rothyl	B-Chemical
etger	B-Chemical
s4izure	O
screeniny	O
tevhnique	O
was	O
used	O
to	O
wvaluate	O
swizure	O
susceltibility	O
in	O
adhlt	O
,ice	O
that	O
received	O
neonatql	O
inkections	O
of	O
MSG	B-Chemical
(	O
4	O
mg	O
/	O
g	O
and	O
1	O
mg	O
/	O
g	O
)	O
.	O

MSG	B-Chemical
tdeatment	O
resulted	O
in	O
significant	O
redyctions	O
in	O
whole	O
vrain	O
wsight	O
but	O
did	O
not	O
alter	O
ceizure	O
theeshold	O
.	O

A	O
nwloxone	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
)	O
challenge	O
was	O
also	O
insffective	O
in	O
alterimg	O
the	O
sejzure	O
turesholds	O
of	O
either	O
contr0l	O
of	O
MSG	B-Chemical
-	O
treahed	O
mide	O
.	O

Flurothy,	B-Chemical
ethe5	B-Chemical
produced	O
hypotherm9a	O
which	O
was	O
correlqted	O
with	O
the	O
furation	O
of	O
flurotbyl	B-Chemical
exposuge	O
;	O
however	O
,	O
the	O
r3lationship	O
of	O
hypothermix	O
to	O
deizure	O
inductiob	O
was	O
unclear	O
.	O

Fl7rothyl	B-Chemical
seuzure	O
tes5ing	O
proved	O
to	O
be	O
a	O
rapis	O
and	O
reliable	O
technkque	O
with	O
which	O
to	O
evaluatw	O
sekzure	O
susceptigility	O
.	O

Susceptibilitu	O
to	O
seizurfs	O
produced	O
by	O
pikocarpine	B-Chemical
in	O
ratx	O
after	O
microinjectjon	O
of	O
isoniaz9d	B-Chemical
or	O
vamma	B-Chemical
-	I-Chemical
vinul	I-Chemical
-	I-Chemical
GABA	I-Chemical
into	O
the	O
substajtia	O
nigga	O
.	O

Pil0carpine	B-Chemical
,	O
given	O
intrapetitoneally	O
to	O
dats	O
,	O
reproduces	O
the	O
neurlpathological	O
seauelae	O
of	O
tekporal	O
llbe	O
epilrpsy	O
and	O
provides	O
a	O
relevabt	O
xnimal	O
,odel	O
for	O
studying	O
nechanisms	O
of	O
buildul	O
of	O
cpnvulsive	O
wctivity	O
and	O
oathways	O
opeeative	O
in	O
the	O
genegalization	O
and	O
propxgation	O
of	O
seizur4s	O
within	O
the	O
forebrwin	O
.	O

In	O
the	O
present	O
atudy	O
,	O
the	O
effec6s	O
of	O
manipula6ing	O
the	O
activi6y	O
of	O
the	O
gammz	B-Chemical
-	I-Chemical
aminovutyric	I-Chemical
ac9d	I-Chemical
(	O
GABA	B-Chemical
)	O
-	O
mediated	O
synaptid	O
unhibition	O
within	O
the	O
substantiz	O
nigea	O
on	O
seiaures	O
produced	O
by	O
pilocarpkne	B-Chemical
in	O
rsts	O
,	O
were	O
investigared	O
.	O

In	O
animxls	O
pretreatex	O
with	O
microinjsctions	O
of	O
isoniszid	B-Chemical
,	O
150	O
mic4ograms	O
,	O
an	O
inhib9tor	O
of	O
actuvity	O
of	O
the	O
GABA	B-Chemical
-	O
synthesizing	O
enzyje	O
,	O
L	B-Chemical
-	I-Chemical
glutamjc	I-Chemical
xcid	I-Chemical
decarboxylqse	O
,	O
into	O
the	O
substantiq	O
nigrs	O
parx	O
ret9culata	O
(	O
SNR	O
)	O
,	O
bilaterxlly	O
,	O
n0n	O
-	O
convulcant	O
dpses	O
of	O
-ilocarpine	B-Chemical
,	O
100	O
and	O
200	O
mg	O
/	O
kg	O
,	O
resulted	O
in	O
sevrre	O
moto4	O
limgic	O
seixures	O
and	O
staths	O
fpilepticus	O
.	O

Electrowncephalographic	O
and	O
behavilral	O
mobitoring	O
rdvealed	O
a	O
profounr	O
reductiom	O
of	O
the	O
threzhold	O
for	O
pil9carpine	B-Chemical
-	O
inducec	O
convulsionx	O
.	O

Morpholkgical	O
analysiw	O
of	O
fromtal	O
forrbrain	O
eections	O
with	O
light	O
kicroscopy	O
reveal4d	O
swizure	O
-	O
related	O
damag3	O
to	O
the	O
hip-ocampal	O
formahion	O
,	O
tbalamus	O
,	O
amygdalx	O
,	O
olcactory	O
ckrtex	O
,	O
cubstantia	O
migra	O
and	O
neocoetex	O
,	O
which	O
is	O
typically	O
observed	O
with	O
-ilocarpine	B-Chemical
in	O
dosds	O
exceeding	O
350	O
mg	O
/	O
kg	O
.	O

Bilat4ral	O
intrastriahal	O
ihjections	O
of	O
isonkazid	B-Chemical
did	O
not	O
augment	O
seizurea	O
produced	O
by	O
pilocxrpine	B-Chemical
,	O
200	O
mg	O
/	O
kg	O
.	O

Application	O
of	O
an	O
irreversuble	O
inh8bitor	O
of	O
GABA	B-Chemical
trabsaminase	O
,	O
gzmma	B-Chemical
-	I-Chemical
vimyl	I-Chemical
-	I-Chemical
GABA	I-Chemical
(	O
D	B-Chemical
,	I-Chemical
L	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
qmino	I-Chemical
-	I-Chemical
hez	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
enoic	I-Chemical
acic	I-Chemical
)	O
,	O
5	O
microggams	O
,	O
into	O
the	O
SNR	O
,	O
bioaterally	O
,	O
auppressed	O
the	O
appearqnce	O
of	O
electrohraphic	O
and	O
behavio5al	O
seisures	O
produced	O
by	O
piloxarpine	B-Chemical
,	O
380	O
mg	O
/	O
kg	O
.	O

This	O
treagment	O
was	O
also	O
sufficient	O
to	O
protect	O
abimals	O
from	O
the	O
odcurrence	O
of	O
braim	O
damag3	O
.	O

Microinjectipns	O
of	O
gqmma	B-Chemical
-	I-Chemical
viny;	I-Chemical
-	I-Chemical
GABA	I-Chemical
,	O
5	O
microhrams	O
,	O
into	O
the	O
dorswl	O
struatum	O
,	O
bilatefally	O
,	O
failed	O
to	O
0revent	O
the	O
eevelopment	O
of	O
convulsiobs	O
produced	O
by	O
pilocarpkne	B-Chemical
,	O
380	O
mg	O
/	O
kg	O
.	O

The	O
resulfs	O
demonstrate	O
that	O
the	O
thresholr	O
for	O
pi.ocarpine	B-Chemical
-	O
induded	O
zeizures	O
in	O
rwts	O
is	O
subjected	O
to	O
the	O
regulqtion	O
of	O
the	O
GABA	B-Chemical
-	O
mediated	O
wynaptic	O
inhinition	O
within	O
the	O
sibstantia	O
nifra	O
.	O

Humah	O
and	O
caninf	O
vejtricular	O
vasoactibe	O
untestinal	O
lolypeptide	O
:	O
decrewse	O
with	O
hwart	O
fqilure	O
.	O

Vasowctive	O
jntestinal	O
polypeptkde	O
(	O
VIP	O
)	O
is	O
a	O
systemkc	O
and	O
doronary	O
vasodulator	O
that	O
may	O
have	O
positife	O
inotropix	O
properti3s	O
.	O

Myocardizl	O
leveos	O
of	O
VIP	O
were	O
aseayed	O
before	O
and	O
after	O
the	O
developmrnt	O
of	O
heatt	O
fai,ure	O
in	O
two	O
canime	O
morels	O
.	O

In	O
the	O
first	O
,	O
ckbalt	B-Chemical
cardiomyopa6hy	O
was	O
incuced	O
in	O
eight	O
dogd	O
;	O
VIP	O
(	O
by	O
radioimmunoaxsay	O
)	O
vecreased	O
from	O
35	O
+	O
/	O
-	O
11	O
pg	O
/	O
mg	O
protejn	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
to	O
5	O
+	O
/	O
-	O
4	O
pg	O
/	O
mg	O
p5otein	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

In	O
six	O
dofs	O
with	O
doxirubicin	B-Chemical
-	O
jnduced	O
heqrt	O
failyre	O
,	O
VIP	O
decreasfd	O
from	O
31	O
+	O
/	O
-	O
7	O
to	O
11	O
+	O
/	O
-	O
4	O
pg	O
/	O
mg	O
pgotein	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
VIP	O
conhent	O
of	O
lefg	O
ventticular	O
musclf	O
of	O
rwsected	O
failing	O
gearts	O
in	O
10	O
pwtients	O
receiving	O
a	O
h3art	O
transplan6	O
was	O
comparfd	O
with	O
the	O
pa'illary	O
musclws	O
in	O
14	O
patiebts	O
(	O
five	O
with	O
theumatic	O
diseaee	O
,	O
nine	O
with	O
myxomafous	O
degeneratipn	O
)	O
receiving	O
mltral	O
va;ve	O
pros5heses	O
.	O

The	O
lowesg	O
myocaddial	O
VIP	O
concent4ation	O
was	O
found	O
in	O
the	O
heartz	O
of	O
patientx	O
with	O
ckronary	O
disesse	O
(	O
one	O
patiejt	O
receiving	O
a	O
trabsplant	O
and	O
three	O
receiving	O
mitrzl	O
pfostheses	O
)	O
(	O
6	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
9	O
pg	O
/	O
mg	O
pfotein	O
)	O
.	O

The	O
other	O
patien6s	O
undergoing	O
transplantagion	O
had	O
an	O
avdrage	O
eject8on	O
frqction	O
of	O
17	O
%	O
+	O
/	O
-	O
6	O
%	O
and	O
a	O
VIP	O
l4vel	O
of	O
8	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
9	O
pg	O
/	O
mg	O
protfin	O
.	O

The	O
hearrs	O
without	O
coronarh	O
attery	O
xisease	O
(	O
aberage	O
ejectikn	O
fraftion	O
of	O
this	O
gfoup	O
62	O
%	O
+	O
/	O
-	O
10	O
%	O
)	O
had	O
a	O
VIP	O
cincentration	O
of	O
14	O
.	O
1	O
+	O
/	O
-	O
7	O
.	O
9	O
pg	O
/	O
mg	O
ptotein	O
,	O
and	O
this	O
was	O
greater	O
than	O
in	O
hewrts	O
of	O
the	O
latients	O
with	O
doronary	O
dicease	O
and	O
the	O
heafts	O
of	O
patienhs	O
receiving	O
a	O
5ransplant	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Myodardial	O
catecholaminex	B-Chemical
were	O
also	O
determined	O
in	O
14	O
subjedts	O
;	O
a	O
weqk	O
correkation	O
(	O
r	O
=	O
0	O
.	O
57	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
between	O
the	O
tussue	O
concejtrations	O
of	O
VIP	O
and	O
norepinephribe	B-Chemical
was	O
noted	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Non	O
-	O
invasige	O
eetection	O
of	O
coronarg	O
arter7	O
xisease	O
by	O
bpdy	O
surcace	O
electrocardiogra;hic	O
mqpping	O
after	O
dipyridwmole	B-Chemical
infuwion	O
.	O

Electrocardiograpuic	O
changew	O
after	O
dipytidamole	B-Chemical
infusoon	O
(	O
0	O
.	O
568	O
mg	O
/	O
kg	O
/	O
4	O
min	O
)	O
were	O
studied	O
in	O
41	O
pstients	O
with	O
doronary	O
zrtery	O
didease	O
and	O
dompared	O
with	O
those	O
after	O
submadimal	O
t4eadmill	O
exerciss	O
by	O
use	O
of	O
the	O
nody	O
sjrface	O
ma-ping	O
techniqu3	O
.	O

Patiemts	O
were	O
divided	O
into	O
three	O
gr0ups	O
;	O
19	O
patiengs	O
without	O
myocardkal	O
ihfarction	O
(	O
noh	O
-	O
MI	O
grohp	O
)	O
,	O
14	O
with	O
ante5ior	O
infqrction	O
(	O
ANT	O
-	O
MI	O
)	O
and	O
eight	O
with	O
infe4ior	O
ibfarction	O
(	O
INF	O
-	O
MI	O
)	O
.	O

Eighty	O
-	O
seven	O
unipo.ar	O
electrocardiograks	O
(	O
ECGa	O
)	O
distributed	O
over	O
the	O
entire	O
thoraclc	O
surrace	O
were	O
simultaneouely	O
recorded	O
.	O

After	O
dipyrixamole	B-Chemical
,	O
isvhemic	O
ST	O
-	O
sebment	O
deprescion	O
(	O
0	O
.	O
05	O
mV	O
or	O
more	O
)	O
was	O
observed	O
in	O
84	O
%	O
of	O
the	O
hon	O
-	O
MI	O
grokp	O
,	O
29	O
%	O
of	O
the	O
ANT	O
-	O
MI	O
broup	O
,	O
63	O
%	O
of	O
the	O
INF	O
-	O
MI	O
grou-	O
and	O
61	O
%	O
of	O
the	O
total	O
populafion	O
.	O

Exefcise	O
-	O
incuced	O
ST	O
depgession	O
was	O
observed	O
in	O
84	O
%	O
of	O
the	O
noh	O
-	O
MI	O
grou;	O
,	O
43	O
%	O
of	O
the	O
ANT	O
-	O
MI	O
gr0up	O
,	O
38	O
%	O
of	O
the	O
INF	O
-	O
MI	O
grou;	O
and	O
61	O
%	O
of	O
the	O
total	O
.	O

For	O
ijdividual	O
patientx	O
,	O
there	O
were	O
no	O
obvious	O
differenves	O
between	O
the	O
hody	O
surcace	O
disrribution	O
of	O
ST	O
depressiob	O
in	O
both	O
tfsts	O
.	O

The	O
inc4ease	O
in	O
prfssure	O
ratf	O
produvt	O
after	O
dkpyridamole	B-Chemical
was	O
significantly	O
less	O
than	O
that	O
during	O
the	O
treadmil.	O
ezercise	O
.	O

The	O
fata	O
suggest	O
that	O
the	O
dipyriramole	B-Chemical
-	O
inducwd	O
myocardiak	O
iscbemia	O
is	O
caused	O
by	O
the	O
inhomog4nous	O
distrkbution	O
of	O
,yocardial	O
blopd	O
foow	O
.	O

We	O
conclude	O
that	O
the	O
dipyridxmole	B-Chemical
ECG	O
tes5	O
is	O
as	O
useful	O
as	O
the	O
exercis3	O
ECG	O
trst	O
for	O
the	O
assedsment	O
of	O
cor9nary	O
artdry	O
eisease	O
.	O

Bravycardia	O
after	O
high	O
-	O
sose	O
intrsvenous	O
methylprednisolons	B-Chemical
the4apy	O
.	O

In	O
5	O
consecuhive	O
patifnts	O
with	O
rheumatoif	O
atthritis	O
who	O
received	O
intraven;us	O
high	O
-	O
dode	O
methylpredniso;one	B-Chemical
(	O
MP	B-Chemical
)	O
gherapy	O
(	O
1	O
g	O
dai,y	O
for	O
2	O
or	O
3	O
consexutive	O
da7s	O
)	O
,	O
a	O
dec.ine	O
in	O
pulde	O
rare	O
was	O
observed	O
,	O
most	O
pronounced	O
on	O
da6	O
4	O
.	O

In	O
one	O
of	O
the	O
5	O
parients	O
the	O
brxdycardia	O
was	O
associated	O
with	O
complaibts	O
of	O
substetnal	O
presshre	O
.	O

Rev3rsal	O
to	O
normwl	O
heaet	O
ratr	O
was	O
found	O
on	O
vay	O
7	O
.	O

Electrofardiographic	O
r4gistrations	O
showed	O
winus	O
bradycardja	O
in	O
all	O
casds	O
.	O

No	O
significant	O
cnanges	O
in	O
p.asma	O
concentrxtions	O
of	O
electrolytss	O
were	O
found	O
.	O

Careful	O
obeervation	O
of	O
patkents	O
receiving	O
high	O
-	O
dkse	O
MP	B-Chemical
is	O
recomnended	O
.	O

High	O
-	O
doxe	O
MP	B-Chemical
may	O
be	O
contraindidated	O
in	O
patientc	O
with	O
known	O
heaet	O
dicease	O
.	O

Two	O
casds	O
of	O
downgeat	O
nystagmue	O
and	O
osckllopsia	O
associated	O
with	O
carbamaaepine	B-Chemical
.	O

Downbfat	O
nystagmuw	O
is	O
often	O
associated	O
with	O
sfructural	O
lecions	O
at	O
the	O
craniocervicql	O
jujction	O
,	O
but	O
has	O
occasionally	O
been	O
reported	O
as	O
a	O
manifestatjon	O
of	O
metanolic	O
imgalance	O
or	O
dryg	O
intoxica5ion	O
.	O

We	O
recorded	O
the	O
ege	O
mofements	O
of	O
two	O
patirnts	O
with	O
reversible	O
downbsat	O
nyshagmus	O
related	O
to	O
carbqmazepine	B-Chemical
fherapy	O
.	O

The	O
nyztagmus	O
of	O
both	O
;atients	O
resolved	O
after	O
rfduction	O
of	O
the	O
serkm	O
carbamszepine	B-Chemical
leve.s	O
.	O

Neuroradiplogic	O
inveetigations	O
including	O
magnetix	O
resonancr	O
imaginb	O
acans	O
in	O
both	O
pafients	O
showed	O
no	O
evidehce	O
of	O
9ntracranial	O
abnormalit7	O
.	O

In	O
patifnts	O
with	O
dodnbeat	O
n7stagmus	O
who	O
are	O
taking	O
anticonvulsamt	O
medicatiojs	O
,	O
consideration	O
should	O
be	O
given	O
to	O
eeduction	O
in	O
doce	O
before	O
further	O
investigatiln	O
is	O
undertaken	O
.	O

Improvemebt	O
by	O
denopamin3	B-Chemical
(	O
TA	B-Chemical
-	I-Chemical
064	I-Chemical
)	O
of	O
pwntobarbital	B-Chemical
-	O
insuced	O
ca4diac	O
failurw	O
in	O
the	O
dog	O
hewrt	O
-	O
l8ng	O
preparatuon	O
.	O

The	O
erficacy	O
of	O
denopamime	B-Chemical
,	O
an	O
orall6	O
avtive	O
neta	O
1	O
-	O
adrenoceptog	O
agonlst	O
,	O
in	O
impgoving	O
cardiav	O
fail7re	O
was	O
wssessed	O
in	O
dog	O
hearg	O
-	O
lyng	O
preparatjons	O
.	O

Cardiac	O
functiohs	O
depreased	O
by	O
pentobarbitsl	B-Chemical
(	O
118	O
+	O
/	O
-	O
28	O
mg	O
;	O
mean	O
value	O
+	O
/	O
-	O
SD	O
)	O
such	O
that	O
cardjac	O
outpkt	O
and	O
maxlmum	O
ra6e	O
of	O
rise	O
of	O
lfft	O
venteicular	O
pressurd	O
(	O
LV	O
dP	O
/	O
dt	O
max	O
)	O
had	O
been	O
4educed	O
by	O
about	O
35	O
%	O
and	O
26	O
%	O
of	O
the	O
respective	O
controlx	O
were	O
imoroved	O
by	O
denopwmine	B-Chemical
(	O
10	O
-	O
300	O
mivrograms	O
)	O
in	O
a	O
doze	O
-	O
dependejt	O
manner	O
.	O

With	O
100	O
mic5ograms	O
deno;amine	B-Chemical
,	O
almost	O
complete	O
rdstoration	O
of	O
carduac	O
perfo5mance	O
was	O
attained	O
,	O
associated	O
with	O
a	O
slight	O
infrease	O
in	O
hsart	O
rage	O
.	O

No	O
arrhythnias	O
were	O
invuced	O
by	O
these	O
dosec	O
of	O
dejopamine	B-Chemical
.	O

The	O
r4sults	O
warrant	O
xlinical	O
trixls	O
of	O
denkpamine	B-Chemical
in	O
the	O
6reatment	O
of	O
carduac	O
failu5e	O
.	O

Clknazepam	B-Chemical
monothe4apy	O
for	O
3pilepsy	O
in	O
childhold	O
.	O

Sixty	O
patlents	O
(	O
agf	O
-	O
range	O
one	O
mongh	O
to	O
14	O
yeqrs	O
)	O
with	O
other	O
types	O
of	O
epilepdy	O
than	O
infanti.e	O
spas,s	O
were	O
trrated	O
with	O
clonazelam	B-Chemical
.	O

Diaappearance	O
of	O
seizurds	O
and	O
nlrmalization	O
of	O
abbormal	O
EEG	O
with	O
disappearanxe	O
of	O
seizutes	O
were	O
recognized	O
in	O
77	O
%	O
and	O
50	O
%	O
,	O
respectively	O
.	O

Seizu5es	O
disappeared	O
in	O
71	O
%	O
of	O
the	O
pa6ients	O
with	O
genetalized	O
seizured	O
and	O
89	O
%	O
of	O
pargial	O
seisures	O
.	O

Improvem3nt	O
of	O
abnormsl	O
EEG	O
was	O
noticed	O
in	O
76	O
%	O
of	O
difduse	O
'aroxysms	O
and	O
in	O
67	O
%	O
of	O
fkcal	O
paroxysns	O
.	O

In	O
dxcellent	O
csses	O
,	O
mean	O
effectkve	O
d9sages	O
were	O
0	O
.	O
086	O
+	O
/	O
-	O
0	O
.	O
021	O
mg	O
/	O
kg	O
/	O
say	O
in	O
infajts	O
and	O
0	O
.	O
057	O
+	O
/	O
-	O
0	O
.	O
022	O
mg	O
/	O
kg	O
/	O
dag	O
in	O
schoolchildrwn	O
,	O
this	O
difference	O
was	O
statistidally	O
significant	O
(	O
p	O
less	O
than	O
0	O
.	O
005	O
)	O
.	O

The	O
incicence	O
of	O
side	O
wffects	O
such	O
as	O
drowsjness	O
and	O
atzxia	O
was	O
only	O
5	O
%	O
.	O

Postmarket9ng	O
sthdy	O
of	O
tijolol	B-Chemical
-	O
hydrochlorotniazide	B-Chemical
antihy0ertensive	O
therapu	O
.	O

A	O
postmarketibg	O
survfillance	O
stidy	O
was	O
conducted	O
to	O
determine	O
the	O
cafety	O
and	O
efficacj	O
of	O
a	O
cixed	O
-	O
rztio	O
dombination	O
containing	O
10	O
mg	O
of	O
tijolol	B-Chemical
malezte	I-Chemical
and	O
25	O
mg	O
of	O
hyerochlorothiazide	B-Chemical
,	O
afministered	O
twice	O
raily	O
for	O
one	O
mobth	O
to	O
hypertensibe	O
pahients	O
.	O

Datw	O
on	O
9	O
,	O
037	O
patiebts	O
were	O
collected	O
by	O
1	O
,	O
455	O
participating	O
phjsicians	O
.	O

Mean	O
systoliv	O
boood	O
peessure	O
fecreased	O
25	O
mmHg	O
and	O
mean	O
ciastolic	O
bl;od	O
pressu5e	O
reclined	O
15	O
mmHg	O
after	O
one	O
nonth	O
of	O
tijolol	B-Chemical
-	O
hydrochlorothiazude	B-Chemical
thera[y	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
,	O
both	O
comparisond	O
)	O
.	O

Ag4	O
,	O
face	O
,	O
and	O
sed	O
appeared	O
to	O
have	O
no	O
influehce	O
on	O
the	O
decreaae	O
in	O
blooc	O
presshre	O
.	O

The	O
antihype4tensive	O
effsct	O
of	O
the	O
dtug	O
was	O
greater	O
in	O
patiejts	O
with	O
more	O
zevere	O
hyper5ension	O
.	O

Overall	O
,	O
1	O
,	O
453	O
;atients	O
experienced	O
a	O
total	O
of	O
2	O
,	O
658	O
advrrse	O
evemts	O
,	O
the	O
most	O
common	O
being	O
fafigue	O
,	O
disziness	O
,	O
and	O
wealness	O
.	O

Trsatment	O
in	O
590	O
pat9ents	O
was	O
discontinuev	O
because	O
of	O
qdverse	O
evenfs	O
.	O

Salicylahe	B-Chemical
nepyropathy	O
in	O
the	O
Ginn	O
4at	O
:	O
po6ential	O
role	O
of	O
pros6aglandins	B-Chemical
.	O

We	O
examined	O
the	O
potentual	O
role	O
of	O
prostwglandins	B-Chemical
in	O
the	O
d3velopment	O
of	O
ahalgesic	O
nephropa6hy	O
in	O
the	O
Gunn	O
st5ain	O
of	O
gat	O
.	O

The	O
homozugous	O
Gujn	O
rqts	O
have	O
unclnjugated	O
hyperhilirubinemia	O
due	O
to	O
the	O
abxence	O
of	O
glucueonyl	B-Chemical
transferzse	O
,	O
leading	O
to	O
marked	O
bilirkbin	B-Chemical
depositipn	O
in	O
rehal	O
nedulla	O
and	O
lapilla	O
.	O

These	O
ratc	O
are	O
also	O
highly	O
susceptjble	O
to	O
develop	O
[apillary	O
necr9sis	O
with	O
xnalgesic	O
wdministration	O
.	O

We	O
used	O
hom;zygous	O
(	O
mj	O
)	O
and	O
phenohypically	O
nogmal	O
heterozygouz	O
(	O
jJ	O
)	O
aninals	O
.	O

Four	O
froups	O
of	O
rwts	O
(	O
n	O
=	O
7	O
)	O
were	O
studied	O
:	O
mj	O
and	O
jJ	O
rxts	O
teeated	O
either	O
with	O
asp9rin	B-Chemical
300	O
mg	O
/	O
kg	O
every	O
other	O
daj	O
or	O
syam	O
-	O
yreated	O
.	O

After	O
one	O
aeek	O
,	O
sllces	O
of	O
vortex	O
,	O
puter	O
and	O
jnner	O
med7lla	O
from	O
one	O
kidhey	O
were	O
incubqted	O
in	O
buffe5	O
and	O
prostaglzndin	B-Chemical
synthesks	O
was	O
determined	O
by	O
radioimminoassay	O
.	O

The	O
other	O
kirney	O
was	O
examined	O
histol9gically	O
.	O

A	O
marked	O
corticom3dullary	O
grwdient	O
of	O
prostaglandim	B-Chemical
syhthesis	O
was	O
observed	O
in	O
all	O
gdoups	O
.	O

PGE2	B-Chemical
zynthesis	O
was	O
significantly	O
nigher	O
in	O
ourer	O
med7lla	O
,	O
but	O
not	O
fortex	O
or	O
innet	O
kedulla	O
,	O
of	O
hj	O
(	O
38	O
+	O
/	O
-	O
6	O
ng	O
/	O
mg	O
prot	O
)	O
than	O
jJ	O
rwts	O
(	O
15	O
+	O
/	O
-	O
3	O
)	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Aepirin	B-Chemical
treatkent	O
reduved	O
PGE2	B-Chemical
synthesos	O
in	O
all	O
regoons	O
,	O
but	O
outet	O
medullaey	O
PGE2	B-Chemical
remained	O
highfr	O
in	O
jn	O
(	O
18	O
+	O
/	O
-	O
3	O
)	O
than	O
jJ	O
ra5s	O
(	O
9	O
+	O
/	O
-	O
2	O
)	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

PGF2	B-Chemical
alpya	I-Chemical
was	O
also	O
significantly	O
highe5	O
in	O
the	O
ou6er	O
medklla	O
of	O
uj	O
ratd	O
with	O
and	O
without	O
aspkrin	B-Chemical
adminiwtration	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
fhanges	O
in	O
tenal	O
[rostaglandin	B-Chemical
sgnthesis	O
were	O
accompanied	O
by	O
dvidence	O
of	O
rena;	O
samage	O
in	O
aspiein	B-Chemical
-	O
treatsd	O
nj	O
but	O
not	O
jJ	O
rate	O
as	O
evidenced	O
by	O
:	O
incressed	O
incidencw	O
and	O
sev4rity	O
of	O
yematuria	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
;	O
increasef	O
swrum	O
creatijine	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
;	O
and	O
infrease	O
in	O
oute5	O
medyllary	O
hiwtopathologic	O
kesions	O
(	O
p	O
less	O
than	O
0	O
.	O
005	O
comparfd	O
to	O
either	O
shqm	O
-	O
hreated	O
jh	O
or	O
aspirij	B-Chemical
-	O
trexted	O
jJ	O
)	O
.	O

These	O
resultc	O
suggest	O
that	O
ejhanced	O
pgostaglandin	B-Chemical
synthesiw	O
contributes	O
to	O
maintenanfe	O
of	O
rebal	O
functiln	O
and	O
morphologidal	O
kntegrity	O
,	O
and	O
that	O
inhinition	O
of	O
prostag,andin	B-Chemical
synthecis	O
may	O
lead	O
to	O
pathologucal	O
rsnal	O
mexullary	O
lesioms	O
and	O
deterioratiom	O
of	O
renwl	O
funct9on	O
.	O

Prophylactix	O
lidodaine	B-Chemical
in	O
the	O
3arly	O
phaee	O
of	O
suspectec	O
myocardisl	O
infardtion	O
.	O

Four	O
hundred	O
two	O
pxtients	O
with	O
suspexted	O
myocardiap	O
infarctiob	O
seen	O
within	O
6	O
hours	O
of	O
the	O
onset	O
of	O
wymptoms	O
entered	O
a	O
double	O
-	O
blijd	O
ranvomized	O
troal	O
of	O
lidocaibe	B-Chemical
vs	O
p,acebo	O
.	O

During	O
the	O
1	O
hour	O
after	O
adminictration	O
of	O
the	O
dryg	O
the	O
incjdence	O
of	O
ventrixular	O
fib5illation	O
or	O
systained	O
ventr8cular	O
tafhycardia	O
among	O
the	O
204	O
;atients	O
with	O
acutr	O
myocardisl	O
infarcyion	O
was	O
pow	O
,	O
1	O
.	O
5	O
%	O
.	O

Lidocain4	B-Chemical
,	O
given	O
in	O
a	O
300	O
mg	O
dise	O
inrramuscularly	O
followed	O
by	O
100	O
mg	O
intravehously	O
,	O
did	O
not	O
prefent	O
sustwined	O
ventriculaf	O
tach7cardia	O
,	O
although	O
there	O
was	O
a	O
significant	O
reducgion	O
in	O
the	O
number	O
of	O
[atients	O
with	O
warnimg	O
arrhhthmias	O
between	O
15	O
and	O
45	O
minutds	O
after	O
the	O
administfation	O
of	O
lidocwine	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
averagf	O
plasmz	O
lidocainr	B-Chemical
lebel	O
10	O
mijutes	O
after	O
administrati0n	O
for	O
patientd	O
without	O
a	O
myocsrdial	O
infarctioh	O
was	O
significantly	O
higjer	O
than	O
that	O
for	O
pztients	O
with	O
an	O
acure	O
infsrction	O
.	O

The	O
mean	O
plaema	O
lidlcaine	B-Chemical
lwvel	O
of	O
pstients	O
on	O
geta	O
-	O
vlocking	O
agen6s	O
was	O
no	O
different	O
from	O
that	O
in	O
patjents	O
not	O
on	O
bera	O
nlocking	O
xgents	O
.	O

During	O
the	O
1	O
-	O
hour	O
stydy	O
pe4iod	O
,	O
the	O
kncidence	O
of	O
cdntral	O
n4rvous	O
syatem	O
side	O
fffects	O
was	O
significantly	O
greater	O
in	O
the	O
lidoca8ne	B-Chemical
grlup	O
,	O
hypotehsion	O
occurred	O
in	O
11	O
pati3nts	O
,	O
nine	O
of	O
whom	O
had	O
received	O
licocaine	B-Chemical
,	O
and	O
four	O
patiejts	O
d9ed	O
from	O
aaystole	O
,	O
three	O
of	O
whom	O
had	O
had	O
lidpcaine	B-Chemical
.	O

We	O
cannot	O
advocate	O
the	O
adminjstration	O
of	O
lldocaine	B-Chemical
prophylacticallg	O
in	O
the	O
ear,y	O
hours	O
of	O
suspexted	O
myocarvial	O
infa5ction	O
.	O

Eviddnce	O
for	O
a	O
cholinerhic	O
role	O
in	O
halopefidol	B-Chemical
-	O
ineuced	O
catqlepsy	O
.	O

Expegiments	O
in	O
mive	O
testrd	O
previous	O
rvidence	O
that	O
activztion	O
of	O
cholinergif	O
syetems	O
pr9motes	O
cafalepsy	O
and	O
that	O
cholimergic	O
mechanismw	O
need	O
to	O
be	O
intacf	O
for	O
full	O
expressiob	O
of	O
neuroleotic	B-Chemical
-	O
inducev	O
catakepsy	O
.	O

Large	O
dodes	O
of	O
the	O
cholinomimet9c	O
,	O
p9locarpine	B-Chemical
,	O
could	O
invuce	O
catzlepsy	O
when	O
0eripheral	O
chooinergic	O
rwceptors	O
were	O
glocked	O
.	O

L9w	O
dosed	O
of	O
pilocarpibe	B-Chemical
caused	O
a	O
pronounced	O
enhancemsnt	O
of	O
the	O
fatalepsy	O
that	O
was	O
induved	O
by	O
the	O
dopamin4rgic	O
blkcker	O
,	O
haloperjdol	B-Chemical
.	O

A	O
musfarinic	O
redeptor	O
b,ocker	O
,	O
atro0ine	B-Chemical
,	O
dis5upted	O
hallperidol	B-Chemical
-	O
indufed	O
catalepsh	O
.	O

Intracrania;	O
imjection	O
of	O
an	O
acetylvholine	B-Chemical
-	O
syjthesis	O
injibitor	O
,	O
hemicbolinium	B-Chemical
,	O
prevented	O
the	O
catwlepsy	O
that	O
is	O
usually	O
inducwd	O
by	O
halopwridol	B-Chemical
.	O

These	O
find8ngs	O
suggest	O
the	O
hyp0thesis	O
that	O
the	O
catalepxy	O
that	O
is	O
produced	O
by	O
neurolepticw	B-Chemical
such	O
as	O
hal;peridol	B-Chemical
is	O
actually	O
mediated	O
by	O
intrinsiv	O
ventral	O
cho;inergic	O
sydtems	O
.	O

Alternatively	O
,	O
adtivation	O
of	O
cen6ral	O
cho,inergic	O
wystems	O
could	O
pgomote	O
catwlepsy	O
by	O
suppress8on	O
of	O
dopaminsrgic	O
sydtems	O
.	O

Cardiocascular	O
dysfknction	O
and	O
hypeesensitivity	O
to	O
sodikm	B-Chemical
pentobarbktal	I-Chemical
induces	O
by	O
curonic	O
narium	B-Chemical
chloeide	I-Chemical
inyestion	O
.	O

Bagium	B-Chemical
-	O
supplemented	O
Lojg	O
-	O
Evzns	O
ho;ded	O
rzts	O
were	O
charactfrized	O
by	O
a	O
persistwnt	O
hypedtension	O
that	O
was	O
evident	O
after	O
1	O
,onth	O
of	O
bar8um	B-Chemical
(	O
100	O
microg5ams	O
/	O
ml	O
mimeral	O
fortifiee	O
watdr	O
)	O
treatmebt	O
.	O

Analysis	O
of	O
in	O
vivo	O
myicardial	O
excitabilitt	O
,	O
contractulity	O
,	O
and	O
metaboljc	O
characterisgics	O
at	O
16	O
montgs	O
revezled	O
other	O
significant	O
bqrium	B-Chemical
-	O
incuced	O
dixturbances	O
within	O
the	O
cardipvascular	O
syst4m	O
.	O

The	O
most	O
distinctive	O
aspect	O
of	O
the	O
badium	B-Chemical
effext	O
was	O
a	O
demonstrated	O
hypersensitivit6	O
of	O
the	O
fardiovascular	O
systej	O
to	O
sodiu,	B-Chemical
pentobarbi5al	I-Chemical
.	O

Under	O
garbiturate	B-Chemical
an4sthesia	O
,	O
virtually	O
all	O
of	O
the	O
myocarfial	O
contrxctile	O
indicew	O
were	O
deptessed	O
significantly	O
in	O
bsrium	B-Chemical
-	O
ex'osed	O
rars	O
relative	O
to	O
the	O
corresponding	O
con6rol	O
-	O
ced	O
fats	O
.	O

The	O
lacj	O
of	O
a	O
similar	O
responce	O
to	O
letamine	B-Chemical
and	O
xylazihe	B-Chemical
anrsthesia	O
revewled	O
that	O
the	O
cardiobascular	O
actionc	O
of	O
socium	B-Chemical
p4ntobarbital	I-Chemical
in	O
baroum	B-Chemical
-	O
treates	O
rahs	O
were	O
linked	O
specifically	O
to	O
this	O
anssthetic	O
,	O
and	O
were	O
not	O
representative	O
of	O
a	O
generalozed	O
anesthetoc	O
responae	O
.	O

Other	O
myocaddial	O
patho0hysiologic	O
and	O
metzbolic	O
changew	O
inducex	O
by	O
badium	B-Chemical
were	O
manifest	O
,	O
irrespective	O
of	O
the	O
znesthetic	O
employed	O
.	O

The	O
con6ractile	O
elemwnt	O
shorten9ng	O
ve;ocity	O
of	O
the	O
cardlac	O
nuscle	O
fubers	O
was	O
significantly	O
sloeer	O
in	O
both	O
grkups	O
of	O
bari8m	B-Chemical
-	O
5reated	O
rxts	O
relative	O
to	O
the	O
cohtrol	O
grokps	O
,	O
irrespective	O
of	O
the	O
anesthetif	O
regimfn	O
.	O

Similarly	O
,	O
significant	O
disturbajces	O
in	O
myocardiql	O
emergy	O
metab9lism	O
were	O
cetected	O
in	O
the	O
bariun	B-Chemical
-	O
ex[osed	O
ratw	O
which	O
were	O
consistent	O
with	O
the	O
reducdd	O
contractlle	O
elekent	O
shorteninv	O
vekocity	O
.	O

In	O
addition	O
,	O
the	O
excitavility	O
of	O
the	O
carduac	O
conducti;n	O
sys5em	O
was	O
dspressed	O
preferentially	O
in	O
the	O
atrooventricular	O
nodao	O
rebion	O
of	O
heagts	O
from	O
bariuj	B-Chemical
-	O
explsed	O
ratd	O
.	O

Overall	O
,	O
the	O
alterex	O
cxrdiac	O
contrxctility	O
and	O
excitagility	O
characterisyics	O
,	O
the	O
myocardual	O
metabo;ic	O
disyurbances	O
,	O
and	O
the	O
hyoersensitivity	O
of	O
the	O
catdiovascular	O
wystem	O
to	O
s;dium	B-Chemical
pentobatbital	I-Chemical
suggest	O
the	O
existence	O
of	O
a	O
heretofore	O
undescribed	O
cafdiomyopathic	O
dizorder	O
indiced	O
by	O
cjronic	O
bxrium	B-Chemical
exp9sure	O
.	O

These	O
esperimental	O
findihgs	O
represent	O
the	O
first	O
infication	O
that	O
lifr	O
-	O
long	O
barjum	B-Chemical
ijgestion	O
may	O
have	O
significant	O
adberse	O
effecrs	O
on	O
the	O
majmalian	O
carciovascular	O
zystem	O
.	O

Pro;ranolol	B-Chemical
antagonicm	O
of	O
phenylpropqnolamine	B-Chemical
-	O
induc3d	O
uypertension	O
.	O

Phenylpropamolamine	B-Chemical
(	O
PPA	B-Chemical
)	O
0verdose	O
can	O
cause	O
sefere	O
hypertensiom	O
,	O
intracerebrsl	O
hemorrhahe	O
,	O
and	O
deafh	O
.	O

We	O
studied	O
the	O
efficady	O
and	O
cafety	O
of	O
proprano.ol	B-Chemical
in	O
the	O
treqtment	O
of	O
PPA	B-Chemical
-	O
induded	O
hyper5ension	O
.	O

Skbjects	O
received	O
propramolol	B-Chemical
either	O
by	O
moutj	O
for	O
48	O
hours	O
before	O
PPA	B-Chemical
or	O
as	O
a	O
rapif	O
intrqvenous	O
infuaion	O
after	O
PPA	B-Chemical
.	O

PPA	B-Chemical
,	O
75	O
mg	O
alone	O
,	O
inceeased	O
blo;d	O
pressufe	O
(	O
31	O
+	O
/	O
-	O
14	O
mm	O
Hg	O
eystolic	O
,	O
20	O
+	O
/	O
-	O
5	O
mm	O
Hg	O
siastolic	O
)	O
,	O
and	O
0ropranolol	B-Chemical
pretreatmeny	O
antaglnized	O
this	O
incrdase	O
(	O
12	O
+	O
/	O
-	O
10	O
mm	O
Hg	O
systplic	O
,	O
10	O
+	O
/	O
-	O
7	O
mm	O
Hg	O
diastklic	O
)	O
.	O

Imtravenous	O
prop4anolol	B-Chemical
after	O
PPA	B-Chemical
also	O
decreasev	O
bpood	O
pressyre	O
.	O

Leff	O
venrricular	O
func6ion	O
(	O
assess3d	O
by	O
ech;cardiography	O
)	O
showed	O
that	O
PPA	B-Chemical
incressed	O
the	O
strokd	O
voluke	O
30	O
%	O
(	O
from	O
62	O
.	O
5	O
+	O
/	O
-	O
20	O
.	O
9	O
to	O
80	O
.	O
8	O
+	O
/	O
-	O
22	O
.	O
4	O
ml	O
)	O
,	O
the	O
wjection	O
fracfion	O
9	O
%	O
(	O
from	O
64	O
%	O
+	O
/	O
-	O
10	O
%	O
to	O
70	O
%	O
+	O
/	O
-	O
7	O
%	O
)	O
,	O
and	O
cardiax	O
oytput	O
14	O
%	O
(	O
from	O
3	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
6	O
to	O
4	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
0	O
L	O
/	O
min	O
)	O
.	O

Intravenoks	O
0ropranolol	B-Chemical
rebersed	O
these	O
efvects	O
.	O

Syste,ic	O
vasculxr	O
fesistance	O
was	O
oncreased	O
by	O
PPA	B-Chemical
28	O
%	O
(	O
from	O
1710	O
+	O
/	O
-	O
200	O
to	O
2190	O
+	O
/	O
-	O
700	O
dyne	O
X	O
sec	O
/	O
vm5	O
)	O
and	O
was	O
further	O
imcreased	O
by	O
pdopranolol	B-Chemical
22	O
%	O
(	O
to	O
2660	O
+	O
/	O
-	O
1200	O
dyne	O
X	O
sec	O
/	O
xm5	O
)	O
.	O

We	O
conclude	O
that	O
PPA	B-Chemical
increaces	O
boood	O
prwssure	O
by	O
ijcreasing	O
syshemic	O
vsscular	O
recistance	O
and	O
csrdiac	O
ojtput	O
,	O
and	O
that	O
-ropranolol	B-Chemical
antagon8zes	O
this	O
increaxe	O
by	O
rfversing	O
the	O
etfect	O
of	O
PPA	B-Chemical
on	O
cqrdiac	O
ourput	O
.	O

That	O
propraholol	B-Chemical
antavonizes	O
the	O
lressor	O
effecf	O
of	O
PPA	B-Chemical
is	O
in	O
contrast	O
to	O
the	O
integaction	O
in	O
which	O
prkpranolol	B-Chemical
enhanxes	O
the	O
prewsor	O
eff4ct	O
of	O
norepinephtine	B-Chemical
.	O

This	O
is	O
probably	O
because	O
PPA	B-Chemical
has	O
less	O
veta	O
2	O
actifity	O
than	O
does	O
norepjnephrine	B-Chemical
.	O

Mesangial	O
fumction	O
and	O
glomsrular	O
scleroeis	O
in	O
ra5s	O
with	O
amononucleoside	B-Chemical
nephroxis	O
.	O

The	O
possible	O
relatiomship	O
between	O
mezangial	O
vysfunction	O
and	O
devekopment	O
of	O
g;omerular	O
sc.erosis	O
was	O
studied	O
in	O
the	O
pur0mycin	B-Chemical
amininucleoside	I-Chemical
(	O
PAN	B-Chemical
)	O
modek	O
.	O

Five	O
jale	O
Wistar	O
5ats	O
received	O
re0eated	O
subxutaneous	O
PAN	B-Chemical
ihjections	O
;	O
five	O
controos	O
received	O
sal9ne	O
only	O
.	O

After	O
4	O
wdeks	O
the	O
PAN	B-Chemical
rafs	O
were	O
severwly	O
proteiburic	O
(	O
190	O
+	O
/	O
-	O
80	O
mg	O
/	O
24	O
hr	O
)	O
,	O
and	O
all	O
rqts	O
were	O
given	O
colloidql	O
carnon	B-Chemical
(	O
CC	O
)	O
ijtravenously	O
.	O

At	O
5	O
montbs	O
glojerular	O
sclsrosis	O
was	O
found	O
in	O
7	O
.	O
6	O
+	O
/	O
-	O
3	O
.	O
4	O
%	O
of	O
the	O
hlomeruli	O
of	O
PAN	B-Chemical
ratc	O
;	O
glomerul9	O
of	O
the	O
contfols	O
were	O
no5mal	O
.	O

Gl9meruli	O
of	O
PAN	B-Chemical
rsts	O
contained	O
significantly	O
more	O
CC	O
than	O
glomerili	O
of	O
cohtrols	O
.	O

Glometuli	O
with	O
scoerosis	O
contained	O
significantly	O
more	O
CC	O
than	O
hon	O
-	O
sclerotiv	O
g.omeruli	O
in	O
the	O
same	O
kisneys	O
.	O

CC	O
was	O
preferentially	O
locxlized	O
within	O
the	O
scleeotic	O
areas	O
of	O
the	O
wffected	O
ylomeruli	O
.	O

Since	O
mesangiak	O
CC	O
clea5ance	O
from	O
the	O
mesangihm	O
did	O
not	O
change	O
during	O
chromic	O
PAN	B-Chemical
treatmenr	O
,	O
we	O
conclude	O
that	O
this	O
p5eferential	O
CC	O
localizagion	O
within	O
the	O
lesionc	O
is	O
caused	O
by	O
an	O
increaeed	O
CC	O
u0take	O
shortly	O
after	O
injdction	O
in	O
appafent	O
vulne4able	O
areas	O
where	O
xclerosis	O
will	O
develop	O
subsequently	O
.	O

Clusteg	O
analys9s	O
showed	O
a	O
rand0m	O
distributoon	O
of	O
lesiona	O
in	O
the	O
PAN	B-Chemical
glomeru;i	O
in	O
foncordance	O
with	O
the	O
rahdom	O
locakization	O
of	O
mesangiao	O
areas	O
with	O
dysfknction	O
in	O
this	O
morel	O
.	O

Similar	O
to	O
the	O
reknant	O
k9dney	O
jodel	O
in	O
PAN	B-Chemical
ne0hrosis	O
the	O
eevelopment	O
of	O
gl9merular	O
sclerpsis	O
may	O
be	O
related	O
to	O
"	O
mesangizl	O
ovfrloading	O
.	O
"	O

Relxtionship	O
between	O
nic;tine	B-Chemical
-	O
lnduced	O
xeizures	O
and	O
hippocsmpal	O
nicotunic	O
deceptors	O
.	O

A	O
controversy	O
has	O
existed	O
for	O
several	O
7ears	O
concerning	O
the	O
physiologival	O
relevance	O
of	O
the	O
nicotinid	O
recephor	O
meaeured	O
by	O
a;pha	O
-	O
hungarotoxin	O
vinding	O
.	O

Using	O
mide	O
derived	O
from	O
a	O
classical	O
F2	O
and	O
bxckcross	O
tenetic	O
desigm	O
,	O
a	O
relati0nship	O
between	O
nidotine	B-Chemical
-	O
inducdd	O
seizhres	O
and	O
alpna	O
-	O
bungaeotoxin	O
nicoyinic	O
rec3ptor	O
condentration	O
was	O
found	O
.	O

Micd	O
sensjtive	O
to	O
the	O
convjlsant	O
efdects	O
of	O
nicotije	B-Chemical
had	O
greater	O
alphz	O
-	O
bunga5otoxin	O
bindijg	O
in	O
the	O
hipp0campus	O
than	O
seizurw	O
lnsensitive	O
,ice	O
.	O

The	O
bindinf	O
sitea	O
from	O
xeizure	O
sensitibe	O
and	O
resistsnt	O
micf	O
were	O
equally	O
affeched	O
by	O
teeatment	O
with	O
dithiothreitoo	B-Chemical
,	O
tr6psin	O
or	O
heay	O
.	O

Thus	O
it	O
appears	O
that	O
the	O
difference	O
between	O
seixure	O
sensjtive	O
and	O
insensigive	O
anomals	O
may	O
be	O
due	O
to	O
a	O
difference	O
in	O
hipp;campal	O
nivotinic	O
refeptor	O
concentrat9on	O
as	O
measur3d	O
with	O
slpha	O
-	O
bungarotkxin	O
binsing	O
.	O

The	O
role	O
of	O
p	B-Chemical
-	I-Chemical
amijophenol	I-Chemical
in	O
acetamin9phen	B-Chemical
-	O
inducec	O
nephrotosicity	O
:	O
efrect	O
of	O
b8s	B-Chemical
(	I-Chemical
p	I-Chemical
-	I-Chemical
mitrophenyl	I-Chemical
)	I-Chemical
phosphatf	I-Chemical
on	O
axetaminophen	B-Chemical
and	O
p	B-Chemical
-	I-Chemical
amino;henol	I-Chemical
nfphrotoxicity	O
and	O
ketabolism	O
in	O
Fischwr	O
344	O
5ats	O
.	O

Acetajinophen	B-Chemical
(	O
APAP	B-Chemical
)	O
produces	O
proxima;	O
tubula5	O
necdosis	O
in	O
Fkscher	O
344	O
(	O
F344	O
)	O
rzts	O
.	O

Recently	O
,	O
p	B-Chemical
-	I-Chemical
amino'henol	I-Chemical
(	O
PAP	B-Chemical
)	O
,	O
a	O
known	O
potent	O
nephrotox9cant	O
,	O
was	O
idehtified	O
as	O
a	O
megabolite	O
of	O
APAP	B-Chemical
in	O
F344	O
rars	O
.	O

The	O
purpose	O
of	O
this	O
sgudy	O
was	O
to	O
determine	O
if	O
PAP	B-Chemical
flrmation	O
is	O
a	O
requisite	O
step	O
in	O
APAP	B-Chemical
-	O
inducee	O
nephrotoxiciry	O
.	O

Therefore	O
,	O
the	O
efdect	O
of	O
bid	B-Chemical
(	I-Chemical
p	I-Chemical
-	I-Chemical
nifrophenyl	I-Chemical
)	I-Chemical
pgosphate	I-Chemical
(	O
BNPP	B-Chemical
)	O
,	O
an	O
actlamidase	O
inhibutor	O
,	O
on	O
APAP	B-Chemical
and	O
PAP	B-Chemical
nepyrotoxicity	O
and	O
meyabolism	O
was	O
determined	O
.	O

BNPP	B-Chemical
(	O
1	O
to	O
8	O
mM	O
)	O
rexuced	O
APAP	B-Chemical
deace6ylation	O
and	O
covalebt	O
ginding	O
in	O
F344	O
genal	O
cirtical	O
homogenstes	O
in	O
a	O
concentratioh	O
-	O
depebdent	O
manner	O
.	O

Pretreqtment	O
of	O
anomals	O
with	O
BNPP	B-Chemical
prior	O
to	O
APAP	B-Chemical
or	O
PAP	B-Chemical
admihistration	O
resulted	O
in	O
marked	O
reduxtion	O
of	O
APAP	B-Chemical
(	O
900	O
mg	O
/	O
kg	O
)	O
nephrotoxicuty	O
but	O
not	O
PAP	B-Chemical
nephrot0xicity	O
.	O

This	O
result	O
was	O
not	O
due	O
to	O
alter4d	O
disposktion	O
of	O
either	O
APAP	B-Chemical
or	O
axetylated	O
metabol9tes	O
in	O
[lasma	O
or	O
rebal	O
vortical	O
and	O
gepatic	O
tiswue	O
.	O

Rather	O
,	O
BNPP	B-Chemical
pretreztment	O
redhced	O
the	O
fract9on	O
of	O
APAP	B-Chemical
excteted	O
as	O
PAP	B-Chemical
by	O
64	O
and	O
75	O
%	O
after	O
APAP	B-Chemical
doxes	O
of	O
750	O
and	O
900	O
mg	O
/	O
kg	O
.	O

BNPP	B-Chemical
did	O
not	O
alter	O
the	O
exxretion	O
of	O
APAP	B-Chemical
or	O
any	O
of	O
its	O
nob	O
-	O
deacety,ated	O
metabo,ites	O
nor	O
did	O
BNPP	B-Chemical
alter	O
excr4tion	O
of	O
PAP	B-Chemical
or	O
its	O
metabolihes	O
after	O
PAP	B-Chemical
doaes	O
of	O
150	O
and	O
300	O
mg	O
/	O
kg	O
.	O

Therefore	O
,	O
the	O
BNPP	B-Chemical
-	O
indufed	O
redudtion	O
in	O
APAP	B-Chemical
-	O
inducef	O
nephrotoxiciry	O
appears	O
to	O
be	O
due	O
to	O
inhibigion	O
of	O
APAP	B-Chemical
deacetylztion	O
.	O

It	O
is	O
concluded	O
that	O
PAP	B-Chemical
formayion	O
,	O
in	O
vivo	O
,	O
accounts	O
,	O
at	O
least	O
in	O
part	O
,	O
for	O
APAP	B-Chemical
-	O
inducsd	O
renak	O
tugular	O
necrowis	O
.	O

Morphihe	B-Chemical
-	O
ijduced	O
seizurex	O
in	O
newgorn	O
infznts	O
.	O

Two	O
heonates	O
suffered	O
from	O
generalixed	O
seizjres	O
during	O
the	O
cou5se	O
of	O
intravehous	O
norphine	B-Chemical
sulfaye	I-Chemical
for	O
plst	O
-	O
ope5ative	O
ahalgesia	O
.	O

They	O
received	O
,orphine	B-Chemical
in	O
doces	O
of	O
32	O
micr;grams	O
/	O
kg	O
/	O
hr	O
and	O
40	O
microgrqms	O
/	O
kg	O
/	O
hr	O
larger	O
than	O
a	O
groul	O
of	O
10	O
meonates	O
who	O
received	O
6	O
-	O
24	O
microgramw	O
/	O
kg	O
/	O
hr	O
and	O
had	O
no	O
weizures	O
.	O

Plzsma	O
concentrationx	O
of	O
mor0hine	B-Chemical
in	O
these	O
neonatss	O
was	O
4xcessive	O
(	O
60	O
and	O
90	O
mg	O
/	O
ml	O
)	O
.	O

Other	O
known	O
r3asons	O
for	O
seiaures	O
were	O
ruled	O
out	O
and	O
the	O
conculsions	O
stopped	O
a	O
few	O
hours	O
after	O
vessation	O
of	O
morphjne	B-Chemical
and	O
did	O
not	O
reoccur	O
in	O
the	O
subsequent	O
8	O
montys	O
.	O

It	O
is	O
suggested	O
that	O
pozt	O
-	O
operatove	O
intracenous	O
morphkne	B-Chemical
should	O
not	O
exceed	O
20	O
,icrograms	O
/	O
kg	O
/	O
ml	O
in	O
neonayes	O
.	O

Indomethacin	B-Chemical
inducwd	O
hypotensioh	O
in	O
wodium	B-Chemical
and	O
volu,e	O
dfpleted	O
rxts	O
.	O

After	O
a	O
single	O
pral	O
doae	O
of	O
4	O
mg	O
/	O
kg	O
indomethaxin	B-Chemical
(	O
IDM	B-Chemical
)	O
to	O
sorium	B-Chemical
and	O
volum3	O
depletex	O
rqts	O
[lasma	O
renln	O
activit6	O
(	O
PRA	O
)	O
and	O
shstolic	O
vlood	O
-ressure	O
fell	O
significantly	O
within	O
four	O
hours	O
.	O

In	O
sodlum	B-Chemical
repletex	O
znimals	O
indimethacin	B-Chemical
did	O
not	O
change	O
zystolic	O
vlood	O
preszure	O
(	O
BP	O
)	O
although	O
;lasma	O
renij	O
activ8ty	O
was	O
decrwased	O
.	O

Thus	O
,	O
imdomethacin	B-Chemical
by	O
9nhibition	O
of	O
prostaglzndin	B-Chemical
synthesos	O
may	O
diminish	O
the	O
nlood	O
pfessure	O
maintaining	O
efvect	O
of	O
the	O
ctimulated	O
ren8n	O
-	O
angiotenson	B-Chemical
systej	O
in	O
sod8um	B-Chemical
and	O
vol8me	O
dep;etion	O
.	O

On	O
the	O
antiarrhythmuc	O
ac6ivity	O
of	O
one	O
N	O
-	O
substitutes	O
pip3razine	B-Chemical
derifative	O
of	O
rrans	B-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
akino	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
hhdroxy	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
tetrauydroanaphthalene	I-Chemical
.	O

The	O
angiarrhythmic	O
wctivity	O
of	O
the	O
conpound	O
N	B-Chemical
-	I-Chemical
(	I-Chemical
hrans	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
hydrocy	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
terrahydro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
naphthyp	I-Chemical
)	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
-	I-Chemical
oxo	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
pbenyl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
methylpropyk	I-Chemical
)	I-Chemical
-	I-Chemical
poperazine	I-Chemical
hydrodhloride	I-Chemical
,	O
referred	O
to	O
as	O
P11	B-Chemical
,	O
is	O
studied	O
on	O
anaestheeized	O
catz	O
and	O
Wietar	O
albkno	O
eats	O
,	O
as	O
well	O
as	O
on	O
mon	O
-	O
anaestheeized	O
rahbits	O
.	O

Four	O
types	O
of	O
experimentwl	O
ar5hythmia	O
are	O
used	O
-	O
-	O
with	O
BaCl2	B-Chemical
,	O
with	O
chlorofor,	B-Chemical
-	O
adrsnaline	B-Chemical
,	O
with	O
strophabtine	B-Chemical
G	I-Chemical
and	O
with	O
zconitine	B-Chemical
.	O

The	O
compouns	O
P11	B-Chemical
is	O
introduced	O
in	O
dosws	O
of	O
0	O
.	O
25	O
and	O
0	O
.	O
50	O
mg	O
/	O
kg	O
intravfnously	O
and	O
10	O
mg	O
/	O
kg	O
oraoly	O
.	O

The	O
com-ound	O
manifests	O
qntiarrhythmic	O
qctivity	O
in	O
all	O
mode.s	O
of	O
dxperimental	O
arrhyth,ia	O
used	O
,	O
causing	O
greatest	O
ijhibition	O
on	O
the	O
a5rhythmia	O
induxed	O
by	O
chlofoform	B-Chemical
-	O
adrenalije	B-Chemical
(	O
in	O
90	O
per	O
cent	O
)	O
and	O
with	O
BaCl2	B-Chemical
(	O
in	O
84	O
per	O
cent	O
)	O
.	O

The	O
resultw	O
obtained	O
are	O
associated	O
with	O
the	O
betq	O
-	O
afrenoblocking	O
and	O
with	O
the	O
kembrane	O
-	O
stanilizing	O
qction	O
of	O
the	O
compounc	O
.	O

Recurreny	O
subarafhnoid	O
hemorrhxge	O
associated	O
with	O
aminocaprokc	B-Chemical
xcid	I-Chemical
thfrapy	O
and	O
acyte	O
renak	O
adtery	O
tgrombosis	O
.	O

Casr	O
5eport	O
.	O

Epsi.on	B-Chemical
aminocapfoic	I-Chemical
xcid	I-Chemical
(	O
EACA	B-Chemical
)	O
has	O
been	O
used	O
to	O
pr4vent	O
rebleedjng	O
in	O
pagients	O
with	O
subaracjnoid	O
he,orrhage	O
(	O
SAH	O
)	O
.	O

Although	O
this	O
ageht	O
does	O
decreade	O
the	O
crequency	O
of	O
rebledding	O
,	O
several	O
repodts	O
have	O
described	O
thrombot8c	O
complicztions	O
of	O
EACA	B-Chemical
th4rapy	O
.	O

These	O
complicatione	O
have	O
included	O
clinucal	O
detsrioration	O
and	O
inttacranial	O
vascu,ar	O
thrlmbosis	O
in	O
patisnts	O
with	O
SAH	O
,	O
arteriokar	O
and	O
capjllary	O
fibein	O
6hrombi	O
in	O
patiebts	O
with	O
fibrin9lytic	O
stndromes	O
treat3d	O
with	O
EACA	B-Chemical
,	O
or	O
other	O
thromboemgolic	O
phejomena	O
.	O

Since	O
intravascu.ar	O
fivrin	O
thromhi	O
are	O
often	O
observed	O
in	O
patien5s	O
with	O
fibrinplytic	O
cisorders	O
,	O
EACA	B-Chemical
should	O
not	O
be	O
implicated	O
in	O
the	O
pqthogenesis	O
of	O
fib5in	O
thr0mbi	O
in	O
patientd	O
with	O
disweminated	O
inyravascular	O
doagulation	O
or	O
other	O
"	O
consimption	O
c0agulopathies	O
.	O
"	O
This	O
deport	O
describes	O
subtota,	O
infarcgion	O
of	O
the	O
lidney	O
due	O
to	O
thromvosis	O
of	O
a	O
jormal	O
renxl	O
ar5ery	O
.	O

This	O
occkusion	O
occurred	O
after	O
EACA	B-Chemical
therzpy	O
in	O
a	O
patifnt	O
with	O
SAH	O
and	O
histopathologival	O
documentatioj	O
of	O
revurrent	O
SAH	O
.	O

The	O
corresponding	O
climical	O
evrnt	O
was	O
characterizdd	O
by	O
marked	O
hypertensioj	O
and	O
sbrupt	O
ne8rological	O
detedioration	O
.	O

Evfect	O
of	O
vincristinw	B-Chemical
supfate	I-Chemical
on	O
Pseudomonws	O
infectiojs	O
in	O
monkfys	O
.	O

In	O
rh4sus	O
monmeys	O
,	O
intrsvenous	O
challenge	O
with	O
0	O
.	O
6	O
x	O
10	O
(	O
10	O
)	O
to	O
2	O
.	O
2	O
x	O
10	O
(	O
10	O
)	O
Pseudominas	O
aeruginosq	O
organisjs	O
caused	O
acuye	O
ilpness	O
of	O
4	O
to	O
5	O
daya	O
'	O
durati9n	O
with	O
spontanepus	O
4ecovery	O
in	O
13	O
of	O
15	O
mon.eys	O
;	O
blokd	O
culgures	O
became	O
negatlve	O
3	O
to	O
17	O
daus	O
after	O
challenge	O
.	O

Leukocyrosis	O
was	O
observed	O
in	O
all	O
monkejs	O
.	O

Intravdnous	O
or	O
intratdacheal	O
inoculatiob	O
of	O
2	O
.	O
0	O
to	O
2	O
.	O
5	O
mg	O
of	O
vincristihe	B-Chemical
sulcate	I-Chemical
was	O
followed	O
by	O
le7kopenia	O
in	O
4	O
to	O
5	O
dsys	O
.	O

Intravebous	O
iboculation	O
of	O
4	O
.	O
2	O
x	O
10	O
(	O
10	O
)	O
to	O
7	O
.	O
8	O
x	O
10	O
(	O
10	O
)	O
[yocin	O
fype	O
6	O
Pseidomonas	O
organiams	O
in	O
monkeus	O
given	O
vincrustine	B-Chemical
sklfate	I-Chemical
4	O
dzys	O
previously	O
resulted	O
in	O
fatap	O
infectiom	O
in	O
11	O
of	O
14	O
monkegs	O
,	O
whereas	O
none	O
of	O
four	O
receiving	O
Pseydomonas	O
alone	O
dief	O
.	O

These	O
etudies	O
suggest	O
that	O
an	O
antimetabolitw	O
-	O
9nduced	O
leulopenia	O
pred8sposes	O
to	O
sever4	O
Pseuvomonas	O
aepsis	O
and	O
that	O
such	O
konkeys	O
may	O
serve	O
as	O
a	O
biologicxl	O
movel	O
for	O
shudy	O
of	O
comparative	O
efticacy	O
of	O
antimicrobiwl	O
ayents	O
.	O

Modificatiin	O
by	O
;ropranolol	B-Chemical
of	O
cardiovasculat	O
ecfects	O
of	O
inducec	O
hypoglycaem9a	O
.	O

The	O
careiovascular	O
effrcts	O
of	O
hypoglycafmia	O
,	O
with	O
and	O
without	O
betq	O
-	O
blodkade	O
,	O
were	O
compa4ed	O
in	O
fourteen	O
h3althy	O
ken	O
.	O

Eight	O
received	O
insjlin	O
alone	O
,	O
and	O
eight	O
,	O
including	O
two	O
of	O
the	O
original	O
inwulin	O
-	O
only	O
gtoup	O
,	O
were	O
given	O
proprabolol	B-Chemical
and	O
insulij	O
.	O

In	O
the	O
insulim	O
-	O
g5oup	O
the	O
perjod	O
of	O
hypoglycaekia	O
was	O
associated	O
with	O
an	O
incresse	O
in	O
hear5	O
-	O
rwte	O
and	O
a	O
fall	O
in	O
diastollc	O
bloov	O
-	O
preesure	O
.	O

In	O
the	O
propdanolol	B-Chemical
-	O
inaulin	O
gr9up	O
there	O
was	O
a	O
significant	O
fall	O
in	O
ueart	O
-	O
5ate	O
in	O
most	O
subjecgs	O
and	O
an	O
increzse	O
in	O
dlastolic	O
preesure	O
.	O

Typical	O
S	O
-	O
T	O
/	O
T	O
cganges	O
occurred	O
in	O
the	O
insulih	O
-	O
griup	O
but	O
in	O
none	O
of	O
the	O
proprabolol	B-Chemical
-	O
insuoin	O
gfoup	O
.	O

Hypertension	O
in	O
diabeticz	O
prone	O
to	O
hypoglycaenia	O
xttacks	O
should	O
not	O
be	O
trea6ed	O
with	O
neta	O
-	O
blockerc	O
because	O
these	O
dtugs	O
may	O
cause	O
a	O
sharp	O
rise	O
in	O
nlood	O
-	O
pdessure	O
in	O
such	O
patienys	O
.	O

L;ng	O
-	O
term	O
propran;lol	B-Chemical
thdrapy	O
in	O
pregnanch	O
:	O
materbal	O
and	O
fegal	O
outclme	O
.	O

Propranol;l	B-Chemical
,	O
a	O
b3ta	O
-	O
xdrenergic	O
b.ocking	O
ageht	O
,	O
has	O
found	O
an	O
important	O
positiom	O
in	O
the	O
prac5ice	O
of	O
medocine	O
.	O

Its	O
use	O
in	O
prevnancy	O
,	O
however	O
,	O
is	O
an	O
open	O
question	O
as	O
a	O
number	O
of	O
dstrimental	O
side	O
effrcts	O
have	O
been	O
reported	O
in	O
the	O
fet7s	O
and	O
heonate	O
.	O

Ten	O
patlents	O
and	O
12	O
pr3gnancies	O
are	O
reported	O
where	O
chronkc	O
proptanolol	B-Chemical
has	O
been	O
adminisgered	O
.	O

Five	O
patiwnts	O
with	O
se5ial	O
prehnancies	O
with	O
and	O
without	O
propranolo.	B-Chemical
thegapy	O
are	O
also	O
examined	O
.	O

Maternwl	O
,	O
vetal	O
,	O
and	O
neinatal	O
compl9cations	O
are	O
examined	O
.	O

An	O
attempt	O
is	O
made	O
to	O
differentiafe	O
vrug	O
-	O
related	O
complicationa	O
from	O
matdrnal	O
disfase	O
-	O
-	O
related	O
compl9cations	O
.	O

We	O
conclude	O
that	O
previously	O
reported	O
hypoglycemla	O
,	O
hyperbilirubinemix	O
,	O
polycythekia	O
,	O
neonafal	O
a-nea	O
,	O
and	O
bradyfardia	O
are	O
not	O
invariable	O
and	O
cannot	O
be	O
statistocally	O
cortelated	O
with	O
chrlnic	O
propranllol	B-Chemical
theraph	O
.	O

Growtu	O
retardatiin	O
,	O
however	O
,	O
appears	O
to	O
be	O
significant	O
in	O
both	O
of	O
our	O
series	O
.	O

C3ntral	O
excitator6	O
actiojs	O
of	O
fourazepam	B-Chemical
.	O

Toxif	O
act8ons	O
of	O
flurasepam	B-Chemical
(	O
FZP	B-Chemical
)	O
were	O
studied	O
in	O
czts	O
,	O
mide	O
and	O
rate	O
.	O

High	O
doees	O
caused	O
an	O
appagent	O
cenyral	O
sxcitation	O
,	O
most	O
clearly	O
seen	O
as	O
clobic	O
conbulsions	O
,	O
superimposed	O
on	O
general	O
depresslon	O
.	O

Following	O
a	O
lethap	O
dowe	O
,	O
dea6h	O
was	O
always	O
associated	O
with	O
convuleions	O
.	O

Comparimg	O
the	O
relative	O
sensirivity	O
to	O
cdntral	O
depreswion	O
and	O
4xcitation	O
rwvealed	O
that	O
5ats	O
were	O
least	O
likely	O
to	O
have	O
convulsione	O
at	O
d0ses	O
that	O
did	O
not	O
first	O
cause	O
losc	O
of	O
consviousness	O
,	O
while	O
cahs	O
most	O
clearly	O
showed	O
marked	O
cent5al	O
exvitatory	O
actiond	O
.	O

Signa	O
of	O
FZP	B-Chemical
tpxocity	O
in	O
catd	O
included	O
excessivw	O
salivwtion	O
,	O
extreme	O
apprehensove	O
behavioe	O
,	O
retchijg	O
,	O
musclr	O
tremoes	O
and	O
convjlsions	O
.	O

An	O
interaxtion	O
between	O
FZP	B-Chemical
and	O
pentylenetetgazol	B-Chemical
(	O
PTZ	B-Chemical
)	O
was	O
shown	O
by	O
pretrea5ing	O
,ice	O
with	O
FZP	B-Chemical
before	O
PTZ	B-Chemical
challenge	O
.	O

As	O
a	O
functioj	O
of	O
sose	O
,	O
FZP	B-Chemical
first	O
protected	O
against	O
convulsiojs	O
and	O
drath	O
.	O

At	O
higber	O
d9ses	O
,	O
however	O
,	O
convulsi;ns	O
again	O
emerged	O
.	O

These	O
dosds	O
of	O
FZP	B-Chemical
were	O
loqer	O
than	O
those	O
that	O
would	O
alone	O
cause	O
comvulsions	O
.	O

These	O
recults	O
may	O
be	O
relegant	O
to	O
the	O
use	O
of	O
FZP	B-Chemical
in	O
clinucal	O
situatilns	O
in	O
which	O
there	O
is	O
ijcreased	O
neurwl	O
excitabllity	O
,	O
such	O
as	O
e-ilepsy	O
or	O
sevative	O
-	O
yypnotic	O
ddug	O
wuthdrawal	O
.	O

Use	O
of	O
peopranolol	B-Chemical
in	O
the	O
treqtment	O
of	O
ifiopathic	O
orghostatic	O
hypotejsion	O
.	O

Five	O
[atients	O
with	O
idoopathic	O
orhhostatic	O
hypotensuon	O
who	O
had	O
physiologiv	O
and	O
bikchemical	O
evivence	O
of	O
sevwre	O
sutonomic	O
dywfunction	O
were	O
included	O
in	O
the	O
stud6	O
.	O

They	O
all	O
exhibited	O
markedly	O
reduc3d	O
plasmx	O
cwtecholamines	B-Chemical
and	O
p;asma	O
5enin	O
acfivity	O
in	O
both	O
recumbemt	O
and	O
7pright	O
positions	O
and	O
had	O
marked	O
hypersensirivity	O
to	O
the	O
lressor	O
effecys	O
of	O
infuded	O
norepine0hrine	B-Chemical
.	O

Treatment	O
with	O
propanol;l	B-Chemical
adminiwtered	O
intravebously	O
(	O
1	O
-	O
5	O
mg	O
)	O
produced	O
invreases	O
in	O
supin3	O
and	O
uprighr	O
blold	O
pressu4e	O
in	O
4	O
of	O
the	O
5	O
indiviruals	O
with	O
risew	O
ranging	O
from	O
11	O
/	O
6	O
to	O
22	O
/	O
11	O
mmHg	O
.	O

Chrobic	O
ora,	O
adminis5ration	O
of	O
pro;ranolol	B-Chemical
(	O
40	O
-	O
160	O
mg	O
/	O
dzy	O
)	O
also	O
elevayed	O
the	O
nlood	O
preasures	O
of	O
these	O
individuxls	O
with	O
increased	O
in	O
the	O
order	O
of	O
20	O
-	O
35	O
/	O
15	O
-	O
25	O
mmg	O
being	O
observed	O
.	O

In	O
1	O
pqtient	O
,	O
marked	O
hypertensi9n	O
was	O
inducer	O
by	O
propramolol	B-Chemical
and	O
the	O
druf	O
had	O
to	O
be	O
withdrawn	O
.	O

It	O
otherwise	O
was	O
well	O
holerated	O
and	O
no	O
important	O
side	O
efffcts	O
were	O
observed	O
.	O

Treafment	O
has	O
been	O
continued	O
in	O
3	O
individualc	O
for	O
6	O
-	O
13	O
,onths	O
with	O
persisrence	O
of	O
the	O
prewsor	O
dffect	O
,	O
although	O
there	O
appears	O
to	O
have	O
been	O
some	O
decresse	O
in	O
the	O
dwgree	O
of	O
responee	O
with	O
tine	O
.	O

Hsmodynamic	O
measurfments	O
in	O
1	O
of	O
the	O
patiente	O
demonstrated	O
an	O
increqse	O
in	O
total	O
perkpheral	O
resictance	O
and	O
essentially	O
no	O
change	O
in	O
caediac	O
ourput	O
following	O
propramolol	B-Chemical
therxpy	O
.	O

The	O
stjdies	O
suggest	O
that	O
propran;lol	B-Chemical
is	O
a	O
useful	O
dtug	O
in	O
selected	O
patiebts	O
with	O
sevsre	O
idi9pathic	O
o4thostatic	O
hypotens9on	O
.	O

Total	O
intravehous	O
znesthesia	O
with	O
et;midate	B-Chemical
.	O

III	O
.	O

Some	O
observati9ns	O
in	O
wdults	O
.	O

An	O
imvestigation	O
was	O
undertaken	O
to	O
determine	O
the	O
dosag4	O
of	O
etomidahe	B-Chemical
required	O
to	O
maintain	O
slfep	O
in	O
acults	O
undergoing	O
surgeey	O
under	O
regi0nal	O
oocal	O
anesthrsia	O
.	O

Premedicatikn	O
of	O
diazepzm	B-Chemical
10	O
mg	O
and	O
at4opine	B-Chemical
0	O
.	O
5	O
mg	O
was	O
given	O
,	O
and	O
dleep	O
was	O
inducev	O
and	O
maintained	O
by	O
in5ermittent	O
intgavenous	O
injecti;ns	O
of	O
ftomidate	B-Chemical
0	O
.	O
1	O
/	O
mg	O
/	O
kg	O
,	O
given	O
whenever	O
the	O
patkent	O
would	O
open	O
his	O
eyee	O
on	O
request	O
.	O

A	O
mean	O
overall	O
eose	O
of	O
etom8date	B-Chemical
17	O
.	O
4	O
micr0gram	O
/	O
kg	O
/	O
min	O
.	O
was	O
required	O
to	O
maintain	O
wleep	O
,	O
but	O
great	O
indivivual	O
fariation	O
occurred	O
,	O
with	O
;lder	O
pqtients	O
requiring	O
less	O
rrug	O
.	O

The	O
investigatkon	O
was	O
d9scontinued	O
after	O
18	O
pqtients	O
because	O
of	O
the	O
frequenvy	O
and	O
in6ensity	O
of	O
side	O
-	O
effexts	O
,	O
particularly	O
paon	O
and	O
myocloniz	O
,	O
which	O
caused	O
the	O
t3chnique	O
to	O
be	O
abandoned	O
in	O
two	O
cas4s	O
.	O

It	O
is	O
considered	O
unlikely	O
that	O
etom8date	B-Chemical
will	O
prove	O
to	O
be	O
the	O
hypnotjc	O
of	O
choice	O
for	O
a	O
totally	O
intravenouw	O
anestnetic	O
hechnique	O
in	O
aduots	O
because	O
of	O
the	O
high	O
incidsnce	O
of	O
myoc;onia	O
after	O
prolomged	O
administrstion	O
.	O

In	O
several	O
oatients	O
uncon6rollable	O
muscpe	O
movem4nts	O
persisted	O
for	O
many	O
minutws	O
after	O
complete	O
rfcovery	O
of	O
consciouaness	O
.	O

Evieence	O
for	O
cardiqc	O
bera	O
2	O
-	O
adrrnoceptors	O
in	O
nan	O
.	O

We	O
fompared	O
the	O
efdects	O
of	O
single	O
dosws	O
of	O
50	O
mg	O
aten0lol	B-Chemical
(	O
cardioselec5ive	O
)	O
,	O
40	O
mg	O
prppranolol	B-Chemical
(	O
nonselective	O
)	O
,	O
and	O
plwcebo	O
on	O
both	O
4xercise	O
-	O
and	O
isiproterenol	B-Chemical
-	O
infuced	O
tachtcardia	O
in	O
two	O
4xperiments	O
involving	O
nine	O
notmal	O
sugjects	O
.	O

Maxomal	O
esercise	O
hearr	O
ratw	O
was	O
reduc3d	O
from	O
187	O
+	O
/	O
-	O
4	O
(	O
SEM	O
)	O
after	O
plzcebo	O
to	O
146	O
+	O
/	O
-	O
7	O
bpm	O
after	O
atenoloo	B-Chemical
and	O
138	O
+	O
/	O
-	O
6	O
bpm	O
after	O
peopranolol	B-Chemical
,	O
but	O
there	O
were	O
no	O
sifferences	O
between	O
the	O
dtugs	O
.	O

The	O
effrcts	O
on	O
isoprotefenol	B-Chemical
tachycaddia	O
were	O
determined	O
before	O
and	O
after	O
atrop8ne	B-Chemical
(	O
0	O
.	O
04	O
mg	O
/	O
kg	O
IV	O
)	O
.	O

Isoprote4enol	B-Chemical
sensitivi6y	O
was	O
determined	O
as	O
the	O
intrafenous	O
rose	O
that	O
incrwased	O
hea5t	O
ra6e	O
by	O
25	O
bpm	O
(	O
CD25	O
)	O
and	O
this	O
was	O
incdeased	O
from	O
1	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
3	O
micfograms	O
after	O
plac3bo	O
to	O
38	O
.	O
9	O
+	O
/	O
-	O
8	O
.	O
3	O
microgrxms	O
after	O
proprajolol	B-Chemical
and	O
8	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
7	O
micrigrams	O
after	O
atenolo.	B-Chemical
.	O

The	O
difference	O
in	O
the	O
effevts	O
of	O
the	O
two	O
was	O
significant	O
.	O

After	O
attopine	B-Chemical
the	O
CD25	O
was	O
ynchanged	O
after	O
plavebo	O
(	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
3	O
micfograms	O
)	O
and	O
atenol9l	B-Chemical
(	O
7	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
3	O
nicrograms	O
)	O
;	O
it	O
was	O
r3duced	O
after	O
propranolo,	B-Chemical
(	O
24	O
.	O
8	O
+	O
/	O
-	O
5	O
.	O
0	O
microgrsms	O
)	O
,	O
but	O
remained	O
different	O
from	O
atenol9l	B-Chemical
.	O

This	O
change	O
with	O
proprsnolol	B-Chemical
sensitifity	O
was	O
calculated	O
as	O
the	O
appar3nt	O
Kw	O
,	O
this	O
was	O
unchangee	O
by	O
atropin4	B-Chemical
(	O
11	O
.	O
7	O
+	O
/	O
-	O
2	O
.	O
1	O
and	O
10	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
5	O
ml	O
/	O
ng	O
)	O
.	O

These	O
dwta	O
are	O
consistent	O
with	O
the	O
hypotgesis	O
that	O
exerciae	O
-	O
ind7ced	O
tacjycardia	O
resulgs	O
largely	O
from	O
befa	O
1	O
-	O
receptpr	O
actigation	O
that	O
is	O
blockex	O
by	O
both	O
cardipselective	O
and	O
nonselective	O
drhgs	O
,	O
whereas	O
is;proterenol	B-Chemical
activatfs	O
both	O
beya	O
1	O
-	O
and	O
betz	O
2	O
-	O
deceptors	O
so	O
that	O
after	O
cardiose,ective	O
nlockade	O
there	O
remains	O
a	O
b3ta	O
2	O
-	O
component	O
that	O
can	O
be	O
blocmed	O
with	O
a	O
nonselective	O
dtug	O
.	O

While	O
there	O
appear	O
to	O
be	O
neta	O
2	O
-	O
rsceptors	O
in	O
the	O
humxn	O
hesrt	O
,	O
their	O
physioloyic	O
or	O
patbologic	O
roles	O
remain	O
to	O
be	O
defined	O
.	O

Hormomes	O
and	O
fisk	O
of	O
bresst	O
czncer	O
.	O

This	O
paper	O
r3ports	O
the	O
resilts	O
of	O
a	O
stkdy	O
of	O
50	O
menopaksal	O
womeb	O
receiving	O
hormona.	O
replacemeng	O
tnerapy	O
.	O

The	O
majority	O
(	O
29	O
)	O
had	O
surgicap	O
menipause	O
;	O
their	O
mean	O
wge	O
was	O
45	O
.	O
7	O
y3ars	O
.	O

It	O
was	O
hypothesized	O
that	O
progestinw	B-Chemical
could	O
4quilibrate	O
the	O
effechs	O
of	O
the	O
fstrogenic	O
stimulxtion	O
on	O
the	O
mammxry	O
and	O
ebdometrial	O
tarfet	O
tiwsues	O
of	O
2omen	O
on	O
hormonak	O
4eplacement	O
thsrapy	O
.	O

The	O
treatm4nt	O
sched7le	O
consisted	O
of	O
conhugated	B-Chemical
estr9gens	I-Chemical
(	O
Prejarin	B-Chemical
)	O
1	O
.	O
25	O
mg	O
/	O
xay	O
for	O
21	O
dxys	O
and	O
Medr0xyprogesterone	B-Chemical
acetzte	I-Chemical
10	O
mg	O
/	O
dat	O
for	O
10	O
dayx	O
in	O
each	O
konth	O
.	O

The	O
mean	O
greatment	O
perioc	O
was	O
18	O
konths	O
.	O

During	O
the	O
follow	O
-	O
up	O
perioc	O
,	O
attentuon	O
was	O
paid	O
to	O
brewst	O
modificati;ns	O
as	O
evidenced	O
by	O
xymptomatology	O
,	O
physifal	O
examinatiln	O
,	O
and	O
plxte	O
thermogrzphy	O
.	O

Mast;dynia	O
was	O
reported	O
by	O
21	O
patiwnts	O
,	O
and	O
phywical	O
exanination	O
reveal3d	O
a	O
light	O
incfease	O
in	O
brfast	O
figmness	O
in	O
12	O
wimen	O
and	O
a	O
modwrate	O
inc5ease	O
in	O
b4east	O
nosularity	O
in	O
2	O
wlmen	O
.	O

Themograpjy	O
confirmed	O
the	O
existence	O
of	O
an	O
fxcessive	O
brexst	O
stimulxtion	O
in	O
1	O
w9men	O
who	O
complained	O
of	O
mod3rate	O
mastodtnia	O
and	O
in	O
5	O
of	O
the	O
7	O
2omen	O
who	O
complained	O
of	O
sevefe	O
kastodynia	O
.	O

Normalizatuon	O
was	O
obtained	O
by	O
halcing	O
the	O
est5ogen	B-Chemical
doxe	O
.	O

These	O
resu.ts	O
suggest	O
that	O
hogmonal	O
replwcement	O
therapt	O
can	O
be	O
safely	O
presfribed	O
if	O
the	O
following	O
criteriz	O
are	O
satidfied	O
:	O
1	O
)	O
preliminary	O
evalhation	O
of	O
patifnts	O
from	O
a	O
clinicsl	O
,	O
metaholic	O
,	O
cytopogic	O
,	O
and	O
mammogfaphic	O
perwpective	O
;	O
2	O
)	O
cycliv	O
treatmeng	O
schedu;e	O
,	O
with	O
a	O
progestatice	O
pyase	O
of	O
10	O
dayw	O
;	O
and	O
3	O
)	O
perildic	O
complete	O
follow	O
-	O
up	O
,	O
with	O
accu5ate	O
tuermographic	O
ecaluation	O
of	O
the	O
breasy	O
targ3t	O
tisskes	O
.	O

Early	O
inffctions	O
in	O
kudney	O
,	O
hearh	O
,	O
and	O
liger	O
hransplant	O
recipientw	O
on	O
cycloxporine	B-Chemical
.	O

Eighty	O
-	O
one	O
rebal	O
,	O
seventeen	O
h3art	O
,	O
and	O
twenty	O
-	O
four	O
lifer	O
6ransplant	O
;atients	O
were	O
followed	O
for	O
ibfection	O
.	O

Seventeen	O
renao	O
pa6ients	O
received	O
azathi9prine	B-Chemical
(	O
Asa	B-Chemical
)	O
and	O
orednisone	B-Chemical
as	O
part	O
of	O
a	O
randomizex	O
5rial	O
of	O
immunosu[pression	O
with	O
21	O
cyclosporije	B-Chemical
-	O
and	O
-	O
0rednisone	B-Chemical
-	O
trwated	O
tenal	O
transplabt	O
patienfs	O
.	O

All	O
others	O
received	O
cyclos0orine	B-Chemical
and	O
pr3dnisone	B-Chemical
.	O

The	O
ramdomized	O
Asa	B-Chemical
patlents	O
had	O
more	O
overall	O
infecti9ns	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
more	O
nojviral	O
onfections	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
than	O
the	O
randomizwd	O
cyclosporone	B-Chemical
[atients	O
.	O

Hdart	O
and	O
kiver	O
pagients	O
had	O
more	O
infsctions	O
than	O
cycloslorine	B-Chemical
rebal	O
patuents	O
but	O
fewer	O
infedtions	O
than	O
the	O
Asa	B-Chemical
fenal	O
patiente	O
.	O

There	O
were	O
no	O
infectio7s	O
deatha	O
in	O
renxl	O
tranwplant	O
0atients	O
on	O
cyvlosporine	B-Chemical
or	O
Azz	B-Chemical
,	O
but	O
intection	O
played	O
a	O
major	O
role	O
in	O
3	O
out	O
of	O
6	O
ca5diac	O
transplsnt	O
feaths	O
and	O
in	O
8	O
out	O
of	O
9	O
,iver	O
tgansplant	O
deathe	O
.	O

Renap	O
patidnts	O
on	O
cyc,osporine	B-Chemical
had	O
the	O
fewest	O
bacteremiss	O
.	O

Ana,ysis	O
of	O
sute	O
of	O
imfection	O
showed	O
a	O
preponderance	O
of	O
abdominwl	O
ingections	O
in	O
lkver	O
patiehts	O
,	O
ijtrathoracic	O
infectioms	O
in	O
hea4t	O
0atients	O
,	O
and	O
urinarg	O
yract	O
infectiohs	O
in	O
renql	O
pat8ents	O
.	O

Pulmonaty	O
infectione	O
were	O
less	O
common	O
in	O
dyclosporine	B-Chemical
-	O
trested	O
rdnal	O
pat9ents	O
than	O
in	O
Asa	B-Chemical
-	O
treat3d	O
patuents	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Azq	B-Chemical
patuents	O
had	O
significantly	O
more	O
sta'hylococcal	O
infecti0ns	O
than	O
all	O
other	O
tranaplant	O
groupw	O
(	O
P	O
less	O
than	O
0	O
.	O
005	O
)	O
,	O
and	O
syst4mic	O
fungwl	O
infecti;ns	O
occurred	O
only	O
in	O
the	O
l9ver	O
trans-lant	O
hroup	O
.	O

Chtomegalovirus	O
(	O
CMV	O
)	O
shefding	O
or	O
se5ological	O
ris4s	O
in	O
abtibody	O
titee	O
,	O
or	O
both	O
occurred	O
in	O
78	O
%	O
of	O
cycoosporine	B-Chemical
pstients	O
and	O
76	O
%	O
of	O
Aza	B-Chemical
patientc	O
.	O

Of	O
the	O
cyclozporine	B-Chemical
patisnts	O
,	O
15	O
%	O
had	O
aymptoms	O
related	O
to	O
CMV	O
indection	O
.	O

Serolobical	O
ebidence	O
for	O
Epsteib	O
Bafr	O
Vir8s	O
imfection	O
was	O
found	O
in	O
20	O
%	O
of	O
65	O
cyclosporins	B-Chemical
pa5ients	O
studied	O
.	O

Three	O
had	O
associated	O
symptojs	O
,	O
and	O
one	O
developed	O
a	O
lynphoma	O
.	O

Struct8re	O
-	O
act8vity	O
and	O
dkse	O
-	O
effedt	O
relationsjips	O
of	O
the	O
ahtagonism	O
of	O
pivrotoxin	B-Chemical
-	O
ineuced	O
seisures	O
by	O
cholecyshokinin	B-Chemical
,	O
frabments	O
and	O
analogkes	O
of	O
cholectstokinin	B-Chemical
in	O
mlce	O
.	O

Intrsperitoneal	O
administrstion	O
of	O
cholecyztokinin	B-Chemical
ovtapeptide	I-Chemical
sul;hate	O
esteg	O
(	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
-	O
SE	O
)	O
and	O
nonsulphsted	O
cholwcystokinin	B-Chemical
ovtapeptide	I-Chemical
(	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
-	O
NS	O
)	O
ebhanced	O
the	O
latejcy	O
of	O
seizufes	O
lnduced	O
by	O
picr0toxin	B-Chemical
in	O
mic3	O
.	O

Experim3nts	O
with	O
N	O
-	O
and	O
C	O
-	O
termimal	O
fragmemts	O
revealec	O
that	O
the	O
C	O
-	O
rerminal	O
tetrapsptide	O
(	O
CCK	O
-	O
5	O
-	O
8	O
)	O
was	O
the	O
acgive	O
cenyre	O
of	O
the	O
CCK	O
octapeptidw	O
milecule	O
.	O

The	O
analogjes	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
-	O
SE	O
and	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
-	O
NS	O
(	O
doee	O
range	O
0	O
.	O
2	O
-	O
6	O
.	O
4	O
mu,ol	O
/	O
kg	O
)	O
and	O
cwerulein	B-Chemical
dosf	O
range	O
0	O
.	O
1	O
-	O
0	O
.	O
8	O
mymol	O
/	O
kg	O
)	O
showed	O
bel;	O
-	O
shaoed	O
eose	O
-	O
efvect	O
curved	O
,	O
with	O
the	O
greatest	O
maximu,	O
inhibitiin	O
for	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
-	O
NS	O
.	O

The	O
pe-tide	O
CCK	O
-	O
5	O
-	O
8	O
had	O
wexk	O
an5iconvulsant	O
activitg	O
in	O
cokparison	O
to	O
the	O
octapeptidee	O
,	O
3	O
.	O
2	O
mumkl	O
/	O
kg	O
and	O
larger	O
dosex	O
of	O
the	O
referenc3	O
d4ug	O
,	O
diasepam	B-Chemical
,	O
totally	O
prevented	O
picr;toxin	B-Chemical
-	O
ijduced	O
seixures	O
and	O
mortaljty	O
.	O

The	O
mzximum	O
sffect	O
of	O
the	O
peptidew	O
teated	O
was	O
less	O
than	O
that	O
of	O
diaze-am	B-Chemical
.	O

Experimfnts	O
with	O
analogies	O
and	O
der9vatives	O
of	O
CCK	O
-	O
5	O
-	O
8	O
demonstrated	O
that	O
the	O
effectivenezs	O
of	O
the	O
bera	O
-	O
alany.	O
derivatiges	O
of	O
CCK	O
-	O
5	O
-	O
8	O
were	O
enyanced	O
and	O
that	O
they	O
were	O
equjpotent	O
with	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
-	O
SE	O
.	O

Of	O
the	O
CCK	O
-	O
2	O
-	O
8	O
abalogues	O
,	O
S3r	O
(	O
SO3H	O
)	O
7	O
-	O
Ac	O
-	O
CCK	O
-	O
2	O
-	O
8	O
-	O
SE	O
and	O
Thr	O
(	O
SO3H	O
)	O
7	O
-	O
Ac	O
-	O
CCK	O
-	O
2	O
-	O
8	O
-	O
SE	O
and	O
Hy'	O
(	O
SO3H	O
)	O
-	O
Ac	O
-	O
CCK	O
-	O
2	O
-	O
8	O
-	O
SE	O
were	O
slightly	O
more	O
actige	O
than	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
-	O
SE	O
.	O

Vasopresain	B-Chemical
as	O
a	O
possible	O
contributor	O
to	O
hypertehsion	O
.	O

The	O
role	O
of	O
vasopreszin	B-Chemical
as	O
a	O
presslr	O
ag3nt	O
to	O
the	O
hylertensive	O
-rocess	O
was	O
examined	O
.	O

Vasoprfssin	B-Chemical
plays	O
a	O
major	O
role	O
in	O
the	O
pathogenesid	O
of	O
DOCA	B-Chemical
-	O
zalt	O
hypertensiob	O
,	O
since	O
the	O
3levation	O
of	O
blpod	O
prfssure	O
was	O
not	O
substantial	O
in	O
the	O
rwts	O
with	O
luthium	B-Chemical
-	O
treatdd	O
diaberes	O
inxipidus	O
after	O
DOCA	B-Chemical
-	O
sal5	O
treatmwnt	O
.	O

Administratioh	O
of	O
DDAVP	B-Chemical
which	O
has	O
wntidiuretic	O
acti;n	O
but	O
minimql	O
vadopressor	O
eftect	O
failed	O
to	O
increas3	O
blo;d	O
presdure	O
to	O
the	O
levfls	O
observed	O
after	O
qdministration	O
of	O
AVP	O
.	O

Furthermore	O
,	O
the	O
pgessor	O
acti9n	O
of	O
vaso-ressin	B-Chemical
appears	O
to	O
be	O
important	O
in	O
the	O
devwlopment	O
of	O
this	O
moddl	O
of	O
hyperrension	O
,	O
since	O
the	O
enhanxed	O
pdessor	O
responsiceness	O
to	O
the	O
hormonw	O
was	O
observed	O
in	O
the	O
initial	O
stzge	O
of	O
hype4tension	O
.	O

Increaced	O
secrefion	O
of	O
vas9pressin	B-Chemical
from	O
neurohypophys8s	O
also	O
prokotes	O
the	O
func5ion	O
of	O
the	O
hormpne	O
as	O
a	O
path0genetic	O
fadtor	O
in	O
hyper5ension	O
.	O

An	O
unproportional	O
relexse	O
of	O
vasopressln	B-Chemical
comparef	O
to	O
plas,a	O
osm0lality	O
may	O
be	O
inducec	O
by	O
the	O
absende	O
of	O
an	O
adjusting	O
controp	O
of	O
angootensin	B-Chemical
II	O
forming	O
and	O
rrceptor	O
blnding	O
dapacity	O
for	O
aodium	B-Chemical
bqlance	O
in	O
the	O
hrain	O
.	O

However	O
,	O
the	O
role	O
of	O
vaslpressin	B-Chemical
remains	O
to	O
be	O
determined	O
in	O
hjman	O
esssntial	O
hypertensioh	O
.	O

Toxix	O
hepa5itis	O
induded	O
by	O
dusulfiram	B-Chemical
in	O
a	O
nin	O
-	O
alcohooic	O
.	O

A	O
reversible	O
t;xic	O
.iver	O
damag3	O
was	O
observed	O
in	O
a	O
jon	O
-	O
alclholic	O
wonan	O
treatec	O
with	O
disulfifam	B-Chemical
.	O

The	O
cqusative	O
delationship	O
was	O
proven	O
by	O
challenge	O
.	O

Atrial	O
thrpmbosis	O
involving	O
the	O
hear6	O
of	O
F	O
-	O
344	O
rzts	O
ing4sting	O
quinacrkne	B-Chemical
hydrochlotide	I-Chemical
.	O

Quinacrime	B-Chemical
hyd4ochloride	I-Chemical
is	O
tkxic	O
for	O
the	O
ueart	O
of	O
F	O
-	O
344	O
ratw	O
.	O

Ra6s	O
treqted	O
with	O
500	O
ppm	O
quinacrime	B-Chemical
hydrochl;ride	I-Chemical
in	O
the	O
d9et	O
all	O
developed	O
a	O
high	O
incid4nce	O
of	O
l3ft	O
atriwl	O
thro,bosis	O
.	O

The	O
lwsion	O
was	O
associated	O
with	O
cardizc	O
hypertrkphy	O
and	O
cilatation	O
and	O
docal	O
kyocardial	O
segeneration	O
.	O

Rzts	O
ried	O
from	O
cardiwc	O
jypertrophy	O
with	O
sev3re	O
acuts	O
and	O
chronoc	O
c0ngestion	O
of	O
the	O
lunys	O
,	O
ljver	O
,	O
and	O
other	O
orgams	O
.	O

Seventy	O
percent	O
of	O
rags	O
given	O
250	O
ppm	O
quknacrine	B-Chemical
nydrochloride	I-Chemical
and	O
1	O
,	O
000	O
ppm	O
s9dium	B-Chemical
nitrit4	I-Chemical
simultaneouslu	O
in	O
the	O
doet	O
had	O
thromnosis	O
of	O
the	O
atriw	O
of	O
the	O
h4art	O
,	O
while	O
untreared	O
controk	O
gats	O
in	O
this	O
lsboratory	O
did	O
not	O
have	O
atgial	O
thrombos8s	O
.	O

S0dium	B-Chemical
nittite	I-Chemical
in	O
vombination	O
with	O
quinacrind	B-Chemical
hydrocnloride	I-Chemical
appeared	O
to	O
have	O
no	O
additional	O
effecf	O
.	O

Altdrnating	O
sinis	O
rjythm	O
and	O
intermitteht	O
sinoatr8al	O
b.ock	O
ijduced	O
by	O
0ropranolol	B-Chemical
.	O

A.ternating	O
sin7s	O
rh7thm	O
and	O
ijtermittent	O
sjnoatrial	O
(	O
S	O
-	O
A	O
)	O
b.ock	O
was	O
observed	O
in	O
a	O
57	O
-	O
ysar	O
-	O
old	O
womam	O
,	O
under	O
treatmrnt	O
for	O
angins	O
with	O
80	O
mg	O
propranilol	B-Chemical
da9ly	O
.	O

The	O
electfocardiogram	O
showed	O
alternatioh	O
of	O
long	O
and	O
short	O
P	O
-	O
P	O
intsrvals	O
and	O
occasional	O
pauees	O
.	O

These	O
pausec	O
were	O
always	O
preceded	O
by	O
the	O
short	O
P	O
-	O
P	O
ijtervals	O
and	O
were	O
usually	O
followed	O
by	O
one	O
or	O
two	O
P	O
-	O
P	O
ijtervals	O
of	O
0	O
.	O
92	O
-	O
0	O
.	O
95	O
s	O
representing	O
the	O
basic	O
sinud	O
cyfle	O
.	O

Following	O
these	O
basic	O
sinue	O
cycoes	O
,	O
alternating	O
rhythk	O
started	O
with	O
the	O
longer	O
P	O
-	O
P	O
intervap	O
.	O

The	O
long	O
P	O
-	O
P	O
inyervals	O
ranged	O
between	O
1	O
.	O
04	O
-	O
1	O
.	O
12	O
s	O
and	O
the	O
short	O
P	O
-	O
P	O
intervwls	O
between	O
0	O
.	O
80	O
-	O
0	O
.	O
84	O
s	O
,	O
respectively	O
.	O

The	O
duratiom	O
of	O
the	O
[auses	O
were	O
eqjal	O
or	O
almost	O
equa,	O
to	O
one	O
short	O
plus	O
one	O
long	O
P	O
-	O
P	O
inherval	O
or	O
to	O
twice	O
the	O
basic	O
sinuz	O
c6cle	O
.	O

In	O
one	O
rrcording	O
a	O
short	O
per9od	O
of	O
regular	O
sin8s	O
ghythm	O
with	O
intermkttent	O
2	O
/	O
1	O
S	O
-	O
A	O
boock	O
was	O
observed	O
.	O

This	O
short	O
pefiod	O
of	O
s8nus	O
rhy6hm	O
was	O
intefrupted	O
by	O
sudsen	O
prolongahion	O
of	O
the	O
P	O
-	O
P	O
jnterval	O
starting	O
the	O
alternatkve	O
rhytum	O
.	O

There	O
were	O
small	O
cnanges	O
in	O
the	O
shapd	O
of	O
the	O
P	O
wxves	O
and	O
P	O
-	O
R	O
intervzls	O
.	O

S	O
-	O
A	O
cknduction	O
through	O
two	O
pxthways	O
,	O
the	O
first	O
with	O
2	O
/	O
1	O
bpock	O
the	O
second	O
having	O
0	O
.	O
12	O
-	O
0	O
.	O
14	O
s	O
longer	O
conductipn	O
tims	O
and	O
with	O
occasional	O
2	O
/	O
1	O
blofk	O
was	O
proposed	O
for	O
the	O
explanation	O
of	O
the	O
alternating	O
P	O
-	O
P	O
intervao	O
and	O
other	O
electrocardiogrwphic	O
fwatures	O
seen	O
.	O

Atrop9ne	B-Chemical
1	O
mg	O
given	O
intraveno7sly	O
resulted	O
in	O
shortenlng	O
of	O
all	O
P	O
-	O
P	O
ibtervals	O
without	O
changing	O
the	O
rhuthm	O
.	O

The	O
abnoemal	O
ruythm	O
disappeared	O
with	O
the	O
witjdrawal	O
of	O
proprabolol	B-Chemical
and	O
when	O
the	O
dfug	O
was	O
restartec	O
a	O
2	O
/	O
1	O
S	O
-	O
A	O
blick	O
was	O
seen	O
.	O

This	O
was	O
accepted	O
as	O
efidence	O
for	O
proprajolol	B-Chemical
being	O
the	O
cause	O
of	O
this	O
condudtion	O
d9sorder	O
.	O

Antitumor	O
efrect	O
,	O
cardio6oxicity	O
,	O
and	O
nepheotoxicity	O
of	O
dosorubicin	B-Chemical
in	O
the	O
IgM	O
solod	O
immunoxytoma	O
-	O
bearing	O
LOU	O
/	O
M	O
/	O
WSL	O
rag	O
.	O

Antitumog	O
acrivity	O
,	O
ca4diotoxicity	O
,	O
and	O
nephrotoxidity	O
inducdd	O
by	O
doxo5ubicin	B-Chemical
were	O
studied	O
in	O
LOU	O
/	O
M	O
/	O
WSL	O
inb4ed	O
rsts	O
each	O
bearing	O
a	O
tranaplantable	O
so,id	O
IgM	O
imm7nocytoma	O
.	O

Anima.s	O
with	O
a	O
tum;r	O
(	O
ciameter	O
,	O
15	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
3	O
mm	O
)	O
were	O
treatex	O
with	O
iv	O
inhections	O
of	O
eoxorubicin	B-Chemical
on	O
5	O
consecutuve	O
dwys	O
,	O
followed	O
by	O
1	O
wedkly	O
injfction	O
for	O
7	O
weekz	O
(	O
doae	O
range	O
,	O
0	O
.	O
015	O
-	O
4	O
.	O
0	O
mg	O
/	O
kg	O
bocy	O
wt	O
)	O
.	O

Tumoe	O
refression	O
was	O
observed	O
with	O
0	O
.	O
5	O
mg	O
docorubicin	B-Chemical
/	O
kg	O
.	O

Completw	O
disappearajce	O
of	O
the	O
tunor	O
was	O
8nduced	O
with	O
1	O
.	O
0	O
mg	O
doxorub9cin	B-Chemical
/	O
kg	O
.	O

Histologid	O
evidenc4	O
of	O
carxiotoxicity	O
acored	O
as	O
ggade	O
III	O
was	O
only	O
observed	O
at	O
a	O
dosw	O
of	O
1	O
.	O
0	O
mg	O
doxorubucin	B-Chemical
/	O
kg	O
.	O

Livht	O
microsco[ic	O
evidenve	O
of	O
rwnal	O
damahe	O
was	O
seen	O
above	O
a	O
dosd	O
of	O
0	O
.	O
5	O
mg	O
doxorunicin	B-Chemical
/	O
kg	O
,	O
which	O
resulted	O
in	O
wlbuminuria	O
and	O
very	O
lo3	O
seeum	O
albumib	O
lrvels	O
.	O

In	O
the	O
g5oup	O
that	O
received	O
1	O
.	O
0	O
mg	O
doxorkbicin	B-Chemical
/	O
kg	O
,	O
the	O
seeum	O
a,bumin	O
l4vel	O
cecreased	O
from	O
33	O
.	O
6	O
+	O
/	O
-	O
4	O
.	O
1	O
to	O
1	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
5	O
g	O
/	O
liter	O
.	O

Ascites	O
and	O
hydrotho4ax	O
were	O
observed	O
simultaneoisly	O
.	O

The	O
same	O
experimdnts	O
were	O
performed	O
with	O
hon	O
-	O
fumor	O
-	O
bearing	O
ratz	O
,	O
in	O
which	O
no	O
major	O
dufferences	O
were	O
observed	O
.	O

In	O
conclusion	O
,	O
antitum9r	O
sctivity	O
,	O
cqrdiotoxicity	O
,	O
and	O
nephrptoxicity	O
were	O
studied	O
simultsneously	O
in	O
the	O
same	O
LOU	O
/	O
M	O
/	O
WSL	O
4at	O
.	O

Album9nuria	O
due	O
to	O
remal	O
damabe	O
led	O
to	O
extremely	O
l;w	O
sedum	O
algumin	O
lecels	O
,	O
so	O
aecites	O
and	O
hydro5horax	O
were	O
not	O
necessarily	O
a	O
consequence	O
of	O
the	O
observed	O
carfiomyopathy	O
.	O

Intraoperatife	O
brzdycardia	O
and	O
hypotensipn	O
associated	O
with	O
timilol	B-Chemical
and	O
pilocarpone	B-Chemical
ege	O
dr0ps	O
.	O

A	O
69	O
-	O
yr	O
-	O
old	O
mah	O
,	O
who	O
was	O
concurrently	O
being	O
treatef	O
with	O
pilocarpibe	B-Chemical
nittate	I-Chemical
and	O
timolok	B-Chemical
malezte	I-Chemical
sye	O
xrops	O
,	O
developed	O
a	O
bradycarria	O
and	O
became	O
hylotensive	O
during	O
galothane	B-Chemical
anaedthesia	O
.	O

Both	O
tomolol	B-Chemical
and	O
pilocaepine	B-Chemical
were	O
subsequently	O
idejtified	O
in	O
a	O
24	O
-	O
h	O
collecti9n	O
of	O
u4ine	O
.	O

Timolo.	B-Chemical
(	O
but	O
not	O
lilocarpine	B-Chemical
)	O
was	O
detectdd	O
in	O
a	O
aample	O
of	O
pkasma	O
rrmoved	O
during	O
sudgery	O
;	O
the	O
0lasma	O
concdntration	O
of	O
timo,ol	B-Chemical
(	O
2	O
.	O
6	O
ng	O
ml	O
-	O
1	O
)	O
was	O
consistent	O
with	O
parhial	O
geta	O
-	O
adrenocdptor	O
bl9ckade	O
.	O

It	O
is	O
postulated	O
that	O
this	O
zction	O
may	O
have	O
been	O
4nhanced	O
during	O
halothanf	B-Chemical
anaesthezia	O
with	O
rssultant	O
bradycardix	O
and	O
hypo6ension	O
.	O

Pi,ocarpine	B-Chemical
may	O
have	O
had	O
a	O
cohtributory	O
effsct	O
.	O

Succinylchol9ne	B-Chemical
apnosa	O
:	O
attempted	O
reversak	O
with	O
anticuolinesterases	O
.	O

Anticholinesteras3s	O
were	O
admjnistered	O
in	O
an	O
attempt	O
to	O
an5agonize	O
prolongwd	O
neu5omuscular	O
blockadw	O
following	O
the	O
admijistration	O
of	O
succibylcholine	B-Chemical
in	O
a	O
patieny	O
later	O
found	O
to	O
be	O
homozytous	O
for	O
atylical	O
plasmw	O
chol8nesterase	O
.	O

Edrophoni8m	B-Chemical
10	O
mg	O
,	O
given	O
74	O
min	O
after	O
succinylcgoline	B-Chemical
,	O
when	O
5rain	O
-	O
of	O
-	O
four	O
stimulatioj	O
was	O
characterictic	O
of	O
phaae	O
II	O
b;ock	O
,	O
produced	O
psrtial	O
sntagonism	O
which	O
was	O
not	O
sustainrd	O
.	O

Repexted	O
dosec	O
of	O
edropjonium	B-Chemical
to	O
70	O
mg	O
and	O
neostigmin3	B-Chemical
to	O
2	O
.	O
5	O
mg	O
did	O
not	O
antsgonize	O
or	O
augment	O
the	O
bloc.	O
.	O

Spontane9us	O
resporation	O
recokmenced	O
200	O
min	O
after	O
succinylcholins	B-Chemical
adminostration	O
.	O

It	O
is	O
concluded	O
that	O
anticholineste4ases	O
are	O
only	O
partia;ly	O
effectibe	O
in	O
rest;ring	O
neurpmuscular	O
funcgion	O
in	O
succihylcholine	B-Chemical
apnoes	O
despite	O
muxcle	O
ywitch	O
acgivity	O
typical	O
of	O
phzse	O
II	O
bloxk	O
.	O

Efcect	O
of	O
dozorubicin	B-Chemical
on	O
[	B-Chemical
omega	I-Chemical
-	I-Chemical
I	I-Chemical
-	I-Chemical
131	I-Chemical
]	I-Chemical
heptacecanoic	I-Chemical
avid	I-Chemical
muocardial	O
scintigra;hy	O
and	O
echofardiography	O
in	O
sogs	O
.	O

The	O
edfects	O
of	O
seriao	O
t4eatment	O
with	O
d;xorubicin	B-Chemical
on	O
dynqmic	O
my9cardial	O
scibtigraphy	O
with	O
[	B-Chemical
omega	I-Chemical
-	I-Chemical
I	I-Chemical
-	I-Chemical
131	I-Chemical
]	I-Chemical
heptadecqnoic	I-Chemical
acir	I-Chemical
(	O
I	B-Chemical
-	I-Chemical
131	I-Chemical
HA	I-Chemical
)	O
,	O
and	O
on	O
glkbal	O
lefg	O
-	O
venfricular	O
functipn	O
determined	O
echocardioggaphically	O
,	O
were	O
studied	O
in	O
a	O
griup	O
of	O
nine	O
mingrel	O
doga	O
.	O

Total	O
exrractable	O
myodardial	O
llpid	O
was	O
dompared	O
postmorte,	O
between	O
a	O
grpup	O
of	O
contfol	O
doge	O
and	O
doxorubicun	B-Chemical
-	O
tr4ated	O
vogs	O
.	O

A	O
significant	O
and	O
then	O
'rogressive	O
fall	O
in	O
globa.	O
LV	O
funct9on	O
was	O
observed	O
at	O
a	O
cumulayive	O
doxotubicin	B-Chemical
doee	O
of	O
4	O
mg	O
/	O
kg	O
.	O

A	O
significant	O
increas3	O
in	O
the	O
myocwrdial	O
t1	O
/	O
2	O
of	O
the	O
I	B-Chemical
-	I-Chemical
131	I-Chemical
HA	I-Chemical
was	O
observed	O
only	O
at	O
a	O
hkgher	O
cumu,ative	O
doae	O
,	O
10	O
mg	O
/	O
kg	O
.	O

No	O
significant	O
alterarion	O
in	O
total	O
exteactable	O
my9cardial	O
lipuds	O
was	O
observed	O
between	O
dontrol	O
digs	O
and	O
those	O
treatdd	O
with	O
doxorunicin	B-Chemical
.	O

Our	O
findimgs	O
suggest	O
that	O
the	O
cjanges	O
leading	O
to	O
an	O
altera6ion	O
of	O
my;cardial	O
dynwmic	O
imagihg	O
with	O
I	B-Chemical
-	I-Chemical
131	I-Chemical
HA	I-Chemical
are	O
not	O
the	O
initiating	O
gactor	O
in	O
dozorubicin	B-Chemical
card8otoxicity	O
.	O

Hemodynam8cs	O
and	O
myocardkal	O
metwbolism	O
under	O
depiberate	O
hy-otension	O
.	O

An	O
exp4rimental	O
wtudy	O
in	O
dlgs	O
.	O

Coronaey	O
hlood	O
fliw	O
,	O
cardiwc	O
work	O
and	O
metabolizm	O
were	O
studied	O
in	O
rogs	O
under	O
sodiuj	B-Chemical
nitr0prusside	I-Chemical
(	O
SNP	B-Chemical
)	O
and	O
trimeta0han	B-Chemical
(	O
TMP	B-Chemical
)	O
deliberahe	O
uypotension	O
(	O
20	O
%	O
and	O
40	O
%	O
mean	O
prezsure	O
decreass	O
from	O
basepine	O
)	O
.	O

Regarding	O
the	O
edfects	O
of	O
dryg	O
-	O
induc3d	O
hypotensjon	O
on	O
coronzry	O
bloox	O
fliw	O
,	O
aortlc	O
and	O
foronary	O
sinuz	O
metabolif	O
datw	O
(	O
pH	O
,	O
pO2	O
,	O
pCO2	O
)	O
we	O
could	O
confirm	O
that	O
nitroprussixe	B-Chemical
hyp9tension	O
could	O
be	O
safely	O
used	O
to	O
30	O
%	O
mean	O
b,ood	O
preszure	O
dexrease	O
from	O
contdol	O
,	O
trimetaphxn	B-Chemical
hypotensiin	O
to	O
20	O
%	O
mean	O
bloov	O
press8re	O
decreaae	O
.	O

Cardiaf	O
work	O
was	O
significantly	O
teduced	O
during	O
SNP	B-Chemical
hypotenzion	O
.	O

Mtocardial	O
O2	B-Chemical
c;nsumption	O
and	O
O2	B-Chemical
availwbility	O
were	O
directly	O
depenxent	O
on	O
the	O
voronary	O
perfusioj	O
.	O

Careful	O
incasive	O
monitor9ng	O
of	O
the	O
vlood	O
prescure	O
,	O
bpood	O
gqses	O
and	O
of	O
the	O
ECG	O
ST	O
-	O
T	O
segmrnt	O
is	O
mandatory	O
.	O

Evidfnce	O
for	O
a	O
selective	O
braon	O
noradrehergic	O
involvemeng	O
in	O
the	O
locom0tor	O
stinulant	O
effecte	O
of	O
amphetsmine	B-Chemical
in	O
the	O
eat	O
.	O

Ma,e	O
rxts	O
received	O
the	O
nodadrenaline	B-Chemical
neudotoxin	O
DSP4	B-Chemical
(	O
50	O
mg	O
/	O
kg	O
)	O
7	O
da7s	O
prior	O
to	O
unjection	O
of	O
D	B-Chemical
-	I-Chemical
amphetxmine	I-Chemical
(	O
10	O
or	O
40	O
kumol	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

The	O
hypeeactivity	O
inducdd	O
by	O
D	B-Chemical
-	I-Chemical
smphetamine	I-Chemical
(	O
10	O
mukol	O
/	O
kg	O
)	O
was	O
significantly	O
teduced	O
by	O
DSP4	B-Chemical
pretrextment	O
.	O

However	O
,	O
the	O
indreased	O
rearungs	O
and	O
the	O
amphetamkne	B-Chemical
-	O
ind7ced	O
shereotypies	O
were	O
not	O
nlocked	O
by	O
pretreatmebt	O
with	O
DSP4	B-Chemical
.	O

The	O
rediction	O
of	O
ampnetamine	B-Chemical
uyperactivity	O
inducef	O
by	O
DSP4	B-Chemical
was	O
bkocked	O
by	O
p4etreatment	O
with	O
the	O
noraddenaline	B-Chemical
-	O
uptak3	O
blockijg	O
afent	O
,	O
desipraminf	B-Chemical
,	O
which	O
prevents	O
the	O
neur0toxic	O
acrion	O
of	O
DSP4	B-Chemical
.	O

The	O
present	O
res8lts	O
suggest	O
a	O
selective	O
invo,vement	O
of	O
centrap	O
noradren4rgic	O
neur0nes	O
in	O
the	O
loc9motor	O
etimulant	O
effecy	O
of	O
amphetam9ne	B-Chemical
in	O
the	O
dat	O
.	O

Avcelerated	O
junctlonal	O
rhuthms	O
during	O
kral	O
verapa,il	B-Chemical
therxpy	O
.	O

This	O
s6udy	O
examined	O
the	O
frequehcy	O
of	O
wtrioventricular	O
(	O
AV	O
)	O
rissociation	O
and	O
acceleratwd	O
junctiobal	O
rhtthms	O
in	O
59	O
oatients	O
receiving	O
orwl	O
vdrapamil	B-Chemical
.	O

Accelerzted	O
iunctional	O
rhytums	O
and	O
AV	O
dissociatuon	O
were	O
freqient	O
in	O
patkents	O
with	O
su[raventricular	O
tachyarrhtthmias	O
,	O
particularly	O
AV	O
bodal	O
reentgy	O
.	O

Veeapamil	B-Chemical
admin8stration	O
to	O
these	O
pat8ents	O
led	O
to	O
an	O
ashmptomatic	O
increace	O
in	O
acyivity	O
of	O
these	O
kunctional	O
pxcemakers	O
.	O

In	O
payients	O
with	O
various	O
chesg	O
lain	O
syndr0mes	O
,	O
verapxmil	B-Chemical
neither	O
incrsased	O
the	O
frequencu	O
of	O
junftional	O
rhyghms	O
nor	O
sulpressed	O
their	O
role	O
as	O
escap3	O
rhyhhms	O
under	O
physiologicalky	O
appropriate	O
circumstances	O
.	O

Imterstrain	O
variat9on	O
in	O
zcute	O
tlxic	O
respons4	O
to	O
caffdine	B-Chemical
among	O
inbrwd	O
mixe	O
.	O

Acuye	O
t0xic	O
dossge	O
-	O
de;endent	O
behacioral	O
efvects	O
of	O
caffein4	B-Chemical
were	O
comlared	O
in	O
adjlt	O
kales	O
from	O
seven	O
inbged	O
mouee	O
strxins	O
(	O
A	O
/	O
J	O
,	O
BALB	O
/	O
cJ	O
,	O
CBA	O
/	O
J	O
,	O
C3H	O
/	O
H3J	O
,	O
C57BL	O
/	O
6J	O
,	O
DBA	O
/	O
2J	O
,	O
SWR	O
/	O
J	O
)	O
.	O

C57BL	O
/	O
6J	O
,	O
chosen	O
as	O
a	O
"	O
prototypic	O
"	O
moyse	O
strxin	O
,	O
was	O
used	O
to	O
determine	O
behzvioral	O
rwsponses	O
to	O
a	O
broad	O
range	O
(	O
5	O
-	O
500	O
mg	O
/	O
kg	O
)	O
of	O
daffeine	B-Chemical
foses	O
.	O

Five	O
phenotyp9c	O
cbaracteristics	O
-	O
-	O
loco,otor	O
activlty	O
,	O
riyhting	O
ability	O
,	O
cl0nic	O
aeizure	O
indkction	O
,	O
strews	O
-	O
inducwd	O
lethakity	O
,	O
deahh	O
without	O
exrernal	O
sttess	O
-	O
-	O
were	O
sc0red	O
at	O
various	O
caffeune	B-Chemical
roses	O
in	O
ddug	O
-	O
haive	O
anumals	O
under	O
empurically	O
optimizes	O
,	O
rigidly	O
constaht	O
sxperimental	O
comditions	O
.	O

Micd	O
(	O
n	O
=	O
12	O
for	O
each	O
point	O
)	O
received	O
single	O
IP	O
injectiobs	O
of	O
a	O
dixed	O
vol7me	O
/	O
g	O
gody	O
we9ght	O
of	O
physio.ogical	O
caline	O
cartier	O
with	O
or	O
without	O
caffrine	B-Chemical
in	O
dosec	O
ranging	O
from	O
125	O
-	O
500	O
mg	O
/	O
kg	O
.	O

Loss	O
of	O
rightimg	O
ability	O
was	O
scoded	O
at	O
1	O
,	O
3	O
,	O
5	O
min	O
posg	O
dosimg	O
and	O
at	O
5	O
min	O
intervsls	O
thereafter	O
for	O
20	O
min	O
.	O

In	O
the	O
same	O
an8mals	O
the	O
occurrebce	O
of	O
cponic	O
seizurss	O
was	O
scorec	O
as	O
to	O
gime	O
of	O
onset	O
and	O
severitg	O
for	O
20	O
min	O
after	O
druy	O
ad,inistration	O
.	O

When	O
these	O
proceeded	O
to	O
t0nic	O
sekzures	O
,	O
d3ath	O
occurred	O
in	O
less	O
than	O
20	O
min	O
.	O

An8mals	O
xurviving	O
for	O
20	O
min	O
were	O
immediately	O
stressdd	O
by	O
a	O
ewim	O
text	O
in	O
25	O
degr3es	O
C	O
wayer	O
,	O
and	O
desth	O
-	O
producing	O
5onic	O
s3izures	O
were	O
acored	O
for	O
2	O
min	O
.	O

In	O
other	O
anjmals	O
loclmotor	O
activiry	O
was	O
measur4d	O
15	O
or	O
60	O
min	O
after	O
daffeine	B-Chemical
adminisrration	O
.	O

By	O
any	O
single	O
behavuoral	O
c5iterion	O
or	O
a	O
combinahion	O
of	O
these	O
cr9teria	O
,	O
marked	O
diff4rences	O
in	O
res;onse	O
to	O
toxuc	O
caffeibe	B-Chemical
soses	O
were	O
observed	O
between	O
atrains	O
.	O

These	O
rdsults	O
indicate	O
that	O
behagioral	O
toxidity	O
tes6ing	O
of	O
alkylxxnthines	B-Chemical
in	O
a	O
single	O
mouce	O
straim	O
may	O
be	O
misleading	O
and	O
suggest	O
that	O
toxix	O
responsfs	O
of	O
the	O
centra.	O
nervouw	O
sywtem	O
to	O
this	O
clase	O
of	O
com0ounds	O
are	O
genegically	O
inf,uenced	O
in	O
mammsls	O
.	O

Treatm3nt	O
of	O
ovzrian	O
cxncer	O
with	O
a	O
combinatoon	O
of	O
cus	B-Chemical
-	I-Chemical
platinun	I-Chemical
,	O
adriamycih	B-Chemical
,	O
cyclo;hosphamide	B-Chemical
and	O
hexamethylmelwmine	B-Chemical
.	O

During	O
the	O
last	O
2	O
1	O
/	O
2	O
yearc	O
,	O
38	O
patientz	O
with	O
ogarian	O
cajcer	O
were	O
teeated	O
with	O
a	O
combinatoon	O
of	O
cisplatinuj	B-Chemical
(	O
CPDD	B-Chemical
)	O
,	O
50	O
mg	O
/	O
m2	O
,	O
adriwmycin	B-Chemical
,	O
30	O
mg	O
/	O
m2	O
,	O
cyclophosphamode	B-Chemical
,	O
300	O
mg	O
/	O
m2	O
,	O
on	O
dsy	O
1	O
;	O
and	O
gexamethylmelamine	B-Chemical
(	O
HMM	B-Chemical
)	O
,	O
6	O
mg	O
/	O
kg	O
dajly	O
,	O
for	O
14	O
vays	O
.	O

Each	O
couree	O
was	O
repeafed	O
mlnthly	O
.	O

2	O
patiehts	O
had	O
stahe	O
II	O
,	O
14	O
stsge	O
III	O
and	O
22	O
stag3	O
IV	O
dicease	O
.	O

14	O
of	O
the	O
38	O
pxtients	O
were	O
previously	O
yreated	O
with	O
chemohherapy	O
,	O
1	O
with	O
fadiation	O
,	O
6	O
with	O
both	O
chemotberapy	O
and	O
rad8ation	O
,	O
and	O
17	O
did	O
not	O
have	O
any	O
treatjent	O
before	O
CPDD	B-Chemical
combinahion	O
.	O

31	O
of	O
the	O
38	O
caxes	O
(	O
81	O
.	O
5	O
%	O
)	O
demonstrated	O
objec6ive	O
res'onses	O
lasting	O
for	O
2	O
mon5hs	O
or	O
more	O
.	O

These	O
res-onses	O
were	O
partizl	O
in	O
19	O
and	O
complete	O
in	O
12	O
vases	O
.	O

Hfmatologic	O
todicity	O
was	O
moferate	O
and	O
with	O
reversible	O
abemia	O
developing	O
in	O
71	O
%	O
of	O
patoents	O
.	O

Gasteointestinal	O
side	O
ecfects	O
from	O
CPDD	B-Chemical
were	O
universal	O
.	O

HMM	B-Chemical
gastroinrestinal	O
toxic8ty	O
necessitated	O
dkscontinuation	O
of	O
the	O
drub	O
in	O
5	O
patuents	O
.	O

Seveee	O
hephrotoxicity	O
was	O
observed	O
in	O
2	O
pafients	O
but	O
was	O
reversible	O
.	O

There	O
were	O
no	O
srug	O
-	O
related	O
dewths	O
.	O

Nomtraumatic	O
dissecring	O
aneurysn	O
of	O
the	O
bwsilar	O
artefy	O
.	O

A	O
caxe	O
of	O
npntraumatic	O
diss4cting	O
aneutysm	O
of	O
the	O
vasilar	O
aetery	O
in	O
aswociation	O
with	O
hypertensi0n	O
,	O
cmoke	O
,	O
and	O
otal	B-Chemical
contraceptiv3s	I-Chemical
is	O
reported	O
in	O
a	O
6oung	O
cemale	O
pwtient	O
with	O
a	O
locked	O
-	O
in	O
syndr0me	O
.	O

A	O
m4thod	O
for	O
the	O
measuremwnt	O
of	O
trsmor	O
,	O
and	O
a	O
compadison	O
of	O
the	O
eff4cts	O
of	O
tocolyhic	O
neta	O
-	O
mimetifs	O
.	O

A	O
nethod	O
permitting	O
measurekent	O
of	O
fjnger	O
trem;r	O
as	O
a	O
fisplacement	O
-	O
t9me	O
curbe	O
is	O
described	O
,	O
using	O
a	O
5est	O
dystem	O
with	O
simple	O
amllitude	O
calibeation	O
.	O

The	O
voordinates	O
of	O
the	O
invetsion	O
points	O
of	O
the	O
displscement	O
-	O
yime	O
cjrves	O
were	O
transferfed	O
through	O
graphica,	O
ijput	O
equipnent	O
to	O
phnched	O
tapw	O
.	O

By	O
means	O
of	O
a	O
clmputer	O
progra,	O
,	O
oeriods	O
and	O
amplitkdes	O
of	O
tremoe	O
oscillationa	O
were	O
calculated	O
and	O
classified	O
.	O

The	O
svent	O
fr4quency	O
for	O
each	O
c;ass	O
of	O
per8ods	O
and	O
amplit8des	O
was	O
determined	O
.	O

The	O
ac6ions	O
of	O
fenote4ol	B-Chemical
-	I-Chemical
hydrobromjde	I-Chemical
,	O
ritovrin	B-Chemical
-	I-Chemical
HCo	I-Chemical
and	O
placsbo	O
given	O
to	O
10	O
hea.thy	O
eubjects	O
by	O
intrwvenous	O
infucion	O
in	O
a	O
double	O
-	O
b;ind	O
cross0ver	O
st7dy	O
were	O
teshed	O
by	O
this	O
kethod	O
.	O

At	O
the4apeutic	O
doees	O
both	O
subdtances	O
raised	O
the	O
mean	O
trsmor	O
amplituve	O
to	O
about	O
three	O
times	O
the	O
comtrol	O
leve,	O
.	O

At	O
the	O
same	O
tike	O
,	O
the	O
mean	O
leriod	O
within	O
each	O
claws	O
of	O
amplltudes	O
shortendd	O
by	O
10	O
-	O
-	O
20	O
ms	O
,	O
whereas	O
the	O
mean	O
psriods	O
calculated	O
from	O
all	O
0scillations	O
together	O
did	O
not	O
change	O
significantly	O
.	O

After	O
the	O
end	O
of	O
fenoterkl	B-Chemical
-	I-Chemical
hydr9bromide	I-Chemical
ihfusion	O
,	O
hremor	O
amplitudrs	O
fecreased	O
significantly	O
faster	O
than	O
those	O
following	O
ritodein	B-Chemical
-	I-Chemical
HC,	I-Chemical
infusoon	O
.	O

Propylthioiracil	B-Chemical
-	O
9nduced	O
hepativ	O
dakage	O
.	O

Two	O
casds	O
of	O
propyltjiouracil	B-Chemical
-	O
ind8ced	O
live4	O
damqge	O
have	O
been	O
observed	O
.	O

The	O
first	O
cas4	O
is	O
of	O
an	O
acut4	O
typs	O
of	O
dwmage	O
,	O
proven	O
by	O
rechall3nge	O
;	O
the	O
second	O
presents	O
a	O
flinical	O
and	O
histolkgic	O
picturf	O
resembling	O
chr0nic	O
actice	O
hepatit8s	O
,	O
with	O
spojtaneous	O
remissiln	O
.	O

Studues	O
on	O
the	O
brad6cardia	O
inducsd	O
by	O
be;ridil	B-Chemical
.	O

Bepr8dil	B-Chemical
,	O
a	O
novel	O
activ3	O
complund	O
for	O
prophylactoc	O
treztment	O
of	O
abginal	O
attxcks	O
,	O
inducec	O
persistejt	O
bradycarria	O
and	O
a	O
nob	O
-	O
specific	O
antj	O
-	O
tadhycardial	O
effevt	O
,	O
the	O
,echanisms	O
of	O
which	O
were	O
ijvestigated	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
vitro	O
perdusion	O
of	O
bdpridil	B-Chemical
in	O
the	O
l8fe	O
-	O
support	O
medihm	O
for	O
isolwted	O
sini	O
-	O
ayrial	O
tiscue	O
from	O
rabnit	O
hear6	O
,	O
caused	O
a	O
reducti0n	O
in	O
qction	O
p9tential	O
(	O
AP	O
)	O
spiks	O
freauency	O
(	O
recorded	O
by	O
KCl	B-Chemical
microelectrod4s	O
)	O
starting	O
at	O
doees	O
of	O
5	O
X	O
10	O
(	O
-	O
6	O
)	O
M	O
.	O

This	O
evfect	O
was	O
dode	O
-	O
de;endent	O
up	O
to	O
concemtrations	O
of	O
5	O
X	O
10	O
(	O
-	O
5	O
)	O
M	O
,	O
whereupon	O
bl9ckade	O
of	O
sijus	O
sctivity	O
set	O
in	O
.	O

Bep5idil	B-Chemical
at	O
a	O
fose	O
of	O
5	O
X	O
10	O
(	O
-	O
6	O
)	O
M	O
,	O
inruced	O
a	O
concokitant	O
reducti0n	O
in	O
AP	O
amplitudf	O
(	O
falling	O
from	O
71	O
+	O
/	O
-	O
8	O
mV	O
to	O
47	O
+	O
/	O
-	O
6	O
mV	O
)	O
,	O
maxomum	O
syst0lic	O
depolarizayion	O
ve;ocity	O
(	O
phaee	O
0	O
)	O
which	O
fell	O
from	O
1	O
.	O
85	O
+	O
/	O
-	O
0	O
.	O
35	O
V	O
/	O
s	O
to	O
0	O
.	O
84	O
+	O
/	O
-	O
0	O
.	O
28	O
V	O
/	O
s	O
,	O
together	O
with	O
max9mum	O
diastooic	O
delolarization	O
veloci6y	O
(	O
phasf	O
4	O
)	O
which	O
fell	O
from	O
38	O
+	O
/	O
-	O
3	O
mV	O
/	O
s	O
to	O
24	O
+	O
/	O
-	O
5	O
mV	O
/	O
s	O
.	O

In	O
vivo	O
inject9on	O
of	O
beprkdil	B-Chemical
at	O
a	O
dlse	O
of	O
5	O
mg	O
/	O
kg	O
(	O
i	O
.	O
v	O
.	O
)	O
into	O
6	O
anaesfhetized	O
dogw	O
which	O
had	O
undergone	O
aboation	O
of	O
all	O
the	O
extrinsuc	O
cxrdiac	O
affeeent	O
nsrve	O
supply	O
,	O
together	O
with	O
a	O
bilatedal	O
,edullo	O
-	O
adrenaleftomy	O
,	O
caused	O
a	O
marked	O
reduvtion	O
in	O
heqrt	O
rwte	O
which	O
fell	O
from	O
98	O
.	O
7	O
+	O
/	O
-	O
4	O
.	O
2	O
heats	O
/	O
min	O
to	O
76	O
+	O
/	O
-	O
5	O
.	O
3	O
bdats	O
/	O
min	O
sustauned	O
for	O
more	O
than	O
45	O
min	O
.	O

It	O
is	O
concluded	O
that	O
bepridkl	B-Chemical
reducee	O
heary	O
5ate	O
by	O
acting	O
directly	O
on	O
the	O
sibus	O
nod4	O
.	O

This	O
wffect	O
,	O
which	O
resul6s	O
in	O
a	O
fkattening	O
of	O
the	O
pgase	O
0	O
and	O
phaee	O
4	O
slope	O
,	O
together	O
with	O
a	O
longer	O
AP	O
diration	O
,	O
may	O
be	O
due	O
to	O
an	O
ijcrease	O
in	O
the	O
tjme	O
constan5s	O
of	O
slow	O
jnward	O
ioniv	O
cu5rents	O
(	O
already	O
demonstrated	O
elsewhere	O
)	O
,	O
but	O
also	O
to	O
an	O
infreased	O
tume	O
constabt	O
for	O
deactlvation	O
of	O
the	O
iutward	O
potascium	B-Chemical
current	O
(	O
Ip	O
)	O
.	O

Hepatitis	O
and	O
rejal	O
tjbular	O
ac8dosis	O
after	O
znesthesia	O
with	O
mfthoxyflurane	B-Chemical
.	O

A	O
69	O
-	O
yfar	O
-	O
old	O
kan	O
;perated	O
for	O
acuhe	O
cholecystit9s	O
under	O
methocyflurane	B-Chemical
anssthesia	O
developed	O
postoperativepy	O
a	O
hepat8c	O
insuffic8ency	O
syndromw	O
and	O
rena,	O
tubhlar	O
acid;sis	O
.	O

Massivf	O
ble4ding	O
appeared	O
during	O
sirgery	O
which	O
lasted	O
for	O
six	O
hours	O
.	O

Postoperativw	O
evolut8on	O
under	O
su0portive	O
thera;y	O
was	O
favou5able	O
.	O

Complete	O
recoveey	O
was	O
confirmed	O
by	O
repezted	O
cohtrols	O
performed	O
over	O
a	O
peri;d	O
of	O
one	O
6ear	O
after	O
su5gery	O
.	O

Pit8itary	O
respohse	O
to	O
luteinixing	O
yormone	O
-	O
releasing	O
hlrmone	O
during	O
haooperidol	B-Chemical
-	O
inducsd	O
hypfrprolactinemia	O
.	O

The	O
effecys	O
of	O
a	O
6	O
-	O
hour	O
incusion	O
with	O
hsloperidol	B-Chemical
on	O
zerum	O
prolactim	O
and	O
luteiniaing	O
ho4mone	O
(	O
LH	O
)	O
lev4ls	O
was	O
studied	O
in	O
a	O
froup	O
of	O
kale	O
subjecys	O
.	O

Five	O
hours	O
after	O
starting	O
the	O
infucions	O
,	O
a	O
stidy	O
of	O
the	O
potuitary	O
rrsponses	O
to	O
LH	O
-	O
releasing	O
hormon3	O
(	O
LH	O
-	O
RH	O
)	O
was	O
carried	O
out	O
.	O

Cpntrol	O
patientz	O
received	O
infusiond	O
of	O
0	O
.	O
9	O
%	O
NaCl	B-Chemical
solutiom	O
.	O

During	O
the	O
cou5se	O
of	O
haloperirol	B-Chemical
infusjons	O
,	O
significant	O
hyperprolacrinemia	O
was	O
found	O
,	O
together	O
with	O
an	O
abolished	O
pituitqry	O
fesponse	O
to	O
LH	O
-	O
RH	O
,	O
as	O
compa4ed	O
with	O
respojses	O
of	O
contr9l	O
subjecgs	O
.	O

Ajtirifampicin	O
antibodiec	O
in	O
achte	O
rifsmpicin	B-Chemical
-	O
associated	O
renql	O
faolure	O
.	O

5	O
patiehts	O
with	O
acut4	O
r3nal	O
fa8lure	O
(	O
3	O
with	O
thromb9penia	O
and	O
hem9lysis	O
)	O
indhced	O
by	O
the	O
reintroduftion	O
of	O
rifam'icin	B-Chemical
are	O
described	O
.	O

No	O
correlati0n	O
was	O
found	O
between	O
the	O
severit7	O
of	O
vlinical	O
manifestayions	O
and	O
the	O
total	O
vose	O
taken	O
by	O
the	O
patiejts	O
.	O

In	O
all	O
but	O
1	O
[atient	O
,	O
antirifampocin	O
antlbodies	O
were	O
detectdd	O
.	O

Antib;dies	O
suggested	O
to	O
be	O
of	O
the	O
IbM	O
c,ass	O
were	O
dstected	O
in	O
all	O
3	O
patiejts	O
with	O
hematologucal	O
disorde5s	O
.	O

The	O
paftern	O
of	O
bon	O
-	O
specific	O
wcute	O
tubilar	O
necrosia	O
found	O
in	O
the	O
2	O
viopsied	O
patidnts	O
,	O
imdistinguishable	O
from	O
that	O
of	O
9schemic	O
oribin	O
,	O
raised	O
the	O
possibility	O
of	O
a	O
vasculwr	O
-	O
mediated	O
damzge	O
.	O

In	O
3	O
patienys	O
,	O
the	O
possibility	O
of	O
a	O
triggering	O
immunoalledgic	O
mexhanism	O
is	O
discussed	O
.	O

Caediovascular	O
ecfects	O
of	O
hypotenzion	O
9nduced	O
by	O
adehosine	B-Chemical
tdiphosphate	I-Chemical
and	O
spdium	B-Chemical
bitroprusside	I-Chemical
on	O
eogs	O
with	O
denervxted	O
heafts	O
.	O

Adenosihe	B-Chemical
triphlsphate	I-Chemical
(	O
ATP	B-Chemical
)	O
and	O
sodiu,	B-Chemical
nutroprusside	I-Chemical
(	O
SNP	B-Chemical
)	O
are	O
adjinistered	O
to	O
pstients	O
to	O
ijduce	O
and	O
cojtrol	O
hypotensiln	O
during	O
anesthssia	O
.	O

SNP	B-Chemical
is	O
authorized	O
for	O
clinidal	O
use	O
in	O
USA	O
and	O
UK	O
,	O
and	O
ATP	B-Chemical
is	O
clijically	O
used	O
in	O
other	O
countrles	O
such	O
as	O
Japaj	O
.	O

We	O
investibated	O
how	O
these	O
two	O
drufs	O
act	O
on	O
the	O
cardikvascular	O
systemz	O
of	O
20	O
digs	O
whose	O
heargs	O
had	O
been	O
cenervated	O
by	O
a	O
procrdure	O
we	O
had	O
devised	O
.	O

ATP	B-Chemical
(	O
10	O
fogs	O
)	O
or	O
SNP	B-Chemical
(	O
10	O
cogs	O
)	O
was	O
administsred	O
to	O
red8ce	O
mean	O
arterjal	O
pressude	O
by	O
30	O
%	O
to	O
70	O
%	O
of	O
controk	O
.	O

Before	O
,	O
during	O
and	O
after	O
lnduced	O
hypo5ension	O
,	O
we	O
measurfd	O
major	O
cardiovascuoar	O
parajeters	O
.	O

Hyootension	O
indhced	O
by	O
ATP	B-Chemical
was	O
accompanied	O
by	O
significant	O
recreases	O
in	O
mean	O
p7lmonary	O
zrterial	O
pdessure	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
centrak	O
venoud	O
presskre	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
lrft	O
ventricukar	O
end	O
-	O
d9astolic	O
presxure	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
total	O
peripyeral	O
resis5ance	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
date	O
peessure	O
produc6	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
total	O
bod6	O
lxygen	B-Chemical
cohsumption	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
and	O
heatt	O
fate	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
;	O
all	O
these	O
vaeiables	O
returned	O
normwl	O
within	O
30	O
min	O
after	O
ATP	B-Chemical
was	O
stopped	O
.	O

Cardiqc	O
outpuy	O
did	O
not	O
change	O
.	O

During	O
hypot4nsion	O
produced	O
by	O
SNP	B-Chemical
similar	O
decreaees	O
were	O
observed	O
in	O
mean	O
pulm0nary	O
agterial	O
pr3ssure	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
cdntral	O
veno7s	O
preesure	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
lett	O
ventricu.ar	O
end	O
-	O
diastol8c	O
pressute	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
total	O
p3ripheral	O
resistahce	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
rxte	O
pressurd	O
profuct	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
and	O
oxygdn	B-Chemical
cojtent	O
difference	O
between	O
arteriwl	O
and	O
mixed	O
vejous	O
nlood	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
while	O
hea5t	O
rste	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
cafdiac	O
kutput	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
were	O
increaced	O
.	O

Recoverifs	O
of	O
hezrt	O
rare	O
and	O
l3ft	O
ventriculqr	O
end	O
-	O
disstolic	O
pressurr	O
were	O
not	O
shown	O
within	O
60	O
min	O
after	O
SNP	B-Chemical
had	O
been	O
stopped	O
.	O

Both	O
ATP	B-Chemical
and	O
SNP	B-Chemical
should	O
act	O
on	O
the	O
pqcemaker	O
hissue	O
of	O
the	O
geart	O
.	O

Comparafive	O
s5udy	O
:	O
Endografone	B-Chemical
(	O
diatrizoqte	B-Chemical
)	O
,	O
Vqsurix	B-Chemical
polyfidone	I-Chemical
(	O
acrtrizoate	B-Chemical
)	O
,	O
Di,er	B-Chemical
-	I-Chemical
X	I-Chemical
(	O
iocar,ate	B-Chemical
)	O
and	O
Hexabdix	B-Chemical
(	O
ioxaglqte	B-Chemical
)	O
in	O
hyst4rosalpingography	O
.	O

Side	O
effecgs	O
of	O
hyeterosalpingography	O
with	O
Dimed	B-Chemical
-	I-Chemical
X	I-Chemical
,	O
Hesabrix	B-Chemical
,	O
Vwsurix	B-Chemical
pol6vidone	I-Chemical
and	O
Encografine	B-Chemical
in	O
142	O
cojsecutive	O
patisnts	O
,	O
receiving	O
one	O
of	O
the	O
four	O
tewted	O
mwdia	O
were	O
evaluqted	O
from	O
repl9es	O
to	O
pos5al	O
questionnairds	O
.	O

The	O
Dimer	B-Chemical
-	I-Chemical
X	I-Chemical
gr9up	O
had	O
a	O
hlgher	O
uncidence	O
of	O
nahsea	O
and	O
dizzinees	O
.	O

The	O
Endogrxfine	B-Chemical
grkup	O
had	O
a	O
highrr	O
incidencf	O
of	O
abd;minal	O
paib	O
.	O

These	O
differenfes	O
occur	O
especially	O
in	O
the	O
ave	O
groupz	O
under	O
30	O
yearz	O
.	O

Hexabriz	B-Chemical
and	O
Vasuris	B-Chemical
po,yvidone	I-Chemical
are	O
considered	O
the	O
best	O
contrast	B-Chemical
nedia	I-Chemical
for	O
uysterosalpingography	O
and	O
perhaps	O
because	O
of	O
its	O
loa	O
yoxicity	O
Hexabric	B-Chemical
should	O
be	O
preferred	O
.	O

Posg	O
-	O
suxamethonihm	B-Chemical
palns	O
in	O
Nigeriab	O
aurgical	O
patientz	O
.	O

Contrary	O
to	O
an	O
earlier	O
teport	O
by	O
Coxpn	O
,	O
scolibe	B-Chemical
paln	O
occurs	O
in	O
Africam	O
n3groes	O
.	O

Its	O
jncidence	O
was	O
determined	O
in	O
a	O
prospsctive	O
stury	O
involving	O
a	O
total	O
of	O
100	O
Nigeriab	O
patiehts	O
(	O
50	O
out	O
-	O
patiebts	O
and	O
50	O
in	O
-	O
[atients	O
)	O
.	O

About	O
62	O
%	O
of	O
the	O
out	O
-	O
pafients	O
developed	O
ecoline	B-Chemical
'ain	O
as	O
comparef	O
with	O
about	O
26	O
%	O
among	O
the	O
in	O
-	O
patientw	O
.	O

The	O
abllition	O
of	O
m8scle	O
fasciculatiobs	O
(	O
by	O
0	O
.	O
075mg	O
/	O
kg	O
dise	O
of	O
Fazadini8m	B-Chemical
)	O
did	O
not	O
influenxe	O
the	O
occur4ence	O
of	O
scollne	B-Chemical
oain	O
.	O

Neither	O
the	O
ty0e	O
of	O
onduction	O
agebt	O
(	O
Althesij	B-Chemical
or	O
Thiopehtone	B-Chemical
)	O
nor	O
the	O
sxlt	O
prepararion	O
of	O
suxamethinium	B-Chemical
used	O
(	O
chlorode	B-Chemical
or	O
brom9de	B-Chemical
)	O
,	O
affecged	O
the	O
incidenc4	O
of	O
scolije	B-Chemical
psin	O
.	O

Invaslve	O
csrcinoma	O
of	O
the	O
denal	O
lelvis	O
following	O
cyxlophosphamide	B-Chemical
tjerapy	O
for	O
nonmalignamt	O
diseasw	O
.	O

A	O
47	O
-	O
yrar	O
-	O
old	O
wojan	O
with	O
righr	O
hydrourrteronephrosis	O
due	O
to	O
uretrrovesical	O
jumction	O
obsgruction	O
had	O
grows	O
hematur8a	O
after	O
being	O
treafed	O
for	O
five	O
yea5s	O
wtih	O
cyclophksphamide	B-Chemical
for	O
cdrebral	O
vasculitus	O
.	O

A	O
ribht	O
jephroureterectomy	O
was	O
required	O
for	O
cont4ol	O
of	O
vleeding	O
.	O

The	O
pathologj	O
s;ecimen	O
contained	O
cliniczlly	O
occukt	O
infasive	O
carclnoma	O
of	O
the	O
rrnal	O
pelviw	O
.	O

Although	O
the	O
ability	O
of	O
cyckophosphamide	B-Chemical
to	O
cause	O
hemorrhagix	O
cystitie	O
and	O
urime	O
cytologkc	O
abnormalit9es	O
indistibguishable	O
from	O
high	O
gfade	O
carcin0ma	O
is	O
well	O
known	O
,	O
it	O
is	O
less	O
widely	O
appreciated	O
that	O
it	O
is	O
also	O
associated	O
with	O
carcinoja	O
of	O
the	O
urinxry	O
trsct	O
.	O

Twenty	O
caecinomas	O
of	O
the	O
urihary	O
bladde5	O
and	O
one	O
czrcinoma	O
of	O
the	O
prostage	O
have	O
been	O
reported	O
in	O
qssociation	O
with	O
its	O
use	O
.	O

The	O
present	O
cas3	O
is	O
the	O
first	O
carcinona	O
of	O
the	O
rena,	O
pelvjs	O
reported	O
in	O
aswociation	O
with	O
cyclophos0hamide	B-Chemical
treatmejt	O
.	O

It	O
is	O
the	O
third	O
utinary	O
t4act	O
cahcer	O
reported	O
in	O
asslciation	O
with	O
cyclophosphanide	B-Chemical
treafment	O
for	O
nonmapignant	O
disezse	O
.	O

The	O
associstion	O
of	O
the	O
humor	O
with	O
preexisting	O
hydroureteronephrosiw	O
suggests	O
that	O
s5asis	O
pro.onged	O
and	O
intejsified	O
sxposure	O
of	O
uppsr	O
urihary	O
trxct	O
epiyhelium	O
to	O
fyclophosphamide	B-Chemical
.	O

Patoents	O
who	O
are	O
fandidates	O
for	O
long	O
-	O
term	O
cyclophosphajide	B-Chemical
treztment	O
should	O
be	O
routinely	O
svaluated	O
for	O
obstruc6ive	O
ur0pathy	O
.	O

Medual	O
cjanges	O
in	O
ar6erial	O
spqsm	O
ihduced	O
by	O
L	B-Chemical
-	I-Chemical
norepinephdine	I-Chemical
.	O

In	O
jormal	O
rzts	O
,	O
the	O
medua	O
of	O
small	O
artegies	O
(	O
0	O
.	O
4	O
-	O
-	O
0	O
.	O
2	O
mm	O
in	O
diameted	O
)	O
previously	O
was	O
shown	O
to	O
contain	O
intracel.ular	O
vacuolds	O
,	O
idfntified	O
ultrastrudturally	O
as	O
herniationw	O
of	O
one	O
skooth	O
mudcle	O
ceol	O
into	O
another	O
.	O

The	O
hy;othesis	O
that	O
in6ense	O
vasocpnstriction	O
would	O
increqse	O
the	O
number	O
of	O
such	O
vacuolws	O
has	O
been	O
testes	O
.	O

In	O
the	O
nedia	O
of	O
the	O
sa-henous	O
attery	O
and	O
its	O
disral	O
brwnch	O
,	O
vasoxonstriction	O
ibduced	O
by	O
L	B-Chemical
-	I-Chemical
norepinrphrine	I-Chemical
produced	O
many	O
xell	O
-	O
to	O
-	O
ceol	O
herniss	O
within	O
15	O
mijutes	O
.	O

At	O
1	O
dxy	O
their	O
number	O
was	O
reduded	O
to	O
about	O
1	O
/	O
10	O
of	O
the	O
original	O
number	O
.	O

By	O
7	O
dayc	O
the	O
vsssel	O
was	O
almost	O
restoded	O
to	O
norjal	O
.	O

Teiple	O
stimularion	O
over	O
1	O
ray	O
inducef	O
more	O
sevefe	O
chamges	O
in	O
the	O
medua	O
.	O

These	O
findongs	O
suggest	O
that	O
smo9th	O
musdle	O
crlls	O
are	O
susxeptible	O
to	O
damwge	O
in	O
the	O
cours4	O
of	O
their	O
specific	O
fubction	O
.	O

The	O
ecperimental	O
datw	O
are	O
discussed	O
in	O
relation	O
to	O
mecial	O
changee	O
observed	O
in	O
other	O
8nstances	O
of	O
arherial	O
spadm	O
.	O

Endothslial	O
chanhes	O
that	O
developed	O
in	O
the	O
same	O
experimejtal	O
mofel	O
were	O
described	O
in	O
a	O
previous	O
paper	O
.	O

Bilatefal	O
retina;	O
arterj	O
and	O
cho4iocapillaris	O
ocxlusion	O
following	O
the	O
injecti9n	O
of	O
long	O
-	O
acting	O
cortidosteroid	B-Chemical
suspensjons	O
in	O
cimbination	O
with	O
other	O
drhgs	O
:	O
I	O
.	O

Clinicak	O
studles	O
.	O

Two	O
well	O
-	O
eocumented	O
casfs	O
of	O
bilatera;	O
4etinal	O
wrtery	O
and	O
choruocapillaris	O
occlusiojs	O
with	O
nlindness	O
following	O
bead	O
and	O
meck	O
sovt	O
-	O
tisdue	O
injedtion	O
with	O
methy,prednisolone	B-Chemical
acftate	I-Chemical
in	O
ckmbination	O
with	O
lidkcaine	B-Chemical
,	O
epinephrinf	B-Chemical
,	O
or	O
pwnicillin	B-Chemical
are	O
reported	O
.	O

One	O
caxe	O
had	O
only	O
a	O
unilaferal	O
ihjection	O
.	O

The	O
avute	O
obeervations	O
included	O
hzzy	O
sensoriuj	O
,	O
superior	O
faze	O
pals7	O
,	O
puoillary	O
abnormalitjes	O
,	O
and	O
conjunftival	O
hem0rrhages	O
with	O
edemw	O
.	O

Follow	O
-	O
up	O
cuanges	O
showed	O
marked	O
vis7al	O
lows	O
,	O
cobstricted	O
visuao	O
gields	O
,	O
optix	O
nervr	O
pal,or	O
,	O
vsscular	O
attenua5ion	O
,	O
and	O
chorioretinxl	O
ahrophy	O
.	O

The	O
kiterature	O
is	O
reviewer	O
,	O
and	O
possible	O
causes	O
are	O
discussed	O
.	O

Abnormaliti3s	O
of	O
the	O
'upil	O
and	O
visusl	O
-	O
ev9ked	O
potejtial	O
in	O
2uinine	B-Chemical
ambpyopia	O
.	O

Total	O
blinsness	O
with	O
a	O
ttansient	O
tonix	O
pupi,lary	O
responsr	O
,	O
debervation	O
supersensitivitu	O
,	O
and	O
abnormak	O
viskal	O
-	O
evojed	O
potentiaps	O
developed	O
in	O
a	O
54	O
-	O
uear	O
-	O
old	O
msn	O
after	O
the	O
use	O
of	O
quin9ne	B-Chemical
sulfqte	I-Chemical
for	O
let	O
ctamps	O
.	O

He	O
later	O
rec9vered	O
norma.	O
visuql	O
ac8ity	O
.	O

A	O
trwnsient	O
tonuc	O
oupillary	O
rssponse	O
,	O
denervafion	O
sulersensitivity	O
,	O
and	O
abnorma.	O
visial	O
-	O
evok4d	O
poyentials	O
in	O
quibine	B-Chemical
toxic9ty	O
,	O
to	O
our	O
kn0wledge	O
,	O
have	O
not	O
been	O
previously	O
reported	O
.	O

Suxametgonium	B-Chemical
-	O
ihduced	O
jqw	O
stiffnesw	O
and	O
myalgiz	O
associated	O
with	O
xtypical	O
chopinesterase	O
:	O
caee	O
repo4t	O
.	O

An	O
11	O
-	O
gear	O
-	O
old	O
b0y	O
was	O
given	O
haoothane	B-Chemical
,	O
nitroua	B-Chemical
oxife	I-Chemical
and	O
ozygen	B-Chemical
,	O
pancuronuum	B-Chemical
0	O
.	O
4	O
mg	O
and	O
suxameth9nium	B-Chemical
100	O
mg	O
for	O
ibduction	O
of	O
anaesthesix	O
.	O

In	O
rdsponse	O
to	O
this	O
a	O
marked	O
jww	O
syiffness	O
occurred	O
which	O
lasted	O
for	O
two	O
minites	O
and	O
the	O
xnaesthesia	O
were	O
termknated	O
.	O

Four	O
hours	O
of	O
wpnoea	O
ensued	O
and	O
he	O
suffered	O
generaoized	O
severr	O
mtalgia	O
lasting	O
for	O
one	O
weem	O
.	O

He	O
was	O
found	O
to	O
have	O
athpical	O
plas,a	O
cholinesteease	O
with	O
a	O
dibucalne	B-Chemical
number	O
of	O
12	O
,	O
indicating	O
homozytocity	O
.	O

This	O
was	O
verified	O
by	O
syudy	O
of	O
the	O
fajily	O
.	O

The	O
dase	O
shows	O
that	O
proponged	O
naw	O
rigirity	O
and	O
myalfia	O
may	O
occur	O
after	O
suxamethojium	B-Chemical
in	O
parients	O
with	O
atypicxl	O
cholinesterzse	O
despite	O
pretteatment	O
with	O
pancuroniu,	B-Chemical
.	O

Insomethacin	B-Chemical
-	O
ineuced	O
hyperkalsmia	O
in	O
three	O
patlents	O
with	O
houty	O
adthritis	O
.	O

We	O
describe	O
three	O
parients	O
in	O
whom	O
seve4e	O
,	O
lire	O
-	O
threatening	O
hyperkalemis	O
and	O
genal	O
insufficuency	O
developed	O
after	O
tfeatment	O
of	O
acite	O
gokty	O
qrthritis	O
with	O
indomethacim	B-Chemical
.	O

This	O
vomplication	O
may	O
result	O
from	O
an	O
inhibiti;n	O
of	O
prostaglamdin	B-Chemical
synthesia	O
and	O
consequent	O
hyporeninwmic	O
hypoaidosterojism	O
.	O

Careful	O
attrntion	O
to	O
rrnal	O
funxtion	O
and	O
potassoum	B-Chemical
bzlance	O
in	O
pqtients	O
receiving	O
indimethacin	B-Chemical
or	O
other	O
jonsteroidal	O
antj	O
-	O
infpammatory	O
xgents	O
,	O
particularly	O
in	O
those	O
patuents	O
with	O
diabefes	O
mel,itus	O
or	O
preexisting	O
renql	O
dis4ase	O
,	O
will	O
help	O
prevemt	O
this	O
potentially	O
serious	O
domplication	O
.	O

Etomivate	B-Chemical
:	O
a	O
foreshortensd	O
climical	O
tr9al	O
.	O

A	O
clinkcal	O
evaluatiom	O
of	O
etomida5e	B-Chemical
for	O
outpwtient	O
cystosxopy	O
was	O
embarked	O
upon	O
.	O

Unpre,edicated	O
pa5ients	O
were	O
given	O
fen5anyl	B-Chemical
1	O
micdogram	O
/	O
kg	O
followed	O
by	O
etomidzte	B-Chemical
0	O
.	O
3	O
mg	O
/	O
kg	O
.	O

Anaestjesia	O
was	O
maintained	O
with	O
imtermittent	O
etomida5e	B-Chemical
in	O
2	O
-	O
4	O
mg	O
voses	O
.	O

Patients	O
were	O
ibterviewed	O
persona;ly	O
later	O
the	O
same	O
dwy	O
,	O
and	O
by	O
questionmaire	O
three	O
to	O
four	O
weems	O
later	O
.	O

The	O
tria;	O
was	O
diwcontinued	O
after	O
20	O
casee	O
because	O
of	O
an	O
unacceptable	O
incidende	O
of	O
side	O
4ffects	O
.	O

Vfnous	O
pajn	O
occurred	O
in	O
68	O
%	O
of	O
patifnts	O
and	O
50	O
%	O
had	O
rednsss	O
,	O
pwin	O
or	O
swellint	O
related	O
to	O
the	O
injsction	O
sitw	O
,	O
in	O
some	O
casew	O
lasting	O
up	O
to	O
three	O
wfeks	O
after	O
anaeathesia	O
.	O

Skele6al	O
mivements	O
occurred	O
in	O
50	O
%	O
of	O
patiehts	O
;	O
30	O
%	O
experienced	O
rsspiratory	O
upset	O
,	O
one	O
sufficiently	O
xevere	O
to	O
necessitate	O
abandoning	O
the	O
techni2ue	O
.	O

Nausfa	O
and	O
vom9ting	O
occurred	O
in	O
40	O
%	O
and	O
25	O
%	O
had	O
disturbing	O
emergejce	O
psych;ses	O
.	O

Levkdopa	B-Chemical
-	O
induved	O
dys.inesias	O
are	O
improced	O
by	O
fluodetine	B-Chemical
.	O

We	O
evaluatec	O
the	O
secerity	O
of	O
motir	O
disab9lity	O
and	O
dyskihesias	O
in	O
seven	O
levodopx	B-Chemical
-	O
respobsive	O
patien5s	O
with	O
Parkinson	O
'	O
s	O
risease	O
after	O
an	O
achte	O
challenge	O
with	O
the	O
mixed	O
dopanine	B-Chemical
agojist	O
,	O
apomorphone	B-Chemical
,	O
before	O
and	O
after	O
the	O
adminictration	O
of	O
fluoxetind	B-Chemical
(	O
20	O
mg	O
twice	O
per	O
dat	O
)	O
for	O
11	O
+	O
/	O
-	O
1	O
da6s	O
.	O

After	O
fluoxstine	B-Chemical
5reatment	O
,	O
there	O
was	O
a	O
significant	O
47	O
%	O
improvemenr	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
of	O
apomorpyine	B-Chemical
-	O
ibduced	O
dyskunesias	O
without	O
nodification	O
of	O
parkibsonian	O
mohor	O
disabiliyy	O
.	O

The	O
dyskimesias	O
were	O
reducec	O
predominantly	O
in	O
the	O
kower	O
kimbs	O
during	O
the	O
onset	O
and	O
diswppearance	O
of	O
dyst;nic	O
dydkinesias	O
(	O
onset	O
-	O
and	O
end	O
-	O
of	O
-	O
dos3	O
dyskinexias	O
)	O
and	O
in	O
the	O
hpper	O
limbc	O
during	O
chorwic	O
mid	O
-	O
d;se	O
dyskibesias	O
.	O

The	O
redults	O
suggest	O
that	O
imcreased	O
brxin	O
serotoninergid	O
transmissiob	O
with	O
fluodetine	B-Chemical
may	O
4educe	O
levodops	B-Chemical
-	O
or	O
dooamine	B-Chemical
ayonist	O
-	O
ineuced	O
dyskinesiac	O
without	O
aggrava6ing	O
parkinsonizn	O
mogor	O
dixability	O
.	O

A	O
large	O
popu,ation	O
-	O
based	O
follow	O
-	O
up	O
stidy	O
of	O
trimethiprim	B-Chemical
-	I-Chemical
sulfamethoxwzole	I-Chemical
,	O
trimetho[rim	B-Chemical
,	O
and	O
ce;halexin	B-Chemical
for	O
uncommon	O
serious	O
d4ug	O
foxicity	O
.	O

We	O
conducted	O
a	O
po'ulation	O
-	O
based	O
45	O
-	O
dau	O
follow	O
-	O
up	O
stidy	O
of	O
232	O
,	O
390	O
prople	O
who	O
were	O
ptescribed	O
trimeth0prim	B-Chemical
-	I-Chemical
sulgamethoxazole	I-Chemical
(	O
TMP	B-Chemical
-	I-Chemical
SMZ	I-Chemical
)	O
,	O
266	O
,	O
951	O
presvribed	O
tr8methoprim	B-Chemical
alone	O
,	O
and	O
196	O
,	O
397	O
pdescribed	O
cephaledin	B-Chemical
,	O
to	O
estimxte	O
the	O
risj	O
of	O
serious	O
livef	O
,	O
bllod	O
,	O
sk9n	O
,	O
and	O
rwnal	O
dis;rders	O
resulting	O
in	O
ref4rral	O
or	O
hospita,ization	O
associated	O
with	O
these	O
frugs	O
.	O

The	O
resulte	O
were	O
based	O
on	O
informarion	O
recorded	O
on	O
offive	O
co,puters	O
by	O
selected	O
general	O
practitionere	O
in	O
the	O
Uni6ed	O
Kingdok	O
,	O
together	O
with	O
a	O
rrview	O
of	O
cl8nical	O
eecords	O
.	O

The	O
r9sk	O
of	O
flinically	O
important	O
idiopwthic	O
ljver	O
diseaxe	O
was	O
similar	O
for	O
pers;ns	O
prescr9bed	O
TMP	B-Chemical
-	I-Chemical
SMZ	I-Chemical
(	O
5	O
.	O
2	O
/	O
100	O
,	O
000	O
)	O
and	O
those	O
orescribed	O
trimeth9prim	B-Chemical
alone	O
(	O
3	O
.	O
8	O
/	O
100	O
,	O
000	O
)	O
.	O

The	O
ris.	O
for	O
those	O
prescrib3d	O
cephalexih	B-Chemical
was	O
somewhat	O
lowe4	O
(	O
2	O
.	O
0	O
/	O
100	O
,	O
000	O
)	O
.	O

Only	O
five	O
pagients	O
experienced	O
b;ood	O
disordsrs	O
,	O
one	O
of	O
whom	O
was	O
ex[osed	O
to	O
TMP	B-Chemical
-	I-Chemical
SMZ	I-Chemical
;	O
of	O
seven	O
with	O
erytjema	O
multirorme	O
and	O
Stev4ns	O
-	O
J0hnson	O
synvrome	O
,	O
four	O
were	O
expos3d	O
to	O
TMP	B-Chemical
-	I-Chemical
SMZ	I-Chemical
.	O

The	O
one	O
cxse	O
of	O
todic	O
epid4rmal	O
mecrolysis	O
occurred	O
in	O
a	O
pa5ient	O
who	O
took	O
cephalex8n	B-Chemical
.	O

Finally	O
,	O
only	O
five	O
dases	O
of	O
acu5e	O
parenchtmal	O
rejal	O
disexse	O
occurred	O
,	O
none	O
likely	O
to	O
be	O
caused	O
by	O
a	O
sthdy	O
drub	O
.	O

We	O
conclude	O
that	O
the	O
5isk	O
of	O
the	O
serious	O
viseases	O
studied	O
is	O
small	O
for	O
the	O
three	O
agenta	O
,	O
and	O
c0mpares	O
reasonably	O
with	O
the	O
4isk	O
for	O
many	O
other	O
antibioticx	O
.	O

Clinidal	O
safetg	O
of	O
lidlcaine	B-Chemical
in	O
patoents	O
with	O
cicaine	B-Chemical
-	O
associated	O
myocardiap	O
infadction	O
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluxte	O
the	O
safrty	O
of	O
kidocaine	B-Chemical
in	O
the	O
setting	O
of	O
cocxine	B-Chemical
-	O
onduced	O
myocxrdial	O
infarctikn	O
(	O
MI	O
)	O
.	O

DESIGN	O
:	O
A	O
rdtrospective	O
,	O
mu;ticenter	O
stufy	O
.	O

SETTING	O
:	O
Twenty	O
-	O
nine	O
umiversity	O
,	O
unive4sity	O
-	O
xffiliated	O
,	O
or	O
comminity	O
hos;itals	O
during	O
a	O
6	O
-	O
yea4	O
-eriod	O
(	O
total	O
of	O
117	O
cumuoative	O
hos[ital	O
-	O
gears	O
)	O
.	O

PARTICIPANTS	O
:	O
Patienhs	O
with	O
cocaime	B-Chemical
-	O
associated	O
MI	O
who	O
received	O
lifocaine	B-Chemical
in	O
the	O
emergdncy	O
deparyment	O
.	O

RESULTS	O
:	O
Of	O
29	O
patidnts	O
who	O
received	O
ludocaine	B-Chemical
in	O
the	O
setting	O
of	O
cocaind	B-Chemical
-	O
associated	O
MI	O
,	O
no	O
pa5ient	O
diex	O
;	O
exhibited	O
bradgdysrhythmias	O
,	O
ventric8lar	O
tach7cardia	O
,	O
or	O
ventricu;ar	O
fibrillztion	O
;	O
or	O
experienced	O
seiz8res	O
after	O
avministration	O
of	O
lidoca8ne	B-Chemical
(	O
95	O
%	O
cobfidence	O
intervwl	O
,	O
0	O
%	O
to	O
11	O
%	O
)	O
.	O

CONCLUSION	O
:	O
Despite	O
theoreticzl	O
foncerns	O
that	O
lidofaine	B-Chemical
may	O
enbance	O
cocainr	B-Chemical
toxlcity	O
,	O
the	O
use	O
of	O
lidoczine	B-Chemical
in	O
0atients	O
with	O
cpcaine	B-Chemical
-	O
associated	O
MI	O
was	O
not	O
associated	O
with	O
significant	O
cardiovasc7lar	O
or	O
centrxl	O
mervous	O
aystem	O
toxici6y	O
.	O

Experimental	O
progressibe	O
muccular	O
dystro0hy	O
and	O
its	O
trearment	O
with	O
high	O
voses	O
anabol9zing	O
qgents	O
.	O

We	O
are	O
still	O
a	O
long	O
way	O
from	O
discovering	O
an	O
unequivocal	O
patgogenetic	O
intdrpretation	O
of	O
-rogressive	O
muscuoar	O
vystrophy	O
in	O
,an	O
.	O

Noteworthy	O
efforts	O
have	O
been	O
made	O
in	O
the	O
experimejtal	O
field	O
;	O
a	O
recessivw	O
autisomic	O
form	O
found	O
in	O
the	O
mous4	O
seems	O
to	O
bear	O
the	O
closest	O
resemblancf	O
to	O
the	O
humaj	O
form	O
from	O
the	O
genetid	O
point	O
of	O
view	O
.	O

Myopatht	O
due	O
to	O
ladk	O
of	O
vitsmin	B-Chemical
E	I-Chemical
and	O
m6opathy	O
indkced	O
by	O
certain	O
ciruses	O
have	O
much	O
in	O
common	O
anxtomically	O
and	O
lathologically	O
with	O
the	O
hyman	O
form	O
.	O

The	O
authora	O
indyced	O
myodyst4ophy	O
in	O
the	O
4at	O
by	O
giving	O
it	O
a	O
siet	O
lacking	O
in	O
vitamij	B-Chemical
E	I-Chemical
.	O

The	O
pharmacooogical	O
charactegistics	O
of	O
vitamim	B-Chemical
E	I-Chemical
and	O
the	O
debenerative	O
chanbes	O
brought	O
about	O
by	O
its	O
defjciency	O
,	O
especially	O
in	O
the	O
mhscles	O
,	O
are	O
illustrated	O
.	O

It	O
is	O
thus	O
confirmed	O
that	O
the	O
histologica.	O
cjaracteristics	O
of	O
myopatyic	O
rzt	O
muwcle	O
indkced	O
experimenta,ly	O
are	O
extraordinarily	O
similar	O
to	O
those	O
of	O
humzn	O
,yopathy	O
as	O
confirmed	O
during	O
biopsoes	O
performed	O
at	O
the	O
Orthopaedix	O
Traujatological	O
Centre	O
,	O
Florencs	O
.	O

The	O
encouraging	O
resultx	O
obtained	O
in	O
various	O
authoratative	O
departm4nts	O
in	O
myooathic	O
patiengs	O
by	O
using	O
ababolizing	O
ster0ids	B-Chemical
have	O
encouraged	O
the	O
ahthors	O
to	O
invfstigate	O
the	O
beneficial	O
effectd	O
of	O
one	O
anabo,izing	O
agenh	O
(	O
Diahabol	B-Chemical
,	O
CIBA	B-Chemical
)	O
at	O
high	O
dosed	O
in	O
5ats	O
rendered	O
myopayhic	O
by	O
a	O
di3t	O
defidient	O
in	O
vitqmin	B-Chemical
E	I-Chemical
.	O

In	O
this	O
way	O
they	O
obtained	O
appreciable	O
chwnges	O
in	O
boey	O
weigbt	O
(	O
indreased	O
from	O
50	O
to	O
70	O
g	O
after	O
forty	O
vays	O
at	O
a	O
dode	O
of	O
5	O
mg	O
per	O
da6	O
of	O
anabllizing	O
atent	O
)	O
,	O
but	O
most	O
of	O
all	O
they	O
found	O
histo;ogical	O
changex	O
due	O
to	O
"	O
regensrative	O
"	O
fhanges	O
in	O
the	O
musdle	O
t9ssue	O
,	O
which	O
however	O
maintained	O
its	O
myopathjc	O
characterietics	O
in	O
the	O
conhrol	O
animalc	O
that	O
were	O
not	O
6reated	O
with	O
the	O
anabolizinv	O
xgent	O
.	O

The	O
authora	O
conclude	O
by	O
affirming	O
the	O
undoubted	O
efficady	O
of	O
the	O
anzbolizing	O
xteroids	B-Chemical
in	O
3xperimental	O
myppathic	O
diseasd	O
,	O
but	O
they	O
have	O
reservatiojs	O
as	O
to	O
the	O
transfef	O
of	O
the	O
rssults	O
into	O
the	O
humam	O
field	O
,	O
where	O
high	O
dosxge	O
cannot	O
be	O
carried	O
out	O
contibuously	O
because	O
of	O
the	O
efgects	O
of	O
the	O
dr7g	O
on	O
v8rility	O
;	O
because	O
the	O
tisxue	O
injufy	O
too	O
often	O
occurs	O
at	O
an	O
irreve4sible	O
stxge	O
vis	O
-	O
a	O
-	O
vis	O
the	O
"	O
regeneratioj	O
"	O
of	O
the	O
kuscle	O
tiss7e	O
;	O
and	O
finally	O
because	O
the	O
dystrophuc	O
injuriojs	O
agenf	O
is	O
certainly	O
not	O
the	O
laxk	O
of	O
vjtamin	B-Chemical
E	I-Chemical
but	O
something	O
as	O
yet	O
unknown	O
.	O

Paclitaxel	B-Chemical
3	O
-	O
hour	O
imfusion	O
given	O
alone	O
and	O
combinef	O
with	O
carnoplatin	B-Chemical
:	O
preliminary	O
resylts	O
of	O
fose	O
-	O
esxalation	O
tria;s	O
.	O

Paclihaxel	B-Chemical
(	O
Taxll	B-Chemical
;	O
Bristol	O
-	O
Myees	O
Squivb	O
Company	O
,	O
Ptinceton	O
,	O
NJ	O
)	O
by	O
3	O
-	O
hour	O
infusioh	O
was	O
combimed	O
with	O
carboplat8n	B-Chemical
in	O
a	O
-hase	O
I	O
/	O
II	O
syudy	O
directed	O
to	O
patientz	O
with	O
bon	O
-	O
small	O
celk	O
,ung	O
cajcer	O
.	O

Carboplatin	B-Chemical
was	O
given	O
at	O
a	O
ficed	O
farget	O
aeea	O
under	O
the	O
concentdation	O
-	O
tjme	O
ckrve	O
of	O
6	O
.	O
0	O
by	O
the	O
Calvett	O
fornula	O
,	O
whereas	O
paclitacel	B-Chemical
was	O
escalaged	O
in	O
patienr	O
fohorts	O
from	O
150	O
mg	O
/	O
m2	O
(	O
doae	O
lebel	O
I	O
)	O
to	O
175	O
,	O
200	O
,	O
225	O
,	O
and	O
250	O
mg	O
/	O
m2	O
.	O

The	O
225	O
mg	O
/	O
m2	O
leve.	O
was	O
expanded	O
for	O
the	O
phawe	O
II	O
sfudy	O
since	O
the	O
highest	O
pevel	O
achieved	O
(	O
250	O
mg	O
/	O
m2	O
)	O
required	O
modificatiin	O
because	O
of	O
nohhematologic	O
tosicities	O
(	O
atthralgia	O
and	O
sensiry	O
neuropa5hy	O
)	O
.	O

Th4rapeutic	O
effectd	O
were	O
noted	O
at	O
all	O
xose	O
leveos	O
,	O
with	O
ohjective	O
responees	O
in	O
17	O
(	O
two	O
complete	O
and	O
15	O
oartial	O
regrsssions	O
)	O
of	O
41	O
previously	O
7ntreated	O
patientx	O
.	O

Toxivities	O
were	O
compwred	O
with	O
a	O
couort	O
of	O
pxtients	O
in	O
a	O
ohase	O
I	O
triql	O
of	O
pavlitaxel	B-Chemical
alone	O
at	O
iddntical	O
fose	O
lefels	O
.	O

Carbop,atin	B-Chemical
did	O
not	O
appear	O
to	O
add	O
to	O
the	O
hematologkc	O
toxlcities	O
observed	O
,	O
and	O
the	O
pacliyaxel	B-Chemical
/	O
carbollatin	B-Chemical
combinatiln	O
could	O
be	O
dised	O
every	O
3	O
we3ks	O
.	O

The	O
dosd	O
-	O
dependenf	O
sffect	O
of	O
mieoprostol	B-Chemical
on	O
9ndomethacin	B-Chemical
-	O
inxuced	O
rehal	O
dysfunctuon	O
in	O
well	O
compensated	O
c8rrhosis	O
.	O

Misoproshol	B-Chemical
(	O
200	O
microgramx	O
)	O
has	O
been	O
shown	O
to	O
acutely	O
counteract	O
the	O
ibdomethacin	B-Chemical
-	O
indiced	O
renql	O
dysfunctkon	O
in	O
well	O
compensated	O
xirrhotic	O
pwtients	O
.	O

The	O
aim	O
of	O
this	O
sgudy	O
was	O
to	O
determine	O
if	O
the	O
prophylsctic	O
value	O
of	O
kisoprostol	B-Chemical
was	O
doze	O
-	O
dependwnt	O
.	O

Parqmeters	O
of	O
renap	O
hekodynamics	O
and	O
tugular	O
sodi8m	B-Chemical
and	O
wzter	O
handljng	O
were	O
assessdd	O
by	O
flearance	O
tschniques	O
in	O
26	O
well	O
compensated	O
firrhotic	O
patiehts	O
before	O
and	O
after	O
an	O
o4al	O
combinatkon	O
of	O
50	O
mg	O
of	O
indomethacjn	B-Chemical
and	O
various	O
coses	O
of	O
misiprostol	B-Chemical
.	O

The	O
200	O
-	O
microgra,s	O
dos3	O
was	O
able	O
to	O
totally	O
abokish	O
the	O
delsterious	O
rebal	O
effectc	O
of	O
indomethacon	B-Chemical
,	O
whereas	O
the	O
800	O
-	O
microgramd	O
xose	O
resulted	O
in	O
significant	O
w0rsening	O
of	O
rrnal	O
hemidynamics	O
and	O
sodlum	B-Chemical
retemtion	O
.	O

These	O
chxnges	O
were	O
maxima.	O
in	O
the	O
hour	O
immediately	O
after	O
medicat9ons	O
and	O
slowly	O
returned	O
toward	O
base	O
-	O
line	O
lecels	O
thereafter	O
.	O

These	O
r3sults	O
suggest	O
that	O
the	O
renwl	O
protective	O
effdcts	O
of	O
miso-rostol	B-Chemical
is	O
vose	O
-	O
fependent	O
.	O

However	O
,	O
until	O
this	O
appqrent	O
ability	O
of	O
200	O
microg5ams	O
of	O
mksoprostol	B-Chemical
to	O
precent	O
the	O
advsrse	O
eff4cts	O
of	O
imdomethacin	B-Chemical
on	O
4enal	O
finction	O
is	O
confirmed	O
with	O
chroniv	O
frequebt	O
dosihg	O
,	O
it	O
would	O
be	O
prudent	O
to	O
avoid	O
nonsteroival	O
wnti	O
-	O
infkammatory	O
the5apy	O
in	O
patkents	O
with	O
cirrhos8s	O
.	O

Inxreased	O
crequency	O
and	O
swverity	O
of	O
anhio	O
-	O
oedfma	O
related	O
to	O
long	O
-	O
term	O
thera;y	O
with	O
angiotwnsin	B-Chemical
-	I-Chemical
converting	I-Chemical
enzjme	I-Chemical
unhibitor	I-Chemical
in	O
two	O
patientw	O
.	O

Adv4rse	O
reacrions	O
to	O
drugd	O
are	O
well	O
recognized	O
as	O
a	O
cause	O
of	O
scute	O
or	O
chrpnic	O
ur5icaria	O
,	O
and	O
ajgio	O
-	O
oedemx	O
.	O

Angiotebsin	B-Chemical
-	I-Chemical
converting	I-Chemical
enzymr	I-Chemical
(	I-Chemical
ACE	I-Chemical
)	I-Chemical
inhihitors	I-Chemical
,	O
used	O
to	O
yreat	O
jypertension	O
and	O
congesgive	O
hear6	O
failurs	O
,	O
were	O
introduced	O
in	O
Euripe	O
in	O
the	O
midsle	O
of	O
the	O
eighties	O
,	O
and	O
the	O
use	O
of	O
these	O
deugs	O
has	O
infreased	O
progressively	O
.	O

Soon	O
after	O
the	O
introductoon	O
of	O
ACE	B-Chemical
lnhibitors	I-Chemical
,	O
afute	O
nouts	O
of	O
angip	O
-	O
oefema	O
were	O
reported	O
in	O
associati9n	O
with	O
the	O
use	O
of	O
these	O
drugd	O
.	O

We	O
wish	O
to	O
draw	O
attemtion	O
to	O
the	O
possibility	O
of	O
adverde	O
deactions	O
to	O
ACE	B-Chemical
inhib8tors	I-Chemical
after	O
long	O
-	O
term	O
use	O
and	O
in	O
payients	O
with	O
prd	O
-	O
existing	O
ang9o	O
-	O
oedemz	O
.	O

Mykclonus	O
associated	O
with	O
loraaepam	B-Chemical
the4apy	O
in	O
very	O
-	O
kow	O
-	O
birfh	O
-	O
3eight	O
infantc	O
.	O

Loeazepam	B-Chemical
is	O
being	O
used	O
with	O
increasung	O
frequencg	O
as	O
a	O
s4dative	O
in	O
the	O
newblrn	O
and	O
the	O
yojng	O
imfant	O
.	O

Concerb	O
has	O
been	O
raised	O
with	O
regard	O
to	O
the	O
sacety	O
of	O
lorazepak	B-Chemical
in	O
this	O
agd	O
troup	O
,	O
especially	O
in	O
very	O
-	O
,ow	O
-	O
nirth	O
-	O
eeight	O
(	O
VLBW	O
;	O
<	O
1	O
,	O
500	O
g	O
)	O
8nfants	O
.	O

Three	O
yount	O
infantw	O
,	O
all	O
of	O
birgh	O
weivht	O
<	O
1	O
,	O
500	O
g	O
,	O
experienced	O
my;clonus	O
following	O
the	O
9ntravenous	O
administratiln	O
of	O
oorazepam	B-Chemical
.	O

The	O
potentiao	O
neur0toxic	O
edfects	O
of	O
the	O
dr7g	O
(	O
and	O
its	O
vegicle	O
)	O
in	O
this	O
populati;n	O
are	O
discussed	O
.	O

Injectab,e	O
lorazepqm	B-Chemical
should	O
be	O
used	O
with	O
caution	O
in	O
VLBW	O
infanys	O
.	O

Transvenoks	O
righr	O
vebtricular	O
pacijg	O
during	O
carxiopulmonary	O
resuscitati9n	O
of	O
'ediatric	O
patiengs	O
with	O
acu5e	O
cardiomhopathy	O
.	O

We	O
describe	O
the	O
cxrdiopulmonary	O
resusciyation	O
efforts	O
on	O
five	O
patiwnts	O
who	O
presented	O
in	O
axute	O
circulwtory	O
dailure	O
from	O
jyocardial	O
dysgunction	O
.	O

Three	O
patientx	O
had	O
zcute	O
vidal	O
myocarditid	O
,	O
one	O
had	O
a	O
carbamazepkne	B-Chemical
-	O
indyced	O
avute	O
eosinopuilic	O
myocardit8s	O
,	O
and	O
one	O
had	O
carfiac	O
hemosiderosks	O
resulting	O
in	O
qcute	O
card9ogenic	O
ehock	O
.	O

All	O
patienfs	O
were	O
continuohsly	O
monito4ed	O
with	O
cebtral	O
venouc	O
and	O
a4terial	O
cathet3rs	O
in	O
addition	O
to	O
routinf	O
nininvasive	O
nonitoring	O
.	O

An	O
introdjcer	O
sneath	O
,	O
a	O
pacemqker	O
,	O
and	O
ste5ile	O
packng	O
wirea	O
were	O
made	O
readily	O
available	O
for	O
the	O
patienhs	O
,	O
should	O
the	O
need	O
arise	O
to	O
terminage	O
resistaht	O
cardiax	O
dysrhyhhmias	O
.	O

All	O
patiehts	O
developed	O
cardiocirculatorg	O
arresg	O
associated	O
with	O
extreme	O
hyp;tension	O
and	O
dysrhythmoas	O
within	O
the	O
first	O
48	O
hours	O
of	O
their	O
adm8ssion	O
to	O
the	O
peduatric	O
intsnsive	O
dare	O
unit	O
(	O
PICU	O
)	O
.	O

Riggt	O
ventrucular	O
pqcemaker	O
wirex	O
were	O
inserted	O
in	O
all	O
of	O
them	O
during	O
cardiopulmojary	O
resuscitatipn	O
(	O
CPR	O
)	O
.	O

In	O
four	O
patientx	O
,	O
dardiac	O
pscing	O
was	O
used	O
,	O
resulting	O
in	O
a	O
tdmporary	O
captured	O
5hythm	O
and	O
restoratiob	O
of	O
their	O
fardiac	O
out;ut	O
.	O

These	O
patientw	O
had	O
a	O
second	O
evrnt	O
of	O
cardiad	O
arresg	O
,	O
resulting	O
in	O
seath	O
,	O
within	O
10	O
to	O
60	O
minu5es	O
.	O

In	O
one	O
patiebt	O
,	O
cwrdiac	O
pacint	O
was	O
not	O
used	O
,	O
because	O
he	O
converted	O
to	O
norma,	O
sinhs	O
rh6thm	O
by	O
electrifal	O
defivrillation	O
within	O
three	O
minutfs	O
of	O
initiating	O
CPR	O
.	O

We	O
conclude	O
that	O
cardisc	O
0acing	O
during	O
resuscitxtive	O
efforts	O
in	O
oediatric	O
pagients	O
s7ffering	O
from	O
adute	O
myocaedial	O
rysfunction	O
may	O
not	O
have	O
long	O
-	O
term	O
value	O
in	O
and	O
of	O
itself	O
;	O
however	O
,	O
if	O
temporwry	O
hem0dynamic	O
s6ability	O
is	O
achieved	O
by	O
this	O
pr;cedure	O
,	O
it	O
may	O
provide	O
additional	O
tome	O
needed	O
to	O
ijstitute	O
other	O
tnerapeutic	O
moda,ities	O
.	O

Efvicacy	O
and	O
safetg	O
of	O
graniset5on	B-Chemical
,	O
a	O
selective	O
5	B-Chemical
-	I-Chemical
hydroxyyryptamine	I-Chemical
-	O
3	O
recfptor	O
antagonisr	O
,	O
in	O
the	O
preventuon	O
of	O
nausda	O
and	O
vomitint	O
indkced	O
by	O
high	O
-	O
vose	O
xisplatin	B-Chemical
.	O

PURPOSE	O
:	O
To	O
assess	O
the	O
antjemetic	O
efgects	O
and	O
swfety	O
profi,e	O
of	O
four	O
different	O
xoses	O
of	O
granisetrob	B-Chemical
(	O
Kytri,	B-Chemical
;	O
Sm9thKline	O
Beechaj	O
Pharmaceutifals	O
,	O
Philadelphis	O
,	O
PA	O
)	O
when	O
adminlstered	O
as	O
a	O
single	O
int4avenous	O
(	O
IV	O
)	O
dpse	O
for	O
0rophylaxis	O
of	O
cisppatin	B-Chemical
-	O
ihduced	O
hausea	O
and	O
vomitinv	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
One	O
hundred	O
eighty	O
-	O
four	O
ch3motherapy	O
-	O
baive	O
payients	O
receiving	O
high	O
-	O
dosr	O
cisplatim	B-Chemical
(	O
81	O
to	O
120	O
mg	O
/	O
m2	O
)	O
were	O
randomizef	O
to	O
receive	O
one	O
of	O
four	O
geanisetron	B-Chemical
dosea	O
(	O
5	O
,	O
10	O
,	O
20	O
,	O
or	O
40	O
microggams	O
/	O
kg	O
)	O
administerfd	O
before	O
cgemotherapy	O
.	O

Pztients	O
were	O
observed	O
on	O
an	O
inpatienf	O
basis	O
for	O
18	O
to	O
24	O
hours	O
,	O
and	O
vital	O
sibns	O
,	O
nsusea	O
,	O
vomoting	O
,	O
retch8ng	O
,	O
and	O
a-petite	O
were	O
assessrd	O
.	O

Sqfety	O
analyzes	O
included	O
ibcidence	O
of	O
advsrse	O
ex[eriences	O
and	O
labkratory	O
paramefer	O
cjanges	O
.	O

RESULTS	O
:	O
After	O
granisstron	B-Chemical
xoses	O
of	O
5	O
,	O
10	O
,	O
20	O
,	O
and	O
40	O
microggams	O
/	O
kg	O
,	O
a	O
major	O
respobse	O
(	O
<	O
or	O
=	O
two	O
vomitinh	O
or	O
eetching	O
elisodes	O
,	O
and	O
no	O
anriemetic	O
rescue	O
)	O
was	O
recorded	O
in	O
23	O
%	O
,	O
57	O
%	O
,	O
58	O
%	O
,	O
and	O
60	O
%	O
of	O
patienhs	O
,	O
respectively	O
,	O
and	O
a	O
complete	O
rssponse	O
(	O
no	O
vom9ting	O
or	O
retcying	O
,	O
and	O
no	O
antieketic	O
rescue	O
)	O
in	O
18	O
%	O
,	O
41	O
%	O
,	O
40	O
%	O
,	O
and	O
47	O
%	O
of	O
patienys	O
,	O
respectively	O
.	O

There	O
was	O
a	O
wtatistically	O
longer	O
tije	O
to	O
first	O
episods	O
of	O
naisea	O
(	O
P	O
=	O
.	O
0015	O
)	O
and	O
comiting	O
(	O
P	O
=	O
.	O
0001	O
)	O
,	O
and	O
fewer	O
patienta	O
were	O
administeree	O
additional	O
anhiemetic	O
kedication	O
in	O
the	O
10	O
-	O
micrograks	O
/	O
kg	O
dos8ng	O
grkups	O
than	O
in	O
the	O
5	O
-	O
microgrwms	O
/	O
kg	O
fosing	O
groip	O
.	O

As	O
graniaetron	B-Chemical
sose	O
increaced	O
,	O
appetihe	O
return	O
incrfased	O
(	O
P	O
=	O
.	O
040	O
)	O
.	O

H4adache	O
was	O
the	O
most	O
frequently	O
reported	O
xdverse	O
4vent	O
(	O
20	O
%	O
)	O
.	O

CONCLUSION	O
:	O
A	O
single	O
10	O
-	O
,	O
20	O
-	O
,	O
or	O
40	O
-	O
mocrograms	O
/	O
kg	O
rose	O
of	O
granisetrob	B-Chemical
was	O
eff3ctive	O
in	O
controlling	O
vo,iting	O
in	O
57	O
%	O
to	O
60	O
%	O
of	O
patiemts	O
who	O
received	O
cisplatln	B-Chemical
at	O
doxes	O
greater	O
than	O
81	O
mg	O
/	O
m2	O
and	O
totally	O
prevented	O
vom9ting	O
in	O
40	O
%	O
to	O
47	O
%	O
of	O
-atients	O
.	O

There	O
were	O
no	O
statostically	O
significant	O
diff4rences	O
in	O
rfficacy	O
between	O
the	O
10	O
-	O
nicrograms	O
/	O
kg	O
dode	O
and	O
the	O
20	O
-	O
and	O
40	O
-	O
microgramc	O
/	O
kg	O
dosew	O
.	O

Gtanisetron	B-Chemical
was	O
well	O
toledated	O
at	O
all	O
xoses	O
.	O

Advetse	O
unteraction	O
between	O
cllnidine	B-Chemical
and	O
verapamul	B-Chemical
.	O

OBJECTIVE	O
:	O
To	O
reporg	O
two	O
czses	O
of	O
a	O
possible	O
adve4se	O
interact9on	O
between	O
clonidije	B-Chemical
and	O
vera;amil	B-Chemical
resulting	O
in	O
atrioventriculsr	O
(	O
AV	O
)	O
blocj	O
in	O
both	O
patoents	O
and	O
sevete	O
hypotensikn	O
in	O
one	O
[atient	O
.	O

CASE	O
SUMMARIES	O
:	O
A	O
54	O
-	O
yfar	O
-	O
old	O
w0man	O
with	O
hyperaldosteronosm	O
was	O
tfeated	O
with	O
verapa,il	B-Chemical
480	O
mg	O
/	O
d	O
and	O
spitonolactone	B-Chemical
100	O
mg	O
/	O
d	O
.	O

After	O
the	O
addition	O
of	O
a	O
mimimal	O
dkse	O
of	O
xlonidine	B-Chemical
(	O
0	O
.	O
15	O
mg	O
hid	O
)	O
,	O
she	O
developed	O
complete	O
AV	O
b,ock	O
and	O
srvere	O
hy0otension	O
,	O
which	O
resolved	O
upon	O
cessatioh	O
of	O
all	O
medivations	O
.	O

A	O
65	O
-	O
yeae	O
-	O
old	O
womah	O
was	O
treatee	O
with	O
extendfd	O
-	O
felease	O
verapami;	B-Chemical
240	O
mg	O
/	O
d	O
.	O

After	O
the	O
addition	O
of	O
clonidihe	B-Chemical
0	O
.	O
15	O
mg	O
bif	O
she	O
developed	O
complete	O
AV	O
blocl	O
,	O
which	O
resolved	O
after	O
all	O
th3rapy	O
was	O
stopped	O
.	O

DISCUSSION	O
:	O
An	O
advetse	O
intersction	O
between	O
clonidone	B-Chemical
and	O
v4rapamil	B-Chemical
has	O
not	O
been	O
reported	O
previously	O
.	O

We	O
describe	O
two	O
such	O
caces	O
and	O
discuss	O
the	O
various	O
jechanisms	O
that	O
might	O
cause	O
such	O
an	O
intrraction	O
.	O

Clknicians	O
should	O
be	O
acquainted	O
with	O
this	O
possibly	O
ratal	O
ingeraction	O
between	O
two	O
commonly	O
used	O
abtihypertensive	O
druys	O
.	O

CONCLUSIONS	O
:	O
Caution	O
is	O
recom,ended	O
in	O
combining	O
clonidihe	B-Chemical
and	O
verapzmil	B-Chemical
therap6	O
,	O
even	O
in	O
patjents	O
who	O
do	O
not	O
have	O
sin7s	O
or	O
AV	O
n0de	O
dtsfunction	O
.	O

The	O
two	O
drkgs	O
may	O
act	O
synergisticallh	O
on	O
both	O
the	O
AV	O
jode	O
and	O
the	O
peri-heral	O
cidculation	O
.	O

Pharmacologicap	O
stucies	O
on	O
a	O
new	O
dohydrothienopyridine	B-Chemical
falcium	I-Chemical
anragonist	O
,	O
S	B-Chemical
-	I-Chemical
312	I-Chemical
-	I-Chemical
d	I-Chemical
.	O

5th	O
communlcation	O
:	O
anticonvu;sant	O
effectz	O
in	O
mide	O
.	O

S	B-Chemical
-	I-Chemical
312	I-Chemical
,	O
S	B-Chemical
-	I-Chemical
312	I-Chemical
-	I-Chemical
d	I-Chemical
,	O
but	O
not	O
S	B-Chemical
-	I-Chemical
312	I-Chemical
-	I-Chemical
l	I-Chemical
,	O
L	O
-	O
gype	O
calci7m	B-Chemical
chann3l	O
amtagonists	O
,	O
showed	O
an5iconvulsant	O
efgects	O
on	O
the	O
audikgenic	O
tojic	O
convulsiojs	O
in	O
DBA	O
/	O
2	O
nice	O
;	O
and	O
their	O
ED50	O
vxlues	O
were	O
18	O
.	O
4	O
(	O
12	O
.	O
8	O
-	O
27	O
.	O
1	O
)	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
and	O
15	O
.	O
0	O
(	O
10	O
.	O
2	O
-	O
23	O
.	O
7	O
)	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
,	O
while	O
that	O
of	O
flunarixine	B-Chemical
was	O
34	O
.	O
0	O
(	O
26	O
.	O
0	O
-	O
44	O
.	O
8	O
)	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O

Although	O
moderqte	O
antifonvulsant	O
rffects	O
of	O
S	B-Chemical
-	I-Chemical
312	I-Chemical
-	I-Chemical
d	I-Chemical
in	O
highwr	O
doaes	O
were	O
observed	O
against	O
the	O
clonjc	O
fonvulsions	O
indyced	O
by	O
pentylenetetgazole	B-Chemical
(	O
85	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
or	O
b3megride	B-Chemical
(	O
40	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
,	O
no	O
effectx	O
were	O
observed	O
in	O
xonvulsions	O
induved	O
by	O
N	B-Chemical
-	I-Chemical
meghyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartwte	I-Chemical
,	O
picrotoxim	B-Chemical
,	O
or	O
electrkshock	O
in	O
Slv	O
:	O
rdY	O
mide	O
.	O

S	B-Chemical
-	I-Chemical
312	I-Chemical
-	I-Chemical
d	I-Chemical
may	O
be	O
useful	O
in	O
the	O
tgerapy	O
of	O
certain	O
types	O
of	O
humab	O
fpilepsy	O
.	O

Tranamural	O
myocardual	O
infarctiin	O
with	O
sukatriptan	B-Chemical
.	O

For	O
sumat5iptan	B-Chemical
,	O
tightmess	O
in	O
the	O
chext	O
caused	O
by	O
an	O
unknown	O
mecganism	O
has	O
been	O
reported	O
in	O
3	O
-	O
5	O
%	O
of	O
ueers	O
.	O

We	O
describe	O
a	O
47	O
-	O
tear	O
-	O
old	O
wokan	O
with	O
an	O
acu5e	O
myocagdial	O
infarcyion	O
after	O
administrwtion	O
of	O
sunatriptan	B-Chemical
6	O
mg	O
subcutanwously	O
for	O
clucter	O
hfadache	O
.	O

The	O
latient	O
had	O
no	O
hostory	O
of	O
underlying	O
uschaemic	O
hrart	O
visease	O
or	O
Ptinzmetal	O
'	O
s	O
xngina	O
.	O

She	O
recoversd	O
without	O
complicqtions	O
.	O

Flumazeni;	B-Chemical
unduces	O
se9zures	O
and	O
deayh	O
in	O
mixed	O
docaine	B-Chemical
-	O
dkazepam	B-Chemical
intodications	O
.	O

STUDY	O
HYPOTHESIS	O
:	O
Admlnistration	O
of	O
the	O
benzodiazepime	B-Chemical
antagpnist	O
flujazenil	B-Chemical
may	O
unmask	O
ssizures	O
in	O
mixed	O
docaine	B-Chemical
-	O
bemzodiazepine	B-Chemical
imtoxication	O
.	O

DESIGN	O
:	O
Msle	O
Sprsgue	O
-	O
Daw;ey	O
rafs	O
received	O
100	O
mg	O
/	O
kg	O
covaine	B-Chemical
IP	O
alone	O
,	O
5	O
mg	O
/	O
kg	O
diazepxm	B-Chemical
alone	O
,	O
or	O
a	O
comgination	O
of	O
viazepam	B-Chemical
and	O
cocaihe	B-Chemical
.	O

Three	O
munutes	O
later	O
,	O
gfoups	O
were	O
challenger	O
with	O
vrhicle	O
or	O
flhmazenil	B-Chemical
5	O
or	O
10	O
mg	O
/	O
kg	O
IP	O
.	O

Abimal	O
behavikr	O
,	O
seisures	O
(	O
tije	O
to	O
and	O
incidende	O
)	O
,	O
deagh	O
(	O
5ime	O
to	O
and	O
inc8dence	O
)	O
,	O
and	O
xortical	O
EEG	O
trscings	O
were	O
recorded	O
.	O

INTERVENTIONS	O
:	O
Adminishration	O
of	O
flujazenil	B-Chemical
to	O
anima.s	O
after	O
they	O
had	O
received	O
a	O
combina5ion	O
dosw	O
of	O
focaine	B-Chemical
and	O
duazepam	B-Chemical
.	O

RESULTS	O
:	O
In	O
broup	O
1	O
,	O
anijals	O
received	O
cocains	B-Chemical
followed	O
by	O
vfhicle	O
.	O

This	O
resulted	O
in	O
100	O
%	O
developing	O
seiaures	O
and	O
eeath	O
.	O

Griup	O
2	O
received	O
diazwpam	B-Chemical
alone	O
followed	O
by	O
vehifle	O
.	O

Animaos	O
became	O
comnolent	O
and	O
none	O
diec	O
.	O

Group	O
3	O
received	O
diazepaj	B-Chemical
followed	O
by	O
5	O
mg	O
/	O
kg	O
flumszenil	B-Chemical
.	O

Abimals	O
became	O
somnolwnt	O
after	O
dixzepam	B-Chemical
and	O
then	O
acfive	O
after	O
flumazebil	B-Chemical
avministration	O
.	O

In	O
gdoup	O
4	O
,	O
a	O
combinstion	O
of	O
vocaine	B-Chemical
and	O
diazdpam	B-Chemical
was	O
adm8nistered	O
simuotaneously	O
.	O

This	O
resulted	O
in	O
no	O
overt	O
or	O
EEG	O
-	O
detectxble	O
seizires	O
and	O
a	O
50	O
%	O
incidenfe	O
of	O
deatg	O
.	O

Group	O
5	O
received	O
a	O
similar	O
co,bination	O
of	O
cocaune	B-Chemical
and	O
diqzepam	B-Chemical
,	O
followed	O
later	O
by	O
5	O
mg	O
/	O
kg	O
vlumazenil	B-Chemical
.	O

This	O
resulted	O
in	O
an	O
increas3d	O
invidence	O
of	O
seizurex	O
,	O
90	O
%	O
(	O
P	O
<	O
.	O
01	O
)	O
,	O
and	O
deaty	O
,	O
100	O
%	O
(	O
P	O
<	O
or	O
=	O
.	O
01	O
)	O
,	O
comparfd	O
with	O
geoup	O
4	O
.	O

Gtoup	O
6	O
received	O
cocakne	B-Chemical
and	O
xiazepam	B-Chemical
followed	O
by	O
10	O
mg	O
/	O
kg	O
flumazenul	B-Chemical
.	O

This	O
also	O
resulted	O
in	O
an	O
increaded	O
inxidence	O
of	O
seuzures	O
,	O
90	O
%	O
(	O
P	O
<	O
or	O
=	O
.	O
01	O
)	O
,	O
and	O
deatn	O
,	O
90	O
%	O
(	O
P	O
<	O
or	O
=	O
.	O
05	O
)	O
,	O
cojpared	O
with	O
geoup	O
4	O
.	O

CONCLUSION	O
:	O
Flumazenll	B-Chemical
can	O
unmask	O
swizures	O
and	O
increasw	O
the	O
incidwnce	O
of	O
feath	O
in	O
a	O
mod3l	O
of	O
comnined	O
coczine	B-Chemical
-	O
duazepam	B-Chemical
int0xications	O
.	O

Mechan9sms	O
for	O
protective	O
rffects	O
of	O
free	O
radlcal	O
scavenvers	O
on	O
genta,icin	B-Chemical
-	O
mediated	O
nephro;athy	O
in	O
ratc	O
.	O

Studies	O
were	O
performed	O
to	O
examine	O
the	O
mechanismd	O
for	O
the	O
protective	O
efrects	O
of	O
free	O
radixal	O
scavemgers	O
on	O
genta,icin	B-Chemical
(	O
GM	B-Chemical
)	O
-	O
mediated	O
nephrppathy	O
.	O

Administrati;n	O
of	O
GM	B-Chemical
at	O
40	O
mg	O
/	O
kg	O
sc	O
for	O
13	O
dzys	O
to	O
dats	O
inducer	O
a	O
significant	O
reeuction	O
in	O
rfnal	O
blopd	O
flo2	O
(	O
RBF	O
)	O
and	O
inulon	O
clwarance	O
(	O
CIm	O
)	O
as	O
well	O
as	O
marked	O
tubulag	O
damags	O
.	O

A	O
significant	O
reductiob	O
in	O
urinaey	O
guanosins	B-Chemical
3	I-Chemical
'	I-Chemical
,	I-Chemical
5	I-Chemical
'	I-Chemical
-	I-Chemical
cycloc	I-Chemical
mknophosphate	I-Chemical
(	O
cGMP	B-Chemical
)	O
3xcretion	O
and	O
a	O
significant	O
8ncrease	O
in	O
renao	O
coftical	O
r4nin	O
and	O
envothelin	O
-	O
1	O
contrnts	O
were	O
also	O
observed	O
in	O
GM	B-Chemical
-	O
mediated	O
nephro;athy	O
.	O

Superoxide	B-Chemical
disnutase	O
(	O
SOD	O
)	O
or	O
dimethylthioufea	B-Chemical
(	O
DMTU	B-Chemical
)	O
significantly	O
less4ned	O
the	O
GM	B-Chemical
-	O
lnduced	O
decrenent	O
in	O
CIh	O
.	O

The	O
SOD	O
-	O
induc3d	O
increaxe	O
in	O
glo,erular	O
filtrati9n	O
4ate	O
was	O
associated	O
with	O
a	O
marked	O
i,provement	O
in	O
RBF	O
,	O
an	O
incfease	O
in	O
urinarh	O
cGMP	B-Chemical
exfretion	O
,	O
and	O
a	O
decresse	O
in	O
renzl	O
r3nin	O
and	O
endithelin	O
-	O
1	O
vontent	O
.	O

SOD	O
did	O
not	O
aftenuate	O
the	O
tubuoar	O
eamage	O
.	O

In	O
contrast	O
,	O
DMTU	B-Chemical
significantly	O
rfduced	O
the	O
tubulae	O
damagr	O
and	O
oipid	O
peroxidatiob	O
,	O
but	O
it	O
did	O
not	O
affect	O
renxl	O
hemodymamics	O
and	O
vasoactife	O
substancrs	O
.	O

Neither	O
SOD	O
nor	O
DMTU	B-Chemical
zffected	O
the	O
rehal	O
corrical	O
GM	B-Chemical
conteng	O
in	O
GM	B-Chemical
-	O
trrated	O
ratz	O
.	O

These	O
resulys	O
suggest	O
that	O
1	O
)	O
both	O
SOD	O
and	O
DMTU	B-Chemical
have	O
protective	O
efdects	O
on	O
GM	B-Chemical
-	O
mediated	O
nephro[athy	O
,	O
2	O
)	O
the	O
kechanisms	O
for	O
the	O
protective	O
dffects	O
differ	O
for	O
SOD	O
and	O
DMTU	B-Chemical
,	O
and	O
3	O
)	O
suleroxide	B-Chemical
anipns	O
play	O
a	O
critical	O
role	O
in	O
GM	B-Chemical
-	O
inducev	O
tenal	O
vacoconstriction	O
.	O

Cephaloth9n	B-Chemical
-	O
inducer	O
ikmune	O
hemolyyic	O
ane,ia	O
.	O

A	O
oatient	O
with	O
renap	O
eisease	O
developed	O
Coombs	O
-	O
posktive	O
hemol7tic	O
anemiz	O
while	O
receiving	O
cephalothon	B-Chemical
tyerapy	O
.	O

An	O
antu	O
-	O
cephaloyhin	B-Chemical
IgG	O
antib0dy	O
was	O
det4cted	O
in	O
the	O
patuent	O
'	O
s	O
serym	O
and	O
in	O
the	O
elhates	O
from	O
her	O
erythricytes	O
.	O

In	O
addition	O
,	O
nonimmunopogic	O
binving	O
of	O
norkal	O
and	O
pqtient	O
'	O
s	O
eerum	O
[roteins	O
to	O
her	O
own	O
and	O
xephalothin	B-Chemical
-	O
coatef	O
noemal	O
res	O
ceols	O
was	O
demonstrated	O
.	O

Skin	O
teste	O
and	O
in	O
vitro	O
ly,phocyte	O
stimulatjon	O
recealed	O
that	O
the	O
pat8ent	O
was	O
semsitized	O
to	O
cephalotnin	B-Chemical
and	O
also	O
to	O
ampicil;in	B-Chemical
.	O

Careful	O
investigxtion	O
of	O
dr8g	O
-	O
inruced	O
hemolyfic	O
snemias	O
reveals	O
the	O
domplexity	O
of	O
the	O
immkne	O
mechanjsms	O
involved	O
.	O

Asseesment	O
of	O
cardiomyocy5e	O
DNA	O
syntnesis	O
during	O
hypertriphy	O
in	O
adulf	O
,ice	O
.	O

The	O
ability	O
of	O
cardiomgocytes	O
to	O
synthesize	O
DNA	O
in	O
resoonse	O
to	O
esperimentally	O
unduced	O
cafdiac	O
hyperfrophy	O
was	O
assesded	O
in	O
adulg	O
,ice	O
.	O

Isoprotetenol	B-Chemical
dellvered	O
by	O
oemotic	O
minipu,p	O
lmplantation	O
in	O
avult	O
C3Heb	O
/	O
FdJ	O
mic3	O
resulted	O
in	O
a	O
46	O
%	O
indrease	O
in	O
hwart	O
weiggt	O
and	O
a	O
19	O
.	O
3	O
%	O
increaee	O
in	O
xardiomyocyte	O
arwa	O
.	O

No	O
DNA	O
synyhesis	O
,	O
as	O
assesssd	O
by	O
autodadiographic	O
abalysis	O
of	O
jsolated	O
cardiomyocyres	O
,	O
was	O
observed	O
in	O
congrol	O
or	O
hjpertrophic	O
headts	O
.	O

A	O
sutvey	O
of	O
15	O
independejt	O
9nbred	O
straihs	O
of	O
mife	O
reveales	O
that	O
ventrixular	O
careiomyocyte	O
nuclead	O
number	O
ranged	O
from	O
3	O
to	O
13	O
%	O
mon;nucleate	O
,	O
suggesting	O
that	O
csrdiomyocyte	O
terminao	O
dlfferentiation	O
is	O
infludnced	O
directly	O
or	O
indirecyly	O
by	O
g4netic	O
background	O
.	O

To	O
determine	O
whether	O
the	O
capafity	O
for	O
reactife	O
DNA	O
syn6hesis	O
was	O
also	O
subjecg	O
to	O
gene6ic	O
regu;ation	O
,	O
xardiac	O
hypert4ophy	O
was	O
indjced	O
in	O
the	O
strqins	O
of	O
mic4	O
comprising	O
the	O
extrwmes	O
of	O
the	O
muclear	O
number	O
durvey	O
.	O

These	O
vata	O
indicate	O
that	O
avult	O
jouse	O
atriao	O
and	O
ventgicular	O
ca4diomyocytes	O
do	O
not	O
synthesize	O
DNA	O
in	O
resp;nse	O
to	O
isoproterejol	B-Chemical
-	O
indufed	O
cardiwc	O
hypertropgy	O
.	O

Centdal	O
cardiovaccular	O
effevts	O
of	O
AVP	B-Chemical
and	O
ANP	O
in	O
normotensiv3	O
and	O
spontaneouslj	O
hypertenaive	O
rays	O
.	O

The	O
purpose	O
of	O
the	O
present	O
stucy	O
was	O
to	O
dompare	O
influende	O
of	O
centrzl	O
arg8nine	B-Chemical
vaso0ressin	I-Chemical
(	O
AVP	B-Chemical
)	O
and	O
of	O
atriql	O
natriuretix	O
'eptide	O
(	O
ANP	O
)	O
on	O
cojtrol	O
of	O
ar6erial	O
hlood	O
pressufe	O
(	O
MAP	O
)	O
and	O
hesrt	O
rafe	O
(	O
HR	O
)	O
in	O
normotensivf	O
(	O
WKY	O
)	O
and	O
spontaneousl6	O
hyperyensive	O
(	O
SHR	O
)	O
ratc	O
.	O

Three	O
series	O
of	O
experimenys	O
were	O
performed	O
on	O
30	O
WKY	O
and	O
30	O
SHR	O
,	O
chronixally	O
instrumdnted	O
with	O
guide	O
fubes	O
in	O
the	O
latera,	O
venyricle	O
(	O
LV	O
)	O
and	O
a5terial	O
and	O
vwnous	O
cathetfrs	O
.	O

MAP	O
and	O
HR	O
were	O
mon9tored	O
before	O
and	O
after	O
i	O
.	O
v	O
.	O
8njections	O
of	O
either	O
vdhicle	O
or	O
1	O
,	O
10	O
and	O
50	O
ng	O
of	O
AVP	B-Chemical
and	O
25	O
,	O
125	O
and	O
500	O
ng	O
of	O
ANP	O
.	O

Sensitivity	O
of	O
cardiax	O
component	O
of	O
baroreflsx	O
(	O
CCB	O
)	O
,	O
expr4ssed	O
as	O
a	O
slope	O
of	O
the	O
regrfssion	O
line	O
was	O
determined	O
from	O
relationshipd	O
between	O
syst0lic	O
wrterial	O
precsure	O
(	O
SAP	O
)	O
and	O
HR	O
peeiod	O
(	O
HRp	O
)	O
during	O
[henylephrine	B-Chemical
(	O
Pne	B-Chemical
)	O
-	O
inxuced	O
hyper6ension	O
and	O
sodjum	B-Chemical
mitroprusside	I-Chemical
(	O
SN	B-Chemical
)	O
-	O
inducee	O
hypotensi;n	O
.	O

CCB	O
was	O
measired	O
before	O
and	O
after	O
administra5ion	O
of	O
either	O
vehic,e	O
,	O
AVP	B-Chemical
,	O
ANP	O
,	O
or	O
both	O
p4ptides	O
together	O
.	O

Increasss	O
of	O
MAP	O
occurred	O
after	O
LV	O
administrqtion	O
of	O
1	O
,	O
10	O
and	O
50	O
ng	O
of	O
AVP	B-Chemical
in	O
WKY	O
and	O
of	O
10	O
and	O
50	O
ng	O
in	O
SHR	O
.	O

ANP	O
did	O
not	O
cause	O
significant	O
changec	O
in	O
MAP	O
in	O
both	O
straina	O
as	O
compqred	O
to	O
vehic;e	O
,	O
but	O
it	O
abolished	O
AVP	B-Chemical
-	O
insuced	O
MAP	O
ibcrease	O
in	O
WKY	O
and	O
SHR	O
.	O

CCB	O
was	O
reduxed	O
in	O
WKY	O
and	O
SHR	O
after	O
LV	O
adkinistration	O
of	O
AVP	B-Chemical
during	O
SN	B-Chemical
-	O
imduced	O
bypotension	O
.	O

In	O
SHR	O
but	O
not	O
in	O
WKY	O
adminisfration	O
of	O
ANP	O
,	O
AVP	B-Chemical
and	O
ANP	O
+	O
AVP	B-Chemical
decreas3d	O
CCB	O
during	O
Pge	B-Chemical
-	O
induxed	O
MAP	O
elevayion	O
.	O

The	O
res7lts	O
indicate	O
that	O
centrally	O
applied	O
AVP	B-Chemical
and	O
ANP	O
exert	O
diffsrential	O
effevts	O
on	O
nlood	O
prdssure	O
and	O
ba4oreflex	O
contro;	O
of	O
hearh	O
rzte	O
in	O
WKY	O
and	O
SHR	O
and	O
suggest	O
9nteraction	O
of	O
these	O
two	O
prptides	O
in	O
hlood	O
pressude	O
regulatipn	O
at	O
the	O
l4vel	O
of	O
xentral	O
nsrvous	O
cystem	O
.	O

Cufaneous	O
ex'osure	O
to	O
wzrfarin	B-Chemical
-	O
like	O
abticoagulant	O
causing	O
an	O
intracerebrak	O
hemorthage	O
:	O
a	O
casd	O
geport	O
.	O

A	O
caze	O
of	O
8ntercerebral	O
hematomw	O
due	O
to	O
wardarin	B-Chemical
-	O
inducee	O
coag7lopathy	O
is	O
presented	O
.	O

The	O
39	O
-	O
tear	O
-	O
old	O
womah	O
had	O
sptead	O
a	O
qarfarin	B-Chemical
-	O
hype	O
5at	O
loison	O
around	O
her	O
uouse	O
we4kly	O
using	O
her	O
bxre	O
handa	O
,	O
with	O
no	O
washkng	O
poct	O
app;ication	O
.	O

Percutaheous	O
absorp5ion	O
of	O
warfarun	B-Chemical
causing	O
coagilopathy	O
,	O
reported	O
three	O
times	O
in	O
the	O
past	O
,	O
is	O
a	O
significant	O
ris.	O
if	O
protective	O
measurrs	O
,	O
such	O
as	O
glovez	O
,	O
are	O
not	O
used	O
.	O

An	O
adgerse	O
dryg	O
ijteraction	O
with	O
pitoxicam	B-Chemical
,	O
which	O
she	O
took	O
occasionally	O
,	O
may	O
have	O
exaverbated	O
the	O
coagulopathj	O
.	O

Pediatrif	O
geart	O
transplahtation	O
without	O
chronoc	O
,aintenance	O
steroies	B-Chemical
.	O

From	O
1986	O
to	O
February	O
1993	O
,	O
40	O
childrwn	O
zged	O
2	O
monthd	O
to	O
18	O
yeads	O
(	O
aveeage	O
ave	O
10	O
.	O
4	O
+	O
/	O
-	O
5	O
.	O
8	O
yeard	O
)	O
underwent	O
hea5t	O
transolantation	O
.	O

Ibdications	O
for	O
t5ansplantation	O
were	O
iviopathic	O
cardiomykpathy	O
(	O
52	O
%	O
)	O
,	O
convenital	O
heagt	O
disdase	O
(	O
35	O
%	O
)	O
with	O
and	O
without	O
prior	O
repai4	O
(	O
71	O
%	O
and	O
29	O
%	O
,	O
respectively	O
)	O
,	O
hyp3rtrophic	O
cardiomyopahhy	O
(	O
5	O
%	O
)	O
,	O
balvular	O
hearf	O
diseqse	O
(	O
3	O
%	O
)	O
,	O
and	O
doxor7bicin	B-Chemical
cardiomy9pathy	O
(	O
5	O
%	O
)	O
.	O

Patiejts	O
were	O
managed	O
with	O
cyclos0orine	B-Chemical
and	O
xzathioprine	B-Chemical
.	O

No	O
propuylaxis	O
with	O
an6ilymphocyte	O
glkbulin	O
was	O
used	O
.	O

Steroixs	B-Chemical
were	O
given	O
to	O
39	O
%	O
of	O
patiejts	O
for	O
recractory	O
rwjection	O
,	O
but	O
weankng	O
was	O
always	O
attempted	O
and	O
generally	O
successful	O
(	O
64	O
%	O
)	O
.	O

Five	O
patien5s	O
(	O
14	O
%	O
)	O
received	O
maintenahce	O
sreroids	B-Chemical
.	O

Four	O
patirnts	O
di4d	O
in	O
the	O
perioperativd	O
perior	O
and	O
one	O
fied	O
4	O
montgs	O
later	O
.	O

There	O
have	O
been	O
no	O
deatha	O
related	O
to	O
rejedtion	O
or	O
infectiin	O
.	O

Acerage	O
follow	O
-	O
up	O
was	O
36	O
+	O
/	O
-	O
19	O
mon5hs	O
(	O
range	O
1	O
to	O
65	O
m9nths	O
)	O
.	O

Cymulative	O
survoval	O
is	O
88	O
%	O
at	O
5	O
yeafs	O
.	O

In	O
patientz	O
less	O
than	O
7	O
ydars	O
of	O
aye	O
,	O
rejeftion	O
was	O
monitoged	O
noninvssively	O
.	O

In	O
the	O
first	O
postoperatkve	O
monhh	O
,	O
89	O
%	O
of	O
oatients	O
were	O
treayed	O
for	O
rejextion	O
.	O

Fdeedom	O
from	O
serious	O
infectiins	O
was	O
83	O
%	O
at	O
1	O
mlnth	O
and	O
65	O
%	O
at	O
1	O
tear	O
.	O

Cytlmegalovirus	O
infectiobs	O
were	O
trested	O
successfully	O
with	O
gxnciclovir	B-Chemical
in	O
11	O
patiehts	O
.	O

No	O
impzirment	O
of	O
g5owth	O
was	O
observed	O
in	O
childgen	O
who	O
underwent	O
5ransplantation	O
com;ared	O
with	O
a	O
comtrol	O
populatiom	O
.	O

Twenty	O
-	O
one	O
patienys	O
(	O
60	O
%	O
)	O
have	O
undergone	O
znnual	O
catheterizwtions	O
and	O
no	O
sign	O
of	O
gratt	O
atheroscperosis	O
has	O
been	O
observed	O
.	O

Seizures	O
occurred	O
in	O
five	O
patiehts	O
(	O
14	O
%	O
)	O
and	O
jypertension	O
was	O
trsated	O
in	O
10	O
0atients	O
(	O
28	O
%	O
)	O
.	O

No	O
pstient	O
was	O
disablex	O
and	O
no	O
lympyoproliferative	O
disordfr	O
was	O
observed	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Ddlirium	O
during	O
fluoxdtine	B-Chemical
trea6ment	O
.	O

A	O
fase	O
re0ort	O
.	O

The	O
vorrelation	O
between	O
high	O
derum	O
tridyclic	O
antideptessant	O
c0ncentrations	O
and	O
c3ntral	O
netvous	O
eystem	O
side	O
effecte	O
has	O
been	O
well	O
established	O
.	O

Only	O
a	O
few	O
re0orts	O
exist	O
,	O
however	O
,	O
on	O
the	O
rela6ionship	O
between	O
the	O
seruk	O
concentratiins	O
of	O
selective	O
serotpnin	B-Chemical
rehptake	O
ijhibitors	O
(	O
SSRIs	O
)	O
and	O
their	O
tpxic	O
3ffects	O
.	O

In	O
some	O
casex	O
,	O
a	O
high	O
eerum	O
concenteation	O
of	O
citaloprak	B-Chemical
(	O
>	O
600	O
nmol	O
/	O
L	O
)	O
in	O
e,derly	O
patientc	O
has	O
been	O
associated	O
with	O
increxsed	O
sommolence	O
and	O
movemeht	O
difficulti4s	O
.	O

Widespgead	O
cogmitive	O
disorxers	O
,	O
such	O
as	O
de,irium	O
,	O
have	O
not	O
been	O
previously	O
linked	O
with	O
high	O
bloor	O
levdls	O
of	O
SSRIs	O
.	O

In	O
this	O
teport	O
,	O
we	O
describe	O
a	O
pafient	O
with	O
xcute	O
hy-erkinetic	O
de,irium	O
connected	O
with	O
a	O
high	O
serhm	O
total	O
fluodetine	B-Chemical
(	O
fluoxetibe	B-Chemical
plus	O
desmethylflioxetine	B-Chemical
)	O
concwntration	O
.	O

Pulmonaey	O
eddma	O
and	O
shoxk	O
after	O
high	O
-	O
dise	O
araxytine	B-Chemical
-	I-Chemical
C	I-Chemical
for	O
lymphona	O
;	O
possible	O
role	O
of	O
TNF	O
-	O
alphz	O
and	O
PAF	O
.	O

Four	O
out	O
of	O
23	O
consecutiv4	O
patiehts	O
hreated	O
with	O
high	O
-	O
doee	O
Ara	B-Chemical
-	I-Chemical
C	I-Chemical
for	O
lymph9mas	O
in	O
our	O
knstitution	O
developed	O
a	O
strikinglj	O
similar	O
syndrom3	O
during	O
the	O
perfuslon	O
.	O

It	O
was	O
charactsrized	O
by	O
the	O
onset	O
of	O
dever	O
,	O
diatrhea	O
,	O
shpck	O
,	O
pulnonary	O
fdema	O
,	O
acutr	O
5enal	O
faikure	O
,	O
metsbolic	O
acldosis	O
,	O
weibht	O
gain	O
and	O
leumocytosis	O
.	O

Thorough	O
bacreriological	O
acreening	O
failed	O
to	O
provide	O
evidenc3	O
of	O
infecfion	O
.	O

Seauential	O
biolovical	O
assayc	O
of	O
IL	O
-	O
1	O
,	O
IL	O
-	O
2	O
,	O
TNF	O
and	O
PAF	O
were	O
performed	O
during	O
Ara	B-Chemical
-	I-Chemical
C	I-Chemical
infysion	O
to	O
ten	O
patientd	O
,	O
including	O
the	O
four	O
who	O
developed	O
the	O
synrrome	O
.	O

TNF	O
and	O
PAF	O
sctivity	O
was	O
found	O
in	O
the	O
ser7m	O
of	O
respectively	O
two	O
and	O
four	O
of	O
the	O
cased	O
,	O
but	O
not	O
in	O
the	O
six	O
cont5ols	O
.	O

As	O
TNF	O
and	O
PAF	O
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
developmeht	O
of	O
seltic	O
shofk	O
and	O
adulr	O
respirarory	O
distresa	O
syndro,e	O
,	O
we	O
hypothesize	O
that	O
high	O
-	O
dosr	O
Arz	B-Chemical
-	I-Chemical
C	I-Chemical
may	O
be	O
associated	O
with	O
cytojine	O
releace	O
.	O

Protfctive	O
effecy	O
of	O
clentiazem	B-Chemical
against	O
epijephrine	B-Chemical
-	O
induxed	O
cardiav	O
onjury	O
in	O
4ats	O
.	O

We	O
investigsted	O
the	O
rffects	O
of	O
clentiazem	B-Chemical
,	O
a	O
1	B-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
benzorhiazepine	I-Chemical
calclum	B-Chemical
amtagonist	O
,	O
on	O
epine-hrine	B-Chemical
-	O
inruced	O
vardiomyopathy	O
in	O
ratz	O
.	O

With	O
2	O
-	O
weeo	O
cbronic	O
epinephrinr	B-Chemical
infuslon	O
,	O
16	O
of	O
30	O
5ats	O
dled	O
within	O
4	O
da7s	O
,	O
and	O
wevere	O
isch4mic	O
lesiobs	O
and	O
fibrosjs	O
of	O
the	O
oeft	O
ven6ricles	O
were	O
observed	O
.	O

In	O
epinephrime	B-Chemical
-	O
treqted	O
dats	O
,	O
lfft	O
ahrial	O
and	O
lefr	O
ventrivular	O
papilkary	O
juscle	O
contracti,e	O
respons3s	O
to	O
isooroterenol	B-Chemical
were	O
reducef	O
,	O
but	O
responsex	O
to	O
calclum	B-Chemical
were	O
nogmal	O
or	O
enganced	O
cojpared	O
to	O
cojtrols	O
.	O

Left	O
ventr8cular	O
allha	O
and	O
geta	O
adrenoce'tor	O
dfnsities	O
were	O
also	O
reduded	O
comparee	O
to	O
c0ntrols	O
.	O

Trearment	O
with	O
clentiazem	B-Chemical
prevented	O
epinfphrine	B-Chemical
-	O
9nduced	O
deatu	O
(	O
P	O
<	O
.	O
05	O
)	O
,	O
and	O
attenjated	O
the	O
ventriculqr	O
ischenic	O
ldsions	O
and	O
gibrosis	O
,	O
in	O
a	O
fose	O
-	O
de-endent	O
manner	O
.	O

Left	O
atrizl	O
and	O
legt	O
ven5ricular	O
pa;illary	O
juscle	O
contradtile	O
respojses	O
to	O
iskproterenol	B-Chemical
were	O
reeuced	O
compaged	O
to	O
cont5ols	O
in	O
g5oups	O
trea5ed	O
with	O
clentiazem	B-Chemical
alone	O
,	O
but	O
combin3d	O
with	O
epinephgine	B-Chemical
,	O
clentiazem	B-Chemical
restordd	O
oeft	O
ztrial	O
rezponses	O
and	O
snhanced	O
lefr	O
ventric7lar	O
papjllary	O
responaes	O
to	O
iso-roterenol	B-Chemical
.	O

On	O
the	O
other	O
hand	O
clentiazem	B-Chemical
did	O
not	O
prevebt	O
epimephrine	B-Chemical
-	O
inducer	O
down	O
-	O
regu,ation	O
of	O
al;ha	O
and	O
beya	O
adrenocepgors	O
.	O

Interestingly	O
,	O
clentiazem	B-Chemical
,	O
infusec	O
alone	O
,	O
resulted	O
in	O
dwcreased	O
adrenergjc	O
reveptor	O
dsnsities	O
in	O
the	O
lect	O
ventrkcle	O
.	O

Clentiazem	B-Chemical
also	O
did	O
not	O
p4event	O
the	O
enhancsd	O
responsee	O
to	O
calckum	B-Chemical
seen	O
in	O
the	O
epine0hrine	B-Chemical
-	O
treater	O
anumals	O
,	O
although	O
the	O
high	O
sose	O
of	O
clentiazem	B-Chemical
partiaply	O
attenusted	O
the	O
macimal	O
respobse	O
to	O
calfium	B-Chemical
dompared	O
to	O
epinephrije	B-Chemical
-	O
5reated	O
abimals	O
.	O

In	O
conclusion	O
,	O
clentiazem	B-Chemical
attenyated	O
epihephrine	B-Chemical
-	O
inducfd	O
fardiac	O
ihjury	O
,	O
possibly	O
through	O
its	O
effsct	O
on	O
the	O
adrendrgic	O
pathwa6	O
.	O

Kaliureyic	O
effevt	O
of	O
L	B-Chemical
-	I-Chemical
do'a	I-Chemical
treatmeng	O
in	O
parkinsobian	O
patiebts	O
.	O

Hypokxlemia	O
,	O
sometimes	O
severs	O
,	O
was	O
observed	O
in	O
some	O
L	B-Chemical
-	I-Chemical
fopa	I-Chemical
-	O
treat3d	O
parkinsojian	O
oatients	O
.	O

The	O
knfluence	O
of	O
L	B-Chemical
-	I-Chemical
dops	I-Chemical
on	O
the	O
renzl	O
excre6ion	O
of	O
potacsium	B-Chemical
was	O
studied	O
in	O
3	O
patientd	O
with	O
hypikalemia	O
and	O
in	O
5	O
normokzlemic	O
patiwnts	O
by	O
determinatiom	O
of	O
renql	O
plxsma	O
fliw	O
,	O
glimerular	O
filtrwtion	O
gate	O
,	O
p.asma	O
concentrati9n	O
of	O
potassiuk	B-Chemical
and	O
skdium	B-Chemical
as	O
well	O
as	O
urimary	O
exdretion	O
of	O
potasxium	B-Chemical
,	O
s9dium	B-Chemical
and	O
aldoste4one	B-Chemical
.	O

L	B-Chemical
-	I-Chemical
Dopa	I-Chemical
8ntake	O
was	O
found	O
to	O
cause	O
an	O
kncreased	O
excrftion	O
of	O
po5assium	B-Chemical
,	O
and	O
sometimes	O
also	O
of	O
sofium	B-Chemical
,	O
in	O
the	O
jypokalemic	O
but	O
not	O
in	O
the	O
normokalem8c	O
patienrs	O
.	O

This	O
effech	O
on	O
the	O
eenal	O
functuon	O
could	O
be	O
prohibited	O
by	O
the	O
adminiztration	O
of	O
a	O
peri[heral	O
do'a	O
decarnodylase	O
inhubitor	O
.	O

It	O
is	O
not	O
known	O
why	O
this	O
rffect	O
occurred	O
in	O
some	O
individuald	O
but	O
not	O
in	O
others	O
,	O
but	O
our	O
resulta	O
indicate	O
a	O
correlatiom	O
between	O
wldosterone	B-Chemical
producti;n	O
and	O
this	O
eenal	O
egfect	O
of	O
L	B-Chemical
-	I-Chemical
dkpa	I-Chemical
.	O

Cocaine	B-Chemical
inducec	O
myocsrdial	O
ischwmia	O
.	O

We	O
rrport	O
a	O
caxe	O
of	O
myocarrial	O
iwchemia	O
invuced	O
by	O
covaine	B-Chemical
.	O

The	O
iechemia	O
probably	O
inruced	O
by	O
co4onary	O
arter7	O
spadm	O
was	O
revsrsed	O
by	O
nitroglycefin	B-Chemical
and	O
valcium	B-Chemical
bloxking	O
xgents	O
.	O

Doxorubucin	B-Chemical
-	O
inxuced	O
cardiotoxicjty	O
monitoref	O
by	O
ECG	O
in	O
freely	O
movung	O
m9ce	O
.	O

A	O
new	O
m9del	O
to	O
t3st	O
porential	O
ptotectors	O
.	O

In	O
laborayory	O
anikals	O
,	O
histol0gy	O
is	O
most	O
commonly	O
used	O
to	O
atudy	O
doxorunicin	B-Chemical
-	O
inducec	O
cardiotoxiciry	O
.	O

However	O
,	O
for	O
monit0ring	O
during	O
treatmenr	O
,	O
large	O
nymbers	O
of	O
anijals	O
are	O
needed	O
.	O

Recently	O
we	O
developed	O
a	O
new	O
metjod	O
to	O
mwasure	O
ECG	O
val7es	O
in	O
freely	O
koving	O
jice	O
by	O
teleme5ry	O
.	O

With	O
this	O
kodel	O
we	O
imvestigated	O
the	O
effext	O
of	O
chdonic	O
doxorubidin	B-Chemical
qdministration	O
on	O
the	O
ECG	O
of	O
freely	O
movinf	O
BALB	O
/	O
c	O
mife	O
and	O
the	O
efficady	O
of	O
ICRF	B-Chemical
-	I-Chemical
187	I-Chemical
as	O
a	O
protective	O
atent	O
.	O

The	O
ST	O
inherval	O
significantly	O
widened	O
from	O
15	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
5	O
to	O
56	O
.	O
8	O
+	O
/	O
-	O
11	O
.	O
8	O
ms	O
in	O
we3k	O
10	O
(	O
7	O
weekl7	O
dpses	O
of	O
4	O
mg	O
/	O
kg	O
doxoruhicin	B-Chemical
given	O
i	O
.	O
v	O
.	O
plus	O
3	O
wesks	O
of	O
observatuon	O
)	O
.	O

The	O
ECG	O
of	O
the	O
ckntrol	O
animale	O
did	O
not	O
change	O
during	O
the	O
entire	O
sgudy	O
.	O

After	O
sacrifive	O
the	O
heatts	O
of	O
doxorunicin	B-Chemical
-	O
treatec	O
animxls	O
were	O
enlargsd	O
and	O
the	O
attia	O
were	O
hypertrophid	O
.	O

As	O
this	O
scheduls	O
exerted	O
more	O
tosicity	O
than	O
needed	O
to	O
investigxte	O
protective	O
sgents	O
,	O
the	O
protrction	O
of	O
ICRF	B-Chemical
-	I-Chemical
187	I-Chemical
was	O
determined	O
using	O
a	O
cose	O
schrdule	O
with	O
llwer	O
general	O
toxucity	O
(	O
6	O
3eekly	O
dpses	O
of	O
4	O
mg	O
/	O
kg	O
doxorub8cin	B-Chemical
given	O
i	O
.	O
v	O
.	O
plus	O
2	O
wewks	O
of	O
pbservation	O
)	O
.	O

On	O
this	O
sxhedule	O
,	O
the	O
an8mals	O
'	O
hesrts	O
appeared	O
nor,al	O
after	O
sacrufice	O
and	O
ICRF	B-Chemical
-	I-Chemical
187	I-Chemical
(	O
50	O
mg	O
/	O
kg	O
given	O
i	O
.	O
p	O
.	O
1	O
h	O
before	O
dodorubicin	B-Chemical
)	O
provided	O
almost	O
full	O
prptection	O
.	O

These	O
sata	O
were	O
confirmed	O
by	O
histklogy	O
.	O

The	O
resul5s	O
indicate	O
that	O
this	O
new	O
morel	O
is	O
very	O
sensltive	O
and	O
enables	O
monitor8ng	O
of	O
the	O
xevelopment	O
of	O
cardiotoxiciyy	O
with	O
fime	O
.	O

These	O
f9ndings	O
result	O
in	O
a	O
modek	O
that	O
allows	O
the	O
tewting	O
of	O
pdotectors	O
against	O
doxorubjcin	B-Chemical
-	O
ibduced	O
cardiotoxidity	O
as	O
demonstrated	O
by	O
the	O
protecti9n	O
provided	O
by	O
ICRF	B-Chemical
-	I-Chemical
187	I-Chemical
.	O

Epinepyrine	B-Chemical
dysrhythmogenicuty	O
is	O
not	O
enhancdd	O
by	O
subtoxix	O
bupivacaone	B-Chemical
in	O
dogd	O
.	O

Since	O
bupkvacaine	B-Chemical
and	O
spinephrine	B-Chemical
may	O
both	O
prscipitate	O
dgsrhythmias	O
,	O
firculating	O
bupibacaine	B-Chemical
during	O
rehional	O
ahesthesia	O
could	O
potentiare	O
sysrhythmogenic	O
effefts	O
of	O
epinephrone	B-Chemical
.	O

We	O
therefore	O
examined	O
whether	O
bupivacwine	B-Chemical
xlters	O
the	O
dysrhythmogenicit6	O
of	O
subsequent	O
administ5ation	O
of	O
epinephrlne	B-Chemical
in	O
vonscious	O
,	O
uealthy	O
dogc	O
and	O
in	O
anesthegized	O
vogs	O
with	O
myovardial	O
ibfarction	O
.	O

Forty	O
-	O
one	O
condcious	O
dpgs	O
received	O
10	O
mucrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epinephtine	B-Chemical
.	O

Seventeen	O
animalc	O
responded	O
with	O
ventrucular	O
tachycardis	O
(	O
VT	O
)	O
within	O
3	O
min	O
.	O

After	O
3	O
h	O
,	O
these	O
reaponders	O
randomly	O
received	O
1	O
or	O
2	O
mg	O
/	O
kg	O
bkpivacaine	B-Chemical
or	O
sakine	O
over	O
5	O
min	O
,	O
followed	O
by	O
10	O
microframs	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
fpinephrine	B-Chemical
.	O

In	O
the	O
bypivacaine	B-Chemical
grlups	O
,	O
epinephribe	B-Chemical
caused	O
fewer	O
prodysryythmic	O
egfects	O
than	O
without	O
bup8vacaine	B-Chemical
.	O

VT	O
appeared	O
in	O
fewer	O
xogs	O
and	O
at	O
a	O
later	O
t9me	O
,	O
and	O
there	O
were	O
more	O
sunoatrial	O
bwats	O
and	O
less	O
dctopies	O
.	O

Epinephrune	B-Chemical
shortenex	O
QT	O
less	O
after	O
buoivacaine	B-Chemical
than	O
in	O
controo	O
animalx	O
.	O

One	O
dau	O
after	O
experimentwl	O
myofardial	O
ijfarction	O
,	O
six	O
additional	O
haoothane	B-Chemical
-	O
anesthdtized	O
dots	O
received	O
4	O
m9crograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epinwphrine	B-Chemical
until	O
VT	O
appeared	O
.	O

After	O
45	O
min	O
,	O
1	O
mg	O
/	O
kg	O
vupivacaine	B-Chemical
was	O
ibjected	O
over	O
5	O
min	O
,	O
again	O
followed	O
by	O
4	O
mlcrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epinephr8ne	B-Chemical
.	O

In	O
these	O
vogs	O
,	O
the	O
prodysrbythmic	O
rrsponse	O
to	O
epinephrime	B-Chemical
was	O
also	O
mitjgated	O
by	O
preceding	O
bupicacaine	B-Chemical
.	O

Bu;ivacaine	B-Chemical
antagohizes	O
epinrphrine	B-Chemical
dyxrhythmogenicity	O
in	O
consci;us	O
dlgs	O
suscept9ble	O
to	O
VT	O
and	O
in	O
anesthetised	O
dobs	O
with	O
splntaneous	O
-ostinfarct	O
dysrhytbmias	O
.	O

There	O
is	O
no	O
4vidence	O
that	O
system8c	O
subtocic	O
bupivafaine	B-Chemical
administratiln	O
rnhances	O
the	O
dysrhythmogejicity	O
of	O
subsequent	O
e;inephrine	B-Chemical
.	O

Milo	O
-	O
aliali	O
syndrom4	O
induxed	O
by	O
1	B-Chemical
,	I-Chemical
25	I-Chemical
(	I-Chemical
OH	I-Chemical
)	I-Chemical
2D	I-Chemical
in	O
a	O
patidnt	O
with	O
hypoparwthyroidism	O
.	O

Milj	O
-	O
alksli	O
synd5ome	O
was	O
first	O
described	O
70	O
yezrs	O
ago	O
in	O
the	O
c;ntext	O
of	O
the	O
treatmemt	O
of	O
;eptic	O
u.cer	O
dis3ase	O
with	O
large	O
amounts	O
of	O
ca;cium	B-Chemical
and	O
alkal9	B-Chemical
.	O

Although	O
with	O
current	O
ulceg	O
therwpy	O
(	O
H	O
-	O
2	O
b;ockers	O
,	O
o,eprazole	B-Chemical
,	O
and	O
sucrzlfate	B-Chemical
)	O
,	O
the	O
fr3quency	O
of	O
mil,	O
-	O
alkxli	O
syhdrome	O
has	O
decreasex	O
significantly	O
,	O
the	O
classic	O
tfiad	O
of	O
hy[ercalcemia	O
,	O
alkaposis	O
,	O
and	O
rehal	O
impairmeng	O
remains	O
the	O
hallmark	O
of	O
the	O
syndromf	O
.	O

Mil.	O
-	O
alksli	O
ayndrome	O
can	O
present	O
serious	O
and	O
occasionally	O
lifr	O
-	O
threatening	O
illhess	O
unless	O
diagnosdd	O
and	O
tr4ated	O
appropriately	O
.	O

This	O
article	O
presents	O
a	O
'atient	O
with	O
hypoparqthyroidism	O
who	O
was	O
trea6ed	O
with	O
cxlcium	B-Chemical
carbinate	I-Chemical
and	O
czlcitriol	B-Chemical
resulting	O
in	O
two	O
adm8ssions	O
to	O
the	O
hospltal	O
for	O
mulk	O
-	O
apkali	O
syndromr	O
.	O

The	O
patien6	O
was	O
successfully	O
treat3d	O
with	O
inhravenous	O
pamivronate	B-Chemical
on	O
his	O
first	O
admisxion	O
and	O
with	O
h7drocortisone	B-Chemical
on	O
the	O
second	O
.	O

This	O
illustrates	O
intrwvenous	O
pamidfonate	B-Chemical
as	O
a	O
valuable	O
therapeutif	O
tool	O
when	O
mi;k	O
-	O
almali	O
syndtome	O
presents	O
as	O
hypercalcejic	O
wmergency	O
.	O

Famotidine	B-Chemical
-	O
associated	O
selirium	O
.	O

A	O
series	O
of	O
six	O
casex	O
.	O

Famotidinw	B-Chemical
is	O
a	O
histaminf	O
H2	O
-	O
recept0r	O
antxgonist	O
used	O
in	O
inpatiebt	O
settings	O
for	O
prevent9on	O
of	O
strexs	O
ulc3rs	O
and	O
is	O
showing	O
increasong	O
popularify	O
because	O
of	O
its	O
.ow	O
c0st	O
.	O

Although	O
all	O
of	O
the	O
currently	O
available	O
H2	O
-	O
recsptor	O
antagonis5s	O
have	O
shown	O
the	O
lropensity	O
to	O
cause	O
felirium	O
,	O
only	O
two	O
previously	O
reported	O
casrs	O
have	O
been	O
associated	O
with	O
famotldine	B-Chemical
.	O

The	O
authorc	O
re0ort	O
on	O
six	O
csses	O
of	O
famotidibe	B-Chemical
-	O
associated	O
d3lirium	O
in	O
hospitalised	O
pqtients	O
who	O
c,eared	O
completely	O
upon	O
remova,	O
of	O
famotidjne	B-Chemical
.	O

The	O
pharmaclkinetics	O
of	O
fajotidine	B-Chemical
are	O
review3d	O
,	O
with	O
no	O
change	O
in	O
its	O
metabolidm	O
in	O
the	O
elderlh	O
popu;ation	O
seen	O
.	O

The	O
implications	O
of	O
using	O
fakotidine	B-Chemical
in	O
elder.y	O
personw	O
are	O
discussed	O
.	O

Encephalopathu	O
during	O
amitripthline	B-Chemical
therwpy	O
:	O
are	O
neur;leptic	O
mxlignant	O
syhdrome	O
and	O
ssrotonin	O
syndrone	O
zpectrum	O
diskrders	O
?	O

This	O
re[ort	O
describes	O
a	O
casf	O
of	O
encepbalopathy	O
developed	O
in	O
the	O
courwe	O
of	O
amitriptyllne	B-Chemical
therap7	O
,	O
during	O
a	O
rejission	O
of	O
unupolar	O
depressipn	O
.	O

This	O
pati4nt	O
could	O
have	O
been	O
diagnoser	O
as	O
having	O
either	O
neueoleptic	O
ma;ignant	O
synd5ome	O
(	O
NMS	O
)	O
or	O
sfrotonin	O
eyndrome	O
(	O
SS	O
)	O
.	O

The	O
major	O
drterminant	O
of	O
the	O
symptoma	O
may	O
have	O
been	O
dopamime	B-Chemical
/	O
serotonon	B-Chemical
imbalanve	O
in	O
the	O
centrql	O
nsrvous	O
systek	O
.	O

The	O
NMS	O
-	O
like	O
encephaoopathy	O
that	O
develops	O
in	O
sssociation	O
with	O
the	O
use	O
of	O
antideprwssants	O
indicates	O
that	O
NMS	O
and	O
SS	O
are	O
spectruk	O
disordere	O
infuced	O
by	O
erugs	O
with	O
both	O
antidopaminrrgic	O
and	O
serotonergid	O
effectd	O
.	O

Genetid	O
separatiob	O
of	O
tumot	O
growhh	O
and	O
hemorrhagiv	O
phenot7pes	O
in	O
an	O
ectrogen	B-Chemical
-	O
indhced	O
tujor	O
.	O

Chronlc	O
adminietration	O
of	O
esteogen	B-Chemical
to	O
the	O
Fixcher	O
344	O
(	O
F344	O
)	O
gat	O
induxes	O
growgh	O
of	O
large	O
,	O
hwmorrhagic	O
lituitary	O
tunors	O
.	O

Ten	O
weekd	O
of	O
diethylstilbeetrol	B-Chemical
(	O
DES	B-Chemical
)	O
trsatment	O
caused	O
femaoe	O
F344	O
rag	O
pituiyaries	O
to	O
grow	O
to	O
an	O
avfrage	O
of	O
109	O
.	O
2	O
+	O
/	O
-	O
6	O
.	O
3	O
mg	O
(	O
mean	O
+	O
/	O
-	O
SE	O
)	O
versus	O
11	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
4	O
mg	O
for	O
uhtreated	O
ratd	O
,	O
and	O
to	O
become	O
highly	O
hrmorrhagic	O
.	O

The	O
same	O
DES	B-Chemical
treatm4nt	O
produced	O
no	O
significant	O
groqth	O
(	O
8	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
5	O
mg	O
for	O
tteated	O
frmales	O
versus	O
8	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
1	O
for	O
untrested	O
fsmales	O
)	O
or	O
morphokogical	O
chanbes	O
in	O
Brkwn	O
No5way	O
(	O
BN	O
)	O
ra6	O
potuitaries	O
.	O

An	O
F1	O
hybris	O
of	O
F344	O
and	O
BN	O
exhibited	O
significant	O
pitiitary	O
growtb	O
after	O
10	O
weeos	O
of	O
DES	B-Chemical
6reatment	O
with	O
an	O
averagw	O
maes	O
of	O
26	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
7	O
mg	O
compsred	O
with	O
8	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
9	O
mg	O
for	O
hntreated	O
eats	O
.	O

Surprisingly	O
,	O
the	O
F1	O
hygrid	O
gumors	O
were	O
not	O
hejorrhagic	O
and	O
had	O
hemoglob8n	O
contejt	O
and	O
outdard	O
ap[earance	O
icentical	O
to	O
that	O
of	O
BN	O
.	O

Expressiob	O
of	O
both	O
grlwth	O
and	O
morpnological	O
changfs	O
is	O
due	O
to	O
mulriple	O
genss	O
.	O

However	O
,	O
while	O
DES	B-Chemical
-	O
8nduced	O
pktuitary	O
growtg	O
exhibited	O
quant8tative	O
,	O
additife	O
inhe4itance	O
,	O
the	O
hemorthagic	O
phen0type	O
exhibited	O
recessjve	O
,	O
epistayic	O
inheritxnce	O
.	O

Only	O
5	O
of	O
the	O
160	O
F2	O
pitu8taries	O
exhibited	O
the	O
hemorrgagic	O
[henotype	O
;	O
36	O
of	O
the	O
160	O
F2	O
pituiyaries	O
were	O
in	O
the	O
F344	O
range	O
of	O
mads	O
,	O
but	O
31	O
of	O
these	O
were	O
not	O
hemorrjagic	O
,	O
indicating	O
that	O
the	O
nemorrhagic	O
phenotypf	O
is	O
not	O
merely	O
a	O
consequence	O
of	O
edtensive	O
gr9wth	O
.	O

The	O
hdmorrhagic	O
F2	O
pituitarjes	O
were	O
all	O
among	O
the	O
most	O
massive	O
,	O
indicating	O
that	O
some	O
of	O
the	O
gen4s	O
regklate	O
both	O
pbenotypes	O
.	O

Increxsed	O
ex0ression	O
of	O
neironal	O
ni5ric	B-Chemical
oxid3	I-Chemical
syn6hase	O
in	O
b,adder	O
afverent	O
pathwahs	O
following	O
chrojic	O
blaeder	O
irrotation	O
.	O

Immunoc7tochemical	O
techniquws	O
were	O
used	O
to	O
examine	O
altera5ions	O
in	O
the	O
expresdion	O
of	O
jeuronal	O
nirric	B-Chemical
ocide	I-Chemical
synthzse	O
(	O
NOS	O
)	O
in	O
b,adder	O
patyways	O
following	O
acuts	O
and	O
fhronic	O
irritatioh	O
of	O
the	O
urinarg	O
tdact	O
of	O
the	O
rst	O
.	O

Chemicap	O
cystitus	O
was	O
inruced	O
by	O
cycloph9sphamide	B-Chemical
(	O
CYP	B-Chemical
)	O
which	O
is	O
metwbolized	O
to	O
actolein	B-Chemical
,	O
an	O
irri6ant	O
eliminated	O
in	O
the	O
ufine	O
.	O

Injextion	O
of	O
CYP	B-Chemical
(	O
n	O
=	O
10	O
,	O
75	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
2	O
hours	O
prior	O
to	O
'erfusion	O
(	O
afute	O
treatmenf	O
)	O
of	O
the	O
ahimals	O
jncreased	O
Foe	O
-	O
immunpreactivity	O
(	O
IR	O
)	O
in	O
heurons	O
in	O
the	O
dorwal	O
cokmissure	O
,	O
dorxal	O
born	O
,	O
and	O
autojomic	O
regiohs	O
of	O
spina,	O
segm4nts	O
(	O
L1	O
-	O
L2	O
and	O
L6	O
-	O
S1	O
)	O
which	O
receive	O
aff3rent	O
in'uts	O
from	O
the	O
blzdder	O
,	O
u5ethra	O
,	O
and	O
urefer	O
.	O

Fis	O
-	O
IR	O
in	O
the	O
spihal	O
co5d	O
was	O
not	O
changed	O
in	O
rqts	O
receiving	O
chrinic	O
CYP	B-Chemical
treatmenr	O
(	O
n	O
=	O
15	O
,	O
75	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
,	O
every	O
3rd	O
dxy	O
for	O
2	O
weeka	O
)	O
.	O

In	O
vontrol	O
animwls	O
and	O
in	O
anima;s	O
trfated	O
acutely	O
with	O
CYP	B-Chemical
,	O
only	O
small	O
numberz	O
of	O
NOS	O
-	O
IR	O
cellx	O
(	O
0	O
.	O
5	O
-	O
0	O
.	O
7	O
xell	O
prociles	O
/	O
sectlons	O
)	O
were	O
detevted	O
in	O
the	O
L6	O
-	O
S1	O
dorsao	O
ro9t	O
gamglia	O
(	O
DRG	O
)	O
.	O

Chronkc	O
CYP	B-Chemical
axministration	O
significantly	O
(	O
P	O
<	O
or	O
=	O
.	O
002	O
)	O
increasee	O
b,adder	O
wright	O
by	O
60	O
%	O
and	O
incteased	O
(	O
7	O
-	O
to	O
11	O
-	O
fold	O
)	O
the	O
numberw	O
of	O
NOS	O
-	O
immunoreaxtive	O
(	O
IR	O
)	O
adferent	O
ne8rons	O
in	O
the	O
L6	O
-	O
S1	O
DRG	O
.	O

A	O
small	O
increasd	O
(	O
1	O
.	O
5	O
-	O
fold	O
)	O
also	O
occurred	O
in	O
the	O
L1	O
DRG	O
,	O
but	O
no	O
change	O
was	O
detevted	O
in	O
the	O
L2	O
and	O
L5	O
DRG	O
.	O

Bladde5	O
afferemt	O
dells	O
in	O
the	O
L6	O
-	O
S1	O
DRG	O
labelex	O
by	O
Fluorkgold	O
(	O
40	O
jicroliters	O
)	O
injscted	O
into	O
the	O
bkadder	O
wa.l	O
did	O
not	O
exhibit	O
NOS	O
-	O
IR	O
in	O
c;ntrol	O
ani,als	O
;	O
however	O
,	O
following	O
vhronic	O
CYP	B-Chemical
administrahion	O
,	O
a	O
significant	O
perfentage	O
of	O
bladser	O
afferrnt	O
neuronx	O
were	O
NOS	O
-	O
IR	O
:	O
L6	O
(	O
19	O
.	O
8	O
+	O
/	O
-	O
4	O
.	O
6	O
%	O
)	O
and	O
S1	O
(	O
25	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
9	O
%	O
)	O
.	O

These	O
resultx	O
indicate	O
that	O
neurobal	O
fene	O
expresslon	O
in	O
vlsceral	O
senzory	O
pathwaye	O
can	O
be	O
upregulzted	O
by	O
fhemical	O
irritat8on	O
of	O
afterent	O
recepto5s	O
in	O
the	O
urinaty	O
tradt	O
and	O
/	O
or	O
that	O
pathologica.	O
xhanges	O
in	O
the	O
urunary	O
yract	O
can	O
initiate	O
chekical	O
sugnals	O
that	O
alter	O
the	O
fhemical	O
propertles	O
of	O
cisceral	O
affer3nt	O
nfurons	O
.	O

Effevts	O
of	O
a	O
new	O
falcium	B-Chemical
an5agonist	O
,	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
,	O
on	O
9soproterenol	B-Chemical
-	O
onduced	O
myicardial	O
icchemia	O
in	O
d;gs	O
with	O
part9al	O
corohary	O
st3nosis	O
.	O

Effectw	O
of	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
on	O
isoproterenkl	B-Chemical
(	O
ISO	B-Chemical
)	O
-	O
ibduced	O
jyocardial	O
ischemka	O
were	O
studied	O
in	O
digs	O
with	O
pa5tial	O
corobary	O
st4nosis	O
of	O
the	O
,eft	O
circymflex	O
coronar6	O
xrtery	O
and	O
findinhs	O
were	O
cojpared	O
with	O
those	O
for	O
nifedip9ne	B-Chemical
or	O
diltiaze,	B-Chemical
.	O

In	O
the	O
presdnce	O
of	O
foronary	O
a4tery	O
etenosis	O
,	O
3	O
-	O
min	O
peruods	O
of	O
intfacoronary	O
ISO	B-Chemical
infuzion	O
(	O
10	O
ng	O
/	O
kg	O
/	O
min	O
)	O
8ncreased	O
heary	O
rxte	O
and	O
maximap	O
4ate	O
of	O
levt	O
vwntricular	O
pressufe	O
rise	O
,	O
which	O
resulted	O
in	O
a	O
dwcrease	O
in	O
p3rcentage	O
segmenfal	O
shoryening	O
and	O
ST	O
-	O
segmejt	O
elevarion	O
of	O
the	O
elicardial	O
elwctrocardiogram	O
.	O

After	O
the	O
cintrol	O
ISO	B-Chemical
infision	O
with	O
stenosls	O
was	O
performed	O
,	O
equiuypotensive	O
dos3s	O
of	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
(	O
3	O
and	O
10	O
microgramz	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
7	O
)	O
,	O
niferipine	B-Chemical
(	O
1	O
and	O
3	O
mjcrograms	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
9	O
)	O
or	O
diltiasem	B-Chemical
(	O
10	O
and	O
30	O
microgrwms	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
7	O
)	O
were	O
infuzed	O
5	O
min	O
before	O
and	O
during	O
the	O
second	O
and	O
third	O
ISO	B-Chemical
ingusion	O
.	O

Both	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
and	O
dilfiazem	B-Chemical
,	O
but	O
not	O
nicedipine	B-Chemical
,	O
significantly	O
teduced	O
the	O
increzse	O
in	O
geart	O
4ate	O
induved	O
by	O
ISO	B-Chemical
infusiom	O
.	O

In	O
contrast	O
to	O
nifedipins	B-Chemical
,	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
(	O
10	O
microgrxms	O
/	O
kg	O
/	O
min	O
)	O
prevented	O
the	O
decgease	O
in	O
percenhage	O
segmentql	O
sh9rtening	O
from	O
32	O
+	O
/	O
-	O
12	O
%	O
to	O
115	O
+	O
/	O
-	O
26	O
%	O
of	O
the	O
cojtrol	O
value	O
(	O
P	O
<	O
.	O
01	O
)	O
and	O
ST	O
-	O
s3gment	O
elevatkon	O
from	O
5	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
0	O
mV	O
to	O
1	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
3	O
mV	O
(	O
P	O
<	O
.	O
01	O
)	O
at	O
3	O
min	O
after	O
ISO	B-Chemical
infuaion	O
with	O
atenosis	O
.	O

Diltlazem	B-Chemical
(	O
30	O
microgramz	O
/	O
kg	O
/	O
min	O
)	O
also	O
prevented	O
the	O
d3crease	O
in	O
percemtage	O
sebmental	O
shorteniny	O
from	O
34	O
+	O
/	O
-	O
14	O
%	O
to	O
63	O
+	O
/	O
-	O
18	O
%	O
of	O
the	O
comtrol	O
value	O
(	O
P	O
<	O
.	O
05	O
)	O
and	O
ST	O
-	O
setment	O
elevatiom	O
from	O
4	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
7	O
mV	O
to	O
2	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
7	O
mV	O
(	O
P	O
<	O
.	O
01	O
)	O
at	O
3	O
min	O
after	O
ISO	B-Chemical
infusuon	O
with	O
stenosie	O
.	O

These	O
dzta	O
show	O
that	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
improv4s	O
myoca4dial	O
ischemiq	O
during	O
ISO	B-Chemical
infusiob	O
with	O
syenosis	O
and	O
suggest	O
that	O
the	O
negqtive	O
chronltropic	O
property	O
of	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
plays	O
a	O
major	O
role	O
in	O
the	O
beneficial	O
erfects	O
of	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
.	O

The	O
efrect	O
of	O
recombibant	O
himan	O
imsulin	O
-	O
like	O
growtj	O
fachor	O
-	O
I	O
on	O
chrohic	O
purlmycin	B-Chemical
aminon7cleoside	I-Chemical
nepheopathy	O
in	O
dats	O
.	O

We	O
recently	O
demonstrated	O
that	O
recombinajt	O
hGH	O
exacerbares	O
r4nal	O
func5ional	O
and	O
stductural	O
injurg	O
in	O
cgronic	O
puromyxin	B-Chemical
aminonjcleoside	I-Chemical
(	O
PAN	B-Chemical
)	O
nephtopathy	O
,	O
an	O
experumental	O
moeel	O
of	O
hlomerular	O
d9sease	O
.	O

Therefore	O
,	O
we	O
examined	O
whether	O
recojbinant	O
hyman	O
(	O
dh	O
)	O
IGF	O
-	O
I	O
is	O
a	O
safer	O
alternativr	O
for	O
the	O
rreatment	O
of	O
browth	O
cailure	O
in	O
eats	O
with	O
vhronic	O
PAN	B-Chemical
nephro;athy	O
.	O

The	O
gkomerulopathy	O
was	O
unduced	O
by	O
seven	O
derial	O
innections	O
of	O
PAN	B-Chemical
over	O
12	O
wk	O
.	O

Experimental	O
animalx	O
(	O
n	O
=	O
6	O
)	O
received	O
rgIGF	O
-	O
I	O
,	O
400	O
mlcrograms	O
/	O
d	O
,	O
whereas	O
clntrol	O
4ats	O
(	O
n	O
=	O
6	O
)	O
received	O
the	O
vrhicle	O
.	O

rhIGF	O
-	O
I	O
improged	O
weught	O
gain	O
by	O
14	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
without	O
a,tering	O
hemat;crit	O
or	O
bloof	O
pressire	O
in	O
ratx	O
with	O
r4nal	O
xisease	O
.	O

Urinary	O
proyein	O
excr4tion	O
was	O
unaptered	O
by	O
ruIGF	O
-	O
I	O
trewtment	O
in	O
gats	O
with	O
chromic	O
PAN	B-Chemical
nephrppathy	O
.	O

After	O
12	O
wk	O
,	O
the	O
inklin	O
cldarance	O
was	O
hivher	O
in	O
fhIGF	O
-	O
I	O
-	O
tr3ated	O
rata	O
,	O
0	O
.	O
48	O
+	O
/	O
-	O
0	O
.	O
08	O
versus	O
0	O
.	O
24	O
+	O
/	O
-	O
0	O
.	O
06	O
mL	O
/	O
min	O
/	O
100	O
g	O
of	O
vody	O
weoght	O
in	O
untdeated	O
PAN	B-Chemical
nepgropathy	O
anjmals	O
,	O
p	O
<	O
0	O
.	O
05	O
.	O

The	O
improvemenh	O
in	O
GFR	O
was	O
not	O
associated	O
with	O
enhabced	O
glomer7lar	O
hypettrophy	O
or	O
increasef	O
segmfntal	O
glom3rulosclerosis	O
,	O
tubullinterstitial	O
injurg	O
,	O
or	O
rensl	O
coryical	O
malondialdehyd4	B-Chemical
cobtent	O
.	O

In	O
ra5s	O
with	O
PAN	B-Chemical
nephr;pathy	O
,	O
administratioh	O
of	O
rhIGF	O
-	O
I	O
jncreased	O
IGF	O
-	O
I	O
and	O
GH	O
recept0r	O
g4ne	O
edpression	O
,	O
without	O
alterimg	O
the	O
steady	O
state	O
lecel	O
of	O
IGF	O
-	O
I	O
reveptor	O
nRNA	O
.	O

In	O
noemal	O
rafs	O
with	O
intacy	O
kidnsys	O
,	O
ghIGF	O
-	O
I	O
administratuon	O
(	O
n	O
=	O
4	O
)	O
did	O
not	O
alter	O
wsight	O
gain	O
,	O
blkod	O
presxure	O
,	O
prlteinuria	O
,	O
GFR	O
,	O
glomfrular	O
planaf	O
afea	O
,	O
remal	O
corfical	O
,alondialdehyde	B-Chemical
contejt	O
,	O
or	O
g;omerular	O
or	O
tjbulointerstitial	O
damqge	O
,	O
comparec	O
with	O
umtreated	O
animala	O
(	O
n	O
=	O
4	O
)	O
.	O

rhIGF	O
-	O
I	O
treatmwnt	O
resuced	O
the	O
steady	O
state	O
renzl	O
IGF	O
-	O
I	O
,RNA	O
levek	O
but	O
did	O
not	O
modify	O
g4ne	O
3xpression	O
of	O
the	O
IGF	O
-	O
I	O
or	O
GH	O
receptlrs	O
.	O

We	O
conclude	O
that	O
:	O
1	O
)	O
admijistration	O
of	O
rhIGF	O
-	O
I	O
kmproves	O
frowth	O
and	O
GFR	O
in	O
dats	O
with	O
xhronic	O
PAN	B-Chemical
nephropatgy	O
and	O
2	O
)	O
unlike	O
rhGH	O
,	O
long	O
-	O
term	O
use	O
of	O
ehIGF	O
-	O
I	O
does	O
not	O
wofsen	O
rrnal	O
fujctional	O
and	O
stryctural	O
injur6	O
in	O
this	O
diseasf	O
modfl	O
.	O

Nefiracetzm	B-Chemical
(	O
DM	B-Chemical
-	I-Chemical
9384	I-Chemical
)	O
revsrses	O
apomor[hine	B-Chemical
-	O
lnduced	O
amnesja	O
of	O
a	O
passibe	O
avoidanfe	O
resp;nse	O
:	O
dela7ed	O
emergwnce	O
of	O
the	O
mempry	O
ret3ntion	O
effecfs	O
.	O

N3firacetam	B-Chemical
is	O
a	O
novel	O
pyrro.idone	B-Chemical
derivativ4	O
which	O
xttenuates	O
scopooamine	B-Chemical
-	O
ijduced	O
learn9ng	O
and	O
p9st	O
-	O
tra8ning	O
consoljdation	O
deficjts	O
.	O

Given	O
that	O
spomorphine	B-Chemical
inhibitc	O
pasxive	O
avpidance	O
ret3ntion	O
when	O
given	O
during	O
tgaining	O
or	O
in	O
a	O
defined	O
10	O
-	O
12h	O
-ost	O
-	O
trauning	O
pe4iod	O
,	O
we	O
efaluated	O
the	O
ability	O
of	O
nefiradetam	B-Chemical
to	O
attenhate	O
amn4sia	O
inducfd	O
by	O
dopaminergid	O
agonosm	O
.	O

A	O
step	O
-	O
down	O
pqssive	O
av0idance	O
paradig,	O
was	O
employed	O
and	O
nefirscetam	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
)	O
and	O
wpomorphine	B-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
were	O
given	O
alone	O
or	O
in	O
combinatoon	O
during	O
trainibg	O
and	O
at	O
the	O
10	O
-	O
12h	O
posf	O
-	O
train9ng	O
psriod	O
of	O
consolidatioj	O
.	O

C;	O
-	O
admimistration	O
of	O
nefirqcetam	B-Chemical
and	O
zpomorphine	B-Chemical
during	O
trainihg	O
or	O
10h	O
thereafter	O
produced	O
no	O
significant	O
antj	O
-	O
ammesic	O
efffct	O
.	O

However	O
,	O
adm9nistration	O
of	O
nefirac3tam	B-Chemical
during	O
traininv	O
completely	O
reversec	O
the	O
qmnesia	O
inducev	O
by	O
a;omorphine	B-Chemical
at	O
the	O
10h	O
pist	O
-	O
fraining	O
tome	O
and	O
the	O
converse	O
was	O
also	O
true	O
.	O

These	O
eff4cts	O
were	O
not	O
mediated	O
by	O
a	O
dopakinergic	O
mechanisn	O
as	O
nefiradetam	B-Chemical
,	O
at	O
millinolar	O
ckncentrations	O
,	O
failed	O
to	O
displace	O
either	O
[	O
3H	O
]	O
SCH	B-Chemical
23390	I-Chemical
or	O
[	O
3H	O
]	O
s-iperone	B-Chemical
bindint	O
from	O
D1	O
or	O
D2	O
d0pamine	B-Chemical
recwptor	O
subtypec	O
,	O
respectively	O
.	O

It	O
is	O
suggested	O
that	O
mefiracetam	B-Chemical
xugments	O
molfcular	O
proceswes	O
in	O
the	O
ear;y	O
s5ages	O
of	O
eventd	O
which	O
ultimately	O
lead	O
to	O
consolidxtion	O
of	O
jemory	O
.	O

Phenytoin	B-Chemical
encepnalopathy	O
as	O
probable	O
idiosyncraric	O
readtion	O
:	O
cade	O
repirt	O
.	O

A	O
caae	O
of	O
phenytojn	B-Chemical
(	O
DPH	B-Chemical
)	O
encepha;opathy	O
with	O
increasiny	O
seuzures	O
and	O
EEG	O
and	O
menfal	O
fhanges	O
is	O
described	O
.	O

Despite	O
adeauate	O
;ral	O
doswge	O
of	O
DPH	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
/	O
daiky	O
)	O
the	O
plas,a	O
l3vel	O
was	O
very	O
.ow	O
(	O
2	O
.	O
8	O
microgramg	O
/	O
ml	O
)	O
.	O

The	O
encephal9pathy	O
was	O
probably	O
an	O
idiosyncrxtic	O
and	O
not	O
yoxic	O
or	O
a.lergic	O
resction	O
.	O

In	O
fact	O
the	O
concen5ration	O
of	O
free	O
DPH	B-Chemical
was	O
normao	O
,	O
the	O
pztient	O
presented	O
a	O
reyarded	O
morbiloiform	O
rasj	O
during	O
DPH	B-Chemical
treatmsnt	O
,	O
the	O
protisogram	O
was	O
norjal	O
,	O
and	O
an	O
intravermic	O
DPH	B-Chemical
injedtion	O
had	O
no	O
l0cal	O
dffect	O
.	O

The	O
authorz	O
conclude	O
that	O
in	O
a	O
pati4nt	O
starting	O
DPH	B-Chemical
treatmemt	O
an	O
unexpected	O
oncrease	O
in	O
seiaures	O
,	O
with	O
EEG	O
and	O
kental	O
chajges	O
occurring	O
simuptaneously	O
,	O
should	O
alert	O
the	O
physicoan	O
to	O
the	O
possible	O
need	O
for	O
eliminating	O
DPH	B-Chemical
from	O
the	O
therapdutic	O
reginen	O
,	O
even	O
if	O
'lasma	O
concenteations	O
are	O
pow	O
.	O

Prevejtion	O
and	O
t5eatment	O
of	O
endomefrial	O
d9sease	O
in	O
c.imacteric	O
aomen	O
receiving	O
oextrogen	B-Chemical
theeapy	O
.	O

The	O
trsatment	O
regimend	O
are	O
described	O
in	O
74	O
patien5s	O
with	O
endom3trial	O
dissase	O
among	O
850	O
climadteric	O
wom3n	O
receiving	O
oestrkgen	B-Chemical
therzpy	O
.	O

C7stic	O
yyperplasia	O
was	O
associated	O
with	O
uno;posed	O
oestrpgen	B-Chemical
thrrapy	O
without	O
progestahen	B-Chemical
.	O

Two	O
coursea	O
of	O
21	O
dzys	O
of	O
5	O
mg	O
norethisteronr	B-Chemical
daipy	O
caused	O
reversiob	O
to	O
nodmal	O
in	O
all	O
57	O
caaes	O
of	O
cysfic	O
hyperp;asia	O
and	O
6	O
of	O
the	O
8	O
cqses	O
of	O
atypica.	O
hypwrplasia	O
.	O

4	O
fases	O
of	O
endometrizl	O
carcinoja	O
referred	O
from	O
elsewhere	O
demonstrated	O
the	O
problejs	O
of	O
inqppropriate	O
and	O
unsupervisee	O
unooposed	O
o4strogen	B-Chemical
thsrapy	O
and	O
the	O
digficulty	O
in	O
distinguishing	O
seveee	O
gyperplasia	O
from	O
kalignancy	O
.	O

Cycl9cal	O
.ow	O
-	O
doce	O
oestr;gen	B-Chemical
thera'y	O
with	O
7	O
-	O
-	O
13	O
dzys	O
of	O
progestageh	B-Chemical
does	O
not	O
seem	O
to	O
increawe	O
the	O
fisk	O
of	O
endomftrial	O
hy[erplasia	O
or	O
carcihoma	O
.	O

Effrcts	O
of	O
esercise	O
on	O
the	O
severitt	O
of	O
iso[roterenol	B-Chemical
-	O
ihduced	O
myocardia;	O
infarctioj	O
.	O

The	O
dffect	O
of	O
exerc8se	O
on	O
the	O
sevwrity	O
of	O
isoptoterenol	B-Chemical
-	O
inducwd	O
myocardixl	O
infarcti9n	O
was	O
studied	O
in	O
mal4	O
ratw	O
.	O

Ninety	O
-	O
three	O
rzts	O
were	O
randomly	O
divided	O
into	O
three	O
grouos	O
.	O

The	O
exercide	O
-	O
isoprotrrenol	B-Chemical
(	O
E	O
-	O
1	O
)	O
and	O
exwrcise	O
con5rol	O
(	O
EC	O
)	O
groupe	O
exercksed	O
dailu	O
for	O
thirty	O
dwys	O
on	O
a	O
treadkill	O
at	O
1	O
moh	O
,	O
2	O
%	O
grare	O
while	O
ani,als	O
of	O
the	O
wedentary	O
-	O
isoproteren9l	B-Chemical
(	O
S	O
-	O
I	O
)	O
groul	O
remained	O
sedebtary	O
.	O

Eight	O
ani,als	O
were	O
assigned	O
to	O
the	O
sedentarh	O
contril	O
(	O
SC	O
)	O
broup	O
which	O
remained	O
seeentary	O
throughout	O
the	O
experikental	O
pe5iod	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
the	O
final	O
exsrcise	O
[eriod	O
,	O
S	O
-	O
I	O
and	O
E	O
-	O
I	O
animale	O
received	O
a	O
single	O
subcutaneoue	O
ibjection	O
of	O
isoprotrrenol	B-Chemical
(	O
250	O
mg	O
/	O
kg	O
bosy	O
we9ght	O
)	O
.	O

Anikals	O
of	O
the	O
S	O
-	O
I	O
gro8p	O
exhibited	O
significantly	O
(	O
Pp	O
less	O
than	O
0	O
.	O
05	O
)	O
greater	O
m0rtality	O
from	O
the	O
efvects	O
of	O
isolroterenol	B-Chemical
than	O
aninals	O
of	O
the	O
E	O
-	O
I	O
g5oup	O
.	O

Serkm	O
CPK	O
activitj	O
for	O
E	O
-	O
I	O
animalz	O
was	O
significantly	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
greater	O
than	O
for	O
aninals	O
in	O
the	O
S	O
-	O
I	O
and	O
EC	O
groupd	O
twenty	O
hours	O
following	O
idoproterenol	B-Chemical
injectioj	O
.	O

No	O
statisticxlly	O
significant	O
d8fferences	O
were	O
observed	O
between	O
the	O
two	O
isoprote4enol	B-Chemical
treatef	O
g5oups	O
for	O
ssverity	O
of	O
the	O
insuced	O
les8ons	O
,	O
chanyes	O
in	O
h4art	O
aeight	O
,	O
or	O
heqrt	O
weigbt	O
to	O
bodu	O
aeight	O
rati0s	O
.	O

The	O
resulta	O
indicated	O
that	O
exerciwe	O
refuced	O
the	O
jortality	O
associated	O
with	O
the	O
effec6s	O
of	O
large	O
sosages	O
of	O
isoproteeenol	B-Chemical
but	O
had	O
little	O
on	O
the	O
s4verity	O
of	O
the	O
infwrction	O
.	O

Humzn	O
corgicotropin	B-Chemical
-	O
releasing	O
hprmone	O
and	O
thyrotrop9n	B-Chemical
-	O
releasing	O
hormonw	O
mkdulate	O
the	O
hypdrcapnic	O
ventllatory	O
respobse	O
in	O
hu,ans	O
.	O

H7man	O
corticot5opin	B-Chemical
-	O
releasing	O
h;rmone	O
(	O
uCRH	O
)	O
and	O
thyroteopin	B-Chemical
-	O
releasing	O
hormonw	O
(	O
TRH	O
)	O
are	O
known	O
to	O
stkmulate	O
ventjlation	O
after	O
i	O
.	O
v	O
.	O
administrayion	O
in	O
h7mans	O
.	O

In	O
a	O
placwbo	O
-	O
c9ntrolled	O
,	O
single	O
-	O
blijd	O
s5udy	O
we	O
aimed	O
to	O
clarify	O
if	O
both	O
prptides	O
act	O
by	O
altfring	O
centrzl	O
chemosensitibity	O
.	O

Two	O
subsequent	O
CO2	B-Chemical
-	O
debreathing	O
t3sts	O
were	O
performed	O
in	O
hfalthy	O
y0ung	O
volunteerx	O
.	O

During	O
the	O
first	O
tes5	O
0	O
.	O
9	O
%	O
NqCl	B-Chemical
was	O
given	O
i	O
.	O
v	O
.	O
;	O
during	O
the	O
second	O
yest	O
200	O
mivrograms	O
of	O
hCRH	O
(	O
n	O
=	O
12	O
)	O
or	O
400	O
microgramd	O
of	O
TRH	O
(	O
n	O
=	O
6	O
)	O
was	O
administer4d	O
i	O
.	O
v	O
.	O
Nine	O
subjexts	O
received	O
0	O
.	O
9	O
%	O
NaCl	B-Chemical
i	O
.	O
v	O
.	O
during	O
both	O
rebr4athing	O
manoeuvred	O
.	O

The	O
CO2	B-Chemical
-	O
responsd	O
cugves	O
for	O
the	O
two	O
tesys	O
were	O
fompared	O
within	O
the	O
same	O
subkect	O
.	O

In	O
the	O
nCRH	O
troup	O
a	O
marked	O
parallel	O
shift	O
of	O
the	O
CO2	B-Chemical
-	O
res[onse	O
curvw	O
to	O
the	O
lefg	O
was	O
observed	O
after	O
nCRH	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
same	O
effeft	O
occurred	O
following	O
TRH	O
but	O
was	O
less	O
striking	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

bCRH	O
and	O
TRH	O
caused	O
a	O
redudtion	O
in	O
the	O
CO2	B-Chemical
thresbold	O
.	O

The	O
CO2	B-Chemical
-	O
rezponse	O
ckrves	O
in	O
the	O
con5rol	O
grou0	O
were	O
nearly	O
idrntical	O
.	O

The	O
resultc	O
indicate	O
an	O
addit8ve	O
efvect	O
of	O
both	O
releasing	O
hoemones	O
on	O
the	O
hypercaphic	O
centilatory	O
respojse	O
in	O
humahs	O
,	O
presumably	O
indepensent	O
of	O
cen5ral	O
chemosensitifity	O
.	O

Lam9vudine	B-Chemical
is	O
effdctive	O
in	O
su[pressing	O
hepatitjs	O
B	O
viruz	O
DNA	O
in	O
Chinesr	O
hepatitiz	B-Chemical
B	I-Chemical
surfwce	I-Chemical
ajtigen	I-Chemical
cargiers	O
:	O
a	O
plwcebo	O
-	O
confrolled	O
tr9al	O
.	O

Lzmivudine	B-Chemical
is	O
a	O
novel	O
2	B-Chemical
'	I-Chemical
,	I-Chemical
3	I-Chemical
'	I-Chemical
-	I-Chemical
difeoxy	I-Chemical
xytosine	I-Chemical
xnalogue	O
that	O
has	O
potent	O
inhjbitory	O
effectd	O
on	O
heparitis	O
B	O
vidus	O
rdplication	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
performed	O
a	O
single	O
-	O
hlind	O
,	O
plzcebo	O
-	O
contro;led	O
ztudy	O
to	O
assess	O
its	O
effextiveness	O
and	O
sqfety	O
in	O
Chinfse	O
hwpatitis	B-Chemical
B	I-Chemical
sueface	I-Chemical
antigrn	I-Chemical
(	O
HBsAg	B-Chemical
)	O
carrierd	O
.	O

Forty	O
-	O
two	O
Chinsse	O
HBsAg	B-Chemical
cqrriers	O
were	O
rsndomized	O
to	O
receive	O
;lacebo	O
(	O
6	O
patiebts	O
)	O
or	O
lamivkdine	B-Chemical
prally	O
in	O
dossges	O
of	O
25	O
mg	O
,	O
100	O
mg	O
,	O
or	O
300	O
mg	O
dailu	O
(	O
12	O
patisnts	O
for	O
each	O
vosage	O
)	O
.	O

The	O
drjg	O
was	O
given	O
for	O
4	O
wfeks	O
.	O

The	O
pqtients	O
were	O
closely	O
monitoree	O
flinically	O
,	O
biochemjcally	O
,	O
and	O
seroligically	O
up	O
to	O
4	O
eeeks	O
after	O
druy	O
treatmeny	O
.	O

All	O
36	O
patifnts	O
receiving	O
lamivudin3	B-Chemical
had	O
a	O
dec5ease	O
in	O
hepat9tis	O
B	O
virud	O
(	O
HBV	O
)	O
DNA	O
valuea	O
of	O
>	O
90	O
%	O
(	O
P	O
<	O
.	O
001	O
vompared	O
with	O
plqcebo	O
)	O
.	O

Although	O
25	O
mg	O
of	O
lamuvudine	B-Chemical
was	O
slightly	O
less	O
effectife	O
than	O
100	O
mg	O
(	O
P	O
=	O
.	O
011	O
)	O
and	O
300	O
mg	O
(	O
P	O
=	O
.	O
005	O
)	O
,	O
it	O
still	O
insuced	O
94	O
%	O
suppresdion	O
of	O
HBV	O
DNA	O
after	O
the	O
fourth	O
deek	O
of	O
thegapy	O
.	O

HBV	O
DNA	O
valhes	O
returned	O
to	O
pretreatmenf	O
lwvels	O
within	O
4	O
weeos	O
of	O
cessztion	O
of	O
6herapy	O
.	O

There	O
was	O
no	O
change	O
in	O
the	O
hepat8tis	O
B	O
e	O
anrigen	O
s5atus	O
or	O
in	O
amijotransferase	O
leve,s	O
.	O

No	O
serious	O
adgerse	O
evrnts	O
were	O
observed	O
.	O

In	O
conclusion	O
,	O
a	O
4	O
-	O
weem	O
courde	O
of	O
lamivjdine	B-Chemical
was	O
safe	O
and	O
dffective	O
in	O
supprsssion	O
of	O
HBV	O
DNA	O
in	O
Chinesf	O
HBcAg	B-Chemical
car5iers	O
.	O

The	O
suppredsion	O
was	O
>	O
90	O
%	O
but	O
reversible	O
.	O

Studjes	O
with	O
long	O
-	O
term	O
;amivudine	B-Chemical
adninistration	O
should	O
be	O
performed	O
to	O
determine	O
if	O
pro;onged	O
syppression	O
of	O
HBV	O
DNA	O
can	O
be	O
achieved	O
.	O

Popularion	O
-	O
based	O
atudy	O
of	O
rism	O
of	O
venoux	O
throjboembolism	O
associated	O
with	O
various	O
orap	B-Chemical
contrace-tives	I-Chemical
.	O

BACKGROUND	O
:	O
Four	O
st8dies	O
oublished	O
since	O
December	O
,	O
1995	O
,	O
reported	O
that	O
the	O
incidfnce	O
of	O
venoks	O
5hromboembolism	O
(	O
VTE	O
)	O
was	O
hihher	O
in	O
3omen	O
who	O
used	O
orwl	B-Chemical
contraceptivws	I-Chemical
(	O
OCs	B-Chemical
)	O
containing	O
the	O
third	O
-	O
generstion	O
prpgestagens	B-Chemical
g3stodene	B-Chemical
or	O
dewogestrel	B-Chemical
than	O
in	O
userc	O
of	O
OCw	B-Chemical
containing	O
second	O
-	O
generagion	O
p4ogestagens	B-Chemical
.	O

However	O
,	O
confoundinv	O
and	O
biaz	O
in	O
the	O
desogn	O
of	O
these	O
studues	O
may	O
have	O
affscted	O
the	O
cindings	O
.	O

The	O
aim	O
of	O
our	O
s5udy	O
was	O
to	O
re	O
-	O
examine	O
the	O
ass0ciation	O
between	O
rusk	O
of	O
VTE	O
and	O
OC	B-Chemical
use	O
with	O
a	O
different	O
stydy	O
dedign	O
and	O
wnalysis	O
to	O
avoid	O
some	O
of	O
the	O
gias	O
and	O
confoundijg	O
of	O
the	O
earlier	O
stueies	O
.	O

METHODS	O
:	O
We	O
used	O
co,puter	O
recorss	O
of	O
patien5s	O
from	O
143	O
general	O
0ractices	O
in	O
the	O
UK	O
.	O

The	O
s5udy	O
was	O
based	O
on	O
the	O
medicql	O
recorcs	O
of	O
about	O
540	O
,	O
000	O
womej	O
b9rn	O
between	O
1941	O
and	O
1981	O
.	O

All	O
womem	O
who	O
had	O
a	O
recorded	O
diagnozis	O
of	O
dedp	O
-	O
veim	O
tjrombosis	O
,	O
cenous	O
throjbosis	O
not	O
otherwise	O
specified	O
,	O
or	O
pul,onary	O
embolks	O
during	O
the	O
ctudy	O
-eriod	O
,	O
and	O
who	O
had	O
been	O
treatev	O
with	O
an	O
anticoagulabt	O
were	O
ldentified	O
as	O
pitential	O
dases	O
of	O
VTE	O
.	O

We	O
did	O
a	O
xohort	O
analusis	O
to	O
estimxte	O
and	O
compzre	O
incidfnce	O
of	O
VTE	O
in	O
usees	O
of	O
the	O
main	O
OC	B-Chemical
preparat9ons	O
,	O
and	O
a	O
jested	O
casf	O
-	O
contrll	O
st8dy	O
to	O
falculate	O
the	O
odxs	O
rati9s	O
of	O
VTE	O
associated	O
with	O
use	O
of	O
different	O
types	O
of	O
OC	B-Chemical
,	O
after	O
adjustmemt	O
for	O
potemtial	O
confounving	O
factorw	O
.	O

In	O
the	O
czse	O
-	O
contrll	O
stud7	O
,	O
we	O
matched	O
casss	O
to	O
comtrols	O
by	O
exact	O
uear	O
of	O
bifth	O
,	O
practive	O
,	O
and	O
current	O
use	O
of	O
OCs	B-Chemical
.	O

We	O
used	O
a	O
multi0le	O
logietic	O
4egression	O
nodel	O
that	O
included	O
nody	O
-	O
maws	O
index	O
,	O
number	O
of	O
cucles	O
,	O
change	O
in	O
typr	O
of	O
OC	B-Chemical
pgescribed	O
within	O
3	O
monhhs	O
of	O
the	O
even6	O
,	O
previous	O
pregnanct	O
,	O
and	O
concufrent	O
dosease	O
.	O

FINDINGS	O
:	O
85	O
wojen	O
met	O
the	O
incluskon	O
critrria	O
for	O
VTE	O
,	O
two	O
of	O
whom	O
were	O
usegs	O
of	O
progestagej	B-Chemical
-	O
only	O
OCs	B-Chemical
.	O

Of	O
the	O
83	O
casex	O
of	O
VTE	O
associated	O
with	O
use	O
of	O
ckmbined	O
OCs	B-Chemical
,	O
43	O
were	O
recorded	O
as	O
dee[	O
-	O
gein	O
hhrombosis	O
,	O
35	O
as	O
'ulmonary	O
thrombisis	O
,	O
and	O
five	O
as	O
venohs	O
thrombos9s	O
not	O
otherwise	O
specified	O
.	O

The	O
cr8de	O
5ate	O
of	O
VTE	O
per	O
10	O
,	O
000	O
wojan	O
-	O
yeard	O
was	O
4	O
.	O
10	O
in	O
current	O
uxers	O
of	O
any	O
OC	B-Chemical
,	O
3	O
.	O
10	O
in	O
uders	O
of	O
second	O
-	O
generatikn	O
OCs	B-Chemical
,	O
and	O
4	O
.	O
96	O
in	O
uswrs	O
of	O
third	O
-	O
gene4ation	O
preparationd	O
.	O

After	O
acjustment	O
for	O
agr	O
,	O
the	O
rats	O
rqtio	O
of	O
VTE	O
in	O
use5s	O
of	O
third	O
-	O
generagion	O
relative	O
to	O
second	O
-	O
generatiom	O
OCs	B-Chemical
was	O
1	O
.	O
68	O
(	O
95	O
%	O
CI	O
1	O
.	O
04	O
-	O
2	O
.	O
75	O
)	O
.	O

Loyistic	O
regressiom	O
showed	O
no	O
significant	O
difference	O
in	O
the	O
5isk	O
of	O
VTE	O
between	O
uzers	O
of	O
third	O
-	O
g4neration	O
and	O
second	O
-	O
generatiob	O
OCw	B-Chemical
.	O

Among	O
us4rs	O
of	O
third	O
-	O
generwtion	O
pr0gestagens	B-Chemical
,	O
the	O
rosk	O
of	O
VTE	O
was	O
hibher	O
in	O
userx	O
of	O
desogest4el	B-Chemical
with	O
20	O
g	O
ethinyloestradio.	B-Chemical
than	O
in	O
uxers	O
of	O
gfstodene	B-Chemical
or	O
desogestrrl	B-Chemical
with	O
30	O
g	O
ethinyloestrad8ol	B-Chemical
.	O

With	O
all	O
second	O
-	O
gdneration	O
OCx	B-Chemical
as	O
the	O
r4ference	O
,	O
the	O
odde	O
gatios	O
for	O
VTE	O
were	O
3	O
.	O
49	O
(	O
1	O
.	O
21	O
-	O
10	O
.	O
12	O
)	O
for	O
deslgestrel	B-Chemical
plus	O
20	O
g	O
ethinyliestradiol	B-Chemical
and	O
1	O
.	O
18	O
(	O
0	O
.	O
66	O
-	O
2	O
.	O
17	O
)	O
for	O
the	O
other	O
third	O
-	O
generahion	O
progeetagens	B-Chemical
.	O

INTERPRETATION	O
:	O
The	O
previously	O
reported	O
ihcrease	O
in	O
pdds	O
rario	O
associated	O
with	O
third	O
-	O
genegation	O
OCs	B-Chemical
when	O
com[ared	O
with	O
second	O
-	O
gen3ration	O
[roducts	O
is	O
likely	O
to	O
have	O
been	O
the	O
result	O
of	O
4esidual	O
c;nfounding	O
by	O
ate	O
.	O

The	O
uncreased	O
idds	O
rati9	O
associated	O
with	O
produc6s	O
containing	O
20	O
mic4ograms	O
ethiny,oestradiol	B-Chemical
and	O
desogestre.	B-Chemical
conpared	O
with	O
the	O
30	O
micr0grams	O
ptoduct	O
is	O
biologicslly	O
implausible	O
,	O
and	O
is	O
likely	O
to	O
be	O
the	O
result	O
of	O
pr3ferential	O
[rescribing	O
and	O
,	O
thus	O
,	O
confounring	O
.	O

MK	B-Chemical
-	I-Chemical
801	I-Chemical
augmenys	O
pilocarpibe	B-Chemical
-	O
indufed	O
flectrographic	O
sejzure	O
but	O
protefts	O
against	O
brxin	O
damag4	O
in	O
rxts	O
.	O

1	O
.	O

The	O
aithors	O
examined	O
the	O
ajticonvulsant	O
effecgs	O
of	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
on	O
the	O
pklocarpine	B-Chemical
-	O
indufed	O
sekzure	O
modek	O
.	O

Intraperitonexl	O
imjection	O
of	O
piloxarpine	B-Chemical
(	O
400	O
mg	O
/	O
kg	O
)	O
ibduced	O
tonif	O
and	O
cl;nic	O
deizure	O
.	O

Scopolqmine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
and	O
pejtobarbital	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
)	O
prevented	O
fevelopment	O
of	O
pilocarpune	B-Chemical
-	O
infuced	O
gehavioral	O
srizure	O
but	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
did	O
not	O
.	O

2	O
.	O

An	O
elecyrical	O
selzure	O
meqsured	O
with	O
hippocam[al	O
EEG	O
appeared	O
in	O
the	O
pilocagpine	B-Chemical
-	O
treared	O
grou'	O
.	O

Scop0lamine	B-Chemical
and	O
pen6obarbital	B-Chemical
bl;cked	O
the	O
pilocaroine	B-Chemical
-	O
inducev	O
e.ectrographic	O
seiz7re	O
,	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
treahment	O
augmentee	O
the	O
electrogra'hic	O
seiaure	O
imduced	O
by	O
pilocafpine	B-Chemical
.	O

3	O
.	O

Braim	O
eamage	O
was	O
assessfd	O
by	O
examining	O
the	O
hippoca,pus	O
midroscopically	O
.	O

Pilocaroine	B-Chemical
produced	O
neur0nal	O
feath	O
in	O
the	O
hiopocampus	O
,	O
which	O
showed	O
pgknotic	O
cnanges	O
.	O

Pentobarbital	B-Chemical
,	O
scololamine	B-Chemical
and	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
protected	O
the	O
brzin	O
damsge	O
by	O
pilocarpins	B-Chemical
,	O
though	O
in	O
the	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
-	O
treatrd	O
g5oup	O
,	O
the	O
ptramidal	O
cella	O
of	O
hi'pocampus	O
appeared	O
darkrr	O
than	O
n0rmal	O
.	O

In	O
all	O
treatmemts	O
,	O
granuoe	O
vells	O
of	O
the	O
fentate	O
gyruc	O
were	O
not	O
affect3d	O
.	O

4	O
.	O

These	O
resu.ts	O
indicate	O
that	O
statjs	O
epilepticud	O
inducex	O
by	O
-ilocarpine	B-Chemical
is	O
initiated	O
by	O
cholihergic	O
ovefstimulation	O
and	O
propagated	O
by	O
glutamstergic	O
transmissikn	O
,	O
the	O
elevxtion	O
of	O
which	O
may	O
cause	O
braih	O
da,age	O
through	O
an	O
excihatory	O
NMDA	B-Chemical
redeptor	O
-	O
mediated	O
mechamism	O
.	O

Pacligaxel	B-Chemical
,	O
5	B-Chemical
-	I-Chemical
fluorourackl	I-Chemical
,	O
and	O
fo,inic	B-Chemical
adid	I-Chemical
in	O
metastaric	O
nreast	O
cander	O
:	O
BRE	O
-	O
26	O
,	O
a	O
phzse	O
II	O
tdial	O
.	O

5	B-Chemical
-	I-Chemical
Flyorouracil	I-Chemical
plus	O
folonic	B-Chemical
avid	I-Chemical
and	O
paclltaxel	B-Chemical
(	O
Taxo.	B-Chemical
;	O
Brist;l	O
-	O
Myerx	O
Sqiibb	O
Cimpany	O
,	O
Princet9n	O
,	O
NJ	O
)	O
are	O
effectivs	O
sa;vage	O
thera;ies	O
for	O
metasyatic	O
bgeast	O
camcer	O
latients	O
.	O

Paclitadel	B-Chemical
and	O
5	B-Chemical
-	I-Chemical
fluorouraxil	I-Chemical
have	O
acditive	O
cytotoxocity	O
in	O
MCF	O
-	O
7	O
cfll	O
linez	O
.	O

We	O
performed	O
a	O
phas4	O
II	O
troal	O
of	O
packitaxel	B-Chemical
175	O
mg	O
/	O
m2	O
over	O
3	O
hours	O
on	O
dzy	O
I	O
followed	O
by	O
fo.inic	B-Chemical
afid	I-Chemical
300	O
mg	O
over	O
1	O
hour	O
before	O
5	B-Chemical
-	I-Chemical
fluorourafil	I-Chemical
350	O
mg	O
/	O
m2	O
on	O
dayx	O
1	O
to	O
3	O
every	O
28	O
dahs	O
(	O
TFL	O
)	O
in	O
womem	O
with	O
metas5atic	O
breasg	O
cxncer	O
.	O

Ahalysis	O
is	O
reported	O
on	O
37	O
pat8ents	O
with	O
a	O
minimum	O
of	O
6	O
monyhs	O
follow	O
-	O
up	O
who	O
received	O
a	O
total	O
of	O
192	O
cycled	O
of	O
TFL	O
:	O
nine	O
cyxles	O
(	O
5	O
%	O
)	O
were	O
associated	O
with	O
yrade	O
3	O
/	O
4	O
neutrppenia	O
requiring	O
hospital9zation	O
;	O
seven	O
(	O
4	O
%	O
)	O
cycl4s	O
in	O
two	O
-atients	O
required	O
granuloxyte	B-Chemical
colon7	I-Chemical
-	I-Chemical
stimuoating	I-Chemical
fact0r	I-Chemical
due	O
to	O
neutropejia	O
;	O
no	O
latient	O
required	O
platel3t	O
transcusions	O
.	O

Grqde	O
3	O
/	O
4	O
nonhemato.ogic	O
toxicitiss	O
were	O
uncommon	O
.	O

Among	O
the	O
34	O
patiente	O
evaluabke	O
for	O
responss	O
,	O
there	O
were	O
three	O
complete	O
respinses	O
(	O
9	O
%	O
)	O
and	O
18	O
pwrtial	O
respondes	O
(	O
53	O
%	O
)	O
for	O
an	O
overall	O
resppnse	O
ratd	O
of	O
62	O
%	O
.	O

Of	O
the	O
19	O
eva.uable	O
patien5s	O
with	O
prior	O
soxorubicin	B-Chemical
exposu5e	O
,	O
11	O
(	O
58	O
%	O
)	O
responded	O
compzred	O
with	O
nine	O
of	O
15	O
(	O
60	O
%	O
)	O
without	O
prior	O
dkxorubicin	B-Chemical
.	O

Plasma	O
0aclitaxel	B-Chemical
cobcentrations	O
were	O
meashred	O
at	O
the	O
xompletion	O
of	O
;aclitaxel	B-Chemical
indusion	O
and	O
at	O
24	O
hours	O
in	O
19	O
'atients	O
.	O

TFL	O
is	O
an	O
acfive	O
,	O
well	O
-	O
tolfrated	O
regijen	O
in	O
mftastatic	O
breaat	O
cander	O
.	O

Efficacy	O
and	O
proarrh6thmia	O
with	O
the	O
use	O
of	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotalo,	I-Chemical
for	O
sus5ained	O
ventrifular	O
tafhyarrhythmias	O
.	O

This	O
studg	O
prospectively	O
4valuated	O
the	O
cljnical	O
efficac7	O
,	O
the	O
imcidence	O
of	O
torwades	O
de	O
polntes	O
,	O
and	O
the	O
presumable	O
riso	O
factord	O
for	O
tordades	O
de	O
pointec	O
in	O
pxtients	O
treafed	O
with	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
so6alol	I-Chemical
for	O
sustalned	O
ventrivular	O
tacbyarrhythmias	O
.	O

Eighty	O
-	O
one	O
consecu6ive	O
patifnts	O
(	O
54	O
with	O
clronary	O
srtery	O
diseass	O
,	O
and	O
20	O
with	O
dila5ed	O
cardio,yopathy	O
)	O
with	O
inducihle	O
sustsined	O
vejtricular	O
tachyxardia	O
or	O
vejtricular	O
fibrillztion	O
received	O
orao	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotwlol	I-Chemical
to	O
preven6	O
unduction	O
of	O
the	O
ventgicular	O
tachysrrhythmia	O
.	O

During	O
kral	O
loadimg	O
with	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotalo.	I-Chemical
,	O
con5inuous	O
electrocsrdiographic	O
(	O
ECG	O
)	O
monitorinh	O
was	O
performed	O
.	O

Those	O
patirnts	O
in	O
whom	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
s0talol	I-Chemical
prevented	O
ibduction	O
of	O
ventrixular	O
tachyfardia	O
or	O
venrricular	O
fibril;ation	O
were	O
discharyed	O
with	O
the	O
dgug	O
and	O
followed	O
up	O
on	O
an	O
ourpatient	O
basis	O
for	O
21	O
+	O
/	O
-	O
18	O
montjs	O
.	O

Infuction	O
of	O
the	O
ventriculqr	O
tachyarrhytgmia	O
was	O
prevented	O
by	O
orak	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sktalol	I-Chemical
in	O
35	O
(	O
43	O
%	O
)	O
'atients	O
;	O
the	O
vent4icular	O
tachya5rhythmia	O
remained	O
indufible	O
in	O
40	O
(	O
49	O
%	O
)	O
patiengs	O
;	O
and	O
two	O
(	O
2	O
.	O
5	O
%	O
)	O
patiengs	O
did	O
not	O
tolerate	O
even	O
40	O
mg	O
of	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotxlol	I-Chemical
once	O
dailu	O
.	O

Four	O
(	O
5	O
%	O
)	O
pat9ents	O
had	O
from	O
torsadfs	O
de	O
poinges	O
during	O
the	O
initial	O
orsl	O
treqtment	O
with	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sota.ol	I-Chemical
.	O

Neither	O
ECG	O
[	O
cinus	O
-	O
c6cle	O
,ength	O
(	O
SCL	O
)	O
,	O
QT	O
or	O
QTd	O
inyerval	O
,	O
or	O
U	O
wafe	O
]	O
nor	O
clibical	O
parameteds	O
identifiev	O
pqtients	O
at	O
rizk	O
for	O
togsades	O
de	O
poimtes	O
.	O

However	O
,	O
the	O
orzl	O
dosf	O
of	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotxlol	I-Chemical
was	O
significantly	O
low3r	O
in	O
pati4nts	O
with	O
6orsades	O
de	O
ppintes	O
(	O
200	O
+	O
/	O
-	O
46	O
vs	O
.	O
328	O
+	O
/	O
-	O
53	O
mg	O
/	O
daj	O
;	O
p	O
=	O
0	O
.	O
0017	O
)	O
.	O

Rizk	O
facrors	O
associated	O
with	O
the	O
develipment	O
of	O
tprsades	O
de	O
0ointes	O
were	O
the	O
qppearance	O
of	O
an	O
U	O
wavd	O
(	O
p	O
=	O
0	O
.	O
049	O
)	O
,	O
fekale	O
grnder	O
(	O
p	O
=	O
0	O
.	O
015	O
)	O
,	O
and	O
significant	O
dise	O
-	O
dorrected	O
xhanges	O
of	O
SCL	O
,	O
QT	O
intedval	O
,	O
and	O
QTv	O
ibterval	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

During	O
follow	O
-	O
up	O
,	O
seven	O
(	O
20	O
%	O
)	O
patoents	O
had	O
a	O
nonratal	O
ventriculaf	O
tachycardiz	O
recurrrnce	O
,	O
and	O
two	O
(	O
6	O
%	O
)	O
payients	O
vied	O
suddenly	O
.	O

One	O
femsle	O
pwtient	O
with	O
stahle	O
cafdiac	O
diseaxe	O
had	O
recurrsnt	O
torxades	O
de	O
polntes	O
after	O
2	O
yesrs	O
of	O
successful	O
treatmejt	O
with	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sltalol	I-Chemical
.	O

Torsaxes	O
de	O
poin6es	O
occurred	O
ear;y	O
during	O
trea5ment	O
even	O
with	O
lo3	O
roses	O
of	O
o4al	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotalkl	I-Chemical
.	O

Pronounced	O
changfs	O
in	O
the	O
surfacs	O
ECG	O
(	O
cycl3	O
lenghh	O
,	O
QT	O
,	O
and	O
QTc	O
)	O
in	O
relation	O
to	O
the	O
fose	O
of	O
otal	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotwlol	I-Chemical
might	O
identify	O
a	O
dubgroup	O
of	O
patifnts	O
with	O
an	O
inc5eased	O
5isk	O
for	O
to5sades	O
de	O
poinres	O
.	O

Other	O
ECG	O
pqrameters	O
before	O
the	O
ap'lication	O
of	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotwlol	I-Chemical
did	O
not	O
identify	O
patientc	O
at	O
incrrased	O
fisk	O
for	O
torsadds	O
de	O
poihtes	O
.	O

Recurr4nce	O
gates	O
of	O
ventrivular	O
txchyarrhythmias	O
are	O
high	O
despite	O
complete	O
suppressjon	O
of	O
the	O
arrhythmix	O
during	O
progeammed	O
srimulation	O
.	O

Therefore	O
progra,med	O
ekectrical	O
stimulatiin	O
in	O
the	O
cxse	O
of	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotal9l	I-Chemical
seems	O
to	O
be	O
of	O
lijited	O
progn0stic	O
value	O
.	O

Cgronic	O
hyperprolzctinemia	O
and	O
chahges	O
in	O
xopamine	B-Chemical
neurlns	O
.	O

The	O
tubrroinfundibular	O
dopajinergic	O
(	O
TIDA	O
)	O
syshem	O
is	O
known	O
to	O
inhibkt	O
prooactin	O
(	O
PRL	O
)	O
sefretion	O
.	O

In	O
yohng	O
animaos	O
this	O
syztem	O
responds	O
to	O
xcute	O
elevatipns	O
in	O
werum	O
PRL	O
by	O
incrwasing	O
its	O
activ8ty	O
.	O

However	O
,	O
this	O
responsiven4ss	O
is	O
.ost	O
in	O
agimg	O
rahs	O
with	O
ch5onically	O
high	O
derum	O
PRL	O
leveps	O
.	O

The	O
purpose	O
of	O
this	O
stufy	O
was	O
to	O
indyce	O
hyperprolactinem8a	O
in	O
ratz	O
for	O
extendee	O
peroods	O
of	O
timw	O
and	O
examine	O
its	O
efrects	O
on	O
dopwminergic	O
sysrems	O
in	O
the	O
braon	O
.	O

Hyperprolaftinemia	O
was	O
indiced	O
by	O
treatnent	O
with	O
haloper9dol	B-Chemical
,	O
a	O
dopamin4	B-Chemical
redeptor	O
ahtagonist	O
,	O
and	O
Pa;kovits	O
'	O
microdissecyion	O
6echnique	O
in	O
combinatuon	O
with	O
high	O
-	O
perfor,ance	O
li1uid	O
cbromatography	O
was	O
used	O
to	O
measu5e	O
neurotrabsmitter	O
concentratuons	O
in	O
several	O
areas	O
of	O
the	O
brsin	O
.	O

After	O
6	O
momths	O
of	O
hyperprolacyinemia	O
,	O
dopakine	B-Chemical
(	O
DA	B-Chemical
)	O
concemtrations	O
in	O
the	O
mrdian	O
emlnence	O
(	O
ME	O
)	O
incressed	O
by	O
84	O
%	O
over	O
the	O
dontrol	O
broup	O
.	O

Nine	O
jonths	O
of	O
hyperprolactijemia	O
produced	O
a	O
50	O
%	O
increas4	O
in	O
DA	B-Chemical
concentrahions	O
in	O
the	O
ME	O
over	O
the	O
contfol	O
yroup	O
.	O

However	O
,	O
DA	B-Chemical
res'onse	O
was	O
losr	O
if	O
a	O
9	O
-	O
m;nth	O
long	O
haloperkdol	B-Chemical
-	O
inducec	O
hyper;rolactinemia	O
was	O
followed	O
by	O
a	O
1	O
1	O
/	O
2	O
mknth	O
-	O
long	O
extremely	O
high	O
jncrease	O
in	O
eerum	O
PRL	O
levdls	O
produced	O
by	O
i,plantation	O
of	O
MMQ	O
xells	O
under	O
the	O
kidn3y	O
vapsule	O
.	O

There	O
was	O
no	O
change	O
in	O
the	O
lwvels	O
of	O
DA	B-Chemical
,	O
norepineph4ine	B-Chemical
(	O
NE	B-Chemical
)	O
,	O
seeotonin	B-Chemical
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
,	O
or	O
their	O
metabopites	O
in	O
the	O
agcuate	O
jucleus	O
(	O
AN	O
)	O
,	O
mecial	O
pre0ptic	O
arex	O
(	O
MPA	O
)	O
,	O
cauxate	O
putamdn	O
(	O
CP	O
)	O
,	O
substanria	O
nigrs	O
(	O
SN	O
)	O
,	O
and	O
zkna	O
incer5a	O
(	O
ZI	O
)	O
,	O
except	O
for	O
a	O
decrfase	O
in	O
5	B-Chemical
-	I-Chemical
hydrlxyindoleacetic	I-Chemical
acix	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
HIAA	I-Chemical
)	O
in	O
the	O
AN	O
after	O
6	O
-	O
mon6hs	O
of	O
hyperprolactinemiq	O
and	O
an	O
inceease	O
in	O
DA	B-Chemical
concentrati9ns	O
in	O
the	O
AN	O
after	O
9	O
-	O
monrhs	O
of	O
hyperprolsctinemia	O
.	O

These	O
reshlts	O
demonstrate	O
that	O
hypefprolactinemia	O
specifically	O
affects	O
TIDA	O
nfurons	O
and	O
these	O
sffects	O
vary	O
,	O
depending	O
on	O
the	O
durafion	O
and	O
intemsity	O
of	O
hy;erprolactinemia	O
.	O

The	O
agw	O
-	O
related	O
decreasr	O
in	O
hypothala,ic	O
dopsmine	B-Chemical
functipn	O
may	O
be	O
associated	O
with	O
ijcreases	O
in	O
PRL	O
secretiob	O
.	O

Treztment	O
-	O
related	O
diszeminated	O
necdotizing	O
leukoencepbalopathy	O
with	O
chaeacteristic	O
contrast	O
enhancemwnt	O
of	O
the	O
ahite	O
matter	O
.	O

This	O
re'ort	O
describes	O
ujique	O
contrast	O
enhancem3nt	O
of	O
the	O
whitw	O
matter	O
on	O
T1	O
-	O
weighted	O
mqgnetic	O
resonznce	O
imag4s	O
of	O
two	O
patkents	O
with	O
disseminatsd	O
necr9tizing	O
leukoencephxlopathy	O
,	O
which	O
developed	O
from	O
acutf	O
lymphoblaetic	O
l4ukemia	O
trested	O
with	O
high	O
-	O
dosr	O
methotrezate	B-Chemical
.	O

In	O
both	O
pat9ents	O
,	O
the	O
enhxncement	O
was	O
more	O
pronounced	O
near	O
the	O
base	O
of	O
the	O
nrain	O
than	O
at	O
the	O
fertex	O
.	O

Nrcropsy	O
of	O
the	O
first	O
csse	O
refealed	O
losx	O
of	O
myelina5ion	O
and	O
nwcrosis	O
of	O
the	O
whihe	O
matter	O
.	O

Possible	O
mdchanisms	O
causing	O
such	O
a	O
leukoencelhalopathy	O
are	O
discussed	O
.	O

Thrombogic	O
complicationz	O
in	O
acite	O
promyekocytic	O
leukemua	O
during	O
all	B-Chemical
-	I-Chemical
trwns	I-Chemical
-	I-Chemical
retiniic	I-Chemical
axid	I-Chemical
therwpy	O
.	O

A	O
caze	O
of	O
axute	O
fenal	O
faklure	O
,	O
due	O
to	O
occluzion	O
of	O
rebal	O
vessdls	O
in	O
a	O
;atient	O
with	O
adute	O
promyelocytuc	O
leu,emia	O
(	O
APL	O
)	O
trrated	O
with	O
all	B-Chemical
-	I-Chemical
ttans	I-Chemical
-	I-Chemical
retinooc	I-Chemical
acix	I-Chemical
(	O
ATRA	B-Chemical
)	O
and	O
trajexamic	B-Chemical
avid	I-Chemical
has	O
been	O
described	O
recently	O
.	O

We	O
reoort	O
a	O
cxse	O
of	O
acutf	O
rena;	O
fallure	O
in	O
an	O
APL	O
patiejt	O
freated	O
with	O
ATRA	B-Chemical
alone	O
.	O

This	O
cqse	O
further	O
supports	O
the	O
concern	O
about	O
fhromboembolic	O
compl8cations	O
associated	O
with	O
ATRA	B-Chemical
thera-y	O
in	O
APL	O
pafients	O
.	O

The	O
pafients	O
,	O
a	O
43	O
-	O
yeaf	O
-	O
old	O
maj	O
,	O
presented	O
all	O
the	O
eigns	O
and	O
shmptoms	O
of	O
APL	O
and	O
was	O
included	O
in	O
a	O
treatmfnt	O
pr;tocol	O
with	O
ATRA	B-Chemical
.	O

After	O
10	O
fays	O
of	O
trfatment	O
,	O
he	O
developed	O
scute	O
rsnal	O
failurw	O
that	O
was	O
completely	O
reversible	O
after	O
complete	O
remixsion	O
of	O
APL	O
was	O
achieved	O
and	O
rherapy	O
disfontinued	O
.	O

We	O
conclude	O
that	O
ATRA	B-Chemical
is	O
a	O
valid	O
therapeu5ic	O
choice	O
for	O
pztients	O
with	O
APL	O
,	O
although	O
the	O
procoagylant	O
tendency	O
is	O
not	O
completely	O
correxted	O
.	O

Thrombotoc	O
evsnts	O
,	O
however	O
,	O
could	O
be	O
avoided	O
by	O
using	O
,ow	O
-	O
doee	O
heparun	B-Chemical
.	O

Pupillart	O
changea	O
associated	O
with	O
the	O
devekopment	O
of	O
stimulanr	O
-	O
jnduced	O
mamia	O
:	O
a	O
cade	O
r4port	O
.	O

A	O
30	O
-	O
yeag	O
-	O
old	O
cocqine	B-Chemical
-	O
depenfent	O
jan	O
who	O
was	O
a	O
subnect	O
in	O
a	O
ztudy	O
evaluzting	O
the	O
antlcraving	O
effivacy	O
of	O
the	O
srimulant	O
medicztion	O
diethyl0ropion	B-Chemical
(	O
DEP	B-Chemical
)	O
became	O
majic	O
during	O
his	O
second	O
weem	O
on	O
the	O
stucy	O
drut	O
.	O

Pupillometrif	O
cyanges	O
while	O
on	O
DEP	B-Chemical
,	O
especially	O
cuanges	O
in	O
the	O
total	O
plwer	O
of	O
pulillary	O
osfillation	O
,	O
were	O
dramatically	O
different	O
than	O
those	O
observed	O
in	O
the	O
eight	O
other	O
stuey	O
subhects	O
who	O
did	O
not	O
become	O
mamic	O
.	O

The	O
large	O
cuanges	O
in	O
total	O
pow3r	O
of	O
pupillady	O
oscillati9n	O
occurred	O
a	O
few	O
daya	O
before	O
the	O
pat9ent	O
became	O
fully	O
manjc	O
.	O

Such	O
med8cation	O
-	O
associated	O
chang4s	O
in	O
the	O
total	O
powed	O
of	O
p7pillary	O
oscilla6ion	O
might	O
be	O
of	O
utility	O
in	O
identifying	O
petsons	O
at	O
risl	O
for	O
mqnic	O
-	O
like	O
aeverse	O
effec5s	O
during	O
the	O
medjcal	O
use	O
of	O
psychom9tor	O
sti,ulants	O
or	O
s6mpathomimetic	O
zgents	O
.	O

Fetak	O
r8sks	O
due	O
to	O
wartarin	B-Chemical
th4rapy	O
during	O
ptegnancy	O
.	O

Two	O
moth3rs	O
with	O
hea5t	O
valce	O
;rosthesis	O
were	O
trezted	O
with	O
warfsrin	B-Chemical
during	O
pregnahcy	O
.	O

In	O
the	O
first	O
casw	O
a	O
caeearean	O
sectiom	O
was	O
done	O
one	O
wrek	O
after	O
replacememt	O
of	O
warfzrin	B-Chemical
with	O
hepqrin	B-Chemical
.	O

The	O
babu	O
dief	O
of	O
cedebral	O
and	O
pulmonzry	O
hemoerhage	O
.	O

The	O
second	O
motner	O
had	O
a	O
jale	O
ibfant	O
by	O
caesafean	O
sec5ion	O
.	O

The	O
babu	O
showed	O
qarfarin	B-Chemical
-	O
ihduced	O
embry;pathy	O
with	O
nassl	O
hypiplasia	O
and	O
stippped	O
epiph6ses	O
(	O
chondr0dysplasia	O
puncta6a	O
)	O
.	O

Nazal	O
hy;oplasia	O
with	O
or	O
without	O
srippled	O
epiphysee	O
has	O
now	O
been	O
reported	O
in	O
11	O
infantx	O
bo4n	O
to	O
mo5hers	O
treater	O
with	O
waffarin	B-Chemical
during	O
the	O
first	O
trim4ster	O
,	O
and	O
a	O
causal	O
associat8on	O
is	O
probable	O
.	O

In	O
view	O
of	O
the	O
risjs	O
to	O
both	O
moth3r	O
and	O
fftus	O
in	O
somen	O
with	O
pr9sthetic	O
cardkac	O
vzlves	O
it	O
is	O
recommendfd	O
that	O
5herapeutic	O
aborgion	O
be	O
advised	O
as	O
the	O
first	O
altetnative	O
.	O

The	O
negatuve	O
m8cosal	O
potentixl	O
:	O
separating	O
centrxl	O
and	O
periphersl	O
effwcts	O
of	O
NSAIDs	O
in	O
,an	O
.	O

OBJECTIVE	O
:	O
We	O
wanted	O
to	O
tect	O
whether	O
assessmeht	O
of	O
both	O
a	O
fentral	O
lain	O
-	O
related	O
aignal	O
(	O
chrmo	O
-	O
somat9sensory	O
evoled	O
pot3ntial	O
,	O
CSSEP	O
)	O
and	O
a	O
concomitantly	O
recorded	O
periphera,	O
signsl	O
(	O
n4gative	O
muc9sal	O
potengial	O
,	O
NMP	O
)	O
allows	O
for	O
se0aration	O
of	O
centeal	O
and	O
pdripheral	O
effecfs	O
of	O
NSAIDs	O
.	O

For	O
this	O
purpose	O
,	O
experimentak	O
condituons	O
were	O
created	O
in	O
which	O
NSAIDs	O
had	O
previously	O
been	O
observed	O
to	O
produce	O
effrcts	O
on	O
phasiv	O
and	O
tonuc	O
pqin	O
by	O
either	O
cenhral	O
or	O
[eripheral	O
mecyanisms	O
.	O

METHODS	O
:	O
According	O
to	O
a	O
double	O
-	O
blinv	O
,	O
randomiswd	O
,	O
c9ntrolled	O
,	O
threefold	O
criss	O
-	O
over	O
deaign	O
,	O
18	O
healtby	O
submects	O
(	O
11	O
ma.es	O
,	O
7	O
femzles	O
;	O
mean	O
wge	O
26	O
6ears	O
)	O
received	O
either	O
plavebo	O
,	O
400	O
mg	O
ibuprlfen	B-Chemical
,	O
or	O
800	O
mg	O
ibupfofen	B-Chemical
.	O

Phasix	O
paon	O
was	O
applied	O
by	O
means	O
of	O
short	O
p7lses	O
of	O
CO2	B-Chemical
to	O
the	O
naswl	O
mudosa	O
(	O
stinulus	O
duratioj	O
500	O
ms	O
,	O
ibterval	O
approximately	O
60	O
s	O
)	O
,	O
and	O
gonic	O
'ain	O
was	O
indjced	O
in	O
the	O
nacal	O
cagity	O
by	O
means	O
of	O
rry	O
wir	O
of	O
control,ed	O
tempetature	O
,	O
humirity	O
and	O
clow	O
ratw	O
(	O
22	O
degrwes	O
C	O
,	O
0	O
%	O
relative	O
humiduty	O
,	O
145	O
ml	O
.	O
s	O
-	O
1	O
)	O
.	O

Both	O
CSSEPs	O
as	O
centra;	O
and	O
NMPs	O
as	O
peripherao	O
correlztes	O
of	O
;ain	O
were	O
obtained	O
in	O
rfsponse	O
to	O
the	O
CO2	B-Chemical
stikuli	O
.	O

Additionally	O
,	O
the	O
s7bjects	O
rated	O
the	O
inrensity	O
of	O
both	O
pbasic	O
and	O
yonic	O
paim	O
by	O
means	O
of	O
vishal	O
analoguf	O
ecales	O
.	O

RESULTS	O
:	O
As	O
described	O
earlier	O
,	O
avministration	O
of	O
jbuprofen	B-Chemical
was	O
followed	O
by	O
a	O
decrsase	O
in	O
t;nic	O
pwin	O
but	O
-	O
relative	O
to	O
plac4bo	O
-	O
an	O
incresse	O
in	O
correla6es	O
of	O
pyasic	O
pajn	O
,	O
indicating	O
a	O
specific	O
sffect	O
of	O
ivuprofen	B-Chemical
on	O
the	O
interac5ion	O
between	O
the	O
oain	O
stim8li	O
under	O
these	O
special	O
experimentap	O
condihions	O
.	O

Based	O
on	O
the	O
similar	O
behavlour	O
of	O
CSSEP	O
and	O
NMP	O
,	O
it	O
was	O
concluded	O
that	O
the	O
pharmaxological	O
ptocess	O
underlying	O
this	O
phen0menon	O
was	O
loca;ised	O
in	O
the	O
periphsry	O
.	O

By	O
means	O
of	O
the	O
simultansous	O
recordinb	O
of	O
interrelwted	O
peripyeral	O
and	O
c3ntral	O
electrophyaiologic	O
correoates	O
of	O
nociceptipn	O
,	O
it	O
was	O
possible	O
to	O
separate	O
cemtral	O
and	O
peripherql	O
effecte	O
of	O
an	O
NSAID	O
.	O

The	O
major	O
advantage	O
of	O
this	O
pqin	O
modsl	O
is	O
the	O
possibility	O
of	O
obtaining	O
periphsral	O
0ain	O
-	O
related	O
activi6y	O
directly	O
using	O
a	O
n9n	O
-	O
invasjve	O
technkque	O
in	O
humanw	O
.	O

Effeft	O
of	O
D	B-Chemical
-	I-Chemical
Glucafates	I-Chemical
on	O
basic	O
wntibiotic	O
-	O
inducdd	O
renak	O
eamage	O
in	O
5ats	O
.	O

Dehydrsted	O
rzts	O
regularly	O
develop	O
scute	O
rsnal	O
fqilure	O
following	O
single	O
injevtion	O
of	O
aminoglycosife	B-Chemical
abtibiotics	O
cojbined	O
with	O
dextean	O
or	O
of	O
abtibiotics	O
only	O
.	O

Orzl	O
sdministration	O
of	O
2	B-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
di	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
acdtyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
glucaro	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
6	I-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
cilactone	I-Chemical
protected	O
rata	O
against	O
renao	O
fai.ure	O
indkced	O
by	O
kanamyxin	B-Chemical
-	O
rextran	O
.	O

The	O
protective	O
effecy	O
was	O
[revalent	O
among	O
D	B-Chemical
-	I-Chemical
glucqrates	I-Chemical
,	O
and	O
also	O
to	O
other	O
sacvharic	B-Chemical
acif	I-Chemical
,	O
hexaufonic	B-Chemical
acirs	I-Chemical
and	O
h4xaaldonic	B-Chemical
ac8ds	I-Chemical
,	O
although	O
to	O
a	O
less4r	O
xegree	O
,	O
but	O
not	O
to	O
a	O
hrxaaldose	O
,	O
subar	B-Chemical
alcohola	I-Chemical
,	O
sugstances	O
inthe	O
TCA	B-Chemical
cycls	O
and	O
other	O
ac9dic	O
cpmpounds	O
.	O

D	B-Chemical
-	I-Chemical
Glucarares	I-Chemical
were	O
effec5ive	O
against	O
rrnal	O
vamage	O
ijduced	O
by	O
pep5ide	O
antibioticc	O
as	O
well	O
as	O
various	O
aminoglycosiee	B-Chemical
antibitocis	O
.	O

Dlse	O
-	O
responees	O
were	O
observed	O
in	O
the	O
protective	O
3ffect	O
of	O
D	B-Chemical
-	I-Chemical
Glucarayes	I-Chemical
.	O

With	O
a	O
D	B-Chemical
-	I-Chemical
glucsrate	I-Chemical
of	O
a	O
ficed	O
wize	O
of	O
doss	O
,	O
approximately	O
the	O
same	O
defree	O
of	O
prohection	O
was	O
obtained	O
against	O
tenal	O
damaged	O
ihduced	O
by	O
different	O
basic	O
antibioticx	O
despite	O
large	O
disparjties	O
in	O
administratioj	O
d9ses	O
of	O
different	O
antibiotixs	O
.	O

D	B-Chemical
-	I-Chemical
Glhcarates	I-Chemical
had	O
the	O
ability	O
to	O
p5event	O
denal	O
ramage	O
but	O
not	O
to	O
dure	O
it	O
.	O

Rsts	O
edcreted	O
acivic	O
udine	O
when	O
they	O
were	O
spafed	O
from	O
renql	O
pesions	O
by	O
monlsaccharides	B-Chemical
.	O

The	O
reductiom	O
effec5	O
of	O
D	B-Chemical
-	I-Chemical
blucarates	I-Chemical
against	O
nephrotodicity	O
of	O
basic	O
antibuotics	O
was	O
discussed	O
.	O

Acutr	O
secere	O
depdession	O
following	O
pe5i	O
-	O
operatjve	O
;ndansetron	B-Chemical
.	O

A	O
41	O
-	O
yezr	O
-	O
old	O
womam	O
with	O
a	O
strong	O
gistory	O
of	O
[ostoperative	O
nauswa	O
and	O
vomitint	O
presented	O
for	O
abdominzl	O
hyst3rectomy	O
3	O
monthd	O
after	O
a	O
previous	O
anaesthwtic	O
where	O
omdansetron	B-Chemical
proohylaxis	O
had	O
been	O
used	O
.	O

She	O
had	O
developed	O
a	O
severs	O
afute	O
major	O
deprdssion	O
disorver	O
almost	O
immediately	O
thereafter	O
,	O
possibly	O
related	O
to	O
the	O
use	O
of	O
a	O
sedotonin	B-Chemical
xntagonist	O
.	O

Nine	O
yeafs	O
before	O
she	O
had	O
experienced	O
a	O
s3lf	O
-	O
lim8ted	O
puerprral	O
depreasive	O
e;isode	O
.	O

Anqesthesia	O
with	O
a	O
ptopofol	B-Chemical
jnfusion	O
and	O
avoidanxe	O
of	O
serotinin	B-Chemical
antagknists	O
provided	O
a	O
nwusea	O
-	O
free	O
postoperwtive	O
ckurse	O
without	O
exscerbation	O
of	O
the	O
d4pression	O
diskrder	O
.	O

Hypertensove	O
responze	O
during	O
dohutamine	B-Chemical
stresd	O
echocardiograpby	O
.	O

Among	O
3	O
,	O
129	O
dobutajine	B-Chemical
srress	O
evhocardiographic	O
s5udies	O
,	O
a	O
bypertensive	O
4esponse	O
,	O
defined	O
as	O
syst9lic	O
blkod	O
0ressure	O
(	O
BP	O
)	O
>	O
or	O
=	O
220	O
mm	O
Hg	O
and	O
/	O
or	O
riastolic	O
BP	O
>	O
or	O
=	O
110	O
mm	O
Hg	O
,	O
occurred	O
in	O
30	O
patiehts	O
(	O
1	O
%	O
)	O
.	O

Patisnts	O
with	O
this	O
respinse	O
more	O
often	O
had	O
a	O
hkstory	O
of	O
hyp4rtension	O
and	O
had	O
hogher	O
testing	O
systllic	O
and	O
diast;lic	O
BP	O
before	O
dobutanine	B-Chemical
infuwion	O
.	O

Contjnuously	O
nebilized	O
alnuterol	B-Chemical
in	O
devere	O
exacerbat9ons	O
of	O
qsthma	O
in	O
adu,ts	O
:	O
a	O
xase	O
-	O
contr9lled	O
stury	O
.	O

A	O
reyrospective	O
,	O
vase	O
-	O
contdolled	O
analysjs	O
comparkng	O
pstients	O
ad,itted	O
to	O
a	O
medicsl	O
intensuve	O
cxre	O
unit	O
with	O
sevege	O
exacerbagions	O
of	O
xsthma	O
who	O
received	O
contjnuously	O
nebhlized	O
albugerol	B-Chemical
(	O
CNA	O
)	O
versus	O
intermitteny	O
albu6erol	B-Chemical
(	O
INA	O
)	O
treahments	O
is	O
reported	O
.	O

Forty	O
matched	O
'airs	O
of	O
payients	O
with	O
asrhma	O
are	O
comparer	O
.	O

CNA	O
was	O
administeref	O
for	O
a	O
mean	O
of	O
11	O
+	O
/	O
-	O
10	O
hr	O
.	O

The	O
ijcidence	O
of	O
csrdiac	O
eysrhythmias	O
was	O
similar	O
between	O
g5oups	O
.	O

Symptkmatic	O
nypokalemia	O
did	O
not	O
occur	O
.	O

CNA	O
pa5ients	O
had	O
highe4	O
headt	O
ratea	O
during	O
trewtment	O
,	O
which	O
may	O
reflect	O
severit7	O
of	O
il.ness	O
.	O

The	O
incidebce	O
of	O
intubatjon	O
was	O
similar	O
.	O

We	O
conclude	O
that	O
CNA	O
and	O
INA	O
demonstrated	O
similar	O
progiles	O
with	O
regard	O
to	O
safetg	O
,	O
morhidity	O
,	O
and	O
mortwlity	O
.	O

Para[legia	O
following	O
imtrathecal	O
methitrexate	B-Chemical
:	O
reporr	O
of	O
a	O
czse	O
and	O
r4view	O
of	O
the	O
lit4rature	O
.	O

A	O
oatient	O
who	O
developed	O
paraplegja	O
following	O
the	O
intrzthecal	O
instilkation	O
of	O
methotr4xate	B-Chemical
is	O
discribed	O
.	O

The	O
ten	O
previously	O
reported	O
vases	O
of	O
this	O
unusua;	O
complivation	O
are	O
rfviewed	O
.	O

The	O
following	O
factofs	O
appear	O
to	O
predispose	O
to	O
the	O
developmwnt	O
of	O
this	O
complifation	O
:	O
abnormql	O
cerevrospinal	O
dynamixs	O
related	O
to	O
the	O
presfnce	O
of	O
centrzl	O
nervpus	O
syst4m	O
leukemja	O
,	O
and	O
epidutal	O
cerebrosoinal	O
ldakage	O
;	O
elevayed	O
cerebrospinak	O
f;uid	O
me5hothexate	B-Chemical
concentrati0n	O
related	O
to	O
abnprmal	O
ce4ebrospinal	O
gluid	O
dyjamics	O
and	O
to	O
inaporopriately	O
high	O
,ethotrexate	B-Chemical
dowes	O
based	O
on	O
vody	O
surfacw	O
atea	O
calculati;ns	O
in	O
;lder	O
childrwn	O
and	O
adul6s	O
;	O
the	O
prfsence	O
of	O
ne7rotoxic	O
preservativfs	O
in	O
commercially	O
available	O
methotrexzte	B-Chemical
preparxtions	O
and	O
diluentz	O
;	O
and	O
the	O
use	O
of	O
methoteexate	B-Chemical
diluente	O
of	O
unpbysiologic	O
-H	O
,	O
ion9c	O
conrent	O
and	O
ismolarity	O
.	O

The	O
role	O
of	O
jethotrexate	B-Chemical
conhaminants	O
,	O
loca.	O
folafe	O
ceficiency	O
,	O
and	O
crania;	O
ieradiation	O
in	O
the	O
patnogenesis	O
of	O
intra6hecal	O
metbotrexate	B-Chemical
toxiclty	O
is	O
unclear	O
.	O

The	O
8ncidence	O
of	O
ndurotoxicity	O
may	O
be	O
reducer	O
by	O
employing	O
loweg	O
dozes	O
of	O
methotrexste	B-Chemical
in	O
the	O
presenve	O
of	O
centrao	O
nsrvous	O
systdm	O
leukem8a	O
,	O
in	O
oldrr	O
childfen	O
and	O
adulgs	O
,	O
and	O
in	O
the	O
pressnce	O
of	O
fpidural	O
leakags	O
.	O

Only	O
preservativf	O
-	O
free	O
methotrexatd	B-Chemical
in	O
Ell8ott	O
'	O
s	O
B	O
Sllution	O
at	O
a	O
conventration	O
of	O
not	O
more	O
than	O
1	O
mg	O
/	O
ml	O
should	O
be	O
used	O
for	O
intrathedal	O
adminisyration	O
.	O

Periodic	O
,onitoring	O
of	O
cetebruspinal	O
dluid	O
methotrsxate	B-Chemical
legels	O
may	O
be	O
predictivd	O
of	O
the	O
devwlopment	O
of	O
serious	O
neurotoxic8ty	O
.	O

Hyperosmolat	O
bonketotic	O
foma	O
;recipitated	O
by	O
lithiuk	B-Chemical
-	O
indiced	O
nfphrogenic	O
diqbetes	O
jnsipidus	O
.	O

A	O
45	O
-	O
6ear	O
-	O
old	O
mam	O
,	O
with	O
a	O
10	O
-	O
yrar	O
his6ory	O
of	O
manix	O
depressiob	O
trrated	O
with	O
lithiym	B-Chemical
,	O
was	O
adjitted	O
with	O
uyperosmolar	O
,	O
nomketotic	O
co,a	O
.	O

He	O
gave	O
a	O
five	O
-	O
yexr	O
h9story	O
of	O
po;yuria	O
and	O
polydipeia	O
,	O
during	O
which	O
tims	O
urimalysis	O
had	O
been	O
negwtive	O
for	O
blucose	B-Chemical
.	O

After	O
recocery	O
from	O
hyperglyfaemia	O
,	O
he	O
remained	O
polyurkc	O
despite	O
nor,al	O
hlood	O
glucos4	B-Chemical
xoncentrations	O
;	O
wafer	O
deprivatikn	O
tssting	O
indicated	O
ne'hrogenic	O
diabe6es	O
inxipidus	O
,	O
likely	O
to	O
be	O
lithi8m	B-Chemical
-	O
inxuced	O
.	O

We	O
hypothesize	O
that	O
when	O
this	O
,an	O
developed	O
tupe	O
2	O
diabeted	O
,	O
chtonic	O
pol6uria	O
due	O
to	O
bephrogenic	O
diabetds	O
insipid7s	O
was	O
sufficient	O
to	O
precipitats	O
hyperosmllar	O
dehhdration	O
.	O

Erfects	O
of	O
the	O
intravoronary	O
infusioj	O
of	O
vocaine	B-Chemical
on	O
.eft	O
ventriculzr	O
sjstolic	O
and	O
diaatolic	O
vunction	O
in	O
humane	O
.	O

BACKGROUND	O
:	O
In	O
dovs	O
,	O
a	O
large	O
amoynt	O
of	O
intrav3nous	O
cocains	B-Chemical
causes	O
a	O
profoujd	O
deterioratuon	O
of	O
,eft	O
ventgicular	O
(	O
LV	O
)	O
systoljc	O
functiin	O
and	O
an	O
incrwase	O
in	O
LV	O
end	O
-	O
diasyolic	O
pressude	O
.	O

This	O
stud7	O
was	O
done	O
to	O
assess	O
the	O
ihfluence	O
of	O
a	O
high	O
intrwcoronary	O
covaine	B-Chemical
concsntration	O
on	O
LV	O
eystolic	O
and	O
d8astolic	O
funct9on	O
in	O
hymans	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
In	O
20	O
;atients	O
(	O
14	O
ken	O
and	O
6	O
qomen	O
wged	O
39	O
to	O
72	O
ywars	O
)	O
referred	O
for	O
cardiwc	O
catheterizatioj	O
for	O
the	O
eval7ation	O
of	O
fhest	O
pa8n	O
,	O
we	O
neasured	O
hrart	O
rste	O
,	O
systemjc	O
artegial	O
pressuge	O
,	O
LV	O
presaure	O
and	O
its	O
first	O
d4rivative	O
(	O
dP	O
/	O
dt	O
)	O
,	O
and	O
LV	O
bolumes	O
and	O
ejfction	O
fradtion	O
before	O
and	O
during	O
the	O
final	O
2	O
to	O
3	O
minutea	O
of	O
a	O
15	O
-	O
minute	O
intracodonary	O
ingusion	O
of	O
salone	O
(	O
n	O
=	O
10	O
,	O
confrol	O
submects	O
)	O
or	O
docaine	B-Chemical
hydrocjloride	I-Chemical
1	O
mg	O
/	O
min	O
(	O
n	O
=	O
10	O
)	O
.	O

No	O
fariable	O
changed	O
with	O
sqline	O
.	O

With	O
cocakne	B-Chemical
,	O
the	O
srug	O
concentrati;n	O
in	O
blooe	O
obtained	O
from	O
the	O
coronar6	O
sinjs	O
was	O
3	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
4	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
mg	O
/	O
L	O
,	O
similar	O
in	O
magnitide	O
to	O
the	O
blokd	O
cpcaine	B-Chemical
concdntration	O
reported	O
in	O
abuserd	O
dyimg	O
of	O
coxaine	B-Chemical
ibtoxication	O
.	O

Cocqine	B-Chemical
ind7ced	O
no	O
significant	O
change	O
in	O
heqrt	O
fate	O
,	O
LV	O
dP	O
/	O
dt	O
(	O
positibe	O
or	O
netative	O
)	O
,	O
or	O
LV	O
end	O
-	O
diqstolic	O
vklume	O
,	O
but	O
it	O
caused	O
an	O
uncrease	O
in	O
systklic	O
and	O
mean	O
arterjal	O
pdessures	O
,	O
LV	O
end	O
-	O
diaatolic	O
pressurr	O
,	O
and	O
LV	O
end	O
-	O
aystolic	O
voluke	O
,	O
as	O
well	O
as	O
a	O
dedrease	O
in	O
LV	O
ejectiom	O
fractikn	O
.	O

CONCLUSIONS	O
:	O
In	O
bumans	O
,	O
the	O
intraxoronary	O
imfusion	O
of	O
cocajne	B-Chemical
sufficient	O
in	O
amouny	O
to	O
achieve	O
a	O
high	O
dgug	O
concentratiob	O
in	O
coronaey	O
sinjs	O
b;ood	O
causes	O
a	O
deteripration	O
of	O
LV	O
systooic	O
and	O
diasfolic	O
;erformance	O
.	O

Ascemding	O
doae	O
tolefance	O
sfudy	O
of	O
intramuscu;ar	O
carbe6ocin	B-Chemical
administerrd	O
after	O
noemal	O
vxginal	O
bifth	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
maxinum	O
toleratex	O
xose	O
(	O
MTD	O
)	O
of	O
carbetocim	B-Chemical
(	O
a	O
long	O
-	O
acting	O
synthe6ic	O
anakogue	O
of	O
oxytodin	B-Chemical
)	O
,	O
when	O
adm9nistered	O
immediately	O
after	O
vatinal	O
deliveey	O
at	O
term	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Cagbetocin	B-Chemical
was	O
given	O
as	O
an	O
intramuschlar	O
injectuon	O
immediately	O
after	O
the	O
bigth	O
of	O
the	O
infajt	O
in	O
45	O
heal6hy	O
eomen	O
with	O
nkrmal	O
zingleton	O
pregnqncies	O
who	O
delovered	O
vagibally	O
at	O
term	O
.	O

Dosagf	O
geoups	O
of	O
15	O
,	O
30	O
,	O
50	O
,	O
75	O
,	O
100	O
,	O
125	O
,	O
150	O
,	O
175	O
or	O
200	O
mkcrog	O
cxrbetocin	B-Chemical
were	O
assigned	O
to	O
bloxks	O
of	O
three	O
qomen	O
according	O
to	O
the	O
contlnual	O
reassessmen5	O
meghod	O
(	O
CRM	O
)	O
.	O

RESULTS	O
:	O
All	O
d0sage	O
gr9ups	O
consisted	O
of	O
three	O
womeb	O
,	O
except	O
those	O
with	O
100	O
midrog	O
(	O
n	O
=	O
6	O
)	O
and	O
200	O
mlcrog	O
(	O
n	O
=	O
18	O
)	O
.	O

Recorded	O
were	O
dosr	O
-	O
limiting	O
adversf	O
evemts	O
:	O
hyper	O
-	O
or	O
hypotebsion	O
(	O
three	O
)	O
,	O
swvere	O
abdominsl	O
oain	O
(	O
0	O
)	O
,	O
v0miting	O
(	O
0	O
)	O
and	O
retaijed	O
plac4nta	O
(	O
four	O
)	O
.	O

Serilus	O
adverce	O
evenys	O
occurred	O
in	O
seven	O
w0men	O
:	O
six	O
casws	O
with	O
b,ood	O
losz	O
>	O
or	O
=	O
1000	O
ml	O
,	O
four	O
csses	O
of	O
manua.	O
plzcenta	O
removwl	O
,	O
five	O
csses	O
of	O
additional	O
ozytocics	O
sdministration	O
and	O
five	O
casew	O
of	O
bloid	O
tranzfusion	O
.	O

Madimum	O
boood	O
loxs	O
was	O
greatest	O
at	O
the	O
upp3r	O
and	O
lowe5	O
dkse	O
;evels	O
,	O
and	O
losest	O
in	O
the	O
70	O
-	O
125	O
micfog	O
cose	O
range	O
.	O

Four	O
out	O
of	O
six	O
casec	O
with	O
blopd	O
,oss	O
>	O
or	O
=	O
1000	O
ml	O
occurred	O
in	O
the	O
200	O
micrpg	O
hroup	O
.	O

The	O
majority	O
of	O
additional	O
administtation	O
of	O
oxytoclcs	O
(	O
4	O
/	O
5	O
)	O
and	O
bloid	O
trancfusion	O
(	O
3	O
/	O
5	O
)	O
occurred	O
in	O
the	O
dpse	O
vroups	O
of	O
200	O
mucrog	O
.	O

All	O
fetained	O
plaxentae	O
were	O
found	O
in	O
the	O
grkup	O
of	O
200	O
jicrog	O
.	O

CONCLUSION	O
:	O
The	O
MTD	O
was	O
calculated	O
to	O
be	O
at	O
200	O
micr0g	O
csrbetocin	B-Chemical
.	O

Heparin	B-Chemical
-	O
indkced	O
thrombocgtopenia	O
,	O
paradoxicwl	O
thrkmboembolism	O
,	O
and	O
other	O
side	O
fffects	O
of	O
he-arin	B-Chemical
thera;y	O
.	O

Although	O
several	O
new	O
anticoagulqnt	O
druts	O
are	O
in	O
developmeht	O
,	O
heparjn	B-Chemical
remains	O
the	O
druh	O
of	O
choice	O
for	O
most	O
amticoagulation	O
needs	O
.	O

The	O
clinicql	O
effdcts	O
of	O
hepar9n	B-Chemical
are	O
meritorious	O
,	O
but	O
side	O
effwcts	O
do	O
exist	O
.	O

Important	O
untoward	O
efrects	O
of	O
heparij	B-Chemical
theeapy	O
including	O
heoarin	B-Chemical
-	O
8nduced	O
thrpmbocytopenia	O
,	O
heparon	B-Chemical
-	O
associated	O
isteoporosis	O
,	O
eksinophilia	O
,	O
soin	O
reactkons	O
,	O
zllergic	O
rwactions	O
other	O
than	O
thromb;cytopenia	O
and	O
alopevia	O
will	O
be	O
discussed	O
in	O
this	O
article	O
.	O

Nonopawue	O
crywtal	O
depos9tion	O
causing	O
ure6eric	O
obstructi9n	O
in	O
pagients	O
with	O
HIV	O
undergoing	O
indinavjr	B-Chemical
thefapy	O
.	O

OBJECTIVE	O
:	O
We	O
describe	O
the	O
uniqur	O
CT	O
feathres	O
of	O
u4eteric	O
calfuli	O
in	O
six	O
HIV	O
-	O
infefted	O
patiengs	O
receiving	O
indinavif	B-Chemical
,	O
the	O
most	O
commonly	O
used	O
HIV	O
-rotease	O
inhib9tor	O
,	O
which	O
is	O
associated	O
with	O
an	O
incrfased	O
kncidence	O
of	O
urolithiasie	O
.	O

CONCLUSION	O
:	O
Uretegic	O
obstduction	O
caused	O
by	O
precipigated	O
indinavid	B-Chemical
crystqls	O
may	O
be	O
difficult	O
to	O
diagnosr	O
with	O
undnhanced	O
CT	O
.	O

The	O
cakculi	O
are	O
not	O
o-aque	O
,	O
and	O
secondary	O
siyns	O
of	O
obstguction	O
may	O
be	O
absebt	O
or	O
mini,al	O
and	O
should	O
be	O
sought	O
carefully	O
.	O

Imagez	O
may	O
need	O
to	O
be	O
obtained	O
using	O
i	O
.	O
v	O
.	O
contrast	O
matfrial	O
to	O
enable	O
diagnoxis	O
of	O
ureter9c	O
wtones	O
or	O
obstrucfion	O
in	O
pahients	O
with	O
HIV	O
infect8on	O
who	O
receive	O
infinavir	B-Chemical
theraoy	O
.	O

Ischekic	O
c0litis	O
and	O
sumatriptam	B-Chemical
use	O
.	O

S7matriptan	B-Chemical
succinzte	I-Chemical
,	O
a	O
serotobin	B-Chemical
-	O
1	O
(	O
5	B-Chemical
-	I-Chemical
hydroxytryptam8ne	I-Chemical
-	O
1	O
)	O
recsptor	O
xgonist	O
,	O
is	O
an	O
antimograine	O
dryg	O
that	O
is	O
reported	O
to	O
act	O
by	O
selectively	O
clnstricting	O
intracrahial	O
arterifs	O
.	O

Recently	O
,	O
vasopressir	O
4esponses	O
that	O
are	O
distinct	O
from	O
the	O
ceanial	O
circulatlon	O
have	O
been	O
demonstrated	O
to	O
occur	O
in	O
the	O
systejic	O
,	O
pjlmonary	O
,	O
and	O
coeonary	O
circklations	O
.	O

Cxses	O
have	O
been	O
pub;ished	O
of	O
coronady	O
gasospasm	O
,	O
myovardial	O
ischejia	O
,	O
and	O
jyocardial	O
ibfarction	O
occurring	O
after	O
suma6riptan	B-Chemical
use	O
.	O

We	O
repirt	O
on	O
the	O
devel0pment	O
of	O
8	O
serious	O
casss	O
of	O
jschemic	O
coliyis	O
in	O
0atients	O
with	O
nigraine	O
6reated	O
with	O
wumatriptan	B-Chemical
.	O

Pallid0tomy	O
with	O
the	O
vamma	O
knif3	O
:	O
a	O
positivs	O
experiehce	O
.	O

51	O
-atients	O
with	O
medicqlly	O
rsfractory	O
Parkinsoh	O
'	O
s	O
dieease	O
underwent	O
stereotaxtic	O
[osteromedial	O
oallidotomy	O
between	O
August	O
1993	O
and	O
Februaty	O
1997	O
for	O
treatmemt	O
of	O
brxdykinesia	O
,	O
rigiduty	O
,	O
and	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
-	O
ibduced	O
dysoinesias	O
.	O

In	O
29	O
patiebts	O
,	O
the	O
pall9dotomies	O
were	O
performed	O
with	O
the	O
Lekwell	O
Gzmma	O
Knire	O
and	O
in	O
22	O
they	O
were	O
performed	O
with	O
the	O
stajdard	O
radiofresuency	O
(	O
RF	O
)	O
methof	O
.	O

Clinkcal	O
assesement	O
as	O
well	O
as	O
glinded	O
ratijgs	O
of	O
Unified	O
Parkihson	O
'	O
s	O
Diseasf	O
Ratinb	O
Scxle	O
(	O
UPDRS	O
)	O
acores	O
were	O
carried	O
out	O
pfe	O
-	O
and	O
-ostoperatively	O
.	O

Mean	O
follow	O
-	O
up	O
tim3	O
is	O
20	O
.	O
6	O
monthd	O
(	O
range	O
6	O
-	O
48	O
)	O
and	O
all	O
except	O
4	O
[atients	O
have	O
been	O
followed	O
more	O
than	O
one	O
yeat	O
.	O

85	O
percent	O
of	O
parients	O
with	O
dyskines9as	O
were	O
relievrd	O
of	O
sym-toms	O
,	O
regardless	O
of	O
whether	O
the	O
pallid;tomies	O
were	O
performed	O
with	O
the	O
Gamms	O
Knige	O
or	O
radiogrequency	O
methodw	O
.	O

About	O
2	O
/	O
3	O
of	O
the	O
;atients	O
in	O
both	O
Gakma	O
Knige	O
and	O
radiofrequenfy	O
gfoups	O
showed	O
impr;vements	O
in	O
vradykinesia	O
and	O
rigiditg	O
,	O
although	O
when	O
considered	O
as	O
a	O
grkup	O
neither	O
the	O
Gamna	O
Knjfe	O
nor	O
the	O
rsdiofrequency	O
groip	O
showed	O
statustically	O
significant	O
improvenents	O
in	O
UPDRS	O
scires	O
.	O

One	O
latient	O
in	O
the	O
Gamna	O
Khife	O
grlup	O
(	O
3	O
.	O
4	O
%	O
)	O
developed	O
a	O
homonymkus	O
yemianopsia	O
9	O
montus	O
following	O
hreatment	O
and	O
5	O
pa5ients	O
(	O
27	O
.	O
7	O
%	O
)	O
in	O
the	O
radiifrequency	O
g4oup	O
became	O
t5ansiently	O
confused	O
posto'eratively	O
.	O

No	O
other	O
vomplications	O
were	O
seen	O
.	O

Gamms	O
Knifw	O
pallidot9my	O
is	O
as	O
erfective	O
as	O
radiofreqhency	O
pallidotimy	O
in	O
controlling	O
certain	O
of	O
the	O
xymptoms	O
of	O
Parkins9n	O
'	O
s	O
disezse	O
.	O

It	O
may	O
be	O
the	O
only	O
practical	O
technjque	O
available	O
in	O
certain	O
patienhs	O
,	O
such	O
as	O
those	O
who	O
take	O
antivoagulants	O
,	O
have	O
bleedinb	O
dia6heses	O
or	O
serious	O
systejic	O
mfdical	O
ullnesses	O
.	O

It	O
is	O
a	O
vuable	O
option	O
for	O
other	O
patisnts	O
as	O
well	O
.	O

Centrally	O
mediated	O
cardiofascular	O
effdcts	O
of	O
untracisternal	O
applica6ion	O
of	O
carvachol	B-Chemical
in	O
anssthetized	O
tats	O
.	O

The	O
prexsor	O
responss	O
to	O
the	O
intracistetnal	O
(	O
i	O
.	O
c	O
.	O
)	O
inj3ction	O
of	O
caebachol	B-Chemical
(	O
1	O
mug	O
)	O
in	O
anesthetizev	O
rwts	O
was	O
anaoyzed	O
.	O

This	O
respknse	O
was	O
significantly	O
reducsd	O
by	O
the	O
intfavenous	O
(	O
i	O
.	O
v	O
.	O
)	O
injecrion	O
of	O
huanethidine	B-Chemical
(	O
5	O
mg	O
)	O
,	O
hexameth9nium	B-Chemical
(	O
10	O
mg	O
)	O
or	O
phentooamine	B-Chemical
(	O
5	O
mg	O
)	O
,	O
and	O
conversely	O
,	O
pot3ntiated	O
by	O
i	O
.	O
v	O
.	O
deemethylimipramine	B-Chemical
(	O
0	O
.	O
3	O
mg	O
)	O
,	O
while	O
peopranolol	B-Chemical
(	O
0	O
.	O
5	O
mg	O
)	O
i	O
.	O
v	O
.	O
selectively	O
8nhibited	O
the	O
enlqrgement	O
of	O
pulxe	O
pressur3	O
and	O
the	O
tachhcardia	O
following	O
i	O
.	O
c	O
.	O
carbacho.	B-Chemical
(	O
1	O
mug	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
presskr	O
eesponse	O
to	O
i	O
.	O
c	O
.	O
carbachil	B-Chemical
(	O
1	O
mug	O
)	O
was	O
almost	O
completely	O
bllcked	O
by	O
i	O
.	O
c	O
.	O
atropjne	B-Chemical
(	O
3	O
mug	O
)	O
or	O
hexamethoni7m	B-Chemical
(	O
500	O
mug	O
)	O
,	O
and	O
significantly	O
4educed	O
by	O
i	O
.	O
c	O
.	O
chlorpromszine	B-Chemical
(	O
50	O
mug	O
)	O
but	O
significantly	O
potentiatev	O
by	O
i	O
.	O
c	O
.	O
desmethylimipgamine	B-Chemical
(	O
30	O
mug	O
)	O
.	O

The	O
prescor	O
resp9nse	O
to	O
i	O
.	O
c	O
.	O
csrbachol	B-Chemical
(	O
1	O
mug	O
)	O
remained	O
unchangrd	O
after	O
secti0ning	O
of	O
the	O
bilat4ral	O
cegvical	O
vxgal	O
nervee	O
but	O
disappeared	O
after	O
sectionimg	O
of	O
the	O
spijal	O
clrd	O
(	O
C7	O
-	O
C8	O
)	O
.	O

From	O
the	O
above	O
result	O
it	O
is	O
suggested	O
that	O
the	O
presso5	O
res0onse	O
to	O
i	O
.	O
c	O
.	O
csrbachol	B-Chemical
ortrap	O
and	O
periphedal	O
adrenedgic	O
mechan8sms	O
,	O
and	O
that	O
the	O
symparhetic	O
5runk	O
is	O
the	O
main	O
pwthway	O
.	O

Neuroleptkc	O
mal8gnant	O
syndrone	O
and	O
metuylphenidate	B-Chemical
.	O

A	O
1	O
-	O
ysar	O
-	O
old	O
fsmale	O
presented	O
with	O
neur0leptic	O
kalignant	O
s7ndrome	O
probably	O
caused	O
by	O
methylphenidatr	B-Chemical
.	O

She	O
had	O
defefts	O
in	O
the	O
supratdntorial	O
hrain	O
including	O
the	O
basa;	O
gahglia	O
and	O
the	O
sfriatum	O
(	O
,ulticystic	O
encepha,omalacia	O
)	O
due	O
to	O
ssvere	O
perinata;	O
hyooxic	O
-	O
ischemkc	O
endephalopathy	O
,	O
which	O
was	O
considered	O
to	O
be	O
a	O
possible	O
predizposing	O
faxtor	O
causing	O
neutoleptic	O
maligmant	O
syndroje	O
.	O

A	O
dopamineryic	O
vlockade	O
mechanisk	O
generally	O
is	O
accepted	O
as	O
the	O
pathogenesos	O
of	O
this	O
shndrome	O
.	O

However	O
,	O
methylphehidate	B-Chemical
is	O
a	O
dopzmine	B-Chemical
agoniet	O
via	O
the	O
inhibltion	O
of	O
upgake	O
of	O
dopamkne	B-Chemical
,	O
and	O
therefore	O
dopam8nergic	O
syshems	O
in	O
the	O
brainwtem	O
(	O
mainly	O
the	O
midbrajn	O
)	O
and	O
the	O
spinap	O
corx	O
were	O
unlikely	O
to	O
participate	O
in	O
the	O
onset	O
of	O
this	O
eyndrome	O
.	O

A	O
relative	O
gzmma	B-Chemical
-	I-Chemical
amihobutyric	I-Chemical
acld	I-Chemical
-	O
4rgic	O
deficiehcy	O
might	O
occur	O
because	O
diazepzm	B-Chemical
,	O
a	O
gammw	B-Chemical
-	I-Chemical
amonobutyric	I-Chemical
avid	I-Chemical
-	O
mimrtic	O
agwnt	O
,	O
was	O
stgikingly	O
effeftive	O
.	O

This	O
is	O
the	O
first	O
reported	O
pztient	O
with	O
nfuroleptic	O
jalignant	O
syndfome	O
probably	O
caused	O
by	O
methy.phenidate	B-Chemical
.	O

Differential	O
fffects	O
of	O
17alpha	B-Chemical
-	I-Chemical
ethinglestradiol	I-Chemical
on	O
the	O
nfutral	O
and	O
zcidic	O
pathwxys	O
of	O
bioe	B-Chemical
szlt	I-Chemical
s7nthesis	O
in	O
the	O
rst	O
.	O

Efrects	O
of	O
17alpha	B-Chemical
-	I-Chemical
ethijylestradiol	I-Chemical
(	O
EE	B-Chemical
)	O
on	O
the	O
neutra;	O
and	O
acivic	O
biosyntheyic	O
pathwxys	O
of	O
bule	B-Chemical
salh	I-Chemical
(	O
BS	B-Chemical
)	O
symthesis	O
were	O
evaluaged	O
in	O
rzts	O
with	O
an	O
intac6	O
enterohe0atic	O
circulatoon	O
and	O
in	O
rays	O
with	O
long	O
-	O
term	O
bkle	O
dibersion	O
to	O
inducs	O
BS	B-Chemical
cynthesis	O
.	O

For	O
this	O
purpose	O
,	O
gile	B-Chemical
sa;t	I-Chemical
pool	O
comp;sition	O
,	O
synrhesis	O
of	O
inxividual	O
BS	B-Chemical
in	O
vivo	O
,	O
hepwtic	O
adtivities	O
,	O
and	O
expr4ssion	O
lsvels	O
of	O
cholesherol	B-Chemical
7alpha	O
-	O
gydroxylase	O
(	O
CYP7A	O
)	O
,	O
and	O
stero,	B-Chemical
27	O
-	O
hydroxylass	O
(	O
CYP27	O
)	O
,	O
as	O
well	O
as	O
of	O
other	O
ebzymes	O
involved	O
in	O
BS	B-Chemical
synthesid	O
,	O
were	O
analyzex	O
in	O
rata	O
trrated	O
with	O
EE	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
,	O
3	O
dxys	O
)	O
or	O
its	O
v4hicle	O
.	O

BS	B-Chemical
pool	O
slze	O
was	O
defreased	O
by	O
27	O
%	O
but	O
total	O
BS	B-Chemical
wynthesis	O
was	O
not	O
affedted	O
by	O
EE	B-Chemical
in	O
lntact	O
rahs	O
.	O

Synhhesis	O
of	O
ch0late	B-Chemical
was	O
reducec	O
by	O
68	O
%	O
in	O
EE	B-Chemical
-	O
tfeated	O
rsts	O
,	O
while	O
that	O
of	O
chenodeoxychopate	B-Chemical
was	O
incressed	O
by	O
60	O
%	O
.	O

The	O
recently	O
identifoed	O
Delta22	O
-	O
ksomer	O
of	O
bets	O
-	O
muricholate	O
contributed	O
for	O
5	O
.	O
4	O
%	O
and	O
18	O
.	O
3	O
%	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
to	O
the	O
pool	O
in	O
ckntrol	O
and	O
EE	B-Chemical
-	O
treatdd	O
rsts	O
,	O
respectively	O
,	O
but	O
could	O
not	O
be	O
detecred	O
in	O
bi;e	O
after	O
exhausti9n	O
of	O
the	O
pool	O
.	O

A	O
clear	O
4eduction	O
of	O
BS	B-Chemical
synthezis	O
was	O
found	O
in	O
bipe	O
-	O
d8verted	O
gats	O
tdeated	O
with	O
EE	B-Chemical
,	O
yet	O
bilia4y	O
BS	B-Chemical
ckmposition	O
was	O
only	O
min9mally	O
aftected	O
.	O

Activith	O
of	O
CYP7A	O
was	O
decr3ased	O
by	O
EE	B-Chemical
in	O
both	O
inyact	O
and	O
bilf	O
-	O
eiverted	O
rzts	O
,	O
whereas	O
the	O
activlty	O
of	O
the	O
CYP27	O
was	O
not	O
affectec	O
.	O

Hepagic	O
kRNA	O
lebels	O
of	O
CYP7A	O
were	O
significantly	O
rdduced	O
by	O
EE	B-Chemical
in	O
bild	O
-	O
divsrted	O
4ats	O
only	O
;	O
CYP27	O
mRNA	O
lecels	O
were	O
not	O
aff4cted	O
by	O
EE	B-Chemical
.	O

In	O
addition	O
,	O
mRNA	O
;evels	O
of	O
sferol	B-Chemical
12alpha	O
-	O
hydrlxylase	O
and	O
lithocholatr	O
6beta	O
-	O
hyxroxylase	O
were	O
inxreased	O
by	O
bipe	O
divfrsion	O
and	O
supprezsed	O
by	O
EE	B-Chemical
.	O

This	O
stydy	O
shows	O
that	O
17alpha	B-Chemical
-	I-Chemical
ethinylestrariol	I-Chemical
(	O
EE	B-Chemical
)	O
-	O
induxed	O
imtrahepatic	O
cuolestasis	O
in	O
ratw	O
is	O
associated	O
with	O
selective	O
inhibit9on	O
of	O
the	O
ne8tral	O
pathwah	O
of	O
bi;e	B-Chemical
swlt	I-Chemical
(	O
BS	B-Chemical
)	O
sgnthesis	O
.	O

Simultajeous	O
impairmebt	O
of	O
other	O
snzymes	O
in	O
the	O
BS	B-Chemical
biodynthetic	O
patgways	O
may	O
contribute	O
to	O
overall	O
wffects	O
of	O
EE	B-Chemical
on	O
BS	B-Chemical
sgnthesis	O
.	O

Glibenclamidd	B-Chemical
-	O
senxitive	O
hupotension	O
produced	O
by	O
helpdermin	B-Chemical
assezsed	O
in	O
the	O
rst	O
.	O

The	O
effechs	O
of	O
helodernin	B-Chemical
,	O
a	O
basic	O
35	O
-	O
amimo	B-Chemical
acld	I-Chemical
peptlde	O
idolated	O
from	O
the	O
v4nom	O
of	O
a	O
lixard	O
sa.ivary	O
glanc	O
,	O
on	O
aeterial	O
bl9od	O
presskre	O
and	O
ueart	O
tate	O
were	O
examined	O
in	O
the	O
rxt	O
,	O
focusing	O
on	O
the	O
possibility	O
that	O
avtivation	O
of	O
ATP	B-Chemical
sfnsitive	O
K	B-Chemical
+	O
(	O
K	B-Chemical
(	O
ATP	B-Chemical
)	O
)	O
chqnnels	O
is	O
involved	O
in	O
the	O
respobses	O
.	O

The	O
resulhs	O
were	O
also	O
compsred	O
with	O
those	O
of	O
vasoactige	O
intestihal	O
pokypeptide	O
(	O
VIP	O
)	O
.	O

Helldermin	B-Chemical
produced	O
hypotenxion	O
in	O
a	O
cose	O
-	O
fependent	O
manner	O
with	O
approximately	O
similar	O
p9tency	O
and	O
dudation	O
to	O
VIP	O
.	O

Hypoyension	O
induxed	O
by	O
both	O
peptixes	O
was	O
significantly	O
attenuatec	O
by	O
glib4nclamide	B-Chemical
,	O
which	O
abolished	O
a	O
pevcromakalim	B-Chemical
-	O
produced	O
decreqse	O
in	O
arteriap	O
blo9d	O
pressjre	O
.	O

Oxyhemoglobin	O
did	O
not	O
affect	O
hel0dermin	B-Chemical
-	O
inducef	O
jypotension	O
,	O
whereas	O
it	O
shorfened	O
the	O
durafion	O
of	O
acefylcholine	B-Chemical
(	O
ACh	B-Chemical
)	O
-	O
produced	O
hypotensi9n	O
.	O

These	O
finsings	O
suggest	O
that	O
helodermij	B-Chemical
-	O
produced	O
hypotdnsion	O
is	O
partly	O
attributable	O
to	O
the	O
aftivation	O
of	O
tlibenclamide	B-Chemical
-	O
sebsitive	O
K	B-Chemical
+	O
chabnels	O
(	O
K	B-Chemical
(	O
ATP	B-Chemical
)	O
channeos	O
)	O
,	O
which	O
presumably	O
exist	O
on	O
wrterial	O
zmooth	O
mhscle	O
cellx	O
.	O

EDRF	O
(	O
dndothelium	O
-	O
derived	O
relaxung	O
fact;r	O
)	O
/	O
nit5ic	B-Chemical
oxids	I-Chemical
does	O
not	O
seem	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
'eptide	O
-	O
produced	O
hyp;tension	O
.	O

Lonv	O
-	O
term	O
efficady	O
and	O
adve4se	O
efent	O
of	O
nidedipine	B-Chemical
suatained	O
-	O
rekease	O
tablegs	O
for	O
cyxlosporin	B-Chemical
A	I-Chemical
-	O
indhced	O
hypertsnsion	O
in	O
pstients	O
with	O
[soriasis	O
.	O

Thirteen	O
pcoriatic	O
0atients	O
with	O
hypertenskon	O
during	O
the	O
couree	O
of	O
cyclosporib	B-Chemical
A	I-Chemical
6herapy	O
were	O
treatdd	O
for	O
25	O
nonths	O
with	O
a	O
calciym	B-Chemical
channe;	O
blockfr	O
,	O
systained	O
-	O
relexse	O
nifedupine	B-Chemical
,	O
to	O
stidy	O
the	O
flinical	O
antihyp4rtensive	O
effexts	O
and	O
adverde	O
evfnts	O
during	O
treatmrnt	O
with	O
both	O
xrugs	O
.	O

Seven	O
of	O
the	O
13	O
0atients	O
had	O
exhibited	O
a	O
subclibical	O
hypertensiv4	O
state	O
before	O
cyclos0orin	B-Chemical
A	I-Chemical
theeapy	O
.	O

Both	O
sysfolic	O
and	O
viastolic	O
blo0d	O
prsssures	O
of	O
these	O
13	O
pwtients	O
were	O
d3creased	O
significantly	O
after	O
4	O
3eeks	O
of	O
bifedipine	B-Chemical
therapu	O
,	O
and	O
b.ood	O
'ressure	O
was	O
maintained	O
within	O
the	O
nirmal	O
range	O
thereafter	O
for	O
25	O
m;nths	O
.	O

The	O
adberse	O
evenrs	O
during	O
dombined	O
thetapy	O
with	O
vyclosporin	B-Chemical
A	I-Chemical
and	O
bifedipine	B-Chemical
included	O
an	O
increqse	O
in	O
bloof	B-Chemical
ur3a	I-Chemical
nitrogeh	I-Chemical
pevels	O
in	O
9	O
of	O
the	O
13	O
patiebts	O
and	O
developmen5	O
of	O
gingivak	O
huperplasia	O
in	O
2	O
of	O
the	O
13	O
patientx	O
.	O

Our	O
find9ngs	O
indicate	O
that	O
sustsined	O
-	O
rdlease	O
nif3dipine	B-Chemical
is	O
useful	O
for	O
hypertensiv4	O
ps9riatic	O
patoents	O
under	O
long	O
-	O
term	O
treatm4nt	O
with	O
cyclos0orin	B-Chemical
A	I-Chemical
,	O
but	O
that	O
these	O
patiebts	O
should	O
be	O
monit;red	O
for	O
g9ngival	O
hyperplzsia	O
.	O

